<SEC-DOCUMENT>0001193125-17-288562.txt : 20170920
<SEC-HEADER>0001193125-17-288562.hdr.sgml : 20170920
<ACCEPTANCE-DATETIME>20170919191446
ACCESSION NUMBER:		0001193125-17-288562
CONFORMED SUBMISSION TYPE:	F-1/A
PUBLIC DOCUMENT COUNT:		19
FILED AS OF DATE:		20170920
DATE AS OF CHANGE:		20170919

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zai Lab Ltd
		CENTRAL INDEX KEY:			0001704292
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-219980
		FILM NUMBER:		171093011

	BUSINESS ADDRESS:	
		STREET 1:		1043 HALEI ROAD
		STREET 2:		ZHANGJIANG HI-TECH PARK
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201203
		BUSINESS PHONE:		862161632588

	MAIL ADDRESS:	
		STREET 1:		1043 HALEI ROAD
		STREET 2:		ZHANGJIANG HI-TECH PARK
		CITY:			SHANGHAI
		STATE:			F4
		ZIP:			201203
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1/A
<SEQUENCE>1
<FILENAME>d358845df1a.htm
<DESCRIPTION>F-1/A
<TEXT>
<HTML><HEAD>
<TITLE>F-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>As filed with the Securities and Exchange Commission on September 19, 2017 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Registration No.&nbsp;333-219980 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>SECURITIES
AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Washington, D.C. 20549 </B></FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Amendment No. 3 </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>to
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>FORM F-1 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>REGISTRATION STATEMENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>UNDER </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>THE SECURITIES ACT
OF&nbsp;1933 </B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>Zai Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">(Exact name of
registrant as specified in its charter) </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Not applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">(Translation of Registrant&#146;s name into English) </FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Cayman Islands</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>2834</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">98-1144595</FONT></B></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">(State or other jurisdiction of</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">incorporation or organization)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">(Primary Standard Industrial</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">Classification Code Number)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">(I.R.S. Employer Identification</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">Number)</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>4560 Jinke Road </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Bldg. 1, 4F, Pudong, Shanghai, China 201210 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2"><B>Telephone: &#043;86 21 6163 2588 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">(Address, including zip code, and telephone number, including
area code, </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">of registrant&#146;s principal executive offices) </FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Law Debenture Corporate Services Inc. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; " ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2"><B>801 2<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT> Avenue, Suite 403 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>New York, New York 10017 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>Telephone: (212) 750-6474 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">(Name, address, including zip code, and telephone number, including area code, </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">of agent for service) </FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Copies to:
</I></B></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Patrick O&#146;Brien</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">Ropes&nbsp;&amp; Gray LLP</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Prudential Tower</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">800 Boylston Street</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Boston, MA
02199-3600</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Telephone: (617) <FONT STYLE="white-space:nowrap">951-7000</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Samantha Du</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">Chief Executive Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Zai Lab Limited</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">4560 Jinke Rd</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Bldg. 1, Fourth
Floor</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Pudong</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Shanghai,
China 201210</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Telephone: &#043;86 21 6163 2588</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Richard D. Truesdell, Jr., Esq.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">Li He</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Davis Polk&nbsp;&amp; Wardwell LLP</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">450 Lexington Avenue</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">New York, NY
10017</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Telephone: (212) <FONT STYLE="white-space:nowrap">450-4000</FONT></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:3px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Approximate date of commencement of proposed sale to public:</B> As soon as practicable after this Registration Statement is declared effective. </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of
1933, check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="2">&#9744;</FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If this Form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="2">&#9744;</FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective
registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="2">&#9744;</FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective
registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="2">&#9744;</FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933. </FONT></P>
<P STYLE="margin-top:3px;margin-bottom:0px; margin-left:1%; text-indent:-1%"><FONT STYLE="font-family:arial" SIZE="2">Emerging growth company&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT><FONT
STYLE="font-family:arial" SIZE="2"></FONT> </FONT></P> <P STYLE="margin-top:3px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">If an emerging growth company that prepares its financial statements in accordance with
U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#134;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"> provided pursuant to Section 7(a)(2)(B) of the Securities
Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> </FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&#134;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The term &#147;new or revised financial accounting standard&#148; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification
after April&nbsp;5, 2012. </FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><B>CALCULATION OF REGISTRATION FEE </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Title of each class of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>securities to be registered<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Amount&nbsp;to&nbsp;be</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>registered<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)(3)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Proposed Maximum<BR>Offering Price</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Per Share<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Proposed Maximum<BR>Aggregate</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Offering&nbsp;Price<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Amount of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Registration</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1"><B>Fee<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></B></FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ordinary Shares, par value $0.00006 per share</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">9,200,000</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$18.00</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">165,600,000</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$19,194</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">American depositary shares issuable upon deposit of ordinary shares registered hereby will be registered under a separate registration statement on Form&nbsp;F-6 (Registration
No.&nbsp;333-220256). Each American depositary share represents one&nbsp;ordinary share.</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes ordinary shares that are issuable upon the exercise of the underwriters&#146; option to purchase additional shares. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Estimated solely for the purpose of determining the amount of the registration fee in accordance with Rule&nbsp;457(a) under the Securities Act
of&nbsp;1933.</FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes $14,115 the Registrant previously paid in connection with previous filings of this Registration Statement. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a
further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective
on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2" COLOR="#ff0000"><B>The information in this prospectus is not complete and may be changed. We may not sell these
securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where
the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2" COLOR="#ff0000"><B>Subject to
completion </B></FONT></P>  <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2" COLOR="#ff0000"><B>Preliminary prospectus dated&nbsp;September&nbsp;19, 2017 </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Prospectus </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="6"><B>Zai Lab Limited </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g358845g23n28.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><I>8,000,000 American depositary shares </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B><I>Representing 8,000,000 ordinary shares </I></B></FONT></P>  <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are offering American depositary shares, or ADSs. Each
ADS represents one ordinary share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This is our initial public offering in the United States, and no public market currently exists for our ADSs.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We currently expect the initial public offering price to be between $16.00 and $18.00 per ADS. After pricing of the offering, we expect that the shares
will trade on the Nasdaq Global Market under the symbol &#147;ZLAB.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>We are eligible to be treated as an &#147;emerging growth company&#148; as
defined in Section 2(a) of the Securities Act of 1933, as amended, and, as a result, are subject to reduced public company reporting requirements. See &#147;Prospectus summary&#151;Implications of being an emerging growth company and a foreign
private issuer.&#148; </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Investing in our ADSs involves risks that are described in the &#147;<A HREF="#rom358845_2">Risk factors</A>&#148; section
beginning on page&nbsp;13 of this prospectus. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Per&nbsp;ADS</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Underwriting discount(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Proceeds to Zai Lab Limited before expenses</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"></FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">See &#147;Underwriting&#148; for a detailed description of compensation payable to the underwriters. </FONT></TD></TR></TABLE>  <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">To the extent that the underwriters sell more than 8,000,000 ADSs, the underwriters have the option to purchase up to an aggregate of 1,200,000 additional ADSs from us at the initial public offering price less the
underwriting discounts and commissions for 30 days after the date of this prospectus. </FONT></P>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain institutional investors have indicated an interest in
purchasing up to an aggregate of $30.0&nbsp;million in ADSs in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, less or no ADSs in this
offering to any of these investors, or any of these investors may determine to purchase more, less or no ADSs in this offering, including as a result of the pricing terms. See &#145;&#145;Prospectus summary&#151;The offering.&#146;&#146; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters expect to deliver the ADSs to the
purchasers on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="5"><B>J.P. Morgan</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>Citigroup</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="5"><B>Leerink Partners</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>The date of this prospectus
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017 </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="toc"></A>Table of contents </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_1">Prospectus summary</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_2">Risk factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_3">Cautionary note regarding forward-looking statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_3a">Series C conversion</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_4">Use of proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_5">Dividend policy</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">68</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_6">Capitalization</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_7">Dilution</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">71</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_8">Selected consolidated financial data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">73</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_9">Management&#146;s discussion and analysis of financial condition and results of operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">74</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_10">Industry</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">93</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_11">Business</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">99</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_12">Regulation</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">141</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_13">Management</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">177</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_14">Security ownership of beneficial owners and management</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">196</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_15">Related party transactions</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">198</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_16">Description of share capital</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">201</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_17">Description of American depositary shares</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">211</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_18">Shares eligible for future sale</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">223</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_19">Taxation</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">227</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_20">Underwriting</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">236</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_21">Legal matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">247</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_22">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">247</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_23">Enforcement of civil liabilities</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">247</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_24">Expenses relating to this offering</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">250</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#rom358845_25">Where you can find more information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">250</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>We are responsible for the information contained in this prospectus and in any free writing prospectus we prepare or authorize.
We have not, and the underwriters have not, authorized anyone to provide you with different information, and we and the underwriters take no responsibility for any other information others may give you. If anyone provides you with different or
inconsistent information, you should not rely on it. We are not, and the underwriters are not, making an offer to sell these securities in any jurisdiction repetitive of where the offer and sale is not permitted. You should assume that the
information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since such date. </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (the 25th day after the date of this prospectus), all dealers
effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as
underwriters and with respect to their unsold allotments or subscriptions. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">i </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Industry and market data </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Although we are responsible for all disclosure contained in this prospectus, in some
cases we have relied on certain market and industry data obtained from third-party sources that we believe to be reliable. Market estimates are calculated by using independent industry publications, government publications and third-party forecasts
in conjunction with our assumptions about our markets. While we are not aware of any misstatements regarding any market, industry or similar data presented herein, such data involves risks and uncertainties and is subject to change based on various
factors, including those discussed under the headings &#147;Cautionary note regarding forward-looking statements&#148; and &#147;Risk factors&#148; in this prospectus. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Trademarks and service marks </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We own or have rights to trademarks and service marks for use in connection with
the operation of our business, including, but not limited to, ZAI LAB and


<IMG SRC="g358845g05p60.jpg" ALT="LOGO">
.. All other trademarks or service marks appearing in this prospectus that are not identified as marks owned by us are the property of their respective owners. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">Solely for convenience, the trademarks, service marks and trade names referred to in this prospectus may be listed without the <FONT
STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, (TM) and (sm) symbols, but we will assert, to the fullest extent under applicable law, our applicable rights in these
trademarks, service marks and trade names. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">ii </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_1"></A>Prospectus summary </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>This summary highlights information contained in other parts of this prospectus. Because it is only a summary, it does not contain all of the information that you should consider before investing in our ADSs,
and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. You should read the entire prospectus carefully, especially &#147;Risk factors,&#148;
&#147;Selected consolidated financial data,&#148; and the financial statements and the related notes appearing elsewhere in this prospectus, before deciding to buy our ADSs. Unless the context requires otherwise, references in this prospectus to the
&#147;Company,&#148; &#147;Zai Lab,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to Zai Lab Limited and its consolidated subsidiaries. </I></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Overview of our business </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are an innovative biopharmaceutical company based in Shanghai focusing on
discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the areas of oncology, autoimmune and infectious diseases. We believe there exists a
significant opportunity to build an organization that not only addresses such unmet needs but leverages underutilized resources in China to foster innovation. As part of that effort, we have assembled a management team with global experience and an
extensive track record in navigating the regulatory process to develop and commercialize innovative drugs in China. Our mission is to leverage our expertise and insight to address the expanding needs of Chinese patients in order to transform their
lives and eventually utilize our China-based competencies to impact human health worldwide. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, Zai Lab was built on the vision that, despite
having a significant addressable market and sizable growth potential, China has historically lacked access to many innovative therapies available in other parts of the world and its drug development infrastructure has been underutilized. There
remains the need to bring new and transformative therapies to China. In recent years, the Chinese government has focused on promoting local innovation through streamlining regulatory processes, improving drug quality standards and fostering a
favorable environment, which we believe creates an attractive opportunity for the growth of China-based, innovation-focused companies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since our
founding in 2014, we have assembled an innovative pipeline consisting of six drug candidates through partnerships with global biopharmaceutical companies. These include three late-stage assets targeting fast growing segments of China&#146;s
pharmaceutical market and three assets addressing global unmet medical needs. We believe that our management&#146;s extensive global drug development expertise, combined with our demonstrated understanding of the pharmaceutical industry, clinical
resources and regulatory system in China, has provided us, and will continue to provide us, opportunities to partner with global companies aiming to bring innovative products to market in China efficiently. Our lead drug candidate is niraparib, a
PARP inhibitor licensed from Tesaro. We intend to develop niraparib for Chinese patients across multiple tumor types and anticipate beginning two Phase&nbsp;III studies of niraparib in patients with ovarian cancer, one in the second half of 2017 and
the other in the first half of 2018. In addition, we intend to pursue niraparib in other indications. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the longer term, we plan to build a premier,
fully integrated drug discovery and development platform that brings both in-licensed and internally-discovered medicines to patients in China and globally. As our business grows, we plan to build our own commercial team to launch our portfolio of
drug products. Part of our strategy is the ability to produce both large and small molecule therapeutics under global standard current Good Manufacturing Practice, or cGMP. To this end, in the first half of 2017 we built a small molecule drug
product facility capable of supporting clinical and commercial production and have also begun construction of a large molecule facility, which is expected to be utilized for clinical production of our drug candidates. The completion of the large
molecule facility is expected in the first half of 2018. </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our company is led by a management team with extensive pharmaceutical research, development and commercialization
track record in both global and Chinese biopharmaceutical companies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since our founding, we have raised $164.5 million in equity financing from our
dedicated group of investors, including global and China-based healthcare funds. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our innovative pipeline </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with
greater China rights and three drug candidates with global rights. The following table summarizes our drug candidates and programs: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g358845g24j00.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Niraparib <FONT STYLE="white-space:nowrap">(ZL-2306)</FONT></B> is a highly potent and selective oral, small molecule poly ADP ribose polymerase, or PARP 1/2,
inhibitor with the potential to be a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> drug for treatment across multiple solid tumor types in China including ovarian, certain types of breast and lung
cancers. We have licensed niraparib from Tesaro, which in March 2017 received marketing approval for niraparib (Zejula<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>)
from the U.S. Food and Drug Administration, or FDA, as maintenance treatment for women with recurrent platinum-sensitive epithelial ovarian cancer. Niraparib was commercially launched in the United States in April 2017. Niraparib does not require
BRCA mutation or other biomarker testing as is necessary for other approved PARP inhibitors which, we believe, significantly expands its availability to ovarian cancer patients in China. As niraparib has been approved in the United States, if
approved by the European Medicines Agency, or EMA, we anticipate commercializing niraparib in Hong Kong and Macau approximately 12 months after it is approved by the EMA. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1" COLOR="#FFFFFF">Program Commercial rights Indication Zai Lab&nbsp;clinical stage Partnerships Partner clinical&nbsp;stage ZL-2306 (Niraparib)
Ovarian&nbsp;cancer Phase 3(1) Commercial Breast cancer Phase 3(1) Phase 3 Lung cancer Phase 2(1) Phase 2 ZL-2401 (Omadacycline) ABSSSI Phase 3(2) Phase 3 CABP Phase 3(2) Phase 3 ZL-2301 HCC Phase 2 Phase 3 ZL-3101 (Fugan) Eczema,&nbsp;Psoriasis
Phase 2 ZL-2302 NSCLC Pre-clinical ZL-1101 GVHD, SLE Pre-clinical Internal Discovery Programs Multiple&nbsp;(Immuno-oncology) Pre-clinical </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
In China, our clinical trial application, or CTA, for niraparib has been approved as a Category 1 drug by the China Food and Drug Administration, or CFDA. We anticipate initiating Phase III
studies of niraparib in patients with recurrent platinum-sensitive ovarian cancer as a second-line maintenance therapy in the second half of 2017, and as a first-line maintenance therapy in the first half of 2018. These studies are expected to be
similar in design to Tesaro&#146;s clinical studies of niraparib. We also anticipate beginning a Phase III study in patients with gBRCA positive breast cancer in the first half of 2018. In addition, we intend to study niraparib in patients with
triple negative breast cancer, squamous-type <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer and small cell lung cancer in China. Niraparib has the potential to be the first PARP inhibitor marketed in China. In addition to
niraparib monotherapy in the potential indications stated, we also intend to explore the combination of niraparib with other potential therapies such as immune-oncology therapy, targeted therapy and chemotherapy in the clinically relevant
indications. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Omadacycline <FONT STYLE="white-space:nowrap">(ZL-2401)</FONT></B> is a broad-spectrum antibiotic in a new class of tetracycline derivatives, known as
aminomethylcyclines. We have licensed omadacycline from Paratek, where it is primarily being developed for acute bacterial skin/skin structure infections, or ABSSSI, community-acquired bacterial pneumonia, or CABP, and urinary tract infections, or
UTIs. Omadacycline is designed to overcome the two major mechanisms of tetracycline resistance, known as pump efflux and ribosome protection. Omadacycline has been granted Qualified Infectious Disease Product, or QIDP, status in the United States
and has been granted Fast Track status by the FDA. If approved, omadacycline is expected to be available in intravenous, or IV, and once-daily oral, or PO, formulations. Paratek has reported the results of two pivotal IV-to-oral Phase III studies of
omadacycline in ABSSSI and CABP. Both trials used an IV/oral sequential dosing design. Both of these studies achieved their primary endpoints. Paratek also reported <FONT STYLE="white-space:nowrap">top-line</FONT> data from its oral-only Phase III
ABSSSI study in July 2017. This study also achieved its primary endpoints. We are in the technology transfer stage and plan to discuss our China development plan with key opinion leaders and the CFDA. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">ZL-2301</FONT></B> is an oral, small molecule dual target tyrosine kinase inhibitor, or TKI, which blocks both vascular
endothelial growth factor receptor, or VEGFR, and fibroblast growth factor receptor, or FGFR. <FONT STYLE="white-space:nowrap">ZL-2301</FONT> was studied by our partner Bristol-Myers Squibb mainly for the treatment of hepatocellular carcinoma, or
HCC, the most common type of liver cancer. In these trials, <FONT STYLE="white-space:nowrap">ZL-2301</FONT> demonstrated anti-tumor activity and a generally well-established safety profile in HCC patients. In 2012, Bristol-Myers Squibb terminated
its development program of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> after it missed the primary endpoints in two Phase III trials with advanced HCC patients. Based on our review of the results from Bristol-Myers Squibb&#146;s development
program for <FONT STYLE="white-space:nowrap">ZL-2301,</FONT> our understanding of the etiology and current standard of care of HCC in Chinese patients and our ongoing research, we believe that <FONT STYLE="white-space:nowrap">ZL-2301</FONT> has the
potential to be an effective treatment option for Chinese HCC patients and merits further clinical trials. The CFDA has approved our CTA for <FONT STYLE="white-space:nowrap">ZL-2301</FONT> as a Category 1 drug, and in the second quarter of 2017 we
initiated a Phase II trial of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> as a second-line treatment for advanced HCC patients in China. Pending results from this Phase II trial, we plan to initiate a Phase III clinical trial shortly thereafter.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Fugan <FONT STYLE="white-space:nowrap">(ZL-3101)</FONT></B> is a novel steroid-sparing topical product for the treatment of eczema and psoriasis. We are
developing fugan as a botanical formulation to offer patients with eczema and psoriasis a natural alternative to topical steroid treatments, which are currently the main forms of treatment and are known to have many side effects associated with
long-term use. We licensed the exclusive worldwide rights to fugan from GSK in 2016. We initiated a Phase II study of fugan in patients with eczema in China in the second quarter of 2017. Pending results from this Phase II study, we plan to initiate
a Phase III global, multi-center clinical trial. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">ZL-2302</FONT></B> is a multi-targeted TKI with activity against both anaplastic lymphoma kinase, or ALK, mutation and
crizotinib-resistant ALK mutations being developed for the treatment of patients with <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
cancer who have ALK mutations and who have developed crizotinib resistance and/or brain metastasis. We licensed the exclusive worldwide rights to <FONT STYLE="white-space:nowrap">ZL-2302</FONT>
from Sanofi in 2015. Our preclinical studies demonstrated that <FONT STYLE="white-space:nowrap">ZL-2302</FONT> has ability to penetrate the blood-brain barrier, which could make <FONT STYLE="white-space:nowrap">ZL-2302</FONT> an effective therapy
for a subset of patients who have <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer with ALK mutations and brain metastasis. Such patients typically have limited treatment options, poor prognosis and low quality of life. Our CTA for
<FONT STYLE="white-space:nowrap">ZL-2302</FONT> has been accepted as a Category 1 drug by the CFDA, and we expect to initiate a Phase I study of <FONT STYLE="white-space:nowrap">ZL-2302</FONT> in China in the first half of 2018.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">ZL-1101</FONT></B> is<B> </B>an anti-OX40 antagonistic antibody with <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> potential for the treatment of a range of autoimmune diseases such as graft-versus-host disease or systemic lupus erythematosus. We licensed the exclusive worldwide rights to <FONT
STYLE="white-space:nowrap">ZL-1101</FONT> from UCB in 2015. Its anti-inflammatory activities have been validated by a variety of inflammatory and autoimmune disease models. <FONT STYLE="white-space:nowrap">ZL-1101&#146;s</FONT> bioactivities and
functional potency have been investigated both <I>in vitro</I> and<I> in vivo </I>studies. In such studies, cellular proliferation and production of inflammatory cytokines was markedly suppressed, demonstrating that
<FONT STYLE="white-space:nowrap">ZL-1101</FONT> effectively inhibits lymphocyte activation. <FONT STYLE="white-space:nowrap">ZL-1101</FONT> was also found to be highly potent. We intend to file an investigational new drug application, or IND, in
2018. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Industry </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As an
innovative biopharmaceutical company, we believe we are well positioned to take advantage of industry trends which are favorable to China-based innovation. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Evolution of China&#146;s emerging innovative pharmaceutical market </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">China&#146;s pharmaceutical market
is the second largest pharmaceutical market in the world and is projected to grow from $115&nbsp;billion in 2016 to $160&nbsp;billion by 2021 and $237&nbsp;billion by 2026, according to BMI Research. This growth is driven by strong fundamental
demand for therapeutic treatments and the Chinese government&#146;s focus on providing better quality care to patients including by encouraging greater usage of innovative drugs. We believe that the significant market opportunities for innovative
therapies in the China market are due to several trends, including demographics and disease incidence, improving access to healthcare, increasing affordability and demand for healthcare and focusing on innovation. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Historically, China&#146;s pharmaceutical market was dominated by mature and generic products. In recent years, the Chinese government has focused on promoting
innovation especially in areas of high unmet medical need through streamlining regulatory processes, improving drug quality standards and fostering a favorable environment for innovation. Going forward, innovative patented therapeutics are projected
to grow at over 10% annually until 2020, which is expected to surpass the growth rate of generic products. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>CFDA regulatory outlook&#151;CFDA
reform to accelerate innovation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In August 2015, China&#146;s State Council released its circular <I>Opinions Concerning the Reform of the Review
and Approval System for Drugs and Medical Devices</I>, or Circular No.&nbsp;44, which sets forth the government&#146;s clear determination to encourage transformation and upgrade the pharmaceutical industry. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">More recently, on May&nbsp;11, 2017, the CFDA issued three new draft policies regarding innovation for public comments. The three draft policies aim to accelerate
the review and approval of new drug and medical device applications (Circular No.&nbsp;52), deregulate the conduct of clinical trials to encourage innovation (Circular No.&nbsp;53), and enhance post-market supervision throughout a product&#146;s
entire life cycle (Circular No.&nbsp;54). </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The CFDA was admitted as a new regulatory member by the International Conference on Harmonisation, or ICH, on
June 1, 2017 and will reform its regulatory process in order to conform its policies and regulations to ICH guidelines. We believe it is likely that the draft policies will be adopted and benefit China-based companies that are experienced with
global standards of innovative drug development. If the draft policies are not fully adopted, we believe that China-based, innovation-focused pharmaceutical companies will still enjoy competitive advantages over foreign peers. Under the current CFDA
regulations, foreign pharmaceutical companies are typically allowed to receive NDAs in China after their products are approved by a foreign regulatory authority. This requirement typically causes delays in time to market for foreign pharmaceutical
companies. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Medical insurance and drug spending outlook&#151;multiple engines for improving affordability for innovation </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Over the past decade, the Chinese national government has been working on alleviating the burden on individuals by expanding health insurance coverage from
approximately 30% in 2003 to over 95% in 2013 with a goal of achieving universal coverage by 2020. At the same time, medical insurance plans at the provincial level have been introduced to complement the basic insurance programs. This increase in
health insurance coverage has had a dramatic impact on drug reimbursement and affordability in China. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Aside from the Chinese government&#146;s efforts
to improve public reimbursement, a large part of China&#146;s population has become increasingly affluent and has demonstrated an ability and willingness to pay
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> for innovative efficacious drugs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to
government health insurance and <FONT STYLE="white-space:nowrap">self-pay,</FONT> there is also growing government support for the development of commercial private health insurance to provide support for China&#146;s growing middle and upper
classes. Favorable industry policies such as tax incentives to consumers have been issued. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The advantages of being a China-based,
innovation-focused biopharmaceutical platform </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">China has undertaken significant efforts to encourage innovation and stimulate greater
productivity in its economy to transform the competitive landscape of the domestic pharmaceutical market, with incentives which include grants, tax incentives and supporting greater investment and global talent recruitment. We expect that this
multi-pronged approach will support the emergence of innovative, globally competitive China-based biopharmaceutical companies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Some of the key
advantages of being a fully integrated, China-based and innovation-focused biopharmaceutical development and manufacturing platform include: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Accelerated time to market; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Market exclusivity for up to five years for Category&nbsp;1 drugs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Customized development programs which are tailored to Chinese patients&#146; specific unmet medical needs, and higher efficiency in executing clinical
development programs; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Commercialization of innovative therapies. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our vision and strategy </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our vision is to become a leading
global innovative biopharmaceutical company based in China and deliver transformative medicines to patients in China and around the world. We intend to utilize our strengths to pursue the following strategies: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Rapidly advance and commercialize our <FONT STYLE="white-space:nowrap">in-licensed</FONT> late stage clinical drug
candidates.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We have built a broad and sustainable drug pipeline for the greater China and global market and will focus on rapidly advancing and commercializing our <FONT STYLE="white-space:nowrap">in-licensed</FONT>
drug candidates. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Capitalize on our location in China, our management team&#146;s domestic and international drug development experience and our track record of licensing to
further solidify our position as a strategic gateway partner into China for biopharmaceutical companies outside of China.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We believe the combination of our management&#146;s experience and knowledge, the changing
regulatory landscape in China, our manufacturing capabilities, the commercial capabilities we are developing and the global pharmaceutical industry&#146;s current approach to the China market makes us an ideal gateway partner for global
biopharmaceutical companies seeking to access the China market. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Continue to license promising programs for global rights.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>We have a track record of
<FONT STYLE="white-space:nowrap">in-licensing</FONT> the global rights of drug candidates from leading global biopharmaceutical companies such as GSK, Sanofi and UCB. We will continue to seek new <FONT STYLE="white-space:nowrap">in-licensing</FONT>
opportunities which grant us the global rights for differentiated drug candidates for which we can utilize the advantages of development in China to establish proof of concept prior to pursuing further late-stage development for the global market.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Build a fully integrated platform with drug discovery, development, manufacturing and commercialization capabilities in China and expand
globally.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We will continue to execute our strategy to become a fully integrated biopharmaceutical company in China serving the global market. By focusing on developing and commercializing our late-stage <FONT
STYLE="white-space:nowrap">in-licensed</FONT> drug candidates in parallel with expanding our earlier-stage internal research and discovery capabilities, we believe we can rapidly establish a fully integrated manufacturing and commercialization
platform. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Leverage our senior management&#146;s experience.</I></B> Our management team has extensive experience in the pharmaceutical industry in the United States
and China and is led by our Chief Executive Officer, Samantha Du, Ph.D., who is widely recognized as a leading figure in the China biotech industry. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Risks associated with our business </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There are a number of risks that you should understand before making an
investment decision regarding this offering. These risks are discussed more fully in the section entitled &#147;Risk factors&#148; following this prospectus summary. These risks include, but are not limited to: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We have incurred significant losses since our inception, including a net loss of $37.5 million for the year ended December 31, 2016, and anticipate that we will
continue to incur losses in the future and may never achieve or maintain profitability. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Even if we consummate this offering, we will likely need substantial additional funding for our drug development programs and commercialization efforts, which
may not be available on acceptable terms, or at all. If we are unable to raise capital on acceptable terms when needed, we could incur losses or be forced to delay, reduce or terminate such efforts. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We have a very limited operating history, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">All of our drug candidates are still in development. If we are unable to obtain regulatory approval and ultimately commercialize our drug candidates or
experience significant delays in doing so, our business, financial condition, results of operations and prospects will be materially adversely harmed. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">If we breach our license or other intellectual property-related agreements for our drug candidates or otherwise experience disruptions to our business
relationships with our licensors, we could lose the ability to continue the development and commercialization of our drug candidates. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">In addition to <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquiring drug candidates, we may engage in future business acquisitions that could
disrupt our business, cause dilution to our ADS holders and harm our financial condition and operating results. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Pharmaceutical companies in China are required to comply with extensive regulations and hold a number of permits and licenses to carry on their business. Our
ability to obtain and maintain these regulatory approvals is uncertain, and future government regulation may place additional burdens on our efforts to commercialize our drug candidates. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We depend on our licensors or patent owners of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights to prosecute and maintain patents and patent
applications that are material to our business. Any failure by our licensors or such patent owners to effectively protect these patent rights could adversely impact our business and operations. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The People&#146;s Republic of China&#146;s, or PRC, economic, political and social conditions, as well as governmental policies, could affect the business
environment and financial markets in China, our ability to operate our business, our liquidity and our access to capital. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Corporate information </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Zai Lab Limited was incorporated in
the Cayman Islands on March&nbsp;28, 2013 as an exempted company with limited liability under the Companies Law, Cap 22 (Law&nbsp;3 of 1961, as consolidated and revised) of the Cayman Islands, which we refer to as the Companies Law. The address of
our registered office in the Cayman Islands is Harbour Place 2nd Floor, 103 South Church Street, P.O. Box 472, George Town, Grand Cayman KY1-1106, Cayman Islands. Our principal executive offices are located at 4560 Jinke Road, Bldg. 1, 4F, Pudong,
Shanghai, China 201210. Our telephone number at that address is &#043;86 21 6163 2588. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Investor inquiries should be directed to us at the address and
telephone number of our principal executive offices set forth above. Our website address is www.zailaboratory.com. Our website and the information contained on our website do not constitute a part of this prospectus. Our agent for service of process
in the United States is&nbsp;Law Debenture Corporate Services Inc., located at 801 2nd Avenue, Suite 403, New York, New York 10017. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Implications of
being an emerging growth company and a foreign private issuer </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a company with less than $1.07&nbsp;billion in revenue during our most recently
completed fiscal year as of the initial filing date of the registration statement of which this prospectus forms a part, we qualify as an &#147;emerging growth company&#148; as defined in Section 2(a) of the Securities Act of 1933, as amended, which
we refer to as the Securities Act, as modified by the Jumpstart our Business Startups Act of 2012, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise
applicable generally to public companies that are not emerging growth companies. These provisions include exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting. The JOBS Act permits an
emerging growth company such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Upon consummation of this offering, we will report under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> company with foreign private
issuer status. As a foreign private issuer, we may take advantage of certain provisions in the Nasdaq listing rules that allow us to follow Cayman Islands law for </FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
certain corporate governance matters. See &#147;Management&#151;Foreign private issuer status.&#148; Even after we no longer qualify as an emerging growth company, as long as we qualify as a
foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit
from trades made in a short period of time; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the rules under the Exchange Act requiring the filing with the Securities and Exchange Commission, or SEC, of quarterly reports on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> containing unaudited financial and other specified information, or current reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K,</FONT> upon the occurrence of specified significant events;
and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Regulation Fair Disclosure, or Regulation&nbsp;FD, which regulates selective disclosures of material information by issuers. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>The offering </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>ADSs offered by us </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">8,000,000 ADSs. </FONT></TD></TR></TABLE>  <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>ADSs to be outstanding immediately after completion of this offering </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">8,000,000 ADSs (9,200,000 ADSs if the underwriters exercise their option to purchase additional ADSs in full). </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Ordinary shares to be outstanding immediately<BR> after completion of this offering </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">49,049,731 ordinary shares (50,249,731 ordinary shares if the underwriters exercise their option to purchase additional ADSs in full). Immediately after completion of this offering and assuming the
underwriters do not exercise their option to purchase additional ADSs, approximately 16.31% of our ordinary shares represented by ADSs will be held by our public shareholders. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>The ADSs </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">Each ADS represents one ordinary share, par value $0.00006 per share. The ADSs may be evidenced by ADRs. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">The depositary will hold the ordinary shares underlying your ADSs, and you will have the rights of an ADS holder as provided in the deposit agreement among us, the depositary and
the holders and beneficial owners of ADSs. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">If we declare dividends on our ordinary shares, the depositary will pay you the cash dividends and other distributions it receives on our ordinary shares, after deducting its
fees and expenses. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">You may turn in your ADSs to the depositary for cancellation and receipt of the corresponding ordinary shares. The depositary will charge you fees for the cancellation of ADSs
and delivery of the corresponding ordinary shares. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">We may amend or terminate the deposit agreement without your consent. If an amendment becomes effective and you continue to hold your ADSs, you will be bound by the deposit
agreement as amended. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">To better understand the terms of the ADSs, you should carefully read &#147;Description of American depositary shares&#148; in this prospectus. You should also read the deposit
agreement, which is filed as an exhibit to the registration statement that includes this prospectus. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Depositary </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">Citibank, N.A. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Option to purchase<BR> additional ADSs </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">The underwriters have an option for a period of 30 days after the date of this prospectus to purchase up to an additional 1,200,000 ADSs. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Use of proceeds </B></FONT></P></TD>
<TD> <P><FONT STYLE="font-family:arial" SIZE="2">We estimate that the net proceeds from this offering will be approximately $123.2&nbsp;million, or approximately $142.2&nbsp;million if the underwriters exercise their
</FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
option to purchase additional ADSs in full, at an assumed initial public offering price of $17.00 per ADS, the midpoint of the price range set forth on the cover of this prospectus, after
deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="27%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">We intend to use the net proceeds of this offering to advance the clinical development of our multiple drug candidates and for working capital and other general corporate
purposes. See &#147;Use of proceeds&#148; for additional information. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Dividend policy </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">We do not expect to pay any dividends on our ADSs in the foreseeable future. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Risk factors </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">You should read the &#147;Risk factors&#148; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in our ADSs. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Proposed Nasdaq trading symbol </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">We have applied for listing of the ADSs on the Nasdaq Global Market under the symbol &#147;ZLAB.&#148; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="27%"> <P STYLE="margin-bottom:1px"><FONT STYLE="font-family:arial" SIZE="2"><B>Indications of interest </B></FONT></P></TD>
<TD><FONT STYLE="font-family:arial" SIZE="2">Certain institutional investors have indicated an interest in purchasing up to an aggregate of $30.0&nbsp;million in ADSs in this offering. However, because indications of interest are not binding
agreements or commitments to purchase, the underwriters may determine to sell more, less or no ADSs in this offering to any of these investors, or any of these investors may determine to purchase more, less or no ADSs in this offering, including as
a result of the pricing terms. The underwriters will receive the same underwriting discounts on any ADSs purchased by these investors as they will on any other ADSs sold to the public in this offering. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The number of ordinary shares outstanding after this offering is based on 12,067,487&nbsp;ordinary shares outstanding as of June&nbsp;30, 2017, and excludes:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">6,448,415 shares issuable upon the exercise of options outstanding as of June&nbsp;30, 2017 pursuant to our 2015 Omnibus Equity Incentive Plan (the &#147;2015
Plan&#148;) at a weighted-average exercise price of $1.01 per share; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">1,924,327 shares reserved for future issuance under our 2017 Equity Incentive Plan (the &#147;2017 Equity Plan&#148;), which was adopted in connection with this
offering. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Unless otherwise indicated, this prospectus reflects and assumes the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the effectiveness of our fourth amended and restated memorandum and articles of association, which will occur immediately upon the closing of this offering;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the conversion of our outstanding preferred shares into an aggregate of 28,520,436 ordinary shares upon the closing of this offering;</FONT><FONT
STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"> </FONT></P></TD></TR></TABLE>
<P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT><FONT
STYLE="font-family:arial" SIZE="2"></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">In connection with the completion of this offering, all of our preferred shares will convert into ordinary shares. Other than our Series C preferred shares, all outstanding
preferred shares convert to ordinary shares on a one-to-one basis. Our Series C preferred shares convert to ordinary shares on the basis of a formula that is based on the price of this offering. Assuming an initial public offering price of $17.00
per ADS (the midpoint of the range set forth on the cover of this prospectus), the 1,998,958 outstanding shares of Series C preferred shares would convert into 2,076,119 ordinary shares. See &#147;Series C conversion&#148; for further discussion.
</FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">10 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">461,808 shares issuable upon the exercise of outstanding warrants as of June&nbsp;30, 2017 at an exercise price of $2.1651 per share;</FONT><FONT
STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"> </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">no issuance or exercise of options on or after June&nbsp;30, 2017; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">no exercise by the underwriters of their option to purchase up to an additional 1,200,000 ADSs in this offering; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a one-for-six reverse stock split of our ordinary shares and preferred shares effected on August 30, 2017. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">On July 19, 2017, the investor holding
the warrants exercised the warrants to purchase the full 461,808 Series A1 preferred shares, which will convert into 461,808 ordinary shares upon the closing of this offering. </FONT></P></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our summary consolidated financial data </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following summary consolidated financial data for the years ended December&nbsp;31, 2015 and December&nbsp;31, 2016 and the selected balance sheet data as of December&nbsp;31, 2015 and December&nbsp;31, 2016
have been derived from our audited consolidated financial statements appearing elsewhere in this prospectus. The summary consolidated financial data for the six months ended June&nbsp;30, 2016 and June&nbsp;30, 2017 and the selected balance sheet
data as of June&nbsp;30, 2017 have been derived from our unaudited condensed consolidated financial statements appearing elsewhere in this prospectus. The unaudited condensed interim consolidated financial statements reflect, in the opinion of
management, all adjustments of a normal, recurring nature that are necessary for the fair presentation of the financial statements. Our consolidated financial statements appearing in this prospectus have been prepared in accordance with U.S.
generally accepted accounting principles, or U.S. GAAP. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our historical results for any prior period are not necessarily indicative of results to be
expected in any future period. The following information should be read in conjunction with &#147;Risk factors,&#148; &#147;Capitalization,&#148; &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148;
and our consolidated financial statements and the related notes included elsewhere in this prospectus. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Six&nbsp;months&nbsp;ended June 30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(13,587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(32,149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,915</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(38,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fair value of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">341</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,534</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,835</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,835</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average shares used in calculating net loss per ordinary share, basic and diluted(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,242,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,630,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,693,655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,439,028</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share, basic and diluted(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As
of<BR>June&nbsp;30,<BR>2017</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Balance sheet data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">92,562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">83,949</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">103,865</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,940</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">88,907</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total shareholders&#146; deficits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(71,152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(51,552</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">880</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">See Note 2 within our notes to our financial statements appearing elsewhere in this prospectus for a description of the method used to calculate basic and diluted net loss per
share. </FONT></TD></TR></TABLE>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P></div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">12 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_2"></A>Risk factors </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Investing in our ADSs involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this prospectus, including
our consolidated financial statements and their related notes appearing at the end of this prospectus, before deciding to invest in our ADSs. If any of the following risks actually occurs, our business, prospects, operating results and financial
condition could suffer materially, the trading price of our ADSs could decline and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not
presently known to us or that we currently believe to be immaterial may also adversely affect our business. </I></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to our financial
position and need for additional capital </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We have incurred significant losses since our inception and anticipate that we will continue to incur
losses in the future and may never achieve or maintain profitability. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a clinical stage biopharmaceutical company with a limited operating
history. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that a drug candidate will fail to gain regulatory approval or become commercially
viable. To date, we have financed our activities primarily through private placements. We have not generated any revenue from product sales to date, and we continue to incur significant development and other expenses related to our ongoing
operations. As a result, we are not profitable and have incurred losses in each period since our inception in 2014. For the two years ended December&nbsp;31, 2016 and 2015, we reported a net loss of $37.5&nbsp;million and $18.0&nbsp;million,
respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect to continue to incur losses in the foreseeable future, and we expect these losses to increase as we: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">continue our development and commence clinical trials of our drug candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">seek regulatory approvals for our drug candidates that successfully complete clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">commercialize any of our drug candidates for which we may obtain marketing approval; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">complete construction of and maintain our manufacturing facilities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">hire additional clinical, operational, financial, quality control and scientific personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">establish a sales, marketing and commercialization infrastructure for any products that obtain regulatory approval; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">seek to identify additional drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtain, maintain, expand and protect our intellectual property portfolio; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">enforce and defend intellectual property-related claims; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other intellectual property, drug candidates and technologies. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To become and remain profitable, we must develop and eventually commercialize drug candidates with significant market potential. This will require us to be
successful in a range of challenging activities, including completing preclinical testing and clinical trials of our drug candidates, obtaining marketing approval for these drug candidates, manufacturing, marketing and selling those drug candidates
for which we may obtain marketing approval and satisfying any post-marketing requirements. We may never succeed in any or all of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">13 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
these activities and, even if we do, we may never generate revenues that are significant or large enough to achieve profitability. We may encounter unforeseen expenses, difficulties,
complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Even if we achieve
profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research
and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Even if we consummate this offering, we will likely need substantial additional funding for our drug development programs and commercialization efforts, which may not be available on acceptable terms, or at
all. If we are unable to raise capital on acceptable terms when needed, we could incur losses or be forced to delay, reduce or terminate such efforts. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">To date, we have financed our activities primarily through private placements. Through June&nbsp;30, 2017, we have raised $164.5 million in equity financing. Our operations have consumed substantial amounts of cash
since inception. The net cash used in our operating activities was $11.5&nbsp;million and $32.2 million for the years ended December&nbsp;31, 2015 and 2016, respectively, and $8.8 million and $17.7 million for the six months ended June 30, 2016 and
2017, respectively. We expect our expenses to increase significantly in connection with our ongoing activities, particularly as we advance the clinical development of our four clinical-stage drug candidates and continue research and development of
our preclinical-stage drug candidates and initiate additional clinical trials of, and seek regulatory approval for, these and other future drug candidates. In addition, if we obtain regulatory approval for any of our drug candidates, we expect to
incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. In particular, the costs that may be required for the manufacture of any drug candidate that receives regulatory approval may be
substantial as we may have to modify or increase the production capacity at our current manufacturing facilities or contract with third-party manufacturers. We may also incur expenses as we create additional infrastructure to support our operations
as a U.S. public company. Accordingly, we will likely need to obtain substantial additional funding in connection with our continuing operations through public or private equity offerings, debt financing, collaborations or licensing arrangements or
other sources. If we are unable to raise capital when needed or on acceptable terms, we could incur losses and be forced to delay, reduce or terminate our research and development programs or any future commercialization efforts. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe our cash and cash equivalents as of June&nbsp;30, 2017, combined with the net proceeds from this offering, will enable us to fund our operating expenses
and capital expenditure requirements through fiscal year 2020. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend
on many factors, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the number and development requirements of the drug candidates we pursue; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the scope, progress, timing, results and costs of researching and developing our drug candidates, and conducting
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the cost, timing and outcome of regulatory review of our drug candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the cost and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our drug candidates
for which we receive regulatory approval; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the cash received, if any, received from commercial sales of any drug candidates for which we receive regulatory approval; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">14 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to establish and maintain strategic partnerships, collaboration, licensing or other arrangements and the financial terms of such agreements;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the cost, timing and outcome of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending
any intellectual property-related claims; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the extent to which we acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other drug candidates and technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our headcount growth and associated costs; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the costs of operating as a public company in the United States. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Raising additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our technologies or drug candidates. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Identifying and acquiring rights to develop potential drug candidates and conducting <FONT STYLE="white-space:nowrap">pre-clinical</FONT> testing and clinical
trials is a time-consuming, expensive and uncertain process that may take years to complete, and our commercial revenue, if any, will be derived from sales of drug candidates that we do not expect to be commercially available until we receive
regulatory approval, if at all. We may never generate the necessary data or results required to obtain regulatory approval and achieve product sales, and even if one or more of our drug candidates is approved, they may not achieve commercial
success. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may seek additional funding through a combination of equity offerings, debt financings, collaborations, licensing arrangements, strategic alliances and marketing
or distribution arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that
adversely affect your rights as a holder of our ADSs. The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in certain additional restrictive
covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability
to conduct our business. In addition, issuance of additional equity securities, or the possibility of such issuance, may cause the market price of our ADSs to decline. In the event that we enter into collaborations or licensing arrangements to raise
capital, we may be required to accept unfavorable terms, including relinquishing or licensing to a third party on unfavorable terms our rights to technologies or drug candidates that we otherwise would seek to develop or commercialize ourselves or
potentially reserve for future potential arrangements when we might be able to achieve more favorable terms. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to our business and
industry </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We have a very limited operating history, which may make it difficult for you to evaluate the success of our business to date and to
assess our future viability. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We commenced our operations in 2014. Our operations to date have been limited to organizing and staffing our
company, identifying potential partnerships and drug candidates, acquiring product and technology rights, and conducting research and development activities for our drug candidates. We have not yet demonstrated the ability to successfully complete
large-scale, pivotal clinical trials. We have also not yet obtained regulatory approval for, or demonstrated an ability to manufacture or commercialize, any of our drug candidates. Consequently, any predictions about our future success, performance
or viability may not be as accurate as they could be if we had a longer operating history and/or approved products on the market. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">15 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our limited operating history, particularly in light of the rapidly evolving drug research and development industry in
which we operate, may make it difficult to evaluate our current business and prospects for future performance. Our short history makes any assessment of our future performance or viability subject to significant uncertainty. We will encounter risks
and difficulties frequently experienced by early-stage companies in rapidly evolving fields as we seek to transition to a company capable of supporting commercial activities. In addition, as a new business, we may be more likely to encounter
unforeseen expenses, difficulties, complications and delays due to limited experience. If we do not address these risks and difficulties successfully, our business will suffer. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>All of our drug candidates are still in development. If we are unable to obtain regulatory approval and ultimately commercialize our drug candidates or experience significant delays in doing so, our business,
financial condition, results of operations and prospects will be materially adversely harmed. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">All of our drug candidates are still in
development. Four of our drug candidates are in clinical development and various others are in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development. Our ability to generate revenue from our drug candidates is dependent on their receipt
of regulatory approval and successfully commercializing such products, which may never occur. Each of our drug candidates will require additional <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and/or clinical development, regulatory approval
in multiple jurisdictions, development of manufacturing supply and capacity, substantial investment and significant marketing efforts before we generate any revenue from product sales. The success of our drug candidates will depend on several
factors, including the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">successful completion of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and/or clinical studies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">successful enrollment in, and completion of, clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">receipt of regulatory approvals from applicable regulatory authorities for planned clinical trials, future clinical trials or drug registrations, manufacturing
and commercialization; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">successful completion of all safety studies required to obtain regulatory approval in China, the United States and other jurisdictions for our drug candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">adapting our commercial manufacturing capabilities to the specifications for our drug candidates for clinical supply and commercial manufacturing;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">making and maintaining arrangements with third-party manufacturers; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtaining and maintaining patent, trade secret and other intellectual property protection and/or regulatory exclusivity for our drug candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">launching commercial sales of our drug candidates, if and when approved, whether alone or in collaboration with others; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">acceptance of the drug candidates, if and when approved, by patients, the medical community and third-party payors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">effectively competing with other therapies and alternative drugs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtaining and maintaining healthcare coverage and adequate reimbursement; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">successfully enforcing and defending intellectual property rights and claims; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">maintaining a continued acceptable safety profile of the drug candidates following regulatory approval. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The success of our business is dependent upon our ability to develop and commercialize our clinical-stage drug candidates, particularly niraparib, which received
FDA approval as maintenance treatment for recurrent </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">16 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
ovarian cancer patients. As niraparib has been approved in the United States, if approved by the EMA, we anticipate commercializing niraparib in Hong Kong and Macau approximately 12 months after
it is approved by the EMA. We anticipate initiating Phase III studies of niraparib in patients with recurrent platinum-sensitive ovarian cancer as a second-line maintenance therapy in the second half of 2017, and as a first-line maintenance therapy
in the first half of 2018. We also anticipate initiating a Phase III study in patients with gBRCA positive breast cancer in the first half of 2018. Additionally, we plan to study niraparib in patients with triple negative breast cancer,
squamous-type non-small cell lung cancer and small cell lung cancer in China. For omadacycline, we are in the technology transfer stage and plan to discuss our China development plan with key opinion leaders and the CFDA. We initiated a Phase II
trial in advanced HCC patients in China to investigate <FONT STYLE="white-space:nowrap">ZL-2301&#146;s</FONT> optimal treatment schedule and dosage as a second-line treatment in the second quarter of 2017 and, pending successful Phase II results,
plan to conduct a Phase III registration trial. As a result, our business is substantially dependent on our ability to complete the development of, obtain regulatory approval for, and successfully commercialize niraparib, omadacycline and <FONT
STYLE="white-space:nowrap">ZL-2301</FONT> and our other drug candidates in a timely manner. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We cannot commercialize drug candidates in China without
first obtaining regulatory approval from the CFDA. Similarly, we cannot commercialize drug candidates in the United States or another jurisdiction outside of China without obtaining regulatory approval from the FDA or comparable foreign regulatory
authorities. The process to develop, obtain regulatory approval for and commercialize drug candidates is long, complex and costly both inside and outside of China and approval may not be granted. Clinical trials conducted in one country may not be
accepted by regulatory authorities in other countries, and obtaining regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among countries and can involve additional
product testing and validation and additional administrative review periods. Even if our drug candidates were to successfully obtain approval or, in the case of niraparib, have obtained approval, from the FDA and comparable foreign regulatory
authorities, we would still need to seek approval in China and any other jurisdictions where we plan to market the product. For example, we will need to conduct clinical trials of each of our drug candidates in patients in China prior to seeking
regulatory approval in China. Even if our drug candidates have successfully completed clinical trials outside of China, there is no assurance that clinical trials conducted with Chinese patients will be successful. Any safety issues, product recalls
or other incidents related to products approved and marketed in other jurisdictions may impact approval of those products by the CFDA. If we are unable to obtain regulatory approval for our drug candidates in one or more jurisdictions, or any
approval contains significant limitations, or are imposed on certain drug candidates, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of our drug candidates or any other drug candidate that
we may <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or develop in the future. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may allocate our limited resources to pursue a
particular drug candidate or indication and fail to capitalize on drug candidates or indications that may later prove to be more profitable or for which there is a greater likelihood of success. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Because we have limited financial and managerial resources, we must limit our licensing, research and development programs to specific drug candidates that we
identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other drug candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us
to fail to capitalize on viable commercial drugs or profitable market opportunities. In addition, if we do not accurately evaluate the commercial potential or target market for a particular drug candidate, we may relinquish valuable rights to that
drug candidate through collaboration, licensing or other royalty arrangements when it would have been more advantageous for us to retain sole development and commercialization rights to such drug candidate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">17 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our drug candidates are subject to extensive regulation, and we cannot give any assurance that any of our drug
candidates will receive regulatory approval or be successfully commercialized. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our drug candidates and the activities associated with their
development and commercialization, including their design, testing, manufacture, safety, efficacy, quality control, recordkeeping, labeling, packaging, storage, approval, advertising, promotion, sale, distribution, import and export are subject to
comprehensive regulation by the CFDA, FDA and EMA and other regulatory agencies in China and the United States and by comparable authorities in other countries. We are not permitted to market any of our drug candidates in China, the United States
and other jurisdictions unless and until we receive regulatory approval from the CFDA, FDA and EMA and other comparable authorities, respectively. Securing regulatory approval requires the submission of extensive
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the drug candidate&#146;s safety and efficacy. Securing regulatory
approval may also require the submission of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Our drug candidates may not be effective, may be only moderately
effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining regulatory approval or prevent or limit commercial use. Although niraparib was approved in the United States,
we cannot provide any assurance that we will ever obtain regulatory approval for niraparib in China or for any of our other drug candidates in any jurisdiction or that any of our drug candidates will be successfully commercialized, even if we
receive regulatory approval. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The process of obtaining regulatory approvals in China, the United States and other countries is expensive, may take many
years if additional clinical trials are required and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the drug candidates involved. Changes in regulatory approval policies during the development
period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted new drug application, or NDA, <FONT STYLE="white-space:nowrap">pre-market</FONT> approval or equivalent application type,
may cause delays in the approval or rejection of an application. The CFDA, FDA and EMA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our
data are insufficient for approval and require additional <FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical or other studies. Our drug candidates could be delayed in receiving, or fail to receive, regulatory approval for many reasons,
including the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">disagreement with the CFDA, FDA and EMA or comparable regulatory authorities regarding the number, design, size, conduct or implementation of our clinical
trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">failure to demonstrate to the satisfaction of the CFDA, FDA and EMA or comparable regulatory authorities that a drug candidate is safe and effective for its
proposed indication; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">failure of contract research organizations, or CROs, clinical study sites or investigators to comply with the <FONT STYLE="white-space:nowrap">ICH-good</FONT>
clinical practice, or GCP, requirements imposed by the CFDA, FDA and EMA or comparable regulatory authorities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">failure of the clinical trial results to meet the level of statistical significance required by the CFDA, FDA and EMA or comparable regulatory authorities for
approval; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">failure to demonstrate that a drug candidate&#146;s clinical and other benefits outweigh its safety risks; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the CFDA, FDA and EMA or comparable regulatory authorities disagreeing with our interpretation of data from <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
studies or clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">insufficient data collected from clinical trials to support the submission of an NDA or other submission or to obtain regulatory approval in China, the United
States or elsewhere; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the CFDA, FDA and EMA or comparable regulatory authorities not approving the manufacturing processes for our clinical and commercial supplies;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">18 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">changes in the approval policies or regulations of the CFDA, FDA or comparable regulatory authorities rendering our clinical data insufficient for approval;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the CFDA, FDA or comparable regulatory authorities restricting the use of our products to a narrow population; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our CROs or licensors taking actions that materially and adversely impact the clinical trials. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, even if we were to obtain approval, regulatory authorities may revoke approval, approve any of our drug candidates for fewer or more limited
indications than we request, may monitor the price we intend to charge for our drugs, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a drug candidate with a label that does not include the
labeling claims necessary or desirable for the successful commercialization of that drug candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our drug candidates. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If safety, efficacy, manufacturing or supply issues arise with any therapeutic that we use in combination with our drug candidates, we may be unable to market
such drug candidate or may experience significant regulatory delays or supply shortages, and our business could be materially harmed. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We plan to
develop certain of our drug candidates for use as a combination therapy. For example, Tesaro, Inc., or Tesaro, is currently developing, and we also plan to develop, niraparib as both a monotherapy and in combination with any potential anti-VEGF or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatments. However, we did not develop or obtain regulatory approval for, and we do not manufacture or sell, any anti-VEGF or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatments or any other therapeutic we use in combination with our drug candidates. We may also seek to develop our drug candidates in combination with other therapeutics in the future. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the CFDA, FDA or another regulatory agency revokes its approval of any anti-VEGF or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatments or another therapeutic we use in combination with our drug candidates, we will not be able to market our drug candidates in combination with such
revoked therapeutic. If safety or efficacy issues arise with these or other therapeutics that we seek to combine with our drug candidates in the future, we may experience significant regulatory delays, and we may be required to redesign or terminate
the applicable clinical trials. In addition, if manufacturing or other issues result in a supply shortage of any anti-VEGF or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT> treatments or any other
combination therapeutics, we may not be able to complete clinical development of niraparib and/or another of our drug candidates on our current timeline or at all. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Even if one or more of our drug candidates were to receive regulatory approval for use in combination with any anti-VEGF or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-1/PD-L1</FONT></FONT>
treatments, as applicable, or another therapeutic, we would continue to be subject to the risk that the CFDA, FDA or another regulatory agency could revoke its approval of the combination therapeutic, or that safety, efficacy, manufacturing or
supply issues could arise with one of these combination therapeutics. This could result in niraparib or one of our other products being removed from the market or being less successful commercially. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We face substantial competition, which may result in our competitors discovering, developing or commercializing drugs before or more successfully than we do,
or develop therapies that are more advanced or effective than ours, which may adversely affect our financial condition and our ability to successfully market or commercialize our drug candidates. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The development and commercialization of new drugs is highly competitive. We face competition with respect to our current drug candidates, and will face competition
with respect to any drug candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. For example, there are a number of large
pharmaceutical </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">19 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
and biotechnology companies that currently market drugs or are pursuing the development of therapies in the field of PARP inhibition to treat cancer. Some of these competitive drugs and therapies
are based on scientific approaches that are the same as or similar to that of our drug candidates. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct
research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. Specifically, there are a large number of companies developing or marketing treatments for oncology, autoimmune
and infectious diseases including many major pharmaceutical and biotechnology companies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Many of the companies against which we are competing or against
which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> testing, conducting clinical trials, obtaining
regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors.
Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified
scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize drugs that are safer, more effective, have fewer or less
severe side effects, are more convenient or are less expensive than drugs that we may develop. Our competitors also may obtain CFDA, FDA or other regulatory approval for their drugs more rapidly than we may obtain approval for ours, which could
result in our competitors establishing a strong market position before we are able to enter the market. Additionally, technologies developed by our competitors may render our potential drug candidates uneconomical or obsolete, and we may not be
successful in marketing our drug candidates against competitors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, as a result of the expiration or successful challenge of our patent
rights, we could face more litigation with respect to the validity and/or scope of patents relating to our competitors&#146; products. The availability of our competitors&#146; products could limit the demand, and the price we are able to charge,
for any products that we may develop and commercialize. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Clinical development involves a lengthy and expensive process with an uncertain outcome.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There is a risk of failure for each of our drug candidates. It is difficult to predict when or if any of our drug candidates will prove
effective and safe in humans or will receive regulatory approval. Before obtaining regulatory approval from regulatory authorities for the sale of any drug candidate, our drug candidates must complete
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and then conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. Clinical testing is expensive, difficult to design and implement, and
can take many years to complete. The outcomes of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical
trial do not necessarily predict final results. Moreover, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their drug
candidates performed satisfactorily in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and clinical trials have nonetheless failed to obtain regulatory approval of their drug candidates. Future clinical trials of our drug candidates may
not be successful. For example, <FONT STYLE="white-space:nowrap">ZL-2301</FONT> failed to meet its primary endpoint of overall survival noninferiority for <FONT STYLE="white-space:nowrap">ZL-2301</FONT> versus sorafenib in Phase III trials in
patients with HCC conducted by Bristol-Myers Squibb Company, or Bristol-Myers Squibb, before we licensed the development rights from them. Although we believe that <FONT STYLE="white-space:nowrap">ZL-2301</FONT> has the potential to be an effective
treatment for Chinese patients and merits further clinical trials patients, we cannot guarantee that our future clinical trials of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> in Chinese patients will be successful. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">20 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Commencement of clinical trials is subject to finalizing the trial design based on ongoing discussions with the CFDA,
FDA and/or other regulatory authorities. The CFDA, FDA and other regulatory authorities could change their position on the acceptability of trial designs or clinical endpoints, which could require us to complete additional clinical trials or impose
approval conditions that we do not currently expect. Successful completion of our clinical trials is a prerequisite to submitting an NDA (or analogous filing) to the CFDA, FDA and/or other regulatory authorities for each drug candidate and,
consequently, the ultimate approval and commercial marketing of our drug candidates. We do not know whether the clinical trials for our drug candidates will begin or be completed on schedule, if at all. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may incur additional costs or experience delays in completing <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical trials, or ultimately be
unable to complete the development and commercialization of our drug candidates. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may experience delays in completing our <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> or clinical trials, and numerous unforeseen events could arise during, or as a result of, future clinical trials, which could delay or prevent us from receiving regulatory approval, including:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">regulators or institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators to commence or conduct a clinical trial at a
prospective trial site; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may experience delays in reaching, or may fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs who conduct clinical
trials on our behalf, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us or them, to conduct additional clinical trials or
we may decide to abandon drug development programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the number of patients required for clinical trials of our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower
than we anticipate or participants may drop out of these clinical trials or fail to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up</FONT> at a higher rate than we anticipate; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">third-party contractors used in our clinical trials may fail to comply with regulatory requirements or meet their contractual obligations in a timely manner, or
at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the ability to conduct a companion diagnostic test to identify patients who are likely to benefit from our drug candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research for various reasons,
including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements or a finding that participants are being exposed to unacceptable health risks; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the cost of clinical trials of our drug candidates may be greater than we anticipate; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate;
and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our drug candidates may have undesirable side effects or unexpected characteristics, causing us or our investigators, regulators, IRBs or ethics committees to
suspend or terminate the trials, or reports may arise from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical testing of other cancer therapies that raise safety or efficacy concerns about our drug candidates.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We could encounter regulatory delays if a clinical trial is suspended or terminated by us or, as applicable, the IRBs or the ethics
committee of the institutions in which such trials are being conducted, by the data safety </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">21 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
monitoring board, which is an independent group of experts that is formed to monitor clinical trials while ongoing, or by the CFDA, FDA or other regulatory authorities. Such authorities may
impose a suspension or termination due to a number of factors, including: a failure to conduct the clinical trial in accordance with regulatory requirements or the applicable clinical protocols, inspection of the clinical trial operations or trial
site by the CFDA, FDA or other regulatory authorities that results in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or
administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our drug
candidates. Further, the CFDA, FDA or other regulatory authorities may disagree with our clinical trial design or our interpretation of data from clinical trials, or may change the requirements for approval even after it has reviewed and commented
on the design for our clinical trials. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we are required to conduct additional clinical trials or other testing of our drug candidates beyond those
that are currently contemplated, if we are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety
concerns, we may: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">be delayed in obtaining regulatory approval for our drug candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">not obtain regulatory approval at all; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtain approval for indications or patient populations that are not as broad as intended or desired; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">be subject to post-marketing testing requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">encounter difficulties obtaining or be unable to obtain reimbursement for use of certain drugs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">be subject to restrictions on the distribution and/or commercialization of drugs; and/or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">have the drug removed from the market after obtaining regulatory approval. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our drug development costs will also increase if we experience delays in testing or regulatory approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or
will be completed on schedule, or at all. Significant <FONT STYLE="white-space:nowrap">pre-clinical</FONT> study or clinical trial delays also could allow our competitors to bring products to market before we do and impair our ability to
successfully commercialize our drug candidates and may harm our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition and prospects significantly. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we experience delays or difficulties in the enrollment of patients in clinical trials, the progress of such clinical trials and our receipt of necessary
regulatory approvals could be delayed or prevented. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may not be able to initiate or continue clinical trials for our drug candidates if we are
unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the CFDA, FDA or similar regulatory authorities. In particular, we have designed many of our clinical trials, and expect to design
future trials, to include some patients with the applicable genomic mutation with a view to assessing possible early evidence of potential therapeutic effect. Genomically defined diseases, however, may have relatively low prevalence, and it may be
difficult to identify patients with the applicable genomic mutation. In addition, for our trials studying niraparib in ovarian cancer patients and certain of our other drug candidates, we plan to focus on enrolling patients who have failed their
first or second-line treatments, which limits the total size of the patient population available for such trials. The inability to enroll a sufficient number of patients with the applicable genomic alteration or that meet other applicable criteria
for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">22 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, some of our competitors have ongoing clinical trials for drug candidates that treat the same indications
as our drug candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#146; drug candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Patient enrollment may be affected by other factors including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the severity of the disease under investigation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the total size and nature of the relevant patient population; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the design and eligibility criteria for the clinical trial in question; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the availability of an appropriate genomic screening test; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the perceived risks and benefits of the drug candidate under study; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the efforts to facilitate timely enrollment in clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the patient referral practices of physicians; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the availability of competing therapies also undergoing clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the ability to monitor patients adequately during and after treatment; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the proximity and availability of clinical trial sites for prospective patients. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Enrollment delays in our clinical trials may result in increased development costs for our drug candidates, which could cause the value of our company to decline and limit our ability to obtain additional
financing. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our drug candidates may cause undesirable side effects that could delay or prevent their regulatory approval, limit the commercial
profile of an approved label, or result in significant negative consequences following regulatory approval, if any. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Undesirable side effects
caused by our drug candidates could cause us to interrupt, delay or halt clinical trials or could cause regulatory authorities to interrupt, delay or halt our clinical trials and could result in a more restrictive label or the delay or denial of
regulatory approval by the CFDA, FDA or other regulatory authorities. In particular, as is the case with all oncology drugs, it is likely that there may be side effects, such as fatigue, nausea and low blood cell levels, associated with the use of
certain of our oncology drug candidates. For example, the known adverse events for niraparib include thrombocytopenia, anemia and neutropenia and for ZL-2301, the known adverse events include hyponatremia, AST elevation, fatigue, hand-foot skin
reaction and hypertension. The results of our drug candidates&#146; trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, trials of our drug candidates could be suspended or terminated
and the CFDA, FDA or comparable regulatory authorities could order us to cease further development of or deny approval of our drug candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the
ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, our drug candidates could cause undesirable side effects related to <FONT STYLE="white-space:nowrap">off-target</FONT> toxicity. For example, many of
the currently approved PARP inhibitors have been associated with <FONT STYLE="white-space:nowrap">off-target</FONT> toxicities. While we believe that the superior selectivity of niraparib has the potential to significantly improve the unfavorable
adverse <FONT STYLE="white-space:nowrap">off-target</FONT> toxicity issues, if patients were to experience off-target toxicity, we may not be able to achieve an effective dosage level (especially in combination therapies), receive approval to
market, or achieve the commercial success we anticipate with respect to, any of our drug candidates, which could prevent us from ever generating revenue or achieving profitability. Many compounds that initially showed promise in early stage testing
for treating cancer have later been found to cause side effects that prevented further development of the compound. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">23 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Clinical trials assess a sample of the potential patient population. With a limited number of patients and duration of
exposure, rare and severe side effects of our drug candidates may only be uncovered with a significantly larger number of patients exposed to the drug candidate. If our drug candidates receive regulatory approval and we, our partners or others
identify undesirable side effects caused by such drug candidates (or any other similar drugs) after such approval, a number of potentially significant negative consequences could result, including: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the CFDA, FDA or other comparable regulatory authorities may withdraw or limit their approval of such drug candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the CFDA, FDA or other comparable regulatory authorities may require the addition of labeling statements, such as a &#147;boxed&#148; warning or a
contra-indication; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may be required to change the way such drug candidates are distributed or administered, conduct additional clinical trials or change the labeling of our drug
candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the CFDA, FDA or other comparable regulatory authorities may require a Risk Evaluation and Mitigation Strategy, or REMS (or analogous requirement), plan to
mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may be subject to regulatory investigations and government enforcement actions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may decide to remove such drug candidates from the marketplace; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we could be sued and held liable for injury caused to individuals exposed to or taking our drug candidates; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our reputation may suffer. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any of these events
could prevent us from achieving or maintaining market acceptance of the affected drug candidates and could substantially increase the costs of commercializing our drug candidates, if approved, and significantly impact our ability to successfully
commercialize our drug candidates and generate revenue. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we are unable to obtain CFDA approval for our drug candidates to be eligible for an
expedited registration pathway as Category 1 drug candidates, the time and cost we incur to obtain regulatory approvals may increase. Even if we receive such Category 1 designation, it may not lead to a faster development, review or approval
process. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The CFDA categorizes domestically-manufactured innovative drug applications as Category 1, provided such drug has a new and clearly
defined structure, pharmacological property and apparent clinical value and has not been marketed anywhere in the world. Domestically developed and manufactured innovative drugs will be attributed to Category 1 for their CTA and NDA applications.
While some multinational pharmaceutical companies may file CTAs with the CFDA prior to approval of a drug in another country in order to take advantage of Category 1 classification, such drug will most likely be assigned to Category 5 for NDA
approval purposes because, based on historical observations, multinational pharmaceutical companies will typically not prioritize applying for local manufacturing rights in China, hence subjecting the drug to the imported drug status. Our CTAs for
niraparib and ZL-2301 were approved as Category 1 drugs by the CFDA, and our CTA for <FONT STYLE="white-space:nowrap">ZL-2302</FONT> was accepted as a Category 1 drug by the CFDA. Other than fugan, all our other clinical stage drug candidates are
eligible for Category 1 designation. These two categories have distinct approval pathways. We believe the local drug registration pathway is a faster and more efficient path to approval in the China market
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">24 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
than the imported drug registration pathway. The imported drug registration pathway is more complex and is evolving. Imported drug registration applications in China may only be submitted after a
drug has obtained an NDA approval and received the Certificate of Pharmaceutical Product granted by a major drug regulatory authority, such as the FDA. A Category 1 designation by the CFDA may not be granted for any of our drug candidates or may not
lead to faster development or regulatory review or approval process. Moreover, a Category 1 designation does not increase the likelihood that our drug candidates will receive regulatory approval. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, there has been recent regulatory initiatives in China, including (i)&nbsp;the China&#146;s State Council&#146;s August 2015 statement, <I>Opinions on
Reforming the Review and Approval Process for Pharmaceutical Products and Medical Devices</I>, which declared the Chinese government&#146;s clear determination to encourage transformation and upgrade of the pharmaceutical industry, (ii)&nbsp;the
CFDA&#146;s November 2015 release, <I>Circular Concerning Several Policies on Drug Registration Review and Approval</I>, with aims to accelerate the approval process of clinical trials and (iii)&nbsp;the CFDA&#146;s February 2016 release,
<I>Opinions on Priority Review and Approval for Resolving Drug Registration Applications Backlog</I>, which further clarified that a fast track clinical trial approval or drug registration pathway will be available to certain designated drugs. As
such, the regulatory process in China is evolving and subject to change. Any future policies, or changes to current polices, that the CFDA approves might require us to change our planned clinical study design or otherwise spend additional resources
and effort to obtain approval of our drug candidates. In addition, policy changes may contain significant limitations related to use restrictions for certain age groups, warnings, precautions or contraindications, or may be subject to burdensome
post-approval study or risk management requirements. If we are unable to obtain regulatory approval for our drug candidates in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient
funding or generate sufficient revenue to continue the development of our drug candidates or any other drug candidate that we may <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or develop in the future. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Even if we receive regulatory approval for any of our drug candidates, we will be subject to ongoing obligations and continued regulatory review, which may
result in significant additional expense, and if we fail to comply with ongoing regulatory requirements or experience any unanticipated problems with any of our drug candidates, we may be subject to penalties. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the CFDA, FDA or a comparable regulatory authority approves any of our drug candidates, the manufacturing processes, labeling, packaging, distribution, adverse
event reporting, storage, advertising, promotion and recordkeeping for the drug will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports,
registration, and continued compliance with cGMPs and GCPs. Any regulatory approvals that we receive for our drug candidates may also be subject to limitations on the approved indicated uses for which the drug may be marketed or to the conditions of
approval, or contain requirements for potentially costly post-marketing testing, including Phase IV studies for the surveillance and monitoring the safety and efficacy of the drug. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, once a drug is approved by the CFDA, FDA or a comparable regulatory authority for marketing, it is possible that there could be a subsequent discovery of previously unknown problems with the drug,
including problems with third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements. If any of the foregoing occurs with respect to our drug products, it may result in, among other things: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">restrictions on the marketing or manufacturing of the drug, withdrawal of the drug from the market, or voluntary or mandatory drug recalls;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">fines, warning letters or holds on clinical trials; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">25 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">refusal by the CFDA, FDA or comparable regulatory authority to approve pending applications or supplements to approved applications filed by us, or suspension or
revocation of drug license approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">drug seizure or detention, or refusal to permit the import or export of drugs; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">injunctions or the imposition of civil, administrative or criminal penalties. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Any government investigation of alleged violations of law could require us to expend significant time and resources and could generate negative publicity. Moreover, regulatory policies may change or additional
government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates. If we are not able to maintain regulatory compliance, regulatory approval that has been obtained may be lost and we may not achieve
or sustain profitability, which may harm our business, financial condition and prospects significantly. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The incidence and prevalence for target
patient populations of our drug candidates are based on estimates and third-party sources. If the market opportunities for our drug candidates are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the
patient population, our revenue and ability to achieve profitability might be materially and adversely affected. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Periodically, we make estimates
regarding the incidence and prevalence of target patient populations for particular diseases based on various third-party sources and internally generated analysis and use such estimates in making decisions regarding our drug development strategy,
including acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> drug candidates and determining indications on which to focus in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> or clinical trials. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunity will depend on, among other things, their
acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our drugs, or
new patients may become increasingly difficult to identify or gain access to, all of which may significantly harm our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our future success depends on our ability to retain key executives and to attract, retain
and motivate qualified personnel. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are highly dependent on the expertise of the members of our research and development team, as well as the
other principal members of our management, including Samantha Du, our founder, Chairman and Chief Executive Officer. Although we have entered into employment letter agreements with our executive officers, each of them may terminate their employment
with us at any time with one months&#146; prior written notice. We do not maintain &#147;key person&#148; insurance for any of our executives or other employees. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Recruiting and retaining qualified management, scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other
key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may
be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize drugs.
Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar
personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">26 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
institutions. In addition, our management will be required to devote significant time to new compliance initiatives from our status as a U.S. public company, which may require us to recruit more
management personnel. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified scientific personnel. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We
will need to increase the size and capabilities of our organization, and we may experience difficulties in managing our growth. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We expect to
experience significant growth in the number of our employees and consultants and the scope of our operations, particularly in the areas of drug development, regulatory affairs and business development. To manage our anticipated future growth, we
must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of
our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to
significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations, and have a materially adverse effect on our business.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We have concluded that there is a material weakness in internal control over financial reporting in the past and cannot assure you that additional
material weaknesses will not be identified in the future. This weakness may not be timely eliminated and general reputational harm could result or persist, which could materially and adversely affect our business, operations and financial condition.
Our failure to implement and maintain effective internal control over financial reporting could result in material misstatements in our financial statements which could require us to restate financial statements, cause investors to lose confidence
in our reported financial information and have a negative effect on our stock price. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prior to the completion of this offering, we have been a
private company with limited accounting personnel to adequately execute our accounting processes and other supervisory resources with which to address our internal control over financial reporting. Our management has not completed an assessment of
the effectiveness of our internal control over financial reporting and our independent registered public accounting firm has not conducted an audit of our internal control over financial reporting. In the course of auditing our consolidated
financial statements for the year ended December 31, 2016, we and our independent registered public accounting firm identified one material weakness in our internal control over financial reporting as of December 31, 2016, in accordance with the
standards established by the Public Company Accounting Oversight Board of the United States. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable
possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis. The material weakness related to the lack of sufficient accounting personnel with U.S. GAAP knowledge and SEC financial
reporting requirements for the purpose of financial reporting, and lack of accounting policies and procedures over financial reporting in accordance with U.S. GAAP. We are seeking to remedy this material weakness by adding staff with extensive U.S.
GAAP experience to our accounting team and developing, communicating and implementing an accounting policy manual for our financial reporting personnel for recurring transactions and <FONT STYLE="white-space:nowrap">period-end</FONT> closing
processes, although no assurance can be given as to whether these steps will be sufficient. The implementation of these improvements may increase our administrative expenses. To the extent these steps are not successful, we could be forced to incur
additional management time and expense. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We cannot assure you that additional material weaknesses or significant deficiencies in our internal control
over financial reporting will not be identified in the future. Any failure to maintain or implement required new or improved controls, or any difficulties we encounter in their implementation, could result in additional
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">27 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
significant deficiencies or material weaknesses, cause us to fail to meet our periodic reporting obligations or result in material misstatements in our financial statements. Any such failure
could also adversely affect the results of periodic management evaluations regarding the effectiveness of our internal control over financial reporting. Furthermore, we will be required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish
a report by management on, among other things, the effectiveness of our internal control over financial reporting as of the end of our fiscal year ending on December 31, 2018. However, for as long as we are an &#147;emerging growth company&#148;
under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. We could be an emerging growth company for up to five
years. An independent assessment of the effectiveness of our internal control over financial reporting could detect problems that our management&#146;s assessment might not. The existence of a material weakness could result in errors in our
financial statements that could result in a restatement of financial statements, cause us to fail to meet our reporting obligations and cause investors to lose confidence in our reported financial information, leading to a decline in our stock
price. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>In addition to <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquiring drug candidates, we may engage in future business
acquisitions that could disrupt our business, cause dilution to our ADS holders and harm our financial condition and operating results. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">While we
currently have no specific plans to acquire any other businesses, we have, from time to time, evaluated acquisition opportunities and may, in the future, make acquisitions of, or investments in, companies that we believe have products or
capabilities that are a strategic or commercial fit with our current drug candidates and business or otherwise offer opportunities for our company. In connection with these acquisitions or investments, we may: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">issue stock that would dilute our ADS holders&#146; percentage of ownership; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">incur debt and assume liabilities; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">incur amortization expenses related to intangible assets or incur large and immediate write-offs. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We also may be unable to find suitable acquisition candidates and we may not be able to complete acquisitions on favorable terms, if at all. If we do complete an
acquisition, we cannot assure you that it will ultimately strengthen our competitive position or that it will not be viewed negatively by customers, financial markets or investors. Further, future acquisitions could also pose numerous additional
risks to our operations, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">problems integrating the purchased business, products or technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">increases to our expenses; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the failure to have discovered undisclosed liabilities of the acquired asset or company; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">diversion of management&#146;s attention from their <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> responsibilities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">harm to our operating results or financial condition; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">entrance into markets in which we have limited or no prior experience; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">potential loss of key employees, particularly those of the acquired entity. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We may not be able to complete one or more acquisitions or effectively integrate the operations, products or personnel gained through any such acquisition without a material adverse effect on our business,
financial condition and results of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">28 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to
market and sell our drug candidates, we may be unable to generate any revenue. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We do not currently have an organization for the sales, marketing
and distribution of pharmaceutical products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved by the CFDA, FDA and comparable
regulatory authorities, we must build our sales, marketing, managerial and other <FONT STYLE="white-space:nowrap">non-technical</FONT> capabilities or make arrangements with third parties to perform these services. If we are unable to establish
adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenue and may not become profitable. We will be competing with many companies that currently have
extensive and well-funded sales and marketing operations. Without an internal commercial organization or the support of a third party to perform sales and marketing functions, we may be unable to compete successfully against these more established
companies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Reimbursement may not be immediately available for our drug candidates in China, the United States or other countries, which could
diminish our sales or affect our profitability. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The regulations that govern pricing and reimbursement for pharmaceuticals vary widely from
country to country. In China, the Ministry of Human Resources and Social Security of the PRC or provincial or local human resources and social security authorities, together with other government authorities, review the inclusion or removal of drugs
from the PRC&#146;s National Drug Catalog for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance, or the National Reimbursement Drug List, or the NRDL, or provincial or local medical insurance catalogues for the National
Medical Insurance Program regularly, and the tier under which a drug will be classified, both of which affect the amounts reimbursable to program participants for their purchases of those drugs. These determinations are made based on a number of
factors, including price and efficacy. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In February 2017, the Ministry of Human Resources and Social Security of the PRC released a new edition of the
NRDL, or the 2017 NRDL. The 2017 NRDL expands its scope by including an additional 339 drugs. The 2017 NRDL reflects an emphasis on innovative drugs and drugs that treat cancer and other serious diseases. For instance, most of the innovative
chemical drugs and biological products approved in China between 2008 and the first half of 2016 have been included in the 2017 NRDL or its candidate list. Most of our drug candidates targeted at treating oncology diseases, including niraparib, are
unlikely to be included in the NRDL for the National Medical Insurance Program at least in the short-term. Products included in the NRDL are typically generic and essential drugs. Innovative drugs, like niraparib, have historically been more limited
on their inclusion in the NRDL due to the affordability of the government&#146;s Basic Medical Insurance. More recently, the government has started to include more innovative drugs in the 2017 NRDL. As a result, if we were to successfully launch
commercial sales of our oncology-based drug candidates, including niraparib, our revenue from such sales is largely expected to be self-paid by patients, which may make our drug candidates less desirable. On the other hand, if the Ministry of Human
Resources and Social Security of the PRC or any of its local counterparts accepts our application for the inclusion of our drug candidates in the NRDL or provincial or local medical insurance catalogues, which may increase the demand for our drug
candidates, our potential revenue from the sales of our drug candidates may still decrease as a result of lower prices we may be required to charge for our drug candidates that are included in the NRDL or provincial or local medical insurance
catalogues. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs which may affect
reimbursement rates of our drug candidates if approved. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the Affordable Care Act, was passed, which
substantially changed the way health care is financed by both governmental and private insurers. The Affordable Care Act, among other things, subjects biologic products to potential competition by lower-cost biosimilars and establishes annual fees
and taxes on manufacturers of certain branded prescription drugs. It also establishes a new Medicare Part D coverage gap </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">29 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
discount program, in which manufacturers must agree to offer 50% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of
applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D. In addition, other legislative changes have been proposed and adopted
in the United States since the Affordable Care Act was enacted. We expect that additional U.S. state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will
pay for healthcare products and services, which could result in reduced demand for our drug candidates or additional pricing pressures. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Some of the
provisions of the Affordable Care Act have yet to be fully implemented, while certain provisions have been subject to judicial and Congressional challenges. In January 2017, Congress voted to adopt a budget resolution for fiscal year 2017, that
while not a law, is widely viewed as the first step toward the passage of legislation that would repeal certain aspects of the Affordable Care Act. Further, on January&nbsp;20, 2017, President Trump signed an Executive Order directing federal
agencies with authorities and responsibilities under the Affordable Care Act to waive, defer, grant exemptions from, or delay the implementation of any provision of the Affordable Care Act that would impose a fiscal burden on states or a cost, fee,
tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. Congress also could consider subsequent legislation to replace elements of the Affordable Care Act that
are repealed. Thus, the full impact of the Affordable Care Act, or any law replacing elements of it, on our business remains unclear. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to
generate revenue, attain profitability, or commercialize our drugs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Moreover, eligibility for reimbursement in either China or the United States does
not imply that any drug will be paid for in all cases or at a rate that covers our costs, including licensing fees, research, development, manufacture, sale and distribution. Interim U.S. reimbursement levels for new drugs, if applicable, may also
not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and
may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by U.S. government healthcare programs or private payors and by any future relaxation of laws that
presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors in the United States often rely upon Medicare coverage policy and payment limitations in setting their own
reimbursement policies. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any approved drugs that we develop could have a material adverse effect on our operating results, our
ability to raise capital needed to commercialize drugs and our overall financial condition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Pharmaceutical companies in China are required to
comply with extensive regulations and hold a number of permits and licenses to carry on their business. Our ability to obtain and maintain these regulatory approvals is uncertain, and future government regulation may place additional burdens on our
efforts to commercialize our drug candidates. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The pharmaceutical industry in China is subject to extensive government regulation and
supervision. The regulatory framework addresses all aspects of operating in the pharmaceutical industry, including approval, registration, production, distribution, packaging, labelling, storage and shipment, advertising, licensing and certification
requirements and procedures, periodic renewal and reassessment processes, registration of new drugs and environmental protection. Violation of applicable laws and regulations may materially and adversely affect our business. In order to
commercialize our drug candidates and manufacture and distribute pharmaceutical products in China, we are required to: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtain a pharmaceutical manufacturing permit and GMP certificate for each production facility from the CFDA and its relevant branches for trading and
distribution of drugs not manufactured by the drug registration certificate holder; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">30 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtain a drug registration certificate, which includes a drug approval number, from the CFDA for each drug manufactured by us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtain a pharmaceutical distribution permit and good supply practice, or GSP, certificate from the CFDA and its relevant branches; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">renew the pharmaceutical manufacturing permits, the pharmaceutical distribution permits, drug registration certificates, GMP certificates and GSP certificates
every five years, among other requirements. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we are unable to obtain or renew such permits or any other permits or licenses required
for our operations, will not be able to engage in the commercialization, manufacture and distribution of our drug candidates and our business may be adversely affected. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The regulatory framework governing the pharmaceutical industry in China is subject to change and amendment from time to time. Any such change or amendment could materially and adversely impact our business,
financial condition and prospects. The PRC government has introduced various reforms to the Chinese healthcare system in recent years and may continue to do so, with an overall objective to expand basic medical insurance coverage and improve the
quality and reliability of healthcare services. The specific regulatory changes under the reform still remain uncertain. The implementing measures to be issued may not be sufficiently effective to achieve the stated goals, and as a result, we may
not be able to benefit from such reform to the level we expect, if at all. Moreover, the reform could give rise to regulatory developments, such as more burdensome administrative procedures, which may have an adverse effect on our business and
prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For further information regarding government regulation in China and other jurisdictions, see &#147;Regulation&#151;Government regulation of
pharmaceutical product development and approval,&#148; &#147;Regulation&#151;Coverage and reimbursement&#148; and &#147;Regulation&#151;Other healthcare laws.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>If we breach our license or other intellectual property-related agreements for our drug candidates or otherwise experience disruptions to our business relationships with our licensors, we could lose the
ability to continue the development and commercialization of our drug candidates. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our business relies, in large part, on our ability to develop
and commercialize drug candidates we have licensed and sublicensed from third parties including niraparib from Tesaro, <FONT STYLE="white-space:nowrap">ZL-2301</FONT> from Bristol-Myers Squibb, omadacycline from Paratek Bermuda, Ltd., a subsidiary
of Paratek Pharmaceuticals, Inc., or Paratek, fugan from GlaxoSmithKline (China) R&amp;D Co., Ltd., an affiliate of GlaxoSmithKline plc, or GSK, <FONT STYLE="white-space:nowrap">ZL-2302</FONT> from Sanofi and
<FONT STYLE="white-space:nowrap">ZL-1101</FONT> from UCB Biopharma Sprl, an affiliate of Union Chimique Belge, or UCB. Because our licenses from Paratek, GSK and UCB are granted to us by a subsidiary or an affiliate of Paratek, GSK or UCB, as
applicable, our licenses may not encumber all intellectual property rights owned or controlled by the affiliates of our licensors and relevant to our drug candidates. If we have not obtained a license to all intellectual property rights owned or
controlled by such affiliates of our licensors that are relevant to our drug candidates, we may need to obtain additional licenses to such intellectual property rights which may not be available on an exclusive basis, on commercially reasonable
terms or at all. In addition, if our licensors breach such agreements, we may not be able to enforce such agreements against our licensors&#146; parent entity or affiliates. Under each of our license and intellectual property-related agreements, in
exchange for licensing or sublicensing us the right to develop and commercialize the applicable drug candidates, our licensors will be eligible to receive from us milestone payments, tiered royalties from commercial sales of such drug candidates,
assuming relevant approvals from government authorities are obtained, or other payments. Our license and intellectual property-related agreements also require us to comply with other obligations including development and diligence obligations,
providing certain information regarding our activities with respect to such drug candidates and/or maintaining the confidentiality of information we receive from our licensors. For example, under our agreements relating to niraparib and <FONT
STYLE="white-space:nowrap">ZL-2301,</FONT> we are required to use commercially reasonable efforts to conduct the necessary </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">31 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
<FONT STYLE="white-space:nowrap">pre-clinical,</FONT> clinical, regulatory and other activities necessary to develop and commercialize such drug candidates in the licensed territories. We are
also obligated to use commercially reasonable efforts to develop and commercialize omadacycline, fugan, ZL-2302 and ZL-1101 in certain of their respective licensed territories, in each case, under their respective license agreements. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we fail to meet any of our obligations under our license and intellectual property-related agreements, our licensors have the right to terminate our licenses and
sublicenses and, upon the effective date of such termination, have the right to <FONT STYLE="white-space:nowrap">re-obtain</FONT> the licensed and <FONT STYLE="white-space:nowrap">sub-licensed</FONT> technology and intellectual property. If any of
our licensors terminate any of our licenses or sublicenses, we will lose the right to develop and commercialize our applicable drug candidates and other third parties may be able to market drug candidates similar or identical to ours. In such case,
we may be required to provide a grant back license to the licensors under our own intellectual property with respect to the terminated products. For example, if our agreement with Sanofi for <FONT STYLE="white-space:nowrap">ZL-2302</FONT> terminates
for any reason, we are required to grant Sanofi an exclusive license with respect to certain of our owned patents and <FONT STYLE="white-space:nowrap">know-how</FONT> that are necessary to exploit <FONT STYLE="white-space:nowrap">ZL-2302</FONT> in
the field of oncology in the regions where the license is terminated. In addition, if our agreements with UCB for <FONT STYLE="white-space:nowrap">ZL-1101</FONT> and Tesaro for niraparib terminate for any reason, we are required to grant UCB or
Tesaro, as applicable, an exclusive license to certain of our intellectual property rights that relate to <FONT STYLE="white-space:nowrap">ZL-1101</FONT> or niraparib, as applicable. While we would expect to exercise all rights and remedies
available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under the intellectual property rights licensed and sublicensed to us, we may not be able to do so in a timely manner, at an acceptable cost or at
all. In particular, some of the milestone payments are payable upon our drug candidates reaching development milestones before we have commercialized, or received any revenue from, sales of such drug candidate, and we cannot guarantee that we will
have sufficient resources to make such milestone payments. Any uncured, material breach under the license agreements could result in our loss of exclusive rights and may lead to a complete termination of our rights to the applicable drug candidate.
Any of the foregoing could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition,
disputes may further arise regarding intellectual property subject to a license agreement, including, but not limited to: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the scope of rights granted under the license agreement and other <FONT STYLE="white-space:nowrap">interpretation-related</FONT> issues;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the extent to which our technology and processes infringe, misappropriate or otherwise violate on intellectual property of the licensor that is not subject to
the licensing agreement; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the sublicensing of patent and other rights under our collaborative development relationships; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use of intellectual
property by our licensors and us and our partners; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the priority of invention of patented technology. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Moreover, certain of our licensors do not own some or all of the intellectual property included in the license, but instead have licensed such intellectual property from a third party, and have granted us a <FONT
STYLE="white-space:nowrap">sub-license.</FONT> As a result, the actions of our licensors or of the ultimate owners of the intellectual property may affect our rights to use our sublicensed intellectual property, even if we are in compliance with all
of the obligations under our license agreements. For example, our licenses from Tesaro and Paratek comprise sublicenses to us of certain intellectual property rights owned by third parties that are not our direct licensors. If our licensors were to
fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">32 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
sublicensed to us, or should such agreements be terminated or amended, our rights to the applicable licensed intellectual property may be terminated or narrowed, our exclusive licenses may be
converted to <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses, and our ability to produce and sell our products and drug candidates may be materially harmed. In addition, our license from Paratek is limited to intellectual property
rights under the control of Paratek Bermuda, Ltd. To the extent Paratek Bermuda, Ltd. loses control over any of the licensed intellectual property rights for any reason, we will no longer be licensed to such intellectual property rights to use,
develop and otherwise commercialize omadacycline. Also, our license from GSK for fugan includes license agreements between GSK and third parties, which were assigned to us. If we do not comply with our license agreement with GSK or with such other
third parties, any such agreements may be terminated or narrowed and we may lose our rights to the licensed intellectual property rights and be required to cease development and commercialization of fugan. Any of the foregoing could have a material
adverse effect on our business, financial conditions, results of operations, and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, the agreements under which we currently license
intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what
we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on
our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed or sublicensed prevent or impair our ability to maintain our current licensing arrangements on
commercially acceptable terms, we may be unable to successfully develop and commercialize the affected drug candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Product liability claims or lawsuits could cause us to incur substantial liabilities. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We face an inherent risk of product liability exposure related to the use of our drug candidates in clinical trials or any drug candidates we may decide to
commercialize and manufacture in the future. If we cannot successfully defend against claims that the use of such drug candidates in our clinical trials or any products we may choose to manufacture at our production facilities in the future,
including any of our drug candidates which receive regulatory approval, caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">significant negative media attention and reputational damage; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">withdrawal of clinical trial participants and inability to continue clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">significant costs to defend the related litigation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">substantial monetary awards to trial participants or patients; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the inability to commercialize any drug candidates that we may develop; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">initiation of investigations by regulators; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a diversion of management&#146;s time and our resources; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a decline in the ADS price. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Existing PRC laws
and regulations do not require us to have, nor do we currently, maintain liability insurance to cover product liability claims. We do not have business liability, or in particular, product liability insurance for each of our drug candidates. Any
litigation might result in substantial costs and diversion of resources. While we maintain liability insurance for certain clinical trials (which covers the patient human clinical trial liabilities
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">33 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
including, among others, bodily injury), this insurance may not fully cover our potential liabilities. Inability to obtain sufficient insurance coverage at an acceptable cost or otherwise to
protect against potential product liability claims could prevent or inhibit the commercialization of drugs we develop, alone or with our collaborators. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The research and development projects under our internal discovery programs are at an early stage of development. As a result, we are unable to predict if or
when we will successfully develop or commercialize any drug candidates under such programs. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our internal discovery programs are at an early
stage of development and will require significant investment and regulatory approvals prior to commercialization. We currently have no drug candidates beyond <FONT STYLE="white-space:nowrap">pre-clinical</FONT> trials under our internal discovery
programs. Each of our drug candidates will require additional clinical and preclinical development, management of clinical, preclinical and manufacturing activities, obtaining regulatory approval, obtaining manufacturing supply, building of a
commercial organization, substantial investment and significant marketing efforts before they generate any revenue from product sales. We are not permitted to market or promote any of our drug candidates before we receive regulatory approval from
the CFDA, the FDA or comparable regulatory authorities, and we may never receive such regulatory approval for any such drug candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We cannot be
certain that clinical development of any drug candidates from our internal discovery programs will be successful or that we will obtain regulatory approval or be able to successfully commercialize any of our drug candidates and generate revenue.
Success in preclinical testing does not ensure that clinical trials will be successful, and the clinical trial process may fail to demonstrate that our drug candidates are safe and effective for their proposed uses. Any such failure could cause us
to abandon further development of any one or more of our drug candidates and may delay development of other drug candidates. Any delay in, or termination of, our clinical trials will delay and possibly preclude the filing of any NDAs, with the CFDA,
the FDA or comparable regulatory authorities and, ultimately, our ability to commercialize our drug candidates and generate product revenue. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If
our manufacturing facilities are not approved by regulators, are damaged or destroyed or production at such facilities is otherwise interrupted, our business and prospects would be negatively affected. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In early 2017 we built a small molecule facility capable of supporting clinical and commercial production and have begun construction of a large molecule facility
capable of supporting clinical production of our drug candidates. The construction of the large molecule facility is expected to be completed in the first half of 2018. We intend to rely on these facilities for the manufacture of clinical and
commercial supply of some of our product candidates. Prior to being permitted to sell any drugs produced at these facilities the facilities will need to be inspected and approved by regulatory authorities. If either facility is not approved by
regulators or is damaged or destroyed, or otherwise subject to disruption, it would require substantial lead-time to replace our manufacturing capabilities. In such event, we would be forced to identify and rely partially or entirely on third-party
contract manufacturers for an indefinite period of time. Any new facility needed to replace an existing production facility would need to comply with the necessary regulatory requirements and be tailored to our production requirements and processes.
We also would need regulatory approvals before using any products manufactured at a new facility in clinical trials or selling any products that are ultimately approved. Any disruptions or delays at our facility or its failure to meet regulatory
compliance would impair our ability to develop and commercialize our product candidates, which would adversely affect our business and results of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">34 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to our dependence on third parties </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>We rely on third parties to conduct our preclinical and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain
regulatory approval for or commercialize our drug candidates and our business could be substantially harmed. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have relied upon and plan to
continue to rely upon third-party CROs to monitor and manage data for some of our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical and clinical trials, and control only certain aspects of their
activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our
regulatory responsibilities. We also rely on third parties to assist in conducting our preclinical studies in accordance with Good Laboratory Practices, or GLP, and the Administrative Regulations on Experimental Animals or the Animal Welfare Act
requirements. We and our CROs are required to comply with GCP regulations and guidelines enforced by the CFDA, and comparable foreign regulatory authorities for all of our drug candidates in clinical development. Regulatory authorities enforce these
GCP requirements through periodic inspections of trial sponsors, investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and
the CFDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory
authority will determine that any of our clinical trials comply with <FONT STYLE="white-space:nowrap">ICH-GCP</FONT> requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Failure to comply
with these regulations may require us to repeat preclinical and clinical trials, which would delay the regulatory approval process. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our CROs are not our
employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our <FONT STYLE="white-space:nowrap">on-going</FONT> clinical, nonclinical and
preclinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our
clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result, our
results of operations and the commercial prospects for our drug candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed or compromised. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Because we rely on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves risk that third parties may not perform to our standards, may not produce results
in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be
misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify and monitor our third-party providers. To the extent we are unable to identify and successfully manage the performance
of third-party service providers in the future, our business may be adversely affected. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or
that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we lose our
relationships with CROs, our drug development efforts could be delayed. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We rely on third-party vendors and CROs for some of our preclinical
studies and clinical trials related to our drug development efforts. Switching or adding additional CROs involves additional cost and requires </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">35 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
management time and focus. Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate
their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are
liquidated. Identifying, qualifying and managing performance of third-party service providers can be difficult, time-consuming and cause delays in our development programs. In addition, there is a natural transition period when a new CRO commences
work and the new CRO may not provide the same type or level of services as the original provider. If any of our relationships with our third-party CROs are terminated, we may not be able to enter into arrangements with alternative CROs or to do so
on commercially reasonable terms, and we may not be able to meet our desired clinical development timelines. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We have no experience manufacturing
our drug candidates on a large clinical or commercial scale and have built or just started building our manufacturing facilities. We may be dependent on third party manufacturers for the manufacture of our drug candidates as well as on third parties
for our supply chain, and if we experience problems with any of these third parties, the manufacture of our drug candidates or products could be delayed, which could harm our results of operations. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In early 2017 we built a small molecule facility capable of supporting clinical and commercial production and have begun construction of a large molecule facility
capable of supporting clinical production of our drug candidates. The construction of the large molecule facility is expected to be completed in the first half of 2018. If either of these two facilities is unable to meet our intended production
capacity in a timely fashion, we may have to engage a CMO for the production of clinical supplies of our drug candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, in order to
successfully commercialize our drug candidates, we will need to identify qualified CMOs for the scaled production of a commercial supply of certain of our drug candidates. The CMOs should be drug manufacturers holding GMP certificates with a scope
that can cover our drug registration candidates, and such CMO arrangement should be approved by the CFDA&#146;s provincial level branches. We have not yet identified suppliers to support scaled production. If we are unable to arrange for alternative
third-party manufacturing sources, or to do so on commercially reasonable terms or in a timely manner, or to obtain the CFDA approval for our CMO arrangement in a timely manner, we may not be able to complete development of our drug candidates, or
market or distribute them. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we were to rely on third-party manufacturers to manufacture our drug candidates, such reliance entails risks to which we
would not be subject to if we manufactured drug candidates or products ourselves, including reliance on the third party for regulatory compliance and quality assurance, the possibility of breach of the manufacturing agreement by the third party
because of factors beyond our control (including a failure to synthesize and manufacture our drug candidates or any products we may eventually commercialize in accordance with our specifications) and the possibility of termination or nonrenewal of
the agreement by the third party, based on its own business priorities, at a time that is costly or damaging to us. In addition, the CFDA and other regulatory authorities require that our drug candidates and any products that we may eventually
commercialize be manufactured according to cGMP standards. Any failure by our third-party manufacturers to comply with cGMP standards or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of drug
candidates in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of any of our drug candidates. In addition, such failure could be the basis for the CFDA to issue a warning or untitled letter, withdraw approvals for
drug candidates previously granted to us, or take other regulatory or legal action, including recall or seizure, total or partial suspension of production, suspension of ongoing clinical trials, refusal to approve pending applications or
supplemental applications, detention or product, refusal to permit the import or export of products, injunction, or imposing civil and criminal penalties. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">36 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any significant disruption in our potential supplier relationships could harm our business. We currently source key
materials from third parties, either directly through agreements with suppliers or indirectly through our manufacturers who have agreements with suppliers, as well as through our licensors. We anticipate that, in the near term, all key materials
will be sourced through third parties. There are a small number of suppliers for certain capital equipment and key materials that are used to manufacture some of our drugs. Such suppliers may not sell these key materials to us or our manufacturers
at the times we need them or on commercially reasonable terms. We currently do not have any agreements for the commercial production of these key materials. Any significant delay in the supply of a drug candidate or its key materials for an ongoing
clinical study could considerably delay completion of our clinical studies, product testing and potential regulatory approval of our drug candidates. If we or our manufacturers are unable to purchase these key materials after regulatory approval has
been obtained for our drug candidates, the commercial launch of our drug candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our drug candidates. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, because of the complex nature of our compounds, we or our manufacturers may not be able to manufacture our compounds at a cost or in quantities or in a
timely manner necessary to make commercially successful products. In addition, as our drug development pipeline increases and matures, we will have a greater need for clinical study and commercial manufacturing capacity. We have no experience
manufacturing pharmaceutical products on a commercial scale and some of our current suppliers will need to increase their scale of production to meet our projected needs for commercial manufacturing, the satisfaction of which on a timely basis may
not be met. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We depend on our licensors or patent owners of our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights to prosecute and
maintain patents and patent applications that are material to our business. Any failure by our licensors or such patent owners to effectively protect these patent rights could adversely impact our business and operations. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have licensed and sublicensed patent rights from third parties for some of our development programs, including niraparib from Tesaro, omadacycline from Paratek, <FONT
STYLE="white-space:nowrap">ZL-2301</FONT> from Bristol-Myers Squibb and <FONT STYLE="white-space:nowrap">ZL-2302</FONT> from Sanofi. As a licensee and sublicensee of third parties, we rely on these third parties to file and prosecute patent
applications and maintain patents and otherwise protect the licensed intellectual property under certain of our license agreements. In addition, we have not had and do not have primary control over these activities for certain of our patents or
patent applications and other intellectual property rights that we jointly own with certain of our licensors and <FONT STYLE="white-space:nowrap">sub-licensors.</FONT> We cannot be certain that these patents and patent applications have been or will
be prepared, filed, prosecuted or maintained by such third parties in compliance with applicable laws and regulations, in a manner consistent with the best interests of our business, or in a manner that will result in valid and enforceable patents
or other intellectual property rights that cover our drug candidates. If our licensors or such third parties fail to prepare, prosecute, or maintain such patent applications and patents, or lose rights to those patent applications or patents, the
rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our drug candidates that are subject of such licensed rights could be adversely affected. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or
defense of any claims asserting the invalidity or unenforceability of these patents. For example, under our agreement with Bristol-Myers Squibb for <FONT STYLE="white-space:nowrap">ZL-2301,</FONT> Bristol-Myers Squibb has the first right to enforce
the licensed patents in China, Hong Kong and Macau, subject to certain exceptions. In addition, with respect to the patent portfolio for omadacycline, which we <FONT STYLE="white-space:nowrap">sub-license</FONT> from Paratek, Paratek has the first
right to enforce such patent portfolio in territories outside of China, Hong Kong, Macau and Taiwan. Similarly, with respect to the patent portfolio for niraparib, which we <FONT STYLE="white-space:nowrap">sub-license</FONT> from Tesaro, we have the
first right to enforce such patent portfolio within China, Hong Kong and Macau. However, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">37 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Tesaro maintains the right to enforce such patent portfolio in all other territories or, if we fail to bring an action within 90 days within China, Hong Kong or Macau, Tesaro can control such
enforcement actions in those areas as well. In the case where Tesaro controls such enforcement actions, although we have rights to consult with Tesaro on such actions within China, Hong Kong and Macau, rights granted by Tesaro under niraparib to
another licensee, such as Janssen Biotech, Inc. to whom Tesaro has granted an exclusive right to develop niraparib for the treatment of prostate cancer, could potentially influence Tesaro&#146;s interests in the exercise of its prosecution,
maintenance and enforcement rights in a manner that may favor the interests of such other licensee as compared with us, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Even if we are permitted to pursue the enforcement or defense of our licensed and <FONT STYLE="white-space:nowrap">sub-licensed</FONT> patents, we will
require the cooperation of our licensors and any applicable patent owners and such cooperation may not be provided to us. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such
patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual
property that we may need to operate our business. If we lose any of our licensed intellectual property, our right to develop and commercialize any of our drug candidates that are subject of such licensed rights could be adversely affected.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Other risks and risks related to doing business in China </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>If we fail to comply with environmental, health and safety laws and regulations of the PRC, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the
success of our business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory
procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations primarily occur in China and involve the use of hazardous materials, including chemical materials. Our operations also produce
hazardous waste products. We are therefore subject to PRC laws and regulations concerning the discharge of waste water, gaseous waste and solid waste during our processes of research and development of drugs. We engage competent third party
contractors for the transfer and disposal of these materials and wastes. We may not at all times comply fully with environmental regulations. Any violation of these regulations may result in substantial fines, criminal sanctions, revocations of
operating permits, shutdown of our facilities and obligation to take corrective measures. We cannot completely eliminate the risk of contamination or injury from these materials and wastes. In the event of contamination or injury resulting from the
use or discharge of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil, administrative or criminal fines and penalties.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Although we maintain workers&#146; compensation insurance to cover costs and expenses incurred due to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">on-the-job</FONT></FONT> injuries to our employees and third party liability insurance for injuries caused by unexpected seepage, pollution or contamination, such insurance may not provide adequate coverage against
potential liabilities. Furthermore, the PRC government may take steps towards the adoption of more stringent environmental regulations. Due to the possibility of unanticipated regulatory or other developments, the amount and timing of future
environmental expenditures may vary substantially from those currently anticipated. If there is any unanticipated change in the environmental regulations, we may need to incur substantial capital expenditures to install, replace, upgrade or
supplement our manufacturing facility and equipment or make operational changes to limit any adverse impact or potential adverse impact on the environment in order to comply with new environmental protection laws and regulations. If such costs
become prohibitively expensive, we may be forced to cease certain aspects of our business operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">38 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The PRC&#146;s economic, political and social conditions, as well as governmental policies, could affect the
business environment and financial markets in China, our ability to operate our business, our liquidity and our access to capital. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Substantially
all of our operations are conducted in China. Accordingly, our business, results of operations, financial condition and prospects may be influenced to a significant degree by economic, political, legal and social conditions in China. China&#146;s
economy differs from the economies of developed countries in many respects, including with respect to the amount of government involvement, level of development, growth rate, control of foreign exchange and allocation of resources. While the PRC
economy has experienced significant growth over the past 30&nbsp;years, growth has been uneven across different regions and among various economic sectors of China. The PRC government has implemented various measures to encourage economic
development and guide the allocation of resources. Some of these measures may benefit the overall PRC economy, but may have a negative effect on us. For example, our financial condition and results of operations may be adversely affected by
government control over capital investments or changes in tax regulations that are currently applicable to us. In addition, in the past the PRC government implemented certain measures, including interest rate increases, to control the pace of
economic growth. These measures may cause decreased economic activity in China, which may adversely affect our business and results of operation. More generally, if the business environment in China deteriorates from the perspective of domestic or
international investment, our business in China may also be adversely affected. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Uncertainties with respect to the PRC legal system and changes in
laws, regulations and policies in China could materially and adversely affect us. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We conduct our business primarily through our subsidiaries in
China. PRC laws and regulations govern our operations in China. Our subsidiaries are generally subject to laws and regulations applicable to foreign investments in China, which may not sufficiently cover all of the aspects of our economic activities
in China. In addition, the implementation of laws and regulations may be in part based on government policies and internal rules that are subject to the interpretation and discretion of different government agencies (some of which are not published
on a timely basis or at all) that may have a retroactive effect. As a result, we may not always be aware of any potential violation of these policies and rules. Such unpredictability regarding our contractual, property and procedural rights could
adversely affect our business and impede our ability to continue our operations. Furthermore, since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be more
difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy than in more developed legal systems. These uncertainties could materially and adversely affect our business and results of
operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In January 2015, the Ministry of Commerce of the PRC, or the MOFCOM, published a discussion draft of the proposed Foreign Investment Law.
The MOFCOM has solicited comments on this draft and substantial uncertainties exist with respect to its enactment timetable, interpretation and implementation. If enacted as proposed, the Foreign Investment Law may materially impact our current
corporate governance practice and business operations in many aspects and may increase our compliance costs. For instance, the proposed Foreign Investment Law would impose stringent ad hoc and periodic information reporting requirements on foreign
investors and the applicable foreign invested entities. Depending on the seriousness of the circumstances, non-compliance with the information reporting obligations, concealment of information or&nbsp;providing misleading or false information could
result in monetary fines or criminal charges. In addition, the draft Foreign Investment Law embodies an expected PRC regulation trend of rationalizing the foreign investment regulatory regime in line with prevailing international practice and the
legislative efforts to unify the corporate legal requirements for both foreign and domestic investments. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">39 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, the CFDA&#146;s recent reform of the drug and approval system may face implementation challenges. The
timing and full impact of such reforms is uncertain and could prevent us from commercializing our drug candidates in a timely manner. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, any
administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act, or FCPA, and Chinese <FONT STYLE="white-space:nowrap">anti-corruption</FONT>
laws, and any determination that we have violated these laws could have a material adverse effect on our business or our reputation. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Following
this offering, we will be subject to the FCPA. The FCPA generally prohibits us from making improper payments to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> officials for the purpose of obtaining or retaining business. We are also subject to the
anti-bribery laws of other jurisdictions, particularly China. As our business expands, the applicability of the FCPA and other anti-bribery laws to our operations will increase. Our procedures and controls to monitor anti-bribery compliance may fail
to protect us from reckless or criminal acts committed by our employees or agents. If we, due to either our own deliberate or inadvertent acts or those of others, fail to comply with applicable anti-bribery laws, our reputation could be harmed and
we could incur criminal or civil penalties, other sanctions and/or significant expenses, which could have a material adverse effect on our business, including our financial condition, results of operations, cash flows and prospects. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Restrictions on currency exchange may limit our ability to receive and use financing in foreign currencies, including proceeds from this offering,
effectively. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our PRC subsidiaries&#146; ability to obtain foreign exchange is subject to significant foreign exchange controls and, in the case
of transactions under the capital account, requires the approval of and/or registration with PRC government authorities, including the state administration of foreign exchange, or SAFE. In particular, if we finance our PRC subsidiaries by means of
foreign debt from us or other foreign lenders, the amount is not allowed to, among other things, exceed the statutory limits and such loans must be registered with the local counterpart of the SAFE. If we finance our PRC subsidiaries by means of
additional capital contributions, the amount of these capital contributions must first be approved or filed by the relevant government approval authority. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the light of the various requirements imposed by PRC regulations on loans to, and direct investment in, PRC entities by offshore holding companies, we cannot
assure you that we will be able to complete the necessary government registrations or obtain the necessary government approvals on timely basis, if at all, with respect to future loans or capital contributions by us to our PRC subsidiaries. If we
fail to complete such registrations or obtain such approval, our ability to use the proceeds we receive from this offering and to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially and adversely affect
our liquidity and our ability to fund and expand our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>PRC regulations relating to the establishment of offshore special purpose companies
by PRC residents may subject our PRC resident beneficial owners or our wholly foreign-owned subsidiaries in China to liability or penalties, limit our ability to inject capital into these subsidiaries, limit these subsidiaries&#146; ability to
increase their registered capital or distribute profits to us, or may otherwise adversely affect us. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In 2014, SAFE promulgated the Circular on
Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#146; Offshore Investment and Financing and Roundtrip Investment through Special Purpose Vehicles, or SAFE Circular 37. SAFE Circular 37 requires PRC residents to register
with local branches of SAFE or competent banks designated by SAFE in connection with their direct establishment or indirect control of an offshore entity, for the purpose of overseas investment and financing, with such PRC residents&#146; legally
owned assets or equity </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">40 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
interests in domestic enterprises or offshore assets or interests, referred to in SAFE Circular 37 as a &#147;special purpose vehicle.&#148; The term &#147;control&#148; under SAFE Circular 37 is
broadly defined as the operation rights, beneficiary rights or decision-making rights acquired by the PRC residents in the offshore special purpose vehicles or PRC companies by such means as acquisition, trust, proxy, voting rights, repurchase,
convertible bonds or other arrangements. SAFE Circular 37 further requires amendment to the registration in the event of any changes with respect to the basic information of or any significant changes with respect to the special purpose vehicle. If
the shareholders of the offshore holding company who are PRC residents do not complete their registration with the local SAFE branches, the PRC subsidiaries may be prohibited from distributing their profits and proceeds from any reduction in
capital, share transfer or liquidation to the offshore company, and the offshore company may be restricted in its ability to contribute additional capital to its PRC subsidiaries. Moreover, failure to comply with SAFE registration and amendment
requirements described above could result in liability under PRC law for evasion of applicable foreign exchange restrictions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To our knowledge, there
are no PRC residents who hold direct or indirect interests in our company, and we will request PRC residents who we know hold direct or indirect interests in our company, if any, to make the necessary applications, filings and amendments as required
under SAFE Circular 37 and other related rules. However, we may not be informed of the identities of all the PRC residents holding direct or indirect interest in our company, and we cannot provide any assurance that these PRC residents will comply
with our request to make or obtain any applicable registrations or comply with other requirements under SAFE Circular 37 or other related rules. The failure or inability of our PRC resident shareholders to comply with the registration procedures set
forth in these regulations may subject us to fines and legal sanctions, restrict our cross-border investment activities, limit the ability of our wholly foreign-owned subsidiaries in China to distribute dividends and the proceeds from any reduction
in capital, share transfer or liquidation to us, and we may also be prohibited from injecting additional capital into these subsidiaries. Moreover, failure to comply with the various foreign exchange registration requirements described above could
result in liability under PRC law for circumventing applicable foreign exchange restrictions. As a result, our business operations and our ability to distribute profits to you could be materially and adversely affected. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>PRC regulations establish complex procedures for some acquisitions of Chinese companies by foreign investors, which could make it more difficult for us to
pursue growth through acquisitions in China. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">PRC regulations and rules concerning mergers and acquisitions including the Regulations on Mergers
and Acquisitions of Domestic Companies by Foreign Investors, or the M&amp;A Rules, and other recently adopted regulations and rules with respect to mergers and acquisitions established additional procedures and requirements that could make merger
and acquisition activities by foreign investors more time consuming and complex. For example, the M&amp;A Rules require that the MOFCOM be notified in advance of any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">change-of-control</FONT></FONT> transaction in which a foreign investor takes control of a PRC domestic enterprise, if (i)&nbsp;any important industry is concerned, (ii)&nbsp;such
transaction involves factors that have or may have impact on the national economic security, or (iii)&nbsp;such transaction will lead to a change in control of a domestic enterprise which holds a famous trademark or PRC time-honored brand. Moreover,
according to the Anti-Monopoly Law of PRC promulgated on August&nbsp;30, 2007 and the Provisions on Thresholds for Prior Notification of Concentrations of Undertakings, or the Prior Notification Rules issued by the State Council in August 2008, the
concentration of business undertakings by way of mergers, acquisitions or contractual arrangements that allow one market player to take control of or to exert decisive impact on another market player must also be notified in advance to the MOFCOM
when the threshold is crossed and such concentration shall not be implemented without the clearance of prior notification. In addition, the Regulations on Implementation of Security Review System for the Merger and Acquisition of Domestic Enterprise
by Foreign Lenders, or the Security Review Rules issued by the MOFCOM that became effective in September 2011 specify that mergers and acquisitions by foreign investors that raise &#147;national defense and security&#148; concerns and mergers and
acquisitions through which foreign investors may </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">41 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
acquire the de facto control over domestic enterprises that raise &#147;national security&#148; concerns are subject to strict review by the MOFCOM, and the rules prohibit any activities
attempting to bypass a security review by structuring the transaction through, among other things, trusts, entrustment or contractual control arrangements. In the future, we may grow our business by acquiring complementary businesses. Complying with
the requirements of the above-mentioned regulations and other relevant rules to complete such transactions could be time consuming, and any required approval processes, including obtaining approval from the MOFCOM or its local counterparts may delay
or inhibit our ability to complete such transactions. It is unclear whether our business would be deemed to be in an industry that raises &#147;national defense and security&#148; or &#147;national security&#148; concerns. However, the MOFCOM or
other government agencies may publish explanations in the future determining that our business is in an industry subject to the security review, in which case our future acquisitions in the PRC, including those by way of entering into contractual
control arrangements with target entities, may be closely scrutinized or prohibited. Our ability to expand our business or maintain or expand our market share through future acquisitions would as such be materially and adversely affected.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our business benefits from certain financial incentives and discretionary policies granted by local governments. Expiration of, or changes to,
these incentives or policies would have an adverse effect on our results of operations. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the past, local governments in China granted certain
financial incentives from time to time to our PRC subsidiaries as part of their efforts to encourage the development of local businesses. We received approximately $2.41&nbsp;million and $0.36&nbsp;million in financial incentives from local
governments in China relating to our business operations in 2016 and 2015, respectively. We also received approximately $0.37&nbsp;million in financial incentives from local governments in Australia as part of its tax incentive program in 2016. The
timing, amount and criteria of government financial incentives are determined within the sole discretion of the local government authorities and cannot be predicted with certainty before we actually receive any financial incentive. We generally do
not have the ability to influence local governments in making these decisions. Local governments may decide to reduce or eliminate incentives at any time. In addition, some of the government financial incentives are granted on a project basis and
subject to the satisfaction of certain conditions, including compliance with the applicable financial incentive agreements and completion of the specific project therein. We cannot guarantee that we will satisfy all relevant conditions, and if we do
so we may be deprived of the relevant incentives. We cannot assure you of the continued availability of the government incentives currently enjoyed by us. Any reduction or elimination of incentives would have an adverse effect on our results of
operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax
consequences to us and our <FONT STYLE="white-space:nowrap">non-PRC</FONT> shareholders or ADS holders. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The PRC Enterprise Income Tax Law, or
the EIT Law and the Regulation on the Implementation of the EIT Law, effective as of January&nbsp;1, 2008, define the term &#147;de facto management bodies&#148; as &#147;bodies that substantially carry out comprehensive management and control on
the business operation, employees, accounts and assets of enterprises.&#148; Under the EIT Law, an enterprise incorporated outside of PRC whose &#147;de facto management bodies&#148; are located in PRC is considered a &#147;resident enterprise&#148;
and will be subject to a uniform 25% enterprise income tax, or EIT, rate on its global income. On April&nbsp;22, 2009, PRC&#146;s State Administration of Taxation, or the SAT, in the Notice Regarding the Determination of <FONT
STYLE="white-space:nowrap">Chinese-Controlled</FONT> <FONT STYLE="white-space:nowrap">Offshore-Incorporated</FONT> Enterprises as PRC Tax Resident Enterprises on the Basis of De Facto Management Bodies, or SAT Circular&nbsp;82, further specified
certain criteria for the determination of what constitutes &#147;de facto management bodies.&#148; If all of these criteria are met, the relevant foreign enterprise may be regarded to have its &#147;de facto management bodies&#148; located in China
and therefore be considered a PRC resident enterprise. These criteria include: (i)&nbsp;the enterprise&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operational management is primarily exercised in
China; (ii)&nbsp;decisions relating to the enterprise&#146;s </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">42 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
financial and human resource matters are made or subject to approval by organizations or personnel in China; (iii)&nbsp;the enterprise&#146;s primary assets, accounting books and records, company
seals, and board and shareholders&#146; meeting minutes are located or maintained in China; and (iv)&nbsp;50% or more of voting board members or senior executives of the enterprise habitually reside in China. Although SAT Circular&nbsp;82 only
applies to foreign enterprises that are <FONT STYLE="white-space:nowrap">majority-owned</FONT> and controlled by PRC enterprises, not those owned and controlled by foreign enterprises or individuals, the determining criteria set forth in SAT
Circular&nbsp;82 may be adopted by the PRC tax authorities as the test for determining whether the enterprises are PRC tax residents, regardless of whether they are <FONT STYLE="white-space:nowrap">majority-owned</FONT> and controlled by PRC
enterprises. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that neither Zai Lab Limited nor any of our subsidiaries outside of China is a PRC resident enterprise for PRC tax purposes.
However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities, and uncertainties remain with respect to the interpretation of the term &#147;de facto management body.&#148; If the PRC tax authorities
determine that Zai Lab Limited or any of its subsidiaries outside of China is a PRC resident enterprise for enterprise income tax purposes, that entity would be subject to a 25% enterprise income tax on its global income. If such entity derives
income other than dividends from its wholly-owned subsidiaries in China, a 25% EIT on its global income may increase our tax burden. Dividends paid to a PRC resident enterprise from its wholly-owned subsidiaries in China may be regarded as <FONT
STYLE="white-space:nowrap">tax-exempt</FONT> income if such dividends are deemed to be &#147;dividends between qualified PRC resident enterprises&#148; under the EIT Law and its implementation rules. However, we cannot assure you that such dividends
will not be subject to PRC withholding tax, as the PRC tax authorities, which enforce the withholding tax, have not yet issued relevant guidance. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In
addition, if Zai Lab Limited is classified as a PRC resident enterprise for PRC tax purposes, we may be required to withhold tax at a rate of 10% from dividends we pay to our shareholders, including the holders of our ADSs, that are <FONT
STYLE="white-space:nowrap">non-resident</FONT> enterprises. In addition, <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprise shareholders (including our ADS holders) may be subject to a 10% PRC withholding tax on gains realized on the
sale or other disposition of ADSs or ordinary shares, if such income is treated as sourced from within China. Furthermore, gains derived by our <FONT STYLE="white-space:nowrap">non-PRC</FONT> individual shareholders from the sale of our shares and
ADSs may be subject to a 20% PRC withholding tax. It is unclear whether our non-PRC individual shareholders (including our ADS holders) would be subject to any PRC tax (including withholding tax) on dividends received by such non-PRC individual
shareholders in the event we are determined to be a PRC resident enterprise. If any PRC tax were to apply to such dividends, it would generally apply at a rate of 20%. The PRC tax liability may be reduced under applicable tax treaties. However, it
is unclear whether our <FONT STYLE="white-space:nowrap">non-PRC</FONT> shareholders would be able to claim the benefits of any tax treaties between their country of tax residence and the PRC in the event that Zai Lab Limited is treated as a PRC
resident enterprise. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may rely on dividends and other distributions on equity paid by our PRC subsidiaries to fund any cash and financing
requirements we may have, and any limitation on the ability of our PRC subsidiaries to make payments to us could have a material and adverse effect on our ability to conduct our business. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a holding company, and we may rely on dividends and other distributions on equity paid by our PRC subsidiaries for our cash and financing requirements,
including the funds necessary to pay dividends and other cash distributions to our shareholders or to service any debt we may incur. If any of our PRC subsidiaries incur debt on its own behalf in the future, the instruments governing the debt may
restrict its ability to pay dividends or make other distributions to us. Under PRC laws and regulations, our PRC subsidiaries, each of which is a wholly foreign-owned enterprise may pay dividends only out of its respective accumulated profits as
determined in accordance with PRC accounting standards and regulations. In addition, a wholly foreign-owned enterprise is required to set aside at least 10% of its accumulated <FONT STYLE="white-space:nowrap">after-tax</FONT> profits each year, if
any, to fund a certain statutory reserve fund, until the aggregate amount of such fund reaches 50% of its registered capital. Such reserve funds cannot be distributed to us as dividends. At its discretion, a wholly foreign-owned enterprise
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">43 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
may allocate a portion of its <FONT STYLE="white-space:nowrap">after-tax</FONT> profits based on PRC accounting standards to an enterprise expansion fund, or a staff welfare and bonus fund.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our PRC subsidiaries generate primarily all of their revenue in renminbi, which is not freely convertible into other currencies. As result, any
restriction on currency exchange may limit the ability of our PRC subsidiaries to use their Renminbi revenues to pay dividends to us. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In response to the
persistent capital outflow in China and renminbi&#146;s depreciation against U.S. dollar in the fourth quarter of 2016, the PBOC and the SAFE have promulgated a series of capital control measure over recent months, including stricter vetting
procedures for domestic companies to remit foreign currency for overseas investments, dividends payments and shareholder loan repayments. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The PRC
government may continue to strengthen its capital controls, and more restrictions and substantial vetting process may be put forward by SAFE for cross-border transactions falling under both the current account and the capital account. Any limitation
on the ability of our PRC subsidiaries to pay dividends or make other kinds of payments to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends, or
otherwise fund and conduct our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We and our shareholders face uncertainties in the PRC with respect to indirect transfers of equity
interests in PRC resident enterprises. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The indirect transfer of equity interest in PRC resident enterprises by a
<FONT STYLE="white-space:nowrap">non-PRC</FONT> resident enterprise, or Indirect Transfer, is potentially subject to income tax in China at a rate of 10% on the gain if such transfer is considered as not having a commercial purpose and is carried
out for tax avoidance. The SAT has issued several rules and notices to tighten the scrutiny over acquisition transactions in recent years. SAT Circular 7 sets out the scope of Indirect Transfers, which includes any changes in the shareholder&#146;s
ownership of a foreign enterprise holding PRC assets directly or indirectly in the course of a group&#146;s overseas restructuring, and the factors to consider in determining whether an Indirect Transfer has a commercial purpose. An Indirect
Transfer satisfying all the following criteria will be deemed to lack a bona fide commercial purpose and be taxable under PRC laws: (i) 75% or more of the equity value of the intermediary enterprise being transferred is derived directly or
indirectly from the PRC taxable assets; (ii)&nbsp;at any time during the <FONT STYLE="white-space:nowrap">one-year</FONT> period before the indirect transfer, 90% or more of the asset value of the intermediary enterprise (excluding cash) is
comprised directly or indirectly of investments in China, or 90% or more of its income is derived directly or indirectly from China; (iii)&nbsp;the functions performed and risks assumed by the intermediary enterprise and any of its subsidiaries that
directly or indirectly hold the PRC taxable assets are limited and are insufficient to prove their economic substance; and (iv)&nbsp;the <FONT STYLE="white-space:nowrap">non-PRC</FONT> tax payable on the gain derived from the indirect transfer of
the PRC taxable assets is lower than the potential PRC income tax on the direct transfer of such assets. Nevertheless, a <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprise&#146;s buying and selling shares or ADSs of the same listed
foreign enterprise on the public market will fall under the safe harbor available under SAT Circular 7 and will not be subject to PRC tax pursuant to SAT Circular 7. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">However, as these rules&nbsp;and notices are relatively new and there is a lack of clear statutory interpretation, we face uncertainties regarding the reporting required for and impact on future private equity
financing transactions, share exchange or other transactions involving the transfer of shares in our company by investors that are <FONT STYLE="white-space:nowrap">non-PRC</FONT> resident enterprises, or the sale or purchase of shares in other <FONT
STYLE="white-space:nowrap">non-PRC</FONT> resident companies or other taxable assets by us. For example, the PRC tax authorities may consider that our current offering involves an indirect change of shareholding in our PRC subsidiaries and therefore
it may be regarded as an Indirect Transfer under SAT Circular 7. Although we believe no SAT Circular 7 reporting is required on the basis that the current offering has commercial purposes and is not conducted for tax avoidance, the PRC tax
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">44 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
authorities may pursue us to report under SAT Circular 7 and request that we and our PRC subsidiaries assist in the filing. As a result, we and our subsidiaries may be required to expend
significant resources to provide assistance and comply with SAT Circular 7, or establish that we or our <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprises should not be subject to tax under SAT Circular 7, for the current offering or
other transactions, which may have an adverse effect on our and their financial condition and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Any failure to comply with PRC regulations regarding the registration requirements for our employee equity incentive plans may subject us to fines and other
legal or administrative sanctions, which could adversely affect our business, financial condition and results of operations. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In
February&nbsp;2012, the SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plans of Overseas Publicly Listed Companies, or the Stock Option Rules. In
accordance with the Stock Option Rules and relevant rules and regulations, PRC citizens or <FONT STYLE="white-space:nowrap">non-PRC</FONT> citizens residing in China for a continuous period of not less than one year, who participate in any stock
incentive plan of an overseas publicly listed company, subject to a few exceptions, are required to register with SAFE through a domestic qualified agent, which could be a PRC subsidiary of such overseas listed company, and complete certain
procedures. We and our employees who are PRC citizens or who reside in China for a continuous period of not less than one year and who participate in our stock incentive plan will be subject to such regulation. We plan to assist our employees to
register their share options or shares. However, any failure of our PRC individual beneficial owners and holders of share options or shares to comply with the SAFE registration requirements may subject them to fines and legal sanctions and may limit
the ability of our PRC subsidiaries to distribute dividends to us. We also face regulatory uncertainties that could restrict our ability to adopt additional incentive plans for our directors and employees under PRC law. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Proceedings brought by the SEC against the Big Four <FONT STYLE="white-space:nowrap">PRC-based</FONT> accounting firms, including our independent registered
public accounting firm, could result in our inability to file future financial statements in compliance with the requirements of the Exchange Act. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In December 2012, the SEC instituted administrative proceedings under Rule 102(e)(1)(iii) of the SEC&#146;s Rules of Practice against the Big Four <FONT
STYLE="white-space:nowrap">PRC-based</FONT> accounting firms, including our independent registered public accounting firm, alleging that these firms had violated U.S. securities laws and the SEC&#146;s rules and regulations thereunder by failing to
provide to the SEC the firms&#146; audit work papers with respect to certain <FONT STYLE="white-space:nowrap">PRC-based</FONT> companies under the SEC&#146;s investigation. On January 22, 2014, the administrative law judge, or the ALJ, presiding
over the matter rendered an initial decision that each of the firms had violated the SEC&#146;s rules of practice by failing to produce audit workpapers to the SEC. The initial decision censured each of the firms and barred them from practicing
before the SEC for a period of six months. On February 12, 2014, the Big Four <FONT STYLE="white-space:nowrap">PRC-based</FONT> accounting firms appealed the ALJ&#146;s initial decision to the SEC. On February 6, 2015, the four China-based
accounting firms each agreed to a censure and to pay a fine to the SEC to settle the dispute and avoid suspension of their ability to practice before the SEC and audit U.S.-listed companies. The settlement required the firms to follow detailed
procedures and to seek to provide the SEC with access to Chinese firms&#146; audit documents via the CSRC, in response to future document requests by the SEC made through the CSRC. If the Big Four <FONT STYLE="white-space:nowrap">PRC-based</FONT>
accounting firms fail to comply with the documentation production procedures that are in the settlement agreement or if there is a failure of the process between the SEC and the CSRC, the SEC could restart the proceedings against the firms.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event that the SEC restarts the administrative proceedings, depending upon the final outcome, listed companies in the United States with major
PRC operations may find it difficult or impossible to retain auditors in respect of their operations in the PRC, which could result in financial statements being determined to not be in compliance with the requirements of the Exchange Act, including
possible delisting. Moreover, any negative news about the proceedings against these audit firms may cause investor uncertainty regarding <FONT STYLE="white-space:nowrap">PRC-based,</FONT> United States-listed companies and the market price of our
ADSs may be adversely affected. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">45 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the accounting firms are subject to additional remedial measures, our ability to file our financial statements in
compliance with SEC requirements could be impacted. A determination that we have not timely filed financial statements in compliance with SEC requirements would substantially reduce or effectively terminate the trading of our ADSs in the United
States. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Risks related to intellectual property </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we are unable to obtain and maintain patent protection for our drug candidates through intellectual property rights, or if the scope of such intellectual
property rights obtained is not sufficiently broad, third parties may compete directly against us. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our success depends, in part, on our ability
to protect our drug candidates from competition by obtaining, maintaining and enforcing our intellectual property rights, including patent rights. We seek to protect the drug candidates and technology that we consider commercially important by
filing PRC and international patent applications, relying on trade secrets or pharmaceutical regulatory protection or employing a combination of these methods. We also seek to protect our proprietary position by
<FONT STYLE="white-space:nowrap">in-licensing</FONT> intellectual property relating to our technology and drug candidates. We do not own or exclusively license any issued patents with respect to certain of our drug candidates in all territories in
which we plan to commercialize our drug candidates. For example, we do not own or exclusively license any issued patents covering niraparib in Hong Kong and Macau. Additionally, we do not own or exclusively license any issued patents covering
ZL-2302 in the PRC, but we do in-license a pending patent application relating to ZL-2302 in the PRC. However, we cannot predict whether such patent application or any of our other owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> pending
patent applications will result in the issuance of any patents that effectively protect our drug candidates. If we or our licensors are unable to obtain or maintain patent protection with respect to our drug candidates and technology we develop, our
business, financial condition, results of operations, and prospects could be materially harmed. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The patent prosecution process is expensive,
time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, our license and intellectual property-related
agreements may not provide us with exclusive rights to use our <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property rights relating to the applicable drug candidates in all relevant fields of use and in all territories in which
we may wish to develop or commercialize our technology and products in the future. For example, under our agreements with Tesaro for niraparib, Paratek for omadacycline and Bristol-Myers Squibb for <FONT STYLE="white-space:nowrap">ZL-2301,</FONT>
our exclusive licenses are limited to China, Hong Kong, Macau and, in the case of our agreement for omadacycline, Taiwan. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in all such
fields and territories. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Patents may be invalidated and patent applications, including our in-licensed patent application relating to ZL-2302, may not be
granted for a number of reasons, including known or unknown prior art, deficiencies in the patent application or the lack of novelty of the underlying invention or technology. It is also possible that we will fail to identify patentable aspects of
our research and development output in time to obtain patent protection. Although we enter into <FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to confidential or patentable aspects
of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and any other third parties, any of these parties may breach such agreements and
disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent
applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases, not at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed
in our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or pending patent applications or that we or our licensors were the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">46 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
first to file for patent protection of such inventions. Furthermore, the PRC and, recently, the United States have adopted the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system under which whoever first files a patent application will be awarded the patent if all other patentability requirements are met. Under
the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> system, third parties may be granted a patent relating to a technology, which we invented. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, under PRC Patent Law, any organization or individual that applies for a patent in a foreign country for an invention or utility model accomplished in China is required to report to the State
Intellectual Property Office, or SIPO, for confidentiality examination. Otherwise, if an application is later filed in China, the patent right will not be granted. Moreover, even if patents do grant from any of the applications, the grant of a
patent is not conclusive as to its scope, validity or enforceability. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The coverage claimed in a patent application can be significantly reduced before
the patent is issued, and its scope can be reinterpreted after issuance. Even if patent applications we license or own currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection,
prevent competitors or other third parties from competing with us, or otherwise provide us with any competitive advantage. In addition, the patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex
legal and factual questions, and has been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent
offices in the PRC, United States and abroad. We and our licensors may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or USPTO, or become involved in opposition, derivation,
revocation, <FONT STYLE="white-space:nowrap">re-examination,</FONT> <FONT STYLE="white-space:nowrap">post-grant</FONT> and <I>inter partes</I> review, or interference proceedings or similar proceedings in foreign jurisdictions challenging our patent
rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent rights, allow third
parties to commercialize our technology or drug candidates and compete directly with us without payment to us, or result in our inability to manufacture or commercialize drug candidates without infringing, misappropriating or otherwise violating <FONT
STYLE="white-space:nowrap">third-party</FONT> patent rights. Moreover, we, or one of our licensors, may have to participate in interference proceedings declared by the USPTO to determine priority of invention or in
<FONT STYLE="white-space:nowrap">post-grant</FONT> challenge proceedings, such as oppositions in a foreign patent office, that challenge the priority of our or our licensor&#146;s invention or other features of patentability of our owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications. Such challenges may result in loss of patent rights, loss of exclusivity, or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our
ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and drug candidates. Such proceedings also may result in substantial costs and
require significant time from our scientists and management, even if the eventual outcome is favorable to us. Consequently, we do not know whether any of our technology or drug candidates will be protectable or remain protected by valid and
enforceable patents. Our competitors or other third parties may be able to circumvent our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents by developing similar or alternative technologies or products in a <FONT
STYLE="white-space:nowrap">non-infringing</FONT> manner. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, the terms of patents are finite. The patents we own or <FONT
STYLE="white-space:nowrap">in-license</FONT> and the patents that may issue from our currently pending owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications generally have a <FONT STYLE="white-space:nowrap">20-year</FONT>
protection period starting from such patents and patent applications&#146; earliest filing date. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such drug candidates
might expire before or shortly after such drug candidates are commercialized. As a result, our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications may not provide us with sufficient rights to exclude others
from commercializing products similar or identical to ours. Moreover, some of our patents and patent applications are, and may in the future be, <FONT STYLE="white-space:nowrap">co-owned</FONT> with third parties. If we are unable to obtain an
exclusive license to any such third party <FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">47 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
in such patents or patent applications, such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including our competitors, and our
competitors could market competing products and technology. In addition, we may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> of our patents in order to enforce such patents against third parties, and such
cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents could be found invalid or unenforceable if challenged in court or before the USPTO or
comparable foreign authority. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We or our licensors may become involved in patent litigation against third parties to enforce our owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patent rights, to invalidate patents held by such third parties, or to defend against such claims. A court may refuse to stop the other party from using the technology at issue on the grounds that our
owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents do not cover the <FONT STYLE="white-space:nowrap">third-party</FONT> technology in question. Further, such third parties could counterclaim that we infringe, misappropriate or
otherwise violate their intellectual property or that a patent we or our licensors have asserted against them is invalid or unenforceable. In patent litigation, defendant counterclaims challenging the validity, enforceability or scope of asserted
patents are commonplace and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. In addition, third parties may initiate legal proceedings before administrative bodies in the United States or
abroad, even outside the context of litigation, against us or our licensors with respect to our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> intellectual property to assert such challenges to such intellectual property rights. Such
mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> <I>inter partes </I>review, post-grant review, interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition
proceedings). Such proceedings could result in revocation, cancellation or amendment to our patents in such a way that they no longer cover and protect our drug candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The outcome of any such proceeding is generally unpredictable. Grounds for a validity challenge could be, among other things, an alleged failure to meet any of several statutory requirements, including lack of
novelty, obviousness, lack of written description or <FONT STYLE="white-space:nowrap">non-enablement.</FONT> Grounds for an unenforceability assertion could be, among other things, an allegation that someone connected with prosecution of the patent
withheld relevant information or made a misleading statement during prosecution. It is possible that prior art of which we and the patent examiner were unaware during prosecution exists, which could render our patents invalid. Moreover, it is also
possible that prior art may exist that we are aware of but do not believe is relevant to our current or future patents, but that could nevertheless be determined to render our patents invalid. Even if we are successful in defending against such
challenges, the cost to us of any patent litigation or similar proceeding could be substantial, and it may consume significant management and other personnel time. We do not maintain insurance to cover intellectual property infringement,
misappropriation or violation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">An adverse result in any litigation or other intellectual property proceeding could put one or more of our patents at
risk of being invalidated, rendered unenforceable or interpreted narrowly. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability of our patents covering one or more of our drug candidates, we would lose at least
part, and perhaps all, of the patent protection covering such drug candidates. Competing drugs may also be sold in other countries in which our patent coverage might not exist or be as strong. If we lose a foreign patent lawsuit, alleging our
infringement of a competitor&#146;s patents, we could be prevented from marketing our drugs in one or more foreign countries. Any of these outcomes would have a materially adverse effect on our business, financial condition, results of operations
and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may not be able to protect our intellectual property in the PRC. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The validity, enforceability and scope of protection available under the relevant intellectual property laws in the PRC are uncertain and still evolving.
Implementation and enforcement of PRC intellectual property-related laws </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">48 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
have historically been deficient and ineffective. Accordingly, intellectual property and confidentiality legal regimes in China may not afford protection to the same extent as in the United
States or other countries. Policing unauthorized use of proprietary technology is difficult and expensive, and we may need to resort to litigation to enforce or defend patents issued to us or to determine the enforceability, scope and validity of
our proprietary rights or those of others. The experience and capabilities of PRC courts in handling intellectual property litigation varies, and outcomes are unpredictable. Further, such litigation may require a significant expenditure of cash and
may divert management&#146;s attention from our operations, which could harm our business, financial condition and results of operations. An adverse determination in any such litigation could materially impair our intellectual property rights and
may harm our business, prospects and reputation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may not be able to protect our intellectual property and proprietary rights throughout the
world. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Filing, prosecuting, maintaining and defending patents on drug candidates in all countries throughout the world would be prohibitively
expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United
States or PRC or from selling or importing products made using our inventions in and into the United States, the PRC or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to
develop their own competing products and, further, may export otherwise infringing products to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with our
products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Many companies have
encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions, including China. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of
patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation
of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects
of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits
that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant
commercial advantage from the intellectual property that we develop or license. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, many countries have compulsory licensing laws under which a
patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies,
which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business,
financial condition, results of operations and prospects may be adversely affected. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Developments in patent law could have a negative impact on our
business. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Changes in either the patent laws or interpretation of the patent laws in the United States, PRC and other government authorities
could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents, including changing the standards of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">49 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
patentability, and any such changes could have a negative impact on our business. For example, in the United States, the <FONT STYLE="white-space:nowrap">Leahy-Smith</FONT> America Invents Act,
or the America Invents Act, which was signed into law in September 2011, includes a number of significant changes to U.S. patent law. These changes include a transition from a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-invent&#148;</FONT></FONT> system to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system as of March
2013, changes to the way issued patents are challenged, and changes to the way patent applications are disputed during the examination process. These include allowing third party submission of prior art to the USPTO during patent prosecution and
additional procedures to attack the validity of a patent by USPTO administered post grant proceedings, including post grant review, <I>inter partes</I> review, and derivation proceedings. As a result of these changes, patent law in the United States
may favor larger and more established companies that have greater resources to devote to patent application filing and prosecution. The USPTO has developed new and untested regulations and procedures to govern the full implementation of the America
Invents Act, and many of the substantive changes to patent law associated with the America Invents Act, and, in particular, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-to-file</FONT></FONT> provisions became effective
in March 2013. Substantive changes to patent law associated with the America Invents Act may affect our ability to obtain patents, and if obtained, to enforce or defend them. Accordingly, it is not clear what, if any, impact the America Invents Act
will have on the cost of prosecuting our patent applications and our ability to obtain patents based on our discoveries and to enforce or defend any patents that may issue from our patent applications, all of which could have a material adverse
effect on our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, the patent positions of companies in the development and
commercialization of biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain
situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations
governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we are unable to maintain the confidentiality of our trade secrets, our business and competitive position may be harmed. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to the protection afforded by registered patents and pending patent applications, we rely upon unpatented trade secret protection, unpatented <FONT
STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. We also
seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with parties that have access to them, such as our partners, collaborators, scientific advisors, employees, consultants and other third
parties, and invention assignment agreements with our consultants and employees. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and
processes. We may not be able to prevent the unauthorized disclosure or use of our technical <FONT STYLE="white-space:nowrap">know-how</FONT> or other trade secrets by the parties to these agreements, however, despite the existence generally of
confidentiality agreements and other contractual restrictions. If any of the partners, collaborators, scientific advisors, employees and consultants who are parties to these agreements breaches or violates the terms of any of these agreements or
otherwise discloses our proprietary information, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Enforcing a claim that a third party illegally disclosed or misappropriated our
trade secrets, including through intellectual property litigations or other proceedings, is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, courts in China and other jurisdictions inside and outside the United
States are less prepared, less willing or unwilling to protect trade secrets. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">50 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our trade secrets could otherwise become known or be independently discovered by our competitors or other third
parties. For example, competitors could purchase our drug candidates and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe, misappropriate or otherwise violate our intellectual
property rights, design around our intellectual property protecting such technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be disclosed or
independently developed by a competitor, we would have no right to prevent them, or others to whom they communicate it, from using that technology or information to compete against us, which may have a material adverse effect on our business,
prospects, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If our drug candidates infringe, misappropriate or otherwise violate the intellectual
property rights of third parties, we may incur substantial liabilities, and we may be unable to sell commercialize these drug candidates. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our
commercial success depends significantly on our ability to develop, manufacture, market and sell our drug candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the patents and other proprietary
rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. In the PRC and the United States, invention patent applications are
generally maintained in confidence until their publication 18&nbsp;months from the filing date. The publication of discoveries in the scientific or patent literature frequently occurs substantially later than the date on which the underlying
discoveries were made and invention patent applications are filed. Even after reasonable investigation, we may not know with certainty whether any <FONT STYLE="white-space:nowrap">third-party</FONT> may have filed a patent application without our
knowledge while we are still developing or producing that product. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and any drug candidates we may
develop, including interference proceedings, <FONT STYLE="white-space:nowrap">post-grant</FONT> review, <I>inter partes</I> review and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. Even if
we believe <FONT STYLE="white-space:nowrap">third-party</FONT> intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of infringement, validity, enforceability or priority. A court of
competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize any drug candidates we may develop and any other drug candidates or
technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. There is no assurance that a court of competent
jurisdiction would invalidate the claims of any such U.S. patent. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we are found to infringe a third party&#146;s patent rights, and we are
unsuccessful in demonstrating that such patents are invalid or unenforceable, we could be required to: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">obtain royalty-bearing licenses from such third party to such patents, which may not be available on commercially reasonable terms, if at all and even if we were
able to obtain such licenses, they could be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors and other third parties access to the same technologies licensed to us, and could require us to make substantial
licensing and royalty payments; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">defend litigation or administrative proceedings; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reformulate product(s) so that it does not infringe the intellectual property rights of others, which may not be possible or could be very expensive and time
consuming; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">51 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">cease developing, manufacturing and commercializing the infringing technology or drug candidates; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">pay such third party significant monetary damages, including treble damages and attorneys&#146; fees, if we are found to have willfully infringed a patent or
other intellectual property right. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Claims that we have misappropriated the confidential information or trade secrets of third parties
could have a similar material adverse effect on our business, financial condition, results of operations, and prospects. Even if we are successful in such litigations or administrative proceedings, such litigations and proceedings may be costly and
could result in a substantial diversion of management resources. Any of the foregoing may have a material adverse effect on our business, prospects, financial condition and results of operations. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Intellectual property litigation and proceedings could cause us to spend substantial resources and distract our personnel from their normal responsibilities.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Even if resolved in our favor, litigation or other legal proceedings relating to our, our licensor&#146;s or other third parties&#146;
intellectual property claims may cause us to incur significant expenses and could distract our personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim
proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our
operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately.
Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties
resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>We may be subject to claims that we or our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of competitors or their current or former employers or are in breach of <FONT
STYLE="white-space:nowrap">non-competition</FONT> or <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreements with competitors or other third parties. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We could in the future be subject to claims that we or our employees, consultants or advisors have inadvertently or otherwise used or disclosed alleged trade secrets or other proprietary information of current or
former employers, competitors or other third parties. Many of our employees, consultants and advisors are currently or were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or
potential competitors. Although we try to ensure that our employees and consultants do not improperly use the intellectual property, proprietary information, <FONT STYLE="white-space:nowrap">know-how</FONT> or trade secrets of others in their work
for us, we may be subject to claims that we or these individuals have breach the terms of his or her <FONT STYLE="white-space:nowrap">non-competition</FONT> or <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, or that we or these
individuals have, inadvertently or otherwise, used or disclosed the alleged trade secrets or other proprietary information of a current or former employer, competitor or other third parties. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management and
research personnel. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our drug candidates, if such technologies or features
are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. An inability to incorporate such technologies or features would have a material adverse effect on our business and may prevent us
from successfully commercializing our drug candidates. In addition, we may lose valuable intellectual property rights or personnel as a result of such claims. Moreover, any such litigation or the threat thereof may adversely affect our ability to
hire employees or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">52 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our drug candidates, which would have a
material adverse effect on our business, results of operations and financial condition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, while it is our policy to require our employees and
contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives
or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be <FONT STYLE="white-space:nowrap">self-executing,</FONT> or the assignment agreements may be breached, and we may be forced to
bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition,
results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We may not be successful in obtaining necessary intellectual property rights to drug candidates for our
development pipeline through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Although we also intend to develop drug
candidates through our own internal research, our near-term business model is predicated, in large part, on our ability to successfully identify and acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> drug candidates to grow our drug
candidate pipeline. However, we may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> intellectual property rights relating to, or necessary for, any such drug candidates from third parties on commercially reasonable terms
or at all, including because we are focusing on specific areas of care such as oncology and inflammatory and infectious diseases. In that event, we may be unable to develop or commercialize such drug candidates. We may also be unable to identify
drug candidates that we believe are an appropriate strategic fit for our company and intellectual property relating to, or necessary for, such drug candidates. Any of the foregoing could have a materially adverse effect on our business, financial
condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The <FONT STYLE="white-space:nowrap">in-licensing</FONT> and acquisition of third-party intellectual
property rights for drug candidates is a competitive area, and a number of more established companies are also pursuing strategies to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire third-party intellectual property rights for drug
candidates that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. Furthermore,
companies that perceive us to be a competitor may be unwilling to assign or license rights to us. If we are unable to successfully obtain rights to suitable drug candidates, our business, financial condition, results of operations and prospects for
growth could suffer. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, we expect that competition for the <FONT STYLE="white-space:nowrap">in-licensing</FONT> or acquisition of third-party
intellectual property rights for drug candidates that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs. We may be unable to <FONT
STYLE="white-space:nowrap">in-license</FONT> or acquire the third-party intellectual property rights for drug candidates on terms that would allow us to make an appropriate return on our investment. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we do not obtain patent term extension and data exclusivity for any drug candidates we may develop, our business may be materially harmed.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Depending upon the timing, duration and specifics of any FDA marketing approval of any drug candidates we may develop, one or more of our owned
or <FONT STYLE="white-space:nowrap">in-licensed</FONT> U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or Hatch Waxman Amendments. The Hatch Waxman
Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the
date of product approval, only one </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">53 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension
because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy
applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. In addition, no patent term extension system has been established in the PRC. As a result, the patents we have <FONT
STYLE="white-space:nowrap">in-licensed</FONT> or own in the PRC are not eligible to be extended for patent term lost during the regulatory review process. If we are unable to obtain patent term extension or term of any such extension is less than we
request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements
imposed by government patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Periodic maintenance fees, renewal fees, annuity fees, and various other government fees on patents and applications will be due to be paid to the USPTO and various government patent agencies outside of the United
States over the lifetime of our owned or licensed patents and applications. In certain circumstances, we rely on our licensing partners to pay these fees due to U.S. and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> patent agencies. The USPTO and
various <FONT STYLE="white-space:nowrap">non-U.S.</FONT> government agencies require compliance with several procedural, documentary, fee payment, and other similar provisions during the patent application process. We are also dependent on our
licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. In some cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the
applicable rules. There are situations, however, in which <FONT STYLE="white-space:nowrap">non-compliance</FONT> can result in abandonment or lapse of the patent or patent application, resulting in a partial or complete loss of patent rights in the
relevant jurisdiction. In such an event, potential competitors might be able to enter the market with similar or identical products or technology, which could have a material adverse effect on our business, financial condition, results of
operations, and prospects. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Intellectual property rights do not necessarily address all potential threats. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not
adequately protect our business or permit us to maintain our competitive advantage. For example: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">others may be able to make gene therapy products that are similar to any drug candidates we may develop or utilize similar gene therapy technology but that are
not covered by the claims of the patents that we license or may own in the future; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we, our licensors, patent owners of patent rights that we have <FONT STYLE="white-space:nowrap">in-licensed,</FONT> or current or future collaborators might not
have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we, our licensors, patent owners of patent rights that we have <FONT STYLE="white-space:nowrap">in-licensed,</FONT> or current or future collaborators might not
have been the first to file patent applications covering certain of our or their inventions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating or otherwise
violating our owned or licensed intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">it is possible that our pending licensed patent applications or those that we may own in the future will not lead to issued patents;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">54 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such
activities to develop competitive products for sale in our major commercial markets; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may not develop additional proprietary technologies that are patentable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the patents of others may harm our business; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">we may choose not to file a patent in order to maintain certain trade secrets or know how, and a third party may discover certain technologies containing such
trade secrets or know how through independent research and development and/or subsequently file a patent covering such intellectual property. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Risks related to our ADSs and this offering </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We have broad discretion to determine how to use the net
proceeds from this offering and may use them in ways that may not enhance our results of operations or the price of the ADSs. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Although we
currently intend to use the net proceeds from this offering in the manner described in the section titled &#147;Use of proceeds&#148; in this prospectus, our management will have broad discretion over the use of net proceeds from this offering, and
we could spend the net proceeds from this offering in ways the holders of the ADSs may not agree with or that do not yield a favorable return. Because of the number and variability of factors that will determine our use of the net proceeds from this
offering, our use of these proceeds may differ substantially from our current plans. The failure by our management to apply these funds effectively could have a material adverse effect on our business, financial condition and results of operation.
You will not have the opportunity, as part of your investment decision, to assess whether proceeds are being used appropriately. You must rely on the judgment of our management regarding the application of the net proceeds of this offering.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>After the completion of the global offering, we may be at an increased risk of securities class action litigation. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Historically, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is
especially relevant for us because biotechnology and biopharmaceutical companies have experienced significant share price volatility in recent years. If we were to be sued, it could result in substantial costs and a diversion of management&#146;s
attention and resources, which could harm our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If securities analysts do not publish research or reports about our business or if they
publish negative evaluations of our business, the price of our ADSs could decline. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The trading market for our ADSs will rely in part on the
research and reports that industry or financial analysts publish about us or our business. We may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock would
likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock,
we could lose visibility in the market for our stock, which in turn could cause our stock price to decline. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">55 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We are eligible to be treated as an &#147;emerging growth company,&#148; as defined in the Securities Act, and
we cannot be certain if the reduced disclosure requirements applicable to us as an &#147;emerging growth company&#148; will make our ADSs less attractive to investors. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are eligible to be treated as an &#147;emerging growth company,&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the JOBS Act, and we may take advantage of certain exemptions from
various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies,&#148; including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the <FONT
STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> Act. As a result, our shareholders may not have access to certain information that they may deem important. We could be an emerging growth company for up to five years, although circumstances could
cause us to lose that status earlier, including if our total annual gross revenue exceeds $1.07&nbsp;billion, if we issue more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during any <FONT
STYLE="white-space:nowrap">three-year</FONT> period, or if the market value of our ordinary shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700.0&nbsp;million. We cannot predict if investors will find our ADSs less
attractive because we may rely on these exemptions. If some investors find our ADSs less attractive as a result, there may be a less active trading market for our ADSs and our stock price may be more volatile. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we fail to establish and maintain proper internal financial reporting controls, our ability to produce accurate financial statements or comply with
applicable regulations could be impaired. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to Section&nbsp;404 of the <FONT STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> Act, we
will be required to file a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However,
while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. The presence of material weaknesses in
internal control over financial reporting could result in financial statement errors which, in turn, could lead to errors in our financial reports and/or delays in our financial reporting, which could require us to restate our operating results. We
might not identify one or more material weaknesses in our internal controls in connection with evaluating our compliance with Section&nbsp;404 of the <FONT STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> Act. In order to maintain and improve the
effectiveness of our disclosure controls and procedures and internal controls over financial reporting, we will need to expend significant resources and provide significant management oversight. Implementing any appropriate changes to our internal
controls may require specific compliance training of our directors and employees, entail substantial costs in order to modify our existing accounting systems, take a significant period of time to complete and divert management&#146;s attention from
other business concerns. These changes may not, however, be effective in maintaining the adequacy of our internal control. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we are unable to conclude
that we have effective internal controls over financial reporting, investors may lose confidence in our operating results, the price of the ADSs could decline and we may be subject to litigation or regulatory enforcement actions. In addition, if we
are unable to meet the requirements of Section&nbsp;404 of the <FONT STYLE="white-space:nowrap">Sarbanes-Oxley</FONT> Act, the ADSs may not be able to remain listed on the NASDAQ Global Market. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>As a foreign private issuer, we are not subject to certain U.S. securities law disclosure requirements that apply to a domestic U.S. issuer, which may limit
the information publicly available to our shareholders. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a foreign private issuer we are not required to comply with all of the periodic
disclosure and current reporting requirements of the Exchange Act and therefore there may be less publicly available information about us than if we were a U.S. domestic issuer. For example, we are not subject to the proxy rules in the United States
and disclosure with respect to our annual general meetings will be governed by the Cayman Islands requirements. In addition, our officers, directors and principal shareholders are exempt from the reporting and
<FONT STYLE="white-space:nowrap">&#147;short-swing&#148;</FONT> profit recovery provisions of Section&nbsp;16 of the Exchange Act and the rules thereunder. Therefore, our shareholders may not know on a timely basis when our officers, directors and
principal shareholders purchase or sell our ordinary shares or ADSs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">56 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>As a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate
governance matters that differ significantly from the NASDAQ Stock Market corporate governance listing standards. These practices may afford less protection to shareholders than they would enjoy if we complied fully with corporate governance listing
standards. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a foreign private issuer, we are permitted to take advantage of certain provisions in the NASDAQ Stock Market listing rules that
allow us to follow Cayman Islands law for certain governance matters. Certain corporate governance practices in the Cayman Islands may differ significantly from corporate governance listing standards as, except for general fiduciary duties and
duties of care, Cayman Islands law has no corporate governance regime which prescribes specific corporate governance standards. When our ADSs are listed on the Nasdaq Global Market, we intend to continue to follow Cayman Islands corporate governance
practices in lieu of the corporate governance requirements of the Nasdaq Stock Market in respect of the following: (i)&nbsp;the majority independent director requirement under Section&nbsp;5605(b)(1) of the NASDAQ Stock Market listing rules,
(ii)&nbsp;the requirement under Section&nbsp;5605(d) of the NASDAQ Stock Market listing rules that a compensation committee comprised solely of independent directors governed by a compensation committee charter oversee executive compensation,
(iii)&nbsp;the requirement under Section&nbsp;5605(e) of the NASDAQ Stock Market listing rules that director nominees be selected or recommended for selection by either a majority of the independent directors or a nominations committee comprised
solely of independent directors and (iv)&nbsp;the requirement under Section&nbsp;5605(b)(2) of the NASDAQ Stock Market listing rules that our independent directors hold regularly scheduled executive sessions. Cayman Islands law does not impose a
requirement that our board of directors consist of a majority of independent directors. Nor does Cayman Islands law impose specific requirements on the establishment of a compensation committee or nominating committee or nominating process.
Therefore, our shareholders may be afforded less protection than they otherwise would have under corporate governance listing standards applicable to U.S. domestic issuers. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>We may lose our foreign private issuer status in the future, which could result in significant additional costs and expenses. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As discussed above, we are a foreign private issuer, and therefore, we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act. The determination of
foreign private issuer status is made annually on the last business day of an issuer&#146;s most recently completed second fiscal quarter, and, accordingly, the next determination will be made with respect to us on June&nbsp;30, 2018. We would lose
our foreign private issuer status if, for example, more than 50% of our ordinary shares are directly or indirectly held by residents of the U.S. and we fail to meet additional requirements necessary to maintain our foreign private issuer status. If
we lose our foreign private issuer status on this date, we will be required to file with the SEC periodic reports and registration statements on U.S. domestic issuer forms beginning on January&nbsp;1, 2019, which are more detailed and extensive than
the forms available to a foreign private issuer. We will also have to mandatorily comply with U.S. federal proxy requirements, and our officers, directors and principal shareholders will become subject to the
<FONT STYLE="white-space:nowrap">short-swing</FONT> profit disclosure and recovery provisions of Section&nbsp;16 of the Exchange Act. In addition, we will lose our ability to rely upon exemptions from certain corporate governance requirements under
the NASDAQ Stock Market listing rules. As a U.S. listed public company that is not a foreign private issuer, we will incur significant additional legal, accounting and other expenses that we will not incur as a foreign private issuer, and
accounting, reporting and other expenses in order to maintain a listing on a U.S. securities exchange. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The audit report included in this
prospectus was prepared by an auditor who is not inspected by the U.S. Public Company Accounting Oversight Board, or the PCAOB, and as such, you are deprived of the benefits of such inspection. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Auditors of companies that are registered with the SEC and traded publicly in the United States, including the independent registered public accounting firm of our
company, must be registered with the PCAOB, and are </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">57 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
required by the laws of the United States to undergo regular inspections by the PCAOB to assess their compliance with the laws of the United States and professional standards. Because
substantially all of our operations are within the PRC, a jurisdiction where the PCAOB is currently unable to conduct inspections without the approval of the Chinese authorities, our auditor is not currently inspected by the PCAOB. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In May&nbsp;2013, the PCAOB announced that it had entered into a Memorandum of Understanding on Enforcement Cooperation with the China Securities Regulatory
Commission, or CSRC, and the Ministry of Finance, which establishes a cooperative framework between the parties for the production and exchange of audit documents relevant to investigations undertaken by the PCAOB in the United States or the CSRC or
the Ministry of Finance in the PRC. The PCAOB continues to be in discussions with the CSRC and the Ministry of Finance to permit joint inspections in the PRC of audit firms that are registered with PCAOB and audit Chinese companies that trade on
U.S. exchanges. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This lack of PCAOB inspections in China prevents the PCAOB from regularly evaluating audits and quality control procedures of any
auditors operating in China, including our auditor. As a result, investors may be deprived of the benefits of PCAOB inspections. The inability of the PCAOB to conduct inspections of auditors in China makes it more difficult to evaluate the
effectiveness of our auditor&#146;s audit procedures or quality control procedures as compared to auditors outside of China that are subject to PCAOB inspections. Investors may lose confidence in our reported financial information and procedures and
the quality of our financial statements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>We do not currently intend to pay dividends on our securities, and, consequently, your ability to achieve
a return on your investment will depend on appreciation in the price of the ADSs. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have never declared or paid any dividends on our ordinary
shares. We currently intend to invest our future earnings, if any, to fund our growth. Therefore, you are not likely to receive any dividends on your ADSs at least in the near term, and the success of an investment in ADSs will depend upon any
future appreciation in its value. Consequently, investors may need to sell all or part of their holdings of ADSs after price appreciation, which may never occur, to realize any future gains on their investment. There is no guarantee that the ADSs
will appreciate in value or even maintain the price at which our investors purchased their ADSs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>There has been no public market in the United
States for our ordinary shares or ADSs prior to this offering, and you may not be able to resell our ADSs at or above the price you paid, or at all. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Prior to this offering, there has been no public market in the United States for our ordinary shares or ADSs. We have applied to have our ADSs listed on the Nasdaq Global Market. Our ordinary shares will not be
listed on any other exchange, or quoted for trading on any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> trading system, in the United States. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The initial public offering price for our ADSs will be determined by negotiations between us and the underwriters and may bear no relationship to the market price
for our ADSs after this initial public offering. We cannot assure you that an active trading market for our ADSs will develop or that the market price of our ADSs will not decline below the initial public offering price. If an active trading market
for our ADSs does not develop after this offering, the market price and liquidity of our ADSs will be materially and adversely affected. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain
institutional investors have indicated an interest in purchasing up to an aggregate of $30.0&nbsp;million in ADSs in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may
determine to sell more, less or no ADSs in this offering to any of these investors, or any of these investors may determine to purchase more, less or no ADSs in this offering, including as a result of the pricing terms. In addition, the underwriters
may place the remaining portion of this offering with a limited number of investors. Therefore, trading of the ADSs may be very limited. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">58 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>The market price for our ADSs may be volatile which could result in substantial loss to you. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The market price for our ADSs is likely to be highly volatile and subject to wide fluctuations in response to factors, including the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">announcements of competitive developments; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">regulatory developments affecting us, our customers or our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">announcements regarding litigation or administrative proceedings involving us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">actual or anticipated fluctuations in our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> operating results;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">changes in financial estimates by securities research analysts; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">additions or departures of our executive officers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">fluctuations of exchange rates between the RMB and the U.S. dollar; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">release or expiry of <FONT STYLE="white-space:nowrap">lock-up</FONT> or other transfer restrictions on our outstanding ordinary shares or ADSs; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">sales or perceived sales of additional ordinary shares or ADSs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are not related to the operating performance of particular companies. For example, since
August&nbsp;2008, multiple exchanges in the United States and other countries and regions, including China, experienced sharp declines in response to the growing credit market crisis and the recession in the United States. As recently as
August&nbsp;2015, the exchanges in China experienced a sharp decline. Prolonged global capital markets volatility may affect overall investor sentiment towards our ADSs, which would also negatively affect the trading prices for our ADSs. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Fluctuations in the value of the renminbi may have a material adverse effect on our results of operations and the value of your investment.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The value of the renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in
political and economic conditions. On July&nbsp;21, 2005, the PRC government changed its <FONT STYLE="white-space:nowrap">decade-old</FONT> policy of pegging the value of the renminbi to the U.S. dollar, and the renminbi appreciated more than 20%
against the U.S. dollar over the following three years. Between July&nbsp;2008 and June&nbsp;2010, this appreciation halted, and the exchange rate between the renminbi and U.S. dollar remained within a narrow band. In June&nbsp;2010, China&#146;s
People&#146;s Bank of China, or PBOC, announced that the PRC government would increase the flexibility of the exchange rate, and thereafter allowed the renminbi to appreciate slowly against the U.S. dollar within the narrow band fixed by the PBOC.
However, more recently, on August&nbsp;11, 12 and 13, 2015, the PBOC significantly devalued the renminbi by fixing its price against the U.S. dollar 1.9%, 1.6%, and 1.1% lower than the previous day&#146;s value, respectively. On October&nbsp;1,
2016, the renminbi joined the International Monetary Fund&#146;s basket of currencies that make up the Special Drawing Right, or SDR, along with the U.S. dollar, the Euro, the Japanese yen and the British pound. In the fourth quarter of 2016, the
renminbi depreciated significantly while the U.S. dollar surged and China experienced persistent capital outflows. With the development of the foreign exchange market and progress towards interest rate liberalization and renminbi
internationalization, the PRC government may in the future announce further changes to the exchange rate system. There is no guarantee that the renminbi will not appreciate or depreciate significantly in value against the U.S. dollar in the future.
It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the renminbi and the U.S. dollar in the future. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">59 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Significant revaluation of the renminbi may have a material adverse effect on your investment. For example, to the
extent that we need to convert U.S. dollars into renminbi for our operations, appreciation of the renminbi against the U.S. dollar would have an adverse effect on the renminbi amount we would receive from the conversion. Conversely, if we decide to
convert our renminbi into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs or for other business purposes, appreciation of the U.S. dollar against the renminbi would have a negative effect on the U.S.
dollar amount available to us. In addition, appreciation or depreciation in the value of the renminbi relative to U.S. dollars would affect our financial results reported in U.S. dollar terms regardless of any underlying change in our business or
results of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Very limited hedging options are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not
entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may decide to enter into hedging transactions in the future, the availability and effectiveness of these hedges may be limited and
we may not be able to adequately hedge our exposure or at all. In addition, our currency exchange losses may be magnified by PRC exchange control regulations that restrict our ability to convert renminbi into foreign currency. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Since the U.S. initial public offering price is substantially higher than our net tangible book value per share, you will incur immediate and substantial
dilution. </I></B></FONT></P>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If you purchase our ADSs in this offering, you will pay more for your ADSs than the amount paid by our existing shareholders for
their ordinary shares on a per ADS basis. As a result, you will experience immediate and substantial dilution of approximately $12.44 per ADS, representing the difference between our net tangible book value per ADS as of June&nbsp;30, 2017, after
giving effect to this offering and an assumed initial public offering price of $17.00 per ADS. In addition, you may experience further dilution to the extent that our ordinary shares are issued upon the exercise of share options. See
&#147;Dilution&#148; for a more complete description of how the value of your investment in our ADSs will be diluted upon completion of this offering. </FONT></P>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Substantial future sales or perceived sales of our ADSs in the public market could cause the price of our ADSs to decline. </I></B></FONT></P>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Sales of our ADSs in the public market after this offering, or the perception that these sales could occur, could cause the market price of our ADSs to decline. Upon completion of this offering, we will have
49,049,731 ordinary shares outstanding, including ordinary shares represented by ADSs. All ADSs sold in this offering will be freely transferable without restriction or additional registration under the Securities Act. The remaining ordinary shares
outstanding after this offering will be available for sale, subject to restrictions as applicable under Rule&nbsp;144 under the Securities Act, upon the expiration of the <FONT STYLE="white-space:nowrap">180-day</FONT>
<FONT STYLE="white-space:nowrap">lock-up</FONT> arrangements entered into among us and the underwriters. There are certain exceptions to these <FONT STYLE="white-space:nowrap">lock-up</FONT> arrangements. See &#147;Underwriting&#148; and
&#147;Shares eligible for future sale&#148; for additional information. We cannot predict what effect, if any, market sales of securities held by our significant shareholders or any other shareholder or the availability of these securities for
future sale will have on the market price of our ADSs. </FONT></P>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Holders of ADSs have fewer rights than shareholders and must act through the
depositary to exercise their rights. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Holders of our ADSs do not have the same rights as our shareholders and may only exercise the voting rights
with respect to the underlying ordinary shares in accordance with the provisions of the deposit agreement. Under our fourth amended and restated memorandum and articles of association, which will be effective immediately upon completion of this
offering, an annual general meeting and any extraordinary general meeting may be called with not less than seven days&#146; notice. When a general meeting is convened, you may not receive sufficient notice of a shareholders&#146; meeting to permit
you to withdraw the ordinary shares underlying </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">60 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
your ADSs to allow you to vote with respect to any specific matter. If we ask for your instructions, we will give the depositary notice of any such meeting and details concerning the matters to
be voted upon at least 30 days in advance of the meeting date and the depositary will send a notice to you about the upcoming vote and will arrange to deliver our voting materials to you. The depositary and its agents, however, may not be able to
send voting instructions to you or carry out your voting instructions in a timely manner. We will make all commercially reasonable efforts to cause the depositary to extend voting rights to you in a timely manner, but we cannot assure you that you
will receive the voting materials in time to ensure that you can instruct the depositary to vote the ordinary shares underlying your ADSs. Furthermore, the depositary will not be liable for any failure to carry out any instructions to vote, for the
manner in which any vote is cast or for the effect of any such vote. As a holder or beneficial owner of ADSs, you may have limited recourse if we or the depositary fail to meet our respective obligations under the deposit agreement or if you wish us
or the depositary to participate in legal proceedings. As a result, you may not be able to exercise your right to vote and you may lack recourse if your ADSs are not voted as you request. In addition, in your capacity as an ADS holder, you will not
be able to call a shareholders&#146; meeting. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>You may not receive distributions on our ADSs or any value for them if such distribution is illegal
or impractical or if any required government approval cannot be obtained in order to make such distribution available to you. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Although we do not
have any present plan to pay any dividends, the depositary of our ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities underlying our ADSs, after
deducting its fees and expenses and any applicable taxes and governmental charges. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent. However, the depositary is not responsible if it decides that
it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution to a holder of ADSs if it consists of securities whose offering would require registration under the
Securities Act but are not so properly registered or distributed under an applicable exemption from registration. The depositary may also determine that it is not reasonably practicable to distribute certain property. In these cases, the depositary
may determine not to distribute such property. We have no obligation to register under the U.S. securities laws any offering of ADSs, ordinary shares, rights or other securities received through such distributions. We also have no obligation to take
any other action to permit the distribution of ADSs, ordinary shares, rights or anything else to holders of ADSs. This means that you may not receive distributions we make on our ordinary shares or any value for them if it is illegal or impractical
for us to make them available to you. These restrictions may cause a material decline in the value of our ADSs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Your right to participate in any
future rights offerings may be limited, which may cause dilution to your holdings. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may from time to time distribute rights to our
shareholders, including rights to acquire our securities. However, we cannot make rights available to you in the United States unless we register the rights and the securities to which the rights relate under the Securities Act or an exemption from
the registration requirements is available. Also, under the deposit agreement, the depositary bank will not make rights available to you unless either both the rights and any related securities are registered under the Securities Act, or the
distribution of them to ADS holders is exempted from registration under the Securities Act. We are under no obligation to file a registration statement with respect to any such rights or securities or to endeavor to cause such a registration
statement to be declared effective. Moreover, we may not be able to establish an exemption from registration under the Securities Act. If the depositary does not distribute the rights, it may, under the deposit agreement, either sell them, if
possible, or allow them to lapse. Accordingly, you may be unable to participate in our rights offerings and may experience dilution in your holdings. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">61 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>If we are classified as a passive foreign investment company, U.S. investors could be subject to adverse U.S.
federal income tax consequences. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Generally, if, for any taxable year, at least 75% of our gross income is passive income, or at least 50% of the
value of our assets is attributable to assets that produce passive income or are held for the production of passive income, including cash, we would be characterized as a &#147;passive foreign investment company,&#148; or PFIC, for U.S. federal
income tax purposes. For purposes of these tests, passive income includes dividends, interest, and gains from the sale or exchange of investment property and rents and royalties other than rents and royalties which are received from unrelated
parties in connection with the active conduct of a trade or business. If we are a PFIC, U.S. holders of our ADSs may suffer adverse tax consequences, including having gains realized on the sale of the ADSs treated as ordinary income rather than
capital gain, the loss of the preferential rate applicable to dividends received on the ADSs by individuals who are U.S. holders, and having interest charges apply to distributions by us and the proceeds of sales of the ADSs. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Whether we are a PFIC for any taxable year is a factual determination that can be made only after the end of each taxable year and which depends on the composition
of our income and the composition and value of our assets for the relevant taxable year. Because we hold, and will continue to hold after this offering, a substantial amount of passive assets, including cash, and because the value of our assets for
purposes of the PFIC rules (including goodwill) may be determined by reference to the market value of our ADSs, which may be especially volatile due to the early stage of our drug candidates, we cannot give any assurance that we will not be a PFIC
for the current or any future taxable year. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Whether or not U.S. holders make a timely &#147;qualified electing fund,&#148; or QEF election or
mark-to-market election may affect the U.S. federal income tax consequences to U.S. holders with respect to the acquisition, ownership and disposition of our ADSs. Prospective investors should consult their own tax advisors regarding all aspects of
the application of the PFIC rules to the ADSs. See &#147;Material United States federal income tax considerations&#151;Passive foreign investment company considerations.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>You may have difficulty enforcing judgments obtained against us. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a company incorporated under
the laws of the Cayman Islands, and substantially all of our assets are located outside the United States. Substantially all of our current operations are conducted in the PRC. In addition, some of our directors and officers are nationals and
residents of countries other than the United States. A substantial portion of the assets of these persons are located outside the United States. As a result, it may be difficult for you to effect service of process within the United States upon
these persons. It may also be difficult for you to enforce in U.S. courts judgments obtained in U.S. courts based on the civil liability provisions of the U.S. federal securities laws against us and our officers and directors, some of whom currently
reside in the United States and whose assets are located outside the United States. In addition, there is uncertainty as to whether the courts of the Cayman Islands or the PRC would recognize or enforce judgments of U.S. courts against us or such
persons predicated upon the civil liability provisions of the securities laws of the United States or any state. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The recognition and enforcement of
foreign judgments are provided for under the PRC Civil Procedures Law. PRC courts may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based either on treaties between China and the country
where the judgment is made or on principles of reciprocity between jurisdictions. China does not have any treaties or other forms of reciprocity with the United States that provide for the reciprocal recognition and enforcement of foreign judgments.
In addition, according to the PRC Civil Procedures Law, the PRC courts will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates the basic principles of PRC laws or national sovereignty,
security or public interest. As a result, it is uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the United States. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">62 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>You may be subject to limitations on transfers of your ADSs. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Your ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems
expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the
depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">63 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_3"></A>Cautionary note regarding forward-looking statements </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This prospectus contains forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are
based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our operational results and other future conditions. Forward-looking statements can be identified by words such as
&#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;target,&#148; &#147;potential,&#148;
&#147;will,&#148; &#147;would,&#148; &#147;could,&#148; &#147;should,&#148; &#147;continue,&#148; &#147;contemplate&#148; and other similar expressions, although not all forward-looking statements contain these identifying words. These
forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this prospectus and include statements regarding our intentions, beliefs or current expectations concerning, among other
things, our results of operations, financial condition, liquidity, prospects, growth, strategies and the industry in which we operate. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">By their nature,
forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We believe that these risks and uncertainties include, but are not limited to, those
described in the &#147;Risk factors&#148; section of this prospectus, which include, but are not limited to, the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to advance our drug candidates into, and successfully complete, clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the ability of our drug candidates to be granted or maintain Category 1 designation with the CFDA and to receive a faster development, review or approval
process; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our reliance on the success of our clinical-stage drug candidates niraparib, omadacycline and <FONT STYLE="white-space:nowrap">ZL-2301</FONT> and certain other
drug candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the timing or likelihood of regulatory filings and approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the commercialization of our drug candidates, if approved; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to develop sales and marketing capabilities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the pricing and reimbursement of our drug candidates, if approved; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to contract on commercially reasonable terms with CROs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the disruption of our business relationships with our licensors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to operate our business without breaching our licenses or other intellectual property-related agreements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">cost associated with defending against intellectual property infringement, product liability and other claims; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">regulatory developments in the United States, China and other jurisdictions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">ability to obtain additional funding for our operations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the rate and degree of market acceptance of our drug candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">developments relating to our competitors and our industry; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to effectively manage our growth; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our ability to retain key executives and to attract, retain and motivate personnel. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">64 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These factors should not be construed as exhaustive and should be read with the other cautionary statements in this
prospectus. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Although we base these forward-looking statements on assumptions that we believe are reasonable when made, we caution you that
forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from those made in or
suggested by the forward-looking statements contained in this prospectus. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate, are consistent with the
forward-looking statements contained in this prospectus, those results or developments may not be indicative of results or developments in subsequent periods. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Given these risks and uncertainties, you are cautioned not to place undue reliance on these forward-looking statements. Any forward-looking statement that we make in this prospectus speaks only as of the date of
such statement, and we undertake no obligation to update any forward-looking statements or to publicly announce the results of any revisions to any of those statements to reflect future events or developments. Comparisons of results for current and
any prior periods are not intended to express any future trends or indications of future performance, unless specifically expressed as such, and should only be viewed as historical data. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">65 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_3a"></A>Series C conversion</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Immediately prior to the completion of this offering, each outstanding Series C preferred share will be converted into&nbsp;a number of ordinary shares determined by dividing (1)&nbsp;the Series C Issue Price,
which is equal to $15.0078, by (2)&nbsp;the lower of (a) the Series C Issue Price and (b) the offering price of an ADS in this offering multiplied by 85%. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the initial public offering price per ADS is greater than $17.6562, then the 1,998,958 outstanding Series C preferred shares will convert into 1,998,958 ordinary
shares, and 40,972,570 ordinary shares will be outstanding immediately after the conversion of the Series&nbsp;C preferred shares and our other series of preferred shares, but before this offering. If the initial public offering price per share is
equal to or less than $17.6562, then the Series&nbsp;C preferred shares will convert into an amount greater than 1,998,958 ordinary shares. The following number of ordinary shares would be outstanding immediately after the conversion of the
Series&nbsp;C preferred shares and our other series of preferred shares, but before this offering, assuming the initial public offering prices as set forth below: </FONT></P> <P STYLE="font-size:16px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$15.50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$16.00&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$16.50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$17.00&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$17.50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Shares&nbsp;Outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">41,250,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">41,179,490</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">41,112,644</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">41,049,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">40,990,413</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">66 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_4"></A>Use of proceeds </B></FONT></P>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We estimate that the net proceeds to us from our issuance and sale of 8,000,000 ADSs in this offering will be approximately $123.2 million, after deducting underwriting discounts and commissions and estimated
offering expenses payable by us. This estimate assumes an initial public offering price of $17.00 per ADS, the midpoint of the price range set forth on the cover page of this prospectus. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">A $1.00 increase (decrease) in the assumed initial public offering price of $17.00 per ADS would increase (decrease) the net proceeds to us from this offering by $7.4 million, assuming the number of ADSs offered by
us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated expenses payable by us. </FONT></P>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We intend to use the net proceeds of this offering, together with the cash generated by our operations and other cash resources, primarily to further advance the clinical development and commercial launch of our
multiple drug candidates. In particular, we currently expect to use the net proceeds from this offering as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">approximately $38.0 million to complete (i) Phase III studies of niraparib (ZL-2306) in patients with ovarian, breast cancer and other indications in China, (ii)
Phase III studies of omadacycline (ZL-2401) in China and (iii) Phase II/III studies of ZL-2301 in patients with HCC in China; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">approximately $20.0 million to support the commercialization efforts for niraparib (ZL-2306) in China, Hong Kong and Macau; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">approximately $40.0 million to fund new business development and licensing opportunities and to accelerate and broaden clinical development of our drug
candidates for which we have exclusive rights to develop and commercialize globally; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">approximately $15.0 million for research and clinical development of other drug candidates; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the remainder for working capital and other general corporate purposes. </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions, which we could change in our discretion in the future as our plans and business
conditions evolve. Due to the many variables inherent to the development of our drug candidates at this time, such as the timing of patient enrollment and evolving regulatory requirements, we cannot currently predict the stage of development we
expect to achieve for our <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial and drug candidates with the net proceeds of this offering. We expect to use the remainder of the net proceeds for working capital and other general
corporate purposes, such as acquiring the commercial rights to other drug products and expanding our research organization and infrastructure. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors,
including the results of the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial of our drug candidates, our operating costs and expenditures and the amount of cash generated by our operations. As a result, our management will
have broad discretion over the use of the net proceeds from this offering. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pending these uses, we intend to invest the net proceeds in investment-grade,
short-term fixed income instruments. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For additional information, see &#147;Management&#146;s discussion and analysis of financial condition and results
of operations&#151;Liquidity and capital resources.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">67 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_5"></A>Dividend policy </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have never declared or paid regular cash dividends on our ordinary shares. We currently expect to retain all future earnings for use in the operation and expansion of our business and do not anticipate paying
cash dividends in the foreseeable future. The declaration and payment of any dividends in the future will be determined by our board of directors, in its discretion, and will depend on a number of factors, including our earnings, capital
requirements, overall financial condition and contractual restrictions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">68 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_6"></A>Capitalization </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table sets forth our cash and cash equivalents and capitalization as of June&nbsp;30, 2017: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">on an actual basis; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">on a pro forma basis to give effect to (i)&nbsp;the conversion of our outstanding preferred shares into an aggregate of 28,520,436 ordinary shares upon the
closing of this offering, (ii)&nbsp;the exercise of warrants to purchase our preferred shares and further conversion of the preferred shares into ordinary shares upon the closing of this offering, and (iii)&nbsp;the effectiveness of our fourth
amended and restated memorandum and articles of association, which will occur immediately upon this closing of this offering; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">on a pro forma and as adjusted basis to reflect the issuance and sale of 8,000,000 ordinary shares in the form of ADSs by us in this offering and the application
of net proceeds from this offering described under &#147;Use of proceeds.&#148; </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The information below is illustrative only, and
assumes an initial public offering price at the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Our
capitalization following this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing, including the amount by which actual offering expenses are higher or lower than
estimated. The table should be read in conjunction with the information contained in &#147;Use of proceeds,&#148; &#147;Selected consolidated financial data&#148; and &#147;Management&#146;s discussion and analysis of financial condition and results
of operations,&#148; as well as our consolidated financial statements and the related notes included elsewhere in this prospectus. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of June&nbsp;30, 2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Pro forma</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Pro&nbsp;forma&nbsp;as<BR>adjusted</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">92,562,012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">93,562,012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">216,742,012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,700,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Series A1, par value $0.00006 per share; 8,466,667 shares authorized; 8,466,665 shares issued and outstanding (actual); no shares
authorized, issued or outstanding (pro forma and pro forma as adjusted)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,028,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Series A2, par value $0.00006 per share; 8,904,032 shares authorized; 8,442,221 shares issued and outstanding (actual); no shares
authorized, issued or outstanding (pro forma and pro forma as adjusted)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,278,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Series B1, par value $0.00006 per share; 5,562,337 shares authorized; 5,562,335 shares issued and outstanding (actual); no shares
authorized, issued or outstanding (pro forma and pro forma as adjusted)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53,100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Series B2, par value $0.00006 per share; 3,973,098 shares authorized; 3,973,096 shares issued and outstanding (actual); no shares
authorized, issued or outstanding (pro forma and pro forma as adjusted)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53,100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Series C, par value $0.00006 per share; 1,998,961 shares authorized; 1,998,958 shares issued and outstanding (actual); no shares
authorized, issued or outstanding (pro forma and pro forma as adjusted)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B></B><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B></B>30,000,000<B></B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B></B><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Shareholders&#146; (deficits) equity:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ordinary shares, par value $0.00006 per share; 83,333,333 shares authorized, 11,264,663 (actual); 40,246,907 issued and outstanding (pro
forma);&nbsp;48,246,907&nbsp;shares issued and outstanding (pro forma as adjusted)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,895</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Subscription receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,756,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">182,962,071</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">306,141,591</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated deficits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(84,586,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(84,586,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(84,586,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated other comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(321,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(321,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(321,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total shareholders&#146; (deficits) equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(71,151,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">98,055,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">221,235,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total capitalization</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">97,055,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">98,055,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">221,235,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">69 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The information above is illustrative only and our capitalization following the completion of this offering will be
adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. </FONT></P>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A $1.00 increase (decrease) in
the assumed initial public offering price of $17.00 per ADS, the midpoint of the estimated price range shown on the cover page of this prospectus, would increase (decrease) the amount of cash and cash equivalents, additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital, total shareholders&#146; equity and total capitalization on a pro forma as adjusted basis by approximately $7.4 million, assuming the number of ADSs offered by us, as set forth on the cover page of
this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 500,000 ADSs offered by us would increase (decrease) cash and cash
equivalents, total shareholders&#146; equity and total capitalization on a pro forma as adjusted basis by approximately $7.9 million, assuming the assumed initial public offering price remains the same, and after deducting underwriting discounts and
commissions and estimated offering expenses payable by us. The pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at
pricing. </FONT></P>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The actual, pro forma and pro forma as adjusted information set forth in the table excludes: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">6,448,415 shares issuable upon the exercise of options outstanding as of June&nbsp;30, 2017 pursuant to our 2015 Plan at a weighted-average exercise price of
$1.01 per share; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">1,924,327 shares reserved for future issuance under our 2017 Equity Plan, which was adopted in connection with this offering. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">70 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_7"></A>Dilution </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If you invest in our ADSs, your investment will be diluted for each ADS you purchase to the extent of the difference between the initial public offering price per ADS and our net tangible book value per ADS after
this offering. Dilution results from the fact that the initial public offering price per ordinary share is substantially in excess of the book value per ordinary share attributable to the existing shareholders for our presently outstanding ordinary
shares. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of June&nbsp;30, 2017, we had a negative net tangible book value of $72.2 million, or $6.41 per ordinary share and $6.41 per ADS. We
calculate net tangible book value per ordinary shares by dividing our total tangible assets less our total liabilities by the number of our ordinary shares outstanding. Pro forma net tangible book value per ordinary share is calculated after giving
effect (i) to the conversion of all of our issued and outstanding preferred shares, (ii) the exercise of warrants to purchase our preferred shares and the further conversion of the preferred shares into ordinary shares and (iii) the effectiveness of
our fourth amended and restated memorandum and articles of association. Pro forma as adjusted net tangible book value per ordinary share is calculated after giving effect to the conversion of all our issued and outstanding preferred shares and the
issuance of ordinary shares in the form of ADSs by us in this offering. Dilution is determined by subtracting pro forma as adjusted net tangible book value per ordinary share from the public offering price per ordinary share. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Without taking into account any other changes in such net tangible book value after June&nbsp;30, 2017, after giving effect to the receipt of the estimated net
proceeds from our sale of ADSs in this offering, assuming an initial public offering price of $17.00 per ADS (the midpoint of the offering range shown on the cover of this prospectus), and the application of the estimated net proceeds therefrom as
described under &#147;Use of proceeds,&#148; our pro forma as adjusted net tangible book value at June 30, 2017 would have been approximately $220.2&nbsp;million, or $4.56 per ordinary share and $4.56 per ADS. This represents an immediate increase
in net tangible book value of $2.15 per ordinary share and $2.15 per ADS to existing shareholders and an immediate dilution in net tangible book value of $12.44 per ordinary share and $12.44 per ADS to you. The following table illustrates this
dilution per ordinary share. </FONT></P>  <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Per<BR>ordinary<BR>share</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Per<BR>ADS</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Assumed initial public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Historical net tangible book value per ordinary share as of June&nbsp;30, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma increase in net tangible book value per share as of June&nbsp;30, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.82</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.82</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma net tangible book value per share as of June&nbsp;30, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Increase in pro forma net tangible book value per share after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Pro forma as adjusted net tangible book value per share after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;4.56</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;4.56</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Dilution per share to new investors in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12.44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12.44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A $1.00 increase (decrease) in the assumed initial public offering price of $17.00 per ADS would decrease (increase) our
pro forma net tangible book value after giving effect to the offering by $7.4&nbsp;million, assuming no change to the number of ADSs offered by us as set forth on the cover page of this prospectus, and after deducting estimated underwriting
discounts and commissions and estimated expenses payable by us. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the underwriters exercise their option to purchase additional ADSs in full, the pro
forma as adjusted net tangible book value would be $4.96 per ordinary shares and $4.96 per ADS, and the dilution in pro forma as adjusted net tangible book value to investors in this offering would be $12.04 per ordinary shares and $12.04 per ADS.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">71 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table sets forth, as of June&nbsp;30, 2017, the number of ordinary shares purchased from us, the total
consideration paid to us and the average price per ordinary share/ADS paid by existing shareholders and to be paid by new investors purchasing ADSs in this offering, before deducting underwriting discounts and commissions and estimated offering
expenses payable by us. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:arial" SIZE="2"><B>Ordinary shares<BR>purchased</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total consideration</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP STYLE="BORDER-TOP:2px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Average<BR>price<BR>per<BR>ordinary<BR>share</B></FONT></P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:1px" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Average<BR>price<BR>per ADS</B></FONT></P>
<P STYLE="font-size:1px;margin-top:0px;margin-bottom:1px" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Existing shareholders</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">41,049,731</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">83.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">182,964,478</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">57.4%</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.46</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4.46</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">New investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">16.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">136,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42.6%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="21" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">49,049,731</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">318,964,478</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6.50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="24" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the underwriters were to fully exercise their option to purchase additional ADSs from us, the percentage of our ordinary
shares held by existing shareholders would be 81.7%, and the percentage of our ordinary shares held by new investors would be 18.3%. </FONT></P>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The above
discussion and tables are based on 12,067,487 ordinary shares issued and outstanding as of June&nbsp;30, 2017 and also reflects the conversion of all outstanding preferred shares into an aggregate of 28,982,244 ordinary shares immediately prior to
the closing of this offering, and excludes: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">6,448,415 shares issuable upon the exercise of options outstanding as of June&nbsp;30, 2017 pursuant to our 2015 Plan at a weighted-average exercise price of
$1.01 per share; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">1,924,327 shares reserved for future issuance under our 2017 Equity Plan, which was adopted in connection with this offering. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To the extent that any share options are exercised, there will be further dilution to new investors. In addition, on July 19, 2017, the investor holding warrants
exercised the warrants to purchase 461,808 Series A1 preferred shares, which will convert into 461,808 ordinary shares upon the closing of this offering. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain institutional investors have indicated an interest in purchasing up to an aggregate of $30.0&nbsp;million in ADSs in this offering. However, because
indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, less or no ADSs in this offering to any of these investors, or any of these investors may determine to purchase more, less or
no ADSs in this offering, including as a result of the pricing terms. The foregoing discussion and tables do not reflect any potential purchases by these investors to the extent any such investor is an existing investor. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">72 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_8"></A>Selected consolidated financial data </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following selected consolidated statement of operations data for the years ended December&nbsp;31, 2015 and December&nbsp;31, 2016 and the selected balance
sheet data as of December&nbsp;31, 2015 and December&nbsp;31, 2016 have been derived from our audited consolidated financial statements included elsewhere in this prospectus. The selected consolidated statements of operations data for the six months
ended June 30, 2016 and June 30, 2017 and the selected balance sheet data as of June 30, 2017 have been derived from our unaudited condensed consolidated financial statements appearing elsewhere in this prospectus. The unaudited condensed interim
consolidated financial statements reflect, in the opinion of management, all adjustments of a normal, recurring nature that are necessary for the fair presentation of the financial statements. Our consolidated financial statements appearing in this
prospectus have been prepared in accordance with U.S. GAAP. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our historical results for any prior period are not necessarily indicative of results to be
expected in any future period. This selected historical consolidated financial data should be read in conjunction with the disclosures set forth under &#147;Capitalization,&#148; &#147;Management&#146;s discussion and analysis of financial condition
and results of operations&#148; and the consolidated financial statements and the related notes thereto appearing elsewhere in this prospectus. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(13,587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(32,149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,915</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(38,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fair value of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">341</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,534</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,835</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,835</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average shares used in calculating net loss per ordinary share, basic and diluted(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,242,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,630,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,693,655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,439,028</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share, basic and diluted(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As&nbsp;of<BR>June&nbsp;
30,<BR>2017</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Balance sheet data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">92,562</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,161</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">83,949</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">103,865</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,940</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">88,907</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total shareholders&#146; deficits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(71,152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(51,552</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,941</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">880</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">See Note 2 within our notes to our financial statements appearing elsewhere in this prospectus for a description of the method used to calculate basic and diluted net loss per
share. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">73 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_9"></A>Management&#146;s discussion and analysis of </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>financial condition and results of operations </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>You should
read the following discussion and analysis of our financial condition and results of operations together with &#147;Selected consolidated financial data,&#148; and our financial statements and the related notes appearing elsewhere in this
prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve
risks and uncertainties. You should read the &#147;Risk factors&#148; and &#147;Cautionary note regarding forward-looking statements&#148; sections of this prospectus for a discussion of important factors that could cause actual results to differ
materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. The terms &#147;Company&#148;, &#147;Zai Lab&#148;, &#147;we&#148;, &#147;our&#148; or &#147;us&#148; as used
herein refer to Zai Lab Limited and its consolidated subsidiaries unless otherwise stated or indicated by context. </I></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Overview </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are an innovative biopharmaceutical company based in Shanghai focusing on discovering or licensing, developing and commercializing proprietary therapeutics that
address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases therapies. Our mission is to transform patients&#146; lives in China and eventually leverage our capabilities to
impact human health worldwide. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since our founding in 2014, we have assembled a pipeline consisting of six drug candidates through partnerships with
global biopharmaceutical companies. These include three late-stage assets targeting fast growing segments of China&#146;s pharmaceutical market and three assets addressing global unmet medical needs. We believe that management&#146;s decades-long
global drug development expertise, combined with our demonstrated understanding of the pharmaceutical industry, clinical resources and regulatory system in China, has provided us, and will continue to provide us, opportunities to partner with global
companies aiming to bring innovative products to market in China efficiently and effectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our consolidated net loss attributable to ordinary
shareholders for the six months ended June&nbsp;30, 2016 and 2017 was $11.8&nbsp;million and $24.4&nbsp;million, respectively. Our consolidated net loss attributable to ordinary shareholders for the years ended December&nbsp;31, 2015 and 2016 was
$18.0&nbsp;million and $37.5&nbsp;million, respectively. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Basis of presentation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our consolidated statement of operations data for the years ended December&nbsp;31, 2015 and December&nbsp;31, 2016 and our consolidated statement of financial position data as of December&nbsp;31, 2015 and
December&nbsp;31, 2016 have been derived from our audited consolidated financial statements included elsewhere in this prospectus. Our consolidated statements of operations data for the six months ended June&nbsp;30, 2016 and June&nbsp;30, 2017 and
our consolidated statement of financial position data as of June&nbsp;30, 2017 have been derived from our unaudited condensed consolidated financial statements appearing elsewhere in this prospectus. The unaudited condensed interim consolidated
financial statements reflect, in the opinion of management, all adjustments of a normal, recurring nature that are necessary for the fair presentation of the financial statements. Our consolidated financial statements appearing elsewhere in this
prospectus have been prepared in accordance with U.S. GAAP. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Factors affecting our results of operations </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Research and development expenses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe our
ability to successfully develop drug candidates will be the primary factor affecting our long-term competitiveness, as well as our future growth and development. Developing high quality drug candidates
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">74 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
requires a significant investment of resources over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area. As a result of this
commitment, our pipeline of drug candidates has been steadily advancing and expanding, with four clinical-stage drug candidates being investigated. For more information on the nature of the efforts and steps necessary to develop our drug candidates,
see &#147;Business&#148; and &#147;Regulation.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To date, we have financed our activities primarily through private placements. Through
June&nbsp;30, 2017, we have raised $164.5&nbsp;million in equity financing. Our operations have consumed substantial amounts of cash since inception. The net cash used in our operating activities was $11.5&nbsp;million and $32.2&nbsp;million for the
years ended December&nbsp;31, 2015 and 2016, respectively. The net cash used in our operating activities was $8.8&nbsp;million and $17.7&nbsp;million for the six months ended June&nbsp;30, 2016 and 2017, respectively. We expect our expenses to
increase significantly in connection with our ongoing activities, particularly as we advance the clinical development of our four clinical-stage drug candidates and continue research and development of our preclinical-stage drug candidates and
initiate additional clinical trials of, and seek regulatory approval for, these and other future drug candidates. These expenses include: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">expenses incurred for payments to CROs, investigators and clinical trial sites that conduct our clinical studies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">employee compensation related expenses, including salaries, benefits and equity compensation expense; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">expenses for licensors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the cost of acquiring, developing, and manufacturing clinical study materials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">facilities, depreciation, and other expenses, which include office leases and other overhead expenses; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">costs associated with <FONT STYLE="white-space:nowrap">pre-clinical</FONT> activities and regulatory operations; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">additional costs associated with operating as a public company upon the completion of this offering. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If completed, the net proceeds to us from this offering will be an important source of funds for our research and development. For more information on the nature of
the intended uses for the proceeds from this offering, see &#147;Use of proceeds.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For more information on the research and development expenses
incurred for the development of our drug candidates, see &#147;Key components of results of operations&#151;Research and development expenses.&#148; </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>General and administrative expenses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our general and
administrative expenses consist primarily of personnel compensation and related costs, including share-based compensation for administrative personnel. Other general and administrative expenses include professional service fees for legal,
intellectual property, consulting, auditing and tax services as well as other direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies used in general and administrative activities. We anticipate that our
general and administrative expenses will increase in future periods to support increases in our research and development activities and as we prepare to manufacture and commercialize our products. These increases will likely include increased
headcount, increased share compensation charges, expanded infrastructure and increased costs for insurance. We also anticipate increased legal, compliance, accounting and investor and public relations expenses associated with being a public company.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our ability to commercialize our drug candidates </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">All of our drug candidates are still in development. Four of our drug candidates are in clinical development and various others are in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development. Our ability
to generate revenue from our drug candidates is dependent on their receipt of regulatory approval for and successful commercialization of such products, which may never occur. Certain of our drug candidates may require additional <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and/or clinical development, regulatory approval in multiple jurisdictions, manufacturing supply, substantial investment and significant marketing efforts before we generate any revenue from product
sales. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">75 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our licensing arrangements </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our results of operations have been, and we expect them to continue to be, affected by our licensing, collaboration and development agreements. We are required to make upfront payments upon our entry into such
agreements and milestone payments upon the achievement of certain development, regulatory and commercial milestones for the relevant drug product under these agreements as well as tiered royalties based on the net sales of the licensed products.
These expenses are recorded in research and development expense in our consolidated financial statements and totaled $1.5 million and $7.8&nbsp;million for the six months ended June&nbsp;30, 2016 and 2017, respectively, and $6.2&nbsp;million and
$17.1&nbsp;million for the years ended December&nbsp;31, 2015 and 2016, respectively. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Critical accounting policies and significant judgments and
estimates </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We prepare our financial statements in conformity with U.S. GAAP, which requires us to make judgments, estimates and assumptions. We
continually evaluate these estimates and assumptions based on the most recently available information, our own historical experiences and various other assumptions that we believe to be reasonable under the circumstances. Since the use of estimates
is an integral component of the financial reporting process, actual results could differ from our expectations as a result of changes in our estimates. Some of our accounting policies require a higher degree of judgment than others in their
application and require us to make significant accounting estimates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The selection of critical accounting policies, the judgments and other
uncertainties affecting application of those policies and the sensitivity of reported results to changes in conditions and assumptions are factors that should be considered when reviewing our financial statements. We believe the following accounting
policies involve the most significant judgments and estimates used in the preparation of our financial statements. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Share-based compensation
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Awards granted to employees </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We grant
share options to eligible employees, management and directors and account for these share-based awards in accordance with ASC 718, <I>Compensation-Stock Compensation</I>, or ASC 718. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Share-based awards are measured at the grant date fair value and recognized as an expense (i)&nbsp;immediately at grant date if no vesting conditions are required or (ii)&nbsp;using a graded vesting method over the
requisite service period, which is the vesting period. See footnote 10 to the consolidated financial statements included elsewhere in this prospectus for further details on the assumptions used to estimate the fair value of share-based awards
granted in prior periods. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">All transactions in which goods or services are received in exchange for equity instruments are accounted for based on the
fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To the extent the
required vesting conditions are not met resulting in the forfeiture of the share-based awards, previously recognized compensation expense relating to those awards are reversed. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We, with the assistance of an independent third party valuation firm, determined the fair value of the stock options granted to employees. The binomial option pricing model was applied in determining the estimated
fair value of the options granted to employees. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Awards granted to <FONT STYLE="white-space:nowrap">non-employees</FONT> </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have accounted for equity instruments issued to <FONT STYLE="white-space:nowrap">non-employees</FONT> in accordance with the provisions of ASC 505,
<I>Equity-Based Payments to <FONT STYLE="white-space:nowrap">Non-Employees</FONT></I>. All transactions in which goods or services are received in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">76 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
exchange for equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.
The measurement date of the fair value of the equity instrument issued is the date on which the counterparty&#146;s performance is completed as there is no associated performance commitment. The expense is recognized in the same manner as if we had
paid cash for the services provided by the <FONT STYLE="white-space:nowrap">non-employees.</FONT> </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Fair value measurements </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We apply ASC Topic 820, <I>Fair Value Measurements and Disclosures</I>, of ASC 820, in measuring fair value. ASC 820 defines fair value, establishes a framework for
measuring fair value and requires disclosures to be provided on fair value measurement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">ASC 820 establishes a three-tier fair value hierarchy, which
prioritizes the inputs used in measuring fair value as follows: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Level 1&#151;Observable inputs that reflect quoted prices (unadjusted) for identical
assets or liabilities in active markets. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Level 2&#151;Include other inputs that are directly or indirectly observable in the marketplace. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Level 3&#151;Unobservable inputs which are supported by little or no market activity. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">ASC 820 describes three main approaches, for example, to measuring the fair value of assets and liabilities: (1)&nbsp;market approach, (2)&nbsp;income approach and (3)&nbsp;cost approach. The market approach uses
prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The
measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Financial instruments of our company primarily include cash and cash equivalents, prepayments and other current assets, accounts payable, warrant liabilities and
other payables. As of each reporting date, the carrying values of cash and cash equivalents, prepayments and other current assets, accounts payable and other payables approximated their fair values due to the short-term maturity of these
instruments. The warrant liabilities were recorded at fair value as determined on the respective issuance dates and subsequently adjusted to the fair value at each reporting date. We determined the fair values of the warrant liabilities with the
assistance of an independent third party valuation firm, and we have measured the warrant liabilities at fair values on a recurring basis using significant unobservable inputs (Level 3) as of each reporting date. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Fair value of our ordinary shares </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a private
company with no quoted market prices for our ordinary shares. We have therefore needed to make estimates of the fair value of our ordinary shares at various dates for the following purposes: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">determining the fair value of our ordinary shares at the date of issuance and the dates of subsequent measurement of convertible instruments as one of the inputs
in determining the intrinsic value of the beneficial conversion feature, if any; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">determining the fair value of our ordinary shares at the date of the grant of a share-based compensation award to our employees and non-employees as one of the
inputs in determining the grant date fair value of the award. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">77 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In determining the fair value of our ordinary shares as of various valuation dates, we first applied an income
approach, specifically a discounted cash flow, or DCF, analysis based on our projected cash flows using management&#146;s best estimates as of the valuation date and the market approach by referring to transaction prices of our private equity
financing transactions with independent third parties to conclude on the equity value. We then applied the option-pricing method to allocate the equity value between preferred shares and ordinary shares. The determination of the equity value
requires complex and subjective judgments to be made regarding prospects of the industry and the products at the respective valuation dates, our projected financial and operating results, our unique business risks and the liquidity of our shares.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The income approach involves applying appropriate discount rates to estimated cash flows that are based on earnings forecasts. However, these fair
values are inherently uncertain and highly subjective. The major assumptions utilized in DCF analysis include: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Financial projection</I>. The
projected cash flows include among other things, an analysis of projected revenue growth, gross margins, effective tax rates, capital expenditures, working capital requirements and depreciation and amortization. The assumptions used in deriving the
fair values are consistent with our business plan. These assumptions include no material changes in the existing political, legal and economic conditions in China; our ability to retain competent management and key personnel to support our ongoing
operations; and no material deviation in historical industry trends and market conditions from current forecasts. These assumptions are inherently uncertain. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Discount Rates</I>. The discount rates were based on the weighted average cost of capital and ranged from 16%-25% where the cost of equity was determined based on a Capital Asset Pricing Model, which includes a
consideration of the factors including risk-free rate, comparative industry risk, equity risk premium, company size and non-systemic risk factors. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Discount for Lack of Marketability, or DLOM</I>. DLOM reflects the fact that our shares were privately-held shares. DLOM was quantified by various valuation
techniques, such as the Black-Scholes option pricing model. Under this method, the cost of the put option, which could be used to hedge the price change before the privately held shares can be sold, was considered as a basis to determine the DLOM.
This option pricing method is one of the methods commonly used in estimating DLOM. The key assumptions of such model includes risk-free rates, timing of a liquidity event, and estimated volatility of our shares. The farther the valuation date is
from an expected liquidity event, the higher the put option value and thus the higher the implied DLOM. The lower DLOM is used for the valuation, the higher is the determined fair value of the ordinary shares. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The equity value of our company determined at the respective valuation dates based on the income approach under the above assumptions and the market approach
referring to transaction price of our private equity financing transactions with independent third parties was allocated between the preferred shares and ordinary shares. The option-pricing method was used to allocate equity value, taking into
account the guidance prescribed by the AICPA Audit and Accounting Practice Aid, &#147;<I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>.&#148; The method treats common stock and preferred stock as call options on
the enterprise&#146;s value, with exercise prices based on the liquidation preference of the preferred stock. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The option-pricing method involves making
estimates of the anticipated timing and probability of a potential liquidity event, such as a sale of our company, an initial public offering, a redemption event (for Series C preferred shares issued in June 2017) and estimates of risk free rate and
the volatility of our equity securities. The anticipated timing and probability were based on the plans of our board of directors and management. The risk free rate is adopted based on the United States Treasury bond yield with a maturity
commensurating with the expected time to liquidity, adjusted by country risk premium between China and the United States. Estimating the volatility of the share price of a privately held company is complex because there is no readily available
market for the shares. We estimated the volatility of our shares to be 70% based on the historical </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">78 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
volatilities of comparable publicly traded companies engaged in similar lines of business. Had we used different estimates of volatility, the allocations between preferred and ordinary shares
would have been different. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Income taxes </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Current income taxes are provided on the basis of net income for financial reporting purposes, adjusted for income and expense items which are not assessable or
deductible for income tax purposes, in accordance with the regulations of the relevant tax jurisdictions. We follow the liability method of accounting for income taxes. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Under this method, deferred tax assets and liabilities are determined based on the temporary differences between the financial statements carrying amounts and tax bases of assets and liabilities by applying enacted
statutory tax rates that will be in effect in the period in which the temporary differences are expected to reverse. We record a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more likely than
not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in our consolidated financial statements in the period of change. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In accordance with the provisions of ASC 740, <I>Income Taxes</I>, we recognize in our financial statements the benefit of a tax position if the tax position is
&#147;more likely than not&#148; to prevail based on the facts and technical merits of the position. Tax positions that meet the &#147;more likely than not&#148; recognition threshold are measured at the largest amount of tax benefit that has a
greater than fifty percent likelihood of being realized upon settlement. We estimate our liability for unrecognized tax benefits which are periodically assessed and may be affected by changing interpretations of laws, rulings by tax authorities,
changes and/or developments with respect to tax audits, and expiration of the statute of limitations. The ultimate outcome for a particular tax position may not be determined with certainty prior to the conclusion of a tax audit and, in some cases,
appeal or litigation process. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We consider positive and negative evidence when determining whether some portion or all of our deferred tax assets will
not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, our historical results of
operations, and our tax planning strategies. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based upon the level of
our historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible, we believe it is more likely than not that we will not realize the deferred tax assets resulted from the tax
loss carried forward in the future periods. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The actual benefits ultimately realized may differ from our estimates. As each audit is concluded,
adjustments, if any, are recorded in our financial statements in the period in which the audit is concluded. Additionally, in future periods, changes in facts, circumstances and new information may require us to adjust the recognition and
measurement estimates with regard to individual tax positions. Changes in recognition and measurement estimates are recognized in the period in which the changes occur. As of December&nbsp;31, 2015 and 2016, we did not have any significant
unrecognized uncertain tax positions. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Key components of results of operations </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Taxation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Cayman Islands </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Zai Lab Limited is incorporated in the Cayman Islands. The Cayman Islands currently levies no taxes on profits, income, gains or appreciation earned by individuals or corporations. In addition, our payment of
dividends, if </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">79 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
any, is not subject to withholding tax in the Cayman Islands. For more information, see &#147;Taxation&#151;Cayman Islands taxation.&#148; </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>People&#146;s Republic of China </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our subsidiaries
incorporated in the PRC are governed by the PRC Enterprise Income Tax Law, or EIT Law, and regulations. Under the EIT Law, the standard Enterprise Income Tax, or EIT, rate is 25% on taxable profits as reduced by available tax losses. Tax losses may
be carried forward to offset any taxable profits for up to following five years. For more information, see &#147;Taxation&#151;People&#146;s Republic of China taxation.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Results of operations </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table sets forth a summary of our consolidated results of operations for
the periods indicated. This information should be read together with our consolidated financial statements and related notes included elsewhere in this prospectus. Our operating results in any period are not necessarily indicative of the results
that may be expected for any future period. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Comprehensive Loss Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(13,587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(32,149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,155</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,915</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(38,529</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">403</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fair value of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">341</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,534</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,835</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss attributable to ordinary shareholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,835</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average shares used in calculating net loss per ordinary share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,242,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,630,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,693,655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,439,028</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">80 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Six Months Ended June&nbsp;30, 2017 Compared to Six Months Ended June&nbsp;30, 2016 </I></B></FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Research and development expenses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following
table sets forth the components of our research and development expenses for the six months indicated. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Six months ended June 30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Research and development expenses:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Personnel compensation and related costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,887</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">21.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,498</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">21.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Licensing fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,811</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">37.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Payment to CROs/CMOs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,991</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">45.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,394</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,259</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B></B>$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B></B>8,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Research and development expense increased by $12.1 million to $20.9 million for six months ended June 30, 2017 from $8.8 million
for six months ended June 30, 2016. The increase in research and development expense included the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">$2.6 million for increased personnel compensation and related costs which was primarily attributable to increased employee compensation costs, due to hiring of
more personnel during six months ended June&nbsp;30, 2017, the grants of new share options and vesting of restricted shares to certain employees; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">$6.3 million for increased licensing fees in connection with the upfront fee paid for licensing agreement with Paratek in the second quarter of 2017, for more
information, see &#147;Business&#151;Overview of our license agreements&#151;Paratek.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table summarizes our
research and development expense by program for the six months ended June 30, 2016 and 2017, respectively: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Six months ended June 30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Research and development expenses:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Clinical programs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,224</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">48.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12,820</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">61.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Preclinical programs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">22.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,888</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Unallocated research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,559</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">29.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">29.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B></B>$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B></B>8,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During the six months ended June 30, 2017, 61% and 9% of our total research and development expenses were attributable clinical
programs and preclinical programs, respectively. During the six months ended June&nbsp;30, 2016, 48% and 23% of our total research and development expenses were attributable to clinical programs and preclinical programs, respectively. ZL-2401
represented approximately 58% of our external research and development expense, which includes licensing fees and payments to CROs and CMOs, for the six months ended June 30, 2017. ZL-2303 represented approximately 36% of our external research and
development expense for the six months ended June 30, 2016. No other programs represented a significant amount of research and development expense for the six months ended June 30, 2017 or 2016. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">81 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Though we maintain our external research and development expenses by program we do not allocate our internal research
and development expenses by program, because our employees and internal resources may be engaged in projects for multiple programs at any time. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>General and administrative expenses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our general and
administrative expenses consist primarily of personnel compensation and related costs, including share-based compensation for administrative personnel. Other general and administrative expenses include professional service fees for legal,
intellectual property, consulting, auditing and tax services as well as other direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies used in general and administrative activities. The following table sets
forth the components of our research and development expenses for the years indicated. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Six months ended June 30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>General and Administrative Expenses:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Personnel compensation and related costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,067</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">44.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,475</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">61.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Professional service fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,059</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">44.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,102</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">27.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">251</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">464</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B></B>$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B></B>2,377</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">General and administrative expenses increased by $1.6 million to $4.0 million for six months ended June 30, 2017 from $2.4 million
for six months ended June 30, 2016. The increase in general and administrative expenses was primarily attributable to a $1.4&nbsp;million for increased personnel compensation and related costs which was primarily attributable to increased
administrative personnel compensation costs, due to hiring of more personnel during six months ended June 30, 2017, the grants of new share options and vesting of restricted shares to certain employees. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Interest Income </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Interest income increased by $0.2
million for six months ended June 30, 2017 due to higher cash on hand in 2017. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Changes in Fair Value of Warrants </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The expense associated with the changes in fair value of warrants reflected the result of the change in value of the preferred shares issuable upon exercise of the
warrants. We determined the fair values of the warrant liabilities with the assistance of an independent third party valuation firm. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">82 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Year Ended December&nbsp;31, 2016 Compared to Year Ended December&nbsp;31, 2015 </I></B></FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Research and development expenses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following
table sets forth the components of our research and development expenses for the years indicated. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Research and development expenses:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Personnel compensation and related costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,095</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Licensing fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">45.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17,108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Payment to CROs/CMOs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,180</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,759</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">21.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,032</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Research and development expense increased by $18.6&nbsp;million to $32.1&nbsp;million for year ended December&nbsp;31, 2016 from
$13.6&nbsp;million for year ended December&nbsp;31, 2015. The increase in research and development expense included the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">$2.9&nbsp;million for increased personnel compensation and related costs which was primarily attributable to increased employee compensation costs, due to hiring
of more personnel during year ended December&nbsp;31, 2016 and the grants of new share options to certain employees; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">$10.9&nbsp;million for increased licensing fees in connection with the upfront fee paid for licensing agreement with Tesaro for
<FONT STYLE="white-space:nowrap">ZL-2306</FONT> in fiscal year 2016 (see &#147;Business&#151;Our clinical pipeline&#151;Niraparib&#148; for further information); and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">$3.6&nbsp;million for increased payment to CROs/CMOs in fiscal year 2016 as we advanced our drug candidate pipeline. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table summarizes our research and development expense by program for the years ended December&nbsp;31, 2015 and December&nbsp;31, 2016, respectively:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Research and development expenses:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Clinical programs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">44.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20,129</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">62.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Preclinical programs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,821</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,839</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Unallocated research and development expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,746</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">27.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,181</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">22.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,587</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">32,149</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During the year ended December&nbsp;31, 2016, 63% and 15% of our total research and development expenses were attributable to
clinical programs and preclinical programs, respectively. During the year ended December 31, 2015, 44% and 28% of our total research and development expenses were attributable to clinical programs and preclinical programs, respectively. Niraparib
represented approximately 63% of our external research and development expense, which includes licensing fees and payments to CROs and CMOs, for the year ended December 31, 2016. ZL-2303 represented approximately 10% and 61% of our external research
and development expense for the years ended December 31, 2016 and December&nbsp;31, 2015, respectively. No other </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">83 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
programs represented a significant amount of research and development expense for the years ended December 31, 2016 or December 31, 2015. Though we manage our external research and development
expenses by program we do not allocate our internal research and development expenses by program because our employees and internal resources may be engaged in projects for multiple programs at any time. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>General and administrative expenses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following
table sets forth the components of our research and development expenses for the years indicated. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>%</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>General and Administrative Expenses:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Personnel compensation and related costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,811</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">65.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,120</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">48.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Professional service fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,691</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">42.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">611</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">22.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">569</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,762</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">General and administrative expenses increased by $3.6&nbsp;million to $6.4&nbsp;million for year ended December&nbsp;31, 2016 from
$2.8&nbsp;million for year ended December&nbsp;31, 2015. The increase in general and administrative expenses included the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">$1.3&nbsp;million for increased personnel compensation and related costs which was primarily attributable to increased administrative personnel compensation
costs, due to hiring of more personnel during year ended December&nbsp;31, 2016 and the grants of new share options to certain employees; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">$2.4&nbsp;million for increased professional service fee due to the increase of legal due diligence expenses in fiscal year 2016. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Interest income </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Interest income increased by
$0.4&nbsp;million for year ended December&nbsp;31, 2016 due to higher cash on hand in 2016. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Fair value change of warrants </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On December 31, 2015, we entered into a warrant agreement with an investor to purchase up to 461,808 of our Series A2 preferred shares at $2.1651 per share. The
fair value of the warrants of $2.0 million was expensed on the date of issuance and an additional $1.9 million change in fair value was expensed in 2016 on the re-measurement date. The warrants were exercised on July 19, 2017. Upon such conversion
of the underlying preferred stock, the preferred stock will be classified as a component of equity and no longer be subject to re-measurement. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Other income </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Other income increased by
$2.2&nbsp;million for year ended December&nbsp;31, 2016 primarily as a result of an increase in governmental subsidies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">84 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Net loss attributable to ordinary shareholders </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As a result of the foregoing, we had net loss attributable to ordinary shareholders of $18.0&nbsp;million the year ended December&nbsp;31, 2015 compared to net loss attributable to ordinary shareholders of
$37.5&nbsp;million for the year ended December&nbsp;31, 2016. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Liquidity and capital resources </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since our inception, we have incurred net losses and negative cash flows from our operations. Substantially all of our losses have resulted from funding our
research and development programs and general and administrative costs associated with our operations. We incurred net losses of $11.8&nbsp;million and $24.4&nbsp;million for the six months ended June&nbsp;30, 2016 and 2017, respectively, and
$18.0&nbsp;million and $37.5&nbsp;million for the years ended December&nbsp;31, 2015 and 2016, respectively. As of June&nbsp;30, 2017, we had an accumulated deficit of $84.6&nbsp;million. Our primary use of cash is to fund research and development
costs. Our operating activities used $8.8&nbsp;million and $17.7&nbsp;million of cash flows during the six months ended June&nbsp;30, 2016 and 2017, respectively, and $11.5&nbsp;million $32.2&nbsp;million of cash flows during the years ended
December&nbsp;31, 2015 and 2016, respectively. Historically, we have financed our operations principally through proceeds from private placements of preferred shares and warrants of $164.5&nbsp;million. At June&nbsp;30, 2017, we had cash and cash
equivalents of $92.6&nbsp;million. We believe that the net proceeds of this offering, together with our existing cash and cash equivalents, will be sufficient to fund our operations through fiscal year 2020. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our ability to pay dividends may depend on receiving distributions of funds from our PRC subsidiaries. Relevant PRC statutory laws and regulations permit payments
of dividends by our PRC subsidiaries only out of their retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in
accordance with U.S. GAAP differ from those reflected in the statutory financial statements of our PRC subsidiaries. In accordance with the relevant applicable PRC laws and regulations, a domestic enterprise is required to provide statutory reserves
of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise&#146;s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus
reserve, at the discretion of the board of directors, from the profits determined in accordance with the enterprise&#146;s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash
dividends. Our PRC subsidiaries were established as domestic enterprises and therefore are subject to the above mentioned restrictions on distributable profits. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">During the six months ended June 30, 2016 and 2017 and the years ended December 31, 2015 and 2016, no appropriation to statutory reserves was made because our PRC subsidiaries had substantial losses during such
periods. As a result of relevant applicable PRC laws and regulations subject to the limit discussed above that require annual appropriations of 10% of after-tax income to be set aside, prior to payment of dividends, as a general reserve fund, our
PRC subsidiaries are restricted in their ability to transfer a portion of its net assets. Foreign exchange and other regulations in the PRC may further restrict our PRC subsidiaries from transferring funds to us in the form of dividends, loans and
advances. As of June&nbsp;30, 2017, amounts restricted are the paid-in capital of our PRC subsidiaries, which amounted to $64.0&nbsp;million. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">85 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table provides information regarding our cash flows for the six months ended June&nbsp;30, 2016 and 2017
and for the years ended December&nbsp;31, 2015 and 2016: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Six&nbsp;months&nbsp;ended&nbsp;June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year&nbsp;ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash (used in) operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,809</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(17,677</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,465</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(32,158</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash (used in) investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,647</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(738</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">106,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">29,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">106,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Effect of foreign exchange rate changes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(524</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net increases in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">97,337</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,613</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,008</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">70,788</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Net cash used in operating activities </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The use of cash resulted primarily from our net losses adjusted for <FONT STYLE="white-space:nowrap">non-cash</FONT> charges and changes in components of our operating assets and liabilities. The primary use of our
cash was to fund the development of our research and development activities, regulatory and other clinical trial costs, and related supporting administration. Our prepayments and other current assets, accounts payable and other payables balances
were affected by the timing of vendor invoicing and payments. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During the six months ended June 30, 2017, our operating activities used $17.7 million of
cash, which resulted principally from our net loss of $24.4 million, adjusted for non-cash charges of $4.3 million, and by cash used in our operating assets and liabilities of $2.4 million. Our net non-cash charges during the six months ended
June&nbsp;30, 2017 primarily consisted of $0.1 million of depreciation expense, $4.4 million of share-based compensation expense and a $0.2 million gain from changes in fair value of warrants. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">During the six months ended June 30, 2016, our operating activities used $8.8 million of cash, which resulted principally from our net loss of $11.8 million, adjusted for non-cash charges of $2.8 million, and by
cash provided by our operating assets and liabilities of $0.2 million. Our net non-cash charges during the six months ended June 30, 2016 primarily consisted of $0.1 million of depreciation expense, $1.8 million of share-based compensation expense
and a $0.9 million loss from changes in fair value of warrants. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During the year ended December&nbsp;31, 2016, our operating activities used
$32.2&nbsp;million of cash, which resulted principally from our net loss of $37.5&nbsp;million, adjusted for <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $7.0&nbsp;million, and by cash used in our operating assets and liabilities of
$1.7&nbsp;million. Our net <FONT STYLE="white-space:nowrap">non-cash</FONT> charges during the year ended December&nbsp;31, 2016 primarily consisted of $0.2&nbsp;million of depreciation expense, $4.9&nbsp;million of share-based compensation expense
and a $1.9&nbsp;million loss from changes in fair value of warrants. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During the year ended December&nbsp;31, 2015, our operating activities used
$11.5&nbsp;million of cash, which resulted principally from our net loss of $18.0&nbsp;million, adjusted for <FONT STYLE="white-space:nowrap">non-cash</FONT> charges of $4.8&nbsp;million, and by cash provided by our operating assets and liabilities
of $1.7&nbsp;million. Our net <FONT STYLE="white-space:nowrap">non-cash</FONT> charges during the year ended December&nbsp;31, 2015 primarily consisted of $0.1&nbsp;million of depreciation expense, $2.7&nbsp;million of share-based compensation
expense and a $2.0 million loss from changes in fair value of warrants. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Net cash used in investing activities </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in investing activities was $3.6 million for the six months ended June 30, 2017 compared to $0.1&nbsp;million for the six months ended June 30, 2016.
The increase in cash used in investing activities was mainly due to the construction of our small molecule commercial facility in 2017. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">86 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in investing activities was $2.7&nbsp;million for the year ended December&nbsp;31, 2016 compared to
$0.7&nbsp;million for the year ended December&nbsp;31, 2015. The increase in cash used in investing activities was due to the construction of our small molecule commercial facility and other investments in 2016. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Net cash provided by financing activities </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash
provided by financing activities was $29.8 million for the six months ended June 30, 2017 compared to $106.2 million cash provided by financing activities for the six months ended June 30, 2016. The financing activities for the six months ended June
30, 2017 primarily consisted of the issuance of $30 million Series C preferred shares. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by financing activities was $106.2&nbsp;million
for the year ended December&nbsp;31, 2016 compared to $18.3&nbsp;million cash provided by financing activities for the year ended December&nbsp;31, 2015. The increase was due to the issuance of $106.2&nbsp;million Series B preferred shares and
warrants to certain investors. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Internal control over financial reporting </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In connection with the audit of our financial statements as of and for the years ended December&nbsp;31, 2015 and 2016, we identified a material weakness in our internal control over financial reporting as of
December&nbsp;31, 2016. The material weakness related to the lack of sufficient accounting personnel with U.S. GAAP knowledge and SEC financial reporting requirements for the purpose of financial reporting, and lack of accounting policies and
procedures over financial reporting in accordance with U.S. GAAP. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are implementing measures designed to improve our internal control over financial
reporting to remediate this material weakness, including the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">hiring additional financial professionals with U.S. GAAP and SEC reporting experience; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">increasing the number of qualified financial reporting personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">improving the capabilities of existing financial reporting personnel through training and education in the accounting and reporting requirements under U.S. GAAP
and SEC rules and regulations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">developing, communicating and implementing an accounting policy manual for our financial reporting personnel for recurring transactions and <FONT
STYLE="white-space:nowrap">period-end</FONT> closing processes; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">establishing effective monitoring and oversight controls for <FONT STYLE="white-space:nowrap">non-recurring</FONT> and complex transactions to ensure the
accuracy and completeness of our consolidated financial statements and related disclosures. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These additional resources and procedures
are designed to enable us to broaden the scope and quality of our internal review of underlying information related to financial reporting and to formalize and enhance our internal control procedures. With the oversight of senior management and our
board of directors, we have begun taking steps and plan to take additional measures to remediate the underlying causes of the material weakness. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We, and
our independent registered public accounting firm, were not required to perform an evaluation of our internal control over financial reporting as of December&nbsp;31, 2016 in accordance with the provisions of the Sarbanes-Oxley Act. Accordingly, we
cannot assure you that we have identified all, or that we will not in the future have additional, material weaknesses. Material weaknesses may still exist when we report on the effectiveness of our internal control over financial reporting as
required by reporting requirements under Section&nbsp;404 of the Sarbanes-Oxley Act after the completion of this offering. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">87 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Contractual obligations </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table sets forth our contractual obligations as of December&nbsp;31, 2016. Amounts we pay in future periods may vary from those reflected in the table. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Less&nbsp;than&nbsp;1</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>year</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>1&nbsp;to&nbsp;3&nbsp;years</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>3&nbsp;to&nbsp;5&nbsp;years</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>More&nbsp;than&nbsp;5<BR>years</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating Lease Obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,119</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">712</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,209</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Purchase Obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,397</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,397</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,516</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,209</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="20" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We also have obligations to make future payments to third party licensors that become due and payable on the achievement of certain
development, regulatory and commercial milestones as well as tiered royalties on net sales. We have not included these commitments on our balance sheet or in the table above because the commitments are cancelable if the milestones are not complete
and achievement and timing of these obligations are not fixed or determinable. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B><FONT STYLE="white-space:nowrap">Off-balance</FONT> sheet
arrangements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We currently do not engage in trading activities involving <FONT STYLE="white-space:nowrap">non-exchange</FONT> traded contracts or
interest rate swap transactions or foreign currency forward contracts. In the ordinary course of our business, we do not enter into transactions involving, or otherwise form relationships with, unconsolidated entities or financial partnerships that
are established for the purpose of facilitating <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements or other contractually narrow or limited purposes. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Qualitative&nbsp;&amp; quantitative disclosures about market risk </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are exposed to market risk including
foreign exchange risk, credit risk, cash flow interest rate risk and liquidity risk. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Foreign exchange risk </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Renminbi (&#147;RMB&#148;) is not a freely convertible currency. The State Administration of Foreign Exchange, under the authority of the People&#146;s Bank of
China, controls the conversion of RMB into foreign currencies. The value of RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange
Trading System market. The cash and cash equivalents of our company included aggregated amounts of RMB3.5&nbsp;million and RMB44.2&nbsp;million, which were denominated in RMB, as of December&nbsp;31, 2015 and 2016, respectively, representing 4% and
8% of the cash and cash equivalents as of December&nbsp;31, 2015 and 2016, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our business mainly operates in the PRC with most of our
transactions settled in RMB, and our financial statements are presented in U.S.&nbsp;dollars. We do not believe that we currently have any significant direct foreign exchange risk and have not used any derivative financial instruments to hedge our
exposure to such risk. Although, in general, our exposure to foreign exchange risks should be limited, the value of your investment in our ADSs will be affected by the exchange rate between the U.S.&nbsp;dollar and the RMB because the value of our
business is effectively denominated in RMB, while the ADSs will be traded in U.S.&nbsp;dollars. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Translation of the net proceeds that we will receive
from this offering into RMB will also expose us to currency risk. The value of the RMB against the U.S.&nbsp;dollar and other currencies may fluctuate and is affected by, among </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">88 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
other things, changes in China&#146;s political and economic conditions. The conversion of RMB into foreign currencies, including U.S.&nbsp;dollars, has been based on rates set by the PBOC. On
July&nbsp;21, 2005, the PRC government changed its <FONT STYLE="white-space:nowrap">decade-old</FONT> policy of pegging the value of the RMB to the U.S.&nbsp;dollar. Under the revised policy, the RMB is permitted to fluctuate within a narrow and
managed band against a basket of certain foreign currencies. This change in policy resulted in a more than 20% appreciation of the RMB against the U.S.&nbsp;dollar in the following three years. Between July&nbsp;2008 and June&nbsp;2010, this
appreciation halted, and the exchange rate between the RMB and U.S.&nbsp;dollar remained within a narrow band. In June&nbsp;2010, the PBOC announced that the PRC government would increase the flexibility of the exchange rate, and thereafter allowed
the RMB to appreciate slowly against the U.S.&nbsp;dollar within the narrow band fixed by the PBOC. However, more recently, on August&nbsp;11, 12 and 13, 2015, the PBOC significantly devalued the RMB by fixing its price against the U.S.&nbsp;dollar
1.9%, 1.6%, and 1.1% lower than the previous day&#146;s value, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To the extent that we need to convert U.S.&nbsp;dollars we receive from
this offering into RMB for our operations or if any of our arrangements with other parties are denominated in U.S. dollars and need to be converted into RMB, appreciation of the RMB against the U.S.&nbsp;dollar would have an adverse effect on the
RMB amount we receive from the conversion. Conversely, if we decide to convert RMB into U.S.&nbsp;dollars for the purpose of making payments for dividends on our ordinary shares or ADSs or for other business purposes, appreciation of the
U.S.&nbsp;dollar against the RMB would have a negative effect on the U.S.&nbsp;dollar amounts available to&nbsp;us. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Credit risk
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our credit risk is primarily attributable to the carrying amounts of cash and cash equivalents. The carrying amounts of cash and cash
equivalents represent the maximum amount of loss due to credit risk. As of December&nbsp;31, 2015 and 2016, all of our cash and cash equivalents were held by major financial institutions located in the PRC and international financial institutions
outside of the PRC which we believe are of high credit quality, and we will continually monitor the credit worthiness of these financial institutions. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Recently issued accounting standards </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In May&nbsp;2014, the
Financial Accounting Standards Board, or FASB, issued Accounting Standards Updates, or ASU, <FONT STYLE="white-space:nowrap">2014-09,</FONT> <I>Revenue from Contracts with Customers (Topic 606)</I>, to clarify the principles of recognizing revenue
and create common revenue recognition guidance between U.S.&nbsp;GAAP and International Financial Reporting Standards, or IFRS. An entity has the option to apply the provisions of ASU <FONT STYLE="white-space:nowrap">2014-09&nbsp;either</FONT>
retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this standard recognized at the date of initial application. ASU <FONT STYLE="white-space:nowrap">2014-09&nbsp;is</FONT>
effective for fiscal years and interim periods within those years beginning after December&nbsp;15, 2016, and early adoption is not permitted. In August, 2015, the FASB updated this standard to ASU <FONT STYLE="white-space:nowrap">2015-14,</FONT>
the amendments in this update defer the effective date of Update <FONT STYLE="white-space:nowrap">2014-09,</FONT> that the update should be applied to annual reporting periods beginning after December&nbsp;15, 2017 and earlier application is
permitted only as of annual reporting periods beginning after December&nbsp;15, 2016, including interim reporting periods within that reporting period. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In May&nbsp;2016, FASB issued ASU <FONT STYLE="white-space:nowrap">2016-12,</FONT> <I>Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements
and Practical Expedients</I>. The amendments in this update do not change the core principle of the guidance in Topic 606. Rather, the amendments in this update affect only the narrow aspects of Topic 606. The areas improved include:
(1)&nbsp;Assessing the Collectability Criterion in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Paragraph&nbsp;606-10-25-1(e)&nbsp;and</FONT></FONT></FONT> Accounting for Contracts That Do Not
Meet the Criteria for Step 1; (2)&nbsp;Presentation of Sales Taxes and Other Similar Taxes Collected from Customers; (3)&nbsp;Noncash Consideration; (4)&nbsp;Contract Modifications at Transition; (5)&nbsp;Completed Contracts at Transition; and
(6)&nbsp;Technical Correction. The effective date and transition requirements for the amendments in this update are the same as the effective date and transition requirements for Topic 606 (and any other topic amended by update <FONT
STYLE="white-space:nowrap">2014-09).</FONT> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">89 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are in a development stage, with no revenues to date, and will evaluate the application of this ASU, but as a
result we have not yet determined the potential effects it may have on the Company&#146;s financial statements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2015, FASB issued ASU <FONT
STYLE="white-space:nowrap">2015-17,</FONT> <I>Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes</I>, which requires deferred income tax liabilities and assets to be classified as noncurrent on the balance sheet rather than
being separated into current and noncurrent. The guidance is effective for public entities for annual periods beginning after December&nbsp;15, 2016, and interim periods within those annual periods with early adoption being permitted. We have
adopted this guidance during the year ended December&nbsp;31, 2016, retrospectively. The adoption of this guidance did not have a material effect on the consolidated financial statements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In January 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-01,</FONT> <I>Financial Instruments-Overall (Subtopic <FONT STYLE="white-space:nowrap">825-10):</FONT> Recognition and Measurement of
Financial Assets and Financial Liabilities</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2016-01&#148;),</FONT> which requires that equity investments, except for those accounted for under the equity method or those that result in consolidation of
the investee, be measured at fair value, with subsequent changes in fair value recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any,
plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. ASU <FONT STYLE="white-space:nowrap">2016-01</FONT> also impacts the presentation and disclosure
requirements for financial instruments. ASU <FONT STYLE="white-space:nowrap">2016-01</FONT> is effective for public business entities for annual periods, and interim periods within those annual periods, beginning after December&nbsp;15, 2017. Early
adoption is permitted only for certain provisions. We are in the process of evaluating the impact of adoption of this guidance on the consolidated financial statements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT><I> Leases (Topic 842)</I>, which requires lessees to recognize most leases on the balance sheet. This ASU requires lessees to
recognize a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and lease liability for all leases with terms of more than 12 months. Lessees are permitted to make an accounting policy election to not
recognize the asset and liability for leases with a term of twelve months or less. The ASU does not significantly change the lessees&#146; recognition, measurement and presentation of expenses and cash flows from the previous accounting standard.
Lessors&#146; accounting under the ASC is largely unchanged from the previous accounting standard. In addition, the ASU expands the disclosure requirements of lease arrangements. Lessees and lessors will use a modified retrospective transition
approach, which includes a number of practical expedients. The provisions of this guidance are effective for annual periods beginning after December&nbsp;15, 2018, and interim periods within those years, with early adoption permitted. We are
currently evaluating this ASU to determine the full impact on its consolidated financial statements, as well as the impact of adoption on policies, practices and systems. As of December&nbsp;31, 2016, we have $2.1&nbsp;million of future minimum
operating lease commitments that are not currently recognized on its consolidated balance sheets. Therefore, we would expect changes to its consolidated balance sheets for the recognition of these and any additional leases entered into in the future
upon adoption. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In March 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-09,</FONT> which simplifies several aspects of the accounting
for employee share-based payment transactions for both public and <FONT STYLE="white-space:nowrap">non-public</FONT> entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as
classification in the statement of cash flows. For public entities, the ASU is effective for annual reporting periods beginning after December&nbsp;15, 2016, including interim periods within those annual reporting periods. Early adoption will be
permitted in any interim or annual period for which financial statements have not yet been issued or have not been made available for issuance. We have elected to early adopt this standard on a modified retrospective basis at the beginning of the
period presented as we elected to account for forfeitures when they occur to reduce the complexity in the accounting of share based compensation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">90 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In August 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-15,</FONT> <I>Statement of Cash Flows (Topic
230)</I>. The update is intended to improve financial reporting in regards to how certain transactions are classified in the statement of cash flows. This update requires that debt extinguishment costs be classified as cash outflows for financing
activities and provides additional classification guidance for the statement of cash flows. The update also requires that the classification of cash receipts and payments that have aspects of more than one class of cash flows to be determined by
applying specific guidance under generally accepted accounting principles. The update also requires that each separately identifiable source or use within the cash receipts and payments be classified on the basis of their nature in financing,
investing or operating activities. The update is effective for public companies for fiscal years beginning after December&nbsp;15, 2017, including interim periods within those fiscal years. We are in the process of evaluating the impact of adoption
of this guidance on the consolidated financial statements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In October 2016, FASB issued ASU <FONT STYLE="white-space:nowrap">2016-16,</FONT> <I>Income
Taxes (Topic 740)</I>. Under the new standard, an entity is to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The new standard does not include new disclosure
requirements; however, existing disclosure requirements might be applicable when accounting for the current and deferred income taxes for an intra-entity transfer of an asset other than inventory. The new standard is effective for annual periods
beginning after December&nbsp;15, 2017, including interim reporting periods within those annual periods. The ASU is not expected impact the consolidated balance sheet upon adoption. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In October 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-18,</FONT> <I>Statement of Cash Flows (Topic 230), Restricted Cash</I>. The update applies to all entities that have restricted cash or
restricted cash equivalents and are required to present a statement of cash flows. The update addresses diversity in practice that exists in the classification and presentation of changes in restricted cash on the statement of cash flows, and
requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. As a result, amounts generally described as
restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">beginning-of-period</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-period</FONT></FONT> total amounts shown on the statement of cash flows. The update is effective for public companies for fiscal years beginning after December&nbsp;15, 2017, and
interim periods within those fiscal years. Early adoption is permitted. The updates should be applied using a retrospective transition method to each period presented. We currently do not have restricted cash balances. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In May 2017, FASB issued ASU No. 2017-09, <I>Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting</I>. The guidance provides clarity and
reduces diversity in practice and cost and complexity when accounting for a change to the terms or conditions of a share-based payment award. The amendments in this update are effective for all entities for annual periods, and interim periods within
those annual periods, beginning after December 15, 2017. Early adoption is permitted. The Group is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>JOBS Act exemptions and foreign private issuer status </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
qualify as an &#147;emerging growth company&#148; as defined in the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. This includes
an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act. We may take advantage of this exemption for up to five years or such earlier time that we
are no longer an emerging growth company. We will cease to be an emerging growth company if we have more than $1.07&nbsp;billion in annual revenue, have more than $700.0&nbsp;million in market value of our ordinary shares held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> or issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. We may choose to take advantage of some but not all of these
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">91 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
reduced burdens. We have irrevocably elected not to take advantage of the extended transition period provided under Section 7(a)(2)(B) of the Securities Act for complying with new or revised
accounting standards. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon consummation of this offering, we will report under the Exchange Act as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
company with foreign private issuer status. Even after we no longer qualify as an emerging growth company, as long as we qualify as a foreign private issuer under the Exchange Act we will be exempt from certain provisions of the Exchange Act that
are applicable to U.S. domestic public companies, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit
from trades made in a short period of time; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> containing unaudited
financial and other specified information, or current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> upon the occurrence of specified significant events; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Regulation FD, which regulates selective disclosures of material information by issuers. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">92 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_10"></A>Industry </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Evolution of China&#146;s emerging innovative pharmaceutical market </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">China&#146;s pharmaceutical market is the
second largest pharmaceutical market in the world and is projected to grow from $115&nbsp;billion in 2016 to $160&nbsp;billion by 2021 and $237&nbsp;billion by 2026, according to BMI Research. This growth is driven by strong fundamental demand for
therapeutic treatments and the Chinese government&#146;s focus on providing better quality care to patients including by encouraging greater usage of innovative drugs. We believe that the significant market opportunities for innovative therapies in
the China market are due to several trends, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">1.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B>Demographics and disease incidence:</B>&nbsp;&nbsp;&nbsp;&nbsp;China&#146;s large and rapidly aging population, increasingly sedentary and westernized lifestyle and
environmental pollution are contributing to rising incidence rates of diseases in China, such as cancer. China had a total annual cancer incidence of 4.3&nbsp;million people, compared to 1.7&nbsp;million in the United States in 2015. For some
specific tumor types, including lung, gastric and liver, China&#146;s incidence represents approximately 40% to 50% of worldwide incidences. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">2.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B>Improving access to healthcare:</B>&nbsp;&nbsp;&nbsp;&nbsp;The Chinese government has been strongly committed to improving healthcare access for patients, including enabling
access to healthcare through universal public insurance coverage. Recently, the Chinese government has encouraged commercial private health insurance to further increase healthcare accessibility. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">3.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B>Increasing affordability and demand for healthcare:</B>&nbsp;&nbsp;&nbsp;&nbsp;According to the Global Wealth Report 2015, China&#146;s middle class population, adjusted for
local purchasing power, amounted to 109&nbsp;million people, which is larger than the 92&nbsp;million middle class population in the United States. Nevertheless, China&#146;s middle class accounted for only 11% of the total Chinese adult population
in 2015, lower than the 38% in the United States, and this share is expected to grow. The rising middle class in China is expected to lead to increasing self-awareness of health issues and demand for more effective treatments.
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">4.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2"><B>Focus on innovation:</B>&nbsp;&nbsp;&nbsp;&nbsp;Historically, China&#146;s pharmaceutical market was dominated by mature and generic products. In 2016, innovative patented
prescription drugs accounted for only 22% of total drug sales in China, significantly lower than the approximately 75% share of patented drugs in the United States. In recent years, the Chinese government has focused on promoting innovation
especially in areas of high unmet medical need through streamlining regulatory processes, improving drug quality standards and fostering a favorable environment for innovation. For example in 2016, the Chinese government announced the &#147;Healthy
China 2030&#148; plan, which included a goal to increase the overall five year survival rate of cancer by 15% by 2030, which we believe underscores the need for innovative therapies. Going forward, innovative patented therapeutics are projected to
grow at over 10% annually until 2020, which is expected to surpass the growth rate of generic products. </FONT></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>CFDA regulatory
outlook&#151;CFDA reform to accelerate innovation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Historically, time to market of new products has been slow in China due to long regulatory
timelines, resulting from large numbers of applications for generic drugs, constrained capability of China&#146;s Center for Drug Evaluation, or CDE, and other factors. In 2014, there were approximately 120 staff members in the CDE to review more
than 8,000 new drug applications every year. This resulted in a large volume of backlog. Recognizing these issues and determined to promote innovation, in August 2015 China&#146;s State Council released its circular <I>Opinions Concerning the Reform
of the Review and Approval System for Drugs and Medical Devices</I>, or Circular No.&nbsp;44, which sets forth the government&#146;s clear determination to encourage transformation and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">93 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
upgrade of the pharmaceutical industry. It also officially started the CFDA&#146;s reform of the drug review and approval system, with five major goals: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">1.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Improve the quality of regulatory approval and establish a more scientific and efficient evaluation system for drug and medical device registration; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">2.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Clear the backlog of registration applications and strictly control the approval of oversupplied drugs; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">3.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Accelerate the conformance assessment of generic drugs; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">4.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Encourage clinically oriented drug innovation, improve the review process of innovative drugs, open approval fast lanes for innovative drugs of high clinical demand and introduce
the pilot Marketing Authorization Holder, or MAH, scheme to incentivize local biopharmaceutical companies to engage in drug development while utilizing contract manufacturers in China to manufacture their drugs; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">5.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Make the approval process more transparent to the public. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since the
launch of this initiative, significant progress has been made by the CFDA. Total CDE staff numbers increased to around 600 by 2016 and the backlog has been almost eliminated, according to the 2016 working report of the CDE. The IND/CTA timeline has
been reduced from an average of 33 months to eight months, and the NDA timeline from 35 months to 11 months, according to the Boston Consulting Group. Meanwhile, priority review for innovative drugs with large unmet need has been established. In
2016, approximately 200 drug applications were granted priority review, of which approximately 40% were oncology, autoimmune or infectious disease therapeutics. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">More recently, on May&nbsp;11, 2017, the CFDA issued three new draft policies regarding innovation for public comments. The three draft policies aim to accelerate the review and approval of new drug and medical
device applications (Circular No.&nbsp;52), deregulate the conduct of clinical trials to encourage innovation (Circular No.&nbsp;53), and enhance post-market supervision throughout a product&#146;s entire life cycle (Circular No.&nbsp;54).
Specifically, several new measures were proposed by the draft policies to reduce government controls over clinical studies and marketing authorizations, including, but not limited to: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Streamline of the clinical trial authorization process.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>Like the IND process in the United States, companies would need to
submit a CTA to the CDE but will only need to wait 60 working days before initiating the study, unless the CDE rejects the application or issues a deficiency notice during the <FONT STYLE="white-space:nowrap">60-day</FONT> period.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Accept foreign clinical study data.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>Foreign clinical data can be submitted to support NDA applications in China as long as
(i)&nbsp;the studies comply with Chinese regulations, (ii)&nbsp;the studies pass the CFDA&#146;s <FONT STYLE="white-space:nowrap">on-site</FONT> audits and (iii)&nbsp;applicants can provide clinical data to prove that no ethnicity difference affects
the drug&#146;s safety and efficacy. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Improve efficiency of ethics reviews.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>Currently, ethics committee review at clinical trial sites occurs after the CDE&#146;s
approval of the CTA. In the proposed regulatory scheme, companies can apply for ethics committee review and approval in parallel to the CDE&#146;s review of the CTA. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Allow conditional approvals for urgently needed therapies.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Drugs that offer new solutions for treating life-threatening
diseases or address critical unmet medical needs could be eligible for conditional approval, as long as early- and <FONT STYLE="white-space:nowrap">mid-stage</FONT> study data in clinical trials indicate their efficacy and predict their clinical
value. Companies receiving conditional approval must develop a risk management plan and initiate confirmatory post-approval studies in accordance with the requirements in the conditional approvals. Innovative drugs sponsored by the National Science
and Technology Major Project can be eligible for expedited review and approval. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">94 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Market access benefits.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Hospitals will be encouraged to prioritize their procurement and use of new drugs with definite
efficacy and reasonable prices. The government will support inclusion of innovative drugs in the basic medical insurance scheme, and the reimbursable drug list will be updated more frequently. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The CFDA was admitted as a new regulatory member by the ICH on June 1, 2017, and will reform its regulatory process in order to conform its policies and regulations
to ICH guidelines. We believe it is likely that the draft policies will be adopted and benefit China-based companies that are experienced with global standards of innovative drug development. If the draft policies are not fully adopted, we believe
that China-based, innovation-focused pharmaceutical companies will still enjoy competitive advantages over foreign peers. Under the current CFDA regulations, foreign pharmaceutical companies are typically allowed to receive NDAs in China after their
products are approved by a foreign regulatory authority. This requirement typically causes delays in time to market for foreign pharmaceutical companies. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Medical insurance and drug spending outlook&#151;multiple engines for improving affordability </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Over the past decade, the Chinese national government has been working on alleviating the burden on individuals by expanding health insurance coverage from approximately 30% of the population in 2003 to over 95% in
2013, with a goal of achieving universal coverage by 2020. At the same time, medical insurance plans at the provincial level have been introduced to complement the basic insurance programs. This increase in health insurance coverage has had a
dramatic impact on drug reimbursement and affordability in China. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">In China, public drug reimbursement schemes depend on the
inclusion on the National Reimbursement Drug List, or NRDL, and/or provincial reimbursement drug lists, or PRDL. Historically, the NRDL generally included basic or mature drugs, which were subject to significant price cuts with the PRDL having some
flexibility to include more expensive and innovative therapies. In early 2017, the Chinese government updated the NRDL for the first time since its last update in 2009. With the strong intention to promote innovation, the Chinese government has
added 339 new drugs to the NRDL, some of which are expensive oncology and autoimmune drugs, including Yi Sai Pu, a local recombinant TNF<FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><FONT
STYLE="font-family:arial" SIZE="2"></FONT> receptor II product for rheumatoid arthritis, and Conmana<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, the first
domestically-developed oncology targeted therapy. In addition to these drugs, the Chinese government created a list with 44 more innovative drugs for price negotiation in 2017. In late July 2017, the government announced the result of the
negotiation; among the 44 drugs, 36 drugs have reached the price agreement successfully, 18 of which are for oncology treatment. The 36 drugs will be included in the NRDL and the PRDL. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">Aside from the Chinese government&#146;s efforts to improve public reimbursement, a large part of China&#146;s population has become
increasingly affluent and has demonstrated an ability and willingness to pay <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> for innovative drugs. For example, in June 2011, Betta Pharmaceutical Co.,
Ltd.&#146;s drug Conmana<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, the first domestically-developed oncology targeted therapy in China, was approved by the CFDA
for second- or third- line treatment of advanced <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer. In November 2014, the approved indication expanded to first-line treatment of patients with advanced-stage non-small cell lung
cancer with epidermal growth factor receptor, or EGFR, mutations. Conmana<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, along with the other EGFR inhibitor
Iressa</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"> </SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> were not included in the NRDL until 2017. Another EGFR inhibitor Tarceva<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT></FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"> </SUP></FONT><FONT
STYLE="font-family:arial" SIZE="2">was included in the NRDL price negotiation list in April 2017. According to the CFDA Southern Medicine Economic Research Institute, aggregate China sales of these three EGFR inhibitors, mostly driven by patient <FONT
STYLE="white-space:nowrap">self-pay,</FONT> grew from approximately $180&nbsp;million since Conmana&#146;s launch in 2011 to nearly $450&nbsp;million in 2015. Although rapidly growing in recent years, this represented only 12.3% of the total lung
cancer market in 2015. These relatively modest penetration rates highlight the growth potential for targeted therapy drugs as supported by both <FONT STYLE="white-space:nowrap">self-pay</FONT> and improving public reimbursement environment.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">95 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to government health insurance and <FONT STYLE="white-space:nowrap">self-pay,</FONT> there is also growing
government support for the development of commercial private health insurance to provide support for China&#146;s growing middle and upper classes. Favorable industry policies such as tax incentives to consumers have been issued. Total private
health insurance premiums increased by over two times, from RMB 158.7&nbsp;billion in 2014 to RMB 404.2&nbsp;billion in 2016, according to the China Insurance Regulatory Commission. There are now already more than 100 private insurers in China
offering some type of medical coverage. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>The advantages of being a China-based, innovation-focused biopharmaceutical platform </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Innovation is one of China&#146;s strategic priorities in its most recent Five-Year Plan, a high-level master plan guiding China&#146;s economic development for a
period of five years. The biopharmaceutical industry is one of the six &#147;pillar industry sectors&#148; in the government&#146;s pathway to transform China from a manufacturing-focused economy to an innovation-focused economy. Multiple
initiatives have been implemented by the government to support this goal. For example, the State Key Healthcare Project designation is granted to promising therapies from China. The grant recipients may benefit from expedited regulatory review and
other favorable conditions for the product, including market access benefits. Meanwhile, the Chinese government is also encouraging venture capital and private equity funds to invest in the biopharmaceutical industry and is providing tax incentives
to companies that invest in the research and development of innovative drugs. Furthermore, the Chinese government introduced a &#147;Thousand Talents Plan&#148; to recruit leading overseas scientists and business leaders to advance high tech
companies and encourage innovation in China. We expect that this multi-pronged approach will support the emergence of innovative, globally competitive China-based biopharmaceutical companies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">However, the China pharmaceutical market remains fragmented and dominated by a large number of generic drug manufacturers. Although the Chinese government is actively promoting consolidation through increasingly
stringent regulatory requirements, the historical lack of investment in research and development has created a deficit in the infrastructure needed to keep pace with the government&#146;s focus on innovative drugs and its requirement to conduct
robust clinical trials in Chinese patients. As a result, while there is a growing demand for innovative drugs to address urgent areas such as oncology, the domestic pharmaceutical companies lack effective clinical development capabilities. We
believe there is a significant opportunity for global standard China-based companies that develop, manufacture and commercialize innovative medicines for the China market and beyond. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Some of the key advantages of being a fully integrated, China-based and innovation-focused biopharmaceutical development and commercialization platform include: </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Accelerated time to market </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The CFDA regulatory
framework for new drug development is modeled on the FDA&#146;s development pathway. Upon completion of its preclinical research, the developer is required to obtain the CFDA&#146;s CTA before initiating clinical trials in China. A three-phase
clinical evaluation program is typically required to demonstrate drug safety and efficacy. Developers then submit an NDA. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The CFDA adopted a
classification system to guide its registration and approval pathways for chemical drugs, botanical drugs and biological drugs. New drugs and generics (or biosimilars) are assigned to different categories. Under the new classification system adopted
by the CFDA in March 2016, chemical drugs are classified into five categories. Category 1 drugs refer to innovative chemical drugs which are not approved anywhere in the world at the time of their initial China CTA submission and are manufactured in
China at the time of their NDA submissions. In comparison, imported drugs that are manufactured outside China or have </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">96 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
been first approved by a foreign regulatory authority are referred to as Category 5 drugs. When a chemical drug candidate is accepted as Category 1, it is entitled to expedited CTA and NDA review
and approval. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Market exclusivity for up to five years </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Innovative drugs which are manufactured in China are monitored for five years by the CFDA following their NDA approval, during which the CFDA will not accept any applications for new drugs with the same active
ingredient. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">By contrast, an imported drug which receives its NDA approval from the CFDA is not afforded any protection from this monitoring requirement.
Therefore, Category 1 new drugs approved by the CFDA and manufactured in China receive a <I>de facto</I> exclusivity (assuming no other applications were already on file) for five years plus the time it would take for the CFDA to accept, review and
approve a competitor&#146;s NDA filing for a drug with the same active ingredient. We believe this regulatory framework provides significant advantages for companies developing and manufacturing new drugs in China. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Customized development programs which are tailored to Chinese patients&#146; specific unmet medical needs, and higher efficiency in executing clinical
development programs </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Companies with China-based research and development operations are more likely to efficiently execute drug development
programs in China. Moreover, we believe that companies with their headquarters and key decision makers in China will be able to develop broad and deep relationships with Chinese key opinion leaders which will have benefits both in the development
and commercialization of drugs. By leveraging these strong working relationships, China-based companies can more efficiently collaborate with key opinion leaders to rapidly design clinical trial protocols to focus on the clinical needs and
characteristics of Chinese patients that are in line with the standard of care in China, which can be different from the standard of care in either the United States or Europe. This localized approach to clinical development allows China-based
companies to generate the clinical data in Chinese patients that satisfies the CFDA&#146;s stringent requirements for clinical trials to identify, or confirm the absence of, ethnicity differences a drug may have in Chinese patients. Through these
interactions with Chinese key opinion leaders, domestic companies are also able to efficiently enroll and conduct their clinical trials in China. Moreover, by engaging with these key opinion leaders through the clinical trial stage, domestic
companies gain prior experience and have superior communication channels to cultivate the endorsement of these key opinion leaders, which is important in commercializing the drug in China. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Global pharmaceutical companies have historically been and, we believe, continue to be focused on accessing familiar, more established markets, such as the United States and Europe, where they have established
clinical development infrastructure. Their reluctance to commence early stage clinical trials in China will hinder the speed of executing clinical development programs for the Chinese market. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Commercialization of innovative therapies </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">China-based, innovation-focused biopharmaceutical companies
have several advantages in commercializing their products in China. By engaging key opinion leaders in the design and conduct of local clinical trials, these drugs benefit from the key opinion leaders&#146; practical experience and endorsement of
their clinical efficacy in the Chinese population, which we believe may allow more rapid acceptance of the drug by physicians and accelerate market uptake. In addition, locally-developed products have other market access benefits, such as advantages
in reimbursement and priority in hospital procurement. These advantages have already been demonstrated in the commercial success of local innovative drugs, which have taken market share from multinationals on several occasions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">97 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For example, in the EGFR inhibitor market, Conmana was launched in 2011, approximately six years after Iressa&#146;s
entry in China. By 2015, despite being the last EGFR inhibitor to enter the market, Conmana gained significant share from Iressa, reaching approximately 33% market share in the lung cancer EGFR inhibitor market, and becoming the second product in
the market, after Iressa&#146;s 44% share. The advantage has also been observed in the case of a local product launched earlier than multinational products. Yi Sai Pu was the first anti-TNF-<FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> product approved for treating rheumatoid arthritis, which was launched in China in 2005. Other anti-TNF-<B><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="2"><B></B></FONT></B> therapies for rheumatoid arthritis such as Enbrel, Humira and Remicade all received CFDA
approval between 2006 and 2010. More than 10 years after its launch, Yi Sai Pu has maintained its leading market position with a market share of over 60% as of 2016, according to 3SBio Inc., the maker of Yi Sai Pu. We believe these examples
demonstrate the unique advantage of a local innovator when commercializing a product in China. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">98 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_11"></A>Business </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Overview of our business </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are an innovative biopharmaceutical company based in Shanghai focusing on
discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. We believe there exists a
significant opportunity to build an organization that not only addresses such unmet needs but leverages underutilized resources in China to foster innovation. As part of that effort, we have assembled a management team with global experience and an
extensive track record in navigating the regulatory process to develop and commercialize innovative drugs in China. Our mission is to leverage our expertise and insight to address the expanding needs of Chinese patients in order to transform their
lives and eventually utilize our China-based competencies to impact human health worldwide. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, Zai Lab was built on the vision that, despite
having a significant addressable market and sizable growth potential, China has historically lacked access to many innovative therapies available in other parts of the world and its drug development infrastructure has been underutilized. There
remains the need to bring new and transformative therapies to China. In recent years, the Chinese government has focused on promoting local innovation through streamlining regulatory processes, improving drug quality standards and fostering a
favorable environment, which we believe creates an attractive opportunity for the growth of China-based, innovation-focused companies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since our
founding in 2014, we have assembled an innovative pipeline consisting of six drug candidates through partnerships with global biopharmaceutical companies. These include three late-stage assets targeting fast growing segments of China&#146;s
pharmaceutical market and three assets addressing global unmet medical needs. We believe that our management&#146;s extensive global drug development expertise, combined with our demonstrated understanding of the pharmaceutical industry, clinical
resources and regulatory system in China, has provided us, and will continue to provide us, opportunities to partner with global companies aiming to bring innovative products to market in China efficiently. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To date, we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> three late-stage clinical drug candidates for development in China, Hong Kong, Macau and, in
certain instances, Taiwan, through partnerships with Tesaro, Bristol-Myers Squibb and Paratek. Our CTAs for two of these drug candidates have been accepted as Category 1 drugs by the CFDA. This classification provides us with a competitive advantage
as Category 1 drugs benefit from an expedited review of CTAs and NDAs as well as commercial benefits. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our lead drug candidate is niraparib <FONT
STYLE="white-space:nowrap">(ZL-2306),</FONT> an oral, once-daily small molecule PARP 1/2 inhibitor being developed and commercialized by our partner Tesaro. In March 2017, Tesaro received FDA marketing approval for niraparib as a maintenance
treatment for women with recurrent platinum-sensitive epithelial ovarian cancer and, in April 2017, commercially launched the product in the United States under the commercial name Zejula. Niraparib is the first PARP inhibitor approved by the FDA
for ovarian cancer that does not require BRCA mutation or other biomarker testing. We believe niraparib is uniquely suited for the China marketplace where BRCA biomarker diagnostic tests are not widely available. We intend to develop niraparib for
Chinese patients across multiple tumor types and anticipate beginning two Phase III studies of niraparib in patients with ovarian cancer, one in the second half of 2017 and the other in the first half of 2018. In addition, we intend to pursue
niraparib in other indications. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As part of our licensing strategy, we have also obtained global development and commercialization rights to three drug
candidates, including one late-stage clinical and two preclinical drug candidates, through partnerships with GSK, Sanofi and UCB. We intend to leverage our resources and competitive advantages in
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">99 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
China, including our ability to access China&#146;s large patient population and conduct efficient clinical trials, to rapidly and cost-effectively establish proof of concept for such candidates
prior to pursuing further late-stage development for the global market. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the longer term, we plan to build a premier, fully integrated drug discovery
and development platform that brings both in-licensed and internally-discovered medicines to patients in China and globally. Our strong <FONT STYLE="white-space:nowrap">in-house</FONT> research and development team had previously been directly
involved in the discovery and development of several successful innovative drug candidates at Hutchison Medi-Pharma, including fruquintinib and savolitinib. These assets were <FONT STYLE="white-space:nowrap">out-licensed</FONT> to Eli Lilly and
AstraZeneca, respectively. Our <FONT STYLE="white-space:nowrap">in-house</FONT> discovery team is currently focused on exploring immuno-oncology approaches to treating cancer. We have collaborations with leading academic institutions in China,
including Tsinghua University and Shanghai Institute of Materia Medica, to expand our <FONT STYLE="white-space:nowrap">in-house</FONT> research projects. We believe this team and our discovery strategy will enable us to achieve our long-term goal of
commercializing our internally discovered innovative medicine for patients worldwide. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As our business grows, we plan to build our own commercial team to
launch our portfolio of drug products. Part of our strategy to become a fully integrated biopharmaceutical company is the ability to produce both large and small molecule therapeutics under global standard cGMP. To this end, in the first half of
2017 we built a small molecule drug product facility capable of supporting clinical and commercial production and have also begun construction of a large molecule facility. Completion of the large molecule facility is expected in the first half of
2018, which we estimate will cost approximately $10.0 million to complete and will be financed with existing cash. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Finally, our company is led by a
management team with extensive pharmaceutical research, development and commercialization track record in both global and Chinese biopharmaceutical companies. Our team is passionate about bringing transformative medicines to patients in China and
worldwide. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since our founding in 2014, we have raised $164.5 million in equity financing from our dedicated group of investors, including global and
China-based healthcare funds. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">100 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our innovative pipeline </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with
global rights. The following table summarizes our drug candidates and programs: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g358845g24j00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our greater China rights drug candidates </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our three late-stage products with greater China rights focus on oncology and infectious diseases, two therapeutic areas where there is a large unmet need and lack of innovative treatment options in China. These
drug candidates include: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Niraparib <FONT STYLE="white-space:nowrap">(ZL-2306)</FONT></B>, a highly potent and selective oral, small molecule PARP 1/2 inhibitor with the potential to
be a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> drug for treatment across multiple solid tumor types in China including ovarian and certain types of breast and lung cancers. We have licensed
niraparib from Tesaro, which in March 2017 received FDA marketing approval for niraparib (Zejula<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>) as maintenance
treatment for women with recurrent platinum-sensitive epithelial ovarian cancer. Niraparib was commercially launched in the United States in April 2017. Niraparib does not require BRCA mutation or other biomarker testing as is necessary for other
approved PARP inhibitors which, we believe, significantly expands its availability to ovarian cancer patients in China. As niraparib has been approved in the United States, if approved by the EMA, we anticipate commercializing niraparib in Hong Kong
and Macau approximately 12 months after it is approved by the EMA. In China, our CTA for niraparib has been approved as a Category 1 drug by the CFDA. We anticipate initiating Phase III studies of niraparib in patients with recurrent
platinum-sensitive ovarian cancer as a second-line maintenance therapy in the second half of 2017, and as a first-line maintenance therapy in the first half of 2018. These studies are expected to be similar in design to Tesaro&#146;s clinical
studies of niraparib. We also anticipate beginning a Phase III </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">101 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
study in patients with gBRCA positive breast cancer in the first half of 2018. In addition, we intend to study niraparib in patients with triple negative breast cancer, squamous-type <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer and small cell lung cancer in China. Niraparib has the potential to be the first PARP inhibitor marketed in China. In addition to niraparib monotherapy in the potential indications stated,
we also intend to explore the combination of niraparib with other potential therapies such as immuno-oncology therapy, targeted therapy and chemotherapy in the clinically relevant indications. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Omadacycline <FONT STYLE="white-space:nowrap">(ZL-2401)</FONT></B> is a broad-spectrum antibiotic in a new class of tetracycline derivatives, known as
aminomethylcyclines. We have licensed omadacycline from Paratek where it is primarily being developed for ABSSSI, CABP and UTI. Omadacycline is designed to overcome the two major mechanisms of tetracycline resistance, known as pump efflux and
ribosome protection. If approved, omadacycline is expected to be available in IV and PO once-daily formulations. Paratek has reported the results of two pivotal IV-to-oral Phase III studies of omadacycline in ABSSSI and CABP. Both of these studies
achieved their primary endpoints. Paratek also reported <FONT STYLE="white-space:nowrap">top-line</FONT> data from its oral-only Phase III ABSSSI study in July 2017. This study also achieved its primary endpoints. We are in the technology transfer
stage and plan to discuss China development plans with key opinion leaders and the CFDA. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">ZL-2301</FONT></B> is an oral, small molecule dual target TKI which blocks both VEGFR and FGFR. <FONT
STYLE="white-space:nowrap">ZL-2301</FONT> was studied by our partner Bristol-Myers Squibb mainly for the treatment of HCC, the most common type of liver cancer. In these trials, <FONT STYLE="white-space:nowrap">ZL-2301</FONT> demonstrated anti-tumor
activity and a generally well-established safety profile in HCC patients. In 2012, Bristol-Myers Squibb terminated its development program of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> after it missed the primary endpoints in two Phase III
trials with advanced HCC patients. Based on our review of the results from Bristol-Myers Squibb&#146;s development program for <FONT STYLE="white-space:nowrap">ZL-2301,</FONT> our understanding of the etiology and current standard of care of HCC in
Chinese patients and our ongoing research, we believe that <FONT STYLE="white-space:nowrap">ZL-2301</FONT> has the potential to be an effective treatment option for Chinese HCC patients and merits further clinical trials. The CFDA has approved our
CTA for <FONT STYLE="white-space:nowrap">ZL-2301</FONT> as a Category&nbsp;1 drug, and in the second quarter of 2017 we initiated a Phase II trial of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> as a second-line treatment for advanced HCC
patients in China. Pending results from this Phase&nbsp;II trial, we plan to initiate a Phase III clinical trial shortly thereafter. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For our late-stage oncology drug candidates with greater China rights, our near-term development plan focuses on specific patient segments. These patient segments
have an estimated annual incidence of approximately 816,000 patients in China. We expect that the commercial success of our products will be driven by their differentiated clinical profiles, efficacy in Chinese patients and ability to provide
clinical benefit over existing standards of care in a market where targeted therapies are either unavailable or less utilized relative to more developed markets. For additional information, please refer to the &#147;Market Opportunity&#148; section
under each our clinical stage product candidates. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to the opportunities available for our oncology products, we believe that, through our
development of omadacycline, we have the chance to introduce into China a new broad-spectrum antibiotic with excellent activity not only against common Gram-positive and Gram-negative bacteria, but also against several MDR pathogens. The profile of
omadacycline includes MRSA, enterococci, ESBL-E. coli and many Acinetobacter isolates. In addition, availability of an IV and oral formulation allows treatment of hospital- and community-acquired infections. The prevalent overuse of antibiotics,
evolution of resistant bacteria and state of current treatment practices are expected to lead to an increase in drug-resistant infection rates. A 2015 study indicated that the total antibiotic usage in China in 2013 accounted for about half of the
global antibiotic usage, with a <FONT STYLE="white-space:nowrap">per-capita</FONT> use of antibiotics in China being more than five times that in Europe and the United States. Based on our estimates, in 2015 there was an incidence of approximately
2.8&nbsp;million ABSSSI patients and 16.5&nbsp;million CABP patients in China. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">102 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>The China market opportunity for our greater China-rights drug candidates </I></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g358845g35e94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>Sources: 1. Cancer Statistics in China, 2015, a study published by Wangqing Chen et. al. in &#147;A Cancer Journal for
Clinicians&#148; in 2016, and based on historical data from 72 local, population-based cancer registries, representing 6.5% of China&#146;s population. 2. Assumes that 10% and 15% of the total breast cancer patients would be with gBRCA&#043;
mutation and triple negative mutation, respectively. According to the study by Kim and Choi in 2013, the percentage of BRCA 1/2 gene mutation in familial breast cancer and early-onset breast cancer patients ranged from 8.0% to 13.5% and from 8.7% to
11.4%, respectively. <FONT STYLE="white-space:nowrap">10-20%</FONT> of breast cancer is Triple-negative, according to the study by Ping-Ping Bao et. al in 2016. 3. American Cancer Society estimated that globally about
<FONT STYLE="white-space:nowrap">80-85%</FONT> of lung cancers are non-small cell lung cancer, and about <FONT STYLE="white-space:nowrap">25-30%</FONT> of lung cancers are squamous cell carcinomas. Calculation is based on 80% for NSCLC, of which 30%
is squamous non-small cell lung cancer, and 20% for small cell lung cancer patients. 4. Management estimate. 5. According to the study by Ran Xu Zhu et. al. in 2016, HCC accounts for 80% of liver cancer patients. </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to mainland China, we intend to seek registration and commercialization of the above drug candidates, where we have applicable rights, in Hong Kong,
Macau and Taiwan. For Hong Kong and Macau, products with existing approvals by the FDA, EMA or a comparable regulatory agency are eligible for an expedited registration process that does not require conducting local clinical trials. In the case of
niraparib, we intend to pursue expedited registration and, if approved by the EMA, expect to launch and commercialize niraparib in Hong Kong and Macau approximately 12 months after it is approved by the EMA. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">While the overall patient population in Hong Kong and Macau is smaller compared to that of China, they are higher income markets with developed medical
infrastructure, widely available private insurance and proven capacity to pay for advanced therapeutics. In addition to local patients, there is a significant opportunity to provide treatment for medical tourists from China, who visit these regions
in order to access <FONT STYLE="white-space:nowrap">high-end</FONT> cancer treatment, including prescription drugs which may not be available in mainland China. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Our global rights drug candidates </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our drug candidates for which we retain global rights include:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B>Fugan <FONT STYLE="white-space:nowrap">(ZL-3101)</FONT></B> is a novel steroid-sparing topical product for the treatment of eczema and psoriasis. We are
developing fugan as a botanical formulation to offer patients with eczema and psoriasis a natural alternative to topical steroid treatments, which are currently the main forms of treatment and are known to have many side effects associated with
long-term use. We licensed the exclusive worldwide rights to fugan from GSK in 2016. We initiated a Phase II study of fugan in patients with eczema in China in the second quarter of 2017. Pending results of this Phase II study, we plan to initiate a
Phase III global, multi-center clinical trial. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">ZL-2302</FONT></B> is a multi-targeted TKI with activity against both ALK mutation and crizotinib-resistant ALK mutations
being developed for the treatment of patients with <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer who have ALK </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">103 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:arial" SIZE="2">
mutations and who have developed crizotinib resistance and/or brain metastasis. We licensed the exclusive worldwide rights to <FONT STYLE="white-space:nowrap">ZL-2302</FONT> from Sanofi in 2015.
Our preclinical studies demonstrated that <FONT STYLE="white-space:nowrap">ZL-2302</FONT> has ability to penetrate the blood-brain barrier, which could make <FONT STYLE="white-space:nowrap">ZL-2302</FONT> an effective therapy for a subset of
patients who have <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer with ALK mutations and brain metastasis. Such patients typically have limited treatment options, poor prognosis and low quality of life. Our CTA for <FONT
STYLE="white-space:nowrap">ZL-2302</FONT> has been accepted as a Category 1 drug by the CFDA, and we expect to initiate a Phase I study of <FONT STYLE="white-space:nowrap">ZL-2302</FONT> in China in the first half of 2018.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">ZL-1101</FONT></B> is<B> </B>an anti-OX40 antagonistic antibody with <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> potential for the treatment of a range of autoimmune diseases such as graft-versus-host disease or systemic lupus erythematosus. We licensed the exclusive worldwide rights to <FONT
STYLE="white-space:nowrap">ZL-1101</FONT> from UCB in 2015. Its anti-inflammatory activities have been validated by a variety of inflammatory and autoimmune disease models. <FONT STYLE="white-space:nowrap">ZL-1101&#146;s</FONT> bioactivities and
functional potency have been investigated in both <I>in vitro</I> and<I> in vivo </I>studies. In such studies, cellular proliferation and production of inflammatory cytokines was markedly suppressed, demonstrating that
<FONT STYLE="white-space:nowrap">ZL-1101</FONT> effectively inhibits lymphocyte activation. <FONT STYLE="white-space:nowrap">ZL-1101</FONT> was also found to be highly potent. We intend to file an IND in 2018. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Our vision and strategy </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our vision is to become a leading
global innovative biopharmaceutical company based in China and deliver transformative medicines to patients in China and around the world. We intend to utilize our strengths to pursue the following strategies: </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Rapidly advance and commercialize our <FONT STYLE="white-space:nowrap">in-licensed</FONT> late stage clinical drug candidates. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Two of our late stage assets, niraparib and ZL-2301, have the potential to address large unmet medical needs in China&#146;s oncology drug market, where there is a
higher total incidence in our targeted indications compared to the United States market. In addition to our oncology products, we believe that through our development of <FONT STYLE="white-space:nowrap">ZL-2401</FONT> we have the chance to introduce
into China a new and effective broad-spectrum antibiotic, while <FONT STYLE="white-space:nowrap">ZL-3101</FONT> could offer eczema and psoriasis patients with a natural alternative to topical steroid treatments, which are known to have many side
effects associated with long-term use. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We intend to advance our lead asset, niraparib, into two Phase III trials in China as a second-line and
first-line maintenance treatment in platinum sensitive ovarian cancer patients, regardless of their gBRCA mutation status, in the second half of 2017 and first half of 2018, respectively. We also anticipate beginning a Phase III study in patients
with gBRCA mutation positive breast cancer in the first half of 2018. Niraparib has the potential to be the first PARP inhibitor marketed in China. As niraparib has been approved in the United States, if approved by the EMA, we anticipate
commercializing niraparib in Hong Kong and Macau approximately 12 months after it is approved by the EMA. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In April 2017, we received an exclusive
sub-license from Paratek to develop, manufacture and commercialize omadacycline in China, Hong Kong, Macau and Taiwan. Based on the clinical data, we believe omadacycline has the potential to be an effective treatment of patients with serious
bacterial infections. We are in the technology transfer stage and plan to discuss China development plans with key opinion leaders and the CFDA. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the
second quarter of 2017, we initiated a Phase II trial for our dual target TKI, <FONT STYLE="white-space:nowrap">ZL-2301,</FONT> in advanced HCC patients in China to investigate its optimal treatment schedule and dosage as a second-line treatment.
Pending Phase II results, we intend to initiate to a Phase III registration trial. We also initiated a Phase II study of fugan, our global rights product, in patients with eczema in China in the second quarter of 2017. Pending results from this
Phase II study, we plan to initiate a Phase III global, multi-center trial. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">104 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Capitalize on our location in China, our management team&#146;s domestic and international drug development
experience and our track record of licensing to further solidify our position as a strategic gateway partner into China for biopharmaceutical companies outside of China. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our drug development team has extensive domestic and international development expertise, combining unique insight in screening drug candidates in global development and an
<FONT STYLE="white-space:nowrap">in-depth</FONT> understanding of the Chinese development pathway. We believe that our management team&#146;s experience navigating the Chinese regulatory framework, combined with potential enrollment efficiencies in
China, including many <FONT STYLE="white-space:nowrap">treatment-na&iuml;ve</FONT> patients, concentrated treatment centers, and relatively lower clinical costs, gives us the ability to bring products to market in China expediently. Moreover, we
benefit from China&#146;s recent regulatory reforms, which aim to elevate drug quality standards and achieve a faster drug application review process. Given our plans to develop and manufacture our current clinical-stage drug candidates in China, we
believe our current clinical drug candidates, other than fugan, will remain Category 1 drugs throughout the development and approval process, making them eligible for expedited regulatory pathways in China. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Conversely, global pharmaceutical companies have historically been and, we believe, continue to be, focused on mature western markets, with which they are more
familiar and where they have established clinical development infrastructure. Their reluctance to commence early stage clinical trials in China and to prioritize obtaining China manufacturing rights for innovative products restricts such drug
candidates potential to be classified as Category 1, which typically results in a longer regulatory review process than a domestically-manufactured drug candidate classified as Category 1. This has resulted in significant medical demand for
innovative treatment options in China. In order to address this unmet medical need and to capture the rapid growth in the Chinese pharmaceutical market, we believe that an increasing number of pharmaceutical companies outside of China will seek to
commercialize their drugs in China through a local partner that can do so in a timely and cost-effective manner. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a result, we believe the combination
of our management&#146;s experience and knowledge, the changing regulatory landscape in China, the manufacturing and commercial capabilities we are developing and the global pharmaceutical industry&#146;s current approach to the China market makes
us an ideal gateway partner for biopharmaceutical companies outside of China seeking access to the China market. The recognition of our team as a local partner of choice in China is evidenced by our partnerships with global biopharmaceutical
companies, including Tesaro, Paratek and Bristol-Myers Squibb, that <FONT STYLE="white-space:nowrap">out-licensed</FONT> their clinical products to Zai Lab. We will continue to actively seek high quality drug candidates and to evaluate inbound
interest we receive. We are currently in active negotiations for multiple promising assets to further our ambitions to bring new medicines to the China market. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Continue to license promising programs for global rights. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have a track record of <FONT
STYLE="white-space:nowrap">in-licensing</FONT> the global rights of drug candidates from leading global biopharmaceutical companies such as GSK, Sanofi and UCB. We will continue to seek new <FONT STYLE="white-space:nowrap">in-licensing</FONT>
opportunities which grant us the global rights for differentiated drug candidates. In particular, we focus on candidates that are complementary to our drug pipeline, have demonstrated promising data in early clinical studies and have large global
market potential. We seek to utilize the advantages of drug development in China, including relatively fast patient enrollment and low clinical costs to rapidly establish proof of concept for such candidates prior to pursuing further global
multi-center trials for the global market. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Build a fully integrated platform with drug discovery, development, manufacturing and
commercialization capabilities in China and expand globally. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We will continue to execute our strategy to become a fully integrated
biopharmaceutical company in China. We have assembled an internal research and development team with extensive capabilities, whom we will leverage </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">105 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
to discover and develop innovative drug candidates in China and globally. By focusing on developing, manufacturing and commercializing our late-stage
<FONT STYLE="white-space:nowrap">in-licensed</FONT> drug candidates in parallel with expanding our earlier-stage internal research and discovery capabilities, we believe we can rapidly establish a fully integrated biopharmaceutical platform. We
believe that building our own China manufacturing and commercialization capabilities presents tangible benefits, which include maintaining better control over the quality and compliance of our operations with increasingly stringent industry
regulations and receiving government manufacturing incentives. In addition, where appropriate, we will use China-based high-quality contract manufacturers as <FONT STYLE="white-space:nowrap">back-up</FONT> and to supplement our internal
manufacturing capabilities. By using our own internal manufacturing facilities or China-based contract manufacturers, we believe that we will be able to seek and maintain a Category 1 classification for our current clinical stage drug candidates
(other than fugan) throughout the IND and NDA review process, where utilizing China-based manufacturing is a necessary condition for such classification. We believe these capabilities make us a more attractive China licensing partner for global
pharmaceutical companies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have already built a cGMP-compliant small molecule facility capable of supporting clinical and commercial production and
have begun construction of a cGMP-compliant large molecule facility capable of supporting clinical production of our drug candidates in China. The construction of the large molecule facility is expected to be completed in the first half of 2018.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, to support our anticipated commercial launch of niraparib in Hong Kong and Macau, we have developed a targeted sales and marketing strategy
and plan to build a specialized sales force to cover major medical centers in greater China, where the administration of innovative treatments for cancers and other diseases tend to be concentrated. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Leverage our senior management&#146;s experience. </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our management team has extensive experience in the global pharmaceutical industry and is led by our Chief Executive Officer, Samantha Du, Ph.D., who is widely
recognized as a leading figure in the China biotech industry. Before the founding of our business, Samantha Du managed the healthcare investment team for Sequoia Capital China, or Sequoia, where she led the fund&#146;s investments, including Betta
Pharma, BGI Genomics, and JHL Biotech. Prior to Sequoia, Samantha Du founded Hutchison Medi-Pharma as its Chief Executive Officer for over 10 years and <FONT STYLE="white-space:nowrap">co-founded</FONT> and served as the Chief Scientific Officer of
Hutchison China MediTech Limited, or Hutchison, a Nasdaq-listed biopharmaceutical company, where she pioneered China-based global biopharmaceutical innovation by bringing five innovative drug candidates into clinical development and for forging drug
collaborations with AstraZeneca, Johnson&nbsp;&amp; Johnson, Eli Lilly and Merck Serono. While at Hutchison, Samantha Du spearheaded the regulatory strategy for securing the very first green channel treatment, a CFDA policy that allows for an
expedited registration process for innovative medical assets, for a Category 1 new drug asset, and also produced two programs that successfully completed multiple global Phase III trials. Prior to Hutchison, she was responsible for its global
metabolic licensing programs on the scientific side for Pfizer in the United States and was also involved in the development of two clinical stage assets which were launched globally. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition to Samantha Du, our senior management team includes our Chief Medical Officer, Oncology, Qi Liu, M.D., Ph.D., a board-certified medical oncologist and hematologist, and our Chief Medical Officer,
Autoimmune and Infectious Diseases, Harald Reinhart, M.D., board-certified in internal medicine and infectious diseases. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prior to joining our company,
Dr.&nbsp;Liu was the clinical lead of the BioVenture group at AstraZeneca and executive medical director of AstraZeneca Oncology Global Medicine Development, where she played an essential role in establishing AstraZeneca&#146;s biologics joint
ventures and was responsible for its joint venture global development programs, regulatory strategy and submissions. She also played an important role in AstraZeneca&#146;s TKI </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">106 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
development program. Dr.&nbsp;Liu completed her post-doctoral fellowship at Memorial Sloan-Kettering Cancer Center and medical oncology and hematology fellowship at the MD Anderson Cancer Center
where she was an assistant professor prior to joining AstraZeneca. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prior to joining our company, Dr.&nbsp;Reinhart was the head of clinical development
and medical affairs at Shionogi US, where he managed a broad portfolio of antibiotics, diabetes, allergy and pain medications, as well as guided a pharmaceutical compound through an NDA submission and approval. He also held senior roles at Novartis,
where he oversaw successful filings of SNDAs and NDAs for Coartem, Famvir, Sebivo and Cubicin. Dr.&nbsp;Reinhart received a medical degree from the University of W&uuml;rzburg in Germany and completed his specialty training in the United States.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our clinical pipeline </I></B></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Niraparib
</I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Niraparib <FONT STYLE="white-space:nowrap">(ZL-2306)</FONT> is a highly potent and selective oral, once-daily small molecule poly <FONT
STYLE="white-space:nowrap">(ADP-ribose)</FONT> polymerase 1/2, or PARP 1/2, inhibitor with the potential to be a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> drug for treatment across multiple solid
tumor types in China. In March 2017, niraparib was approved by the FDA as a maintenance treatment for women with recurrent platinum-sensitive ovarian cancer. Maintenance therapy is for those women who have had prior treatment but are expected to see
their cancer return, with the purpose of avoiding or slowing a recurrence if the cancer is in remission after the prior treatment. A platinum-sensitive cancer is one that responded to initial platinum-based chemotherapy and remained in remission
post-chemo therapy for more than six months. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Niraparib is the first PARP inhibitor to be approved by the FDA for ovarian cancer that does not require
BRCA mutation or other biomarker testing as is required for other approved PARP inhibitors. This makes niraparib suitable for a wide patient population and significantly more accessible to patients in China where BRCA biomarker diagnostic tests are
not widely available. If approved by the CFDA, niraparib may potentially be the first PARP inhibitor on the China market approved for second-line maintenance treatment in all recurrent platinum-sensitive ovarian cancer patients. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We obtained an exclusive license for the development and commercialization of niraparib in China, Hong Kong and Macau in 2016. As niraparib has been approved in the
United States, if approved by the EMA, we anticipate commercializing niraparib in Hong Kong and Macau approximately 12 months after it is approved by the EMA. In addition, our CTA for niraparib has been approved as a Category 1 drug, and we plan to
initiate a Phase&nbsp;I pharmacokinetics, or PK, trial and two Phase III trials for niraparib as a first-line and second-line maintenance treatment in patients with platinum-sensitive ovarian cancer in China. We also intend to study niraparib in
patients with gBRCA positive breast cancer and lung cancer in China, either as a monotherapy or combination. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Market opportunity
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that niraparib represents a significant market opportunity in China, given its differentiated clinical profile, demonstrated clinical
relevance to multiple solid tumor types, potential to provide a notable improvement to existing standards of care, and prospects to be utilized in multiple combination and monotherapy treatment options. We have the right to all indications in
greater China (except prostate cancer), and we intend to pursue the approval and registration of niraparib as a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> treatment in ovarian and certain
types of breast and lung cancers. Across our targeted patient segments in the ovarian, breast cancer and lung indications, we estimate a total annual incidence of 443,000 patients based on 2015 data. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">107 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe niraparib has the potential to be the first PARP inhibitor, or at least the first approved Category&nbsp;1
PARP inhibitor, in China. Based on our understanding, local PARP inhibitor product candidates are currently in early stage China clinical trials. Global PARP inhibitors have either not yet made an application in China or have included a limited
number of Chinese patients as part of their global Phase III studies in BRCA&#043; patient populations, which would likely require additional local clinical trials prior to obtaining CFDA approval. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our currently targeted indications for niraparib include the following: </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Ovarian cancer </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Ovarian cancer had an estimated annual incidence of 52,000 patients in China in 2015,
which is more than double that of the 21,300 patients in the United States and has seen increasing mortality rates. Since early symptoms of ovarian cancer are <FONT STYLE="white-space:nowrap">non-specific</FONT> and difficult to detect, a majority
of women with ovarian cancer are diagnosed when the disease is at an advanced stage, when prognosis is poor. Finding effective therapeutic approaches for advanced ovarian cancer patients represents a large unmet medical need. Given the broad
applicability of niraparib across all patient populations, regardless of gBRCA mutation status, we are currently targeting the entire platinum sensitive ovarian cancer patient population. This represents a significant advantage for patient
convenience and access, given that there is no need for patients to utilize diagnostic tests to determine their gBRCA mutation status, particularly in China where such tests are not widely available. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The current standard of care in China consists of radical surgery and platinum-based chemotherapy. Although platinum-based chemotherapy is effective at inducing an
initial response, ovarian cancer will recur in approximately 85% of women. Many women continue to respond to second-line platinum based chemotherapy, and following a response, the guideline-recommended approach for many patients is surveillance,
monitoring patients for disease progression and managing their symptoms. However, during the surveillance period, ovarian cancer survivors report anxiety about cancer antigen testing and fear of recurrence, many experiencing symptoms associated with
post-traumatic stress disorder. After relapse, patients respond moderately or poorly to subsequent chemotherapy, with later lines of therapy leading to progressively shorter treatment-free intervals. Therefore, we believe effective maintenance
therapies that address a broad patient population are needed to prolong the duration of response following platinum-based treatment. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Breast cancer </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Breast cancer is one
of the leading causes of cancer death among women in China, with a total estimated annual incidence of 268,600 female patients in 2015, which is nearly 16% larger than the incidence of 231,840 female patients in the United States. Breast cancer has
also seen an increasing mortality rate. We initially intend to seek approval for niraparib for treatment of gBRCA positive breast cancer. We also contemplate seeking indication expansion in other patient
<FONT STYLE="white-space:nowrap">sub-groups,</FONT> such as triple negative breast cancer patients. If approved for usage in gBRCA mutation positive and triple negative breast cancer patients, we estimate a target patient pool of approximately
68,000 people, representing about a quarter of total breast cancer incidence in China. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There is no single standard treatment in patients with metastatic
breast cancer who have previously failed anthracycline and taxane treatments. Furthermore, there are no approved treatments for patients with BRCA mutations, and patients are only treated according to the status of their hormone receptor and human
epidermal growth factor receptor 2, or HER2, status, where Herceptin is the recommended targeted therapy. Therefore, more effective therapies that specifically address the gBRCA&#043; patient population are needed. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe niraparib could bring significant benefits to gBRCA&#043; metastatic breast cancer patients in China based on available clinical results from niraparib
and further clinical validation from other PARP inhibitors. In a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">108 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Phase I dose-escalation and confirmation study in participants with advanced solid tumors, two of the four breast cancer patients carrying gBRCA mutations had partial response as best response
(response rate in patients with gBRCA mutations: 50%; 95% CI: 7%, 93%). The clinical potential of PARP inhibitors in this patient population has also been established by the results of a positive Phase III study of AstraZeneca&#146;s olaparib. In
February 2017, AstraZeneca announced that olaparib improved progression-free survival versus standard chemotherapy in patients with gBRCA&#043; metastatic breast cancer, according to findings from its Phase III trial. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Epidemiologic studies of BRCA 1/2 mutations in Chinese breast cancer patients performed in China, Hong Kong, Taiwan, and Singapore have shown a prevalence of BRCA
1/2 gene mutation in familial breast cancer and early-onset breast cancer patients that ranged from 8.0% to 13.5% and from 8.7% to 11.4%, respectively. In addition, triple-negative breast cancer accounts for 10%&#151;20% of all invasive breast
cancer subtypes. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the case of triple negative breast cancer patients, since tumor cells lack the necessary receptors, common treatments like hormone
therapy and drugs that target <FONT STYLE="white-space:nowrap">HER-2</FONT> are ineffective. While chemotherapy is used as standard treatment, there is unmet need for other treatment options that can improve patient survival and overcome the
long-term issue of chemoresistance. Global clinical data has suggested that the combination of a PARP inhibibitor and chemotherapy might be more effective than chemotherapy alone, and we intend to explore usage of niraparib in this patient segment.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Lung cancer </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Lung cancer
has the highest total incidence as well as the highest mortality rate of any cancer in China. Annual incidence was estimated at 733,300 patients in China in 2015, which is more than triple the 221,200 patients in the United States. We intend to
explore niraparib&#146;s efficacy in patients with squamous-type <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer and small cell lung cancer based on the large unmet need for effective treatment for such patients in China.
According to the American Cancer Society, approximately 80% to 85% of lung cancers are <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer and squamous cell carcinoma is about 25% to 30% of lung cancers. Based on an assumption of 80%
share of <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer and 30% of cancers being squamous, we estimate a potential target patient population of 176,000 patients with squamous-type <FONT STYLE="white-space:nowrap">non-small</FONT>
cell lung cancer and 147,000 in small cell lung cancer in China. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">The standard of care for advanced small cell lung cancer and <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer in China is platinum-based chemotherapy. For EGFR mutation positive patients, geftinib (Iressa<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>) and erlotinib (Tarceva<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>) are
recommended as first-line therapies for patients in the advanced/metastatic stage of <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer who are EGFR mutation positive. For <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung
cancer patients with unclear EGFR mutation status, as well as for small cell lung cancer, chemotherapy is the standard of care in China. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe
niraparib has <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> potential in both indications in China, by representing an attractive addition to the current standard of care in small cell lung cancer and
squamous type <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer. While globally monoclonal antibodies, which block the interaction between checkpoint molecules <FONT STYLE="white-space:nowrap">PD-1</FONT> on immune cells and <FONT
STYLE="white-space:nowrap">PD-L1</FONT> on cancer cells, have been used to successfully treat <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer, these drugs have yet been launched in China and remain in clinical trials. Given the
relatively limited therapy options for Chinese physicians and patients we believe that a small molecule PARP inhibitor will offer an attractive addition to the standard of care with an attractive price level relative to large molecule drugs.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to niraparib monotherapy in the potential indications stated above, we also intend to explore the combination of niraparib with other
potential therapies such as immuno-oncology therapy, targeted therapy and chemotherapy in the clinically relevant indications. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">109 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our clinical trial designs and strategy for niraparib in the China market </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Ovarian cancer </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We plan to initiate three clinical studies of
niraparib in ovarian cancer patients in China. One is a Phase I PK study for niraparib in patients with platinum-sensitive ovarian cancer. The other two studies will be Phase III studies of niraparib as a maintenance therapy in patients with
platinum-sensitive ovarian cancer either as a first-line or second-line maintenance therapy. If approved, niraparib may potentially be the first PARP inhibitor on the China market approved as a second-line maintenance therapy in all recurrent
platinum-sensitive ovarian cancer patients, and we would look to rapidly expand niraparib to be available as a first-line maintenance therapy. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our Phase
I PK study is intended to establish the PK profile of niraparib in Chinese patients. We expect to initiate this study in the second half of 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our
first Phase III study is expected to evaluate niraparib as a second-line maintenance therapy in patients with recurrent platinum-sensitive ovarian cancer. Patients with recurrent platinum sensitive ovarian cancer who have responded to a second line
platinum-containing treatment will be enrolled in the study. Patients will be randomly assigned in a 2:1 ratio to receive niraparib or placebo once daily. Patients will be stratified by gBRCA status. The primary endpoint is progression-free
survival. The primary analysis will be conducted in the entire study population, regardless of gBRCA mutation status. If the primary analysis meets the statistical significance, the study will be ended. If it does not, the study will continue for
gBRCA mutation positive patients with the second-step primary analysis conducted in this population. We expect to initiate this study in the second half of 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our second Phase III study is expected to evaluate niraparib as a first-line maintenance therapy in patients with platinum-sensitive ovarian cancer. The details of the clinical trial designs are being discussed
with the CFDA, and, pending authorization, we plan to initiate this trial in the first half of 2018. Tesaro is also evaluating niraparib in the PRIMA trial, a Phase III clinical trial in the first-line maintenance setting in platinum sensitive
ovarian cancer patients. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Breast cancer </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We plan
to initiate a Phase III clinical trial of niraparib in patients with recurrent gBRCA positive breast cancer in China. The details of the clinical trial designs are being discussed with the CFDA and key opinion leaders and, pending authorization, we
plan to initiate this trial in the first half of 2018. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Other indications </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We also intend to initiate Phase II clinical trials to evaluate the efficacy of niraparib in squamous-type <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer and small cell lung cancer patients in
China. Details of the clinical trial designs are being discussed with the CFDA and key opinion leaders. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Background on PARP inhibitors
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">One well-studied area of PARP activity relates to DNA repair. DNA contains genetic instructions used in the development and functioning of most
known living organisms. DNA can be damaged by many types of mutagens, including oxidizing agents, alkylating agents, ultraviolet light and <FONT STYLE="white-space:nowrap">X-rays.</FONT> An important property of DNA is that it can replicate, or make
copies of itself. This is critical when cells divide because each new cell needs to have an exact copy of the DNA present in the old cell. It is also critical to the integrity and survival of </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">110 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
cells that DNA damage can be repaired. Cells have evolved multiple mechanisms to enable such DNA repair, and these mechanisms are complementary to each other, each driving repair of specific
types of DNA damage. If a cell&#146;s DNA damage repair system is overpowered, then the cell is programmed to die. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Radiation and certain chemotherapies
such as alkylating agents and topoisomerase inhibitors induce significant damage to tumor cells, which results in programmed cell death. DNA repair mechanisms may reduce the activity of these anti-cancer therapies and, conversely, inhibition of DNA
repair processes may enhance the effects of <FONT STYLE="white-space:nowrap">DNA-damaging</FONT> anti-cancer therapy. For example, cancer cells can maintain viability despite disruption of the key DNA repair pathway known as the homologous
recombination pathway, but they become particularly vulnerable to chemotherapy if an alternative DNA repair pathway is disrupted. This is known as &#147;synthetic lethality&#148;&#151;a situation where the individual loss of either repair pathway is
compatible with cell viability, but the simultaneous loss of both pathways results in cancer cell deaths. Since PARP inhibitors block DNA repair, PARP inhibition is thought to be an important part of cancer therapy. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Clinical studies have shown that PARP inhibitors are effective as a monotherapy in patients with certain types of cancer, including those with gene mutations as
discussed below. PARP inhibitors have also been explored in numerous clinical trials to enhance chemotherapy treatments, including in combination with temozolomide, cisplatin, carboplatin, gemcitabine and topotecan. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Niraparib mechanism of action </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Many DNA repair
processes involve <FONT STYLE="white-space:nowrap">PARP-1</FONT> and <FONT STYLE="white-space:nowrap">PARP-2,</FONT> which are <FONT STYLE="white-space:nowrap">zinc-finger</FONT> <FONT STYLE="white-space:nowrap">DNA-binding</FONT> enzymes that sense
DNA damage and convert it into intracellular signals to promote DNA repair. PARP inhibitors block DNA repair by the base excision repair pathway. PARP inhibitors appear most effective when used to treat tumors with underlying defects in DNA repair
or when combined with another <FONT STYLE="white-space:nowrap">DNA-damaging</FONT> agent. This is because, in normal cells, the homologous recombination pathway compensates for PARP-mediated inhibition of the base excision repair pathway and
maintains the fidelity of DNA repair. In cells with a deficiency in the homologous recombination pathway, such as those with <FONT STYLE="white-space:nowrap">BRCA-1</FONT> and <FONT STYLE="white-space:nowrap">BRCA-2</FONT> mutations, PARP inhibition
leads to irreparable double-strand breaks, collapsed replication forks, and an increased use of the less effective nonhomologous end joining pathway. These disruptions ultimately result in synthetic lethality, and, in this manner, treatment with
PARP inhibitors represents an opportunity to selectively kill cancer cells with deficiencies in homologous recombination and other DNA repair mechanisms. PARP inhibitors also have an additional mechanism of action known as &#147;PARP trapping.&#148;
The effect of PARP trapping is to poison DNA by stabilizing <FONT STYLE="white-space:nowrap">PARP-1</FONT> and <FONT STYLE="white-space:nowrap">PARP-2</FONT> at sites of DNA damage, generating complexes that may be even more toxic than the
unrepaired single-strand breaks which result from PARP inhibition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Niraparib is designed to be a highly potent, selective inhibitor of <FONT
STYLE="white-space:nowrap">PARP-1</FONT> and <FONT STYLE="white-space:nowrap">PARP-2.</FONT> In an ovarian cancer patient-derived xenograft model, where tumor models are established from transplantation of a human tumor specimen from a cancer
patient directly into a mouse, niraparib has been shown to have greater tumor concentration, allowing it to deliver sustained anti-tumor activity as compared to olaparib, an <FONT STYLE="white-space:nowrap">FDA-approved</FONT> PARP inhibitor
marketed by AstraZenaca for gBRCA&#043; ovarian cancer patients who have received at least three prior lines of chemotherapy. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Niraparib clinical
results </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>NOVA, a Phase III maintenance study of niraparib versus placebo in patients with recurrent platinum-sensitive ovarian cancer.
</I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In March 2017, the FDA approved niraparib as a maintenance treatment for women with recurrent platinum-sensitive ovarian cancer, regardless of BRCA
mutation or biomarker status, three months ahead of the FDA&#146;s </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">111 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
scheduled decision date (PDUFA date). Niraparib&#146;s FDA approval followed the release of successful results from Tesaro&#146;s NOVA trial in which niraparib demonstrated a clinically
meaningful increase in progression-free survival in women with recurrent ovarian cancer, regardless of gBRCA mutation or biomarker status. Treatment with niraparib reduced the risk of disease progression or death by 73% in gBRCA mutation positive
patients (hazard ratio &#061; 0.27) and by 55% in patients without gBRCA mutations (hazard ratio &#061; 0.45). Hazard ratio is the probability of an event (such as disease progression or death) occurring in the treatment arm divided by the
probability of the event occurring in the control arm of a study, with a ratio of less than one indicating a lower probability of an event occurring for patients in the treatment arm. <FONT STYLE="white-space:nowrap">P-value</FONT> is a measure of
the probability of obtaining the observed sample results, with a lower value indicating a higher degree of statistical confidence in these studies. The magnitude of benefit was similar for patients entering the trial with a partial response or a
complete response to platinum treatment. This means that FDA&#146;s approval for niraparib is broader than the approval for AstraZeneca&#146;s PARP inhibitor, olaparib, which is only approved for BRCA mutation positive patients. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The NOVA trial was a phase III randomized double-blind trial that assessed the effectiveness of niraparib compared with placebo to delay tumor progression following
a platinum containing chemotherapy regimen. Patients enrolled into one of two independent cohorts based on gBRCA mutation status. A total of 553 patients were enrolled in the NOVA study at 107 centers worldwide. The study population has 203 patients
assigned to the gBRCA mutation positive cohort and 350 patients assigned to the gBRCA mutation negative cohort. Among the patients in the gBRCA mutation negative cohort, 162 had tumors that were tumors deficient in homologous recombination, or
HRDpos, and 134 had tumors did not have a homologous recombination deficiency, or HRDneg. The homologous recombination deficiency status was not determined for 54 patients. The gBRCA mutation negative cohort analyses included all patients
randomized, regardless of homologous recombination deficiency status. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Within each cohort, patients were randomized 2:1 to receive niraparib or placebo,
and were continuously treated with placebo or niraparib until progression. The primary endpoint of this study was progression free survival. Secondary endpoints included patient-reported outcomes, chemotherapy free interval length, and overall
survival. This trial successfully achieved its primary endpoint in both cohorts, showing that niraparib treatment significantly prolonged progression free survival, compared to control in patients who were gBRCA mutation positive and in patients who
were gBRCA mutation negative. In addition, within the gBRCA mutation negative cohort, niraparib treatment significantly prolonged progression free survival compared to placebo for the prospectively defined patient population with HRDpos tumors. A
high proportion of patients in both treatment groups in both cohorts had received three or four prior lines of chemotherapy. The most common treatment-emergent grade 3/4 adverse events in the niraparib arm of the NOVA study, based on the National
Cancer Institute&#146;s Common Terminology Criteria for Adverse Event, or CTC, which is a set of criteria for the standardized classification of adverse effects of drugs used in cancer therapy (with one and two being relatively mild and higher
numbers (up to five) being more severe), were thrombocytopenia, anemia, and neutropenia. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">112 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The figures below present the results for the primary endpoint of progression free survival for the three primary
efficacy populations. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><I>Figure&nbsp;1: Progression free survival was significantly longer for patients who received niraparib
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><I>compared to those who received placebo for all primary efficacy populations. </I></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g358845g31s68.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Source: Tesaro. </I></FONT></P> <P STYLE="margin-top:4px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Notes:
gBRCAmut &#061; gBRCA</I><I> mutation positive; <FONT STYLE="white-space:nowrap">non-gBRCA</FONT> mut &#061; gBRCA mutation negative </I></FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><I>Figure&nbsp;2: Progression free survival in the gBRCA</I><I> mutation positive cohort of patients treated with niraparib versus placebo
</I></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g358845g36n30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Source: Tesaro. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1" COLOR="#FFFFFF">Median PFS (95% CI) (Months) Hazard Ratio (95% CI) p Value Disease Progression Free (%) Treatment 6 Months 12 Months 18 Months
gBRCAmut Cohort Niraparib (N &#061; 138) 21.0 (12.9, NE) 0.27 (0.173, 0.410) p &lt;0.0001 80% 62% 50% Placebo (N &#061; 65) 5.5 (3.8, 7.2) 43% 16% 16% HRDpos Subgroup Niraparib (N &#061; 106) 12.9 (8.1, 15.9) 0.38 (0.243, 0.586) p &lt;0.0001 69% 51%
37% Placebo (N &#061; 56) 3.8 (3.5, 5.7) 35% 13% 9% Non-gBRCAmut Cohort Niraparib (N &#061; 234) 9.3 (7.2, 11.2) 0.45 (0.338, 0.607) p &lt;0.0001 61% 41% 30% Placebo (N &#061; 116) 3.9 (3.7, 5.5) 36% 14% 12% </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">113 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><I>Figure&nbsp;3: Progression free survival in the HRDpos group of the gBRCA mutation negative cohort
of patients treated with niraparib versus placebo </I></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g358845g46w45.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Source: Tesaro. </I></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2"><I>Figure&nbsp;4: Progression free survival in the overall gBRCA mutation negative cohort of patients treated with niraparib versus placebo </I></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g358845g66p51.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Source: Tesaro. </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Within
the gBRCA mutation positive cohort, the median progression free survival was 21.0 months on niraparib versus 5.5 months on placebo (hazard ratio&#061;0.27; p&lt;0.0001). As shown in the chart above, niraparib&#146;s treatment effect started very
early during treatment as seen by the two curves being separated at first efficacy assessment. Progression free survival was also significantly longer with niraparib in the HRDpos group of the gBRCA mutation negative cohort (median, 12.9 months
versus 3.8 months; hazard ratio&#061;0.38; p&lt;0.0001) and in the overall gBRCA mutation negative cohort (median, 9.3 months versus 3.9 months; hazard ratio &#061; 0.45; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">114 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
p&lt;0.0001). Additionally, in an exploratory pooled analysis that evaluated all patients in both cohorts combined, progression free survival was longer with niraparib (median 11.3 months versus
4.7 months, hazard ratio &#061; 0.38, 95% confidence interval: 0.303, 0.488; p&lt;0.0001). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As it is maintenance therapy, quality of life is important to
patients receiving treatment. Patient-reported outcome data from validated survey tools indicated that niraparib-treated patients reported no significant difference from placebo in measures associated with symptom specific and general quality of
life. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Furthermore, niraparib treatment did not reduce the effectiveness of subsequent therapies, and continued to show carry-over of the beneficial
treatment effect in the secondary efficacy measure of second objective disease progression, which is time from randomization to objective tumor progression on next-line treatment or death from any cause. Overall survival data, while immature, showed
no negative impact of niraparib treatment. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The incidences of CTC grade 3/4 treatment-emergent adverse events (74% vs 23%), serious adverse events (30%
vs 15%), treatment-emergent adverse events leading to treatment interruption (69% vs 5%), treatment-emergent adverse events leading to dose reduction (67% vs 15%), and treatment-emergent adverse events leading to treatment discontinuation (15% vs
2%) were higher for niraparib versus placebo. There were no <FONT STYLE="white-space:nowrap">on-treatment</FONT> deaths reported. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The most commonly
observed hematologic treatment-emergent adverse events (all CTC grades) related to niraparib were thrombocytopenia (61%), anemia (50%) and neutropenia (30%). Although CTC grade 3/4 hematologic laboratory events were common at the initiation of
treatment, no severe clinical sequelae were observed and relatively few patients discontinued due to these adverse events. Dose adjustment based on individual tolerability during the first cycles substantially reduced the incidence of these events
beyond the third <FONT STYLE="white-space:nowrap">28-day</FONT> treatment cycle, indicating the overall effectiveness of the approach to dose modification. Overall the treatment-emergent adverse events were manageable, with no negative impact on
quality of life. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Niraparib preclinical development </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As discussed below, Merck and our partner Tesaro have completed various preclinical trials to evaluate the pharmacodynamics, pharmacokinetics and toxicology profile of niraparib. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2"><I>Pharmacodynamics</I>.&nbsp;&nbsp;&nbsp;&nbsp;In preclinical trials studying niraparib&#146;s pharmacodynamics, niraparib was found to be a
potent and selective <FONT STYLE="white-space:nowrap">PARP-1</FONT> and <FONT STYLE="white-space:nowrap">PARP-2</FONT> inhibitor that displayed at least a <FONT STYLE="white-space:nowrap">100-fold</FONT> selectivity over other PARP-family members <FONT
STYLE="white-space:nowrap">PARP-3,</FONT> <FONT STYLE="white-space:nowrap">v-PARP,</FONT> and <FONT STYLE="white-space:nowrap">Tankyrase-1.</FONT> A commonly used quantitative measure of potency is IC</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUB
STYLE="vertical-align:baseline; position:relative; top:.4ex">90</SUB></FONT><FONT STYLE="font-family:arial" SIZE="2">, which represents the concentration of a drug that is required to suppress 90% of the target enzyme. The IC</FONT><FONT
STYLE="font-family:arial" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">90</SUB></FONT><FONT STYLE="font-family:arial" SIZE="2"> of niraparib for PARylation in BRCA-deficient tumor cells correlates with functional
suppression of single strand breakage repair and anti-tumor effects on BRCA mutation positive tumor cells. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Normal primary cells were resistant to
niraparib with the most sensitive cells (megakaryocytes) exhibiting a <FONT STYLE="white-space:nowrap">13-fold</FONT> selectivity margin as compared to BRCA mutation positive tumor cells <I>in vitro</I>. Maximal
<I><FONT STYLE="white-space:nowrap">in-vivo</FONT></I> efficacy was achieved in BRCA 1 mutation positive ovarian tumor models with once-daily oral administration of niraparib at a dose sufficient to suppress 90% of the PARP enzymatic activity in the
tumor at eight hours after the dose, which translated to greater than 50% inhibition of PARP activity in peripheral blood mononuclear cells at eight hours post dose. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The therapeutic potential of niraparib was evaluated in a study designed to examine the benefit of niraparib in maintenance setting, <I>i.e., </I>daily niraparib treatment following a regression induced with a
platinum-based regimen. In this study, tumors in mice receiving maintenance niraparib therapy became undetectable whereas regrowth was observed in those receiving only the chemotherapy regimen. These data support the concept that
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">115 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
maintenance niraparib therapy after tumor response to chemotherapeutic agents may prolong recurrence-free survival. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Niraparib showed no significant observable effects in nonclinical safety pharmacology studies at clinically relevant doses across the species evaluated. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Pharmacokinetics.&nbsp;&nbsp;&nbsp;&nbsp;</I>Niraparib elicited desirable and consistent pharmacokinetic profiles in nonclinical species<I> in vivo.</I> The oral absorption in rats and dogs was rapid, with
moderate to high bioavailability. The compound is readily distributed to the brains of rats and monkeys to a modest extent, suggesting additional therapeutic potential. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Elimination of niraparib and its metabolites was fecal and renal in rats, while mainly renal in dogs. The potential risk for drug&#151;drug interactions was determined to be minimal for niraparib, due to the lack
of the interactions between niraparib and the hepatic drug-metabolizing CYP enzymes, the major hepatic and renal uptake transporters (OATP1B1, OATP1B3, OAT1, OAT3, and OCT2), and BSEP, an efflux transporter known to be associated with
hepatotoxicity. The <I>in vitro</I> metabolic results, combined with the <I>in vivo</I> pharmacokinetic findings, demonstrated that niraparib had a desirable disposition profile with a minimal potential for drug&#151;drug interactions, consistent
with the development of niraparib as an anticancer agent. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Toxicology</I>.&nbsp;&nbsp;&nbsp;&nbsp;A comprehensive preclinical toxicology program was
conducted to support the administration of niraparib in patients with cancer. This program included oral repeat-dose toxicity studies (up to three-months duration) in dogs and rats, genotoxicity and phototoxicity studies. The results obtained from
the general toxicity studies in rats and dogs indicated that niraparib causes bone marrow suppression which leads to decreases in circulating white and red blood cells. Infections and septicemia were a consequence of bone marrow suppression and
lymphoid depletion. These findings are linked to pharmacology of niraparib and showed reversibility. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Niraparib&#151;Pharmacokinetics </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The pharmacokinetic profile of niraparib has been evaluated in multiple clinical studies, with an overall niraparib-dosed population of 526 patients. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Absorption</I>.&nbsp;&nbsp;&nbsp;&nbsp;Niraparib exhibited linear pharmacokinetic, dose proportional exposure, and dose-independent absorption and clearance.
Following repeat administrations of the daily recommended dose of 300 mg, niraparib accumulation on day 21 was consistent for both the area under the plasma concentration-time curve and maximum concentration (approximately <FONT
STYLE="white-space:nowrap">two-</FONT> to three-fold). Niraparib was shown to be highly orally bioavailable (F ~73%). Bioavailability is a measure of the absorption of drug and is expressed as a percentage of the administrated case of the drug which
reaches the patient&#146;s system. Niraparib can be administered with or without food. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Distribution</I>.&nbsp;&nbsp;&nbsp;&nbsp;Niraparib was
moderately protein bound to human plasma (83.0%). The apparent volume of distribution was 1220 L, indicating an extensive tissue distribution of niraparib. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Metabolism</I>.&nbsp;&nbsp;&nbsp;&nbsp;The carboxylesterases-catalyzed amide hydrolysis was delineated to be the major primary pathway, followed by the
<FONT STYLE="white-space:nowrap">uridine-5&#146;-diphospho-glucuronosyltransferases</FONT> (UGT)-mediated glucuronidation and the other minor secondary pathway (<I>i.e</I>., methylation). The major circulating metabolites in humans are the
carboxylic acid and the glucuronides of carboxylic acid. The metabolic profile seen in humans is consistent with what was detected in the experimental species (rats and dogs). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Elimination</I>.&nbsp;&nbsp;&nbsp;&nbsp;In an absorption, metabolism and elimination study in cancer patients using <FONT STYLE="white-space:nowrap">14C-radioactive</FONT> niraparib, a mean measured total of
86.2% of the radioactive dose was recovered in urine and fecal samples </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">116 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
collected daily from 0 to 504 hours (21 days) post dose after single oral administration of <FONT STYLE="white-space:nowrap">14C-niraparib.</FONT> It suggests minimal long-term retention of
niraparib or its metabolites in body. Moreover, hepatobiliary clearance and renal excretion are the major routes of elimination in humans. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Intrinsic
Effects</I>.&nbsp;&nbsp;&nbsp;&nbsp;Population pharmacokinetic analysis identified no intrinsic factors such as age, race, hepatic impairment, renal impairment would have significant impact on the pharmacokinetic of niraparib. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Omadacycline </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Omadacycline is a broad-spectrum
antibiotic in a new class of tetracycline derivatives, known as aminomethylcyclines. Omadacycline is primarily being developed for ABSSSI, CABP and UTIs in both the hospital and community settings and is designed to overcome the two major mechanisms
of tetracycline resistance, known as pump efflux and ribosome protection. Omadacycline has been granted QIDP status in the U.S. by the FDA and has been granted Fast Track status by the FDA. The drug has been administered to over 1,500 patients and
has an established safety profile. If approved, omadacycline is expected to be available in IV and oral once-daily formulations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Paratek had previously
reached an agreement with the FDA under a Special Protocol Assessment, or SPA, whereby if both the IV to oral Phase&nbsp;III ABSSSI and CABP studies are positive, Paratek could seek approval for both indications. In June 2016, Paratek announced
positive <FONT STYLE="white-space:nowrap">top-line</FONT> efficacy data in a Phase III registration study in ABSSSI which demonstrated the efficacy and safety of IV to oral once-daily omadacycline compared to linezolid. In April 2017, Paratek
announced positive <FONT STYLE="white-space:nowrap">top-line</FONT> results from a global, pivotal Phase III clinical study in CABP which demonstrated the efficacy, general safety and tolerability of IV to oral omadacycline compared to moxifloxacin.
In July&nbsp;2017, Paratek also announced positive top-line results from a Phase&nbsp;III study comparing oral-only administration of omadacycline in ABSSSI compared to oral-only linezolid, which met all of its primary endpoints. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Paratek plans to submit its NDA in the U.S. during the first quarter of 2018 and its EMA submission later in 2018. In addition to its Phase III program for
omadacycline, a Phase Ib study in UTIs was initiated in May 2016 and positive <FONT STYLE="white-space:nowrap">top-line</FONT> PK <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-principle</FONT></FONT> data was reported in
November 2016. Paratek plans to begin enrolling patients in a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> Phase II study of omadacycline in complicated UTI, or cUTI, as early as the fourth quarter
of 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We obtained the exclusive license to develop, manufacture and commercialize omadacycline in the field of all human therapeutic and preventative
uses (other than biodefense) in China, Hong Kong, Macau, and Taiwan in April 2017. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Market opportunity </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe omadacycline addresses an unmet need in China for a broad-spectrum antibiotic that provides a new treatment option for physicians in China challenged by
growing antibiotic resistance. A 2015 study by the State Key Laboratory of Organic Geochemistry under the Chinese Academy of Sciences indicated that the total antibiotic usage in China in 2013 accounted for about half of the antibiotic usage
globally, with the <FONT STYLE="white-space:nowrap">per-capita</FONT> use of antibiotics in China being more than five times that in Europe and the United States. As a result, China has one of the world&#146;s most serious problems with antibiotic
misuse and antibiotic resistance. According to a May 2016 study from the Wellcome Trust in London, antimicrobial resistance in China could cause 1&nbsp;million premature deaths annually by 2050 and cost the country $20 trillion. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In 2015, there were approximately 2.8&nbsp;million ABSSSI patients and 16.5&nbsp;million CABP patients in China. We believe that omadacycline will provide a new
treatment option for patients with such infections, including those </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">117 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
caused by drug-resistant pathogens whose numbers are expected to increase as the result of the abuse of antibiotics. The product has been designed to provide potential advantages over existing
antibiotics, including broad-spectrum, antibacterial activity and activity against resistant bacteria, no known drug interactions and a favorable safety and tolerability profile. In addition, once daily dosing of the oral and IV formulations will
offer a unique advantage by reducing hospital days through a step-down from IV to the oral formulation, which not only has important cost-saving implications but increases patient comfort and reduces exposure to nosocomial pathogens. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The competitive field in China and worldwide is characterized by the wide use of various generic formulations of older tetracyclines, such as oral formulations of
doxycycline. Minocycline is rarely used except for long-term treatment of acne. A member of a new generation of tetracyclines known as glycylcyclines, dominates the market and has experienced a considerable growth rate despite a limited list of
labeled indications, the absence of an oral formulation, and significant tolerability and safety issues. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In three well-controlled Phase III trials,
designed with FDA input, omadacycline was shown to be non-inferior to its study comparators. Omadacycline met all primary efficacy endpoints as stipulated by the FDA and EMA. In all three studies omadacycline was shown to be generally safe and well
tolerated. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">Tigecycline (Tygacil<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>), the most recently approved tetracycline derivative available today, is marketed in China and worldwide. One of omadacycline&#146;s differentiating features is the
availability of a bioequivalent oral formulation while tigecycline is an <FONT STYLE="white-space:nowrap">IV-only</FONT> drug. If approved, omadacycline can be used in the outpatient setting. In the hospital, the ability to switch from IV to oral
administration enables greater flexibility in patient management and potential cost savings. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Omadacycline has a broad microbiologic profile with
effective microbiological activity against a broad spectrum of pathogens, including problem pathogens like MRSA and PRSP, Gram-negative pathogens such as H. influenzae and atypical bacteria such as Legionella. It has strong activity against most of
the pathogens encountered in the indications pursued, ABSSSI, CABP and UTI. It has useful activity against <I>Acinetobacter,</I> a multi-drug resistant pathogen in the health care setting which is frequently encountered in Chinese hospitals.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Our clinical trials designs and strategy for omadacycline in the China market </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are in the technology transfer stage and plan to discuss China development plan with key opinion leaders and the CFDA. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Background on tetracycline antibiotics </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The tetracycline class of antibiotics was introduced into the clinic in
the 1960s and found considerable use in the treatment of respiratory and gastrointestinal infections. They are mostly bacteriostatic drugs interfering with protein synthesis by binding selectively to the bacterial 30S ribosomal subunit. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Tetracyclines provide excellent broad-spectrum coverage of Gram-positive, Gram-negative, anaerobes and special pathogens (e.g., malaria, anthrax, Lyme borrelia,
nocardia). Resistance is due to efflux mechanisms and ribosomal mutations, but despite the gradual and inevitable increase in resistance over many decades of continued use, doxycycline is still an effective and commonly used drug today. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Omadacycline &#150; Pharmacokinetics </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Studies showed that
oral doses of 300 mg provide bioequivalent exposure with the therapeutic IV dose of 100 mg. Like with other tetracyclines, absorption is affected by food and divalent cations. The drug has a long half-life (approximately 16-18 hours) and excellent
penetration into tissues, including alveolar and epithelial lining </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">118 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
fluid. In contrast to other tetracyclines, plasma protein binding is low (20%) and not dose-related. The drug is not metabolized and excretion is predominantly via the biliary route. There is no
need for dose adjustment in hepatic or renal impairment. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Omadacycline clinical results </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><I>Phase III pivotal trial&#151;ABSSSI / OASIS&#151;ABSI 1108 </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Omadacycline was statistically <FONT STYLE="white-space:nowrap">non-inferior</FONT> to linezolid IV/PO in a direct comparison study following a protocol established under an SPA agreed to with the FDA as well as
the criteria outlined by the EMA. In this trial, patients with wound infections, major abscesses, and erysipelas/cellulitis were enrolled in equal numbers. On average, patients received IV omadacycline for 4.4 days, and oral omadacycline for 5.5
days. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">S. aureus (both MSSA and MRSA) was the predominant pathogen isolated from patients followed by streptococci. Clinical response and bacterial
eradication rates showed the high efficacy of omadacycline against skin pathogens including MRSA. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><I>Figure&nbsp;5: Omadacycline vs
Linezolid&#151;ABSSSI Trial&#151;Primary Efficacy Outcomes </I></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g358845g02p22.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">119 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><I>Figure&nbsp;6: Early Clinical Success by Pathogen&#151;micro-mITT Population </I></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><I>


<IMG SRC="g358845g54z99.jpg" ALT="LOGO">
 </I></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The safety / tolerability profile was very similar between the treatment arms with only a slightly higher rate of
gastrointestinal side effects and infusion site reactions in omadacycline recipients. There was no significant imbalance in treatment emergent adverse events, or TEAEs, serious TEAEs, premature discontinuations or deaths. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><I>Figure 7: Study ABSI-1108: Most Frequent TEAEs (&gt; 3%)&#151;Safety Population </I></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g358845g35d56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><I>Phase III Pivotal Trial&#151;CABP / OPTIC&#151;CABP1200 </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Omadacycline was <FONT STYLE="white-space:nowrap">non-inferior</FONT> to moxifloxacin IV/oral in this direct comparison study following a protocol established under
an SPA agreed with the FDA as well as the criteria outlined by the EMA. In this trial, patients with PORT Class&nbsp;II&#151;IV were recruited; less than 25% of patients had received <FONT STYLE="white-space:nowrap">non-study</FONT> antibiotics
before enrollment. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">S. pneumoniae and Mycoplasma pneumoniae were the predominant pathogens isolated, followed by H. influenzae, H. parainfluenzae,
Legionella and Chlamydophila. The clinical response rates were high for all respiratory pathogens isolated at entry and very similar between omadacycline and moxifloxacin, a powerful respiratory fluoroquinolone. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">120 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><I>Figure 8: CABP Study&#151;OPTIC: Primary Efficacy Results&#151;FDA Analysis </I></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g358845g68g30.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><I>Figure 9: CABP Study&#151;OPTIC: Primary Efficacy Results&#151;EMA Analysis </I></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g358845g09j45.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">121 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><I>Figure 10: CABP Study&#151;OPTIC: Clinical Success at PTE by Baseline Pathogen </I></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g358845g94t04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Omadacycline was observed to be generally safe and well tolerated. Neither gastrointestinal side effects nor IV infusion
reactions occurred more frequently in the omadacycline arm than in the comparator arm. Cardiovascular signs and symptoms and liver function test abnormalities occurred in both study arms with similar frequency. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2"><I>Figure 11: TEAEs in CABP Trial </I></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g358845g30j99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><I>Phase III trial &#150; ABSSSI <FONT STYLE="white-space:nowrap">/OASIS-2</FONT> </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Paratek&#146;s third Phase III clinical study <FONT STYLE="white-space:nowrap">(OASIS-2)</FONT> was an oral-only administration of omadacycline in ABSSSI compared
to oral-only linezolid.&nbsp;Oral, once daily omadacycline met the <FONT STYLE="white-space:nowrap">FDA-specified</FONT> primary efficacy endpoint </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">122 </FONT></P>

 <P STYLE="line-height:0pt;margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1" COLOR="#FFFFFF">Omadacycline (N &#061; 204) Moxifloxacin (N &#061; 182) Baseline Pathogen N
Clinical Success n (%) N1 Clinical Success n (%) Atypical Pathogens 118 109 (92.4) 106 97 (91.5) Mycoplasma Pneumoniae 70 66 (94.3) 57 50 (87.7) Chlamydophila Pneumoniae 28 25 (89.3) 28 25 (89.3) Legionella Pneumophila 37 35 (94.6) 37 36 (97.3)
Gram-Negative Bacteria (aerobes) 79 67 (84.8) 68 55 (80.9) Haemophilus Influenzae 32 26 (81.3) 16 16 (100.0) Haemophilus Parainfluenzae 18 15 (83.3) 17 13 (76.5) Klebsiella Pneumoniae 13 10 (76.9) 13 11 (84.6) Gram-Positive Bacteria(aerobes) 61 52
(85.2) 56 49 (87.5) Streptococcus Pneumoniae 43 37 (86.0) 34 31 (91.2) PSSP 26 23 (88.5) 22 21 (95.5) Macrolide Resistant 10 10 (100.0) 5 5 (100.0) Staphylococcus Aureus 11 8 (72.7) 11 9 (81.8) *10 or More Isolates for OmadacyclineOmadacycline (N
&#061; 382) n (%) Moxifloxacin (N &#061; 388) n (%) Subjects with at Least One TEAE 157 (41.1) 188 (48.5) ALT Increased 14 (3.7) 18 (4.6) Hypertension 13 (3.4) 11 (2.8) GGT Increased 10 (2.6) 8 (2.1) Insomnia 10 (2.6) 8 (2.1) Vomiting 10 (2.6) 6
(1.5) Constipation 9 (2.4) 6 (1.5) Nausea 9 (2.4) 21 (5.4) AST Increased 8 (2.1) 14 (3.6) Headache 8 (2.1) 5 (1.3) </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
of statistical <FONT STYLE="white-space:nowrap">non-inferiority</FONT> in the modified <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">intent-to-treat,</FONT></FONT> or mITT,
population (10% <FONT STYLE="white-space:nowrap">non-inferiority</FONT> margin, 95% confidence interval) compared to oral, twice daily linezolid at the early clinical response, or ECR, <FONT STYLE="white-space:nowrap">48-72</FONT> hours after
initiation of therapy. The ECR rates for the omadacycline and linezolid treatment arms were 87.5% and 82.5%, respectively.&nbsp;In addition, omadacycline met specified <FONT STYLE="white-space:nowrap">co-primary</FONT> endpoints for the EMA, which
are key secondary endpoints for the FDA.&nbsp;For these endpoints, <FONT STYLE="white-space:nowrap">non-inferiority</FONT> in the mITT and clinically evaluable populations in at the post treatment evaluation, seven to 14 days after end of treatment,
omadacycline demonstrated a high response rate and met statistical <FONT STYLE="white-space:nowrap">non-inferiority</FONT> to linezolid for both populations using a pre-specified 95% confidence interval. High success rates were observed with
response rates of 84.2% (omadacycline) vs. 80.8% (linezolid) and 97.9% (omadacycline) vs. 95.5% (linezolid), respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Omadacycline was shown to be
generally safe and well tolerated in the <FONT STYLE="white-space:nowrap">OASIS-2</FONT> study, consistent with prior studies of omadacycline. The most common TEAEs in omadacycline-treated patients (occurring in <FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> 3% of patients) were gastrointestinal adverse events of omadacycline vs. linezolid included: vomiting
(16.8% vs. 3.0%), nausea (30.2% vs. 7.6%), diarrhea (4.1% vs. 2.7%).&nbsp;In addition, alanine aminotransferase, or ALT, increase (5.2% with omadacycline vs. 3.0% with linezolid), aspartate aminotransferse increases (4.6% with omadacycline vs. 3.3
for linezolid) and headache (3.5% with omadacycline vs. 2.2% with linezolid).&nbsp;Drug-related TEAEs were 37.8% for omadacycline vs. 14.2% for linezolid (including gastrointestinal events). Discontinuation for TEAEs was uncommon, 1.6% for
omadacycline vs. 0.8% for linezolid. Serious TEAEs occurred in 1.4% of omadacycline patients and 1.4% of linezolid patients; only one serious TEAE was considered related to the study drug and the event occurred in a linezolid patient. The mortality
rate was 0.0% with omadacycline and 0.3% with linezolid. Drug-related serious TEAEs leading to premature discontinuation of test articles were 0.8% with omadacycline and 0.5% with linezolid. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><I>Phase II studies </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In a small study
(N&#061;111) conducted in cSSSI patients omadacycline showed comparable efficacy and safety to linezolid IV/PO </FONT><FONT STYLE="font-family:ARIAL" SIZE="2">&plusmn;</FONT><FONT STYLE="font-family:arial" SIZE="2"> aztreonam. However, the design of
the Phase II study (and a truncated Phase III study with 68 patients) was no longer consistent with newer FDA guidance issued for ABSSSI in 2008 which required, among other changes, an early efficacy <FONT STYLE="white-space:nowrap">read-out</FONT>
at <FONT STYLE="white-space:nowrap">48-72</FONT> hours. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, this early omadacycline program used a 200 mg oral step-down dose that proved to
not be bioequivalent to the 100 mg IV dose. Hence, these data are considered exploratory and cannot be merged easily with the larger pivotal program trials in ABSSSI and CABP that were conducted with FDA guidance and bioequivalent IV to oral
step-down dosing. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><I>Phase I studies </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Omadacycline has been evaluated in more than 20 Phase I studies, including food-effect, age and gender, and renal / hepatic insufficiency studies. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">Omadacycline has a very favorable PK profile. It was absorbed well; its plasma T<FONT SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;1</SUP></FONT><FONT SIZE="2">/</FONT><FONT SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.1ex">2</SUB></FONT><FONT STYLE="font-family:arial" SIZE="2"> of <FONT
STYLE="white-space:nowrap">14-20</FONT> hours permitted once-daily dosing. The drug was not metabolized and drug-drug interactions were minimal. In contrast to other tetracyclines, which paradoxically display dose-dependent increases in protein
binding, 80% of omadacycline remained available as free drug. Excretion was via biliary and urinary routes. Data from hepatic and renal impairment studies showed that dose adjustments are not needed for patients with either condition.
</FONT></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In bioequivalence studies, the 300 mg oral dose was found to match the area under the curve of the 100 mg IV dose within the <FONT
STYLE="white-space:nowrap">80-125%</FONT> range. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Omadacycline was negative on hERG testing and had no appreciable effect on cardiac conduction in a
Thorough QT trial at supra-therapeutic doses. However, in animal tests and during Phase I, a dose-dependent elevation of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">123 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
blood pressure (syst and diast) and heart rate were observed. Omadacycline was found to be an acetylcholine antagonist for muscarinic receptor subtype M2, essentially acting as a vagolytic agent.
In subsequent patient studies, these effects were less pronounced or absent and clinically asymptomatic. All Phase II and III studies included systematic cardiovascular <FONT STYLE="white-space:nowrap">pre-</FONT> and post-dose monitoring of blood
pressure and heart rate to further characterize these effects both qualitatively and quantitatively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">An ELF study showed excellent penetration of
omadacycline into bronchoalveolar lavage fluid and into alveolar macrophages. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A cystitis (uUTI) study was conducted to obtain PK information for
different oral dosing regimens of omadacycline. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">ZL-2301</FONT> </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">ZL-2301</FONT> is an oral, small molecule dual TKI which blocks both VEGFR and FGFR.
<FONT STYLE="white-space:nowrap">ZL-2301</FONT> was studied by our partner Bristol-Myers Squibb mainly for the treatment of HCC, the most common type of liver cancer. To date, <FONT STYLE="white-space:nowrap">ZL-2301</FONT> has been tested in 26
trials, including 19 Phase I trials, two Phase II trials and five Phase III trials, with 2,651 oncology patients around the world. In these trials, <FONT STYLE="white-space:nowrap">ZL-2301</FONT> has demonstrated anti-tumor activity and a generally
well-established safety profile, particularly in HCC patients. In 2012, Bristol-Myers Squibb terminated its development program for <FONT STYLE="white-space:nowrap">ZL-2301</FONT> after it missed the primary endpoints in two Phase III trials with
advanced HCC patients. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Based on our review of the results from Bristol-Myers Squibb&#146;s development program for
<FONT STYLE="white-space:nowrap">ZL-2301,</FONT> our understanding of the etiology of HCC in Chinese patients, standard of care of HCC patients in China and our ongoing research, a number of factors lead us to believe that <FONT
STYLE="white-space:nowrap">ZL-2301</FONT> has the potential to be an effective treatment option for Chinese HCC patients and merits further clinical trials. These factors include: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">in prior clinical trials, <FONT STYLE="white-space:nowrap">ZL-2301</FONT> was observed to have comparable anti-tumor activity in HCC patients to sorafenib,
particularly&nbsp;in patients with HCC induced by hepatitis B infection rather than hepatitis C infection. In Chinese patients HCC is typically induced by hepatitis B infection, rather than hepatitis C infection; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">in China, chemotherapy, rather than TKIs, such as sorafenib, remains the primary first-line treatment for HCC and, as a result, a much greater percentage of
Chinese patients are <FONT STYLE="white-space:nowrap">TKI-naive</FONT> going into second-line treatment, hence more sensitive to TKI treatment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">limited target therapy treatment options for HCC patients, especially in China; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our PD analysis and PK modeling data suggest that there may be a more effective dosing schedule of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> compared to
the dosing schedule studied in prior clinical trials. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In Bristol-Myers Squibb&#146;s <FONT STYLE="white-space:nowrap">BRISK-FL</FONT>
study, which was a Phase III <FONT STYLE="white-space:nowrap">non-inferiority</FONT> study of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> compared to sorafenib in patients without prior systemic treatment, 223 Chinese HCC patients out of 1,155
patients in total participated. Although the study missed the primary end point of overall survival noninferiority for <FONT STYLE="white-space:nowrap">ZL-2301</FONT> versus sorafenib based on the prespecified margin,
<FONT STYLE="white-space:nowrap">ZL-2301</FONT> demonstrated evidence of anti-tumor activity. Median OS was 9.9 months for sorafenib and 9.5 months for <FONT STYLE="white-space:nowrap">ZL-2301.</FONT> TTP, ORR, and DCR were similar between sorafenib
and <FONT STYLE="white-space:nowrap">ZL-2301.</FONT> Most frequent grade 3/4 adverse events for sorafenib and <FONT STYLE="white-space:nowrap">ZL-2301</FONT> were hand-foot skin reaction (15% and 2%, respectively), hyponatremia (9% and 23%,
respectively), AST elevation (17% and 14%, respectively), fatigue (7% and 15%, respectively), and hypertension (5% and 13%, respectively). Discontinuation as a result of adverse events was 33% for sorafenib and 43% for
<FONT STYLE="white-space:nowrap">ZL-2301;</FONT> rates for dose reduction were 50% and 49%, respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">124 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our analysis of Chinese patients in the <FONT STYLE="white-space:nowrap">BRISK-FL</FONT> study showed that <FONT
STYLE="white-space:nowrap">ZL-2301</FONT> demonstrated a trend of efficacy and a safety profile comparable to those of sorafenib. In particular, more Chinese HCC patients experienced no dose reduction compared to
<FONT STYLE="white-space:nowrap">non-Chinese</FONT> patients. Our analysis also showed that less Chinese HCC patients experienced one dose or two dose reductions compared to <FONT STYLE="white-space:nowrap">non-Chinese</FONT> patients. This data
suggests that <FONT STYLE="white-space:nowrap">ZL-2301</FONT> treatment may be better tolerated by Chinese HCC patients than <FONT STYLE="white-space:nowrap">non-Chinese</FONT> patients. While the <FONT STYLE="white-space:nowrap">BRISK-FL</FONT>
study was not designed specifically to determine efficacy and safety in a Chinese patient population, we concluded that our analysis of such clinical data was promising and warranted further clinical trials. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">It has been debated within the HCC expert community that the biology of Chinese HCC may be different from that of <FONT
STYLE="white-space:nowrap">non-Chinese</FONT> HCC. In China, hepatitis B infections are much more prevalent than that of hepatitis C, and as a result HCC among Chinese patients are usually induced by the hepatitis B virus rather than the hepatitis C
virus, which more commonly induces HCC in patients from western countries. We believe that this difference between Chinese HCC patients and <FONT STYLE="white-space:nowrap">non-Chinese</FONT> HCC patients could potentially explain the difference in
outcomes in patients treated with <FONT STYLE="white-space:nowrap">ZL-2301.</FONT> For example, the subgroup analysis of 512 patients enrolled in the <FONT STYLE="white-space:nowrap">BRISK-FL</FONT> study whose HCC was induced by hepatitis B
infection showed overall survival of 8.4 months for <FONT STYLE="white-space:nowrap">ZL-2301</FONT> treated patients compared to 8.1 months for sorafenib treated patients; the subgroup analysis of 235 patients enrolled in the <FONT
STYLE="white-space:nowrap">BRISK-FL</FONT> study whose HCC was induced by hepatitis C infection showed overall survival of 10.9 months for <FONT STYLE="white-space:nowrap">ZL-2301</FONT> treated patients compared to 12.9 months for sorafenib treated
patients. The treatment available to most advanced HCC patients in China is generally limited to traditional chemotherapy, and only a very small portion of Chinese HCC patients have access to sorafenib
(Nexavar<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>), a kinase inhibitor <FONT STYLE="white-space:nowrap">co-developed</FONT> and
<FONT STYLE="white-space:nowrap">co-marketed</FONT> by Bayer Healthcare and Onyx Pharmaceuticals Inc., a subsidiary of Amgen Inc., and used to treat 1</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"> line HCC in the United States and other jurisdictions. Due to the difference in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">standard-of-care</FONT></FONT> in first-line treatment, most Chinese patients are TKI na&iuml;ve, and they are therefore likely more sensitive and responsive to TKI therapy as compared to western second-line HCC patients
who have already been exposed to TKI treatment and in most cases have become TKI resistant. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, our pharmacodynamics analysis and pharmacology
modeling data suggest that a 400 mg <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">twice-a-day</FONT></FONT> treatment regime seems to have better coverage for target inhibition as compared to a regime of 800 mg once daily.
Therefore, we will explore and optimize the dose and dosing schedule in our further trials. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In 2015, we obtained an exclusive license for the
development and commercialization of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> in China, Hong Kong and Macau. The CFDA has approved our CTA for <FONT STYLE="white-space:nowrap">ZL-2301</FONT> as a Category 1 drug, and in the second quarter of
2017 we initiated a Phase II trial of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> as a second-line treatment comparing 800mg once daily to 400mg twice daily for advanced HCC patients in China. Pending results from such Phase II trial, we plan to
initiate a Phase III clinical trial shortly thereafter. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Market opportunity </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The annual incidence for liver cancer was estimated at 466,100 patients in China in 2015, as compared with 35,660 patients in the United States. Among liver cancer patients in China, HCC is largely caused by the
hepatitis B virus, or HBV, while hepatitis C is the main cause for <FONT STYLE="white-space:nowrap">non-Chinese</FONT> HCC patients. HBV is found in more than two thirds of cases in China as compared to only 8% in the United States, according to the
<I>Hepatology Journal</I>. This corresponds to over 10 times more HCC patients in China compared to the US. The number of hepatitis B cases in China is expected to continue to grow as the result of poor control of hepatitis B infection. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">When identified in its early stages, liver cancer can often be treated with surgical resection or liver transplantation. At a more advanced stage, trans-catheter
arterial chemoembolization, or TACE, and systemic drug therapy are considered. TACE is a combination of regional chemotherapy and some form of hepatic artery occlusion. Consistently higher response rates have been reported for TACE when compared
with systemic chemotherapy. Sorafenib, a TKI, and chemotherapy are approved as the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care,</FONT></FONT> first-line targeted
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">125 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
therapies in China. In addition, sorafenib is also recommended for use with TACE as an adjuvant in the China guidelines. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Overall, chemotherapy remains the main drug treatment method for HCC in China. There is only a low level of usage of targeted therapy with agents such as sorafenib, largely due to the low level of engagement of the
leading physicians in the HCC area in China. It has been observed in HCC community that many Chinese patients with HCC who take sorafenib either do not respond well or show poor tolerance to such treatment. We believe this could be the result of a
difference in biology of Chinese patients from <FONT STYLE="white-space:nowrap">non-Chinese</FONT> patients and the fact that HCC is typically secondary to a hepatitis B infection in China. There is, therefore, a large unmet medical need to develop
a widely accessible drug for advanced HCC treatment in China which presents better tolerability for Chinese patients. This is especially relevant since chemotherapy drugs are generally less effective in HCC, compared to other cancers. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Our clinical trial designs and strategy for the China market </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the second quarter of 2017 we initiated a Phase II trial in advanced HCC patients in China to further investigate
<FONT STYLE="white-space:nowrap">ZL-2301&#146;s</FONT> optimal treatment schedule and dosage as a second-line treatment. The study is an open label study of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> with two treatment arms of 30 patients each.
One arm is receiving 800 mg of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> once daily and the other arm is receiving 400 mg of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> twice daily. The primary endpoints of this Phase II trial are disease
control rate at three months post treatment and time to tumor progression. The PK profile of each treatment schedule and dosage level is also being investigated. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Pending results from the Phase II trial, including the optimal dosage level and schedule, we plan to initiate a Phase III double-blind, randomized, parallel trial to compare
<FONT STYLE="white-space:nowrap">ZL-2301</FONT> at the selected treatment schedule/dosage with best supportive care versus placebo with best supportive care as a second-line treatment of advanced HCC patients. We plan to enroll 348 patients at a 2:1
ratio for the Phase III trial. The primary endpoints will be overall survival and the secondary endpoints will be time to tumor progression, disease control rate, objective response rate and overall safety. If this Phase III trial yields positive
results, we plan to use the results to support an NDA submission of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> in China. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Background on tyrosine
kinase inhibitors </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Tyrosine kinases are enzymes responsible for the activation of many proteins by signaling transduction cascades, the process by
which a foreign DNA is introduced into a cell by a virus or viral vector. The tyrosine kinase inhibitors comprise a relatively new group of anticancer drugs that have been developed as oral formulations. The mechanism of action of tyrosine kinase
inhibitors includes modulation of key pathways and mechanisms of angiogenesis, the formation of new blood vessels in human body, and tumorigenesis, the formation of cancers, such as VEGFR. However, tyrosine kinase involvement and activity may vary
from tumor to tumor, resulting in differing responses to different TKIs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">VEGF plays a key role in tumor angiogenesis during the development of cancer,
tumors at an advanced stage can secrete large amounts of VEGF to stimulate excessive angiogenesis around the tumor in order to provide greater blood flow, oxygen, and nutrients to fuel the rapid growth of the tumor. VEGF and other ligands can bind
to three VEGF receptors, VEGFR1, 2 and 3, each of which has been shown to play a role in angiogenesis. Therefore, inhibition of the VEGF/VEGFR signaling pathway can act to stop the growth of the vasculature around the tumor and thereby starve the
tumor of the nutrients and oxygen it needs to grow&nbsp;rapidly. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, a growing body of evidence has demonstrated the oncogenic potential of
FGFR aberrations in driving tumor growth, promoting angiogenesis, and conferring resistance mechanisms to anti-cancer therapies. There is also evidence that anti-VEGF therapy treatment could increase FGFR pathway activation, leading to
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">126 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
drug resistance to anti-VEGF therapies. As a result, simultaneously targeting VEGFR and FGFR is an attractive approach to improve clinical efficacy. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I><FONT STYLE="white-space:nowrap">ZL-2301</FONT> mechanism of action </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">By inhibiting VEGFR and FGFR, <FONT STYLE="white-space:nowrap">ZL-2301</FONT> affects the human vein endothelium cells, which are responsible for angiogenesis. Since essentially all solid tumors require
angiogenesis to progress beyond a few millimeters in diameter, anti-angiogenesis drugs have demonstrated benefits in a wide variety of tumor types. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
exact mechanisms by which <FONT STYLE="white-space:nowrap">ZL-2301</FONT> inhibits tumor growth are not entirely understood, but clinical trial results to date suggest that <FONT STYLE="white-space:nowrap">ZL-2301</FONT> effectively inhibits tumor
growth and such inhibition is associated with the inactivation of <FONT STYLE="white-space:nowrap">VEGFR-2,</FONT> increased apoptosis, a process of programmed cell death, a reduction in microvessel density, inhibition of cell proliferation and
down-regulation of cell cycle regulators. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I><FONT STYLE="white-space:nowrap">ZL-2301</FONT> preclinical and clinical background </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As discussed below, Bristol-Myers Squibb completed various preclinical studies to evaluate the pharmacodynamics, pharmacokinetics and toxicology profile of <FONT
STYLE="white-space:nowrap">ZL-2301.</FONT> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Pharmacodynamics</I>.&nbsp;&nbsp;&nbsp;&nbsp;In preclinical studies,
<FONT STYLE="white-space:nowrap">ZL-2301</FONT> demonstrated strong in vitro inhibitory effects on human umbilical vein endothelial cells when stimulated with VEGF and basic fibroblast growth factor for
<FONT STYLE="white-space:nowrap">VEGFR-2</FONT> and basic fibroblast growth factor <FONT STYLE="white-space:nowrap">receptor-1,</FONT> respectively. Each of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> and
<FONT STYLE="white-space:nowrap">ZL-2301</FONT> alaninate, which becomes the pharmacologically active <FONT STYLE="white-space:nowrap">ZL-2301</FONT> after being metabolized, demonstrated, in vivo, a broad spectrum of antitumor activities, with
cytostasis, the inhibition of cell growth and multiplication, observed in all human tumor models tested. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, when <FONT
STYLE="white-space:nowrap">ZL-2301</FONT> was administered in combination with cetuximab, enhanced antitumor activities were observed against mouse xenograft lung tumor tissue samples. Enhanced antitumor activities were also observed when <FONT
STYLE="white-space:nowrap">ZL-2301</FONT> was administered in combination with ixabepilone and paclitaxel. When tested on a model of human lung carcinoma tissues, <FONT STYLE="white-space:nowrap">ZL-2301</FONT> demonstrated more prolonged tumor
growth delay than sorafenib. Furthermore, complete tumor stasis was also observed in a staged tumor xenograft derived from HCC patients after <FONT STYLE="white-space:nowrap">ZL-2301</FONT> was administered. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Further studies demonstrated that <FONT STYLE="white-space:nowrap">ZL-2301</FONT> effected mainly the gastrointestinal, vascular, skeletal and female reproductive
systems. The effects of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> on these target systems were consistent with the expected pharmacology of <FONT STYLE="white-space:nowrap">ZL-2301.</FONT> In addition, in repeat-dose studies, reversible
increases in serum transaminases were observed in studies conducted on mice, rats and monkeys, total bilirubin and liver weight gains were observed in studies conducted on rats, and microscopic alterations of hepatocellular vacuolation were observed
in studies conducted on rats and monkeys, which indicated that <FONT STYLE="white-space:nowrap">ZL-2301</FONT> has a significant effect on livers. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Pharmacokinetics</I><FONT STYLE="white-space:nowrap">.&nbsp;&nbsp;&nbsp;&nbsp;ZL-2301</FONT> elicited desirable and consistent pharmacokinetic profiles in
nonclinical species in vivo. The oral absorption of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> alaninate in mice, rats, dogs and monkeys was rapid, with bioavailability ranging from 52% to 97%. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Elimination of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> and its metabolites was mainly fecal. <FONT STYLE="white-space:nowrap">ZL-2301</FONT> was also found
to be highly bound to serum proteins and exhibit a moderate level of extravascular distribution. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Toxicology</I>.&nbsp;&nbsp;&nbsp;&nbsp;Comprehensive
preclinical toxicology studies were conducted to support the administration of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> in patients with cancer. These studies indicated that <FONT STYLE="white-space:nowrap">ZL-2301</FONT> alaninate and <FONT
STYLE="white-space:nowrap">ZL-2301</FONT> inhibited hERG/IKr channels resulting in a high, in the case of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> alaninate or moderate, in the case of <FONT STYLE="white-space:nowrap">ZL-2301,</FONT> risk for
QT prolongation. However, neither <FONT STYLE="white-space:nowrap">ZL-2301</FONT> alaninate nor <FONT STYLE="white-space:nowrap">ZL-2301</FONT> produced substantive effects on rabbit Purkinje </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">127 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
fiber action potential duration and no biologically relevant inhibitory effect on any of 53 different receptors, transporters, and ion channels investigated in vitro. <FONT
STYLE="white-space:nowrap">ZL-2301</FONT> produced no central nervous system-related effects on rats and monkeys, and apart from a slight decrease in heart rates on monkeys, dose-dependent increases in blood pressure, and mild decreases in heart
rate in a telemetered rat model, it produced no changes in respiratory function and heart rates or sounds in exploratory or pivotal toxicity studies conducted in dogs or monkeys. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The effects of <FONT STYLE="white-space:nowrap">ZL-2301</FONT> alaninate on male and female fertility have not been studied. However, repeat-dose toxicity studies in rats and monkeys indicated that <FONT
STYLE="white-space:nowrap">ZL-2301</FONT> could potentially impair reproductive function and fertility in females. <FONT STYLE="white-space:nowrap">ZL-2301</FONT> alaninate also produced embryo-fetal developmental toxicity in rats and rabbits at
doses that did not produce maternal toxicity. As a result, <FONT STYLE="white-space:nowrap">ZL-2301</FONT> is considered a selective developmental toxicant in these two species. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">With respect to clinical stage studies, Bristol-Myers Squibb conducted three Phase III studies of <FONT STYLE="white-space:nowrap">ZL-2301.</FONT> The Phase III study called the
<FONT STYLE="white-space:nowrap">BRISK-FL</FONT> study tested the efficacy of <FONT STYLE="white-space:nowrap">ZL-2301&nbsp;against</FONT> sorafenib in patients with advanced HCC without prior systemic treatment. The second study, <FONT
STYLE="white-space:nowrap">BRISK-PS,</FONT> tested <FONT STYLE="white-space:nowrap">ZL-2301</FONT> against best supportive care in patients that failed or were intolerant to sorafenib. In both studies, <FONT STYLE="white-space:nowrap">ZL-2301</FONT>
failed to meet its primary endpoint but nonetheless it did demonstrate some anti-tumor activity. Due to these results, a third Phase III trial in which <FONT STYLE="white-space:nowrap">ZL-2301</FONT> was used as an adjuvant to TACE was terminated by
Bristol-Myers Squibb, prior to its completion in 2012. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Fugan </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Overview </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Fugan <FONT STYLE="white-space:nowrap">(ZL-3101)</FONT> is a novel steroid-sparing topical product
for the treatment of eczema and psoriasis. We licensed the exclusive worldwide rights to fugan in 2016 from GSK. The active botanical ingredients in fugan were originally used in a hospital setting within China to treat patients with eczema and
psoriasis. Our management team, who has extensive experience developing botanical products in the clinical setting, acquired fugan from GSK because it identified fugan as a potential steroid-sparing treatment for eczema and psoriasis sufferers who
have limited natural treatment options. The potential anti-inflammatory benefit of fugan results from its active botanical formula which incorporates the herbs Glycyrrhizae Radix et Rhizoma and Sophorae Flavescentis. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We started our Phase II study in patients with mild to moderate subacute eczema in China in the second quarter of 2017. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Market opportunity </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Eczema.&nbsp;&nbsp;&nbsp;&nbsp;</I>Atopic dermatitis, also known as eczema, is a chronic disease of the skin that is believed to be caused by a combination of
hereditary and environmental factors. The main symptoms of atopic dermatitis include dry, itchy skin leading to rashes on the face, hands, feet, along with inside the elbows and behind the knees. Scratching results in redness, swelling, cracking,
&#147;weeping&#148; clear fluid, and crusting or scaling. Globally, the disease has a prevalence rate of <FONT STYLE="white-space:nowrap">15-20%</FONT> in children and <FONT STYLE="white-space:nowrap">1-3%</FONT> in adults and 90% of eczema cases
represent mild to moderate forms, according to studies by S. Nutten and Zhang JZ, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Most patients with mild to moderate eczema are currently
treated with topical agents such as corticosteroids and moisturizers. Corticosteroids were the first immunomodulators available in topical formulations and exert anti-inflammatory and immunosuppressive effects. However, treatment-related side
effects associated with corticosteroid use, such as local application-site reactions, including skin atrophy with prolonged use, and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">128 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
profound effects on neuroendocrine system, which can lead to growth retardation in adolescents and an increased risk for diabetes, underscore the need for novel therapies to treat this disease.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-steroidal</FONT> medications such as topical calcineurin inhibitors are also sometimes applied to the parts of the
skin affected by eczema for purposes of controlling symptoms for short periods of time, but there are safety risks to application of calcineurin inhibitors to large areas of skin due to systemic absorption of these immunosuppressive agents.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">In recent years, drug makers have responded to the significant unmet need in the market for eczema and have actively been
developing safe and efficacious prescription drug alternatives. In December 2016, the FDA granted approval for Eucrisa&#153; (Pfizer), a topical treatment for mild to moderate eczema, while in March 2017, the FDA granted approval for Dupixent<FONT
STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (Sanofi/Regeneron), a monoclonal antibody for adults with moderate to severe eczema. According to GMR data, sales of
Eucrisa&#153; and Dupixent<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> are estimated to be $2.0&nbsp;billion and $3.8&nbsp;billion, respectively, by 2026. These
products are expected to contribute to a broader and fast growing market opportunity. The global eczema drug market is expected to grow from $0.8&nbsp;billion in 2016, to $10.5&nbsp;billion by 2026, representing a CAGR of 29.4%. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Fugan is a novel botanical topical product, with the key target indication of mild to moderate eczema. We believe fugan could offer a natural, topical,
steroid-sparing product with strong efficacy and limited long-term safety concerns, at a more attractive price point, compared to global competitors. In addition, fugan has shown efficacy and safety in published prototype clinical studies conducted
in China. We believe that fugan will allow us to access a large and fast-growing global market opportunity. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Psoriasis</I>.&nbsp;&nbsp;&nbsp;&nbsp;Psoriasis is a common chronic disorder of the skin characterized by dry scaling patches, called &#147;plaques,&#148; for
which current treatments are few, and those that are available have potentially serious side effects. According to a study (L. Cai) in 2016, the prevalence of psoriasis in China is approximately <FONT STYLE="white-space:nowrap">0.12-0.47%.</FONT>
Globally, prevalence of psoriasis is even higher, with the disease being more prevalent in colder climates. According to WHO, the worldwide prevalence of psoriasis is around 2%. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The majority of psoriasis sufferers have mild cases and are treated with topical steroids that can have undesirable side effects. Biologics treatments treat moderate to severe psoriasis and are not advisable for
people with compromised immune systems. We believe fugan could offer a natural, steroid-sparing product with strong efficacy and limited long-term safety effects for psoriasis patients. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Our clinical trial designs and strategy </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have initiated a Phase II <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> study in patients with mild to moderate subacute eczema in China. This Phase II study is a multi-center, randomized, double-blind, parallel, placebo controlled study to evaluate the efficacy
and safety of different fugan ointment treatment schedule/dose in patients. This study will enroll an estimated 310 patients to ensure at least 250 clinically evaluable patients are available. Enrollment is expected to be completed in early 2018 and
<FONT STYLE="white-space:nowrap">top-line</FONT> results are expected to be reported in <FONT STYLE="white-space:nowrap">mid-2018.</FONT> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Patients will
be recruited and randomized in a ratio of 2:2:1 into groups that receive fugan twice daily, once daily and placebo. Randomization will be stratified by disease severity. The primary objective is to evaluate efficacy of fugan using the Eczema Area
and Severity Index. The Eczema Area and Severity Index is a tool for the measurement of severity of eczema. It ranges from zero (no eczema) to 72. The primary endpoint is Eczema Area and Severity Index score changes from baseline to day 21 of
treatment. The secondary objective is to assess the safety and tolerability of fugan ointment in subjects with mild to moderate subacute eczema. The safety endpoints include incidence, severity and relationship of adverse events, the proportion of
subjects with adverse events leading to discontinuation and local tolerability at various points during the trial. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pending results of the Phase II
study, we plan to initiate a Phase III global, multi-center clinical trial. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">129 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Fugan mechanism of action </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Pharmacologic disease management of eczema and psoriasis is typically aimed at targeting the immune system dysfunction responsible for the inflammatory reaction at the site of the flares, that is, proinflammatory
cytokines and other products of <FONT STYLE="white-space:nowrap">T-cell</FONT> activation. Topical therapies are the mainstay of treatment for most patients with these conditions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our preclinical studies demonstrated that the active components of the formulation is not absorbed systematically, we believe fugan may offer an improved safety profile over currently approved topical therapies and
could significantly improve outcomes for patients globally. Furthermore, GSK-sponsored preclinical studies have demonstrated that fugan may inhibit cell infiltration and suppress inflammatory cytokines that would otherwise go unchecked and continue
to propagate chronic inflammation. Preclinical studies also suggest that fugan can inhibit overexpression of proinflammatory cytokines such as such as tumor necrosis factor, or <FONT STYLE="white-space:nowrap">TNF-</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>, and interferon gamma, <FONT STYLE="white-space:nowrap">IFN-</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>, and <FONT STYLE="white-space:nowrap">ICAM-1,</FONT> a gene that may be associated with <FONT
STYLE="white-space:nowrap">pro-inflammatory</FONT> pathways. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Fugan preclinical development </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In preclinical development, fugan demonstrated inhibitory effects in mouse and rat acute inflammation models, with significant inhibition seen in xylene-induced ear
swelling, skin capillary permeability and carrageenan-induced paw swelling models. The preclinical studies used <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">4-dinitrofluorobenzene-,</FONT></FONT> or DNFB-, induced mice which
more closely reflect the characteristics of chronic <FONT STYLE="white-space:nowrap">T-cell-dependent</FONT> inflammation. The degree of swelling in mouse auricles and the inflammatory cell counts were decreased in DNFB-induced delayed type
hypersensitivity models of dermatitis and eczema. Significant decreases in IFN-<FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> <FONT
STYLE="white-space:nowrap">TNF-</FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT> and <FONT STYLE="white-space:nowrap">ICAM-1</FONT> levels
in auricular tissues were seen following topical application of fugan. Furthermore, histamine-induced itching reactions were reduced in guinea pigs, with significant increases in the itching thresholds following fugan application. These results
suggest that fugan inhibits the overexpression of inflammation-related cytokines (IFN-<FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>) and
intercellular cell adhesion <FONT STYLE="white-space:nowrap">molecule-1</FONT> <FONT STYLE="white-space:nowrap">(ICAM-1),</FONT> subsequently alleviating the inflammatory, anaphylactic and pruritic characteristics of eczema. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to the anti-inflammatory effects, fugan demonstrated potent bacteriostatic or bactericidal effects in vitro against Staphylococcus aureus, <FONT
STYLE="white-space:nowrap">beta-streptococcus</FONT> and candida albicans at a low concentration. Staphylococcus aureus is the most common bacteria to infect and colonize the skin in eczema, the bactericidal effects of fugan could be helpful in
treating eczema. Fugan showed no significant observable effects in preclinical safety pharmacology studies across the species evaluated. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Pharmacokinetics</I>.&nbsp;&nbsp;&nbsp;&nbsp;The systemic exposure of four representative marker compounds from the two herbs used in fugan&#146;s formula was
assessed following single and repeat dose dermal administration of fugan (doses up to 5.6 g herb/kg/day) to miniature pigs for up to 28 days. No consistent kinetic profile was observed for any of the marker compounds prohibiting any conclusion to be
made on the relationship between dose, dose duration and exposure for these four markers. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Toxicology</I>.&nbsp;&nbsp;&nbsp;&nbsp;The results obtained
from preclinical toxicology studies of fugan in in miniature pig and rabbit species indicated there were dermal changes at the application site, including erythema, rash, sores and skin scaling, which primarily occurred in the fourth week of the
dosing period. When averaged over the entire study per CFDA guidelines, the response was classified as &#147;no irritation&#148; at all doses. However, possible adverse events at the application site will be monitored in our clinical trials.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">130 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Our preclinical pipeline </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">ZL-2302</FONT> </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">ZL-2302</FONT> is a
multi-targeted TKI with activity on both ALK and crizotinib-resistant ALK mutations developed for the treatment of patients with <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer who have ALK mutations and have developed
crizotinib-resistant mutations and/or brain metastasis. We licensed the exclusive worldwide rights to <FONT STYLE="white-space:nowrap">ZL-2302</FONT> from Sanofi in 2015. Our preclinical studies demonstrated that
<FONT STYLE="white-space:nowrap">ZL-2302</FONT> has a great ability to penetrate the blood-brain barrier, which could make <FONT STYLE="white-space:nowrap">ZL-2302</FONT> an effective therapy for the significant portion of the patients who have <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer with ALK mutations and brain metastasis. Such patients typically have poor prognosis, a low quality of life and limited treatment options. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Our clinical trial designs and strategy </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our CTA for <FONT
STYLE="white-space:nowrap">ZL-2302</FONT> has been accepted as a Category 1 drug by the CFDA, and we expect to initiate a Phase I study of <FONT STYLE="white-space:nowrap">ZL-2302</FONT> in China in the first half of 2018. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Mechanism of action </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">ZL-2302</FONT> was designed with broad-spectrum activity against resistant ALK mutations and brain penetration as the
next-generation ALK inhibitor. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I><FONT STYLE="white-space:nowrap">ZL-2302</FONT> preclinical development </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Comprehensive preclinical studies have been done to analyze <FONT STYLE="white-space:nowrap">ZL-2302.</FONT> The key results are summarized as indicated below.
Based on the study data, an IND package has been prepared and filed with the CFDA. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>In vitro</I> pharmacology studies demonstrated that <FONT
STYLE="white-space:nowrap">ZL-2302</FONT> can inhibit the ALK kinase in both wild-type and active against activated mutant forms (R1275Q, F1174L and F1245V) as well as the resistance gatekeeper mutant (ALK L1196M) and
<FONT STYLE="white-space:nowrap">EML4-ALK</FONT> oncogenic fusion. Such studies have also shown that it inhibits the proliferation of the Ba/F3 expressing wild-type and mutant forms of <FONT STYLE="white-space:nowrap">EML4-ALK</FONT> and ALK
dependent cell lines <FONT STYLE="white-space:nowrap">NCI-H3122,</FONT> <FONT STYLE="white-space:nowrap">KARPAS-299</FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SU-DHL-1.</FONT></FONT> However, it was shown not to
inhibit the proliferation of PC3, an ALK independent cell line, at concentrations up to 3 <FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT></FONT><FONT STYLE="font-family:arial" SIZE="2"></FONT>M.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>In vivo</I> patient-derived xenograft models showed <FONT STYLE="white-space:nowrap">ZL-2302</FONT> had antitumor activity in mice bearing the <FONT
STYLE="white-space:nowrap">ALK-dependent</FONT> and Crizotinib-resistant tumors. It also has great brain penetration abilities in mice and can inhibit the intracranial tumor growth in the <FONT STYLE="white-space:nowrap">ALK-dependent</FONT>
xenograft model. The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">brain-to-plasma</FONT></FONT> ratio of drug exposure is 1.26, which indicated it has good brain penetration. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Preclinical studies have shown that it can be easily absorbed after oral administration with the <FONT STYLE="white-space:nowrap">15-75%</FONT> bioavailability in
different species. The drug can be widely distributed in the body, but high drug concentration was found in tumor tissues and lung. No drug accumulation was fond after repeated dose administration. Safety pharmacology, general toxicology and gene
toxicity studies in different species showed <FONT STYLE="white-space:nowrap">ZL-2302</FONT> has a good safety profile. No significant toxicity was found. All adverse effects found in the studies are reversible and can be managed and monitored.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">ZL-1101</FONT> </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">ZL-1101</FONT> is an anti-OX40 antagonistic antibody with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> potential for the treatment
of a range of autoimmune diseases such as graft-versus-host disease or systemic lupus erythematosus. We licensed the exclusive worldwide rights to <FONT STYLE="white-space:nowrap">ZL-1101</FONT> from UCB, a multinational biopharmaceutical company
based in Belgium, in 2015. Its anti-inflammatory activities have been validated by a variety of inflammatory and autoimmune pharmacology models. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">131 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Our clinical trial designs and strategy </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We intend to file an IND in 2018. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Mechanism of action </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">OX40, also known as CD134, TNFRSF4, ACT35 or TXGP1L, is a member of the TNF receptor superfamily, which is a group of ligands and receptors involved in diverse
biological processes ranging from the selective induction of cell death in potentially dangerous and superfluous cells to providing costimulatory signals that help mount an effective immune response. OX40 is predominantly expressed on activated <FONT
STYLE="white-space:nowrap">T-cells,</FONT> and its cognate ligand, OX40L, is expressed on activated antigen presenting cells. OX40 functions as a major costimulatory receptor on T cells, and ligation by OX40L delivers activation signals to increase
the proliferation and longevity of effector T cells, increase production of effector cytokines, suppress regulatory function, preserve cellular memory and facilitate migration. When immune activation is excessive or uncontrolled, pathological
allergy, asthma, inflammation, autoimmune and other related diseases may occur. In such instances, activation and differentiation of <FONT STYLE="white-space:nowrap">T-cells</FONT> play an important role. Because OX40 functions to enhance immune
responses, it may exacerbate autoimmune and inflammatory diseases, including graft-versus-host disease, systemic lupus erythematosus, asthma and viral-induced lung inflammation, and therefore drugs which block or suppress OX40 have the potential to
treat a range of such disorders. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">ZL-1101</FONT> is an isolated antagonist antibody that specifically binds to a human
OX40. It exhibits complete blockade of OX40-OX40L interaction with high potency as such it is expected to inhibit pathogenic effector T cells while simultaneously restore regulatory T cell generation and/or function, thus <FONT
STYLE="white-space:nowrap">re-balancing</FONT> the immune system. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I><FONT STYLE="white-space:nowrap">ZL-1101</FONT> preclinical development
</I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">ZL-1101&#146;s</FONT> bioactivities and functional potency have been investigated both <I>in vitro</I> and<I> in
vivo </I>studies. In such studies, cellular proliferation and production of inflammatory cytokines was markedly suppressed, demonstrating that <FONT STYLE="white-space:nowrap">ZL-1101</FONT> effectively inhibits lymphocyte activation. <FONT
STYLE="white-space:nowrap">ZL-1101</FONT> was also found to be highly potent. The efficacy of a single dose of <FONT STYLE="white-space:nowrap">ZL-1101</FONT> has been shown to be potent enough to effectively inhibit human T cell proliferation <I>in
vivo</I>, supporting <FONT STYLE="white-space:nowrap">ZL-1101</FONT> as a viable therapeutic candidate. <I>In vitro</I> activity and cell-based assays demonstrated that <FONT STYLE="white-space:nowrap">ZL-1101</FONT> has a good affinity and
ligand-blocking capacity. In a functional assay, it has been demonstrated that <FONT STYLE="white-space:nowrap">ZL-1101</FONT> is capable of blocking OX40L binding to cynomolgus cell-surface expressed OX40. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, pharmacokinetic and pharmacodynamic studies confirmed it has a profile that is sufficient for development into a drug candidate. Preliminary modeling
to predict the human half-life and the pharmacologically active dose have shown that the expected half-life in humans is 14 days and 17 days when the 0.3 mg/kg data were excluded from the analysis. The target turnover model indicates that
approximately1 mg/kg dose would result in almost complete target engagement. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Internal discovery programs </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our <FONT STYLE="white-space:nowrap">in-house</FONT> research and development team focuses on the development of immuno-oncology large molecules for the treatment
of oncology. Our team members have been directly involved in the discovery, development and commercialization of several successful global drug launches, including fruguintinib and savolitinib while they were at Hutchison Medi-Pharma. We have
collaborations with leading academic institutions in China, Tsinghua University and Shanghai Institute of Materia Medica, to support our <FONT STYLE="white-space:nowrap">in-house</FONT> research projects. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">132 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Overview of our license agreements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Tesaro </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In September 2016, we entered into a collaboration, development and license agreement with
TESARO Inc., or Tesaro, under which we obtained an exclusive sub-license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> that Tesaro licensed from Merck, Sharp&nbsp;&amp; Dohme Corp. (a subsidiary of Merck&nbsp;&amp; Co.
Inc.), or Merck Corp., and AstraZeneca UK Limited to develop, manufacture, use, sell, import and commercialize Tesaro&#146;s proprietary PARP inhibitor, niraparib, in mainland China, Hong Kong and Macau, or licensed territory, in the licensed field
of treatment, diagnosis and prevention of any human diseases or conditions (other than prostate cancer). We also obtained the right of first negotiation to obtain a license from Tesaro to develop and commercialize certain <FONT
STYLE="white-space:nowrap">follow-on</FONT> compounds of niraparib being developed by Tesaro in our licensed field and licensed territory. Under the agreement, we agreed not to research, develop or commercialize certain competing products and we
also granted Tesaro the right of first refusal to license certain immuno-oncology assets developed by us. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are obligated to use commercially
reasonable efforts to develop and commercialize the licensed products in our licensed field and licensed territory. We are also responsible for funding all development and commercialization of the licensed products in our licensed territory. Tesaro
has the option to elect to <FONT STYLE="white-space:nowrap">co-promote</FONT> the licensed products in our licensed territory. This <FONT STYLE="white-space:nowrap">co-marketing</FONT> right must be exercised by Tesaro twelve months prior to the
first commercial sale of niraparib in the licensed territories. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We also agree to take any action or omission reasonably requested by Tesaro that is
necessary or advisable to maintain compliance with the terms of Tesaro&#146;s license agreements with Merck Corp. and AstraZeneca UK Limited. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the
terms of the agreement, we made an upfront payment of $15.0&nbsp;million to Tesaro. If we achieve a specified regulatory, development and commercialization milestones, we may be required to pay aggregate milestone payments up to $39.5 million to
Tesaro. In addition, if we successfully develop and commercialize the licensed products and Tesaro does not exercise its <FONT STYLE="white-space:nowrap">co-promotion</FONT> option, we will pay Tesaro tiered royalties at percentage rates in the <FONT
STYLE="white-space:nowrap">mid-</FONT> to high-teens on the net sales of the licensed products, until the later of the expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> licensed patent
covering the licensed product, the expiration of regulatory exclusivity for the licensed product, or the tenth anniversary of the first commercial sale of the licensed product, in each case on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">region-by-region</FONT></FONT> basis. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The agreement with Tesaro will remain in effect until the expiration of the royalty term and may be earlier terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency or
by mutual agreement of the parties. In addition, we have the right to terminate the agreement for convenience at any time upon advance notice to Tesaro. Upon early termination of the agreement, we must grant to Tesaro an exclusive license under
certain of our intellectual property to develop and commercialize the licensed products outside the licensed territory. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Paratek
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In April 2017, we entered into a license and collaboration agreement with Paratek Bermuda, Ltd., a subsidiary of Paratek Pharmaceuticals, Inc.,
under which we obtained both an exclusive license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> of Paratek Bermuda Ltd. and an exclusive sub-license under certain intellectual property that Paratek Bermuda Ltd. licensed
from Tufts University to develop, manufacture, use, sell, import and commercialize omadacycline in mainland China, Hong Kong, Macau and Taiwan, or licensed territory, in the field of all human therapeutic and preventative uses other than biodefense,
or the licensed field. Under certain circumstances, our exclusive sub-license to certain intellectual property Paratek Bermuda Ltd. licensed from Tufts University may be converted to a non-exclusive license if Paratek Bermuda Ltd.&#146;s exclusive
license from </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">133 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Tufts University is converted to a non-exclusive license under the Tufts Agreement. We also obtained the right of first negotiation to be Paratek Bermuda Ltd.&#146;s partner to develop certain
derivatives or modifications of omadacycline in our licensed territory. Paratek Bermuda Ltd. retains the right to manufacture the licensed product in our licensed territory for use outside our licensed territory. We also granted to Paratek Bermuda
Ltd. a non-exclusive license to certain of our intellectual property for Paratek Bermuda Ltd. to develop and commercialize licensed products outside of our licensed territory. Under the agreement, we agreed not to commercialize certain competing
products in our licensed territory. We are obligated to use commercially reasonable efforts to develop and commercialize the licensed products in our licensed field and licensed territory, including making certain regulatory filings within a
specified period of time. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the terms of the agreement, we made an upfront payment to Paratek Bermuda Ltd. of $7.5&nbsp;million and we may be
required to pay milestone payments up to $54.5 million to Paratek Bermuda Ltd. for the achievement of certain development and sales milestone events. In addition, we will pay to Paratek Bermuda Ltd. tiered royalties at percentage rates in the range
of <FONT STYLE="white-space:nowrap">low-</FONT> to <FONT STYLE="white-space:nowrap">mid-teens</FONT> on the net sales of licensed products, until the later of the abandonment, expiration or invalidation of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">last-to-expire</FONT></FONT> licensed patent covering the licensed product, or the eleventh anniversary of the first commercial sale of the licensed product, in each case on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">region-by-region</FONT></FONT> basis. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The agreement with Paratek Bermuda Ltd. will remain in effect until the expiration of the royalty term and may be earlier terminated by either party for the other party&#146;s uncured material breach, bankruptcy or
insolvency. In addition, we have the right to terminate the agreement for convenience at any time upon advance notice to Paratek Bermuda Ltd. Paratek Bermuda Ltd. has the right to terminate the agreement if we challenge its patents. Upon termination
of the agreement, our license of certain intellectual property to Paratek Bermuda Ltd. will continue for Paratek Bermuda Ltd. to develop and commercialize licensed products worldwide. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Bristol-Myers Squibb </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In March 2015, we entered into a collaboration and license agreement with
Bristol-Myers Squibb Company, or BMS, under which we obtained an exclusive license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> of BMS to develop, manufacture, use, sell, import and commercialize BMS&#146;s proprietary
multi-targeted kinase inhibitor, brivanib in mainland China, Hong Kong and Macau, or licensed territory, in the field of diagnosis, prevention, treatment or control of oncology indications, or licensed field, with the exclusive right to expand our
licensed territory to include Taiwan and Korea under certain conditions. BMS retains the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right to use the licensed compounds to conduct internal research and the exclusive right to use the
licensed compounds to manufacture compounds that are not brivanib. Under the agreement, we agreed not to develop and commercialize certain competing products for specified time periods. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are obligated to use commercially reasonable efforts to develop and commercialize the licensed products in our licensed field and licensed territory. BMS has the option to elect to
<FONT STYLE="white-space:nowrap">co-promote</FONT> the licensed products in our licensed territory. If BMS exercises its <FONT STYLE="white-space:nowrap">co-promotion</FONT> option, BMS will pay us an option exercise fee and we will share equally
with BMS the operating profits and losses of the licensed products in our licensed territory. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If BMS does not exercise its <FONT
STYLE="white-space:nowrap">co-promotion</FONT> option, we may be required to pay BMS milestone payments up to $114.5 million for the achievement of certain development and sales milestone events, and also tiered royalties at percentage rates in the <FONT
STYLE="white-space:nowrap">mid-</FONT> to high-teens on the net sales of the licensed products in our licensed territory, until the later of the expiration of the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> licensed patent covering the licensed product, the expiration of regulatory exclusivity for the licensed product, or the twelfth anniversary of the first
commercial sale of the licensed product, in each case on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">region-by-region</FONT></FONT> basis. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We also have the right to <FONT
STYLE="white-space:nowrap">opt-out</FONT> of the commercialization of the licensed products in our licensed territory under certain conditions. If we elect to <FONT STYLE="white-space:nowrap">opt-out,</FONT> BMS will have the right to commercialize
the licensed products </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">134 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
in our licensed territory and will pay us royalties on the net sales of the licensed products in our licensed territory. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">BMS has the option to use the data generated by us from our development of the licensed products to seek regulatory approval of the licensed products outside our licensed territory, and if BMS exercises such
option, BMS will be obligated to make certain payments to us, including upfront, milestone and royalty payments. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The agreement with BMS will remain in
effect until the expiration of all payment obligations, and may be earlier terminated by either party for the other party&#146;s uncured material breach, safety reasons or failure of the development of the licensed products. In addition, we have the
right to terminate the agreement for convenience after a certain specified time period upon advance notice to BMS. BMS may also terminate the agreement for our bankruptcy or insolvency. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>GSK </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In October 2016, we entered into a license and transfer agreement with GlaxoSmithKline (China)
R&amp;D Co., Ltd, or GSK China, an affiliate of GSK, under which GSK China transferred to us its worldwide, exclusive license under certain patents, <FONT STYLE="white-space:nowrap">know-how,</FONT> inventory and regulatory materials to develop,
manufacture, use and commercialize FUGAN and GRAPE, two formulations comprising extracts from traditional Chinese herbs, for the treatment, diagnosis and prevention of any human diseases. In connection with such transfer, GSK China also assigned to
us its agreements with Chengdu Bater Pharmaceutical Co., Ltd, or Bater, and Traditional Chinese Medical Hospital, Xinjiang Medical University, or Xinjiang, relating to FUGAN and GRAPE. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are obligated to use commercially reasonable efforts to develop at least one licensed product, until the later of the expiration of the last-to-expire licensed patent covering the licensed product, the
expiration of regulatory exclusivity for the licensed product, or an anniversary date in the mid-teens of the first commercial sale of the licensed product, in each case on a product-by-product and country-by-country basis. Under the terms of the
agreement, we made an upfront payment to GSK China of RMB 4.5 million. We may be required to make milestone payments to GSK China up to RMB 55.0 million for the achievement of certain development milestone events. In addition, we will pay to GSK
China tiered royalties at percentage rates in the <FONT STYLE="white-space:nowrap">low-</FONT> to <FONT STYLE="white-space:nowrap">mid-single</FONT> digits on the net sales of FUGAN and GRAPE, until the later of the expiration of the last-to-expire
licensed patent covering the licensed product, the expiration of regulatory exclusivity for the licensed product, or an anniversary date in the mid-teens of the first commercial sale of the licensed product, in each case on a product-by-product and
country-by-country basis. GSK China made a milestone payment to Bater of RMB 4.0&nbsp;million and we have made a milestone payment to Bater of RMB 2.0&nbsp;million. We also assumed the obligation to make additional milestone payments up to RMB
4.0&nbsp;million and RMB 10.0 million under the assigned agreements with Bater and Xinjiang, respectively, for milestones achieved after the assignment of the agreements to us. If we sublicense, sell or otherwise divest the patents and <FONT
STYLE="white-space:nowrap">know-how</FONT> acquired from GSK China to third parties before the completion of certain development phase, we are also required to pay to GSK China half of our income attributed to such sublicense, sale, or divesture.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The agreement with GSK China will remain in effect until the expiration of the royalty term and may be earlier terminated by either party for the other
party&#146;s uncured material breach. In addition, we have the right to terminate the agreement for convenience upon advance notice to GSK China at any time after completion of a certain stage of development work. GSK China has the right to
terminate the agreement if we fail to reach certain development milestones, fail to make payments owed to GSK China, or fail to use commercially reasonable efforts in the development and commercialization of the licensed products and cannot correct
such failure in the agreed period. Upon termination of the agreement with GSK China for our uncured breaches, we must, among other actions, assign back to GSK China and/or Bater and Xinjiang the transferred know-how and the license agreements
between GSK China and Bater and Xinjiang. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">135 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Sanofi </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In July 2015, we entered into a license agreement with Sanofi, under which we obtained an exclusive and worldwide license under certain patents and <FONT
STYLE="white-space:nowrap">know-how</FONT> of Sanofi to develop, manufacture, use, sell, import and commercialize Sanofi&#146;s ALK inhibitor, or the licensed compound, or <FONT STYLE="white-space:nowrap">ZL-2302</FONT> for any oncology indications
in humans. Sanofi retains the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right to use the licensed compound to conduct internal research and manufacture the licensed compound and licensed product for such research. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are obligated to use commercially reasonable efforts to develop and commercialize the licensed product in each of the major market countries. Sanofi has the
option to exclusively negotiate with us to obtain the exclusive rights to commercialize the licensed product in the oncology field in such major market countries or throughout the world under certain circumstances. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the terms of the agreement, we made upfront payments to Sanofi totaling $0.5&nbsp;million. We may be required to make milestone payments to Sanofi up to $31.0
million for the achievement of certain development and regulatory milestone events. In addition, we will pay Sanofi tiered royalties at percentage rates in the range of high single digits to low double digits on the net sales of the licensed
products, until the later of the expiration of the <FONT STYLE="white-space:nowrap">last-to-expire</FONT> licensed patent covering the licensed product, the expiration of regulatory exclusivity for the licensed product, or the tenth anniversary of
the first commercial sale of the licensed product, in each case on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. If we sublicense, transfer or assign (other than through a change of control transaction) the right to the licensed product to third parties,
we are also required to pay to Sanofi a share of our sublicensing income. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The agreement with Sanofi will remain in effect until the expiration of the
royalty term and may be earlier terminated by either party for the other party&#146;s uncured material breach. In addition, we have the right to terminate the agreement for convenience at any time upon advance notice to Sanofi. Sanofi has the right
to terminate the agreement if we challenge any of the licensed patents. Sanofi may also terminate the agreement for our bankruptcy or insolvency. Upon any termination of the agreement, in addition to other obligations, we must grant to Sanofi an
exclusive license under certain of our intellectual property to commercialize the licensed product. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>UCB </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In September 2015, we entered into a license agreement with UCB Biopharma Sprl, under which we obtained an exclusive and worldwide license under certain patents and
<FONT STYLE="white-space:nowrap">know-how</FONT> of UCB Biopharma Sprl to develop, manufacture, use, sell, import and commercialize UCB Biopharma Sprl&#146;s proprietary antibody UCB3000, or the licensed compound, or
<FONT STYLE="white-space:nowrap">ZL-1101</FONT> for the treatment, prevention and diagnosis of any human diseases. UCB Biopharma Sprl retains the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> right to use the licensed compound for its own
research purposes. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are obligated to use commercially reasonable efforts to develop and commercialize at least one licensed product in the U.S. and EU
and to file an IND within a certain specified time period. UCB Biopharma Sprl has the right of first negotiation to acquire the rights to the licensed products back from us upon our successful completion of certain clinical development work.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the terms of the agreement, we made upfront payments to UCB Biopharma Sprl totaling $0.8&nbsp;million. If we successfully develop and
commercialize the licensed products, we may be required to make milestone payments to UCB Biopharma Sprl up to an aggregate of $106.7 million for the achievement of certain development, regulatory and sales milestone events. In addition, we will pay
to UCB Biopharma Sprl royalties at percentage rates in the range of <FONT STYLE="white-space:nowrap">mid-single</FONT> digits to <FONT STYLE="white-space:nowrap">low-double</FONT> digits on the net sales of the licensed products, until the later of
the expiration of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> licensed patent covering the licensed product, the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">136 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
expiration of regulatory exclusivity for the licensed product, or the tenth anniversary of the first commercial sale of the licensed product, in each case on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis. If we sublicense the right to the licensed product to third parties, we are
also required to pay to UCB Biopharma Sprl a low-double digit percentage share of our sublicensing income. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The agreement with UCB Biopharma Sprl will
remain in effect until the expiration of the royalty term and may be earlier terminated by either party for the other party&#146;s uncured material breach, bankruptcy or insolvency. In addition, we have the right to terminate the agreement for
convenience at any time upon advance notice to UCB Biopharma Sprl. Each party also has the right to terminate the agreement if the other party challenges its patents. Upon our termination of the agreement for convenience or UCB Biopharma Sprl&#146;s
termination for our material breach, bankruptcy or patent challenges, among other obligations, we must grant UCB Biopharma Sprl an exclusive license under certain of our intellectual property to develop and commercialize ZL-1101. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Competition </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our industry is highly competitive and subject
to rapid and significant change. While we believe that our management&#146;s research, development and commercialization experience provide us with competitive advantages, we face competition from global and China-based biopharmaceutical companies,
including specialty pharmaceutical companies, generic drug companies, biologics drug companies, academic institutions, government agencies and research institutions. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">For our global product candidates, we expect to face competition from a broad range of global and local pharmaceutical companies. Many of our competitors have significantly greater financial, technical and human
resources than we have, and mergers and acquisitions in the biopharmaceutical industry may result in even more resources being concentrated among a smaller number of our competitors. Our commercial opportunity could be reduced or eliminated if our
competitors develop or market products or other novel therapies that are more effective, safer or less costly than our current or future drug candidates, or obtain regulatory approval for their products more rapidly than we may obtain approval for
our drug candidates. For additional information, please refer to the &#147;Market Opportunity&#148; description under each our drug candidates. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Patents and other intellectual property </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our commercial
success depends in part on our ability to obtain and maintain proprietary or intellectual property protection for our drug candidates and our core technologies and other <FONT STYLE="white-space:nowrap">know-how</FONT> to operate without infringing,
misappropriating or otherwise violating on the proprietary rights of others and to prevent others from infringing, misappropriating or otherwise violating our proprietary or intellectual property rights. We expect that we will seek to protect our
proprietary and intellectual property position by, among other methods, licensing or filing our own U.S., international and foreign patent applications related to our proprietary technology, inventions and improvements that are important to the
development and implementation of our business. We also rely on trade secrets, <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our proprietary and intellectual property position, which
we generally seek to protect through contractual obligations with third parties. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Patents </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Patents, patent applications and other intellectual property rights are important in the sector in which we operate. We consider on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis filing patent applications with a view to protecting certain innovative products, processes, and methods of treatment. We may also license or acquire
rights to patents, patent applications or other intellectual property rights owned by third parties, academic partners or commercial companies which are of interest to us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">137 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify our proprietary and
intellectual property position for our drug candidates and technologies will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, our pending patent applications, and any patent applications that
we may in the future file or license from third parties may not result in the issuance of patents. We also cannot predict the breadth of claims that may be allowed or enforced in our patents. Any issued patents that we may receive or license in the
future may be challenged, invalidated or circumvented. For example, we cannot be certain of the priority of our patents and patent applications over third-party patents and patent applications. In addition, because of the extensive time required for
clinical development and regulatory review of a drug candidate we may develop, it is possible that, before any of our drug candidates can be commercialized, any related patent may expire or remain in force for only a short period following
commercialization, thereby limiting protection such patent would afford the respective product and any competitive advantage such patent may provide. For more information regarding the risks related to our intellectual property, please see
&#147;Risk factors&#151;Risks related to intellectual property.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Niraparib </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As of June&nbsp;30, 2017, we exclusively licensed two issued patents in the PRC directed to niraparib&#146;s free base compound, and salts thereof, and analogues of niraparib. These issued patents are projected to
expire between 2027 and 2028. We also exclusively licensed one pending patent application in the PRC directed to a salt that covers <FONT STYLE="white-space:nowrap">4-methylbenzenesulfonate</FONT> monohydrate, the active pharmaceutical ingredient,
or API, of niraparib. If this patent application issues as a patent, such patent will be projected to expire in 2029. There are no patent term adjustments or patent term extensions available for issued patents in the PRC. We do not own or have an
exclusive license to any patents or patent applications in any jurisdictions outside of the PRC. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Omadacycline </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of June&nbsp;30, 2017, we exclusively licensed three issued patents in the PRC directed to omadacycline&#146;s compound, formulations and crystal form and two
pending patent applications in the PRC directed to other crystalline forms of omadacycline. The issued composition of matter patent covering omadacycline is projected to expire in 2021 and the other two issued patents are projected to expire in
2029. If the two patent applications are issued, they are expected to expire in 2029. There are no patent term adjustments or patent term extensions available for issued patents in the PRC. We have also exclusively licensed an issued patent in Hong
Kong that covers a crystalline salt form of omadacycline, which expires in 2029. We do not own or have an exclusive license to any patents or patent applications in any jurisdictions outside of the PRC, Hong Kong and Taiwan. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I><FONT STYLE="white-space:nowrap">ZL-2301</FONT> </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of
June&nbsp;30, 2017, we exclusively licensed four issued patents in the PRC and one issued patent in Hong Kong that relate to ZL-2301. Of these issued patents, one patent in the PRC is a composition-of-matter patent that covers the ZL-2301 compound
and its analogues. One patent in the PRC covers the medical use of <FONT STYLE="white-space:nowrap">ZL-2301.</FONT> These patents are projected to expire in 2023. Our exclusively licensed patents also include a patent in the PRC that covers a
manufacturing process for intermediates useful in the synthesis of <FONT STYLE="white-space:nowrap">ZL-2301&#146;s</FONT> API. This patent is projected to expire in 2027. In addition, one patent we exclusively licensed in the PRC covers a crystal
form of brivanib alaninate and is projected to expire in 2026. There are no patent term adjustments or patent term extensions available for these issued patents in the PRC. The issued patent in Hong Kong that we exclusively licensed is projected to
expire in 2023. We do not own or have an exclusive license to any patents or patent applications in any jurisdictions other than the PRC and Hong Kong. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">138 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Fugan </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of
June&nbsp;30, 2017, we own one issued patent in the PRC directed to the pharmaceutical composition and therapeutic uses of fugan. Our issued patent in the PRC is projected to expire in 2029. There are no patent term adjustments or patent term
extensions available for this issued patent in the PRC. We do not own or have an exclusive license to any patents or patent applications in any jurisdictions outside of the PRC. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I><FONT STYLE="white-space:nowrap">ZL-2302</FONT> </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of June&nbsp;30, 2017, we exclusively licensed one pending
patent application in the PRC. We also exclusively licensed one issued U.S. patent, two pending U.S. patent applications, and 14 issued patents and 29 pending patent applications in other jurisdictions, including Australia, Canada, Europe, Japan,
South Korea and Taiwan. The issued patents in this portfolio are directed to the pharmaceutical composition and therapeutic uses of <FONT STYLE="white-space:nowrap">ZL-2302,</FONT> and are projected to expire between 2032 and 2033, excluding any
additional term for patent term adjustments or patent term extensions in jurisdictions where such adjustments and extensions are available. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I><FONT
STYLE="white-space:nowrap">ZL-1101</FONT> </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of June&nbsp;30, 2017, we exclusively licensed one issued patent and one pending patent application in
the PRC. We also exclusively licensed three issued U.S. patents, two pending U.S. patent applications and approximately 21 issued patents and 49 pending patent applications in other jurisdictions, including Australia, Canada, Europe, Hong Kong,
Japan, South Korea, South Africa and Taiwan. The issued patents and pending patent applications in this portfolio cover antibody sequences and therapeutic uses of <FONT STYLE="white-space:nowrap">ZL-1101.</FONT> The issued patents in this portfolio
are projected to expire between 2030 and 2032, excluding any additional term for patent term adjustments or patent term extensions in jurisdictions where such adjustments and extensions are available. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Patent Term </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The term of a patent depends upon the laws of
the country in which it is issued. In most jurisdictions, a patent term is 20 years from the earliest filing date of a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. Under the PRC Patent Law, the term of patent
protection starts from the date of application. Patents relating to inventions are effective for twenty years, and utility models and designs are effective for ten years from the date of application. There are no patent term adjustments or patent
term extensions available in the PRC for issued patents. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Trade Secrets </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition to patents, we rely upon unpatented trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our competitive position. However,
trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to protect. We seek to protect our proprietary information, in part, by executing confidentiality agreements with our partners, collaborators, scientific advisors,
employees, consultants and other third parties, and invention assignment agreements with our consultants and employees. We have also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The
confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are developed through our
relationship with the respective counterparty. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes or that these agreements will
afford us adequate protection of our intellectual property and proprietary information rights. If any of the partners, collaborators, scientific advisors, employees and consultants who are parties to these agreements breaches or violates the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">139 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
terms of any of these agreements or otherwise discloses our proprietary information, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a
result. For more information regarding the risks related to our trade secrets, please see &#147;Risk factors&#151;Risks related to intellectual property&#151;If we are unable to maintain the confidentiality of our trade secrets, our business and
competitive position may be harmed. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Trademarks and domain names </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We conduct our business using trademarks with various forms of the &#147;ZAI LAB&#148; and &#147;


<IMG SRC="g358845g64l44.jpg" ALT="LOGO">
&#148; brands, as well as domain names incorporating some or all of these trademarks. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Employees </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of December&nbsp;31, 2016, we employed a total of 50 full-time employees and two part-time employees, including a total of 20 employees with M.D. or Ph.D.
degrees. Of our workforce, 40 employees are engaged in research and development. Due to the initiation of discovery efforts and increase in number of development-stage products, we increased our headcount between fiscal years 2015 and 2016, mainly
in respect of our research and development personnel. None of our employees is represented by labor unions or covered by collective bargaining agreements. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Facilities </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are headquartered in Shanghai where we have our main administrative and laboratory offices,
which is 3,632 square meters in size. The lease for this facility expires in 2020. We also have a 98 square meter office in Beijing, the lease for which expires in 2018. In early 2017, we built a small molecule drug product facility in Suzhou, China
capable of supporting clinical and commercial production and have begun construction of a large molecule facility in Suzhou, China using GE Healthcare FlexFactory platform technology capable of supporting clinical production of our drug candidates.
The construction of the large molecule facility is expected to be completed in the first half of 2018. We believe our current facilities are sufficient to meet our near-term needs. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Quality Control and assurance </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have our own independent quality control system and devote significant
attention to quality control for the designing, manufacturing and testing of our drug candidates. We have established a strict quality control system in accordance with CFDA regulations. Our laboratories are staffed with highly educated and skilled
technicians to ensure quality of all batches of products released. We monitor our operations in real time throughout the entire production process, from inspection of raw and auxiliary materials, to manufacture and delivery of finished products to
clinical testing at hospitals. Our quality assurance team is also responsible for ensuring that we are in compliance with all applicable regulations, standards and internal policies. Our senior management team is actively involved in setting quality
policies and managing the internal and external quality performance of the Company. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Legal proceedings </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are, from time to time, subject to claims and suits arising in the ordinary course of business. Although the outcome of these and other claims cannot be
predicted with certainty, management does not believe that the ultimate resolution of these matters will have a material adverse effect on our financial position or on our results of operations. We are not currently a party to, nor is our property
the subject of, any material legal proceedings. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">140 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_12"></A>Regulation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Government regulation of pharmaceutical product development and approval </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>PRC regulation of
pharmaceutical product development and approval </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Since China&#146;s entry into the World Trade Organization in 2001, the PRC government has made
significant efforts to standardize regulations, develop its pharmaceutical regulatory system and strengthen intellectual property protection. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Regulatory authorities </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the PRC, the CFDA is the
authority under the State Council that monitors and supervises the administration of pharmaceutical products and medical appliances and equipment as well as food (including food additives and health food) and cosmetics. The CFDA&#146;s predecessor,
the State Drug Administration, or the SDA, was established on August&nbsp;19, 1998 as an organization to assume the responsibilities previously handled by the Ministry of Health of the PRC, or the MOH, the State Pharmaceutical Administration Bureau
of the PRC and the State Administration of Traditional Chinese Medicine of the PRC. The SDA was replaced by the State Food and Drug Administration in March 2003 and was later reorganized into the CFDA following the institutional reform of the State
Council in March 2013. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The primary responsibilities of the CFDA include: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">monitoring and supervising the administration of pharmaceutical products, medical appliances and equipment as well as food, health food and cosmetics in the PRC;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">formulating administrative rules and policies concerning the supervision and administration of food, health food, cosmetics and the pharmaceutical industry;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">evaluating, registering and approving of new drugs, generic drugs, imported drugs and traditional Chinese medicine, or TCM; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">approving and issuing permits for the manufacture and export/import of pharmaceutical products and medical appliances and equipment and approving the
establishment of enterprises to be engaged in the manufacture and distribution of pharmaceutical products; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">examining and evaluating the safety of food, health food, pharmaceutical products and cosmetics and handling significant accidents involving these products.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The National Health and Family Planning Commission, or NHFPC, is an authority at the ministerial level under the State Council and is
primarily responsible for national public health. The predecessor of NHFPC is the Ministry of Health, or MOH. Following the establishment of the CFDA in 2003, the MOH was put in charge of the overall administration of the national health in the PRC
excluding the pharmaceutical industry. The MOH performs a variety of tasks in relation to the health industry such as establishing social medical institutes and producing professional codes of ethics for public medical personnel. The MOH is also
responsible for overseas affairs, such as dealings with overseas companies and governments. The MOH was reorganized into the NHFPC following the institutional reform of the State Council in March 2013. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Healthcare system reform </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The PRC government recently
promulgated several healthcare reform policies and regulations to reform the healthcare system. On March&nbsp;17, 2009, the Central Committee of the PRC Communist Party and the State </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">141 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">
Council jointly issued the Guidelines on Strengthening the Reform of Healthcare System. The State Council issued the Notice on the Issuance of the
13</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"> Five-year Plan on Strengthening the Reform of Healthcare System on
December&nbsp;27, 2016. On April&nbsp;21, 2016, the General Office of the State Council issued the Main Tasks of Healthcare System Reform in 2016. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Highlights of these healthcare reform policies and regulations include the following: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">One of the main objectives of the reform was to establish a basic healthcare system to cover both urban and rural residents and provide the Chinese people with
safe, effective, convenient and affordable healthcare services. As of 2017, basic medical insurance coverage has reached more than 95% of the country&#146;s population. By 2020, a basic healthcare system covering both urban and rural residents
should be established. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Another main objective of reform was to improve the healthcare system, through the reform and development of a graded diagnosis and treatment system, modern
hospital management, basic medical insurance, drug supply support and comprehensive supervision. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The reforms aimed to promote orderly market competition and improve the efficiency and quality of the healthcare system to meet the various medical needs of the
Chinese population. From 2009, basic public healthcare services such as preventive healthcare, maternal and child healthcare and health education were to be provided to urban and rural residents. In the meantime, the reforms also encouraged
innovations by pharmaceutical companies to eliminate pharmaceutical products that fail to prove definite efficacy and positive risk-benefit ratio. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The key tasks of the reform in 2016 were as follows: (1)&nbsp;to deepen the reform of public hospitals, (2)&nbsp;to accelerate the development of a graded
diagnosis and treatment system, (3)&nbsp;to consolidate and improve the universal medical insurance system, (4)&nbsp;to guarantee drug supply, (5)&nbsp;to establish and improve a comprehensive supervision system, (6)&nbsp;to cultivate talented
health-care practitioners, (7)&nbsp;to stabilize and perfect the basic public health service equalization system, (8)&nbsp;to advance the construction of health information technology, (9)&nbsp;to accelerate the development of the health services
industry generally, and (10)&nbsp;to strengthen organization and implementation. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Drug administration laws and regulations
</I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The PRC Drug Administration Law as promulgated by the Standing Committee of the National People&#146;s Congress in 1984 and the Implementing
Measures of the PRC Drug Administration Law as promulgated by the MOH in 1989 have laid down the legal framework for the establishment of pharmaceutical manufacturing enterprises and pharmaceutical trading enterprises and for the administration of
pharmaceutical products including the development and manufacturing of new drugs and medicinal preparations by medical institutions. The PRC Drug Administration Law also regulates the packaging, trademarks and advertisements of pharmaceutical
products in the PRC. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain amendments to the PRC Drug Administration Law took effect on December&nbsp;1, 2001. Subsequent amendments were also made on
December&nbsp;28, 2013 and April&nbsp;24, 2015. They were formulated to strengthen the supervision and administration of pharmaceutical products, and to ensure the quality of pharmaceutical products and the safety of pharmaceutical products for
human use. The current PRC Drug Administration Law applies to entities and individuals engaged in the development, production, trade, application, supervision and administration of pharmaceutical products. It regulates and prescribes a framework for
the administration of pharmaceutical manufacturers, pharmaceutical trading companies, and medicinal preparations of medical institutions and the development, research, manufacturing, distribution, packaging, pricing and advertisements of
pharmaceutical products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">142 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">According to the current PRC Drug Administration Law, no pharmaceutical products may be produced in China without a
pharmaceutical production license. A local manufacturer of pharmaceutical products must obtain a pharmaceutical production license from one of CFDA&#146;s provincial level branches in order to commence production of pharmaceuticals. Prior to
granting such license, the relevant government authority will inspect the manufacturer&#146;s production facilities, and decide whether the sanitary conditions, quality assurance system, management structure and equipment within the facilities have
met the required standards. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The PRC Implementing Regulations of the Drug Administration Law promulgated by the State Council took effect on
September&nbsp;15, 2002, were amended on February&nbsp;6, 2016 and serve to provide detailed implementation regulations for the revised PRC Drug Administration Law. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Good laboratories practice certification for nonclinical research </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To improve the quality of animal research,
the CFDA promulgated the Good Laboratories Practice of Preclinical Laboratory in 2003 and began to conduct the certification program of the GLP. In April 2007, the CFDA promulgated the Administrative Measures for Certification of Good Laboratory
Practice of Preclinical Laboratory, providing that the CFDA is responsible for certification of nonclinical research institutions. According to the Administrative Measures for Certification of Good Laboratory Practice of Preclinical Laboratory, the
CFDA decides whether an institution is qualified for undertaking pharmaceutical nonclinical research upon the evaluation of the institution&#146;s organizational administration, personnel, laboratory equipment and facilities and its operation and
management of nonclinical pharmaceutical projects. If all requirements are met, a GLP Certification will be issued by the CFDA and published on the CFDA&#146;s website. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Animal testing permits </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">According to Regulations for the Administration of Affairs Concerning Experimental
Animals promulgated by the State Science and Technology Commission in November 1988, as amended in January 2011, July 2013 and March 2017, and Administrative Measures on the Certificate for Animal Experimentation promulgated by the State Science and
Technology Commission and other regulatory authorities in December 2001, performing experimentation on animals requires a Certificate for Use of Laboratory Animals. Applicants must satisfy the following conditions: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Laboratory animals must be qualified and sourced from institutions that have Certificates for Production of Laboratory Animals; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The environment and facilities for the animals&#146; living and propagating must meet state requirements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The animals&#146; feed and water must meet state requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The animals&#146; feeding and experimentation must be conducted by professionals, specialized and skilled workers, or other trained personnel;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The management systems must be effective and efficient; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The applicable entity must follow other requirements as stipulated by Chinese laws and regulations. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Administrative measures for drug registration </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In July 2007,
the CFDA released the Administrative Measures for Drug Registration which took effect on October&nbsp;1, 2007. The Administrative Measures for Drug Registration cover (1)&nbsp;definitions of drug registration applications and regulatory
responsibilities of the CFDA; (2)&nbsp;general requirements for drug registration; (3)&nbsp;drug </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">143 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
clinical trials; (4)&nbsp;application, examination and approval of drugs; (5)&nbsp;supplemental applications and <FONT STYLE="white-space:nowrap">re-registrations</FONT> of drugs;
(6)&nbsp;inspections; (7) registration standards and specifications; (8)&nbsp;time limit; <FONT STYLE="white-space:nowrap">(9)&nbsp;re-examination;</FONT> and (10)&nbsp;liabilities and other supplementary provisions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In July 2016, the CFDA released the revised Administrative Measures for Drug Registration (Draft for Comments) to seek comments from the public, which as compared
to the current Administrative Measures for Drug Registration, includes the following key highlights: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">encourage clinically oriented drug innovation, under which innovative drugs should have definite clinical value and modified drugs should present obvious
clinical advantages over the drugs being modified; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">broaden the definition of applicants for marketing authorization from &#147;domestic institutions&#148; to &#147;domestic entities&#148; to cover both the drug
research and development institutions and the scientific researchers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">on-site</FONT> inspections and sample taking are not compulsory prerequisites for CFDA approval, and the CFDA may determine
whether to take such steps based on the results of regulatory review of drug registration applications; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">clinical trials can be conducted in the sequence of Phase I, II and III, or different stages can cross-over or overlap; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">recommend that decisions of regulatory review in each stage should be made within the prescribed time frame and the CFDA should establish a priority review
system based on clinical needs and the characteristics of drugs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">remove the section of &#147;application and approval of generic drugs&#148; and set out all relevant provisions in the section of &#147;drug marketing
authorization&#148;; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">change the regulatory review process of bioequivalence study from approval to a more simplified recordal process; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">adjust and stipulate the functions of the CFDA and its branches. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Although there is no definitive timeline for the official enactment of the revised Administrative Measures for Drug Registration (Draft for Comments), it embodies a regulatory trend of promoting drug innovation,
accelerating the drug registration process and setting forth higher quality and technical requirements. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Regulations on the clinical trials and
registration of drugs </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Four phases of clinical trials </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">According to the Administrative Measures for Drug Registration, a clinical development program consists of Phases I, II, III and IV. Phase I refers to the initial clinical pharmacology and safety evaluation studies
in humans. Phase II refers to the preliminary evaluation of a drug candidate&#146;s therapeutic effectiveness and safety for particular indication(s) in patients, which provides evidence and support for the design of Phase III clinical trials and
settles the administrative dose regimen. Phase III refers to clinical trials undertaken to confirm the therapeutic effectiveness of a drug. Phase III is used to further verify the drug&#146;s therapeutic effectiveness and safety on patients with
target indication(s), to evaluate overall benefit-risk relationships of the drug, and ultimately to provide sufficient evidence for the review of drug registration application. Phase IV refers to a new drug&#146;s post-marketing study to assess
therapeutic effectiveness and adverse reactions when the drug is widely used, to evaluate overall benefit-risk relationships of the drug when used among the general population or specific groups and to adjust the administration dose, etc.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">144 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Approval authority for clinical trial application </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">According to the Administrative Measures for Drug Registration, upon completion of its <FONT STYLE="white-space:nowrap">pre-clinical</FONT> research, a research
institution must apply for approval of a CTA before conducting clinical trials. As of May 1, 2017, the clinical trial approval can be directly issued by the CDE on behalf of the CFDA. This delegation of authority can shorten the approval timeline
for the approval of a CTA. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Special examination and approval for domestic Category 1 drugs </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">According to the Administrative Measures for Drug Registration, drug registration applications are divided into three different types, namely Domestic New Drug
Application, Domestic Generic Drug Application, and Imported Drug Application. Drugs fall into one of three general types divided by working mechanism, namely chemical medicine, biological product or traditional Chinese or natural medicine. Under
the Administrative Measures for Drug Registration, a Category 1 drug refers to a new drug that has never been marketed in any country, and is eligible for special review or fast track approval by the CFDA. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In March 2016, the CFDA issued the Reform Plan for Registration Category of Chemical Medicine, or the Reform Plan, which outlined the reclassifications of drug
applications under the Administrative Measures for Drug Registration. Under the Reform Plan, Category 1 drugs refer to new drugs that have not been marketed anywhere in the world. Improved new drugs that are not marketed anywhere in the world fall
into Category 2. Generic drugs, that have equivalent quality and efficacy to the originator&#146;s drugs have been marketed abroad but not yet in China, fall into Category 3. Generic drugs, that have equivalent quality and efficacy to the
originator&#146;s drugs and have been marketed in China, fall into Category 4. Category 5 drugs are drugs which have already been marketed abroad, but are not yet approved in China. Category 1 drugs and Category 5 drugs can be registered through the
Domestic New Drug Application and the Imported Drug Application procedures under the Administrative Measures for Drug Registration, respectively. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">According to the Special Examination and Approval Provisions, the CFDA conducts special examination and approval for new drug registration applications when:
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(1). the effective constituent of drug extracted from plants, animals, minerals, etc. as well as the preparations thereof have never been marketed in
China, and the material medicines and the preparations thereof are newly discovered; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(2). the chemical raw material medicines as well as the
preparations thereof and the biological product have not been approved for marketing home and abroad; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(3). the new drugs are for treating AIDS,
malignant tumors and rare diseases, etc., and have obvious advantages in clinic treatment; or </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(4). the new drugs are for treating diseases with no
effective methods of treatment. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Special Examination and Approval Provisions provide that the applicant may file for special examination and approval
at the CTA stage if the drug candidate falls within items (1)&nbsp;or (2). The provisions provide that for drug candidates that fall within items (3)&nbsp;or (4), the application for special examination and approval cannot be made until filing for
production. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We believe that our current drug candidates fall within items (2)&nbsp;and (3) above. Therefore, we may file an application for special
examination and approval at the CTA stage, which may enable us to pursue a more expedited path to approval in China and bring therapies to patients more quickly. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">145 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Fast track approval for clinical trial and registration of domestic Category 1 drugs
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2015, the CFDA released the <I>Circular Concerning Several Policies on Drug Registration Review and Approval</I>, which further
clarified the following policies, potentially simplifying and accelerating the approval process of clinical trials: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a <FONT STYLE="white-space:nowrap">one-time</FONT> umbrella approval procedure allowing the overall approval of all phases of a new drug&#146;s clinical trials,
replacing the current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">phase-by-phase</FONT></FONT> application and approval procedure, will be adopted for new drugs&#146; CTAs; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a fast track drug registration or clinical trial approval pathway for the following applications: (1)&nbsp;registration of innovative new drugs treating HIV,
cancer, serious infectious diseases and orphan diseases; (2)&nbsp;registration of pediatric drugs; (3)&nbsp;registration of geriatric drugs and drugs treating China-prevalent diseases in elders; (4)&nbsp;registration of drugs listed in national
major science and technology projects or national key research and development plan ; (5) registration of innovative drugs using advanced technology, using innovative treatment methods, or having distinctive clinical benefits; (6)&nbsp;registration
of foreign innovative drugs to be manufactured locally in China; (7)&nbsp;concurrent applications for new drug clinical trials which are already approved in the United States or European Union or concurrent drug registration applications for drugs
which have applied to the competent drug approval authorities for marketing authorization and passed such authorities&#146; onsite inspections in the United States or European Union and are manufactured using the same production line in China; and
(8)&nbsp;CTAs for drugs with urgent clinical need and patent expiry within three years, and manufacturing authorization applications for drugs with urgent clinical need and patent expiry within one year. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, in February 2016, the CFDA released the Opinions on Priority Review and Approval for Resolving Drug Registration Applications Backlog, or the Priority
Review Opinions, which further clarified that a fast track clinical trial approval or drug registration pathway will be available to the following drugs: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the following drugs with distinctive clinical benefits: (1)&nbsp;registration of innovative drugs not sold within or outside China; (2)&nbsp;registration of
innovative drug transferred to be manufactured locally in China; (3)&nbsp;registration of drugs using advanced technology, innovative treatment methods, or having distinctive treatment advantages; (4)&nbsp;CTAs for drugs with patent expiry within
three years, and manufacturing authorization applications for drugs with patent expiry within one year; (5)&nbsp;concurrent applications for new drug clinical trials which are already approved in the United States or European Union, or concurrent
drug registration applications for drugs which have applied to the competent drug approval authorities for marketing authorization and passed such authorities&#146; onsite inspections in the United States or European Union and are manufactured using
the same production line in China; (6)&nbsp;traditional Chinese medicines (including ethnic medicines) with clear position in prevention and treatment of serious diseases; and (7)&nbsp;registration of new drugs listed in national major science and
technology projects or national key research and development plans; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">drugs with distinctive clinical benefits for the prevention and treatment of the following diseases: HIV, phthisis, viral hepatitis, orphan diseases, cancer,
children&#146;s diseases, and generic and prevalent diseases in elders. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Other than fugan, we believe that all of our current clinical
stage drug candidates will be classified as Category 1 drugs. Therefore, we will be entitled to the fast track clinical trial approval or drug registration pathway under the Priority Review Opinions. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">According to the Administrative Measures for Drug Registration, Category 5 drug applications may only be submitted after a company obtains an NDA approval and
receives the Certificate of Pharmaceutical Product </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">146 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
granted by a major regulatory authority, such as the FDA or the EMEA. Multinational companies may need to apply for conducting multi-regional clinical trials, which means that companies do not
have the flexibility to design the clinical trials to fit Chinese patients and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care.</FONT></FONT> Category 5 drug candidates may not always qualify to benefit from fast
track review with priority at the CTA stage. Moreover, a requirement to further conduct local clinical trials when the multi-regional clinical trials do not present sufficient Chinese patient data can potentially delay market access by several years
from its international NDA approval. Further, according to the Reform Plan, the drugs which have already been marketed abroad may no longer be categorized as new drugs under Chinese law in the future, and therefore may not be able to enjoy any
preferential treatment for new drugs. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Drug&nbsp;clinical practice certification and compliance with GCP </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To improve the quality of clinical trials, the CFDA promulgated the Administration of Quality of Drug Clinical Practice in August 2003. In February 2004, the CFDA
issued the Circular on Measures for Certification of Drug Clinical Practice (Trial), providing that the CFDA is responsible for certification of clinical trial institutions, and that the National Health and Family Planning Commission of the PRC,
formerly known as the Ministry of Health, is responsible for certification of clinical trial institutions within its duties. Under the Circular on Measures for Certification of Drug Clinical Practice (trial), the CFDA and the National Health and
Family Planning Commission of the PRC decide whether an institution is qualified for undertaking pharmaceutical clinical trials upon the evaluation of the institution&#146;s organizational administration, its research personnel, its equipment and
facilities, its management system and its standard operational rules. If all requirements are met, a GCP Certification will be issued by the CFDA and the result will be published on the CFDA&#146;s website. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The conduct of clinical trials must adhere to the GCP and the protocols approved by the ethics committees of each study site. Since 2015, the CFDA has strengthened
the enforcement against widespread data integrity issues associated with clinical trials in China. To ensure authenticity and reliability of the clinical data, the CFDA mandates applicants of the pending drug registration submissions to conduct
self-inspection and verification of their clinical trial data. Based on the submitted self-inspection results, the CFDA also regularly launches onsite clinical trial audits over selected applications and reject those found with data forgery.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Pilot plan for the marketing authorization holder system </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Under the authorization of the Standing Committee of the National People&#146;s Congress, the State Council issued the Pilot Plan for the Drug Marketing Authorization Holder Mechanism on May&nbsp;26, 2016, which
provides a detailed pilot plan for the marketing authorization holder system, or the MAH System, for drugs in 10 provinces in China. Under the MAH System, domestic drug research and development institutions and individuals in the piloted regions are
eligible to be holders of drug registrations without having to become drug manufacturers. The marketing authorization holders may engage contract manufacturers for manufacturing, provided that the contract manufacturers are licensed and <FONT
STYLE="white-space:nowrap">GMP-certified,</FONT> and are also located within the piloted regions. Drugs qualified for the MAH System are: (1)&nbsp;new drugs (including Category 1 and 2 drugs under the Reform Plan) approved after the implementation
of the MAH System; (2)&nbsp;generic drugs approved as Category 3 or 4 drugs under the Reform Plan; (3)&nbsp;previously approved generics that have passed the equivalence assessments against originator drugs; and (4)&nbsp;previously approved drugs
whose licenses were held by drug manufacturers originally located within the piloted regions, but have been moved out of the piloted regions due to corporate mergers or other reasons. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Administrative protection and monitoring periods for new drugs </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">According to the Administrative Measures for Drug Registration, the Implementing Regulations of the Drug Administration Law and the Reform Plan, the CFDA may, for the purpose of protecting public health, provide
for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">147 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
an administrative monitoring period of five years for Category 1 new drugs approved to be manufactured, commencing from the date of approval, to continually monitor the safety of those new drugs.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During the monitoring period of a new drug, the CFDA will not accept other applications for new drugs containing the same active ingredient. This
renders an actual five-year exclusivity protection for Category 1 new drugs. The only exception is that the CFDA will continue to handle any application if, prior to the commencement of the monitoring period, the CFDA has already approved the
applicant&#146;s clinical trial for a similar new drug. If such application conforms to the relevant provisions, the CFDA may approve such applicant to manufacture or import the similar new drug during the remainder of the monitoring period.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-inferiority</FONT> standard </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In China, a drug may receive regulatory approval without showing superiority in its primary endpoint. Rather, a drug may be approved for use if it shows <FONT STYLE="white-space:nowrap">non-inferiority</FONT> in
its primary endpoint and superiority in one of its secondary endpoints. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>New drug application </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">When Phases I, II and III of the clinical trials have been completed, the applicant may apply to the CFDA for approval of an NDA. The CFDA then determines whether
to approve the application according to the comprehensive evaluation opinion provided by the CDE of the CFDA. We must obtain approval of an NDA before our drugs can be manufactured and sold in the China market. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>International multi-center clinical trials regulations </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On
January&nbsp;30, 2015, the CFDA promulgated Notice on Issuing the International Multi-Center Clinical Trial Guidelines (Trial), or the Multi-Center Clinical Trial Guidelines, which took effect as of March&nbsp;1, 2015, aiming to provide guidance for
the regulation of application, implementation and administration of international multi-center clinical trials in China. Pursuant to the Multi-Center Clinical Trial Guidelines, international multi-center clinical trial applicants may simultaneously
perform clinical trials in different centers using the same clinical trial protocol. Where the applicant plans to make use of the data derived from the international multi-center clinical trials for application to CFDA for approval of an NDA, such
international multi-center clinical trials shall satisfy, in addition to the requirements set forth in Drug Administration Law and its implementation regulations, Provisions for Drug Registration and relevant laws and regulations, the following
requirements: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The applicant shall first conduct an overall evaluation on the global clinical trial data and further make trend analysis of the Asian and Chinese clinical trial
data. In the analysis of Chinese clinical trial data, the applicant shall consider the representativeness of the research subjects, i.e., the participating patients; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The applicant shall analyze whether the amount of Chinese research subjects is sufficient to assess and adjudicate the safety and effectiveness of the drug under
clinical trial, and satisfy the statistical and relevant legal requirements; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The onshore and offshore international multi-center clinical trial research centers shall be subject to <FONT STYLE="white-space:nowrap">on-site</FONT>
inspections by competent PRC governmental agencies. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">International multi-center clinical trials shall follow international prevailing
GCP principles and ethics requirements. Applications shall ensure the truthfulness, reliability and trustworthiness of clinical trials results; the researchers shall have the qualification and capability to perform relevant clinical trials; and an
ethics committee shall continuously review the trials and protect the subjects&#146; interests, benefits and safety. Before </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">148 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
the performance of the international multi-center clinical trial, applicants shall obtain clinical trial approvals or complete filings pursuant to requirements under the local regulations where
clinical trials are conducted, and register and disclose the information of all major researchers and clinical trial organizations on the CFDA drug clinical trial information platform. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Data derived from international multi-center clinical trials can be used for the NDAs with the CFDA. When using international multi-center clinical trial data to support NDAs in China, applicants shall submit the
completed global clinical trial report, statistical analysis report and database, along with relevant supporting data in accordance with <FONT STYLE="white-space:nowrap">ICH-CTD</FONT> (International Conference on Harmonization-Common Technical
Document) content and format requirements; subgroup research results summary and comparative analysis shall also be conducted concurrently. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Leveraging
the clinical trial data derived from international multi-center clinical trials conducted by our partners, we may avoid unnecessary repetitive clinical trials and thus further accelerate the NDA process in China. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On March 17, 2017, the CFDA released the Decision on Adjusting Items concerning the Administration of Imported Drug Registration (Draft for Comments) for public
comment, which includes the following key points: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">If the International Multicenter Clinical Trial, or IMCCT, of a drug is conducted in China, the IMCCT drug does not need to be approved or entered into either a
Phase II or III clinical trial in a foreign country, except for vaccines. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">If the IMCCT is conducted in China, the application for drug marketing authorization can be submitted directly after the completion of the IMCCT.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">With respect to applications for imported innovative chemical drugs and therapeutic biological products, the marketing authorization in the country or region
where the foreign drug manufacturer is located will not be required. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">With respect to drug applications that have been accepted before the release of this Draft, if relevant requirements are met, importation permission can be
granted if such applications request exemption of clinical trials for the imported drugs based on the data generated from IMCCT. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Uncertainties exist as to when this Draft will be officially enacted and take effect, and significant amendments may be made before then. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Drug technology transfer regulations </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On August&nbsp;19,
2009, the CFDA promulgated the Administrative Regulations for Technology Transfer Registration of Drugs to standardize the registration process of drug technology transfer, which includes application for, and evaluation, examination, approval and
monitoring of, drug technology transfer. Drug technology transfer refers to the transfer of drug production technology by the owner to a drug manufacturer and the application for drug registration by the transferee according to the provisions in the
new regulations. Drug technology transfer includes new drug technology transfer and drug production technology transfer. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Conditions
for the application for new drug technology transfer </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Applications for new drug technology transfer may be submitted prior to the expiration date of
the monitoring period of the new drugs with respect to: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">drugs with new drug certificates only; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">drugs with new drug certificates and drug approval numbers. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">149 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For drugs with new drug certificates only and not yet in the monitoring period, or drug substances with new drug
certificates, applications for new drug technology transfer should be submitted prior to the respective expiration date of the monitoring periods for each drug registration category set forth in the new regulations and after the issue date of the
new drug certificates. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Conditions for the application of drug production technology transfer </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Applications for drug production technology transfer may be submitted if: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the transferor holds new drug certificates or both new drug certificates and drug approval numbers, and the monitoring period has expired or there is no
monitoring period; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">with respect to drugs without new drug certificates, both the transferor and the transferee are legally qualified drug manufacturing enterprises, one of which
holds over 50% of the equity interests in the other, or both of which are majority-owned subsidiaries of the same drug manufacturing enterprise. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">With respect to imported drugs with imported drug licenses, the original applicants for the imported drug registration may transfer these drugs to domestic drug manufacturing enterprises. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Application for, and examination and approval of, drug technology transfer </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Applications for drug technology transfer should be submitted to the provincial food and drug administration where the transferee is located. If the transferor and the transferee are located in different provinces,
the provincial food and drug administration where the transferor is located should provide examination opinions. The provincial food and drug administration where the transferee is located is responsible for examining application materials for
technology transfer and organizing inspections on the production facilities of the transferee. Food and drug control institutes are responsible for testing three batches of drug samples. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The CDE should further review the application materials, provide technical evaluation opinions and form a comprehensive evaluation opinion based on the site inspection reports and the testing results of the
samples. The CFDA should determine whether to approve the application according to the comprehensive evaluation opinion of the CDE. An approval letter of supplementary application and a drug approval number will be issued to qualified applications.
An approval letter of clinical trials will be issued when necessary. For rejected applications, a notification letter of the examination opinions will be issued with the reasons for rejection. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Permits and licenses for manufacturing of drugs </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:arial" SIZE="2"><B>Pharmaceutical manufacturing permit </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To manufacture pharmaceutical products in the PRC, a pharmaceutical
manufacturing enterprise must first obtain a Pharmaceutical Manufacturing Permit issued by the relevant pharmaceutical administrative authorities at the provincial level where the enterprise is located. Among other things, such a permit must set
forth the permit number, the name, legal representative and registered address of the enterprise, the site and scope of production, issuing institution, date of issuance and effective period. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Each Pharmaceutical Manufacturing Permit issued to a pharmaceutical manufacturing enterprise is effective for a period of five years. Any enterprise holding a Pharmaceutical Manufacturing Permit is subject to
review by the relevant regulatory authorities on an annual basis. The enterprise is required to apply for renewal of such permit within six months prior to its expiry and will be subject to reassessment by the issuing authorities in accordance with
then prevailing legal and regulatory requirements for the purposes of such renewal. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">150 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Business licenses </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition to a Pharmaceutical Manufacturing permit, the manufacturing enterprise must also obtain a business license from the administrative bureau of industry and commerce at the local level after it has
obtained the requisite Pharmaceutical Manufacturing Permit. The name, legal representative and registered address of the enterprise specified in the business license must be identical to that set forth in the Pharmaceutical Manufacturing Permit.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>GMP certificates </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The World
Health Organization encourages the adoption of good manufacturing practice, or GMP, standards in pharmaceutical production in order to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final
products. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A GMP certification certifies that a manufacturer&#146;s factory and quality management system have met certain criteria for engaging in the
planning and manufacturing of drug products, which address institution and staff qualifications, production premises and facilities, equipment, hygiene conditions, production management, quality controls, product operation, maintenance of sales
records and manner of handling customer complaints and adverse reaction reports. In January 2011, the MOH issued an updated set of GMP standards, also known as the new GMP, to replace the previous version issued in 1998. There are also five annexes
to the new GMP issued by the CFDA in February 2011, with detailed requirements for the manufacture of sterile drugs, drug/substances/APIs, biologics, blood products and traditional Chinese medicines. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The GMP certificate is valid for a term of five years and an application for renewal must be submitted six months prior to its expiration date. The CFDA and its
provincial branches are authorized to monitor the continued compliance of pharmaceutical manufacturers, for example, by a <FONT STYLE="white-space:nowrap">follow-up</FONT> inspection of implementation of the GMP requirements. Failure to continuously
comply with the statutory requirements may lead to rectification orders imposed on the manufacturers. Penalties for breach of GMP compliance can vary depending on the degree of seriousness. Administrative sanctions range from a rectification notice
to monetary fines, suspension of production and business operation, and revocation of the pharmaceutical manufacturing permit and the Pharmaceutical GMP Certificate. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>U.S. regulation of pharmaceutical product development and approval </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the United States, the FDA
regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining approvals and the subsequent compliance with appropriate federal, state and local rules and regulations requires the
expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. regulatory requirements at any time during the product development process, approval process or after approval may subject an applicant and/or
sponsor to a variety of administrative or judicial sanctions, including refusal by FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product
recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by FDA and
the Department of Justice, or DOJ, or other governmental entities. Drugs are also subject to other federal, state and local statutes and regulations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">151 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our drug candidates must be approved by the FDA through the NDA process before they may be legally marketed in the
United States. The process required by the FDA before a drug may be marketed in the United States generally involves the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">completion of extensive <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, sometimes referred to as
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> laboratory tests, <FONT STYLE="white-space:nowrap">pre-clinical</FONT> animal studies and formulation studies all performed in compliance with applicable regulations, including the FDA&#146;s GLP
regulations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials may begin and must be updated
annually; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">approval by an independent IRB representing each clinical site before each clinical trial may be initiated; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">performance of adequate and well-controlled human clinical trials in accordance with applicable good clinical practices, or GCPs and other clinical trial-related
regulations , to establish the safety and efficacy of the proposed drug product for its proposed indication; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">preparation and submission to the FDA of an NDA; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a determination by the FDA within 60 days of its receipt of an NDA to file the NDA for review and review by an FDA advisory committee, where appropriate or if
applicable; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">satisfactory completion of an FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facility or facilities at which the API
and finished drug product are produced to assess compliance with the FDA&#146;s cGMP; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">potential FDA audit of the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and/or clinical trial sites that generated the data in support of the NDA;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">payment of user fees and FDA review and approval of the NDA prior to any commercial marketing or sale of the drug in the United States; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">compliance with any post-approval requirements, including Risk Evaluation and Mitigation Strategies, or REMS, and post-approval studies required by FDA.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Preclinical studies </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The data
required to support an NDA is generated in two distinct development stages: <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical. For new chemical entities, or NCEs, the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development
stage generally involves synthesizing the active component, developing the formulation and determining the manufacturing process, evaluating purity and stability, as well as carrying out <FONT STYLE="white-space:nowrap">non-human</FONT> toxicology,
pharmacology and drug metabolism studies in the laboratory, which support subsequent clinical testing. The conduct of the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> tests must comply with federal regulations, including GLPs. The sponsor
must submit the results of the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of
the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human trials. The IND
automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that <FONT STYLE="white-space:nowrap">30-day</FONT> time
period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity,
may continue after the IND is submitted. The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns or <FONT STYLE="white-space:nowrap">non-compliance.</FONT> Accordingly,
submission of an IND does not guarantee the FDA will allow clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">152 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Clinical studies </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The clinical stage of development involves the administration of the drug product to human subjects or patients under the supervision of qualified investigators,
generally physicians not employed by or under the trial sponsor&#146;s control, in accordance with GCPs, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical
trial. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject
safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by each institution at which the clinical trial
will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to
anticipated benefits. The IRB also reviews and approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. There are also
requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. For example, information about certain clinical trials must be submitted within specific timeframes to the National Institutes
of Health for public dissemination on their ClinicalTrials.gov website. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Clinical trials are generally conducted in three sequential phases that may
overlap or be combined, known as Phase I, Phase II and Phase III clinical trials. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Phase I: The drug is initially introduced into a small number of healthy volunteers who are initially exposed to a single dose and then multiple doses of the
drug candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, side effect tolerability and safety of the drug. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Phase II: The drug is administered to a limited patient population to determine dose tolerance and optimal dosage required to produce the desired benefits. At
the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, as well as identification of possible adverse effects and safety risks and preliminary evaluation of efficacy. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Phase III: The drug is administered to an expanded number of patients, generally at multiple sites that are geographically dispersed, in well-controlled clinical
trials to generate enough data to demonstrate the efficacy of the drug for its intended use, its safety profile, and to establish the overall benefit/risk profile of the drug and provide an adequate basis for drug approval and labeling of the drug
product. Phase III clinical trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a drug during marketing. Generally, two adequate and well-controlled
Phase III clinical trials are required by the FDA for approval of an NDA. A pivotal study is a clinical study that adequately meets regulatory agency requirements for the evaluation of a drug candidate&#146;s efficacy and safety such that it can be
used to justify the approval of the drug. Generally, pivotal studies are also Phase III studies but may be Phase II studies if the trial design provides a well-controlled and reliable assessment of clinical benefit, particularly in situations where
there is an unmet medical need. Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the
intended therapeutic indication. In certain instances, FDA may mandate the performance of Phase 4 clinical trials. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Progress reports
detailing the results of the clinical trials must be submitted at least annually to the FDA, and more frequently if serious adverse events occur. Written IND safety reports must be submitted to the FDA and the investigators for serious and
unexpected adverse events or any finding from tests in laboratory animals that suggests a significant risk to human subjects. The FDA, the IRB, or the clinical trial sponsor may suspend or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">153 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. The FDA will typically
inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the
clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified
experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the
trial. Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing
the drug in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, cGMPs impose extensive procedural, substantive
and recordkeeping requirements to ensure and preserve the long term stability and quality of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug
candidate does not undergo unacceptable deterioration over its shelf life. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>NDA submission and FDA review process </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Following trial completion, trial results and data are analyzed to assess safety and efficacy. The results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
studies and clinical trials are then submitted to the FDA as part of an NDA, along with proposed labeling for the drug, information about the manufacturing process and facilities that will be used to ensure drug quality, results of analytical
testing conducted on the chemistry of the drug, and other relevant information. The NDA is a request for approval to market the drug and must contain adequate evidence of safety and efficacy, which is demonstrated by extensive <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical testing. The application may include negative or ambiguous results of <FONT STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trials as well as positive findings. Data may come
from company-sponsored clinical trials intended to test the safety and efficacy of a use of a drug, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be
sufficient in quality and quantity to establish the safety and efficacy of the investigational drug product to the satisfaction of the FDA. Under federal law, the submission of most NDAs is subject to the payment of an application user fees; a
waiver of such fees may be obtained under certain limited circumstances. FDA approval of an NDA must be obtained before a drug may be offered for sale in the United States. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, under the Pediatric Research Equity Act, or PREA, an NDA or supplement to an NDA must contain data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric
subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each NDA must be accompanied by an application user fee. The FDA adjusts the PDUFA user fees on an
annual basis. According to the FDA&#146;s fee schedule, effective through September&nbsp;30, 2015, the user fee for an application requiring clinical data, such as an NDA, is $2,335,200. PDUFA also imposes an annual product fee for human drugs
($110,370) and an annual establishment fee ($569,200) on facilities used to manufacture prescription drugs. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed
by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">154 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">The FDA reviews all NDAs submitted before it accepts them for filing and may request additional
information rather than accepting an NDA for filing. The FDA conducts a preliminary review of an NDA within 60 days of receipt and informs the sponsor by the 74</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"> day after FDA&#146;s receipt of the submission to determine whether the application is sufficiently complete to permit
substantive review. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review of the NDA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months from the
filing date in which to complete its initial review of a standard NDA and respond to the applicant, and six months from the filing date for a &#147;priority review&#148; NDA. The FDA does not always meet its PDUFA goal dates for standard and
priority review NDAs, and the review process is often significantly extended by FDA requests for additional information or clarification. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">After the NDA
submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed drug is safe and effective for its intended use, and whether the drug is being manufactured in accordance with cGMP to assure and
preserve the drug&#146;s identity, strength, quality and purity. The FDA may refer applications for novel drugs or drug candidates that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes
clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such
recommendations carefully when making decisions. The FDA may <FONT STYLE="white-space:nowrap">re-analyze</FONT> the clinical trial data, which can result in extensive discussions between the FDA and us during the review process. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Before approving an NDA, the FDA will conduct a <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facilities for the new drug to
determine whether they comply with cGMPs. The FDA will not approve the drug unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the drug within
required specifications. In addition, before approving an NDA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process and manufacturing facilities
where the drug product and/or its API will be produced, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A
Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter usually describes all of the specific deficiencies in the NDA identified by the FDA.
The Complete Response Letter may require additional clinical data and/or an additional pivotal clinical trial(s), and/or other significant, expensive and time-consuming requirements related to clinical trials,
<FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the
application. Even if such data and information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data
differently than we interpret the same data. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If a drug receives marketing approval, the approval may be limited to specific diseases and dosages or the
indications for use may otherwise be limited. Further, the FDA may require that certain contraindications, warnings or precautions be included in the drug labeling or may condition the approval of the NDA on other changes to the proposed labeling,
development of adequate controls and specifications, or a commitment to conduct post-market testing or clinical trials and surveillance to monitor the effects of approved drugs. For example, the FDA may require Phase 4 testing which involves
clinical trials designed to further assess a drug&#146;s safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved drugs that have been commercialized. The FDA may also place other conditions on
approvals including the requirement for a Risk Evaluation and Mitigation Strategy, or REMS, to ensure that the benefits of a drug or biological product outweigh its risks. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a
proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">155 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any
of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of drugs. Drug approvals may be withdrawn for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory
standards or if problems occur following initial marketing. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Section 505(b)(2) NDAs </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">NDAs for most new drug products are based on two full clinical studies which must contain substantial evidence of the safety and efficacy of the proposed new
product. These applications are submitted under Section&nbsp;505(b)(1) of the FDCA. The FDA is, however, authorized to approve an alternative type of NDA under Section&nbsp;505(b)(2) of the FDCA. This type of application allows the applicant to
rely, in part, on the FDA&#146;s previous findings of safety and efficacy for a similar product, or published literature. Specifically, Section&nbsp;505(b)(2) applies to NDAs for a drug for which the investigations made to show whether or not the
drug is safe for use and effective in use and relied upon by the applicant for approval of the application &#147;were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by
or for whom the investigations were conducted.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Section&nbsp;505(b)(2) authorizes the FDA to approve an NDA based on safety and effectiveness data
that were not developed by the applicant. NDAs filed under Section&nbsp;505(b)(2) may provide an alternate and potentially more expeditious pathway to FDA approval for new or improved formulations or new uses of previously approved products. If the
505(b)(2) applicant can establish that reliance on the FDA&#146;s previous approval is scientifically appropriate, the applicant may eliminate the need to conduct certain preclinical or clinical studies of the new product. The FDA may also require
companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which the referenced product has been approved, as
well as for any new indication sought by the Section&nbsp;505(b)(2) applicant. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Special FDA expedited review and approval programs </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The FDA has various programs, including Fast Track Designation, accelerated approval, priority review and Breakthrough Therapy Designation, that are intended to
expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these
programs is to provide important new drugs to patients earlier than under standard FDA review procedures. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Fast track designation
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To be eligible for a Fast Track Designation, the FDA must determine, based on the request of a sponsor, that a drug is intended to treat a serious
or life threatening disease or condition for which there is no effective treatment and demonstrates the potential to address an unmet medical need for the disease or condition. Under the fast track program, the sponsor of a drug candidate may
request FDA to designate the product for a specific indication as a fast track product concurrent with or after the filing of the IND for the drug candidate. The FDA must make a fast track designation determination within 60&nbsp;days after receipt
of the sponsor&#146;s request. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to other benefits, such as the ability to use surrogate endpoints and have greater interactions with FDA, FDA
may initiate review of sections of a fast track product&#146;s NDA before the application is complete. This rolling review is available if the applicant provides, and FDA approves, a schedule for the submission of the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">156 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
remaining information and the applicant pays applicable user fees. However, FDA&#146;s time period goal for reviewing a fast track application does not begin until the last section of the NDA is
submitted. In addition, the fast track designation may be withdrawn by FDA if FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Priority review </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The FDA may give a priority
review designation to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of
ten months under current PDUFA guidelines. These six and ten month review periods are measured from the &#147;filing&#148; date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the
timeline for review and decision from the date of submission. Most products that are eligible for Fast Track Designation are also likely to be considered appropriate to receive a priority review. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Breakthrough therapy designation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the
provisions of the new Food and Drug Administration Safety and Innovation Act, or FDASIA, enacted by Congress in 2012, a sponsor can request designation of a drug candidate as a &#147;breakthrough therapy.&#148; A breakthrough therapy is defined as a
drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing
therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA may take certain
actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:arial" SIZE="2"><B>Accelerated approval </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">FDASIA also codified and expanded on FDA&#146;s accelerated approval regulations, under
which FDA may approve a drug for a serious or life-threatening illness that provides meaningful therapeutic benefit over existing treatments based on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical
endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. This determination takes into account the severity,
rarity or prevalence of the disease or condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform Phase 4 or post-marketing studies
to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures. All promotional materials for drug candidates approved under accelerated
regulations are subject to prior review by the FDA. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Even if a product qualifies for one or more of these programs, the FDA may later decide that the
product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, Fast Track Designation, priority review, accelerated approval and Breakthrough Therapy
Designation, do not change the standards for approval and may not ultimately expedite the development or approval process. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Pediatric trials
</I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the Pediatric Research Equity Act of 2003, a NDA or supplement thereto must contain data that are adequate to assess the safety and
effectiveness of the drug product for the claimed indications in all relevant </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">157 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With the enactment of FDASIA, a sponsor who is
planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must also submit an initial Pediatric Study Plan, or PSP, within sixty
days of an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-Phase</FONT></FONT> II meeting or as may be agreed between the sponsor and FDA. The initial PSP must include an outline of the pediatric study or studies that the
sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a
full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. FDA and the sponsor must reach agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if
changes to the pediatric plan need to be considered based on data collected from <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, early phase clinical trials, and/or other clinical development programs. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Orphan drug designation and exclusivity </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the Orphan
Drug Act, FDA may designate a drug product as an &#147;orphan drug&#148; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there
is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product
designation before submitting a NDA. If the request is granted, FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory
review and approval process, but the product will be entitled to orphan product exclusivity, meaning that FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited
circumstances. Competitors may receive approval of different products for the indication for which the orphan product has exclusivity and may obtain approval for the same product but for a different indication. If a drug or drug product designated
as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Post-marketing requirements </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Following approval of a new drug, a pharmaceutical company and the approved drug
are subject to continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse experiences with the drug, providing the regulatory authorities
with updated safety and efficacy information, drug sampling and distribution requirements, and complying with applicable promotion and advertising requirements, which include, among others, standards for <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, restrictions on promoting drugs for uses or in patient populations that are not described in the drug&#146;s approved labeling (known as
<FONT STYLE="white-space:nowrap">&#147;off-label</FONT> use&#148;), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although physicians may legally
prescribe drugs for <FONT STYLE="white-space:nowrap">off-label</FONT> uses, manufacturers may not market or promote such <FONT STYLE="white-space:nowrap">off-label</FONT> uses. Modifications or enhancements to the drug or its labeling or changes of
the site of manufacture are often subject to the approval of the FDA and other regulators, which may or may not be received or may result in a lengthy review process. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Prescription drug advertising is subject to federal, state and foreign regulations. In the United States, the FDA regulates prescription drug promotion, including <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use. Any distribution of prescription drugs and pharmaceutical samples must
comply with the U.S. Prescription Drug Marketing Act, or the PDMA, a part of the FDCA. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">158 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the United States, once a drug is approved, its manufacture is subject to comprehensive and continuing regulation
by the FDA. The FDA regulations require that drugs be manufactured in specific approved facilities and in accordance with cGMP. Applicants may also rely on third parties for the production of clinical and commercial quantities of drugs, and these
third parties must operate in accordance with cGMP regulations. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to
investigate and correct any deviations from cGMP. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are
subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to
maintain cGMP compliance. These regulations also impose certain organizational, procedural and documentation requirements with respect to manufacturing and quality assurance activities. NDA holders using third party contract manufacturers,
laboratories or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the
FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute drugs manufactured, processed or
tested by them. Discovery of problems with a drug after approval may result in restrictions on a drug, manufacturer, or holder of an approved NDA, including, among other things, recall or withdrawal of the drug from the market, and may require
substantial resources to correct. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The FDA also may require post-approval testing, sometimes referred to as Phase 4 testing, risk minimization action
plans and post-marketing surveillance to monitor the effects of an approved drug or place conditions on an approval that could restrict the distribution or use of the drug. Discovery of previously unknown problems with a drug or the failure to
comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or
criminal penalties, among others. Newly discovered or developed safety or effectiveness data may require changes to a drug&#146;s approved labeling, including the addition of new warnings and contraindications, and also may require the
implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#146;s policies may change, which could delay or prevent regulatory approval of our
drugs under development. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Other U.S. regulatory matters </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Manufacturing, sales, promotion and other activities following drug approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the United States, the Centers
for Medicare&nbsp;&amp; Medicaid Services, other divisions of the Department of Health and Human Services, the Drug Enforcement Administration for controlled substances, the Consumer Product Safety Commission, the Federal Trade Commission, the
Occupational Safety&nbsp;&amp; Health Administration, the Environmental Protection Agency and state and local governments. In the United States, sales, marketing and scientific/educational programs must also comply with state and federal fraud and
abuse laws. Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the Health Care Reform Law, as amended by the Health Care and Education
Affordability Reconciliation Act, or ACA. If drugs are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. The handling of any controlled substances must
comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Drugs must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">159 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Packaging Act. Manufacturing, sales, promotion and other activities are also potentially subject to federal and state consumer protection and unfair competition laws. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The distribution of pharmaceutical drugs is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security
requirements intended to prevent the unauthorized sale of pharmaceutical drugs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The failure to comply with regulatory requirements subjects firms to
possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, recall or seizure of drugs, total or partial
suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. In addition, even if a firm complies with FDA and other requirements, new information
regarding the safety or efficacy of a product could lead the FDA to modify or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example:
(i)&nbsp;changes to our manufacturing arrangements; (ii)&nbsp;additions or modifications to product labeling; (iii)&nbsp;the recall or discontinuation of our products; or (iv)&nbsp;additional record-keeping requirements. If any such changes were to
be imposed, they could adversely affect the operation of our business. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>U.S. patent term restoration and marketing exclusivity </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Depending upon the timing, duration and specifics of the FDA approval of our drug candidates, some of our U.S. patents may be eligible for limited patent term
extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration
cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. The patent term restoration period is generally <FONT STYLE="white-space:nowrap">one-half</FONT> the time between the effective date of an
IND and the submission date of an NDA plus the time between the submission date of an NDA and the approval of that application. Only one patent that covers the approved drug (and to only those patent claims covering the approved drug, a method for
using it, or a method for manufacturing it) is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The United States Patent and Trademark Office, in consultation with the FDA,
reviews and approves the application for any patent term extension or restoration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Marketing exclusivity provisions under the FDCA can also delay the
submission or the approval of certain marketing applications. The FDCA provides a five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity within the United States to the first applicant to obtain approval of an
NDA for a NCE. A drug is a NCE if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not
accept for review an ANDA, or a 505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovator drug or for another indication,
where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or <FONT
STYLE="white-space:nowrap">non-infringement</FONT> to one of the patents listed with the FDA by the innovator NDA holder. Specifically, the applicant must certify with respect to each relevant patent that: the required patent information has not
been filed; the listed patent has expired; the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration, or the listed patent is invalid, unenforceable
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">160 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
or will not be infringed by the new product. A certification that the new product will not infringe the already approved product&#146;s listed patents or that such patents are invalid or
unenforceable is called a Paragraph&nbsp;IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed
patents claiming the referenced product have expired. If the ANDA applicant has provided a Paragraph&nbsp;IV certification to the FDA, the applicant must also send notice of the Paragraph&nbsp;IV certification to the NDA and patent holders once the
ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph&nbsp;IV certification. The filing of a patent infringement lawsuit within
45&nbsp;days after the receipt of a Paragraph&nbsp;IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30&nbsp;months after the receipt of the Paragraph&nbsp;IV notice, expiration of the patent, or a decision
in the infringement case that is favorable to the ANDA applicant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The FDCA also provides three years of marketing exclusivity for an NDA, or supplement
to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages
or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing
the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a
right of reference to all of the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. Orphan drug exclusivity, as described above, may offer
a seven-year period of marketing exclusivity, except in certain circumstances. Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity
periods and patent terms. This <FONT STYLE="white-space:nowrap">six-month</FONT> exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance
with an <FONT STYLE="white-space:nowrap">FDA-issued</FONT> &#147;Written Request&#148; for such a trial. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Rest of the world regulation of
pharmaceutical product development and approval </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For other countries outside of China and the United States, such as countries in Europe, Latin
America or other parts of Asia, the requirements governing the conduct of clinical trials, drug licensing, pricing and reimbursement vary from country to country. In all cases the clinical trials must be conducted in accordance with GCP requirements
and the applicable regulatory requirements and ethical principles. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we fail to comply with applicable foreign regulatory requirements, we may be
subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Coverage and reimbursement </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>PRC coverage and reimbursement </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Historically, most Chinese healthcare costs have been borne by patients
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket,</FONT></FONT> which has limited the growth of more expensive pharmaceutical products. However, in recent years the number of people covered by government and private
insurance has increased. According to the PRC National Bureau of Statistics, as of December&nbsp;31, 2015, 666&nbsp;million urban employees and residents in China were enrolled in the national medical insurance program, representing an increase of
11.44% from December&nbsp;31, 2014. The PRC government has announced a plan to give every person in China access to basic healthcare by year 2020. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">161 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Reimbursement under the national medical insurance program </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The national medical insurance program was adopted pursuant to the Decision of the State Council on the Establishment of the Urban Employee Basic Medical Insurance
Program issued by the State Council on December&nbsp;14, 1998, under which all employers in urban cities are required to enroll their employees in the basic medical insurance program and the insurance premium is jointly contributed by the employers
and employees. The State Council promulgated Guiding Opinions of the State Council about the Pilot Urban Resident Basic Medical Insurance on July&nbsp;10, 2007, under which urban residents of the pilot district, rather than urban employees, may
voluntarily join Urban Resident Basic Medical Insurance. The State Council expects the pilot Urban Resident Basic Medical Insurance to cover the whole nation by 2010. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Participants of the national medical insurance program and their employers, if any, are required to contribute to the payment of insurance premium on a monthly basis. Program participants are eligible for full or
partial reimbursement of the cost of medicines included in the Medical Insurance Catalogue. The Notice Regarding the Tentative Measures for the Administration of the Scope of Medical Insurance Coverage for Pharmaceutical Products for Urban Employee,
jointly issued by several authorities including the Ministry of Labor and Social Security and the MOF, among others, on May&nbsp;12, 1999, provides that a pharmaceutical product listed in the Medical Insurance Catalogue must be clinically needed,
safe, effective, reasonably priced, easy to use, available in sufficient quantity, and must meet the following requirements: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">it is set forth in the Pharmacopoeia of the PRC; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">it meets the standards promulgated by the CFDA; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">if imported, it is approved by the CFDA for import. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Factors that affect the inclusion of a pharmaceutical product in the Medical Insurance Catalogue include whether the product is consumed in large volumes and commonly prescribed for clinical use in the PRC and
whether it is considered to be important in meeting the basic healthcare needs of the general public. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The PRC Ministry of Human Resources and Social
Security, together with other government authorities, has the power to determine the medicines included in the NRDL. In February 2017, the PRC Ministry of Human Resources and Social Security released the 2017 NRDL. The 2017 NRDL expands its scope
and covers 2,535 drugs in total, including 339 drugs that are newly added. The 2017 NRDL reflects an emphasis on innovative drugs and drugs that treat cancer and other serious diseases. For instance, most of the innovative chemical drugs and
biological products approved in China between 2008 and the first half of 2016 have been included in the 2017 NRDL or its candidate list. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Medicines
included in the NRDL are divided into two parts, Part A and Part B. Provincial governments are required to include all Part A medicines listed on the NRDL in their provincial Medical Insurance Catalogue,, but have the discretion to adjust upwards or
downwards by no more than 15% from the number of Part B medicines listed in the NRDL. As a result, the contents of Part B of the provincial Medical Insurance Catalogues may differ from region to region in the PRC. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Patients purchasing medicines included in Part A of the NRDL are entitled to reimbursement of the entire amount of the purchase price. Patients purchasing medicines
included in Part B of the NRDL are required to pay a certain percentage of the purchase price and obtain reimbursement for the remainder of the purchase price. The percentage of reimbursement for Part B medicines differs from region to region in the
PRC. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The total amount of reimbursement for the cost of medicines, in addition to other medical expenses, for an individual participant under the
national medical insurance program in a calendar year is capped at the amounts in such participant&#146;s individual account under such program. The amount in a participant&#146;s account varies, depending on the amount of contributions from the
participant and his or her employer. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">162 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>National list of essential drugs </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">On August&nbsp;18, 2009, MOH and eight other ministries and commissions in the PRC issued the Provisional Measures on the Administration of the National List of Essential Drugs and the Guidelines on the
Implementation of the National List of Essential Drugs System, which aim to promote essential medicines sold to consumers at fair prices in the PRC and ensure that the general public in the PRC has equal access to the drugs contained in the National
List of Essential Drugs. MOH promulgated the National List of Essential Drugs (Catalog for the Basic Healthcare Institutions) on August&nbsp;18, 2009, and promulgated the revised National List of Essential Drugs on March&nbsp;13, 2013. According to
these regulations, basic healthcare institutions funded by government, which primarily include county-level hospitals, county-level Chinese medicine hospitals, rural clinics and community clinics, shall store up and use drugs listed in National List
of Essential Drugs. The drugs listed in National List of Essential Drugs shall be purchased by centralized tender process and shall be subject to the price control by NDRC. Remedial drugs in the National List of Essential Drugs are all listed in the
Medical Insurance Catalogue and the entire amount of the purchase price of such drugs is entitled to reimbursement. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Commercial insurance
</I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On October&nbsp;25, 2016, the State Council and the Communist Party of China jointly issued the Plan for Healthy China 2030. According to the Plan,
the country will establish a multi-level medical security system built around basic medical insurance, with other forms of insurance supplementing the basic medical insurance, including serious illness insurance for urban and rural residents,
commercial health insurance and medical assistance. Furthermore, the Plan encourages enterprises and individuals to participate in commercial health insurance and various forms of supplementary insurance. The evolving medical insurance system makes
innovative drugs more affordable and universally available to the Chinese population, which renders greater opportunities to drug manufacturers that focus on the research and development of innovative drugs, such as high-cost cancer therapeutics.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Price controls </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Instead of direct price controls
which were historically used in China but abolished in June 2016, the government regulates prices mainly by establishing a consolidated procurement mechanism, revising medical insurance reimbursement standards and strengthening regulation of medical
and pricing practices as discussed below. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Centralized procurement and tenders </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Guiding Opinions concerning the Urban Medical and Health System Reform, promulgated on February&nbsp;21, 2000, aims to regulate the purchasing process of pharmaceutical products by medical institution. The MOH
and other relevant government authorities have promulgated a series of regulations and releases in order to implement the tender requirements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">According
to the Notice on Issuing Certain Regulations on the Trial Implementation of Centralised Tender Procurement of Drugs by Medical Institutions promulgated on July&nbsp;7, 2000 and the Notice on Further Improvement on the Implementation of Centralised
Tender Procurement of Drugs by Medical Institutions promulgated on August&nbsp;8, 2001, medical institutions established by county or higher level government or state-owned enterprises (including state-controlled enterprises) are required to
implement centralised tender procurement of drugs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The MOH promulgated the Working Regulations of Medical Institutions for Procurement of Drugs by
Centralised Tender and Price Negotiations (for Trial Implementation), or there Centralised Procurement Regulations, on March&nbsp;13, 2002, and promulgated Sample Document for Medical Institutions for Procurement of Drugs by
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">163 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Centralised Tender and Price Negotiations (for Trial Implementation), or the Centralised Tender Sample Document in November 2001, to implement the tender process requirements and ensure the
requirements are followed uniformly throughout the country. The Centralised Tender Regulations and the Centralised Tender Sample Document provide rules for the tender process and negotiations of the prices of drugs, operational procedures, a code of
conduct and standards or measures of evaluating bids and negotiating prices. On January&nbsp;17, 2009, the MOH, the CFDA and other four national departments jointly promulgated the Opinions on Further Regulating Centralised Procurement of Drugs by
Medical Institutions. According to the notice, public medical institutions owned by the government at the county level or higher or owned by state-owned enterprises (including state-controlled enterprises) shall purchase pharmaceutical products by
online centralised procurement. Each provincial government shall formulate its catalogue of drugs subject to centralised procurement. Except for drugs in the National List of Essential Drugs (the procurement of which shall comply with the relevant
rules on National List of Essential Drugs), certain pharmaceutical products which are under the national government&#146;s special control, such as toxic, radioactive and narcotic drugs and traditional Chinese medicines, in principle, all drugs used
by public medical institutions shall be covered by the catalogue of drugs subject to centralised procurement. On July&nbsp;7, 2010, the MOH and six other ministries and commissions jointly promulgated the Notice on Printing and Distributing the
Working Regulations of Medical Institutions for Centralised Procurement of Drugs to further regulate the centralised procurement of drugs and clarify the code of conduct of the parties in centralised drug procurement. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The centralized tender process takes the form of public tender operated and organised by provincial or municipal government agencies. The centralised tender process
is in principle conducted once every year in the relevant province or city in China. The bids are assessed by a committee composed of pharmaceutical and medical experts who will be randomly selected from a database of experts approved by the
relevant government authorities. The committee members assess the bids based on a number of factors, including but not limited to, bid price, product quality, clinical effectiveness, product safety, qualifications and reputation of the manufacturer,
after-sale services and innovation. Only pharmaceuticals that have won in the centralised tender process may be purchased by public medical institutions funded by the governmental or state-owned enterprise (including state-controlled enterprises) in
the relevant region. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Insurance reform </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
Opinions on Integrating the Basic Medical Insurance Systems for Urban and Rural Residents issued by the State Council on January&nbsp;3, 2016, call for the integration of the urban resident basic medical insurance and the new rural cooperative
medical care system and the establishment of a unified basic medical insurance system, which will cover all urban and rural residents other than rural migrant workers and persons in flexible employment arrangement who participate in the basic
medical insurance for urban employees. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">According to the Main Tasks of Healthcare System Reform in 2016 issued by the General Office of the State Council
on April&nbsp;21, 2016, the key tasks of the medical insurance reform are: (1)&nbsp;to advance the establishment of the mechanisms of stable and sustainable financing and security level adjustment, (2)&nbsp;to advance the integration of the basic
medical insurance systems for urban and rural residents, (3)&nbsp;to consolidate and improve the system for serious illness insurance for urban and rural residents, (4)&nbsp;to reform medical insurance payment methods, and (5)&nbsp;to advance the
development of commercial health insurance. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Human Resources and Social Security Departments issued the Guiding Opinions on Actively Promoting the
Coordinated Healthcare, Medical Insurance and Pharmaceutical Reforms on June&nbsp;29, 2016, which state that reform will focus on exploring and leveraging the fundamental role of medical insurance through further integration of medical insurance
systems in all aspects, deepening the reform of the payment methods for medical insurance and promoting innovation in the medical insurance management system. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">164 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">According to the Notice on the Issuance of the 13th Five-year Plan on Strengthening the Reform of Healthcare System
issued by the State Council on December&nbsp;27, 2016, one of the guiding principles is to insist on the reform of the coordinated development among healthcare, medical insurance and pharmaceutical systems. The reform intends to establish a complete
policy structure in healthcare by 2017, including by perfecting the graded diagnosis and treatment system, establishing and improving the comprehensive supervision and modern hospital management systems, improving the universal medical insurance
system, perfecting drug production and distribution policies and strengthening public health service, medical service, medical insurance, drug supply, supervision and management systems throughout the healthcare industry. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>U.S. coverage and reimbursement </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Successful sales of
our products or drug candidates in the U.S. market, if approved, will depend, in part, on the extent to which our drugs will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare
organizations. Patients who are provided with prescriptions as part of their medical treatment generally rely on such third-party payors to reimburse all or part of the costs associated with their prescriptions and therefore adequate coverage and
reimbursement from such third-party payors are critical to new product acceptance. These third-party payors are increasingly reducing reimbursements for medical drugs and services. Additionally, the containment of healthcare costs has become a
priority of federal and state governments, and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including
price controls, restrictions on reimbursement and requirements for substitution of generic drugs. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and
measures, could further limit our net revenue and results. Decreases in third-party reimbursement for our drug candidates, if approved, or a decision by a third-party payor to not cover our drug candidates could reduce physician usage of such drugs
and have a material adverse effect on our sales, results of operations and financial condition. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Medicare Prescription Drug, Improvement, and
Modernization Act of 2003, or the MMA, established the Medicare Part D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private
entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can
develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not
necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Medicare payment for some of the costs of prescription drugs may
increase demand for drugs for which we receive marketing approval. However, any negotiated prices for our drugs covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA
applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar
reduction in payments from <FONT STYLE="white-space:nowrap">non-governmental</FONT> payors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The American Recovery and Reinvestment Act of 2009 provides
funding for the federal government to compare the effectiveness of different treatments for the same illness. The plan for the research was published in 2012 by the U.S. Department of Health and Human Services, the Agency for Healthcare Research and
Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures will be made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage
policies for public or private payors, if third-party payors do not consider a drug to be cost-</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">165 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
effective compared to other available therapies, they may not cover such drugs as a benefit under their plans or, if they do, the level of payment may not be sufficient. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, enacted in March
2010, has had a significant impact on the health care industry. The ACA expanded coverage for the uninsured while at the same time containing overall healthcare costs. With regard to pharmaceutical products, the ACA, among other things, addressed a
new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under
the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and a new Medicare Part D
coverage gap discount program, in which manufacturers must agree to offer 50% <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible
beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In
addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. On August&nbsp;2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by Congress. A
Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic
reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, started in April 2013, and, due to subsequent legislative amendments, will stay in effect through 2024 unless
additional Congressional action is taken. On January&nbsp;2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, or the ATRA, which among other things, also reduced Medicare payments to several providers, including
hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Rest of the world coverage and reimbursement </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In some foreign countries, the proposed pricing for a drug
must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal drugs for
which their national health insurance systems provide reimbursement and to control the prices of medicinal drugs for human use. A member state may approve a specific price for the medicinal drug or it may instead adopt a system of direct or indirect
controls on the profitability of the Company placing the medicinal drug on the market. Historically, drugs launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Other healthcare laws </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Other PRC healthcare laws
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Advertising of pharmaceutical products </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the Provisions for Drug Advertisement Examination, which were promulgated on March&nbsp;13, 2007 and came into effect on 1&nbsp;May 2007, an enterprise
seeking to advertise its drugs must apply for an advertising approval code. The validity term of an advertisement approval number for pharmaceutical drugs is one year. The content of an approved advertisement may not be altered without prior
approval. Where any alteration to the advertisement is needed, a new advertisement approval number shall be obtained by submitting a reapplication. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">166 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Insert sheet and labels of pharmaceutical products </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">According to the Measures for the Administration of the Insert Sheets and Labels of Drugs effective on June&nbsp;1, 2006, the insert sheets and labels of drugs should be reviewed and approved by the CFDA. A drug
insert sheet should include the scientific data, conclusions and information concerning drug safety and efficacy in order to direct the safe and rational use if drugs. The inner label of a drug should bear such information as the drug&#146;s name,
indication or function, strength, dose and usage, production date, batch number, expiry date and drug manufacturer, and the outer label of a drug should indicate such information as the drug&#146;s name, ingredients, description, indication or
function, strength, dose and usage and adverse reaction. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Packaging of pharmaceutical products </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">According to the Measures for The Administration of Pharmaceutical Packaging effective on September&nbsp;1, 1988, pharmaceutical packaging must comply with the
national and professional standards. If no national or professional standards are available, the enterprise can formulate its own standards and put into implementation after obtaining the approval of the food and drug administration or bureau of
standards at provincial level. The enterprise shall reapply with the relevant authorities if it needs to change its own packaging standard. Drugs that have not developed and received approval for packing standards must not be sold or traded in PRC
(except for drugs for the military). </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Other U.S. healthcare laws </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We may also be subject to healthcare regulation and enforcement by the U.S. federal government and the states where we may market our drug candidates, if approved. These laws include, without limitation, state and
federal anti-kickback, fraud and abuse, false claims, privacy and security and physician sunshine laws and regulations. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Anti-kickback statute
</I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or
providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the
Medicare and Medicaid programs. The majority of states also have anti-kickback laws, which establish similar prohibitions and in some cases may apply to items or services reimbursed by any third-party payor, including commercial insurers. The
Anti-Kickback Statute is subject to evolving interpretations. In the past, the government has enforced the Anti-Kickback Statute to reach large settlements with healthcare companies based on sham consulting and other financial arrangements with
physicians. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting
from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>False
claims </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Additionally, the civil False Claims Act prohibits knowingly presenting or causing the presentation of a false, fictitious or fraudulent
claim for payment to the U.S. government. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Analogous state law equivalents may apply and may be
broader in scope than the federal requirements. Violations of the False Claims Act can result in very significant monetary penalties and treble damages. The </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">167 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
federal government is using the False Claims Act, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies
throughout the U.S., for example, in connection with the promotion of products for unapproved uses and other sales and marketing practices. The government has obtained multi-million and multi-billion dollar settlements under the False Claims Act in
addition to individual criminal convictions under applicable criminal statutes. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating
healthcare providers&#146; and manufacturers&#146; compliance with applicable fraud and abuse laws. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The federal Health Insurance Portability and
Accountability Act of 1996, or HIPAA, also created new federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private
third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a
material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need
to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Payments to physicians
</I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There has also been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The ACA,
among other things, imposes new reporting requirements on drug manufacturers for payments made by them to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Failure
to submit required information may result in civil monetary penalties of up to an aggregate of $150,000 per year (or up to an aggregate of $1&nbsp;million per year for &#147;knowing failures&#148;), for all payments, transfers of value or ownership
or investment interests that are not timely, accurately and completely reported in an annual submission. Drug manufacturers were required to begin collecting data on August&nbsp;1, 2013 and submit reports to the government by March&nbsp;31, 2014 and
June&nbsp;30, 2014, and the 90th day of each subsequent calendar year. Certain states also mandate implementation of compliance programs, impose restrictions on drug manufacturer marketing practices and/or require the tracking and reporting of
gifts, compensation and other remuneration to physicians. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Data privacy and security </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology and Clinical
Health Act, or HITECH, and their respective implementing regulations, including the final omnibus rule published on January&nbsp;25, 2013, imposes specified requirements relating to the privacy, security and transmission of individually identifiable
health information. Among other things, HITECH makes HIPAA&#146;s privacy and security standards directly applicable to &#147;business associates,&#148; defined as independent contractors or agents of covered entities that create, receive, maintain
or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and
possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#146;s fees and costs associated with pursuing federal
civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">168 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Other significant PRC regulation affecting our business activities in China </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>PRC regulation of foreign investment </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Investment
activities in China by foreign investors are principally governed by the Guidance Catalogue of Industries for Foreign Investment, or the Catalogue, which was promulgated and is amended from time to time by the MOFCOM and the National Development and
Reform Commission. Pursuant to the latest Catalogue, amended and issued on June 28, 2017 and effective on July 28, 2017, or the 2017 Catalogue, industries listed therein are divided into two categories: encouraged industries and the industries
within the catalogue of special management measures, or the Negative List. The Negative List is further divided into two sub-categories: restricted industries and prohibited industries. Establishment of wholly foreign-owned enterprises is generally
allowed in industries outside of the Negative List. For the restricted industries within the Negative List, some are limited to equity or contractual joint ventures, while in some cases Chinese partners are required to hold the majority interests in
such joint ventures. In addition, restricted category projects are subject to government approvals and certain special requirements. Foreign investors are not allowed to invest in industries in the prohibited category. Industries not listed in the
Catalogue are generally open to foreign investment unless specifically restricted by other PRC regulations. Pursuant to the 2017 Catalogue, the manufacture of pharmaceutical products falls in the encouraged industries for foreign investments.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under PRC law, the establishment of a wholly foreign-owned enterprise is subject to the approval of, or the requirement for record filing with, the
MOFCOM or its local counterparts and the wholly foreign owned enterprise must register with the competent administrative bureau of industry and commerce. We have duly obtained the approvals from the MOFCOM or its local counterparts for our interest
in our wholly-owned PRC subsidiaries and completed the registration of these PRC subsidiaries with the competent administrative bureau of industry and commerce. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In October 2016, the MOFCOM issued the Interim Measures for Record-filing Administration of the Establishment and Change of Foreign-invested Enterprises, or FIE Record-filing Interim Measures. Pursuant to FIE
Record-filing Interim Measures, the establishment and change of foreign-invested enterprises are subject to record-filing procedures, instead of prior approval requirements, provided that the establishment or change does not involve special entry
administrative measures. If the establishment or change of FIE matters involve the special entry administrative measures, the approval of the MOFCOM or its local counterparts is still required. Pursuant to the Announcement 2016 No.&nbsp;22 of the
National Development and Reform Commission and the MOFCOM dated October&nbsp;8, 2016, the special entry administrative measures for foreign investment apply to restricted and prohibited categories specified in the Catalogue, and the encouraged
categories are subject to certain requirements relating to equity ownership and senior management under the special entry administrative measures. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>PRC regulation of commercial bribery </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pharmaceutical
companies involved in a criminal investigation or administrative proceedings related to bribery are listed in the Adverse Records of Commercial Briberies by its provincial health and family planning administrative department. Pursuant to the
Provisions on the Establishment of Adverse Records of Commercial Briberies in the Medicine Purchase and Sales Industry which became effective on March&nbsp;1, 2014, provincial health and family planning administrative departments formulate the
implementing measures for establishment of Adverse Records of Commercial Briberies. If a pharmaceutical company is listed in the Adverse Records of Commercial Briberies for the first time, their production is not required to be purchased by public
medical institutions. A pharmaceutical company will not be penalized by the relevant PRC government authorities merely by virtue of having contractual relationships with distributors or third party promoters who are engaged in bribery activities, so
long as such pharmaceutical company and its employees are not utilizing </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">169 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
the distributors or third party promoters for the implementation of, or acting in conjunction with them in, the prohibited bribery activities. In addition, a pharmaceutical company is under no
legal obligation to monitor the operating activities of its distributors and third party promoters, and will not be subject to penalties or sanctions by relevant PRC government authorities as a result of failure to monitor their operating
activities. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>PRC regulation of product liability </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to the strict new drug approval process, certain PRC laws have been promulgated to protect the rights of consumers and to strengthen the control of
medical products in the PRC. Under current PRC law, manufacturers and vendors of defective products in the PRC may incur liability for loss and injury caused by such products. Pursuant to the General Principles of the Civil Law of the PRC, or the
PRC Civil Law, promulgated on April&nbsp;12, 1986 and amended on August&nbsp;27, 2009, a defective product which causes property damage or physical injury to any person may subject the manufacturer or vendor of such product to civil liability for
such damage or injury. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On February&nbsp;22, 1993, the Product Quality Law of the PRC, or the Product Quality Law, was promulgated to supplement the PRC
Civil Law aiming to protect the legitimate rights and interests of the <FONT STYLE="white-space:nowrap">end-users</FONT> and consumers and to strengthen the supervision and control of the quality of products. The Product Quality Law was revised by
the Ninth National People&#146;s Congress on July&nbsp;8, 2000 and by the Eleventh National People&#146;s Congress on August&nbsp;27, 2009. Pursuant to the revised Product Quality Law, manufacturers who produce defective products may be subject to
civil or criminal liability and have their business licenses revoked. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Law of the PRC on the Protection of the Rights and Interests of Consumers was
promulgated on October&nbsp;31, 1993 and was amended on August&nbsp;27, 2009 and October&nbsp;25, 2013 to protect consumers&#146; rights when they purchase or use goods and accept services. All business operators must comply with this law when they
manufacture or sell goods and/or provide services to customers. Under the amendment on October&nbsp;25, 2013, all business operators shall pay high attention to protect the customers&#146; privacy and strictly keep it confidential any consumer
information they obtain during the business operation. In addition, in extreme situations, pharmaceutical product manufacturers and operators may be subject to criminal liability if their goods or services lead to the death or injuries of customers
or other third parties. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>PRC tort law </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the
Tort Law of the PRC which became effective on July&nbsp;1, 2010, if damages to other persons are caused by defective products due to the fault of a third party, such as the parties providing transportation or warehousing, the producers and the
sellers of the products have the right to recover their respective losses from such third parties. If defective products are identified after they have been put into circulation, the producers or the sellers shall take remedial measures such as
issuance of a warning, recall of products, etc. in a timely manner. The producers or the sellers shall be liable under tort if they fail to take remedial measures in a timely manner or have not made efforts to take remedial measures, thus causing
damages. If the products are produced or sold with known defects, causing deaths or severe adverse health issues, the infringed party has the right to claim punitive damages in addition to compensatory damages. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>PRC regulation of intellectual property rights </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">China has
made substantial efforts to adopt comprehensive legislation governing intellectual property rights, including patents, trademarks, copyrights and domain names. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">170 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Patents </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Pursuant to the PRC Patent Law, most recently amended in December 2008, and its implementation rules, most recently amended in January 2010, patents in China fall into three categories: invention, utility model and
design. An invention patent is granted to a new technical solution proposed in respect of a product or method or an improvement of a product or method. A utility model is granted to a new technical solution that is practicable for application and
proposed in respect of the shape, structure or a combination of both of a product. A design patent is granted to the new design of a certain product in shape, pattern or a combination of both and in color, shape and pattern combinations
aesthetically suitable for industrial application. Under the PRC Patent Law, the term of patent protection starts from the date of application. Patents relating to invention are effective for twenty years, and utility models and designs are
effective for ten years from the date of application. The PRC Patent Law adopts the principle of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, which provides that where more than
one person files a patent application for the same invention, a patent will be granted to the person who files the application first. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Existing patents
can become narrowed, invalid or unenforceable due to a variety of grounds, including lack of novelty, creativity, and deficiencies in patent application. In China, a patent must have novelty, creativity and practical applicability. Under the PRC
Patent Law, novelty means that before a patent application is filed, no identical invention or utility model has been publicly disclosed in any publication in China or overseas or has been publicly used or made known to the public by any other
means, whether in or outside of China, nor has any other person filed with the patent authority an application that describes an identical invention or utility model and is recorded in patent application documents or patent documents published after
the filing date. Creativity means that, compared with existing technology, an invention has prominent substantial features and represents notable progress, and a utility model has substantial features and represents any progress. Practical
applicability means an invention or utility model can be manufactured or used and may produce positive results. Patents in China are filed with the State Intellectual Property Office, or SIPO. Normally, the SIPO publishes an application for an
invention patent within 18 months after the filing date, which may be shortened at the request of applicant. The applicant must apply to the SIPO for a substantive examination within three years from the date of application. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Article 20 of the PRC Patent Law provides that, for an invention or utility model completed in China, any applicant (not just Chinese companies and individuals),
before filing a patent application outside of China, must first submit it to the SIPO for a confidential examination. Failure to comply with this requirement will result in the denial of any Chinese patent for the relevant invention. This added
requirement of confidential examination by the SIPO has raised concerns by foreign companies who conduct research and development activities in China or outsource research and development activities to service providers in China. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Patent enforcement </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Unauthorized use of
patents without consent from owners of patents, forgery of the patents belonging to other persons, or engagement in other patent infringement acts, will subject the infringers to infringement liability. Serious offences such as forgery of patents
may be subject to criminal penalties. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">When a dispute arises out of infringement of the patent owner&#146;s patent right, Chinese law requires that the
parties first attempt to settle the dispute through mutual consultation. However, if the dispute cannot be settled through mutual consultation, the patent owner, or an interested party who believes the patent is being infringed, may either file a
civil legal suit or file an administrative complaint with the relevant patent administration authority. A Chinese court may issue a preliminary injunction upon the patent owner&#146;s or an interested party&#146;s request before instituting any
legal proceedings or during the proceedings. Damages for infringement are calculated as the loss suffered by the patent holder arising from the infringement, and if the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">171 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
loss suffered by the patent holder arising from the infringement cannot be determined, the damages for infringement shall be calculated as the benefit gained by the infringer from the
infringement. If it is difficult to ascertain damages in this manner, damages may be determined by using a reasonable multiple of the license fee under a contractual license. Statutory damages may be awarded in the circumstances where the damages
cannot be determined by the above mentioned calculation standards. The damage calculation methods shall be applied in the aforementioned order. Generally, the patent owner has the burden of proving that the patent is being infringed. However, if the
owner of an invention patent for manufacturing process of a new product alleges infringement of its patent, the alleged infringer has the burden of proof. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:arial" SIZE="2"><B>Medical patent compulsory license </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">According to the PRC Patent Law, for the purpose of public health, the SIPO
may grant a compulsory license for manufacturing patented drugs and exporting them to countries or regions covered under relevant international treaties to which PRC has acceded. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Exemptions for Unlicensed Manufacture, Use, Sale or Import of Patented Products </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The PRC Patent Law provides five exceptions for unauthorized manufacture, use, sale or import of patented products. None of following circumstances are deemed an infringement of the patent rights, and any person
may manufacture, use, sell or import patented products without authorization granted by the patent owner as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Any person who uses, promises to sell, sells or imports any patented product or product directly obtained in accordance with the patented methods after such
product is sold by the patent owner or by its licensed entity or individual; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Any person who has manufactured an identical product, has used an identical method or has made necessary preparations for manufacture or use prior to the date of
patent application and continues to manufacture such product or use such method only within the original scope; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Any foreign transportation facility that temporarily passes through the territory, territorial waters or territorial airspace of China and uses the relevant
patents in its devices and installations for its own needs in accordance with any agreement concluded between China and that country to which the foreign transportation facility belongs, or any international treaty to which both countries are party,
or on the basis of the principle of reciprocity; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Any person who uses the relevant patents solely for the purposes of scientific research and experimentation; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Any person who manufactures, uses or imports patented drug or patented medical equipment for the purpose of providing information required for administrative
approval, or manufactures, uses or imports patented drugs or patented medical equipment for the abovementioned person. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">However, if
patented drugs are utilized on the ground of exemptions for unauthorized manufacture, use, sale or import of patented drugs prescribed in PRC Patent Law, such patented drugs cannot be manufactured, used, sold or imported for any commercial purposes
without authorization granted by the patent owner. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Trade secrets </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">According to the PRC Anti-Unfair Competition Law, the term &#147;trade secrets&#148; refers to technical and business information that is unknown to the public that has utility and may create business interests or
profits for its legal owners or holders, and is maintained as a secret by its legal owners or holders. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">172 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the PRC Anti-Unfair Competition Law, business persons are prohibited from infringing others&#146; trade secrets
by: (1)&nbsp;obtaining the trade secrets from the legal owners or holders by any unfair methods such as theft, solicitation or coercion; (2)&nbsp;disclosing, using or permitting others to use the trade secrets obtained illegally under item
(1)&nbsp;above; or (3)&nbsp;disclosing, using or permitting others to use the trade secrets, in violation of any contractual agreements or any requirements of the legal owners or holders to keep such trade secrets in confidence. If a third party
knows or should have known of the above-mentioned illegal conduct but nevertheless obtains, uses or discloses trade secrets of others, the third party may be deemed to have committed a misappropriation of the others&#146; trade secrets. The parties
whose trade secrets are being misappropriated may petition for administrative corrections, and regulatory authorities may stop any illegal activities and fine infringing parties in the amount of RMB10,000 to RMB200,000. Alternatively, persons whose
trade secrets are being misappropriated may file lawsuits in a Chinese court for loss and damages incurred due to the misappropriation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The measures to
protect trade secrets include oral or written <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreements or other reasonable measures to require the employees of, or persons in business contact with, legal owners or holders to keep trade
secrets confidential. Once the legal owners or holders have asked others to keep trade secrets confidential and have adopted reasonable protection measures, the requested persons bear the responsibility for keeping the trade secrets confidential.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2"><B>Trademarks and domain names </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Trademark. The PRC Trademark Law and its implementation rules protect registered trademarks. The PRC Trademark Office of State Administration of Industry and
Commerce is responsible for the registration and administration of trademarks throughout the PRC. The Trademark Law has adopted a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> principle
with respect to trademark registration. As of June&nbsp;30, 2017, we had two registered trademarks in China and four trademark applications pending outside China. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Domain Name. Domain names are protected under the Administrative Measures on the Internet Domain Names promulgated by the Ministry of Industry and Information Technology. The Ministry of Industry and Information
Technology is the main regulatory body responsible for the administration of PRC internet domain names. We have registered zaibio.com, zaibiotech.com, zailaboratory.com, zailab.com.cn, zaimedicine.com and zaipharma.com. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>PRC regulation of labor protection </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the Labor Law of
the PRC, effective on January&nbsp;1, 1995 and subsequently amended on August&nbsp;27, 2009, the PRC Employment Contract Law, effective on January&nbsp;1, 2008 and subsequently amended on December&nbsp;28, 2012 and the Implementing Regulations of
the Employment Contract Law, effective on September&nbsp;18, 2008, employers must establish a comprehensive management system to protect the rights of their employees, including a system governing occupational health and safety to provide employees
with occupational training to prevent occupational injury, and employers are required to truthfully inform prospective employees of the job description, working conditions, location, occupational hazards and status of safe production as well as
remuneration and other conditions as requested by the Labor Contract Law of the PRC. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the Law of Manufacturing Safety of the PRC effective on
November&nbsp;1, 2002 and amended on August&nbsp;27, 2009 and August&nbsp;31, 2014, manufacturers must establish a comprehensive management system to ensure manufacturing safety in accordance with applicable laws, regulations, national standards,
and industrial standards. Manufacturers not meeting relevant legal requirements are not permitted to commence their manufacturing activities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">173 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the Administrative Measures Governing the Production Quality of Pharmaceutical Products effective on
March&nbsp;1, 2011, manufacturers of pharmaceutical products are required to establish production safety and labor protection measures in connection with the operation of their manufacturing equipment and manufacturing process. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to applicable PRC laws, rules and regulations, including the Social Insurance Law which became effective on July&nbsp;1, 2011, the Interim Regulations on
the Collection and Payment of Social Security Funds which became effective on January&nbsp;22, 1999, Interim Measures concerning the Maternity Insurance of Employees which become effective on December&nbsp;14, 1994, and the Regulations on
Work-related Injury Insurance which became effective on January&nbsp;1, 2004 and was subsequently amended on December&nbsp;20, 2010, employers are required to contribute, on behalf of their employees, to a number of social security funds, including
funds for basic pension insurance, unemployment insurance, basic medical insurance, work-related injury insurance and maternity insurance. If an employer fails to make social insurance contributions timely and in full, the social insurance
collecting authority will order the employer to make up outstanding contributions within the prescribed time period and impose a late payment fee at the rate of 0.05% per day from the date on which the contribution becomes due. If such employer
fails to make the overdue contributions within such time limit, the relevant administrative department may impose a fine equivalent to one to three times the overdue amount. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Regulations relating to foreign exchange registration of offshore investment by PRC residents </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In July
2014, SAFE issued the SAFE Circular 37, and its implementation guidelines, which abolished and superseded the SAFE Circular 75. Pursuant to SAFE Circular 37 and its implementation guidelines, PRC residents (including PRC institutions and
individuals) must register with local branches of SAFE in connection with their direct or indirect offshore investment in an overseas special purpose vehicle, or SPV, directly established or indirectly controlled by PRC residents for the purposes of
offshore investment and financing with their legally owned assets or interests in domestic enterprises, or their legally owned offshore assets or interests. Such PRC residents are also required to amend their registrations with SAFE when there is a
change to the basic information of the SPV, such as changes of a PRC resident individual shareholder, the name or operating period of the SPV, or when there is a significant change to the SPV, such as changes of the PRC individual resident&#146;s
increase or decrease of its capital contribution in the SPV, or any share transfer or exchange, merger, division of the SPV. Failure to comply with the registration procedures set forth in the Circular 37 may result in restrictions being imposed on
the foreign exchange activities of the relevant onshore company, including the payment of dividends and other distributions to its offshore parent or affiliate, the capital inflow from the offshore entities and settlement of foreign exchange
capital, and may also subject relevant onshore company or PRC residents to penalties under PRC foreign exchange administration regulations. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Regulations relating to employee stock incentive plan </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In
February&nbsp;2012, the SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plans of Overseas Publicly Listed Companies, or the Stock Option Rules, which
replaced the Application Procedures of Foreign Exchange Administration for Domestic Individuals Participating in Employee Stock Ownership Plans or Stock Option Plans of Overseas Publicly Listed Companies issued by SAFE on March&nbsp;28, 2007. In
accordance with the Stock Option Rules and relevant rules and regulations, PRC citizens or <FONT STYLE="white-space:nowrap">non-PRC</FONT> citizens residing in China for a continuous period of not less than one year, who participate in any stock
incentive plan of an overseas publicly listed company, subject to a few exceptions, are required to register with SAFE through a domestic qualified agent, which could be a PRC subsidiary of such overseas listed company, and complete certain
procedures. We and our employees who are PRC citizens or who reside in China for a continuous period of not less than one year and who participate in our stock incentive plan will be subject to such regulation. In addition, the SAT has issued
circulars concerning </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">174 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
employee share options or restricted shares. Under these circulars, employees working in the PRC who exercise share options, or whose restricted shares vest, will be subject to PRC individual
income tax, or the IIT. The PRC subsidiaries of an overseas listed company have obligations to file documents related to employee share options or restricted shares with relevant tax authorities and to withhold IIT of those employees related to
their share options or restricted shares. If the employees fail to pay, or the PRC subsidiaries fail to withhold, their IIT according to relevant laws, rules and regulations, the PRC subsidiaries may face sanctions imposed by the tax authorities or
other PRC government authorities. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Regulations relating to dividend distribution </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The principal regulations governing distribution of dividends paid by wholly foreign-owned enterprises include: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Company Law of the PRC (1993), as amended in 1999, 2004, 2005 and 2013; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Foreign Investment Enterprise Law of the PRC (1986), as amended in 2000 and 2016; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Administrative Rules under the Foreign Investment Enterprise Law (1990), as amended in 2001 and 2014. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under these laws and regulations, foreign-invested enterprises in China may pay dividends only out of their accumulated profits, if any, determined in accordance
with PRC accounting standards and regulations. In addition, a wholly foreign-owned enterprise in China is required to set aside at least 10.0% of its <FONT STYLE="white-space:nowrap">after-tax</FONT> profit based on PRC accounting standards each
year to its general reserves until the accumulative amount of such reserves reach 50.0% of its registered capital. These reserves are not distributable as cash dividends. The foreign-invested enterprise has the discretion to allocate a portion of
its <FONT STYLE="white-space:nowrap">after-tax</FONT> profits to staff welfare and bonus funds. A PRC company is not permitted to distribute any profits until any losses from prior fiscal years have been offset. Profits retained from prior fiscal
years may be distributed together with distributable profits from the current fiscal year. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Regulations relating to foreign exchange </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The principal regulations governing foreign currency exchange in China are the Foreign Exchange Administration Regulations, most recently amended in August 2008.
Under the Foreign Exchange Administration Regulations, payments of current account items, such as profit distributions and trade and service-related foreign exchange transactions can be made in foreign currencies without prior approval from SAFE by
complying with certain procedural requirements. However, approval from or registration with appropriate government authorities is required where RMB is to be converted into foreign currency and remitted out of China to pay capital expenses such as
the repayment of foreign currency-denominated loans. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In August 2008, SAFE issued the Circular on the Relevant Operating Issues Concerning the
Improvement of the Administration of the Payment and Settlement of Foreign Currency Capital of Foreign-Invested Enterprises, or SAFE Circular No.&nbsp;142, regulating the conversion by a foreign-invested enterprise of foreign currency-registered
capital into RMB by restricting how the converted RMB may be used. SAFE Circular No.&nbsp;142 provides that the RMB capital converted from foreign currency registered capital of a foreign-invested enterprise may only be used for purposes within the
business scope approved by the applicable government authority and may not be used for equity investments within China. SAFE also strengthened its oversight of the flow and use of the RMB capital converted from foreign currency registered capital of
foreign-invested enterprises. The use of such RMB capital may not be changed without SAFE&#146;s approval, and such RMB capital may not in any case be used to repay RMB loans if the proceeds of such loans have not been used. In March 2015, SAFE
issued SAFE Circular No.&nbsp;19, which took effective and replaced SAFE Circular No.&nbsp;142 on June&nbsp;1, 2015. Although SAFE Circular No.&nbsp;19 allows for the use of RMB converted from the foreign currency-denominated capital for equity
investments in China, the restrictions continue to apply as to foreign-invested enterprises&#146; use of the converted RMB for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">175 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
purposes beyond the business scope, for entrusted loans or for inter-company RMB loans. SAFE promulgated the Notice of the State Administration of Foreign Exchange on Reforming and Standardizing
the Foreign Exchange Settlement Management Policy of Capital Account, or Circular 16, effective on June&nbsp;9, 2016, which reiterates some of the rules set forth in Circular 19, but changes the prohibition against using RMB capital converted from
foreign currency-denominated registered capital of a foreign-invested company to issue RMB entrusted loans to a prohibition against using such capital to issue loans to nonassociated enterprises. Violations of SAFE Circular 19 or Circular 16 could
result in administrative penalties. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2012, SAFE promulgated the Circular of Further Improving and Adjusting Foreign Exchange Administration
Policies on Foreign Direct Investment which substantially amends and simplifies the current foreign exchange procedure. Pursuant to this circular, the opening of various special purpose foreign exchange accounts (e.g.,
<FONT STYLE="white-space:nowrap">pre-establishment</FONT> expenses accounts, foreign exchange capital accounts and guarantee accounts), the reinvestment of lawful incomes derived by foreign investors in China (e.g. profit, proceeds of equity
transfer, capital reduction, liquidation and early repatriation of investment), and purchase and remittance of foreign exchange as a result of capital reduction, liquidation, early repatriation or share transfer in a foreign-invested enterprise no
longer require SAFE approval, and multiple capital accounts for the same entity may be opened in different provinces, which was not possible before. In addition, SAFE promulgated the Circular on Printing and Distributing the Provisions on Foreign
Exchange Administration over Domestic Direct Investment by Foreign Investors and the Supporting Documents in May 2013, which specifies that the administration by SAFE or its local branches over direct investment by foreign investors in the PRC shall
be conducted by way of registration and banks shall process foreign exchange business relating to the direct investment in China based on the registration information provided by SAFE and its branches. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In February 2015, SAFE promulgated the Circular on Further Simplifying and Improving the Policies Concerning Foreign Exchange Control on Direct Investment, or SAFE
Circular No.&nbsp;13, which took effect on June&nbsp;1, 2015. SAFE Circular No.&nbsp;13 delegates the authority to enforce the foreign exchange registration in connection with the inbound and outbound direct investment under relevant SAFE rules to
certain banks and therefore further simplifies the foreign exchange registration procedures for inbound and outbound direct investment. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Other PRC
national- and provincial-level laws and regulations </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are subject to changing regulations under many other laws and regulations administered by
governmental authorities at the national, provincial and municipal levels, some of which are or may become applicable to our business. For example, regulations control the confidentiality of patients&#146; medical information and the circumstances
under which patient medical information may be released for inclusion in our databases, or released by us to third parties. These laws and regulations governing both the disclosure and the use of confidential patient medical information may become
more restrictive in the future. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We also comply with numerous additional national and provincial laws relating to matters such as safe working
conditions, manufacturing practices, environmental protection and fire hazard control. We believe that we are currently in compliance with these laws and regulations; however, we may be required to incur significant costs to comply with these laws
and regulations in the future. Unanticipated changes in existing regulatory requirements or adoption of new requirements could therefore have a material adverse effect on our business, results of operations and financial condition. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">176 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_13"></A>Management </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Our executive officers and directors </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Below is a list of our directors and executive officers as of the date of
this prospectus, as well as a brief account of the business experience of each of them: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Age</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Position(s)</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Executive Officers</B></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ying (Samantha) Du</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Director, Chairman and Chief executive officer</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Qi Liu</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Chief medical officer, oncology</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Harald Reinhart</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Chief medical officer, autoimmune and infectious diseases</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ning Xu</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Executive vice president, clinical operations and regulatory affairs</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">James Yan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Executive vice president, head of early development and drug safety</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">Non-Management</FONT> Directors</B></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Nisa Leung</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Peter Wirth</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Director; Senior Advisor</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Marietta Wu</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Jianming Yu</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">John Diekman</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Tao Fu</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="7"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Other Key Employees</B></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Minghui Chen</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Vice president, government and regulatory affairs</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Xiaopeng (Tom) Feng</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Vice president, finance</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Jonathan Wang</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Vice president, head of business development</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Bo Zhang</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Senior vice president, chemistry, manufacturing and controls</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Scientific Advisors</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Richard A. Flavell</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">71</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Scientific Advisor</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Gwen Fyfe</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Scientific Advisor</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Neal Rosen</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Scientific Advisor</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="7" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">177 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Executive officers </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Ying (</I><I>Samantha) Du</I>, Ph.D., <FONT STYLE="white-space:nowrap">co-founded</FONT> our company and has been our director, chairman and chief executive officer since our inception. Prior to founding our
company, Dr.&nbsp;Du spent two years as managing director of healthcare investments at Sequoia Capital China, where she led four investments. From 2001 to 2011, Dr.&nbsp;Du was founder and chief executive officer of Hutchison Medi-Pharma and the <FONT
STYLE="white-space:nowrap">co-founder</FONT> and chief scientific officer of Hutchison China MediTech Limited, a Nasdaq-listed biopharmaceutical company, where she pioneered China-based global biopharmaceutical innovation by bringing five
internally-discovered innovative drug candidates into clinical trials, including two global Phase III ready drug candidates. Dr.&nbsp;Du began her career with Pfizer in the United States in 1994, where she was involved in the development and launch
of two global drugs. While at Pfizer, she was responsible for Pfizer&#146;s global metabolic licensing program on the scientific side. She received a Ph.D. in biochemistry from the University of Cincinnati. Dr.&nbsp;Du has also been involved with
and chaired several Chinese regulatory and government related committees. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Qi Liu</I>, M.D., Ph.D. has been our chief medical officer, oncology since
2015. Prior to joining our company, Dr.&nbsp;Liu was the clinical head of the BioVenture group at AstraZeneca and the executive medical director of AstraZeneca Oncology, where she played an important role in establishing AstraZeneca&#146;s biologics
joint ventures and was responsible for its joint venture global clinical development programs and regulatory strategy and submissions. She also played a key role in the TKI development program. Prior to joining AstraZeneca, Dr.&nbsp;Liu was an
assistant professor at the MD Anderson Cancer Center. Dr.&nbsp;Liu received a medical degree from Shanghai Medical University (currently known as Shanghai Medical College of Fudan University) and a Ph.D. in molecular genetics from the University of
Georgia. She completed a post-doctoral fellowship at Memorial Sloan Kettering Cancer Center and a medical oncology and hematology fellowship at the MD Anderson Cancer Center with board certifications in internal medicine, medical oncology and
hematology. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Harald Reinhart</I>, M.D., has been our chief medical officer, autoimmune and infectious diseases since 2017. He is currently adjunct
clinical professor of infectious diseases at the Yale School of Medicine. Prior to joining our company, in 2012, Dr.&nbsp;Reinhart joined Shionogi US as head of Clinical Development and Medical Affairs, where he directed a broad portfolio of
antibiotics, diabetes, allergy and pain medications, as well as guided a pharmaceutical product through NDA submission and approval. Between 2003 and 2011, Dr.&nbsp;Reinhart held senior roles at Novartis, where he oversaw successful filings of SNDAs
and NDAs for Coartem, Famvir, Sebivo, and Cubicin, managed clinical development groups for transplantation, renal disease and immunity, and supervised the transitioning of projects from research into clinics. Dr.&nbsp;Reinhart received a medical
degree from the University of W&uuml;rzburg in Germany. He completed his medical specialty training in the United States with board-certifications in internal medicine and infectious diseases. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Ning Xu</I>, M.D., has been our executive vice president, clinical operations and regulatory affairs since 2014. Prior to joining our company, he served as vice president, head of clinical development service at
Covance China. Before joining Covance, Dr.&nbsp;Xu served as a senior medical and regulatory affairs executive at Johnson&nbsp;&amp; Johnson and GlaxoSmithKline. Dr.&nbsp;Xu received a medical degree from Peking Union Medical College and a master of
business administration from the University of Illinois at Chicago. Dr. Xu also completed a postdoctoral fellowship at the Medical School, University of lllinois at Chicago. Between 2011 and 2015, he was the chairman of the Advisory Council of DIA
China and a director of DIA Global. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>James Yan</I>, Ph.D., has been our executive vice president and head of pre-clinical development and drug safety
since 2015. Prior to joining our company, Dr.&nbsp;Yan was the head of the Covance early development Shanghai site, where he was responsible for all aspects of the business. Between 2009 and 2011, Dr.&nbsp;Yan served as the head of drug safety
evaluation and program management of Hutchison Medi-Pharma. Prior to Hutchison Medi-Pharma, Dr. Yan had significant experience at Pfizer in the United States. Over the course of his career, Dr.&nbsp;Yan was been involved in many IND and NDA filings
for multiple drug candidates and gained substantial experience working </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">178 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
with regulatory agencies in several countries. Dr.&nbsp;Yan received a Ph.D. from Peking Union Medical University and completed post-doctoral training at the University of Chicago&#146;s <FONT
STYLE="white-space:nowrap">Ben-May</FONT> Institute for Cancer Research. He is a diplomat of the American Board of Toxicology, a council member of the China Society of Toxicology and a member of the Drug Toxicity and Drug Safety Evaluation
Committee. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-management</FONT> directors </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Nisa Leung </I>has been our independent director since 2014. Ms.&nbsp;Leung is a Managing Partner at Qiming Venture Partners, where she leads its health care investments. In addition to serving on our board of
directors, Ms.&nbsp;Leung is also a member of the board of directors of Berry Genomics, a biotechnology company that provides prenatal genetic testing; CanSino Biotechnology, a vaccine developer; dMed, a Shanghai-based CRO consulting startup;
Gan&nbsp;&amp; Lee Pharmaceuticals, a developer of insulin analog; Nurotron Biotechnology, a developer of neurostimulation systems; and Venus Medtech, a developer of interventional artificial cardiac valve systems. Ms.&nbsp;Leung received a master
of business administration from the Stanford Graduate School of Business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Peter Wirth</I> has been our director since 2017 and has been our senior
advisor since 2015. He is chairman of FORMA Therapeutics Holdings LLC, a small molecule drug discovery company; executive chairman of ZappRx, a digital health care company; chair of the board of directors at Syros Pharmaceuticals, a Nasdaq-listed
biopharmaceutical company; and director of Aura Biosciences, Inc., a biopharmaceutical company. From 2011 to 2014, Mr.&nbsp;Wirth served as president and director of Lysosomal Therapeutics, Inc., a biopharmaceutical company focused on small molecule
research. From 1996 to 2011, Mr.&nbsp;Wirth served as a senior executive at Genzyme, which is now part of Sanofi, and most recently as its executive vice president of legal and corporate development, chief risk officer and corporate secretary.
During the last five years, Mr.&nbsp;Wirth also served as a director of Synageva BioPharma Corp., a biopharmaceutical company which is now owned by Nasdaq-listed Alexion Pharmaceuticals. Mr.&nbsp;Wirth received a law degree from Harvard Law School.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Marietta Wu</I>, M.D., Ph.D., <FONT STYLE="white-space:nowrap">co-founded</FONT> our company, has been our director since 2014 and served as our
chief operating officer from 2014 to 2017. She also serves as a director of JING Medicine Technology (Shanghai) Ltd., Qiagen (Suzhou) Translational Medicine Co., Ltd. and Kira Pharmaceuticals (Hong Kong) Limited. Prior to founding our company, Dr.
Wu served as general manager of greater China and later managing director of Burrill&nbsp;&amp; Company, or Burrill, where she led Burrill&#146;s operation in greater China and focused on venture capital investing in China and Taiwan related to life
science opportunities. Prior to joining Burrill, Dr. Wu was director of strategy at Edwards Lifesciences. From 2009 to 2010, Dr. Wu also served as acting chief operating officer of Waterstone Pharmaceuticals, a specialty pharmaceutical company with
key operations in China. She also held various financial and business development positions at Eli Lilly&nbsp;&amp; Company. Dr.&nbsp;Wu received her medical degree from Shanghai Jiaotong University School of Medicine, a Ph.D. in Medical Sciences
from Medical College of Ohio and a master of business administration from the University of Michigan Ross School of Business. Dr. Wu is a founding member of the China Healthcare Investment Conference. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Jianming Yu</I>, Ph.D., has been our director since 2016. Dr.&nbsp;Yu is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of New Horizon Capital and has been
its managing partner and chief executive officer since its inception in 2005. Dr.&nbsp;Yu also founded Advantech Capital, a growth fund specializing in innovative technologies and healthcare, and has served as its managing partner since 2015. In
addition, Dr. Yu is founder and managing partner of Redview Capital, a private equity fund with focus on consumer products and services, advanced manufacturing, and new energy sectors. Dr.&nbsp;Yu received a master of business administration from
Kellogg School of Management, Northwestern University, and a Ph.D. in biology from Harvard University. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>John D. Diekman</I>, Ph.D., has been our
independent director since 2017. Dr. Diekman is founding partner of 5AM Ventures, where he has served since 2002. He is chairman of the board of directors of IDEAYA Biosciences, Inc., </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">179 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
an oncology-focused biotechnology company; director of Igenica Biotherapeutics, Inc., a developer of antibody-based oncology treatments; director of Wildcat Discovery Technologies, Inc., a
technology company that discovers materials for energy storage applications; charter trustee of Princeton University; chairman of the board of directors of The Scripps Research Institute; and a member of the advisory board of the Schaeffer Center
for Health Policy and Economics at the University of Southern California. During the last five years, Dr.&nbsp;Diekman also served as director of Calibrium LLC, a biopharmaceutical research company focused on diabetes and other metabolic diseases;
Cellular Research, Inc., a single-cell genomics startup; and PhaseRx Inc., a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children. Dr. Diekman holds an A.B. in Organic Chemistry from
Princeton University and a Ph.D. in Chemistry from Stanford University. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Tao Fu</I> has been our independent director since 2017. He is currently
executive vice president, chief commercial and business officer of Portola Pharmaceuticals, Inc., a publicly traded biotechnology company specializing in cardiovascular disease, hematological disorders and cancer. In this role, Mr. Fu leads
Portola&#146;s commercial operations, marketing, sales and business development functions. Prior to joining Portola in June 2015, Mr. Fu was vice president, business development, head of M&amp;A and alliance management at BMS. Mr. Fu led all
M&amp;A, divestiture, strategic transaction and venture investment opportunities as well as alliance management for BMS. Between 2003 and 2015, Mr. Fu worked at Johnson &amp; Johnson in a number of roles, most recently as vice president, business
development, where he was responsible for global M&amp;A activities in the pharmaceutical sector. Prior to joining Johnson &amp; Johnson, Mr. Fu held managerial positions with Scios Inc., a biotechnology company in California; McKinsey &amp;
Company, a global management consulting firm; and Becton Dickinson, a leading medical device company. Mr. Fu received a master of science in cell biology from the University of Rochester, and a master of business administration in finance and
marketing from Vanderbilt University. Mr. Fu did his undergraduate studies in biology at Tsinghua University and is a Chartered Financial Analyst (CFA). </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Other key employees and advisors </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Minghui Chen</I>
has been our vice president, government and regulatory affairs since 2017. Prior to joining our company, he was senior director at a subsidiary of Wuxi Apptec. From 2012 to 2013, he was vice president at Cenova Ventures. From 2008 to 2011, he was
head of regulatory affairs at Hutchison Medi-Pharma, where he maintained a highly successful track record of leading new drug submissions and obtaining fast approvals through the green channel. Mr. Chen also had significant experience working in the
regulatory affairs department at AstraZeneca in China prior to joining Hutchison Medi-Pharma. Mr.&nbsp;Chen received a bachelor of science in pharmacology from Fudan University Medical School. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Xiaopeng (Tom) Feng</I> has been our vice president, finance since 2017. Prior to joining our company, Mr.&nbsp;Feng was the financial director of Ascletis Bioscience Limited, where he was responsible for
financial reporting and management. From 2012 to 2015, Mr.&nbsp;Feng served as financial controller of GMT Shipping Nigeria. From 2002 to 2011, Mr.&nbsp;Feng served as financial director in various subsidiaries of Hutchison China MediTech Limited.
Mr.&nbsp;Feng received a bachelor of economics from Fudan University. He is a member of CICPA and a fellow member of the FCCA. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Jonathan Wang</I> has
been our vice president, head of business development since 2014. Prior to joining our company, Mr.&nbsp;Wang was an investment professional at OrbiMed, where he was responsible for China healthcare investment and portfolio management. From 2005 to
2011, Mr.&nbsp;Wang worked as a consultant at the Boston Consulting Group in China, where he specialized in pharmaceutical and healthcare engagements, assisting multinational and local companies with their China strategy. Previously, Mr.&nbsp;Wang
also gained financial transactional experience at Goldman Sachs Investment Banking. Mr.&nbsp;Wang received a master of business administration in healthcare management from Wharton Business School. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">180 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Bo Zhang</I> has been our senior vice president, chemistry, manufacturing and controls since 2014. Prior to joining
our company, Dr. Zhang was a director of the nature product business unit at GlaxoSmithKline, where he was responsible for chemistry, manufacturing and controls development. From 2010 to 2013, Dr. Zhang served as senior director of Hutchison
Medi-Pharma, where he was responsible for chemistry, manufacturing and controls development. Before returning to China, Dr. Zhang had significant experience at Pfizer in the United States. Dr.&nbsp;Zhang received a Ph.D. in analytical chemistry from
Iowa State University and a masters degree in chemical fibers from Sichuan University. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Richard A. Flavell</I>, Ph.D., FRS, has served on our
scientific advisory board since 2017. Since 2002, Dr.&nbsp;Flavell has been the Sterling Professor of Immunobiology at Yale University School of Medicine. Prior to joining the Yale faculty in 1988, Dr.&nbsp;Flavell was the President and Chief
Scientific Officer of Biogen Research Corporation. Dr.&nbsp;Flavell received a Ph.D. in biochemistry from the University of Hull, England, and performed postdoctoral work in Amsterdam and Zurich. He is an Investigator of the Howard Hughes Medical
Institute, a fellow of the Royal Society, a member of the National Academy of Sciences, and a member of the Institute of Medicine of the National Academies. He has published over 800 papers and has received many awards, including the Invitrogen
Meritorious Career Award from the American Association of Immunologists. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2"><I>Gwen Fyfe</I>, M.D., has served on our scientific
advisory board since 2016. Since 2009, Dr.&nbsp;Fyfe has been a consultant for venture capital firms and for a variety of biotechnology companies. From 1997 to 2009, Dr.&nbsp;Fyfe held various positions with Genentech Inc. (now a member of the Roche
Group), including Vice President, Oncology Development and Vice President, Avastin Franchise Team, as well as the honorary title of Senior Staff Scientist. Dr.&nbsp;Fyfe played an important role in the development of Genentech&#146;s approved
oncology agents including Rituxan<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, Herceptin<FONT STYLE="font-family:arial" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>, Avastin<FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>&nbsp;and Tarceva<FONT
STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT>. From 1990 to 1997, Dr.&nbsp;Fyfe was Medical Director at Chiron Therapeutics. Dr.&nbsp;Fyfe currently serves as a director of
Array Biopharma, Inc., Cascadian Therapeutics and Molecular Partners AG and previously served as a director of Infinity Pharmaceuticals, Inc. Dr.&nbsp;Fyfe received a medical degree from Washington University and is a board-certified pediatric
oncologist. She has been an invited member of Institute of Medicine panels, National Cancer Institute working groups and grant committees and American Society of Clinical Oncologists oversight committees. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Neal Rosen</I>, M.D., Ph.D. has served on our scientific advisory board since 2016. Dr.&nbsp;Rosen is a Member of the Department of Medicine and a Member of the
Molecular Pharmacology and Chemistry Program at Memorial Sloan Kettering Cancer Center, where he serves as Head of Developmental Therapeutics. He is also a Professor of Pharmacology, Cell Biology and Medicine at Cornell University Medical School. He
has played an important role in the development of tyrosine kinase-mediated signaling inhibitors and has pioneered the concept that cancer cells are dependent on cellular machinery for protein folding. Dr.&nbsp;Rosen received a medical degree and a
Ph.D. in Molecular Biology from the Albert Einstein College of Medicine. He completed a residency in Internal Medicine at the Brigham and Women&#146;s Hospital and post-doctoral training and a fellowship in Medical Oncology at the National Cancer
Institute, where he served on the senior staff prior to joining the faculty of Memorial Sloan Kettering Cancer Center. He was the recipient of the NIH/NCI Outstanding Investigator Award in 2016. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Foreign private issuer status </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The NASDAQ Stock Market
listing rules include certain accommodations in the corporate governance requirements that allow foreign private issuers, such as us, to follow &#147;home country&#148; corporate governance practices in lieu of the otherwise applicable corporate
governance standards of the Nasdaq Stock Market. The application of such exceptions requires that we disclose each noncompliance with the Nasdaq listing rules that we do not follow and describe the Cayman Islands corporate governance practices we do
follow in lieu of the relevant NASDAQ Stock Market corporate governance standard. When our ADSs are listed on the Nasdaq Global </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">181 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Market, we intend to continue to follow Cayman Islands corporate governance practices in lieu of the corporate governance requirements of the Nasdaq Stock Market in respect of the following:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the majority independent director requirement under Section 5605(b)(1) of the NASDAQ Stock Market listing rules; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the requirement under Section 5605(d) of the NASDAQ Stock Market listing rules that a compensation committee comprised solely of independent directors governed
by a compensation committee charter oversee executive compensation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the requirement under Section 5605(e) of the NASDAQ Stock Market listing rules that director nominees be selected or recommended for selection by either a
majority of the independent directors or a nominations committee comprised solely of independent directors; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the requirement under Section 5605(b)(2) of the NASDAQ Stock Market listing rules that the independent directors have regularly scheduled meetings with only the
independent directors present. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Cayman Islands law does not impose a requirement that the board consist of a majority of independent
directors or that such independent directors meet regularly without other members present. Nor does Cayman Islands law impose specific requirements on the establishment of a compensation committee or nominating committee or nominating process.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Code of ethics and corporate governance guidelines </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Prior to the completion of this offering, we will adopt a code of ethics, which will be applicable to all of our directors, executive officers and employees. Following the completion of this offering we will make
our code of ethics publicly available on our website. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, prior to the completion of this offering, we will adopt a set of corporate governance
guidelines covering a variety of matters, including approval of related party transactions. The guidelines will reflect certain guiding principles with respect to our board&#146;s structure, procedures and committees. The guidelines are not intended
to change or interpret any applicable law, rule or regulation or our amended articles of association. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Board of directors </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Composition of our board </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Upon consummation of this
offering, our articles of association will provide that the size of our board of directors will be determined from time to time by resolution of our board of directors. Following the completion of this offering, we anticipate that our board of
directors will consist of&nbsp;seven directors,&nbsp;of whom we expect three to qualify as independent directors under the rules and regulations of the SEC and Nasdaq Stock Market. Prior to the completion of this offering, we will complete our
review of the composition of our board of directors and its committees and the independence of each director. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Duties of directors
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under Cayman Islands law, all of our directors owe us fiduciary duties, including a duty of loyalty, a duty to act honestly and a duty to act in
good faith and in a manner they believe to be in our best interests. Our directors also have a duty to exercise the skill they actually possess and such care and diligence that a reasonably prudent person would exercise in comparable circumstances.
In fulfilling their duty of care to us, our directors must ensure compliance with our amended articles of association, as amended and restated from time to time. We have the right to seek damages if a duty owed by any of our directors is breached.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">182 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Board committees </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Audit committee </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our audit committee consists of Tao Fu, John Diekman and Marietta Wu, with Mr. Fu serving as
chairman of the committee. We have determined that Mr. Fu qualifies as a financial expert as set forth under the applicable rules of the SEC and that Mr. Fu and Dr. Diekman each satisfies the independence requirements under the rules of the Nasdaq
Stock Market and under Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> of the Exchange Act. Within one year following the effective date of the registration statement of which this prospectus forms a part, we anticipate that the audit committee
will consist exclusively of independent directors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The audit committee oversees our accounting and financial reporting processes and the audits of our
financial statements. Our audit committee is responsible for, among other things: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">selecting, and evaluating the qualifications, performance and independence of, the independent auditor; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">approving or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving</FONT> auditing and <FONT STYLE="white-space:nowrap">non-auditing</FONT> services
permitted to be performed by the independent auditor; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">considering the adequacy of our internal accounting controls and audit procedures; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reviewing with the independent auditor any audit problems or difficulties and management&#146;s response; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reviewing and approving related party transactions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reviewing and discussing the annual audited financial statements with management and the independent auditor; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">establishing procedures for the receipt, retention and treatment of complaints received from our employees regarding accounting, internal accounting controls or
auditing matters and the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">meeting separately, periodically, with management, internal auditors and the independent auditor; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reporting regularly to the full board of directors. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Compensation committee </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our compensation committee consists of Peter Wirth, Jianming Yu and Nisa Leung, with
Mr. Wirth serving as chairman of the committee. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our compensation committee will be responsible for, among other things: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reviewing, evaluating and, if necessary, revising our overall compensation policies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reviewing and evaluating the performance of our directors and executive officers and determining the compensation of our executive officers;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">reviewing and approving our executive officers&#146; employment agreements with us; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">183 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">determining performance targets for our executive officers with respect to our incentive compensation plan and equity-based compensation plans;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">administering our equity-based compensation plans in accordance with the terms thereof; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">carrying out such other matters that are specifically delegated to the compensation committee. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Nominating and corporate governance committee </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our
nominating and corporate governance committee consists of Samantha Du, Jianming Yu and Nisa Leung, with Ms. Du serving as chairman of the committee. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our
nominating and corporate governance committee will be responsible for, among other things: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">selecting the board nominees for election by the shareholders or appointment by the board; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">periodically reviewing with the board the current composition of the board with regards to characteristics such as independence, knowledge, skills, experience
and diversity; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">making recommendations on the frequency and structure of board meetings and monitoring the functioning of the committees of the board; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">advising the board periodically with regards to significant developments in corporate governance law and practices as well as our compliance with applicable laws
and regulations, and making recommendations to the board on corporate governance matters. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Scientific advisory board
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The members of our scientific advisory board provide scientific, portfolio and project strategy advice to the company, including the evaluation of
licensing arrangements and research and development strategies. The members of our scientific advisory board receive cash compensation, as well as stock options subject to a three-year time-vesting schedule, as compensation for their service to the
company. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Employment arrangements with our executive officers </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have entered into employment agreements with each of our executive officers and our directors (other than our <FONT STYLE="white-space:nowrap">non-executive</FONT> directors) (together, the &#147;executive
officers&#148;). All of our executive officers are employed by both of our Hong Kong subsidiary, Zai Lab (Hong Kong) Limited, and our Shanghai subsidiary, Zai Lab (Shanghai) Co., Ltd., except Dr. Reinhart, who is employed only by Zai Lab (Hong Kong)
Limited. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Employment agreements with executive officers at Zai Lab (Hong Kong) Limited </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the terms of the Zai Lab (Hong Kong) Limited employment agreements, except with respect to the main founder Dr. Du, we may terminate an executive
officer&#146;s employment with Zai Lab (Hong Kong) Limited at any time, with or without &#147;cause,&#148; by giving such executive officer a notice of termination. Dr. Du&#146;s employment may not be terminated except as expressly provided in her
employment agreement, which does not include a termination without &#147;cause.&#148; In the event of a voluntary termination other than for &#147;good reason&#148; or termination by the company for cause, the executive officer will receive the
unpaid portion of the base salary, computed pro rata to the date of termination, plus reimbursement for unpaid business expenses (&#147;accrued compensation&#148;). In the event of a termination without &#147;cause,&#148; as applicable, or a
resignation of the executive officer for &#147;good reason,&#148; the executive officer will receive the accrued compensation, plus, except for Dr. Du, a separation benefit consisting of either one or three months&#146; base pay (18 months in the
case of Dr. Du) and fringe benefits depending on service (the &#147;severance period&#148;) plus any additional compensation that may be required by applicable law. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">184 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For purposes of the employment agreements, &#147;cause&#148; means (1) the executive officer&#146;s repeated
drunkenness or use of illegal drugs which adversely interferes with the performance of the executive officer&#146;s obligations and duties in the company; (2)&nbsp;the conviction of a felony, or any crime involving fraud or misrepresentation or
violation of applicable securities laws; (3)&nbsp;the executive officer&#146;s gross mismanagement of the business and affairs of the company or of its subsidiaries that directly results in a material loss to the company and for which the company
has reasonable proof was committed by the executive officer; (4)&nbsp;material violation of any terms of the employment agreement or the restrictive covenants agreement between the executive officer and the company; or (5)&nbsp;a conclusive finding
by an independent fact finder appointed by the board of directors for any willful misconduct, dishonesty or acts of moral turpitude by the executive, which is materially detrimental to the interests and well-being of the Company, including, without
limitation harm to its business or reputation. In addition, for this purpose, &#147;good reason&#148; means (1)&nbsp;any material diminution of the executive officer&#146;s duties or responsibilities (except in connection with a termination for
cause, or by reason of death or &#147;disability&#148;) or an assignment of duties or responsibilities that are materially inconsistent with the executive officer&#146;s position, (2) any material breach of the employment agreement by the company
which is not cured within ten (10)&nbsp;business days after written notice is given to the company, or (3)&nbsp;except in the case of Dr. Reinhart, relocation of the executive officer&#146;s original employment location, without consent, to a
location more than thirty (30)&nbsp;kilometers from the original employment location, other than temporary relocations of no longer than six (6)&nbsp;calendar months. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In the event of termination of employment by reason of death or disability, the executive officer except for Dr.&nbsp;Du is entitled to receive the accrued compensation, a payment equal to one month&#146;s base
salary and fringe benefits, plus any other additional compensation required by law. For purposes of the employment agreement, &#147;disability&#148; means the executive officer is incapacitated or disabled by accident, sickness or otherwise, so as
to render him or her unable to mentally or physically incapable of performing the services under the employment agreement for a period of ninety (90)&nbsp;or more consecutive days, or for ninety (90)&nbsp;days during any six (6)&nbsp;month period.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a condition to receiving payments during an applicable severance period, the executive officer must execute a release of claims that is satisfactory
to the Company. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each executive officer has generally agreed to assign to us or our designee all rights and titles to any inventions created while he or
she is performing services within the scope of employment with us or utilizing our facilities. Each executive officer has also agreed, during his or her employment with us and thereafter, not to use, disclose or transfer any confidential information
of our company other than as authorized by us within the scope of his or her duties. Moreover, each of our executive officers has agreed to execute the company&#146;s compliance agreement regarding confidentiality, trade secrets, intellectual
property and competitive activities, which subjects the executive to certain restrictive covenant obligations, including an agreement by the executive, for the term of his or her employment with us at Zai Lab (Hong Kong) Limited and for a period of
one to two years thereafter, not to (i)&nbsp;directly or indirectly, compete with our business within any country where we conduct or, at the time of his or her employment, are actively engaged in planning to conduct, our business or
(ii)&nbsp;solicit for any employees of our company or orders from any person, firm or company which was at any time during the 12&nbsp;months prior to termination of such employment a customer or supplier of our company, or to modify its business
relationship with our company in a manner adverse thereto. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Employment agreements with executive officers at Zai Lab (Shanghai) Co., Ltd.
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Executive officers working for Zai Labs (Shanghai), except Dr.&nbsp;Reinhart, are party to a service agreement with Zai Lab (Shanghai). Zai Lab
(Shanghai) employment agreements, except Dr. Du&#146;s agreement, provide that we engage each executive officer on a fixed term. We provide labor protection and work conditions that comply </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">185 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
with the safety and sanitation requirements stipulated by the relevant PRC laws. Relevant executive officers (except non-PRC nationals) and the company contribute to statutory social insurance
and other benefits. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During any probation period, we may immediately terminate an executive&#146;s employment agreement without payment of severance or
other liability if the executive fails to meet the company&#146;s recruiting requirements. Outside any probation period, we may terminate an executive officer&#146;s employment with Zai Lab (Shanghai) Co., Ltd. by providing the executive with 30
days&#146; notice or one month&#146;s base salary in lieu of such notice and a severance benefit in accordance with local law if (i)&nbsp;the executive is ill or suffers any injury that is not work-related, and fails to perform the original work
after the prescribed treatment period or fails to perform other work arranged by the company; (ii)&nbsp;the executive is not qualified for the job, and still fails to be qualified for the job after training is given or the position is adjusted;
(iii)&nbsp;there is a significant change to the objective circumstances on which this contract is based, resulting in the failure to perform this contract, and after the consultations by both parties, no agreement can be reached in respect of the
modification of the content of this contract; (iv)&nbsp;the company needs to terminate employees during any reorganization to avoid bankruptcy, or because it experiences serious difficulties in production or operation; and (iv)&nbsp;other
circumstances prescribed by PRC laws or regulation. In addition, we may terminate the executive&#146;s employment without notice or payment if the executive (i)&nbsp;seriously or continuously violates, or violates several times the employment rules
and policies of the company; (ii)&nbsp;commits serious dereliction in the performance of his or her duties, or practices graft, or engages in malpractice to seek private benefit, as applicable, in either case causing severe damage to the interests
of the company; (iii)&nbsp;commits fraud or uses coercive measures or takes advantage of the company&#146;s vulnerability to make it enter into this contract or to make amendments thereto against the company&#146;s will; (iv)&nbsp;is prosecuted for
criminal liability, or, except for Dr. Du and Dr. Xu, is subject to <FONT STYLE="white-space:nowrap">re-education</FONT> through labor in accordance with law; or (v)&nbsp;may be terminated as otherwise permitted by PRC laws. The executive officer
may voluntarily terminate his or her contract without cause with 30 days&#146; prior notice to us. The executive officer, except for Dr. Du and Dr. Xu, may also terminate employment immediately without notice if the company engages in certain
actions, including, among other things, directing the executive to perform tasks that are unsafe. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each executive officer has agreed to comply with our
rules and policies regarding confidentiality and, during his or her employment with us and thereafter, not to use or disclose any confidential information of our company other than as authorized by us within the scope of his or her duties. Moreover,
each of our executive officers has agreed that for a certain period of time after his or her employment with us at Zai Lab (Shanghai) Co., Ltd., he or she will not (i)&nbsp;work for another company or individual that is in competition with us or
(ii)&nbsp;manufacture any product or operate any business which is in competition with us. Each of Dr. Du and Dr. Xu are entitled to receive monthly compensation during their 24-month non-compete period in an amount equal to 30% of their respective
average monthly salaries received during the 12 months immediately preceding the termination of their employment. In addition, each of Dr. Du and Dr. Xu have agreed that, during employment and within one year after the termination thereof, certain
&#147;work for hire,&#148; as defined in the agreements, shall belong to the company. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, we have been advised by our PRC counsel, Zhong Lun
Law Firm, that notwithstanding any provision to the contrary in our employment agreements at Zai Lab (Shanghai) Co., Ltd., we may still be required to make severance payments upon termination without Cause to comply with the PRC labor laws and other
relevant PRC regulations, which entitle employees to severance payments in case of early termination. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Compensation of directors and executive
officers </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the year ended December&nbsp;31, 2016, we paid aggregate salaries, bonuses and benefits (excluding equity-based grants) of approximately
$1.4&nbsp;million to our executive officers. Executive officers are eligible to receive an </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">186 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
annual incentive bonus, as determined by our board of directors, based on achievement of <FONT STYLE="white-space:nowrap">pre-established</FONT> individual, departmental and company performance
goals. We do not separately set aside any amounts for pensions, retirement or other benefits for our executive officers, other than pursuant to relevant statutory requirements, and, in the case of executives who are not PRC citizens, health and life
insurance. In the year ended December 31, 2016, we did not pay any compensation to our <FONT STYLE="white-space:nowrap">non-executive</FONT> directors, except that Mr.&nbsp;Wirth received a cash retainer for his service as a senior advisor. For
information regarding equity-based grants to our executive officers and directors, see &#147;&#151;Equity incentive plans.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Equity incentive
plans </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>2015 Plan</I></B><I></I> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our
shareholders originally adopted an equity incentive plan in September 2014, and it was subsequently superseded and replaced in its entirety by a plan approved by our shareholders in August 2015. We refer to this equity incentive plan, as amended
from time to time, as our 2015 Plan. We believe the equity-based incentives provided in our 2015 Plan are vital to attract and retain the best available personnel for positions by providing incentives to our directors, employees and consultants to
promote the success of our business. In connection with this offering, our board of directors has adopted and our shareholders have approved the Zai Lab Limited 2017 Equity Incentive Plan, which is described below. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following describes the material terms of our 2015 Plan. This summary is not a complete description of all provisions of the 2015 Plan and is qualified in its
entirety by reference to such plan, which is filed as an exhibit to the registration statement of which this prospectus is a part. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Administration</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>Our board of directors is responsible for administering our 2015 Plan. As the plan administrator, our
board of directors has the authority to, among other things, determine eligibility for awards to be granted, determine the size, terms and conditions of the awards, accelerate the vesting of or waive any restrictions applicable to the awards,
interpret the terms and provisions of the 2015 Plan, and make all other determinations as it deems necessary or advisable to administer the 2015 Plan. The board of directors&#146; decisions with respect to the 2015 Plan and any awards made under
such plan are binding upon all participants. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Eligibility</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>Under the 2015 Plan, awards may be granted to a
director, employee or consultant of our company and subsidiaries, as applicable. Options intended to qualify as &#147;incentive stock options&#148; under U.S. law may only be granted to an employee of our company or subsidiaries, as applicable.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Authorized shares</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>Subject to certain adjustments for stock splits, reorganizations, mergers,
consolidations, <FONT STYLE="white-space:nowrap">split-up,</FONT> and other changes in our corporate structure, the maximum number of ordinary shares that may be issued pursuant to the awards granted under the 2015 Plan is 7,369,767. If an award
expires or becomes unexercisable without being exercised in full, or is forfeited or repurchased due to a failure to vest, the unpurchased shares subject to such awards will again become available for grant under the 2015 Plan. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Types of awards</I></B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp;The 2015 Plan provides for awards of stock options, share appreciation rights, restricted shares and
restricted share units (the latter, &#147;RSUs&#148;). </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Stock options</I>.&nbsp;&nbsp;&nbsp;&nbsp;The exercise price for our ordinary shares to be issued pursuant to the exercise of stock options granted under the
2015 Plan is determined by our board of directors on the date of such grant, provided that such exercise price shall not be less than the fair market value of our ordinary shares on the date of such grant (110% in the case of incentive stock
options), which will be determined by our board of directors in good faith. To exercise a vested award, the participant must submit a notice of exercise and full payment of the exercise price and applicable tax withholding in a form permitted under
the plan. The term of each option may not extend beyond ten (10)&nbsp;years from the grant date. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">187 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Share appreciation rights</I>.&nbsp;&nbsp;&nbsp;&nbsp;The exercise price used to determine the amount payable to a participant receiving share appreciation
rights under the 2015 Plan is determined by our board of directors, provided that such price my not be less than the fair market value of our ordinary shares on the date of such grant. Upon exercising of a vested share appreciation right, such
participant is entitled to receive from us an amount equal to the difference between the fair market value of our ordinary share on the date of exercise over the exercise price, multiplied by the number of ordinary shares with respect to which such
share appreciation right is exercised. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Restricted shares</I>.&nbsp;&nbsp;&nbsp;&nbsp;A restricted share granted under the 2015 Plan is subject to forfeiture, transfer restrictions and other
restrictions during a certain period of restriction as determined by our board of directors. We keep any restricted shares granted under the 2015 Plan in escrow on behalf of the participants receiving such grant until the end of the applicable
period of restriction, unless our board of directors decides to accelerate the time at which such restrictions will lapse or be removed. During the restriction period, participants holding shares of restricted stock will be entitled to receive
dividends and distributions paid with respect to such shares under the administrator determines otherwise. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>RSUs</I>.&nbsp;&nbsp;&nbsp;&nbsp;A RSU granted under the 2015 Plan entitles a participant receiving such grant to a payment in the form of cash, our ordinary
shares or a combination of both upon the future vesting of such RSU. The form of payment and vesting conditions are determined by our board of directors. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Award agreements</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;Each award granted under the 2015 Plan will be evidenced by an award agreement providing for the number of ordinary shares subject to such award, restrictions
and such other terms and conditions as our board of directors determines in its sole discretion. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Vesting schedule; termination of
employment</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;Awards granted under the 2015 Plan are subject to vesting schedules as specified by the relevant award agreements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In the event of a plan participant&#146;s termination of his or her employment with us other than for Cause, the ordinary shares that are not vested on the date of termination or unexercised will revert to the
company and be available for grant under our 2015 Plan. In the event of a participant&#146;s termination for Cause, ordinary shares covered by any stock option under our 2015 Plan, whether vested or not, will revert to the company and be available
for new or additional grants to participants. In addition, in the event of a participant&#146;s termination, voluntary or involuntary, we have the right to repurchase any unvested restricted shares at par value per ordinary share. A stock option
must be exercised within thirty (30)&nbsp;days of employment termination (or such longer period specified in the award), but before the option&#146;s term expires. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-transferability</FONT> of awards</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>Awards granted under our 2015 Plan may not be transferred other than by will or by the laws of
descent or distribution and may only be exercised by the relevant participant receiving such award. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Change of
control</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;If a merger or change of control of our company occurs, each outstanding award under the 2015 Plan may be treated in the following ways (or any combination of such ways) as our board determines in its sole
discretion: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">assumed or substituted by the acquiring or succeeding corporation (or an affiliate thereof) with appropriate adjustments as to the number and type of shares and
prices; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">terminated upon or immediately prior to the consummation of such merger or change in control upon written notice to participants; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">vested and become exercisable, realizable or payable, or restrictions deemed lapsed, in whole or in part; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">terminated in exchange for cash and/or property or replaced with other rights or property. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">188 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For this purpose a &#147;change of control&#148; will occur if any one person, or more than one person acting as a
group, (together, a &#147;person&#148;) acquires ownership of the company&#146;s stock that, together with the stock held by such person constitutes more than 50% of the total voting power of the company&#146;s stock, excluding any change in stock
ownership resulting from a private financing of the company approved by the company&#146;s board of directors. A change of control may also occur if, while the company has a class of securities registered pursuant to Section 12 of the Securities
Exchange Act of 1934, as amended, a majority of the members of our board of directors is replaced during any twelve month period by directors whose appointment was not endorsed by a majority of our board of directors at the time of such appointment.
In addition, a change of control will occur if any person acquires (or has acquired during the 12 months ending on the date of the most recent acquisition by such person) assets from the company that have a total gross fair market value equal to or
more than 50% of the total gross fair market value of all assets of the company immediately prior to such acquisition. Gross fair market value of the assets is determined without regard to any liabilities associates with the assets. Changes in the
company&#146;s place of incorporation, or for the sole purpose of creating a holding company owned in substantially the same proportions by the persons who held the company&#146;s securities immediate before the transaction is not a change of
control under the 2015 Plan. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Term</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>Unless earlier terminated, our 2015 Plan has a term of ten years.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Amendment and termination</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>Our board of directors may at any time amend, suspend or terminate the 2015 Plan.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>2017 Equity incentive plan</I></B> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection
with this offering, our board of directors has adopted and our shareholders have approved the Zai Lab Limited 2017 Equity Incentive Plan (the &#147;2017 Equity Plan&#148;), and, in connection with and following this offering, all equity-based awards
will be granted under our 2017 Equity Plan. The following summary describes the material terms of our 2017 Equity Plan. This summary is not a complete description of all provisions of our 2017 Equity Plan and is qualified in its entirety by
reference to our 2017 Equity Plan, which is filed as an exhibit to the registration statement of which this prospectus is a part. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Purposes</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;The purposes of our 2017 Equity Plan are to attract, retain and reward key employees and directors of, and
consultants and advisors to, the Company and its subsidiaries, to incentivize them to generate shareholder value, to enable them to participate in the growth of the Company and to align their interests with the interests of our shareholders.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Administration.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Our 2017 Equity Plan will be administered by our compensation committee, which will have the
discretionary authority to interpret our 2017 Equity Plan, determine eligibility for and grant awards, determine, modify and waive the terms and conditions of any award, determine the form of settlement of awards, designate whether an award will be
over, or with respect to, ordinary shares or ADSs, prescribe forms, rules and procedures relating to our 2017 Equity Plan and awards and otherwise do all things necessary or desirable to carry out the purposes of our 2017 Equity Plan. Our
compensation committee may delegate such of its duties, powers and responsibilities as it may determine to one or more of its members, members of our board of directors and, to the extent permitted by law, officers of the Company, and may delegate
to employees and other persons such ministerial tasks as it deems appropriate. As used in this summary, the term &#147;Administrator&#148; refers to our compensation committee and its authorized delegates, as applicable. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Eligibility.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Key employees, directors, consultants and advisors of the Company and its subsidiaries are eligible to participate
in our 2017 Equity Plan. Eligibility for stock options intended to be incentive stock options, or ISOs, is limited to employees of the Company or certain affiliates. Eligibility for stock options, other than ISOs, and stock appreciation rights, or
SARs, is limited to individuals who are providing direct services on the date of grant of the award to the Company or certain affiliates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">189 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Authorized shares.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to adjustment as described below, the maximum number
of shares that may be delivered in satisfaction of awards under our 2017 Equity Plan is 1,924,327 shares, plus an annual increase, to be added as of January 1st of each year from January&nbsp;1, 2018, to January&nbsp;1, 2027, equal to the lesser of
(i)&nbsp;four percent (4%) of the number of shares outstanding as of the close of business on the immediately preceding December 31st; and (ii)&nbsp;the number of shares determined by our board of directors on or prior to such date for such year.
For purposes of our 2017 Equity Plan, &#147;share&#148; means a share of our common stock (an &#147;ordinary share&#148;), unless there are ADSs representing ordinary shares available, in which case &#147;share&#148; means the number of ADSs equal
to an ordinary share. If the ratio of ADSs to ordinary shares is not 1:1, then (a)&nbsp;the maximum number of shares that may be delivered under our 2017 Equity Plan, (b)&nbsp;all award adjustments made pursuant to our 2017 Equity Plan; and
(c)&nbsp;all awards designated as awards over ordinary shares will automatically be adjusted to reflect the ratio of the ADSs to ordinary shares, as reasonably determined by the Administrator. Up to the total number of shares available for awards
under the plan may be delivered in satisfaction of ISOs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Subject to applicable laws, shares delivered under our 2017 Equity Plan may be newly issued
ordinary shares, previously issued ordinary shares acquired by us or ADSs. Any shares underlying awards that are settled or that expire, become unexercisable, terminate or are forfeited or repurchased by us, in each case without the delivery of
shares, will again be available for issuance under our 2017 Equity Plan. In addition, the number of shares delivered in satisfaction of awards will be determined net of shares withheld by us in payment of the exercise price or purchase price of an
award or in satisfaction of tax withholding requirements with respect to an award. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Individual limits.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The maximum
number of shares subject to share options that may be granted to any participant in our 2017 Equity Plan in any calendar year is 577,298 shares and the maximum number of shares subject to SARs that may be granted to any participant in any calendar
year is 288,649 shares. The maximum number of shares subject to awards other than share options and SARs that may be granted to any participant in any calendar year is 288,649 shares. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Director limits.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;In addition to the individual limits described above, the maximum grant date fair value of awards granted under our 2017 Equity Plan to any <FONT
STYLE="white-space:nowrap">non-employee</FONT> director of the Company in respect of his or her service as a director with respect to any calendar year may not exceed $500,000, assuming maximum payout. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Types of awards.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Our 2017 Equity Plan provides for the grant of share options, SARs, restricted and unrestricted shares and
share units, performance awards, and other awards that are convertible into or otherwise based on our shares. Dividend equivalents may also be provided in connection with awards under our 2017 Equity Plan. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Stock options and SARs.</I>&nbsp;&nbsp;&nbsp;&nbsp; The Administrator may grant share options, including ISOs, and SARs. A share option is a right entitling
the holder to acquire shares upon payment of the applicable exercise price. A SAR is a right entitling the holder upon exercise to receive an amount (payable in cash or shares of equivalent value) equal to the excess of the fair market value of the
shares subject to the right over the base value from which appreciation is measured. The exercise price of each share option, and the base value of each SAR, granted under our 2017 Equity Plan shall be no less than 100% of the fair market value of a
share on the date of grant (110% in the case of certain ISOs). Other than in connection with certain corporate transactions or changes to our capital structure, share options and SARs granted under our 2017 Equity Plan may not be repriced or
substituted for with new share options or SARs having a lower exercise price or base value, nor may any consideration be paid upon the cancellation of any share options or SARs that have a per share exercise or base price greater than the fair
market value of a share on the date of such cancellation, in each case, without shareholder approval. Each share option and SAR will have a maximum term of not more than ten years from the date of grant (or five years, in the case of certain ISOs).
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">190 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Restricted and unrestricted shares and share units.</I>&nbsp;&nbsp;&nbsp;&nbsp; The Administrator may grant awards of shares, share units, restricted shares
and restricted share units. A share unit is an unfunded and unsecured promise, denominated in shares, to deliver shares or cash measured by the value of shares in the future, and a restricted share unit is a share unit that is subject to the
satisfaction of specified performance or other vesting conditions. Restricted shares are shares that are subject to restrictions requiring that they be redelivered or offered for sale to the Company if specified conditions are not satisfied.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Performance awards.</I>&nbsp;&nbsp;&nbsp;&nbsp; The Administrator may grant performance awards, which are awards subject to performance criteria. The
Administrator may grant performance awards that are intended to qualify as exempt performance-based compensation under Section&nbsp;162(m), to the extent applicable, and awards that are not intended to so qualify. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Other stock-based awards.</I>&nbsp;&nbsp;&nbsp;&nbsp; The Administrator may grant other awards that are convertible into or otherwise based on shares, subject
to such terms and conditions as it determines. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>Substitute awards.</I>&nbsp;&nbsp;&nbsp;&nbsp; The Administrator may grant substitute awards, which may have terms and conditions that are inconsistent with
the terms and conditions of our 2017 Equity Plan. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Vesting; terms of awards.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator
determines the terms of all awards granted under our 2017 Equity Plan, including the time or times an award vests or becomes exercisable, the terms on which an award remains exercisable, and the effect of termination of a participant&#146;s
employment or service on an award. The Administrator may at any time accelerate the vesting or exercisability of an award. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Transferability of
awards.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Except as the Administrator may otherwise determine, awards may not be transferred other than by will or by the laws of descent and distribution. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Performance criteria.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Our 2017 Equity Plan provides for grants of performance awards subject to &#147;performance criteria.&#148; Performance criteria with respect to those
awards that are intended to qualify as &#147;performance-based compensation&#148; for purposes of Section&nbsp;162(m) are limited to objectively determinable measures of performance relating to any, or any combination of, the following (measured
either absolutely or comparatively (including, without limitation, by reference to an index or indices or the performance of one or more companies) and determined either on a consolidated basis or, as the context permits, on a divisional,
subsidiary, line of business, project or geographical basis or in combinations thereof and subject to such adjustments, if any, as the Administrator specifies, consistent with the requirements of Section&nbsp;162(m) of the Code, to the extent
applicable): sales; revenues; assets; expenses; earnings before or after deduction for all or any portion of interest, taxes, depreciation, or amortization, whether or not on a continuing operations or an aggregate or per share basis; return on
equity, investment, capital or assets; one or more operating ratios; borrowing levels, leverage ratios or credit rating; market share; capital expenditures; cash flow; share or ADS price; shareholder return; sales of particular products or services;
customer acquisition or retention; acquisitions and divestitures (in whole or in part); joint ventures and strategic alliances; spin-offs, <FONT STYLE="white-space:nowrap">split-ups</FONT> and the like; reorganizations; recapitalizations,
restructurings, financings (issuance of debt or equity) or refinancings; or strategic business criteria, consisting of one or more objectives including meeting specified market penetration or value added, product development or introduction
(including, without limitation any clinical trial accomplishments, regulatory or other filings or approvals, or other product development milestones), geographic business expansion, cost targets, cost reductions or savings, customer satisfaction,
operating efficiency, acquisition or retention, employee satisfaction, information technology, corporate development (including, without limitation, licenses, innovation, research or establishment of third-party collaborations), manufacturing or
process development, legal compliance or risk reduction, patent application or issuance goals. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">191 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To the extent consistent with the requirements of the performance-based compensation exception under
Section&nbsp;162(m) of the Code, the Administrator may provide in the case of any award intended to qualify for such exception that one or more of the performance criteria applicable to such award will be adjusted in an objectively determinable
manner to reflect events (for example, but without limitation, acquisitions or dispositions) occurring during the performance period that affect the applicable performance criteria. During a transition period following the completion of this
offering, the Administrator may grant awards under our 2017 Equity Plan that are exempt from Section&nbsp;162(m) of the Code and its requirements under a special transition rule. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Effect of certain transactions.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;In the event of certain covered transactions (including the consummation of a merger, consolidation, or the sale of substantially all of the
Company&#146;s assets or shares, a change in ownership of the Company&#146;s shares, or the dissolution or liquidation of the Company), the Administrator may, with respect to outstanding awards, provide for (in each case, on such terms and subject
to such conditions as it deems appropriate): </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The assumption, substitution or continuation of some or all awards (or any portion thereof) by the acquirer or surviving entity; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The acceleration of exercisability or delivery of shares in respect of any award, in full or in part; and/or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The cash payment in respect of some or all awards (or any portion thereof) equal to the difference between the fair market value of the shares subject to the
award and its exercise or base price, if any. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Except as the Administrator may otherwise determine, each award will automatically
terminate immediately upon the consummation of the covered transaction, other than awards that are substituted for or assumed. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Adjustment
provisions.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;In the event of certain corporate transactions, including an extraordinary cash dividend, share dividend, share split or combination of shares (including a reverse share split), recapitalization or other
change in our capital structure, the Administrator shall make appropriate adjustments to the maximum number of shares that may be issued under our 2017 Equity Plan, the individual award limits, the number and kind of securities subject to, and, if
applicable, the exercise or purchase prices (or base values) of, outstanding awards, and any other provisions affected by such event. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Clawback.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator may provide that any outstanding award or the proceeds of any award or shares acquired thereunder
will be subject to forfeiture and disgorgement to the Company if the participant to whom the award was granted violates a <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT>
confidentiality or other restrictive covenant or to the extent provided in any applicable Company policy that provides for forfeiture or disgorgement, or as otherwise required by law or applicable stock exchange listing standards. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Amendments and termination.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator may at any time amend our 2017 Equity Plan or any outstanding award and may at
any time terminate our 2017 Equity Plan as to future grants. However, except as expressly provided in our 2017 Equity Plan, the Administrator may not alter the terms of an award so as to materially and adversely affect a participant&#146;s rights
without the participant&#146;s consent (unless the Administrator expressly reserved the right to do so at the time the award was granted). Any amendments to our 2017 Equity Plan will be conditioned on shareholder approval to the extent required by
law or applicable stock exchange requirements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with this offering, we expect to grant an option to Mr.&nbsp;Reinhart to purchase 100,000
ordinary shares under our 2017 Equity Plan. The exercise price for such option will be the initial public offering price set forth in this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">192 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Outstanding awards</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;As of June 30, 2017, there were 6,448,415 shares of our
company subject to awards made under the 2015 Plan. The following table summarizes, as of that date, the outstanding share options and restricted shares held by our directors and executive officers, as well as by their affiliates, under the 2015
Plan. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Ordinary&nbsp;shares*<BR>underlying<BR>outstanding<BR>awards,
which<BR>represent<BR>options unless<BR>otherwise<BR>indicated</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Purchase<BR>price<BR>($/share)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exercise<BR>price<BR>($/share)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Date of grant(1)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="4"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Samantha Du</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">216,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">March 5,&nbsp;2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,739,166</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">October&nbsp;22, 2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">604,376</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">March&nbsp;9, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">922,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">August&nbsp;25, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Qi Liu</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">333,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">October&nbsp;22,&nbsp;2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">August&nbsp;25, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Harald Reinhart</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">66,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">May 12, 2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">James Yan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">333,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">October&nbsp;22, 2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">83,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">August&nbsp;25, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ning Xu</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">211,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">March 5, 2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">450,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">October&nbsp;22, 2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Marietta Wu</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">48,611</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">March&nbsp;5,&nbsp;2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(2)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">60,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">October&nbsp;22,&nbsp;2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(2)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">US$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">March&nbsp;9,&nbsp;2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(2)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Peter Wirth</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">166,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">August 10, 2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">58,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">July 15, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">75,000</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">August 25, 2016</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The share options and restricted shares in the aggregate held by each of these directors and executive officers and their affiliates represent less than 1% of our total
outstanding shares. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Options expire on or before the <FONT STYLE="white-space:nowrap">10-year</FONT> anniversary of the grant date. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Options expire on or before April 5, 2019. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents restricted shares. </FONT></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Other compensation programs
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>2017 Cash bonus plan</I></B> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In
connection with this offering, our board of directors has adopted and our shareholders have approved the Zai Lab Limited 2017 Cash Bonus Plan (our &#147;Cash Plan&#148;). Starting in calendar year 2018, annual award opportunities for executive
officers and key employees of the Company and its subsidiaries will be granted under our Cash Plan. The following summary describes the material terms of our Cash Plan. This summary is not a complete description of all provisions of our Cash Plan
and is qualified in its entirety by reference to our Cash Plan, which will be filed as an exhibit to the registration statement of which this prospectus is a part. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Administration.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Our Cash Plan will be administered by our compensation committee and its delegates. As used in this summary, the term &#147;Administrator&#148; refers to our
compensation committee and its authorized delegates, as applicable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">193 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Administrator will have the discretionary authority to interpret our Cash Plan, determine eligibility for and
grant awards, determine, modify or waive the terms and conditions of any award, prescribe forms, rules and procedures relating to our Cash Plan and awards, and otherwise do all things necessary or appropriate to carry out the purposes of our Cash
Plan. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Eligibility and participation.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Executive officers and key employees of the Company and its subsidiaries will
be eligible to participate in our Cash Plan and will be selected from time to time by the Administrator to participate in the plan. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Awards.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;For each award granted under our Cash Plan, the Administrator will establish the performance criteria applicable to the
award, the amount or amounts payable if the performance criteria are achieved and such other terms and conditions as the Administrator deems appropriate. Our Cash Plan permits the grant of awards that are intended to satisfy the requirements of the
performance-based compensation exception under Section&nbsp;162(m) of the Code, to the extent applicable, or Section&nbsp;162(m) Awards, and awards that are not intended to satisfy such requirements. For Section&nbsp;162(m) Awards, the terms of the
award will be established within the time periods required under Section&nbsp;162(m) of the Code. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Performance
criteria.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Awards under our Cash Plan will be made based on, and subject to achieving, specified criteria established by the Administrator. Performance criteria for Section&nbsp;162(m) Awards are limited to objectively
determinable measures of performance relating to any, or any combination of, the following (measured either absolutely or comparatively (including, without limitation, by reference to an index or indices or the performance of one or more companies)
and determined either on a consolidated basis or, as the context permits, on a divisional, subsidiary, line of business, project or geographical basis or in combinations thereof and subject to such adjustments, if any, as the Administrator
specifies, consistent with the requirements of Section&nbsp;162(m) of the Code, to the extent applicable): sales; revenues; assets; expenses; earnings before or after deduction for all or any portion of interest, taxes, depreciation, or
amortization, whether or not on a continuing operations or an aggregate or per share basis; return on equity, investment, capital or assets; one or more operating ratios; borrowing levels, leverage ratios or credit rating; market share; capital
expenditures; cash flow; share or ADS price; shareholder return; sales of particular products or services; customer acquisition or retention; acquisitions and divestitures (in whole or in part); joint ventures and strategic alliances; spin-offs, <FONT
STYLE="white-space:nowrap">split-ups</FONT> and the like; reorganizations; recapitalizations, restructurings, financings (issuance of debt or equity) or refinancings; or strategic business criteria, consisting of one or more objectives based on:
meeting specified market penetration or value added, product development or introduction (including, without limitation any clinical trial accomplishments, regulatory or other filings or approvals, or other product development milestones),
geographic business expansion, cost targets, cost reductions or savings, customer satisfaction, operating efficiency, acquisition or retention, employee satisfaction, information technology, corporate development (including, without limitation,
licenses, innovation, research or establishment of third-party collaborations), manufacturing or process development, legal compliance or risk reduction, patent application or issuance goals. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">To the extent consistent with the requirements of the performance-based compensation exception under Section&nbsp;162(m) of the Code, the Administrator may provide in the case of any award intended to qualify for
such exception that one or more of the performance criteria applicable to such award will be adjusted in an objectively determinable manner to reflect events (for example, but without limitation, acquisitions or dispositions) occurring during the
performance period that affect the applicable performance criteria. During a transition period following the completion of this offering, the Administrator may grant awards under our Cash Plan that are exempt from Section&nbsp;162(m) of the Code and
its requirements under a special transition rule. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Payments under an award; individual limits.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;A participant will be
entitled to payment under an award only if all conditions to payment have been satisfied in accordance with our Cash Plan and the terms of the award. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">194 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
Following the end of a performance period, the Administrator will determine (and, to the extent required by Section&nbsp;162(m) of the Code, take such steps to certify) whether and to what extent
the applicable performance criteria have been satisfied and will determine the amount payable under each award. The Administrator has the discretionary authority to increase or decrease the amount actually paid under any award, provided that the
actual payment of Section&nbsp;162(m) Awards may not be more than the amount indicated by the certified level of achievement. The maximum amount payable to any participant in any calendar year under Section&nbsp;162(m) Awards will be $5,000,000.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Recovery of compensation.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Payments in respect of an award will be subject to forfeiture and disgorgement to the
Company if the participant to whom the award was granted violates a <FONT STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality or other restrictive covenant or to the extent
provided in any applicable Company policy that provides for forfeiture or disgorgement, or as otherwise required by law or applicable stock exchange listing standards. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Amendment and termination.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator may amend or terminate our Cash Plan at any time, except that any amendment or termination that would materially and adversely
affect a participant&#146;s rights under an award will require the consent of the affected participant, unless the Administrator expressly reserved the right to so amend the award at the time of grant, and any amendment will be approved by our
stockholders if required by Section&nbsp;162(m) of the Code. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> director compensation policy
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with this offering, our board of directors has adopted a <FONT STYLE="white-space:nowrap">non-employee</FONT> director
compensation policy under which each member of our board of directors who is not an employee of the Company or one of our affiliates (each a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148;) will be eligible to receive an
annual cash retainer payment of $50,000. In addition, in connection with this offering, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who is appointed to our board of directors following the adoption of this policy and whose
appointment is effective prior to this offering, will be eligible to receive an award of 25,000 restricted shares under our 2017 Equity Plan, which will vest ratably on each of the first three anniversaries of the date of grant, subject to continued
service as a member of our board of directors through such date. Further, commencing in calendar year 2018, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will be eligible to receive an annual grant of 12,500 restricted shares under
our 2017 Equity Plan, which will vest in full on the first anniversary of the date of grant, subject to continued service as a member of our board of directors through such date. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy provides for the following additional annual cash retainer payments for the members and chairpersons of our board
committees: audit committee chair, $20,000; audit committee member, $10,000; compensation committee chair, $15,000; compensation committee member, $7,500; nominating committee chair, $10,000; and nominating committee member, $5,000. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">195 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_14"></A>Security ownership of beneficial owners and management </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We had 12,067,487 ordinary shares outstanding as of June 30, 2017. The following table and accompanying footnotes set forth information relating to the beneficial
ownership of our ordinary shares as of June 30, 2017 by: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding ordinary shares; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">each of our directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">each of our executive officers; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">all of our executive officers and directors as a group. </FONT></P></TD></TR></TABLE>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our major shareholders do not have voting rights that are different from our shareholders in general. The percentage of shares beneficially owned prior to this offering is computed on the basis of 40,510,762
ordinary shares as of June 30, 2017, which reflects the assumed conversion of all of our outstanding shares of preferred shares, at an assumed one to one conversion factor for our Series&nbsp;C preferred shares, into an aggregate of 28,443,275
ordinary shares. For a description of the conversion, upon the completion of this offering, of our Series&nbsp;C preferred shares into ordinary shares, see &#147;Series&nbsp;C conversion.&#148; Other than our Series&nbsp;C preferred shares, all of
our preferred shares convert into ordinary shares on a one to one basis. The percentage of shares beneficially owned after this offering includes 8,000,000 ordinary shares in the form of ADSs issued in connection with this offering, assuming the
underwriters do not exercise their option to purchase additional ADSs. </FONT></P>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Beneficial ownership is determined in accordance with the rules and
regulations of the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, we have included shares that the person has the right to acquire within 60 days, including through the exercise of
any option, warrant or other right or the conversion of any other security. These shares, however, are not included in the computation of the percentage ownership of any other person. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">196 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Ordinary shares</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>beneficially
owned</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>prior to</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>this offering</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Ordinary shares<BR>beneficially&nbsp;owned<BR>after this offering</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name of beneficial owner&#134;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Executive Officers and Directors:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Samantha Du(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,658,549</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20.8%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,658,569</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">17.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Qi Liu(2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">128,889</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">128,889</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ning Xu(3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">267,306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">267,306</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">James Yan(4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">138,889</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">138,889</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Marietta Wu(5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">133,611</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">133,611</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Peter Wirth(6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Nisa Leung</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Jianming Yu</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>All Executive Officers and Directors as a Group</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>9,627,244</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>22.8%</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>9,627,244</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>19.0%</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Beneficial Owners of 5% or More of our Ordinary Shares:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">QM 11 Limited(7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,237,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,237,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">20.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Maxway Investment Limited(8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,734,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">16.6%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,734,064</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">The Z Trust(9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,289,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.6%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,289,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Investment funds affiliated with Sequoia Capital(10)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,884,152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9.6%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,884,152</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7.7%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">KPCB China Fund II, L.P.(11)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,787,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9.3%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,787,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The person beneficially owns less than 1% of our outstanding ordinary shares. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&#134;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">The business address of all directors and officers is 4560 Jinke Road, Bldg. 1, 4F, Pudong, Shanghai, China 201210. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes 1,047,728 ordinary shares issuable to Dr. Du upon exercise of options within 60 days of June 30, 2017. Includes 6,267,488 ordinary shares held by certain holders of
ordinary shares, including Zai management and their affiliates. Although Dr. Du does not have any pecuniary interest in these ordinary shares, these shareholders have granted Dr. Du the right to vote their shares and, therefore, she may be deemed to
be the beneficial owner of the ordinary shares held by these shareholders. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes 128,889 ordinary shares issuable upon exercise of options within 60 days of June 30, 2017. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes 267,306 ordinary shares issuable upon exercise of options within 60 days of June 30, 2017. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(4)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes 138,889 ordinary shares issuable upon exercise of options within 60 days of June 30, 2017. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(5)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes 133,611 ordinary shares issuable upon exercise of vested options. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(6)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes 157,176 restricted ordinary shares which have vested or vest within 60 days of June 30, 2017. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(7)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Consists of (i) 8,958,838 ordinary shares issuable upon conversion of Series A preferred shares, (ii) 1,212,130 ordinary shares issuable upon conversion of Series B preferred
shares and (iii) 66,632 ordinary shares issuable upon conversion of Series C preferred shares. The address for QM 11 Limited is Unit 1904 Gloucester Tower, The Landmark, Central, Hong Kong. </FONT></TD></TR></TABLE>
<P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(8)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Consists of 6,734,064 ordinary shares issuable upon conversion of Series B preferred shares. The address for Maxway Investment Limited is c/o Intertrust Corporate Services
(Cayman) Limited, 190 Elgin Avenue, George Town, Grand Cayman, <FONT STYLE="white-space:nowrap">KY1-9005,</FONT> Cayman Islands. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(9)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Includes 133,264 ordinary shares issuable upon conversion of Series C preferred shares. The address for The Z Trust is 16015 Huebner BLF, San&nbsp;Antonio, Texas 78248-1469.
</FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(10)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Consists of (i) 2,986,278 ordinary shares issuable upon conversion of Series A preferred shares held by Sequoia Capital CV IV Holdco, Ltd. and (ii) 897,874 ordinary shares
issuable upon conversion of Series B preferred shares held by SCC Growth I Holdco A, Ltd. The address for Sequoia Capital CV IV Holdco, Ltd. and SCC Growth I Holdco A, Ltd. is Conyers Trust Company (Cayman) Limited, P.O. Box 2681, Cricket Square,
Hutchins Drive, P.O. Box 2681, Grand Cayman, KY1-1111, Cayman Islands. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(11)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Consists of 3,787,311 ordinary shares issuable upon conversion of Series A preferred shares. The address for KPCB China Fund II, L.P. is Scotia Centre, P.O. Box 268, George Town,
Grand Cayman <FONT STYLE="white-space:nowrap">KY1-1104,</FONT> Cayman Islands. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of June 30, 2017, we had 19 holders of record with
addresses in the United States, and such holders held approximately 14.8% of our outstanding ordinary shares in the aggregate, assuming the conversion of all of our outstanding shares of preferred shares into ordinary shares. None of the holders of
our ordinary shares will have different voting rights from other holders of ordinary shares after the closing of this offering. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">197 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_15"></A>Related party transactions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following is a description of related party transactions we have entered into since January&nbsp;1, 2014 with any members of our board of directors or executive officers and beneficial holders of more than 5%
of our ordinary shares: </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Agreements and transactions with shareholders </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Registration Rights Agreement </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have entered into a shareholders agreement in January 2016, or the
Registration Rights Agreement, with certain of our shareholders. The Registration Rights Agreement provides that certain holders of our ordinary shares have the right to demand that we file a registration statement or request that their ordinary
shares be covered by a registration statement that we are otherwise filing. The registration rights are described in more detail under &#147;Description of share capital&#151;Registration rights.&#148; All rights under the Registration Rights
Agreement, other than the registration rights, will terminate upon the closing of this offering. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Management rights letter </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have entered into a management rights letter, or the MRL, with Vivo Capital Fund VIII, L.P. and Vivo Capital Surplus Fund VIII, L.P., or collectively, Vivo
Capital, on June 26, 2017. The MRL provides Vivo Capital with certain contractual management rights (the &#147;Contractual Management Rights&#148;) solely to the extent necessary for its investment in our company to qualify as a &#147;venture
capital investment&#148; under United States law, including the rights to (i) consult with and advise our management on significant business issues, (ii) inspect our books and records and its facilities upon reasonable advance written request, and
(iii) receive all information and materials provided to our board of directors, other than any information or materials that are highly confidential or proprietary information. The Contractual Management Rights under the MRL will terminate upon the
closing of this offering. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Convertible loan agreements and shareholder private placements </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We entered into a (i) $500,000 convertible loan agreement with QM 11 Limited on March&nbsp;24, 2014, (ii) $1,000,000 convertible loan agreement with Sequoia Capital
CV IV Holdco, Ltd. on April&nbsp;17, 2014, and (iii) $500,000 convertible loan agreement with KPCB China Fund II, L.P. on March&nbsp;27, 2014. Each convertible loan agreement was converted into Series <FONT STYLE="white-space:nowrap">A-1</FONT>
Preferred Shares on August&nbsp;20, 2014. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On August&nbsp;20, 2014, we closed a private placement transaction pursuant to which we issued an aggregate of
8,466,665 Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares for an aggregate cash consideration of $8,028,572. The following table sets forth the number of shares of our Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred
shares that we issued to our 5% stockholders and their affiliates in this transaction: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Investor</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">Shares&nbsp;of&nbsp;Series&nbsp;A-1</FONT><BR>preferred
shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Purchase&nbsp;price&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">QM 11 Limited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(1)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,714,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">KPCB China Fund II, L.P.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,177,777</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(2)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">800,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Sequoia Capital CV IV Holdco, Ltd.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,666,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(3)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">714,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">555,556 of these Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Shares are issued pursuant to a convertible loan agreement converted from a principal amount of
$500,000. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(2)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">555,555 of these Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Shares are issued pursuant to a convertible loan agreement converted from a principal amount of
$500,000. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(3)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">1,111,111 of these Series <FONT STYLE="white-space:nowrap">A-1</FONT> Preferred Shares are issued pursuant to a convertible loan agreement converted from a principal amount of
$1,000,000. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">198 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On April&nbsp;30, 2015, we closed a private placement transaction pursuant to which we issued an aggregate of
9,619,975 Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shares for an aggregate consideration of $20,828,572 of which $5,300,000 was unpaid. The following table sets forth the number of shares of our Series <FONT
STYLE="white-space:nowrap">A-2</FONT> preferred shares that we issued to our 5% stockholders and their affiliates in this transaction: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Investor</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">Shares&nbsp;of&nbsp;Series&nbsp;A-2</FONT><BR>preferred
shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Purchase&nbsp;price&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">QM 11 Limited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,958,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,571,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">KPCB China Fund II, L.P.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,787,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(1)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Sequoia Capital CV IV Holdco, Ltd.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,319,612</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,857,143</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">On September&nbsp;30, 2015, we cancelled 1,177,754 of these Series <FONT STYLE="white-space:nowrap">A-2</FONT> Preferred Shares issued to KPCB China Fund II, L.P. and forgave the
$2,550,000.00 unpaid capital balance. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On January&nbsp;20, 2016, we closed a private placement transaction pursuant to which we sold an
aggregate of 5,562,335 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares for an aggregate consideration of $53,100,000. The following table sets forth the number of shares of our Series <FONT STYLE="white-space:nowrap">B-1</FONT>
preferred shares that we issued to our 5% stockholders and their affiliates in this transaction: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Investor</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">Shares&nbsp;of&nbsp;Series&nbsp;B-1</FONT><BR>preferred
shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Purchase&nbsp;price&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Maxway Investment Limited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,928,204</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">37,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">QM 11 Limited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">707,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,750,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">SCC Growth I HoldCo, Ltd.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">523,760</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On April&nbsp;1, 2016, we closed a private placement transaction pursuant to which we sold an aggregate of 3,973,096 Series <FONT
STYLE="white-space:nowrap">B-2</FONT> preferred shares for an aggregate consideration of $53,100,000. The following table sets forth the number of shares of our Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares that we issued to
our 5% stockholders and their affiliates in this transaction: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Investor</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B><FONT STYLE="white-space:nowrap">Shares&nbsp;of&nbsp;Series&nbsp;B-2</FONT><BR>preferred
shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Purchase&nbsp;price&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Maxway Investment Limited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,805,860</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">37,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">QM 11 Limited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">505,054</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,750,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">SCC Growth I Holdco, Ltd.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">374,114</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On June 26, 2017, we closed a private placement transaction pursuant to which we sold an aggregate of 1,998,958 of Series C
preferred shares for an aggregate consideration of $30,000,000. The following table sets forth the number of shares of our Series C preferred shares we issued to our 5% stockholders and their affiliates in this transaction: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Investor</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Shares&nbsp;of&nbsp;Series&nbsp;C<BR>preferred shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Purchase&nbsp;price&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">The Z Trust</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">133,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">QM 11 Limited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">66,632</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Other relationships </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Voting proxy </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain holders of Zai ordinary shares,
which hold 6,267,488 ordinary shares, have granted Dr. Du the right to vote their ordinary shares. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">199 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Quan Venture Partners I, L.L.C. </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Quan Venture Fund I, L.P., or Quan Fund, is a Cayman Islands exempted limited partnership organized in April 2017 to make capital investments in global public and private companies with a particular focus on the
healthcare industry.&nbsp;Quan Fund&#146;s general partner, which is responsible for investment and divestment decisions related to the Quan Fund, is Quan Venture Partners I, L.L.C., or Quan GP, a Cayman Islands limited liability company. Each of
Dr. Du and Marietta Wu are managers of Quan GP.&nbsp;In the first half of 2017, Zai sold its interest in three entities to the Quan Fund, for a total consideration of approximately $500,000. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Agreements with our directors and executive officers </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Employment agreements </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have entered into employment agreements with our executive officers. For more information regarding these agreements, see &#147;Management&#151;Employment
arrangements with our executive officers.&#148; </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Indemnification agreements </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In connection with this offering, we intend to enter into indemnification agreements with each of our directors and executive officers. We also maintain a general liability insurance policy which covers certain
liabilities of our directors and executive officers arising out of claims based on acts or omissions in their capabilities as directors or&nbsp;officers. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">200 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_16"></A>Description of share capital </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a Cayman Islands company and our affairs are governed by our memorandum and articles of association and the Companies Law. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our authorized share capital is $5,000.00 divided into ordinary shares and preferred shares. In respect of all of our ordinary shares and preferred shares we have
power insofar as is permitted by law, to redeem or purchase any of our shares and to increase or reduce the said capital subject to the provisions of the Companies Law and the articles of association and to issue any part of our capital, whether
original, redeemed or increased with or without any preference, priority or special privilege or subject to any postponement of rights or to any conditions or restrictions and so that unless the conditions of issue shall otherwise expressly declare
every issue of shares whether declared to be preference or otherwise shall be subject to the powers under our memorandum and articles of association. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As
of June 30, 2017 our authorized share capital consists of 56,428,239 Ordinary Shares of par value $0.00006 each, 8,466,667 Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred shares of par value $0.00006 each, 8,904,032 Series <FONT
STYLE="white-space:nowrap">A-2</FONT> preferred shares of par value $0.00006 each, 5,562,337 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares of par value $0.00006 each, 3,973,098 Series <FONT STYLE="white-space:nowrap">B-2</FONT>
preferred shares of par value $0.00006 each and 1,998,961 Series C preferred shares of par value $0.00006 each. As of June 30, 2017, there were 12,067,487 ordinary shares, 8,466,665 Series <FONT STYLE="white-space:nowrap">A-1</FONT> preferred
shares, 8,442,221 Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shares, 5,562,335 Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred shares, 3,973,096 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares
issued and outstanding and 1,998,958 Series C preferred shares issued and outstanding. All of our issued and outstanding convertible preferred shares will automatically convert into 28,520,436 ordinary shares concurrently with the completion of this
initial public offering. Following completion of this offering, our authorized capital will be $5,000.00 divided into 83,333,333 ordinary shares with a par value of $0.00006 per share. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our shareholders have adopted a fourth amended and restated memorandum and articles of association, which will become effective and replace the current third amended and restated memorandum and articles of
association in its entirety immediately upon the completion of this offering. We will issue ordinary shares represented by our ADSs in this offering. All options, regardless of grant dates, will entitle holders to an equivalent number of ordinary
shares once the vesting and exercising conditions are met. The following are summaries of material provisions of our post-offering amended and restated memorandum and articles of association and the Companies Law insofar as they relate to the
material terms of our ordinary shares that we expect will become effective upon the closing of this offering. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Ordinary shares </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>General.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Upon the completion of this offering, our authorized share capital will be $5,000.00 divided into 83,333,333 ordinary
shares, with a par value of $0.00006 each. Holders of ordinary shares will have the same rights except for voting and conversion rights. All of our outstanding ordinary shares are fully paid and
<FONT STYLE="white-space:nowrap">non-assessable.</FONT> Certificates representing the ordinary shares are issued in registered form. Our shareholders who are <FONT STYLE="white-space:nowrap">non-residents</FONT> of the Cayman Islands may freely hold
and transfer their ordinary shares. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Dividends.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The holders of our ordinary shares are entitled to such dividends as
may be declared by our board of directors. Our post-offering amended and restated articles of association provide that dividends may be declared and paid out of our profits, realized or unrealized, or from any reserve set aside from profits which
our board of directors determine is no longer needed. Dividends may also be declared and paid out of share premium account or any other fund or account which can be authorized for this purpose in accordance with the Companies Law. Holders of
ordinary shares will be entitled to the same amount of dividends, if declared. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Voting rights.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;In respect of all
matters subject to a shareholders&#146; vote, each ordinary share is entitled to one vote. Voting at any meeting of shareholders is by show of hands unless a poll is demanded. A poll may be </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">201 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
demanded by the chairman of such meeting or any one or more shareholders present in person or by proxy and who together hold not less than 10% of the nominal value of the total issued voting
shares of our company. Each holder of our ordinary shares is entitled to have one vote for each ordinary share registered in his or her name on our register of members. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">A quorum required for a meeting of shareholders consists of one or more shareholders who hold at least <FONT STYLE="white-space:nowrap">one-third</FONT> of all voting power of our share capital in issue at the date
of the meeting present in person or by proxy or, if a corporation or other <FONT STYLE="white-space:nowrap">non-natural</FONT> person, by its duly authorized representative. Shareholders&#146; meetings may be held annually. Each general meeting,
other than an annual general meeting, shall be an extraordinary general meeting. Extraordinary general meetings may be called by a majority of our board of directors or our chairman or upon a requisition of shareholders holding at the date of
deposit of the requisition not less than <FONT STYLE="white-space:nowrap">one-third</FONT> of the aggregate voting power of our company. Advance notice of at least seven days is required for the convening of our annual general meeting and other
general meetings unless such notice is waived in accordance with our articles of association. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">An ordinary resolution to be passed at a meeting by the
shareholders requires the affirmative vote of a simple majority of the votes attaching to all issued and outstanding shares cast at a meeting, while a special resolution also requires the affirmative vote of no less than <FONT
STYLE="white-space:nowrap">two-thirds</FONT> of the votes cast attaching to the issued and outstanding shares at a meeting. A special resolution will be required for important matters such as a change of name or making changes to our post-offering
amended and restated memorandum and articles of association. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Transfer of ordinary shares.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Subject to the
restrictions set out below, any of our shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or common form or any other form approved by our board of directors. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our board of directors may, in its absolute discretion, decline to register any transfer of any ordinary share which is not fully paid up or on which we have a
lien. Our board of directors may also decline to register any transfer of any ordinary share unless: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it relates and such other evidence as our board of
directors may reasonably require to show the right of the transferor to make the transfer; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the instrument of transfer is in respect of only one class of ordinary shares; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the instrument of transfer is properly stamped, if required; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">in the case of a transfer to joint holders, the number of joint holders to whom the ordinary share is to be transferred does not exceed four;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the shares are free from any lien in favor of the Company; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a fee of such maximum sum as the Nasdaq Stock Market may determine to be payable or such lesser sum as our directors may from time to time require is paid to us
in respect thereof. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If our directors refuse to register a transfer they shall, within two months after the date on which the
instrument of transfer was lodged, send to each of the transferor and the transferee notice of such refusal. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The registration of transfers may, on 14
days&#146; notice being given by advertisement in one or more newspapers or by electronic means, be suspended and the register closed at such times and for such periods as our board of directors may from time to time determine, provided, however,
that the registration of transfers shall not be suspended nor the register closed for more than 30 days in any year. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">202 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Liquidation.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;On a return of capital on winding up or otherwise (other than on
conversion, redemption or purchase of ordinary shares), assets available for distribution among the holders of ordinary shares shall be distributed by a liquidator who may divide our assets for distribution among our shareholders in his discretion.
The liquidator also may vest all or part of our assets in trust. None of our shareholders may be compelled to accept any shares subject to liability. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Calls on ordinary shares and forfeiture of ordinary shares.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may from time to time make calls upon
shareholders for any amounts unpaid on their ordinary shares in a notice served to such shareholders at least 14 clear days prior to the specified time of payment. The ordinary shares that have been called upon and remain unpaid are subject to
forfeiture. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Redemption of ordinary shares.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The Companies Law and our post-offering amended and restated articles of
association permit us to purchase our own shares. In accordance with our post-offering amended and restated articles of association and provided the necessary shareholders or board approval have been obtained, we may issue shares on terms that are
subject to redemption, at our option or at the option of the holders of these shares, on such terms and in such manner, including out of capital, as may be determined by our board of directors. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Variations of rights of shares.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;All or any of the special rights attached to any class of shares may, subject to the provisions
of the Companies Law, be varied with the written consent of the holders of a majority of the issued shares of that class or with the sanction of a special resolution passed at a general meeting of the holders of the shares of that class. The rights
conferred upon the holders of the shares of any class issued shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking <I>pari
passu</I> with such existing class of shares. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Inspection of books and records.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Holders of our ordinary shares have
no general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our corporate records. However, we will provide our shareholders with annual audited financial statements. See &#147;Where you can find additional
information.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Issuance of additional shares.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Our post-offering amended and restated memorandum of association
authorizes our board of directors to issue additional ordinary shares from time to time as our board of directors shall determine, to the extent of available authorized but unissued shares. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our post-offering amended and restated memorandum of association also authorizes our board of directors to establish from time to time one or more series of preferred shares and to determine, with respect to any
series of preferred shares, the terms and rights of that series, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the designation of the series; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the number of shares of the series; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the dividend rights, dividend rates, conversion rights, voting rights; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the rights and terms of redemption and liquidation preferences. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Our board of directors may issue preferred shares without action by our shareholders to the extent authorized but unissued. Issuance of these shares may dilute the voting power of holders of ordinary shares.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Anti-Takeover provisions.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Some provisions of our post-offering amended and restated memorandum and articles of
association may discourage, delay or prevent a change of control of our company or management that shareholders may consider favorable, including provisions that authorize our board of directors to issue preferred shares in one or more series and to
designate the price, rights, preferences, privileges and restrictions of such preferred shares without any further vote or action by our shareholders. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Exempted company.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We are an exempted company with limited liability under the Companies Law. The Companies Law distinguishes
between ordinary resident companies and exempted companies. Any company </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">203 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are
essentially the same as for an ordinary company except that an exempted company: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">does not have to file an annual return of its shareholders with the Registrar of Companies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">is not required to open its register of members for inspection; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">does not have to hold an annual general meeting; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">may issue negotiable or bearer shares or shares with no par value; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 20 years in the first instance);
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">may register as a limited duration company; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">may register as a segregated portfolio company. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&#147;Limited liability&#148; means that the liability of each shareholder is limited to the amount unpaid by the shareholder on the shares of the company.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Differences in corporate law </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Companies Law
is modeled after that of English law but does not follow many recent English law statutory enactments. In addition, the Companies Law differs from laws applicable to United States corporations and their shareholders. Set forth below is a summary of
the significant differences between the provisions of the Companies Law applicable to us and the laws applicable to companies incorporated in the State of Delaware. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Mergers and similar arrangements.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;A merger of two or more constituent companies under Cayman Islands law requires a plan of merger or consolidation to be approved by the
directors of each constituent company and authorization by (i)&nbsp;a special resolution of the shareholders and (ii)&nbsp;such other authorization, if any, as may be specified in such constituent company&#146;s articles of association. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A merger between a Cayman parent company and its Cayman subsidiary or subsidiaries does not require authorization by a resolution of shareholders of that Cayman
subsidiary if a copy of the plan of merger is given to every member of that Cayman subsidiary to be merged unless that member agrees otherwise. For this purpose, a subsidiary is a company of which at least 90% of the issued shares entitled to vote
are owned by the parent company. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The consent of each holder of a fixed or floating security interest over a constituent company is required unless this
requirement is waived by a court in the Cayman Islands. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Save in certain circumstances, a dissentient shareholder of a Cayman constituent company is
entitled to payment of the fair value of his shares upon dissenting to a merger or consolidation. The exercise of appraisal rights will preclude the exercise of any other rights save for the right to seek relief on the grounds that the merger or
consolidation is void or unlawful. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, there are statutory provisions that facilitate the reconstruction and amalgamation of companies,
provided that the arrangement is approved by a majority in number of each class of shareholders and creditors with whom the arrangement is to be made, and who must in addition represent three-fourths in value of each such class of shareholders or
creditors, as the case may be, that are present and voting either in person or by </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">204 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
proxy at a meeting, or meetings, convened for that purpose. The convening of the meetings and subsequently the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a
dissenting shareholder has the right to express to the court the view that the transaction ought not to be approved, the court can be expected to approve the arrangement if it determines that: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the statutory provisions as to the required majority vote have been met; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the shareholders have been fairly represented at the meeting in question and the statutory majority are acting bona fide without coercion of the minority to
promote interests adverse to those of the class; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the arrangement is such that may be reasonably approved by an intelligent and honest man of that class acting in respect of his interest; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the arrangement is not one that would more properly be sanctioned under some other provision of the Companies Law. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">When a takeover offer is made and accepted by holders of 90% of the shares within four months, the offeror may, within a
<FONT STYLE="white-space:nowrap">two-month</FONT> period commencing on the expiration of such four month period, require the holders of the remaining shares to transfer such shares on the terms of the offer. An objection can be made to the Grand
Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless there is evidence of fraud, bad faith or collusion. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If an arrangement and reconstruction is thus approved, the dissenting shareholder would have no rights comparable to appraisal rights, which would otherwise ordinarily be available to dissenting shareholders of
Delaware corporations, providing rights to receive payment in cash for the judicially determined value of the shares. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Shareholders&#146;
suits.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;In principle, we will normally be the proper plaintiff and as a general rule a derivative action may not be brought by a minority shareholder. However, based on English authorities, which would in all likelihood
be of persuasive authority in the Cayman Islands, there are exceptions to the foregoing principle, including when: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a company acts or proposes to act illegally or ultra vires; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the act complained of, although not ultra vires, could only be effected duly if authorized by more than a simple majority vote that has not been obtained; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">those who control the company are perpetrating a &#147;fraud on the minority.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Indemnification of directors and executive officers and limitation of liability.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Cayman Islands law does not limit the extent to which a company&#146;s memorandum and articles
of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the
consequences of committing a crime. Our post-offering amended and restated memorandum and articles of association permit indemnification of officers and directors for losses, damages, costs and expenses incurred in their capacities as such unless
such losses or damages arise from dishonesty or fraud of such directors or officers. This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation. In addition, we intend to enter
into indemnification agreements with our directors and executive officers that provide such persons with additional indemnification beyond that provided in our post-offering amended and restated memorandum and articles of association. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us under the
foregoing provisions, we have been informed that in the opinion of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">205 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>Directors&#146; fiduciary duties.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Under Delaware corporate law, a director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has
two components: the duty of care and the duty of loyalty. The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must
inform himself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director acts in a manner he reasonably believes to be in the best interests of
the corporation. He must not use his corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interest of the corporation and its shareholders take precedence over any interest
possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action
taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by a director, the director must prove
the procedural fairness of the transaction, and that the transaction was of fair value to the corporation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a matter of Cayman Islands law, a director
of a Cayman Islands company is in the position of a fiduciary with respect to the company and therefore it is considered that he or she owes the following duties to the company&#151;a duty to act bona fide in the best interests of the company, a
duty not to make a profit based on his or her position as director (unless the company permits him or her to do so) and a duty not to put himself or herself in a position where the interests of the company conflict with his or her personal interest
or his or her duty to a third party. A director of a Cayman Islands company owes to the company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance of his or her duties a greater degree
of skill than may reasonably be expected from a person of his or her knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these authorities are
likely to be followed in the Cayman Islands. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Shareholder action by written consent.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General
Corporation Law, a corporation may eliminate the right of shareholders to act by written consent by amendment to its certificate of incorporation. Cayman Islands law and our post-offering amended and restated articles of association provide that
shareholders may approve corporate matters by way of a unanimous written resolution signed by or on behalf of each shareholder who would have been entitled to vote on such matter at a general meeting without a meeting being held. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Shareholder proposals.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a shareholder has the right to put any proposal before the
annual meeting of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but
shareholders may be precluded from calling special meetings. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Cayman Islands law does not provide shareholders any right to put proposal before a meeting
or requisition a general meeting. However, these rights may be provided in articles of association. Our post-offering amended and restated articles of association allow our shareholders holding not less than
<FONT STYLE="white-space:nowrap">one-third</FONT> of all voting power of our share capital in issue to requisition a shareholders&#146; meeting. Other than this right to requisition a shareholders&#146; meeting, our post-offering amended and
restated articles of association do not provide our shareholders other right to put proposal before a meeting. As an exempted Cayman Islands company, we are not obliged by law to call shareholders&#146; annual general meetings. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Cumulative voting.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted
unless the corporation&#146;s certificate of incorporation specifically provides for it. Cumulative </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">206 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
voting potentially facilitates the representation of minority shareholders on a board of directors since it permits the minority shareholder to cast all the votes to which the shareholder is
entitled on a single director, which increases the shareholders&#146; voting power with respect to electing such director. There are no prohibitions in relation to cumulative voting under the laws of the Cayman Islands but our post-offering amended
and restated articles of association do not provide for cumulative voting. As a result, our shareholders are not afforded any less protections or rights on this issue than shareholders of a Delaware corporation. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Removal of directors.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a director of a corporation with a classified board may be
removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under our post-offering amended and restated articles of association, directors may be
removed with or without cause, by an ordinary resolution of our shareholders. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Transactions with interested
shareholders.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law contains a business combination statute applicable to Delaware corporations whereby, unless the corporation has specifically elected not to be governed by such statute
by amendment to its certificate of incorporation, it is prohibited from engaging in certain business combinations with an &#147;interested shareholder&#148; for three years following the date that such person becomes an interested shareholder. An
interested shareholder generally is a person or a group who or which owns or owned 15% or more of the target&#146;s outstanding voting share within the past three years. This has the effect of limiting the ability of a potential acquirer to make a <FONT
STYLE="white-space:nowrap">two-tiered</FONT> bid for the target in which all shareholders would not be treated equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes an interested shareholder,
the board of directors approves either the business combination or the transaction which resulted in the person becoming an interested shareholder. This encourages any potential acquirer of a Delaware corporation to negotiate the terms of any
acquisition transaction with the target&#146;s board of directors. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Cayman Islands law has no comparable statute. As a result, we cannot avail ourselves
of the types of protections afforded by the Delaware business combination statute. However, although Cayman Islands law does not regulate transactions between a company and its significant shareholders, it does provide that such transactions must be
entered into bona fide in the best interests of the company and not with the effect of constituting a fraud on the minority shareholders. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Dissolution; winding up.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, unless the board of directors approves the proposal to
dissolve, dissolution must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&#146;s
outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board. Under Cayman Islands law, a company may be wound
up by either an order of the courts of the Cayman Islands or by a special resolution of its members or, if the company is unable to pay its debts as they fall due, by an ordinary resolution of its members. The court has authority to order winding up
in a number of specified circumstances including where it is, in the opinion of the court, just and equitable to do so. Under the Companies Law and our post-offering amended and restated articles of association, our company may be dissolved,
liquidated or wound up by a special resolution of our shareholders. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Variation of rights of shares.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Under the
Delaware General Corporation Law, a corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. Under Cayman Islands law
and our post-offering amended and restated articles of association, if our share capital is divided into more than one class of shares, we may vary the rights attached to any class with the written consent of the holders of a majority of the issued
shares of that class or with the sanction of a special resolution passed at a general meeting of the holders of the shares of that class. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">207 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Amendment of governing documents.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Under the Delaware General Corporation Law, a
corporation&#146;s governing documents may be amended with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. As permitted by Cayman Islands law, our post-offering
amended and restated memorandum and articles of association may only be amended with a special resolution of our shareholders. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Rights of <FONT
STYLE="white-space:nowrap">non-resident</FONT> or foreign shareholders.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;There are no limitations imposed by our post-offering amended and restated memorandum and articles of association on the rights of <FONT
STYLE="white-space:nowrap">non-resident</FONT> or foreign shareholders to hold or exercise voting rights on our shares. In addition, there are no provisions in our post-offering amended and restated memorandum and articles of association governing
the ownership threshold above which shareholder ownership must be disclosed. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>History of securities issuances </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the three years preceding the filing of this registration statement, we have issued the following securities that were not registered under the Securities Act.
We believe that each of the following issuances was exempt from registration under the Securities Act in reliance on Regulation S under the Securities Act regarding sales by an issuer in offshore transactions, Regulation D under the Securities Act,
Rule 701 under the Securities Act or pursuant to Section 4(a)(2) of the Securities Act regarding transactions not involving a public offering. No underwriters were used in the below issuances. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">1.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On April&nbsp;3, 2014, we issued 3,499,999 restricted ordinary shares and 83,333 ordinary shares to Samantha Du for an aggregate cash consideration of $50,210. On the same date,
we issued 8,083,333 ordinary shares to Red Kingdom Investments Limited for an aggregate consideration of $141,971. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">2.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On August&nbsp;20, 2014, we closed a private placement transaction pursuant to which we issued an aggregate of 8,466,665 Series <FONT STYLE="white-space:nowrap">A-1</FONT>
preferred shares for an aggregate cash consideration of $8,028,572 and in consideration for the conversion of convertible loans amounting an aggregate consideration of $2,000,000. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">3.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On April&nbsp;30, 2015, we issued a total of 9,619,975 Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shares in connection with the second closing of the private
placement transaction described above for an aggregate consideration of $20,828,572 of which $5,300,000 remained unpaid. On September&nbsp;30, 2015 we cancelled 1,177,754 of these Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shares
and forgave the $2,550,000 unpaid capital balance. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">4.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On August&nbsp;10, 2015, we issued 166,667 restricted ordinary shares to Peter Karl Wirth. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">5.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On December&nbsp;31, 2015, we granted a warrant to purchase 461,808 Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shares at the purchase price of $2.1651 per share
to OrbiMed Asia Partners II, L.P. for a period commencing on April&nbsp;1, 2016 and ending on the earlier of (i)&nbsp;the sixth anniversary of the date of issuance of this warrant or (ii) 90 calendar days prior to the date on which we consummate
this offering. No consideration was received by us in connection with the issuance of the warrant. As of the date of this prospectus, no Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shares have been purchased by OrbiMed Asia Partners
II, L.P. pursuant to this warrant. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">6.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On January&nbsp;20, 2016, we closed a private placement transaction pursuant to which we sold an aggregate of 5,562,335 Series <FONT STYLE="white-space:nowrap">B-1</FONT>
preferred shares for an aggregate consideration of $53,100,000 in cash. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">7.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On April&nbsp;1, 2016, we issued a total of 3,973,096 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares in connection with the second closing of the private
placement transaction described above for an aggregate consideration of $53,100,000 in cash. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">8.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On July&nbsp;15, 2016 and August&nbsp;25, 2016, we issued an additional 58,333 and 75,000 restricted ordinary shares to Peter Karl Wirth, respectively. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">208 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">9.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On June 26, 2017, we closed a private placement transaction pursuant to which we sold an aggregate of 1,998,958 Series C preferred shares for an aggregate consideration of
$30,000,000 in cash. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to the above, since January&nbsp;1, 2014, we have granted share options to purchase (i)&nbsp;an aggregate
of 4,309,232 ordinary shares, each at an exercise price of $0.60 per share, (ii)&nbsp;an aggregate of 1,157,793 ordinary shares, each at an exercise price of $1.20 per share, (iii)&nbsp;an aggregate of 1,761,200 ordinary shares, each at an exercise
price of $1.74 per share, and (iv) an aggregate of 162,896 ordinary shares, each at an exercise price of $3.00 per share, to our employees, consultants and directors. These grants were made pursuant to written compensatory plans or arrangements with
our employees, consultants and directors in reliance upon the exemption provided by Rule 701 promulgated under the Securities Act or Section 4(a)(2) of the Securities Act for transactions by an issuer not involving a public offering or Regulation S
under the Securities Act. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Registration rights </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with our issuance of Series C preferred shares, we and all of our then shareholders entered into a third amended and restated shareholders agreement
in June 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the shareholders agreement, our preferred shareholders are entitled to registration rights and certain preferential rights,
including, among others, preferential and <FONT STYLE="white-space:nowrap">non-cumulative</FONT> dividend rights, information rights, right of participation to purchase and subscribe for their respective pro rata portions of new securities to be
issued, right of first refusal before any securities of the company may be sold or otherwise transferred or disposed of by any ordinary shareholder and certain principal employees, <FONT STYLE="white-space:nowrap">co-sale</FONT> rights in the event
that any offered securities are not purchased by the preferred shareholders exercising their rights of first refusal, drag-along rights in the event that shareholders approve a drag-along transaction and preferred distribution rights in the event of
a liquidation. Except for the registration rights, all preferred shareholders&#146; rights will automatically terminate upon the completion of this offering. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Pursuant to our shareholders&#146; agreement, we have granted certain registration rights to our shareholders. Such registration rights would terminate with respect to a shareholder upon the earlier of (i) the date
of a deemed liquidation event, (ii) five years following the consummation of this offering and (iii) such time at which all registrable securities held by a shareholder proposed to be sold may be sold under Rule 144 of the Securities Act in any <FONT
STYLE="white-space:nowrap">90-day</FONT> period without registration in compliance with Rule 144 of the Securities Act. Set forth below is a description of the registration rights granted under the agreement. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Demand registration rights.</I>&nbsp;&nbsp;&nbsp;&nbsp;At any time after the earlier of (i)&nbsp;June 26, 2023 or (ii)&nbsp;the date six months following the
consummation of an initial public offering (in the cases of (a) and (b) below, other than this offering), upon a written request from the holders of at least 10% of (a) the voting power of the registrable securities, (b) the then outstanding Series
B preferred shares and any ordinary shares converted from Series B shares together or (c) the then outstanding Series C preferred shares and any ordinary shares converted from Series C preferred shares together we must file a registration statement
covering the offer and sale of the registrable securities held by the requesting shareholders and other holders who choose to participate in the offering in the event that the anticipated gross receipts from this offering are to exceed $10,000,000.
Registrable securities include, among others, our ordinary shares issued or to be issued upon conversion of the preferred shares. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">However, we are not
obligated to proceed with a demand registration if we have, within the <FONT STYLE="white-space:nowrap">six-month</FONT> period preceding the date of such request, already effected a registration under the Securities Act pursuant to the exercise of
the holders&#146; demand registration rights or Form <FONT STYLE="white-space:nowrap">F-3</FONT> registration rights, or in which the holders had an opportunity to participate in the piggyback registration rights, unless the registrable securities
of the holders were excluded from such registration. We have the right to defer filing of a registration statement for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">209 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
up to 90 days if our board of directors determines in good faith that the filing of a registration statement would be materially detrimental to us and our shareholders, but we cannot exercise the
deferral right more than once in any <FONT STYLE="white-space:nowrap">12-month</FONT> period. We are obligated to effect only three demand registrations on forms other than Form <FONT STYLE="white-space:nowrap">F-3</FONT> so long as such
registrations have been declared or ordered effective. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I><FONT STYLE="white-space:nowrap">F-3</FONT> registration
rights.</I>&nbsp;&nbsp;&nbsp;&nbsp;When we are eligible for registration on Form <FONT STYLE="white-space:nowrap">F-3,</FONT> upon a written request from any holder all registrable securities, we must effect a registration on <FONT
STYLE="white-space:nowrap">Form-3</FONT> and any related qualification or compliance covering the offer and sale of the registrable securities. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are
not obligated to effect a Form <FONT STYLE="white-space:nowrap">F-3</FONT> registration, among other things, if we have, within the <FONT STYLE="white-space:nowrap">12-month</FONT> period preceding the date of the request, already effected two
registrations under the Securities Act or if the holders of Registrable securities proposed to sell at an aggregate price to the public less than $2,000,000. We have the right to defer filing of a registration statement for up to 90 days if our
board of directors determines in good faith that the filing of a registration statement would be materially detrimental to us and our shareholders, but we cannot exercise the deferral right more than once in any
<FONT STYLE="white-space:nowrap">12-month</FONT> period. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Piggyback registration rights.</I>&nbsp;&nbsp;&nbsp;&nbsp;If we propose to file a
registration statement under the Securities Act for purposes of effecting a public offering of our securities (including, but not limited to, registration statements relating to secondary offerings of our securities, but excluding registration
statements relating to any employee benefit plan, a corporate reorganization or this offering), we must afford holders of registrable securities an opportunity to include in that registration all or any part of their registrable securities then
held. We have the right to terminate or withdraw any registration initiated by us under the piggyback registration rights prior to the effectiveness of such registration whether or not any holder has elected to include securities in such
registration. The underwriters of any underwritten offering have the right to limit the number of shares with registration rights to be included in the registration statement, subject to certain limitations. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Expenses of registration.</I>&nbsp;&nbsp;&nbsp;&nbsp; We will pay all expenses relating to any demand, Form <FONT STYLE="white-space:nowrap">F-3,</FONT> or
piggyback registration except for the underwriting discounts and selling commissions applicable to the sale of registrable securities and certain other limited exceptions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">210 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_17"></A>Description of American depositary shares </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:arial" SIZE="2">Citibank, N.A. has agreed to act as the depositary bank for the American Depositary Shares. Citibank&#146;s depositary offices are located at
388 Greenwich Street, 23</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">rd</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2"> Floor, New York, New York 10013 USA. American
Depositary Shares are frequently referred to as &#147;ADSs&#148; and represent ownership interests in securities that are on deposit with the depositary bank. ADSs may be<B> </B>represented by certificates that are commonly known as &#147;American
Depositary Receipts&#148; or &#147;ADRs.&#148; The depositary bank typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank, N.A.&#151;Hong Kong<B>, </B>located at 9/F., Citi Tower, One Bay East,
83 Hoi Bun Road, Kwun Tong, Kowloon, Hong Kong<B>.</B> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have<B> </B>appointed<B> </B>Citibank as depositary bank pursuant to a deposit agreement. A
copy of the deposit agreement is on file with the SEC under cover of a Registration Statement on Form <FONT STYLE="white-space:nowrap">F-6.</FONT> You may obtain a copy of the deposit agreement from the SEC&#146;s Public Reference Room at 100 F
Street, N.E., Washington, D.C. 20549 and from the SEC&#146;s website (<U>www.sec.gov</U>). Please refer to Registration Number 333-220256 when retrieving such copy. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are providing you with a summary description of the material terms of the ADSs and of your material rights as an owner of ADSs. Please remember that summaries by their nature lack the precision of the
information summarized and that the rights and obligations of an owner of ADSs will be determined by reference to the terms of the deposit agreement and not by this summary. We urge you to review the deposit agreement in its entirety. The portions
of this summary description that are italicized describe matters that may be relevant to the ownership of ADSs but that may not be contained in the deposit agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Each ADS represents the right to receive, and to exercise the beneficial ownership interests in, one<B> </B>ordinary share that is on deposit with the depositary bank and/or custodian. An ADS also represents the
right to receive, and to exercise the beneficial interests in, any other property received by the depositary bank or the custodian on behalf of the owner of the ADS but that has not been distributed to the owners of ADSs because of legal
restrictions or practical considerations. We and the depositary bank may agree to change the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-share</FONT></FONT> ratio by amending the deposit agreement. This amendment may
give rise to, or change, the depositary fees payable by ADS owners. The custodian, the depositary bank and their respective nominees will hold all deposited property for the benefit of the holders and beneficial owners of ADSs. The deposited
property does not constitute the proprietary assets of the depositary bank, the custodian or their nominees. Beneficial ownership in the deposited property will under the terms of the deposit agreement be vested in the beneficial owners of the ADSs.
The depositary bank, the custodian and their respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. A beneficial owner of ADSs
may or may not be the holder of ADSs. Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests in, the deposited property only through the registered holders of the ADSs, the registered holders of the ADSs
(on behalf of the applicable ADS owners) only through the depositary bank, and the depositary bank (on behalf of the owners of the corresponding ADSs) directly, or indirectly, through the custodian or their respective nominees, in each case upon the
terms of the deposit agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be bound to its
terms and to the terms of any ADR that represents your ADSs. The deposit agreement and the ADR specify our rights and obligations as well as your rights and obligations as owner of ADSs and those of the depositary bank. As an ADS holder you appoint
the depositary bank to act on your behalf in certain circumstances. The deposit agreement and the ADRs are governed by New York law. However, our obligations to the holders of ordinary shares<B> </B>will continue to be governed by the laws of the
Cayman Islands, which may be different from the laws in the United States. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">211 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, applicable laws and regulations may require you to satisfy reporting requirements and obtain regulatory
approvals in certain circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. Neither the depositary bank, the custodian, us or any of their or our respective agents or affiliates shall
be required to take any actions whatsoever on your behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>As an owner of ADSs, we will not treat you as one of our shareholders and you will not have direct shareholder rights. The depositary bank will hold on your behalf the shareholder rights attached to the ordinary
shares</I><B><I> </I></B><I>underlying your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights for the ordinary shares represented by your ADSs through the depositary bank only to the extent contemplated in the deposit
agreement. To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS owner, need to arrange for the cancellation of your ADSs and become a direct shareholder. </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The manner in which you own the ADSs (e.g., in a brokerage account vs. as registered holder, or as holder of certificated vs. uncertificated ADSs) may effect your
rights and obligations, and the manner in which, and extent to which, the depositary bank&#146;s services are made available to you. As an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a brokerage
or safekeeping account, or through an account established by the depositary bank in your name reflecting the registration of uncertificated ADSs directly on the books of the depositary bank (commonly referred to as the &#147;direct registration
system&#148; or &#147;DRS&#148;). The direct registration system reflects the uncertificated (book-entry) registration of ownership of ADSs by the depositary bank. Under the direct registration system, ownership of ADSs is evidenced by periodic
statements issued by the depositary bank to the holders of the ADSs. The direct registration system includes automated transfers between the depositary bank and The Depository Trust Company (&#147;DTC&#148;), the central book-entry clearing and
settlement system for equity securities in the United States. If you decide to hold your ADSs through your brokerage or safekeeping account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers
typically hold securities such as the ADSs through clearing and settlement systems such as DTC. The procedures of such clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your
broker or bank if you have any questions concerning these limitations and procedures. All ADSs held through DTC will be registered in the name of a nominee of DTC. This summary description assumes you have opted to own the ADSs directly by means of
an ADS registered in your name and, as such, we will refer to you as the &#147;holder.&#148; When we refer to &#147;you,&#148; we assume the reader owns ADSs and will own ADSs at the relevant time. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The registration of the ordinary shares in the name of the depositary bank or the custodian shall, to the maximum extent permitted by applicable law, vest in the
depositary bank or the custodian the record ownership in the applicable ordinary shares with the beneficial ownership rights and interests in such ordinary shares being at all times vested with the beneficial owners of the ADSs representing the
ordinary shares. The depositary bank or the custodian shall at all times be entitled to exercise the beneficial ownership rights in all deposited property, in each case only on behalf of the holders and beneficial owners of the ADSs representing the
deposited property. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Dividends and distributions </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a holder of ADSs, you generally have the right to receive the distributions we make on the securities deposited with the custodian. Your receipt of these
distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the deposit agreement in proportion to the number of ADSs held as of the specified record
date, after deduction of the applicable fees, taxes and expenses. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">212 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Distributions of cash </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Whenever we make a cash distribution for the securities on deposit with the custodian, we will deposit the funds with the custodian. Upon receipt of confirmation of the deposit of the requisite funds, the
depositary bank will arrange for the funds received in a currency other than U.S. dollars to be converted into U.S. dollars and for the distribution of the U.S. dollars to the holders, subject to Cayman Islands laws and regulations. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The conversion into U.S. dollars will take place only if practicable and if the U.S. dollars are transferable to the United States. The depositary bank will apply
the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of securities on deposit. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The distribution of cash will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. The depositary bank will hold any cash amounts it is
unable to distribute in a <FONT STYLE="white-space:nowrap">non-interest</FONT> bearing account for the benefit of the applicable holders and beneficial owners of ADSs until the distribution can be effected or the funds that the depositary bank holds
must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Distributions of shares
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Whenever we make a free distribution of ordinary shares for the securities on deposit with the custodian, we will deposit the applicable number of
ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will <U>either</U> distribute to holders new ADSs representing the ordinary shares deposited <U>or</U> modify the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share ratio, in which case each ADS you hold will represent rights and interests in the additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional
entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The distribution of new ADSs or the
modification of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS-to-ordinary</FONT></FONT> share<B> </B>ratio upon a distribution of ordinary shares<B> </B>will be made net of the fees, expenses, taxes and governmental
charges payable by holders under the terms of the deposit agreement. In order to pay such taxes or governmental charges, the depositary bank may sell all or a portion of the new ordinary shares so distributed. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">No such distribution of new ADSs will be made if it would violate a law (<I>e.g.</I>, the U.S. securities laws) or if it is not operationally practicable. If the
depositary bank does not distribute new ADSs as described above, it may sell the ordinary shares<B> </B>received upon the terms described in the deposit agreement and will distribute the proceeds of the sale as in the case of a distribution of cash.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Distributions of rights </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Whenever we intend to
distribute rights to subscribe for additional ordinary shares, we will give prior notice to the depositary bank and we will assist the depositary bank in determining whether it is lawful and reasonably practicable to distribute rights to subscribe
for additional ADSs to holders. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The depositary bank will establish procedures to distribute rights to subscribe for additional ADSs to holders and to
enable such holders to exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the
lawfulness of the transaction). You may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary bank is not obligated to establish procedures to facilitate the
distribution and exercise by holders of rights to subscribe for new ordinary shares other than in the form of ADSs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">213 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The depositary bank will <I>not</I> distribute the rights to you if: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We do not timely request that the rights be distributed to you or we request that the rights not be distributed to you; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We fail to deliver satisfactory documents to the depositary bank; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">It is not reasonably practicable to distribute the rights. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The depositary bank will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The proceeds of such sale will be distributed to holders as in the case of a
cash distribution. If the depositary bank is unable to sell the rights, it will allow the rights to lapse. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Elective distributions </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Whenever we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior notice thereof to the
depositary bank and will indicate whether we wish the elective distribution to be made available to you. In such case, we will assist the depositary bank in determining whether such distribution is lawful and reasonably practicable. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The depositary bank will make the election available to you only if it is reasonably practicable and if we have provided all of the documentation contemplated in
the deposit agreement. In such case, the depositary bank will establish procedures to enable you to elect to receive either cash or additional ADSs, in each case as described in the deposit agreement. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the election is not made available to you, you will receive either cash or additional ADSs, depending on what a shareholder in the Cayman Islands would receive
upon failing to make an election, as more fully described in the deposit agreement. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Other distributions </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Whenever we intend to distribute property other than cash, ordinary shares or rights to subscribe for additional ordinary shares, we will notify the depositary bank
in advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the depositary bank in determining whether such distribution to holders is lawful and reasonably practicable. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If it is reasonably practicable to distribute such property to you and if we provide to the depositary bank all of the documentation contemplated in the deposit
agreement, the depositary bank will distribute the property to the holders in a manner it deems practicable. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The distribution will be made net of fees,
expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes and governmental charges, the depositary bank may sell all or a portion of the property received. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The depositary bank will <I>not</I> distribute the property to you and will sell the property if: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We do not request that the property be distributed to you or if we request that the property not be distributed to you; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We do not deliver satisfactory documents to the depositary bank; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The depositary bank determines that all or a portion of the distribution to you is not reasonably practicable. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The proceeds of such a sale will be distributed to holders as in the case of a cash distribution. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">214 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Redemption </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Whenever we decide to redeem any of the securities on deposit with the custodian, we will notify the depositary bank in advance. If it is practicable and if we
provide all of the documentation contemplated in the deposit agreement, the depositary bank will provide notice of the redemption to the holders. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price. The depositary bank will convert into U.S. dollars upon the terms of the deposit agreement the redemption funds received in a
currency other than U.S. dollars and will establish procedures to enable holders to receive the net proceeds from the redemption upon surrender of their ADSs to the depositary bank. You may have to pay fees, expenses, taxes and other governmental
charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by lot or on a <I>pro rata</I> basis, as the depositary bank may determine. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Changes affecting ordinary shares </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The ordinary
shares<B> </B>held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value, <FONT STYLE="white-space:nowrap">split-up,</FONT> cancellation, consolidation or any other reclassification of such
ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of assets of the Company. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If any such change were to occur, your
ADSs would, to the extent permitted by law and the deposit agreement, represent the right to receive the property received or exchanged in respect of the ordinary shares<B> </B>held on deposit. The depositary bank may in such circumstances deliver
new ADSs to you, amend the deposit agreement, the ADRs and the applicable Registration Statement(s) on Form <FONT STYLE="white-space:nowrap">F-6,</FONT> call for the exchange of your existing ADSs for new ADSs and take any other actions that are
appropriate to reflect as to the ADSs the change affecting the ordinary shares. If the depositary bank may not lawfully distribute such property to you, the depositary bank may sell such property and distribute the net proceeds to you as in the case
of a cash distribution. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Issuance of ADSs upon deposit of ordinary shares </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Upon completion of this offering, the ordinary shares being offered pursuant to this prospectus will be deposited by us with the custodian.&nbsp;Upon receipt of confirmation of such deposit, the depositary bank
will issue ADSs to the underwriters named in this prospectus. After the completion of this offering, the ordinary shares that are being offered for sale pursuant to this prospectus will be deposited by us with the custodian. Upon receipt of
confirmation of such deposit, the depositary bank will issue ADSs to the underwriters named in this prospectus. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">After the closing of this offer, the
depositary bank may create ADSs on your behalf if you or your broker deposit ordinary shares with the custodian. The depositary bank will deliver these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges
and taxes payable for the transfer of the ordinary shares to the custodian. Your ability to deposit ordinary shares and receive ADSs may be limited by U.S. and Cayman Islands legal considerations applicable at the time of deposit. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The issuance of ADSs may be delayed until the depositary bank or the custodian receives confirmation that all required approvals have been given and that the
ordinary shares have been duly transferred to the custodian. The depositary bank will only issue ADSs in whole numbers. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">When you make a deposit of<B>
</B>ordinary shares, you will be responsible for transferring good and valid title to the depositary bank. As such, you will be deemed to represent and warrant that: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The ordinary shares are duly authorized, validly issued, fully paid, <FONT STYLE="white-space:nowrap">non-assessable</FONT> and legally obtained.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">215 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">All preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived or exercised. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">You are duly authorized to deposit the ordinary shares. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim, and are not, and the
ADSs issuable upon such deposit will not be, &#147;restricted securities&#148; (as defined in the deposit agreement). </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The ordinary shares presented for deposit have not been stripped of any rights or entitlements. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If any of the representations or warranties are incorrect in any way, we and the depositary bank may, at your cost and expense, take any and all actions necessary
to correct the consequences of the misrepresentations. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Transfer, combination and split up of ADRs </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs, you will have to surrender
the ADRs to be transferred to the depositary bank and also must: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">provide such proof of identity and genuineness of signatures as the depositary bank deems appropriate; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">provide any transfer stamps required by the State of New York or the United States; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the terms of the deposit agreement, upon the
transfer of ADRs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To have your ADRs either combined or split up, you must surrender the ADRs in question to the depositary bank with
your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a combination or split up of ADRs. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Withdrawal of ordinary shares upon cancellation of ADSs </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As
a holder, you will be entitled to present your ADSs to the depositary bank for cancellation and then receive the corresponding number of underlying ordinary shares<B> </B>at the custodian&#146;s offices. Your ability to withdraw the ordinary shares
held in respect of the ADSs may be limited by U.S. and Cayman Islands considerations applicable at the time of withdrawal. In order to withdraw the ordinary shares represented by your ADSs, you will be required to pay to the depositary bank the fees
for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares. You assume the risk for delivery of all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit
agreement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If you hold ADSs registered in your name, the depositary bank may ask you to provide proof of identity and genuineness of any signature and
such other documents as the depositary bank may deem appropriate before it will cancel your ADSs. The withdrawal of the ordinary shares represented by your ADSs may be delayed until the depositary bank receives satisfactory evidence of compliance
with all applicable laws and regulations. Please keep in mind that the depositary bank will only accept ADSs for cancellation that represent a whole number of securities on deposit. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">You will have the right to withdraw the securities represented by your ADSs at any time except for: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Temporary delays that may arise because (i)&nbsp;the transfer books for the ordinary shares or ADSs are closed, or (ii)&nbsp;ordinary shares are immobilized on
account of a shareholders&#146; meeting or a payment of dividends. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">216 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Obligations to pay fees, taxes and similar charges. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on deposit. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The deposit agreement may not be modified to impair your right to withdraw the securities represented by your ADSs except to comply with mandatory provisions of
law. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Voting rights </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a holder, you
generally have the right under the deposit agreement to instruct the depositary bank to exercise the voting rights for the ordinary shares represented by your ADSs. The voting rights of holders of ordinary shares are described in &#147;Description
of share capital.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">At our request, the depositary bank will distribute to you any notice of shareholders&#146; meeting received from us together
with information explaining how to instruct the depositary bank to exercise the voting rights of the securities represented by ADSs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the depositary
bank timely receives voting instructions from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holder&#146;s ADSs in accordance with such voting instructions as follows<B>:</B> </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>In the event of voting by show of hands</I>, the depositary bank will vote (or cause the custodian to vote) all ordinary shares held on deposit at that time
in accordance with the voting instructions received from a majority of holders of ADSs who provide timely voting instructions. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><I>In the event of voting by poll</I>, the depositary bank will vote (or cause the Custodian to vote) the ordinary shares held on deposit in accordance with the
voting instructions received from the holders of ADSs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event of voting by poll, holders of ADSs in respect of which no timely
voting instructions have been received shall be deemed to have instructed the depositary bank to give a discretionary proxy to a person designated by us to vote the ordinary shares represented by such holders&#146; ADSs; provided, that no such
instructions shall be deemed given and no such discretionary proxy shall be given with respect to any matter as to which we inform the depositary bank that we do not wish such proxy to be given; provided, further, that no such discretionary proxy
shall be given (x)&nbsp;with respect to any matter as to which we inform the depositary that (i)&nbsp;there exists substantial opposition, or (ii)&nbsp;the rights of holders of ADSs or the shareholders of our company will be materially adversely
affected, and (y)&nbsp;in the event that the vote is on a show of hands. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Please note that the ability of the depositary bank to carry out voting
instructions may be limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to enable you to return voting instructions to the depositary bank in a
timely manner. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">217 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Fees and charges </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As an ADS holder, you will be required to pay the following fees under the terms of the deposit agreement: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="28%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Service</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Fees</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Issuance of ADSs (e.g., an issuance of ADS upon a deposit of ordinary shares<B>,</B> upon a change in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS(s)-to-share</FONT></FONT> ratio, or for any other reason), excluding ADS issuances as a result of distributions of ordinary shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Up&nbsp;to&nbsp;U.S.&nbsp;5&#162;&nbsp;per&nbsp;ADS&nbsp;issued</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Cancellation of ADSs (e.g., a cancellation of ADSs for delivery of deposited property, upon a change in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ADS(s)-to-share</FONT></FONT> ratio, or for any other reason)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Up to U.S. 5&#162; per ADS cancelled</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Distribution of cash dividends or other cash distributions (e.g., upon a sale of rights and other
entitlements)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Up to U.S. 5&#162; per ADS held</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Distribution of ADSs pursuant to (i)&nbsp;stock dividends or other free stock distributions, or (ii)&nbsp;exercise of
rights to purchase additional ADSs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Up to U.S. 5&#162; per ADS held</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;Distribution of securities other than ADSs or rights to purchase additional ADSs (e.g., upon a <FONT
STYLE="white-space:nowrap">spin-off)</FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Up to U.S. 5&#162; per ADS held</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&#149;&nbsp;&nbsp;ADS Services</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Up to U.S. 5&#162; per ADS held on the applicable record date(s) established by the depositary bank</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="3" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As an ADS holder you will also be responsible to pay certain charges such as: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">taxes (including applicable interest and penalties) and other governmental charges; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the registration fees as may from time to time be in effect for the registration of ordinary shares<B> </B>on the share register and applicable to transfers of
ordinary shares to or from the name of the custodian, the depositary bank or any nominees upon the making of deposits and withdrawals, respectively; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">certain cable, telex and facsimile transmission and delivery expenses; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the expenses and charges incurred by the depositary bank in the conversion of foreign currency; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the fees and expenses incurred by the depositary bank in connection with compliance with exchange control regulations and other regulatory requirements
applicable to ordinary shares, ADSs and ADRs; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the fees and expenses incurred by the depositary bank, the custodian, or any nominee in connection with the servicing or delivery of deposited property.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">ADS fees and charges payable upon (i)&nbsp;the issuance of ADSs, and (ii)&nbsp;the cancellation of ADSs are charged to the person to
whom the ADSs are issued (in the case of ADS issuances) and to the person whose ADSs are cancelled (in the case of ADS cancellations). In the case of ADSs issued by the depositary bank into DTC, the ADS issuance and cancellation fees and charges may
be deducted from distributions made through DTC, and may be charged to the DTC participant(s) receiving the ADSs being issued or the DTC participant(s) holding the ADSs being cancelled, as the case may be, on behalf of the beneficial owner(s) and
will be charged by the DTC participant(s) to the account of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participants as in effect at the time. ADS fees and charges in respect of distributions and the
ADS service fee are charged to the holders as of the applicable ADS record date. In the case of distributions of cash, the amount of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">218 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i)&nbsp;distributions other than cash and (ii)&nbsp;the ADS service fee, holders as of the ADS
record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash
and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS
fees and charges to the beneficial owners for whom they hold ADSs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event of refusal to pay the depositary bank fees, the depositary bank may,
under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary bank fees from any distribution to be made to the ADS holder. Certain of the depositary fees and charges
(such as the ADS services fee) may become payable shortly after the closing of the ADS offering. Note that the fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary bank. You will receive prior
notice of such changes. The depositary bank may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and
conditions as we and the depositary bank agree from time to time. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Amendments and termination </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We may agree with the depositary bank to modify the deposit agreement at any time without your consent. We undertake to give holders 30 days&#146; prior notice of
any modifications that would materially prejudice any of their substantial rights under the deposit agreement. We will not consider to be materially prejudicial to your substantial rights any modifications or supplements that are reasonably
necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing the fees and charges you are required to pay. In addition, we may not be able to provide you
with prior notice of any modifications or supplements that are required to accommodate compliance with applicable provisions of law. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">You will be bound
by the modifications to the deposit agreement if you continue to hold your ADSs after the modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the ordinary shares
represented by your ADSs (except as permitted by law). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have the right to direct the depositary bank to terminate the deposit agreement. Similarly,
the depositary bank may in certain circumstances on its own initiative terminate the deposit agreement. In either case, the depositary bank must give notice to the holders at least 30 days before termination. Until termination, your rights under the
deposit agreement will be unaffected. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">After termination, the depositary bank will continue to collect distributions received (but will not distribute
any such property until you request the cancellation of your ADSs) and may sell the securities held on deposit. After the sale, the depositary bank will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a <FONT
STYLE="white-space:nowrap">non-interest</FONT> bearing account. At that point, the depositary bank will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction
of applicable fees, taxes and expenses). </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Books of depositary </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The depositary bank will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular business hours but solely for the purpose of communicating with other
holders in the interest of business matters relating to the ADSs and the deposit agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">219 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The depositary bank will maintain in New York facilities to record and process the issuance, cancellation,
combination, <FONT STYLE="white-space:nowrap">split-up</FONT> and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Limitations on obligations and liabilities </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The deposit agreement limits our obligations and the depositary
bank&#146;s obligations to you. Please note the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We and the depositary bank are obligated only to take the actions specifically stated in the deposit agreement without negligence or bad faith.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The depositary bank disclaims any liability for any failure to carry out voting instructions, for any manner in which a vote is cast or for the effect of any
vote, provided it acts in good faith and in accordance with the terms of the deposit agreement. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">The depositary bank disclaims any liability for any failure to determine the lawfulness or practicality of any action, for the content of any document forwarded
to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in ordinary shares, for the validity or worth of the ordinary shares, for any tax consequences that result from the
ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our failure to give notice. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We and the depositary bank will not be obligated to perform any act that is inconsistent with the terms of the deposit agreement. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We and the depositary bank disclaim any liability if we or the depositary bank, or our respective controlling persons or agents are prevented or forbidden from,
or subject to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, or by
reason of present or future provision of any provision of our<B> </B>Articles of Association, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our control.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We and the depositary bank disclaim any liability by reason of any exercise of, or failure to exercise, any discretion provided for in the deposit agreement or
in our Articles of Association or in any provisions of or governing the securities on deposit. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We and the depositary bank further disclaim any liability for any action or inaction in reliance on the advice or information received from legal counsel,
accountants, any person presenting ordinary shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice or information.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We and the depositary bank also disclaim liability for the inability by a holder to benefit from any distribution, offering, right or other benefit that is made
available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We and the depositary bank may rely without any liability upon any written notice, request or other document believed to be genuine and to have been signed or
presented by the proper parties. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">We and the depositary bank also disclaim liability for any consequential, indirect or punitive damages for any breach of the terms of the deposit agreement, or
otherwise. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">220 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Nothing in the deposit agreement gives rise to a partnership or joint venture, or establishes a fiduciary relationship, among us, the depositary bank and you as
ADS holder. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Nothing in the deposit agreement precludes Citibank (or its affiliates) from engaging in transactions in which parties adverse to us or the ADS owners have
interests, and nothing in the deposit agreement obligates Citibank to disclose those transactions, or any information obtained in the course of those transactions, to us or to the ADS owners, or to account for any payment received as part of those
transactions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B><FONT STYLE="white-space:nowrap">Pre-release</FONT> transactions </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Subject to the terms and conditions of the deposit agreement, the depositary bank may issue to broker/dealers ADSs before receiving a deposit of ordinary shares or
release ordinary shares<B> </B>to broker/dealers before receiving ADSs for cancellation. These transactions are commonly referred to as <FONT STYLE="white-space:nowrap">&#147;pre-release</FONT> transactions,&#148; and are entered into between the
depositary bank and the applicable broker/dealer. The deposit agreement limits the aggregate size of pre-release transactions (not to exceed 30% of the ordinary shares on deposit in the aggregate) and imposes a number of conditions on such
transactions (e.g., the need to receive collateral, the type of collateral required, the representations required from brokers, etc.). The depositary bank may retain the compensation received from the
<FONT STYLE="white-space:nowrap">pre-release</FONT> transactions. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Taxes </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the depositary bank and the custodian may deduct from any distribution the
taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. You will be liable for any deficiency if the sale proceeds do not cover the taxes that are
due. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The depositary bank may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release securities on deposit until all taxes and
charges are paid by the applicable holder. The depositary bank and the custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on your behalf. However, you may be required to
provide to the depositary bank and to the custodian proof of taxpayer status and residence and such other information as the depositary bank and the custodian may require to fulfill legal obligations. You are required to indemnify us, the depositary
bank and the custodian for any claims with respect to taxes arising out of any refund of taxes, reduced rate of withholding or of the tax benefit obtained for or by you. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Foreign currency conversion </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The depositary bank will arrange for the conversion of all foreign currency
received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the deposit agreement. You may have to pay fees and expenses incurred in converting foreign currency, such as fees
and expenses incurred in complying with currency exchange controls and other governmental requirements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the conversion of foreign currency is not
practical or lawful, or if any required approvals are denied or not obtainable at a reasonable cost or within a reasonable period, the depositary bank may take the following actions in its discretion: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders for whom the conversion and distribution is lawful
and practical. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">221 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Distribute the foreign currency to holders for whom the distribution is lawful and practical. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Hold the foreign currency (without liability for interest) for the applicable holders. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Governing law/waiver of jury trial </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The deposit
agreement and the ADRs will be interpreted in accordance with the laws of the State of New York. The rights of holders of ordinary shares (including<B> </B>ordinary shares represented by ADSs) is governed by the laws of the Cayman Islands.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">By holding an ADS or an interest therein, you irrevocably agree that any legal suit, action or proceeding against or involving us or the Depositary,
arising out of or based upon the deposit agreement, ADSs or ADRs, may only be instituted in a state or federal court in New York, New York, and you irrevocably waive any objection to the laying of venue and irrevocably submit to the exclusive
jurisdiction of such courts with respect to any such suit, action or proceeding. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">AS A PARTY TO THE DEPOSIT AGREEMENT, YOU IRREVOCABLY WAIVE YOUR RIGHT
TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF THE DEPOSIT AGREEMENT OR THE ADRs AGAINST US AND/OR THE DEPOSITARY BANK. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">222 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_18"></A>Shares eligible for future sale </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Before this offering, no public market existed in the United States for our ordinary shares or the ADSs. Upon completion of this offering, we will have 8,000,000
ADSs outstanding, representing approximately&nbsp;16.31% of our outstanding ordinary shares. All of the ADSs sold in this offering will be freely transferable by persons other than by our &#147;affiliates&#148; without restriction or further
registration under the Securities Act. Sales of substantial amounts of our ADSs in the public market could adversely affect prevailing market prices of our ADSs. We intend to apply to list the ADSs on the Nasdaq Global Market, but we cannot assure
you that a regular trading market will develop for the ADSs. We do not expect that a trading market will develop for our ordinary shares not represented by the ADSs. </FONT></P>  <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B><FONT STYLE="white-space:nowrap">Lock-up</FONT> agreements </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have agreed, for a period of 180 days after the
date of this prospectus and subject to specified exceptions, not to (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or
otherwise transfer or dispose of, directly or indirectly, or file with the Commission a registration statement under the Securities Act relating to, any ordinary shares or ADSs or any securities convertible into or exercisable or exchangeable for
ordinary shares or ADSs, or publicly disclose the intention to make any offer, sale, pledge, disposition or filing, or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of
the ordinary shares or ADSs or any such other securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of ordinary shares or ADSs or such other securities, in cash or otherwise, without the prior
written consent of the representatives of the underwriters, other than (i) the ADSs to be sold hereunder, (ii) any ordinary shares or ADSs issued upon the exercise of options granted under our equity incentive plans, (iii) any options and other
awards granted under our equity incentive plans, (iv) the issuance of securities convertible into or exercisable or exchangeable for ordinary shares in connection with the hiring of new employees provided that such securities cannot be so converted,
exercised or exchanged within the 180-day restricted period, (v) any ordinary shares issued pursuant to the conversion or exchange of convertible or exchangeable securities, including preferred shares and warrants, as described in this registration
statement of which this prospectus forms a part, (vi) the filing of any registration statement on Form S-8 relating to any benefit plans or arrangements disclosed in this registration statement of which this prospectus forms a part and the issuance
of securities registered pursuant thereto, or (vii) any ordinary shares or securities exercisable for, convertible into or exchangeable for ordinary shares in connection with any acquisition, collaboration, licensing or other joint venture or
strategic transaction or any debt financing transaction involving the Company; provided that, in the case of clauses (ii), (iii), (v) and (vii), (x) such issuances shall not in the aggregate be greater than 10% of the total outstanding ordinary
shares immediately following the completion of this offering of ADSs which, for the avoidance of doubt, includes the ordinary shares issuable upon the conversion of preferred shares in connection with this offering, and (y) the recipients of such
shares agree to be bound by a lockup letter in the form executed by directors and officers. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our directors and executive officers, and certain of our
significant shareholders have entered into lock-up agreements with the underwriters prior to the commencement of this offering pursuant to which each of these persons or entities, with limited exceptions, for a period of 180 days after the date of
this prospectus, may not, without the prior written consent of J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Leerink Partners LLC, (1) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract
to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any ADSs or any securities convertible into or exercisable or exchangeable for our
ADSs (including, without limitation, ADSs or such other securities which may be deemed to be beneficially owned by such directors, executive officers, managers and members in accordance with the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">223 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant) or (2) enter into any swap or other agreement that transfers, in whole or in part,
any of the economic consequences of ownership of the ADSs or such other securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of ADSs or such other securities, in cash or otherwise, or (3) make
any demand for or exercise any right with respect to the registration of any ADSs or any security convertible into or exercisable or exchangeable for our ADSs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The restrictions described in the immediately preceding paragraph do not apply to, among other items: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the sale of ADSs to the underwriters in this offering; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">transfers of ADSs or ordinary shares or such other securities as a bona fide gift or gifts or by testate succession or intestate distribution;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">transfers of ADSs or ordinary shares acquired in the open market; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the exercise of stock options or other similar awards granted pursuant to our equity incentive plans, as described herein; provided that the terms of the lock-up
agreement shall apply to any ADSs or ordinary shares issued upon such exercise; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any ordinary shares or such other securities that are used for the primary purpose of satisfying any tax or other governmental withholding obligation, through
cashless surrender or otherwise, with respect to any award or equity-based compensation granted pursuant to our equity incentive plans, as described herein, or in connection with tax or other obligations as a result of testate succession or
intestate distribution; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">transfers to immediate family member or members, or to a trust, the direct or indirect beneficiaries of which are a lock-up party and/or a member or members of
his or her immediate family; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">transfers of ordinary shares or any security convertible into or exercisable or exchangeable for ordinary shares to us pursuant to any contractual arrangement
that provides for the repurchase of the lock-up party&#146;s ordinary shares or such other securities by us or in connection with the termination of the lock-up party&#146;s employment with us or the lock-up party&#146;s failure to meet certain
conditions set out upon receipt of such ordinary shares or other such securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">subject to certain limitations, distributions of ADSs, ordinary shares or such other securities to members or stockholders of the undersigned or to any
corporation, partnership or other person or entity that is a direct or indirect affiliate of the lock-up party; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any transfers, sales, tenders or other dispositions of ordinary shares or any security convertible into or exercisable or exchangeable for ordinary shares
pursuant to a bona fide third party tender offer, merger, amalgamation, consolidation or other similar transaction made to or involving all holders of ordinary shares or such other securities pursuant to which one hundred percent (100%) of our
ownership is transferred to such third party (including, without limitation, the entering into any lock-up, voting or similar agreement pursuant to which the lock-up party may agree to transfer, sell, tender or otherwise dispose of ordinary shares
or other such securities in connection with such transaction, or vote any ordinary shares or other such securities in favor of any such transaction); provided that such tender offer merger, amalgamation, consolidation or other similar transaction is
completed. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Other than this offering, we are not aware of any plans by any significant shareholders to dispose of significant numbers
of our ADSs or ordinary shares. However, one or more existing shareholders or owners of securities convertible or exchangeable into or exercisable for our ADSs or ordinary shares may dispose of significant numbers of our ADSs or ordinary shares in
the future. We cannot predict what effect, if any, future sales of our ADSs or ordinary shares, or the availability of ADSs or ordinary shares for future sale, will have on the trading price of our ADSs from time to time. Sales of substantial
amounts of our ADSs or ordinary shares in the public market, or the perception that these sales could occur, could adversely affect the trading price of our ADSs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">224 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Regulation S </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Regulation S under the Securities Act provides an exemption from registration requirements in the United States for offers and sales of securities that occur
outside the United States. Rule 903 of Regulation S provides the conditions to the exemption for a sale by an issuer, a distributor, their respective affiliates or anyone acting on their behalf, while Rule 904 of Regulation S provides the conditions
to the exemption for a resale by persons other than those covered by Rule 903. In each case, any sale must be completed in an offshore transaction, as that term is defined in Regulation S, and no directed selling efforts, as that term is defined in
Regulation S, may be made in the United States. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a foreign issuer as defined in Regulation S. As a foreign issuer, securities that we sell outside
the United States pursuant to Regulation S are not considered to be restricted securities under the Securities Act, and are freely tradable without registration or restrictions under the Securities Act, unless the securities are held by your
affiliates. Generally, subject to certain limitations, holders of our restricted shares who are not our who are our affiliates solely by virtue of their status as an officer or director of us may, under Regulation S, resell their restricted shares
in an &#147;offshore transaction&#148; if none of the seller, its affiliate nor any person acting on their behalf engages in directed selling efforts in the United States and, in the case of a sale of our restricted shares by an officer or director
who is an affiliate of us solely by virtue of holding such position, no selling commission, fee or other remuneration is paid in connection with the offer or sale other than the usual and customary broker&#146;s commission that would be received by
a person executing such transaction as agent. Additional restrictions are applicable to a holder of our restricted shares who will be an affiliate of us other than by virtue of his or her status as an officer or director of us. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are not claiming the potential exemption offered by Regulation S in connection with the offering of newly issued shares outside the United States and will
register all of the newly issued shares under the Securities Act. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Rule 144 </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">All of our ordinary shares that will be outstanding upon the completion of this offering, other than those ordinary shares sold in this offering, are &#147;restricted securities&#148; as that term is defined in
Rule 144 under the Securities Act and may be sold publicly in the United States only if they are subject to an effective registration statement under the Securities Act or pursuant to an exemption from the registration requirement such as those
provided by Rule 144 and Rule 701 promulgated under the Securities Act. In general, beginning 90 days after the date of this prospectus, a person (or persons whose shares are aggregated) who at the time of a sale is not, and has not been during the
three months preceding the sale, an affiliate of ours and has beneficially owned our restricted securities for at least six months will be entitled to sell the restricted securities without registration under the Securities Act, subject only to the
availability of current public information about us, and will be entitled to sell restricted securities beneficially owned for at least one year without restriction. Persons who are our affiliates and have beneficially owned our restricted
securities for at least six months may sell a number of restricted securities within any three-month period that does not exceed the greater of the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">1% of the then outstanding ordinary shares of the same class, in the form of ADSs or otherwise, which immediately after this offering will equal 490,497 ordinary
shares, assuming the underwriters do not exercise their option to purchase additional ADSs; or </FONT></P></TD></TR></TABLE>  <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the average weekly trading volume of our ordinary shares of the same class, in the form of ADSs or otherwise, during the four calendar weeks preceding the date
on which notice of the sale is filed with the SEC. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Sales by our affiliates under Rule 144 are also subject to certain requirements
relating to manner of sale, notice and the availability of current public information about us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">225 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Rule 701 </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In
general, under Rule 701 of the Securities Act as currently in effect, each of our employees, consultants or advisors who purchases our ordinary shares from us in connection with a compensatory stock plan or other written agreement executed prior to
the completion of this offering is eligible to resell those ordinary shares in reliance on Rule 144, but without compliance with some of the restrictions, including the holding period, contained in Rule 144. However, the Rule 701 shares would remain
subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> arrangements and would only become eligible for sale when the <FONT STYLE="white-space:nowrap">lock-up</FONT> period expires. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">226 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_19"></A>Taxation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Cayman Islands taxation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Cayman Islands currently levies no taxes on individuals or corporations based upon
profits, income, gains or appreciation and there is no taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to us levied by the government of the Cayman Islands except for stamp duties which may be
applicable on instruments executed in, or after execution brought within the jurisdiction of the Cayman Islands. The Cayman Islands is not party to any double tax treaties that are applicable to any payments made to or by our company. There are no
exchange control regulations or currency restrictions in the Cayman Islands. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>People&#146;s Republic of China taxation </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are a holding company incorporated in the Cayman Islands. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under
the EIT Law and its implementation rules, an enterprise established outside of China with a &#147;de facto management body&#148; within China is considered a &#147;resident enterprise,&#148; and will be subject to the enterprise income tax on its
global income at the rate of 25%. The implementation rules define the term &#147;de facto management body&#148; as the body that exercises full and substantial control and overall management over the business, productions, personnel, accounts and
properties of an enterprise. In 2009, the State Administration of Taxation issued SAT Circular 82, which provides certain specific criteria for determining whether the &#147;de facto management body&#148; of a
<FONT STYLE="white-space:nowrap">PRC-controlled</FONT> enterprise that is incorporated offshore is located in China. Although this circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those
controlled by PRC individuals or foreigners, the criteria set forth in the circular may reflect the State Administration of Taxation&#146;s general position on how the &#147;de facto management body&#148; text should be applied in determining the
tax resident status of all offshore enterprises. According to SAT Circular 82, all offshore enterprises controlled by a PRC enterprise or a PRC enterprise will be regarded as a PRC tax resident by virtue of having its &#147;de facto management
body&#148; in China only if all of the following conditions are met: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(i)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the primary location of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operational management is in the PRC;
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(ii)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">decisions relating to the enterprise&#146;s financial and human resource matters are made or are subject to approval by organizations or personnel in the PRC;
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(iii)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the enterprise&#146;s primary assets, accounting books and records, company seals, and board and shareholder resolutions, are located or maintained in China; and
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(iv)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">at least 50% of voting board members or senior executives habitually reside in China. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We believe that none of Zai Lab Limited and its subsidiaries outside of China is a PRC resident enterprise for PRC tax purposes. Zai Lab Limited is not controlled by a PRC enterprise or PRC enterprise group, and we
do not believe that Zai Lab Limited meets all of the conditions above. Zai Lab Limited is a company incorporated outside China. As a holding company, some of its key assets are located, and its records (including the resolutions of its board of
directors and the resolutions of its shareholders) are maintained, outside China. For the same reasons, we believe our other subsidiaries outside of China are also not PRC resident enterprises. However, the tax resident status of an enterprise is
subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#147;de facto management body.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If the PRC tax authorities determine that Zai Lab Limited is a PRC resident enterprise for EIT purposes, we may be required to withhold tax at a rate of 10% on dividends we pay to our shareholders, including
holders of our ADSs, that are <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprises. In addition, <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprise shareholders (including our ADS holders) may be subject to a 10% PRC
withholding tax on gains realized on the sale or other disposition of ADS </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">227 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
or ordinary shares, if such income is treated as sourced from within China. Furthermore, gains derived by our <FONT STYLE="white-space:nowrap">non-PRC</FONT> individual shareholders from the sale
of our shares and ADSs may be subject to a 20% PRC withholding tax. It is unclear whether our <FONT STYLE="white-space:nowrap">non-PRC</FONT> individual shareholders (including our ADS holders) would be subject to any PRC tax (including withholding
tax) on dividends received by such non-PRC individual shareholders in the event we are determined to be a PRC resident enterprise. If any PRC tax were to apply to dividends realized by <FONT STYLE="white-space:nowrap">non-PRC</FONT> individuals, it
will generally apply at a rate of 20%. The PRC tax liability may be reduced under applicable tax treaties. However, it is unclear whether <FONT STYLE="white-space:nowrap">non-PRC</FONT> shareholders of Zai Lab Limited would be able to claim the
benefits of any tax treaty between their country of tax residence and China in the event that Zai Lab Limited is treated as a PRC resident enterprise. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">See &#147;Risk factors&#151;Risks related to doing business in China&#151;If we are classified as a PRC resident enterprise for PRC income tax purposes, such
classification could result in unfavorable tax consequences to us and our <FONT STYLE="white-space:nowrap">non-PRC</FONT> shareholders or ADS holders.&#148; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Pursuant to the EIT Law and its implementation rules, if a <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprise has not set up an organization or establishment in China, or has set up an organization or
establishment but the income derived has no actual connection with such organization or establishment, it will be subject to a withholding tax on its <FONT STYLE="white-space:nowrap">PRC-sourced</FONT> income at a rate of 10%. Pursuant to the
Arrangement between Mainland China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Tax Evasion on Income, the tax rate in respect to dividends paid by a PRC enterprise to a Hong Kong enterprise is reduced to
5% from a standard rate of 10% if the Hong Kong enterprise directly holds at least 25% of the PRC enterprise. Pursuant to the Notice of the State Administration of Taxation on the Issues concerning the Application of the Dividend Clauses of Tax
Agreements, or SAT Circular 81, a Hong Kong resident enterprise must meet the following conditions, among others, in order to enjoy the reduced tax rate: (i)&nbsp;it must directly own the required percentage of equity interests and voting rights in
the PRC resident enterprise; and (ii)&nbsp;it must have directly owned such percentage in the PRC resident enterprise throughout the 12 months prior to receiving the dividends. Furthermore, the Administrative Measures for <FONT
STYLE="white-space:nowrap">Non-Resident</FONT> Enterprises to Enjoy Treatments under Tax Treaties (For Trial Implementation), which became effective in October 2009, require that <FONT STYLE="white-space:nowrap">non-resident</FONT> enterprises must
obtain approval from the relevant tax authority in order to enjoy the reduced tax rate. There are also other conditions for enjoying the reduced tax rate according to other relevant tax rules and regulations. Accordingly, our subsidiary Zai Lab
(HongKong) Limited may be able to enjoy the 5% tax rate for the dividends it receives from its PRC incorporated subsidiaries if they satisfy the conditions prescribed under SAT Circular 81 and other relevant tax rules and regulations and obtain the
approvals as required. However, according to SAT Circular 81, if the relevant tax authorities determine our transactions or arrangements are for the primary purpose of enjoying a favorable tax treatment, the relevant tax authorities may adjust the
favorable tax rate on dividends in the future. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If our Cayman Islands holding company, Zai Lab Limited, is not deemed to be a PRC resident enterprise,
holders of our ADSs and ordinary shares who are not PRC residents will not be subject to PRC income tax on dividends distributed by us or gains realized from the sale or other disposition of our shares or ADSs. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Material United States federal income tax considerations </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following discussion, subject to the limitations set forth below, describes the material U.S. federal income tax consequences for a U.S. Holder (as defined
below) of the acquisition, ownership and disposition of ADSs. This discussion is limited to U.S. Holders who are initial purchasers of ADSs pursuant to this offering and hold such ADSs as capital assets (generally, property held for investment). For
purposes of this summary, a &#147;U.S. Holder&#148; is a beneficial owner of an ADS that is for U.S. federal income tax purposes: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a citizen or individual resident of the United States; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">228 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a corporation (or any other entity treated as a corporation for U.S. federal income tax purposes) organized in or under the laws of the United States or any
state thereof, or the District of Columbia; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a trust if (i)&nbsp;it has a valid election in effect to be treated as a U.S. person for U.S. federal income tax purposes or (ii)&nbsp;a U.S. court can exercise
primary supervision over its administration and one or more U.S. persons have the authority to control all of its substantial decisions. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Except as explicitly set forth below, this summary does not address all aspects of U.S. federal income taxation that may be applicable to U.S. Holders subject to
special rules, including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">banks or other financial institutions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">insurance companies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">real estate investment trusts; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">regulated investment companies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">grantor trusts; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons holding ADSs through a partnership (including an entity or arrangement treated as a partnership for U.S. federal income tax purposes) or
S&nbsp;corporation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">dealers or traders in securities, commodities or currencies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons whose functional currency is not the U.S. dollar; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">certain former citizens and former long-term residents of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">persons holding ADSs as part of a position in a straddle or as part of a hedging, conversion or integrated transaction for U.S. federal income tax purposes; or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">direct, indirect or constructive owners of 10% or more of our total combined voting power. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, this summary does not address the 3.8% Medicare contribution tax imposed on certain net investment income, the U.S. federal estate and gift tax or the
alternative minimum tax consequences of the acquisition, ownership, and disposition of ADSs. We have not received nor do we expect to seek a ruling from the U.S. Internal Revenue Service, or the IRS, regarding any matter discussed herein. No
assurance can be given that the IRS would not assert, or that a court would not sustain, a position contrary to any of those set forth below. Each prospective investor should consult its own tax advisors with respect to the U.S. federal, state,
local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of acquiring, owning and disposing of ADSs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This discussion is based on the
U.S. Internal Revenue Code of 1986, as amended, or the Code, U.S. Treasury Regulations promulgated thereunder and administrative and judicial interpretations thereof, and the income tax treaty between the PRC and the United States, or the <FONT
STYLE="white-space:nowrap">U.S.-PRC</FONT> Tax Treaty, each as available and in effect on the date hereof, all of which are subject to change or differing interpretations, possibly with retroactive effect, which could affect the tax consequences
described herein. In addition, this summary is based, in part, upon representations made by the depositary to us and assumes that the deposit agreement, and all other related agreements, will be performed in accordance with their terms. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds ADSs, the tax treatment of the partnership and a partner in such
partnership generally will depend on the status of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">229 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
partner and the activities of the partnership. Such partner or partnership should consult its own tax advisors as to the U.S. federal income tax consequences of acquiring, owning and disposing of
ADSs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">PROSPECTIVE INVESTORS SHOULD CONSULT THEIR OWN TAX ADVISORS WITH REGARD TO THE PARTICULAR TAX CONSEQUENCES APPLICABLE TO THEIR SITUATIONS AS WELL
AS THE APPLICATION OF ANY U.S. FEDERAL, STATE, LOCAL, <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> OR OTHER TAX LAWS, INCLUDING GIFT AND ESTATE TAX LAWS. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>ADSs </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A U.S. Holder of ADSs will generally be treated, for U.S. federal income tax purposes, as the
owner of the underlying ordinary shares that such ADSs represent. Accordingly, no gain or loss will be recognized if a U.S. Holder exchanges ADSs for the underlying shares represented by those ADSs. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The U.S. Treasury has expressed concern that parties to whom ADSs are released before shares are delivered to the depositary or intermediaries in the chain of
ownership between holders and the issuer of the security underlying the ADSs, may be taking actions that are inconsistent with the claiming of foreign tax credits by U.S. Holders of ADSs. These actions would also be inconsistent with the claiming of
the reduced rate of tax, described below, applicable to dividends received by certain <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders. Accordingly, the creditability of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> withholding
taxes (if any), and the availability of the reduced tax rate for dividends received by certain <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders, each described below, could be affected by actions taken by such parties or
intermediaries. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Taxation of dividends </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As
described in &#147;Dividend Policy&#148; above, we do not currently anticipate paying any distributions on our ADSs in the foreseeable future. However, subject to the discussion below in &#147;&#151;Passive foreign investment company
considerations,&#148; to the extent there are any distributions made with respect to our ADSs, the gross amount of any distribution on the ADSs (including withheld taxes, if any) made out of our current or accumulated earnings and profits (as
determined for U.S. federal income tax purposes) will generally be taxable to a U.S. Holder as ordinary dividend income on the date such distribution is actually or constructively received. Distributions in excess of our current and accumulated
earnings and profits will be treated as a <FONT STYLE="white-space:nowrap">non-taxable</FONT> return of capital to the extent of the U.S. Holder&#146;s adjusted tax basis in the ADSs and thereafter as capital gain. However, because we do not
maintain calculations of our earnings and profits in accordance with U.S. federal income tax accounting principles, U.S. Holders should expect to treat distributions paid with respect to the ADSs as dividends. Dividends paid to corporate U.S.
Holders generally will not qualify for the dividends received deduction that may otherwise be allowed under the Code. This discussion assumes that distributions on the ADSs, if any, will be paid in U.S. dollars. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Dividends paid to a <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holder by a &#147;qualified foreign corporation&#148; may be subject to reduced rates
of U.S. federal income taxation if certain holding period and other requirements are met. A qualified foreign corporation generally includes a foreign corporation (other than a PFIC) if (1)&nbsp;its ordinary shares (or ADSs backed by ordinary
shares) are readily tradable on an established securities market in the United States or (2)&nbsp;it is eligible for benefits under a comprehensive U.S. income tax treaty that includes an exchange of information program and which the U.S. Treasury
Department has determined is satisfactory for these purposes. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have applied to list the ADSs on the Nasdaq Global Market, which is an established
securities market in the United States. Provided that such listing is approved, IRS guidance indicates that the ADSs will be readily tradable for these purposes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">230 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The United States does not have a comprehensive income tax treaty with the Cayman Islands. However, in the event that
we were deemed to be a PRC resident enterprise under the EIT Law (see &#147;&#151;People&#146;s Republic of China taxation&#148; above), although no assurance can be given, we might be considered eligible for the benefits of the <FONT
STYLE="white-space:nowrap">U.S.-PRC</FONT> Tax Treaty, and if we were eligible for such benefits, dividends paid on the ADSs, regardless of whether the ADSs are readily tradable on an established securities market in the United States, would be
eligible for the reduced rates of U.S. federal income taxation, subject to applicable limitations. U.S. Holders should consult their own tax advisors regarding the availability of the reduced tax rates on dividends in light of their particular
circumstances. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-corporate</FONT> U.S. Holders will not be eligible for reduced rates of U.S. federal income taxation
on any dividends received from us if we are a PFIC in the taxable year in which such dividends are paid or in the preceding taxable year. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event
that we were deemed to be a PRC resident enterprise under the EIT Law (see &#147;&#151;People&#146;s Republic of China taxation&#148; above), ADS holders might be subject to PRC withholding taxes on dividends paid with respect to ADSs. In that case,
subject to certain conditions and limitations, such PRC withholding tax may be treated as a foreign tax eligible for credit against a U.S. Holder&#146;s U.S. federal income tax liability under the U.S. foreign tax credit rules. For purposes of
calculating the U.S. foreign tax credit, dividends paid on the ADSs will be treated as income from sources outside the United States and will generally constitute passive category income. If a U.S. Holder is eligible for <FONT
STYLE="white-space:nowrap">U.S.-PRC</FONT> Tax Treaty benefits, any PRC taxes on dividends will not be creditable against such U.S. Holder&#146;s U.S. federal income tax liability to the extent such tax is withheld at a rate exceeding the applicable
<FONT STYLE="white-space:nowrap">U.S.-PRC</FONT> Tax Treaty rate. An eligible U.S. Holder who does not elect to claim a foreign tax credit for PRC tax withheld may instead be eligible to claim a deduction, for U.S. federal income tax purposes, in
respect of such withholding but only for the year in which such U.S. Holder elects to do so for all creditable foreign income taxes. The U.S. foreign tax credit rules are complex. U.S. Holders should consult their own tax advisors regarding the
foreign tax credit or deduction rules in light of their particular circumstances. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Taxation of capital gains </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Subject to the discussion below in &#147;&#151;Passive foreign investment company considerations&#148; below, upon the sale, exchange, or other taxable disposition
of ADSs, a U.S. Holder generally will recognize gain or loss on the taxable sale or exchange in an amount equal to the difference between the amount realized on such sale or exchange and the U.S. Holder&#146;s adjusted tax basis in the ADSs. The
initial tax basis of ADSs to a U.S. Holder will generally be the U.S. Holder&#146;s U.S. dollar purchase price for the ADS. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Subject to the discussion
below in &#147;&#151;Passive foreign investment company considerations&#148; below, such gain or loss will be capital gain or loss. Under current law, capital gains of <FONT STYLE="white-space:nowrap">non-corporate</FONT> U.S. Holders derived with
respect to capital assets held for more than one year are generally eligible for reduced rates of taxation. The deductibility of capital losses is subject to limitations. Capital gain or loss, if any, recognized by a U.S. Holder generally will be
treated as U.S. source income or loss for U.S. foreign tax credit purposes. U.S. Holders are encouraged to consult their own tax advisors regarding the availability of the U.S. foreign tax credit in consideration of their particular circumstances.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we were treated as a PRC resident enterprise for EIT Law purposes and PRC tax were imposed on any gain (see &#147;&#151;People&#146;s Republic of
China taxation&#148; above), and if a U.S. holder is eligible for the benefits of the <FONT STYLE="white-space:nowrap">U.S.-PRC</FONT> Tax Treaty, the holder may be able to treat such gain as PRC source gain under the treaty for U.S. foreign tax
credit purposes. A U.S. Holder will be eligible for <FONT STYLE="white-space:nowrap">U.S.-PRC</FONT> Tax Treaty benefits if (for purposes of the treaty) such holder is a resident of the United States and satisfies the other requirements specified in
the <FONT STYLE="white-space:nowrap">U.S.-PRC</FONT> Tax Treaty. Because the determination of treaty benefit eligibility is fact-intensive and depends upon a holder&#146;s particular circumstances, U.S. Holders should consult their tax advisors
regarding <FONT STYLE="white-space:nowrap">U.S.-PRC</FONT> Tax Treaty </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">231 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
benefit eligibility. U.S. Holders are also encouraged to consult their own tax advisors regarding the tax consequences in the event PRC tax were to be imposed on a disposition of ADSs, including
the availability of the U.S. foreign tax credit and the ability and whether to treat any gain as PRC source gain for the purposes of the U.S. foreign tax credit in consideration of their particular circumstances. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Passive foreign investment company considerations </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Status as a PFIC </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The rules governing PFICs can have adverse
tax effects on U.S. Holders. We generally will be classified as a PFIC for U.S. federal income tax purposes if, for any taxable year, either: (1)&nbsp;75% or more of our gross income consists of certain types of passive income (the Income Test), or
(2)&nbsp;the average value (determined on a quarterly basis), of our assets that produce, or are held for the production of, passive income (including cash) is 50% or more of the value of all of our assets (the Asset Test). </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Passive income generally includes dividends, interest, rents and royalties (other than certain rents and royalties derived in the active conduct of a trade or
business), annuities and gains from assets that produce passive income. If a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation owns at least 25% by value of the stock of another corporation, the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> corporation is treated for purposes of the PFIC tests as owning its proportionate share of the assets of the other corporation and as receiving directly its proportionate share of the other
corporation&#146;s income. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Whether we are a PFIC for any taxable year is a factual determination that can be made only after the end of each taxable
year and which depends on the composition of our income and the composition and value of our assets for the relevant taxable year. The fair market value of our assets for purposes of the PFIC rules (including goodwill) may be determined in large
part by reference to the quarterly market price of our ADSs, which is likely to fluctuate significantly after the offering. In addition, the composition of our income and assets will be affected by how, and how quickly, we use the cash proceeds from
the offering in our business. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Because we hold, and will continue to hold after this offering, a substantial amount of passive assets, including cash,
and because the value of our assets (including goodwill) may be determined by reference to the market value of our ADSs, which may be especially volatile due to the early stage of our drug candidates, we cannot give any assurance that we will not be
a PFIC for the current or any future taxable year. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we are a PFIC in any taxable year with respect to which a U.S. Holder owns ADSs, we generally will
continue to be treated as a PFIC with respect to such U.S. Holder in all succeeding taxable years, regardless of whether we continue to meet the tests described above, unless the U.S. Holder makes the &#147;deemed sale election&#148; described
below. Prospective investors should consult their own tax advisors regarding our PFIC status for the current or any future taxable years. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>U.S.
federal income tax treatment of a shareholder of a PFIC </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we are a PFIC for any taxable year during which a U.S. Holder owns ADSs, the U.S. Holder,
absent certain elections (including the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> and QEF elections described below), generally will be subject to adverse rules (regardless of whether we continue
to be a PFIC) with respect to (1)&nbsp;any &#147;excess distributions&#148; (generally, any distributions received by the U.S. Holder on its ADSs in a taxable year that are greater than 125% of the average annual distributions received by the U.S.
Holder in the three preceding taxable years or, if shorter, the U.S. Holder&#146;s holding period for its ADSs) and (2)&nbsp;any gain realized on the sale or other disposition, including in certain circumstances a pledge, of its ADSs. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under these adverse rules (a)&nbsp;the excess distribution or gain will be allocated ratably over the U.S. Holder&#146;s holding period, (b)&nbsp;the amount
allocated to the current taxable year and any taxable year prior to the first </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">232 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
taxable year in which we are a PFIC will be taxed as ordinary income and (c)&nbsp;the amount allocated to each other taxable year during the U.S. Holder&#146;s holding period in which we were a
PFIC (i)&nbsp;will be subject to tax at the highest rate of tax in effect for the applicable category of taxpayer for that year and (ii)&nbsp;will be subject to an interest charge at a statutory rate with respect to the resulting tax attributable to
each such other taxable year. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we are a PFIC, a U.S. Holder will generally be treated as owning a proportionate amount (by value) of stock or shares
owned by us in any direct or indirect subsidiaries that are also PFICs, or Lower-tier PFICs, and will be subject to similar adverse rules with respect to any distributions we receive from, and dispositions we make of, the stock or shares of such
subsidiaries. U.S. Holders are urged to consult their tax advisors about the application of the PFIC rules to any of our subsidiaries. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we are
classified as a PFIC and then cease to be so classified, a U.S. Holder may make an election (a &#147;deemed sale election&#148;) to be treated for U.S. federal income tax purposes as having sold such U.S. Holder&#146;s ADSs on the last day of our
taxable year during which we were a PFIC. A U.S. Holder that makes a deemed sale election would then cease to be treated as owning stock in a PFIC by reason of ownership of our ADSs. However, gain recognized as a result of making the deemed sale
election would be subject to the adverse rules described above and loss would not be recognized. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>PFIC <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;mark-to-market&#148;</FONT></FONT> election </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In certain circumstances if we are a PFIC for any taxable year, a U.S.
Holder can be subject to rules different from those described above by making a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election with respect to its ADSs, provided that the ADSs are
&#147;marketable.&#148; ADSs will be marketable if they are &#147;regularly traded&#148; on a &#147;qualified exchange&#148; or other market within the meaning of applicable U.S. Treasury Regulations. ADSs will be treated as &#147;regularly
traded&#148; in any calendar year in which more than a de minimis quantity of the ADSs are traded on a qualified exchange on at least 15&nbsp;days during each calendar quarter. A &#147;qualified exchange&#148; includes a national securities exchange
that is registered with the SEC. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under current law, the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT>
election may be available to U.S. Holders of ADSs if the ADSs are listed on the Nasdaq Global Market (which constitutes a qualified exchange) and such ADSs are &#147;regularly traded&#148; for purposes of the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election (for which no assurance can be given). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A U.S. Holder that makes a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election must include in gross income, as ordinary income, for each taxable year that we are a PFIC an amount equal to the excess, if any, of the fair market
value of the U.S. Holder&#146;s ADSs at the close of the taxable year over the U.S. Holder&#146;s adjusted tax basis in its ADSs. An electing U.S. Holder may also claim an ordinary loss deduction for the excess, if any, of the U.S. Holder&#146;s
adjusted tax basis in its ADSs over the fair market value of its ADSs at the close of the taxable year, but this deduction is allowable only to the extent of any net
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> gains previously included in income. The adjusted tax basis of a U.S. Holder&#146;s ADSs will be adjusted to reflect amounts included in gross income or
allowed as a deduction because of such <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election. If a U.S. Holder makes an effective
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election, gains from an actual sale or other disposition of ADSs in a year in which we are a PFIC will be treated as ordinary income, and any losses
incurred on a sale or other disposition of ADSs will be treated as ordinary losses to the extent of any net <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> gains previously included in income.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we are a PFIC for any taxable year in which a U.S. Holder owns ADSs but before a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is made, the adverse PFIC rules described above will apply to any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> gain recognized in the year the election is made. Otherwise, a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election will be effective for the taxable year for which the election is made and all subsequent taxable years unless the ADSs are no longer regularly
traded on a qualified exchange or the IRS consents to the revocation of the election. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">233 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election is not
permitted for the shares of any of our subsidiaries that are also classified as PFICs. Prospective investors should consult their own tax advisors regarding the availability of, and the procedure for making, a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">mark-to-market</FONT></FONT> election, and whether making the election would be advisable, including in light of their particular circumstances. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>PFIC &#147;QEF&#148; election </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Alternatively, if we provide the necessary information, a U.S. Holder can be
subject to rules different from those described above by electing to treat us (and each Lower-tier PFIC, if any) as a qualified electing fund under Section 1295 of the Code, or QEF, in the first taxable year that we (and each Lower-tier PFIC) are
treated as a PFIC with respect to the U.S. Holder. A U.S. Holder must make the QEF Election for each PFIC by attaching a separate properly completed IRS Form 8621 for each PFIC to the U.S. Holder&#146;s timely filed U.S. federal income tax return.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we determine that we are a PFIC for 2017 or any future year, then upon the request of a U.S. Holder, we will provide the information necessary for a
U.S. Holder to make a QEF election with respect to us and will endeavor to cause each Lower-tier PFIC that we control to provide such information with respect to such Lower-tier PFIC. However, there can be no assurance that we will be able to cause
any Lower-tier PFIC we do not control to provide such information. We may elect to provide the information necessary to make such QEF elections on our website. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If you make a QEF election with respect to a PFIC, you will be taxed currently on your pro rata share of the PFIC&#146;s ordinary earnings and net capital gain (at ordinary income and capital gain rates,
respectively) for each taxable year that the entity is classified as a PFIC, even if no distributions were received. If a U.S. Holder makes a QEF election with respect to us, any distributions paid by us out of our earnings and profits that were
previously included in the U.S. Holder&#146;s income under the QEF election would not be taxable to the U.S. Holder. A U.S. Holder will increase its tax basis in its ADSs by an amount equal to any income included under the QEF election and will
decrease its tax basis by any amount distributed on the ADSs that is not included in the U.S. Holder&#146;s income. In addition, a U.S. Holder will recognize capital gain or loss on the disposition of ADSs in an amount equal to the difference
between the amount realized and the U.S. Holder&#146;s adjusted tax basis in the ADSs, as determined in U.S. dollars. Once made, a QEF election remains in effect unless invalidated or terminated by the IRS or revoked by the U.S. Holder. A QEF
election can be revoked only with the consent of the IRS. A U.S. Holder will not be currently taxed on the ordinary income and net capital gain of a PFIC with respect to which a QEF election was made for any taxable year of the non-U.S. corporation
for which such corporation does not satisfy the PFIC Income Test or Asset Test. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">U.S. Holders should note that if they make QEF elections with respect to
us and any Lower-tier PFIC, they may be required to pay U.S. federal income tax with respect to their ADSs for any taxable year significantly in excess of any cash distributions received on the ADSs for such taxable year. U.S. Holders should consult
their tax advisers regarding the advisability of, and procedure for, making QEF elections in their particular circumstances. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>PFIC information
reporting requirements </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If we are a PFIC in any year with respect to a U.S. Holder, such U.S. Holder will be required to file an annual information
return on IRS Form&nbsp;8621 regarding distributions received on, and any gain realized on the disposition of, our ADSs, and certain U.S. Holders will be required to file an annual information return (also on IRS Form&nbsp;8621) relating to their
ownership of our ADSs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">THE U.S. FEDERAL INCOME TAX RULES RELATING TO PFICS ARE COMPLEX. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR OWN TAX ADVISORS WITH
RESPECT TO THE OPERATION OF THE PFIC RULES AND RELATED </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">234 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
REPORTING REQUIREMENTS IN LIGHT OF THEIR PARTICULAR CIRCUMSTANCES, INCLUDING THE ADVISABILITY OF MAKING ANY ELECTION THAT MAY BE AVAILABLE. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>U.S. Backup Withholding and Information Reporting </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Backup withholding and information reporting requirements may apply to distributions on, and proceeds from the sale or disposition of, ADSs that are held by U.S.
Holders. The payor will be required to backup withhold tax on payments made within the United States, or by a U.S. payor to a U.S. intermediary (and certain subsidiaries thereof), on the ADSs to a U.S. Holder, other than an exempt recipient, if the
U.S. Holder fails to furnish its correct taxpayer identification number or otherwise fails to comply with, or establish an exemption from, the backup withholding requirements. Backup withholding is not an additional tax. Amounts withheld as backup
withholding may be credited against a U.S. Holder&#146;s U.S. federal income tax liability (if any) or refunded provided the required information is furnished to the IRS in a timely manner. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Certain U.S. Holders of specified foreign financial assets with an aggregate value in excess of the applicable dollar threshold are required to report information relating to their holding of ADSs, subject to
certain exceptions (including an exception for shares held in accounts maintained by certain financial institutions) with their tax return for each year in which they hold ADSs. U.S. Holders should consult their own tax advisors regarding the
information reporting obligations that may arise from their acquisition, ownership or disposition of ADSs. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">THE ABOVE DISCUSSION DOES NOT COVER ALL TAX
MATTERS THAT MAY BE OF IMPORTANCE TO A PARTICULAR INVESTOR. PROSPECTIVE INVESTORS ARE STRONGLY URGED TO CONSULT THEIR OWN TAX ADVISORS ABOUT THE TAX CONSEQUENCES OF AN INVESTMENT IN THE ADSs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">235 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_20"></A>Underwriting </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are offering the ADSs described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and Leerink Partners LLC are acting as joint <FONT
STYLE="white-space:nowrap">book-running</FONT> managers of the offering and as representatives of the underwriters. We have entered into an underwriting agreement with the underwriters. Subject to the terms and conditions of the underwriting
agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover page of this prospectus, the number of
ADSs listed next to its name in the following table: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number&nbsp;of<BR>ADSs</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">J.P. Morgan Securities LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Citigroup Global Markets Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Leerink Partners LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters are committed to purchase all the ADSs offered by us if they purchase any ADSs. The underwriting agreement
also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be terminated. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters propose to offer the ADSs directly to the public at the initial public offering price set forth on the cover page of this prospectus and to certain
dealers at that price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS. Any such dealers may resell ADSs to certain other brokers or dealers at a discount of up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS from the initial public offering price. After the initial offering of the ADSs to the public, the offering price and other selling terms may be changed by the underwriters. Sales of ADSs made
outside of the United States may be made by affiliates of the underwriters. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain institutional investors have indicated an interest in purchasing up
to an aggregate of $30.0 million in ADSs in this offering. However, because indications of interest are not binding agreements or commitments to purchase, the underwriters may determine to sell more, less or no ADSs in this offering to any of these
investors, or any of these investors may determine to purchase more, less or no ADSs in this offering, including as a result of the pricing terms. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters have an option to buy up to&nbsp;1,200,000 additional ADSs from us to cover sales of ADSs by the underwriters which exceed the number of ADSs
specified in the table above. The underwriters have 30&nbsp;days from the date of this prospectus to exercise this option to purchase additional ADSs. If any ADSs are purchased with this option to purchase additional ADSs, the underwriters will
purchase ADSs in approximately the same proportion as shown in the table above. If any additional ADSs are purchased, the underwriters will offer the additional ADSs on the same terms as those on which the ADSs are being offered. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriting fee is equal to the public offering price per ADS less the amount paid by the underwriters to us per ADS. The underwriting fee is
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ADS. The following table shows the per ADS and total </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">236 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional ADSs. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Without<BR>option to<BR>purchase<BR>additional<BR>ADSs</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>With full<BR>option to<BR>purchase<BR>additional<BR>ADSs<BR>exercise</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Per ADS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees and legal and
accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $3.3 million. We have also agreed to reimburse the underwriters for certain of their expenses in an amount up to $40,000. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A prospectus in electronic format may be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in
the offering. The underwriters may agree to allocate a number of ADSs to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters and
selling group members that may make Internet distributions on the same basis as other allocations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We<I> </I>have agreed that we will not
(i)&nbsp;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or
indirectly, or file with the Securities and Exchange Commission a registration statement under the Securities Act relating to, any ADSs or securities convertible into or exchangeable or exercisable for any ADSs, or publicly disclose the intention to
make any offer, sale, pledge, disposition or filing, or (ii)&nbsp;enter into any swap or other arrangement that transfers all or a portion of the economic consequences associated with the ownership of any ADSs or any such other securities
(regardless of whether any of these transactions are to be settled by the delivery of ADSs or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC, Citigroup Global Markets Inc.
and Leerink Partners LLC for a period of 180 days after the date of this prospectus, other than (i)&nbsp;the ADSs to be sold hereunder, (ii)&nbsp;any ordinary shares or ADSs issued upon the exercise of options granted under our equity incentive
plans, (iii)&nbsp;any options and other awards granted under our equity incentive plans, (iv)&nbsp;the issuance of securities convertible into or exercisable or exchangeable for ordinary shares in connection with the hiring of new employees provided
that such securities cannot be so converted, exercised or exchanged within the 180-day restricted period, (v)&nbsp;any ordinary shares issued pursuant to the conversion or exchange of convertible or exchangeable securities, including preferred
shares and warrants, as described in this registration statement of which this prospectus forms a part, (vi)&nbsp;the filing of any registration statement on Form S-8 relating to any benefit plans or arrangements disclosed in this registration
statement of which this prospectus forms a part and the issuance of securities registered pursuant thereto, or (vii)&nbsp;any ordinary shares or securities exercisable for, convertible into or exchangeable for ordinary shares in connection with any
acquisition, collaboration, licensing or other joint venture or strategic transaction or any debt financing transaction involving the Company; provided that, in the case of clauses (ii), (iii), (v) and (vii), (x) such issuances shall not in the
aggregate be greater than 10% of the total outstanding ordinary shares immediately following the completion of this offering of ADSs which, for the avoidance of doubt, includes the ordinary shares issuable upon the conversion of preferred shares in
connection with this offering, and (y) the recipients of such shares agree to be bound by a lockup letter in the form executed by directors and officers. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our directors and executive officers, and certain of our significant shareholders have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with
the underwriters prior to the commencement of this offering pursuant to which each of these </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">237 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
persons or entities, with limited exceptions, for a period of 180&nbsp;days after the date of this prospectus, may not, without the prior written consent of J.P. Morgan Securities LLC, Citigroup
Global Markets Inc. and Leerink Partners LLC, (1)&nbsp;offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to
purchase, or otherwise transfer or dispose of, directly or indirectly, any ADSs or any securities convertible into or exercisable or exchangeable for our ADSs (including, without limitation, ADSs or such other securities which may be deemed to be
beneficially owned by such directors, executive officers, managers and members in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant) or (2)&nbsp;enter into any swap or
other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the ADSs or such other securities, whether any such transaction described in clause&nbsp;(1) or&nbsp;(2) above is to be settled by delivery of ADSs
or such other securities, in cash or otherwise, or (3)&nbsp;make any demand for or exercise any right with respect to the registration of any ADSs or any security convertible into or exercisable or exchangeable for our ADSs. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The restrictions described in the immediately preceding paragraph do not apply to, among other items: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the sale of ADSs to the underwriters in this offering; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">transfers of ADSs or ordinary shares or such other securities as a bona fide gift or gifts or by testate succession or intestate distribution;
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">transfers of ADSs or ordinary shares acquired in the open market; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the exercise of stock options or other similar awards granted pursuant to our equity incentive plans, as described herein; provided that the terms of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement shall apply to any ADSs or ordinary shares issued upon such exercise; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any ordinary shares or such other securities that are used for the primary purpose of satisfying any tax or other governmental withholding obligation, through
cashless surrender or otherwise, with respect to any award or equity-based compensation granted pursuant to our equity incentive plans, as described herein, or in connection with tax or other obligations as a result of testate succession or
intestate distribution; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">transfers to immediate family member or members, or to a trust, the direct or indirect beneficiaries of which are a
<FONT STYLE="white-space:nowrap">lock-up</FONT> party and/or a member or members of his or her immediate family; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">transfers of ordinary shares or any security convertible into or exercisable or exchangeable for ordinary shares to us pursuant to any contractual arrangement
that provides for the repurchase of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#146;s ordinary shares or such other securities by us or in connection with the termination of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
party&#146;s employment with us or the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#146;s failure to meet certain conditions set out upon receipt of such ordinary shares or other such securities; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">subject to certain limitations, distributions of ADSs, ordinary shares or such other securities to members or stockholders of the undersigned or to any
corporation, partnership or other person or entity that is a direct or indirect affiliate of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">any transfers, sales, tenders or other dispositions of ordinary shares or any security convertible into or exercisable or exchangeable for ordinary shares
pursuant to a bona fide third party tender offer, merger, amalgamation, consolidation or other similar transaction made to or involving all holders of ordinary shares or such other securities pursuant to which one hundred percent (100%) of our
ownership is transferred to such third party (including, without limitation, the entering into any <FONT STYLE="white-space:nowrap">lock-up,</FONT> voting or similar agreement pursuant to which the <FONT STYLE="white-space:nowrap">lock-up</FONT>
party may agree to transfer, sell, tender or otherwise dispose of ordinary shares or other such securities in connection with such transaction, or vote any ordinary shares or other such securities in favor of any such transaction); provided that
such tender offer merger, amalgamation, consolidation or other similar transaction is completed. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have agreed to indemnify the
underwriters against certain liabilities, including liabilities under the Securities Act of 1933. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">238 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have applied for listing of the ADSs on the Nasdaq Global Market under the symbol &#147;ZLAB&#148;. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling ADSs in the open
market for the purpose of preventing or retarding a decline in the market price of the ADSs while this offering is in progress. These stabilizing transactions may include making short sales of the ADSs, which involves the sale by the underwriters of
a greater number of ADSs than they are required to purchase in this offering, and purchasing ADSs on the open market to cover positions created by short sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not
greater than the underwriters&#146; option to purchase additional ADSs referred to above, or may be &#147;naked&#148; shorts, which are short positions in excess of that amount. The underwriters may close out any covered short position either by
exercising their option to purchase additional ADSs, in whole or in part, or by purchasing ADSs in the open market. In making this determination, the underwriters will consider, among other things, the price of ADSs available for purchase in the
open market compared to the price at which the underwriters may purchase ADSs through the option to purchase additional ADSs. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure
on the price of the ADSs in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase ADSs in the open market to cover the position.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters have advised us that, pursuant to Regulation&nbsp;M of the Securities Act of 1933, they may also engage in other activities that
stabilize, maintain or otherwise affect the price of the ADSs, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase ADSs in the open market in stabilizing transactions or to cover short sales,
the representatives can require the underwriters that sold those ADSs as part of this offering to repay the underwriting discount received by them. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">These activities may have the effect of raising or maintaining the market price of the ADSs or preventing or retarding a decline in the market price of the ADSs,
and, as a result, the price of the ADSs may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters may carry out these
transactions on the Nasdaq Stock Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Prior to this offering, there has been no public market for our ADSs. The initial public offering price will be determined by negotiations between us and the representatives of the underwriters. In determining the
initial public offering price, we and the representatives of the underwriters expect to consider a number of factors including: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the information set forth in this prospectus and otherwise available to the representatives; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our prospects and the history and prospects for the industry in which we compete; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an assessment of our management; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">our prospects for future earnings; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the general condition of the securities markets at the time of this offering; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the recent market prices of, and demand for, publicly traded ADSs of generally comparable companies; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">other factors deemed relevant by the underwriters and us. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Neither we nor the underwriters can assure investors that an active trading market will develop for our ADSs, or that the ADSs will trade in the public market at or above the initial public offering price.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by
this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in
connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">239 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any
restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an
offer or a solicitation is unlawful. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriters and their respective affiliates are full service financial institutions engaged in various
activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and
their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory, commercial banking and investment banking services for us and our affiliates, for which they received or will receive
customary fees and expenses. In the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related
derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve our securities and/or instruments. The underwriters and
their respective affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or
short positions in such securities and instruments. For instance, in August 2017, J.P. Morgan Securities LLC was paid approximately $900,000 for its service as a financial advisor in connection with our Series C preferred shares private placement
transaction. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Australia </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">This prospectus: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">does not constitute a product disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth) (the &#147;Corporations Act&#148;);
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">has not been, and will not be, lodged with the Australian Securities and Investments Commission (&#147;ASIC&#148;), as a disclosure document for the purposes of
the Corporations Act and does not purport to include the information required of a disclosure document under Chapter 6D.2 of the Corporations Act; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">does not constitute or involve a recommendation to acquire, an offer or invitation for issue or sale, an offer or invitation to arrange the issue or sale, or an
issue or sale, of interests to a &#147;retail client&#148; (as defined in section 761G of the Corporations Act and applicable regulations) in Australia; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the categories of investors, or Exempt
Investors, available under section 708 of the Corporations Act. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The ADSs may not be directly or indirectly offered for subscription or
purchased or sold, and no invitations to subscribe for or buy the ADSs may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any ADSs may be distributed in Australia, except where
disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the ADSs, you represent and warrant to us that you
are an Exempt Investor. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As any offer of ADSs under this document will be made without disclosure in Australia under Chapter 6D.2 of the Corporations
Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of the exemptions in section 708 applies to that resale. By
applying for the ADSs you undertake to us that you will not, for a period of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">240 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
12 months from the date of issue of the ADSs, offer, transfer, assign or otherwise alienate those securities to investors in Australia except in circumstances where disclosure to investors is not
required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective
investors in Bermuda </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">ADSs may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda
which regulates the sale of securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to
do so under applicable Bermuda legislation. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in the British Virgin Islands </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The ADSs are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on our behalf. The
ADSs may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands), &#147;BVI Companies&#148;), but only where the offer will be made to, and received by, the relevant BVI Company entirely outside of
the British Virgin Islands. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Canada </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The ADSs may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT>
Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions and Ongoing Registrant
Obligations. Any resale of the ADSs must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a
misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any
applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply
with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in China </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This Prospectus does not constitute a public offer of ADSs, whether
by sale or subscription, in the People&#146;s Republic of China (the &#147;PRC&#148;). The ADSs are not being offered or sold directly or indirectly in the PRC to or for the benefit of, legal or natural persons of the PRC. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the ADSs or any beneficial interest therein without obtaining all prior
PRC&#146;s governmental approvals that are required, whether statutorily or otherwise. Persons who come into possession of this document are required by the issuer and its representatives to observe these restrictions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">241 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in the European Economic Area </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a &#147;Relevant Member State&#148;), with
effect from and including the date on which the Prospectus Directive is implemented in that Relevant Member State, no offer of ADSs may be made to the public in that Relevant Member State other than: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">A.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">B.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the prior consent of the underwriters; or
</FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">C.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">provided that no such offer of ADSs shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Directive and each person who initially acquires any ADSs or to whom any offer
is made will be deemed to have represented, acknowledged and agreed to and with each of the underwriters and us that it is a &#147;qualified investor&#148; within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of
the Prospectus Directive. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the case of any ADSs being offered to a financial intermediary as that term is used in Article 3(2) of the Prospectus
Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the ADSs acquired by it in the offer have not been acquired on a <FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf
of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any ADSs to the public other than their offer or resale in a Relevant Member State to qualified investors as so
defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For the purposes
of this provision, the expression an &#147;<B>offer of ADSs to the public</B>&#148; in relation to any ADSs in any Relevant Member State means the communication in any form and by means of sufficient information on the terms of the offer and the
ADSs to be offered so as to enable an investor to decide to purchase ADSs, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression &#147;Prospectus Directive&#148;
means Directive 2003/71/EC (as amended, including by Directive 2010/73/EU), and includes any relevant implementing measure in the Relevant Member State. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Hong Kong </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The ADSs have
not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made
under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong or which do not
constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the ADSs has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether
in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to ADSs which are
or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made under that Ordinance. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Japan </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The ADSs have not
been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the ADSs nor any interest therein may be offered or sold,
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">242 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
directly or indirectly, in Japan or to, or for the benefit of, any &#147;resident&#148; of Japan (which term as used herein means any person resident in Japan, including any corporation or other
entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the
registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Korea </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The ADSs have not
been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and regulations thereunder (the &#147;FSCMA&#148;), and the ADSs have been and will be offered in Korea as a private placement
under the FSCMA. None of the ADSs may be offered, sold or delivered directly or indirectly, or offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of
Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of Korea and the decrees and regulations thereunder (the &#147;FETL&#148;). Furthermore, the purchaser of the ADSs
shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of the ADSs. By the purchase of the ADSs, the relevant holder thereof will be deemed to represent and
warrant that if it is in Korea or is a resident of Korea, it purchased the ADSs pursuant to the applicable laws and regulations of Korea. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to
prospective investors in Malaysia </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">No prospectus or other offering material or document in connection with the offer and sale of the ADSs has been or
will be registered with the Securities Commission of Malaysia (&#147;Commission&#148;) for the Commission&#146;s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus and any other document or material in
connection with the offer or sale, or invitation for subscription or purchase, of the ADSs may not be circulated or distributed, nor may the ADSs be offered or sold, or be made the subject of an invitation for subscription or purchase, whether
directly or indirectly, to persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a Capital Markets Services Licence; (iii)&nbsp;a person who acquires the ADSs, as principal, if the offer is on
terms that the ADSs may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her
spouse exceeds RM3&nbsp;million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign
currencies) per annum in the preceding twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months;
(vii)&nbsp;a corporation with total net assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership with total net assets exceeding RM10&nbsp;million (or its equivalent
in foreign currencies); (ix) a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act
2010; and (xi)&nbsp;any other person as may be specified by the Commission; provided that, in the each of the preceding categories (i)&nbsp;to (xi), the distribution of the ADSs is made by a holder of a Capital Markets Services Licence who carries
on the business of dealing in securities. The distribution in Malaysia of this prospectus is subject to Malaysian laws. This prospectus does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or
purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">243 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Saudi Arabia </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as issued by the board of the Saudi Arabian Capital Market
Authority (&#147;CMA&#148;) pursuant to resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-11-2004</FONT></FONT> dated 4&nbsp;October 2004 as amended by resolution number <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">1-28-2008,</FONT></FONT> as amended (the &#147;CMA Regulations&#148;). The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability whatsoever for any
loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not
understand the contents of this document, you should consult an authorised financial adviser. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in Singapore
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of ADSs may not be circulated or distributed, nor may the ADSs be offered or sold, or be made the subject of an invitation for subscription or
purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;), (ii) to a relevant person
pursuant to Section&nbsp;275(1), or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section&nbsp;275 of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other
applicable provision of the SFA. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Where the ADSs are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which
is owned by one or more individuals, each of whom is an accredited investor; or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited
investor, </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest
(howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the ADSs pursuant to an offer made under Section&nbsp;275 of the SFA except: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section 275(1A) or Section
276(4)(i)(B) of the SFA; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">where no consideration is or will be given for the transfer; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(c)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">where the transfer is by operation of law; </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(d)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">as specified in Section&nbsp;276(7) of the SFA; or </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(e)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore </FONT></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in South Africa </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Due to
restrictions under the securities laws of South Africa, the ADSs are not offered, and the offer shall not be transferred, sold, renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the
following exemptions applies: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">i.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the offer, transfer, sale, renunciation or delivery is to: </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(a)
persons whose ordinary business is to deal in securities, as principal or agent; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">244 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(b) the South African Public Investment Corporation; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">(c) persons or entities regulated by the Reserve Bank of South Africa; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(d) authorised financial service providers
under South African law; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(e) financial institutions recognised as such under South African law; </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">(f) a wholly-owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an authorised portfolio manager for a pension fund or collective investment scheme (in each
case duly registered as such under South African law); or </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">(g) any combination of the person in (a)&nbsp;to (f); or </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">ii.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">No &#147;offer to the public&#148; (as such term is defined in the South African Companies Act, No.&nbsp;71 of 2008 (as amended or
<FONT STYLE="white-space:nowrap">re-enacted)</FONT> (the &#147;South African Companies Act&#148;)) in South Africa is being made in connection with the issue of the ADSs. Accordingly, this document does not, nor is it intended to, constitute a
&#147;registered prospectus&#148; (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and/or filed with, the South African Companies and
Intellectual Property Commission or any other regulatory authority in South Africa. Any issue or offering of the ADSs in South Africa constitutes an offer of the ADSs in South Africa for subscription or sale in South Africa only to persons who fall
within the exemption from &#147;offers to the public&#148; set out in section 96(1)(a) of the South African Companies Act. Accordingly, this document must not be acted on or relied on by persons in South Africa who do not fall within section
96(1)(a) of the South African Companies Act (such persons being referred to as &#147;SA Relevant Persons&#148;). Any investment or investment activity to which this document relates is available in South Africa only to SA Relevant Persons and will
be engaged in South Africa only with SA relevant persons. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Certain of the underwriters and their affiliates have provided in the past to us and our
affiliates and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business, for which they have received and
may continue to receive customary fees and commissions. In addition, from time to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or
their customers, long or short positions in our debt or equity securities or loans, and may do so in the future. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in
Switzerland </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The ADSs may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;) or on any other
stock exchange or regulated trading facility in Switzerland. This document does not constitute a prospectus within the meaning of, and has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art.
1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this
document nor any other offering or marketing material relating to the ADSs or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Neither this document nor any other offering or marketing material relating to the offering, us or the ADSs have been or will be filed with or approved by any Swiss regulatory authority. In particular, this
document will not be filed with, and the offer of ADSs will not be supervised by, the Swiss Financial Market Supervisory Authority </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">245 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
FINMA (FINMA), and the offer of ADSs has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor protection afforded to
acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of ADSs. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in
Taiwan </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The ADSs have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws
and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of
the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorised to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the ADSs in Taiwan. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in the United Arab Emirates </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The ADSs have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai International Financial
Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this prospectus does not constitute a public offer of securities
in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. This prospectus has not been approved by or filed with the Central Bank of the United Arab Emirates, the Securities and
Commodities Authority or the Dubai Financial Services Authority. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Notice to prospective investors in the United Kingdom </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at
persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive)&nbsp;(i) who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such
persons together being referred to as &#147;relevant persons&#148;) or otherwise in circumstances which have not resulted and will not result in an offer to the public of the ADSs in the United Kingdom. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any
action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">246 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_21"></A>Legal matters </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We are being represented by Ropes&nbsp;&amp; Gray LLP with respect to certain legal matters as to United States federal securities and New York State law. The underwriters are being represented by Davis
Polk&nbsp;&amp; Wardwell LLP with respect to certain legal matters as to United States federal securities and New York State law. One of Davis Polk &amp; Wardwell LLP&#146;s partners is the spouse of Nisa Leung, who is one of our directors and a
Managing Partner at Qiming Venture Partners which beneficially owns approximately 25.3% of our ordinary shares prior to this offering. The validity of the ordinary shares represented by the ADSs offered in this offering will be passed upon for us by
Travers Thorp Alberga. Certain legal matters as to PRC law will be passed upon for us by Zhong Lun Law Firm and for the underwriters by Fangda Partners. Ropes&nbsp;&amp; Gray LLP may rely upon Travers Thorp Alberga with respect to matters governed
by Cayman Islands law and Zhong Lun Law Firm with respect to matters governed by PRC law. Davis Polk&nbsp;&amp; Wardwell LLP may rely upon Fangda Partners with respect to matters governed by PRC law. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_22"></A>Experts </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The consolidated
financial statements as of December 31, 2015 and 2016, and for each of the two years in the period ended December 31, 2016, and the related financial statement schedule included in this prospectus have been audited by Deloitte Touche Tohmatsu
Certified Public Accountants LLP, an independent registered public accounting firm, as stated in their report appearing herein. Such financial statements and financial statement schedule are included in reliance upon the report of such firm given
upon their authority as experts in accounting and auditing. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The offices of Deloitte Touche Tohmatsu Certified Public Accountants LLP are located at Bund
Center, 30th Floor 222 Yan An Road East, Shanghai, the People&#146;s Republic of China. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_23"></A>Enforcement of civil liabilities
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are incorporated in the Cayman Islands to take advantage of certain benefits associated with being a Cayman Islands exempted company, such as:
</FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">political and economic stability; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">an effective judicial system; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">a favorable tax system; </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the absence of exchange control or currency restrictions; and </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the availability of professional and support services. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">However, certain disadvantages accompany incorporation in the Cayman Islands. These disadvantages include, but are not limited to: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">the Cayman Islands has a less developed body of securities laws as compared to the United States and these securities laws provide significantly less protection
to investors as compared to the United States; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">Cayman Islands companies may not have standing to sue before the federal courts of the United States. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Our constituent documents do not contain provisions requiring that disputes, including those arising under the securities laws of the United States, between us, our
officers, directors and shareholders, be arbitrated. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Substantially all of our operations are conducted in China, and substantially all of our assets are
located in China. All of our directors and executive officers are nationals or residents of jurisdictions other than the United </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">247 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
States and most of their assets are located outside the United States. As a result, it may be difficult for a shareholder to effect service of process within the United States upon these persons,
or to enforce against us or them judgments obtained in United States courts, including judgments predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We have appointed&nbsp;Law Debenture Corporate Services Inc., located at 801 2nd Avenue, Suite 403, New York, New York 10017 as our agent upon whom process may be
served in any action brought against us under the securities laws of the United States. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Travers Thorp Alberga, our legal counsel as to Cayman Islands
law, and Zhong Lun Law Firm, our legal counsel as to PRC law, have advised us, respectively, that there is uncertainty as to whether the courts of the Cayman Islands and China, respectively, would: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">recognize or enforce judgments of United States courts obtained against us or our directors or officers predicated upon the civil liability provisions of the
securities laws of the United States or any state in the United States; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">entertain original actions brought in each respective jurisdiction against us or our directors or officers predicated upon the securities laws of the United
States or any state in the United States. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There is uncertainty with regard to Cayman Islands law relating to whether a judgment
obtained from the United States courts under civil liability provisions of the securities laws will be determined by the courts of the Cayman Islands as penal or punitive in nature. If such a determination is made, the courts of the Cayman Islands
will not recognize or enforce the judgment against a Cayman Islands company. Because the courts of the Cayman Islands have yet to rule on whether such judgments are penal or punitive in nature, it is uncertain whether they would be enforceable in
the Cayman Islands. Travers Thorp Alberga has advised us that although there is no statutory enforcement in the Cayman Islands of judgments obtained in the federal or state courts of the United States, a judgment in personam obtained in such
jurisdiction will be recognized and enforced in the courts of the Cayman Islands at common law, without any <FONT STYLE="white-space:nowrap">re-examination</FONT> of the merits of the underlying dispute, by an action commenced on the foreign
judgment debt in the Grand Court of the Cayman Islands, provided such judgment: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">is given by a competent foreign court with jurisdiction to give the judgment; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">imposes a specific positive obligation on the judgment debtor (such as an obligation to pay a liquidated sum or perform a specified obligation);
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">is final and conclusive; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">is not in respect of taxes, a fine or a penalty; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">was not obtained in a manner and is not of a kind the enforcement of which is contrary to natural justice or the public policy of the Cayman Islands.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Zhong Lun Law Firm has further advised us that the recognition and enforcement of foreign judgments are provided for under the PRC
Civil Procedures Law. PRC courts may recognize and enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based either on treaties between China and the country where the judgment is made or on principles of
reciprocity between jurisdictions. China does not have any treaties or other form of reciprocity with the United States or the Cayman Islands that provide for the reciprocal recognition and enforcement of foreign judgments. In addition, according to
the PRC Civil Procedures Law, courts in China will not enforce a foreign judgment against us or our directors and officers if they decide that the judgment violates the basic principles of PRC law or national sovereignty, security or social public
interest. As a result, it is uncertain whether and on what basis a PRC court would enforce a judgment rendered </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">248 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
by a court in the United States or in the Cayman Islands. Under the PRC Civil Procedures Law, foreign shareholders may originate actions based on PRC law against a company in China for disputes
if they can establish sufficient nexus to the PRC for a PRC court to have jurisdiction, and meet other procedural requirements, including, among others, the plaintiff must have a direct interest in the case, and there must be a concrete claim, a
factual basis and a cause for the suit. However, it would be difficult for foreign shareholders to establish sufficient nexus to China by virtue only of holding our ADSs or ordinary shares. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, it will be difficult for U.S. shareholders to originate actions against us in China in accordance with PRC laws because we are incorporated under the laws of the Cayman Islands and it will be difficult
for U.S. shareholders, by virtue only of holding our ADSs or ordinary shares, to establish a connection to China for a PRC court to have jurisdiction as required under the PRC Civil Procedures Law. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">249 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_24"></A>Expenses relating to this offering </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table sets forth the costs and expenses, other than the underwriting discounts and commissions, payable by the registrant in connection with the sale
of ordinary shares being registered. All amounts are estimates except for the SEC registration fee, the Financial Industry Regulatory Authority filing fee and The Nasdaq Global Market listing fee. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Item</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Amount&nbsp;to&nbsp;be<BR>paid</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">SEC registration fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">19,194</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">FINRA filing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">The Nasdaq Global Market listing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Printing and engraving expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">250,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Legal fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,055,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounting fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">550,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Miscellaneous expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">200,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="rom358845_25"></A>Where you can find more information </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> under the Securities Act with respect to the ADSs offered hereby. This prospectus, which constitutes a part of
the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For further information with respect to us and the ADSs offered hereby, please refer to the
registration statement and the exhibits and schedules filed therewith. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily
complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. A copy of the registration statement and the exhibits and schedules
filed therewith may be inspected without charge at the public reference room maintained by the SEC, located at 100 F Street N.E., Washington, D.C. 20549, and copies of all or any part of the registration statement may be obtained from such offices
upon the payment of the fees prescribed by the SEC. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information about the
public reference room. The SEC also maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address is www.sec.gov. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We are subject to periodic reporting and other informational requirements of the Exchange Act as applicable to foreign private issuers. Accordingly, we are required
to file reports, including annual reports on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> and other information with the SEC. As a foreign private issuer, we are exempt from the rules of the Exchange Act prescribing the furnishing and content
of proxy statements to shareholders and Section&nbsp;16 short-swing profit reporting for our officer, directors and holders of more than 10% of our ordinary shares. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">250 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="index"></A>Index to consolidated financial statements </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin358845_1">Report of Independent Registered Public Accounting Firm</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">F-2</FONT></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin358845_2">Consolidated Balance Sheets as of December&nbsp;31, 2015 and 2016</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">F-3</FONT></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin358845_3">Consolidated Statements of Operations for the Years Ended December&nbsp;31, 2015 and 2016</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">F-5</FONT></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin358845_4">Consolidated Statements of Comprehensive Loss for the Years Ended December&nbsp;31, 2015 and
2016</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">F-6</FONT></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin358845_5">Consolidated Statements of Changes in Shareholders&#146; Deficits for the Years Ended December&nbsp;
31, 2015 and 2016</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">F-7</FONT></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin358845_6">Consolidated Statements of Cash Flows for the Years Ended December&nbsp;31, 2015 and 2016</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">F-8</FONT></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin358845_7">Notes to Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">F-9</FONT></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin358845_8">Schedule <FONT STYLE="white-space:nowrap">I-Condensed</FONT> Financial Information of Parent
Company</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">F-39</FONT></FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Index to unaudited condensed consolidated financial statements </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin358845_9">Audited Consolidated Balance Sheet as of December&nbsp;
31, 2016 and Unaudited Condensed Consolidated Balance Sheet as of June 30, 2017</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-43</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin358845_10">Unaudited Condensed Consolidated Statements of Operations for the Six Months Ended June 30, 2016 and
2017</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-44</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin358845_11">Unaudited Condensed Consolidated Statements of Comprehensive Loss for the Six Months Ended June&nbsp;
30, 2016 and 2017</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-45</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin358845_11a">Unaudited Condensed Consolidated Statements of Changes in Shareholders&#146; Deficits for the Six Months Ended June 30,
 2016 and 2017 </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-46</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin358845_12">Unaudited Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2016 and
2017</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-47</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="#fin358845_13">Notes to Unaudited Condensed Consolidated Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">F-48</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin358845_1"></A>Report of independent registered public accounting firm </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To the Board of Directors and Shareholders of Zai Lab Limited </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We
have audited the accompanying consolidated balance sheets of Zai Lab Limited (the&nbsp;&#147;Company&#148;) and its subsidiaries (collectively referred to as the &#147;Group&#148;) as of December&nbsp;31, 2015 and 2016, and the related consolidated
statements of operations, comprehensive loss, changes in shareholders&#146; deficits, and cash flows for each of the two years in the period ended December&nbsp;31, 2016 and related financial statement schedule included in Schedule&nbsp;I. These
consolidated financial statements and financial statement schedule are the responsibility of the Group&#146;s management. Our responsibility is to express an opinion on these consolidated financial statements and financial statement schedule based
on our&nbsp;audits. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United&nbsp;States).
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Group is not required to have, nor were we engaged to perform, an audit of its
internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of the Group&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our&nbsp;opinion.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In our opinion, such consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position
of the Group as of December&nbsp;31, 2015 and 2016, and the results of their operations and their cash flows for each of the two years in the period ended December&nbsp;31, 2016, in conformity with accounting principles generally accepted in the
United&nbsp;States of America. Also, in our opinion, such financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set
forth&nbsp;therein. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">/s/ Deloitte Touche Tohmatsu Certified Public Accountants&nbsp;LLP </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Shanghai, China </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">May 30, 2017 (September 1, 2017 as to Note 2(w)) </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin358845_2"></A>Consolidated balance sheets </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In
U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Note</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Current assets:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,160,696</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">83,948,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Prepayments and other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">69,020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">143,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,229,716</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">84,092,297</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cost method investment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Prepayments for Equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,417,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">707,584</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,246,058</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,525</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Long term deposits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">267,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Value added tax recoverable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,376,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,939,825</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">88,907,285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Liabilities, mezzanine equity and shareholders&#146; deficits</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Current liabilities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,453,054</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">523,338</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,980,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,900,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">507,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">750,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,940,985</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,173,456</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred subsidy income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">61,599</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">778,434</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,002,584</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,951,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Commitments and Contingencies (Note 15)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Mezzanine equity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Series A1 convertible preferred shares (par value US$0.00006 per share; 8,466,667 shares authorized, 8,466,665 shares issued and
outstanding as of December&nbsp;31, 2015 and 2016)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,028,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,028,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Series A2 convertible preferred shares (par value US$0.00006 per share; 8,904,032 shares authorized, 8,442,221 shares issued and
outstanding as of December&nbsp;31, 2015 and 2016)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,278,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,278,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Series B1 convertible preferred shares (par value US$0.00006 per share; 5,562,337 shares authorized, 5,562,335 shares issued and
outstanding as of 2016)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53,100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Series B2 convertible preferred shares (par value US$0.00006 per share; 3,973,098 shares authorized, 3,973,096 shares issued and
outstanding as of December&nbsp;31, 2016)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53,100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total mezzanine equity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28,307,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">134,507,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Consolidated balance sheets </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars
(&#147;$&#148;) except for number of shares) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Shareholders&#146; deficits</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ordinary shares (par value of US$0.00006 per share; 83,333,333 shares authorized, 8,885,184 and 9,657,175 shares issued and outstanding as
of December&nbsp;31,2015 and 2016, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Subscription receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Additional <FONT STYLE="white-space:nowrap">Paid-in</FONT> Capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,388,410</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,313,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated deficits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(22,655,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(60,167,437</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated other comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(103,620</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(698,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total shareholders&#146; deficits</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,369,903</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(51,551,749</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total liabilities, mezzanine equity and shareholders&#146; deficits</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,939,825</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">88,907,285</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin358845_3"></A>Consolidated statements of operations </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year
ended</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(13,587,145</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(32,149,157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,762,292</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,380,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(16,349,437</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(38,529,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">403,266</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fair value of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,980,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,920,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">341,112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,533,966</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(38,417</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(143</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,021,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,021,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss attributable to ordinary shareholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,021,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share attributable to ordinary shareholders-basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average shares used in calculating net loss per ordinary share-basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,693,655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,439,028</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin358845_4"></A>Consolidated statements of comprehensive loss </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>December
31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,021,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other comprehensive loss, net of tax of nil:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign currency translation adjustments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(98,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(594,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,120,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(38,107,124</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin358845_5"></A>Consolidated statements of shareholders&#146; deficits </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Ordinary shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Additional<BR>paid in</B></FONT><br><FONT
STYLE="font-family:arial" SIZE="2"><B>capital</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Subscription</B></FONT><br><FONT
STYLE="font-family:arial" SIZE="2"><B>receivables</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Accumulated</B></FONT><br><FONT
STYLE="font-family:arial" SIZE="2"><B>deficits</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Accumulated&nbsp;other</B></FONT><br><FONT
STYLE="font-family:arial" SIZE="2"><B>comprehensive&nbsp;loss</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number<BR>of shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at January&nbsp;1, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,166,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">490</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,687,048</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,633,488</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,727</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,950,677</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Issuance of ordinary shares upon vesting of restricted shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">718,518</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Share-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,701,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,701,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,021,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,021,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign currency translation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(98,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(98,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,885,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,388,410</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(22,655,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(103,620</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,369,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Issuance of ordinary shares upon vesting of restricted shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">771,991</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Share-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,925,278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,925,278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign currency translation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(594,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(594,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,657,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,313,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(60,167,437</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(698,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(51,551,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="28" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin358845_6"></A>Consolidated statements of cash flows </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year
ended</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,021,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Adjustments to reconcile net loss to net cash provided by operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">125,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">198,224</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Amortization of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">733</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">781</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Share-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,701,404</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,925,278</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss on disposal of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">38,417</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fair value of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,980,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,920,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Changes in operating assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Prepayments and other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33,713</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(74,507</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Long term deposits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(267,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Value added tax recoverable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,376,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,287,687</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(929,716</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Payroll payable and other payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">327,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">242,187</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred subsidy income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">61,599</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">716,835</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,464,910</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(32,158,031</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Cash flows from investing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Purchase of cost method investment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Purchases of property and equipment</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Purchase of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(738,470</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:arial" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,223,882</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5,615</FONT></P></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></P></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(738,470</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,729,497</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Cash flows from financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Proceed from issuance of convertible preferred shares and warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,278,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">106,200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,278,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">106,200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Effect of foreign exchange rate changes on cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(66,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(524,398</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net increases in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,008,422</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">70,788,074</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents&#151;beginning of the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,152,274</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,160,696</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents&#151;end of the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,160,696</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">83,948,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these consolidated financial statements </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin358845_7"></A>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of
shares) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>1. Organization and principal activities </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">ZAI Lab Limited (the &#147;Company&#148;) was incorporated on March&nbsp;28, 2013 in the Cayman Islands as an exempted company with limited liability under the Companies Law of the Cayman Islands. The Company and
its subsidiaries (collectively referred to as the &#147;Group&#148;) are principally engaged in discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical needs in the China market,
including in the fields of oncology, autoimmune and infectious disease therapies. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As at December&nbsp;31, 2016, the Group&#146;s significant operating
subsidiaries are as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name of company</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Place of<BR>incorporation</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Date of<BR>incorporation</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percentage&nbsp;of<BR>ownership</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Principal activities</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">ZAI Lab (Hong Kong) Limited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Hong&nbsp;Kong</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">April&nbsp;29,&nbsp;2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100%</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Operating&nbsp;company<BR>for business<BR>development and<BR>R&amp;D activities</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">ZAI Lab (Shanghai) Co., Ltd.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">The&nbsp;People&#146;s<BR>Republic&nbsp;of&nbsp;China<BR>(&#147;PRC&#148;&nbsp;or&nbsp;&#147;China&#148;)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">January&nbsp;6,&nbsp;2014</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100%</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Development and<BR>commercialisation</FONT> <P STYLE="margin-bottom:0px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">of innovative</FONT></P>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">medicines</FONT></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">ZAI Lab (AUST) Pty., Ltd.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Australia</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">December&nbsp;10,&nbsp;2014</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100%</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Clinical trial</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">activities</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">ZAI Lab (Suzhou) Co., Ltd.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PRC</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">October 20, 2015</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100%</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Development and<BR>commercialisation<BR>of innovative<BR>medicines</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="11" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>2. Summary of significant accounting policies </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>(a) Basis of Presentation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The consolidated financial statements have been prepared in accordance with
U.S. generally accepted accounting principles (&#147;U.S. GAAP&#148;). </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(b) Principles of consolidation </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The consolidated financial statements include the financial statements of the Company and its subsidiaries. All intercompany transactions and balances among the
Group and its subsidiaries are eliminated upon consolidation. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(c) Use of estimates </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities, and disclosures of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the period. Areas where management uses subjective judgment include
estimating the useful lives of long-lived assets, assessing the impairment of long-lived assets, valuation of ordinary shares, share-based compensation expenses, recoverability of deferred tax assets and the fair value of the financial instruments.
Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results
could differ from these estimates. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(d) Foreign currency translation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The functional currency of ZAI Lab Limited and ZAI Lab (Hong Kong) Limited are the United States dollar (&#147;$&#148;). The Group&#146;s PRC subsidiaries determined their functional currency to be Chinese Renminbi
(&#147;RMB&#148;). The Group&#146;s Australia subsidiary determined its functional currency to be Australia dollar (&#147;A$&#148;). The determination of the respective functional currency is based on the criteria of Accounting Standard Codification
(&#147;ASC&#148;) 830, <I>Foreign Currency Matters</I>. The Group uses the United States dollar as its reporting currency. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Assets and liabilities are
translated from each entity&#146;s functional currency to U.S. dollars at the exchange rate on the balance sheet date. Equity amounts are translated at historical exchange rates, and expenses, gains and losses are translated using the average rate
for the year. Translation adjustments are reported as cumulative translation adjustments and are shown as a separate component of other comprehensive loss in the consolidated statements of changes in shareholders&#146; deficits and comprehensive
loss. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Monetary assets and liabilities denominated in currencies other than the applicable functional currencies are </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">translated into the functional currencies at the prevailing rates of exchange at the balance sheet date. Nonmonetary assets and liabilities are remeasured into the
applicable functional currencies at historical exchange rates. Transactions in currencies other than the applicable functional currencies during the year are converted into the functional currencies at the applicable rates of exchange prevailing at
the transaction dates. Transaction gains and losses are recognized in the consolidated statements of operations. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(e) Cash and cash equivalents
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group considers all highly liquid investments purchased with original maturities of three months or less to be cash equivalents. Cash and
cash equivalents consist primarily of cash on hand, demand deposits and highly liquid investments with maturity of less than three months and are stated at cost plus interests earned, which approximates fair value. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(f) Cost method investment </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">For investments for which
the Group does not have significant influence or control, the cost method of accounting is used. Under the cost method, the Group carries the investment at cost and recognizes income to the extent of dividends received from the distribution of the
equity investee&#146;s post-acquisition profits. As of December&nbsp;31, 2015 and 2016, investments in cost method investees accounted for under the cost method were nil and $500,000. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-10 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group is required to perform an impairment assessment of its investments whenever events or changes in
business circumstances indicate that the carrying value of the investment may not be fully recoverable. An impairment loss is recorded when there has been a loss in value of the investment that is other than temporary. No impairment was recorded for
the years ended December&nbsp;31, 2015 and 2016. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(g) Prepayments for equipment </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The prepayments for equipment purchase are recorded in long term prepayments considering the prepayments are all related to property and equipment. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>(h) Property and equipment </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment are stated at cost, less accumulated depreciation and
amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Useful life</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Office equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">3&nbsp;years</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Electronic equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">3&nbsp;years</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Vehicle</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">4 years</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Laboratory equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">5 years</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">lesser&nbsp;of&nbsp;useful&nbsp;life&nbsp;or&nbsp;lease&nbsp;term</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="3" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Construction in progress represents property and equipment under construction and pending installation and is stated at cost less
impairment losses if any. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(i) Long term deposits </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Long term deposits represent amounts paid in connection with the Group&#146;s long-term lease agreements. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(j)
Value added tax recoverable </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Value added tax recoverable represent amounts paid by the Group for purchases. The amounts were recorded as long
term assets considering they are expected to be deducted from future value added tax payables arising on the Group&#146;s revenues which it expects to generate in the future. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>(k) Intangible assets </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Intangible assets mainly consist of externally purchased software which are
amortized over five years on a straight-line basis. As of December&nbsp;31, 2015 and 2016, the original value of the Group&#146;s intangible assets is $3,523 and $8,684 with accumulated amortization of $998 and $1,684. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(l) Impairment of long-lived assets </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Long-lived
assets are reviewed for impairment in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-11 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
indicate that their carrying value may not be recoverable. Long-lived assets are reported at the lower of carrying amount or fair value less cost to sell. For the years ended December&nbsp;31,
2015 and 2016, there was no impairment of the value of the Group&#146;s long-lived assets. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(m) Fair value measurements </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group applies ASC topic 820 (&#147;ASC 820&#148;), <I>Fair Value Measurements and Disclosures</I>, in measuring fair value. ASC 820 defines fair value,
establishes a framework for measuring fair value and requires disclosures to be provided on fair value measurement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">ASC 820 establishes a three-tier
fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">Level 1&#151;Observable inputs that reflect
quoted prices (unadjusted) for identical assets or liabilities in active markets. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">Level 2&#151;Include other inputs that are directly or
indirectly observable in the marketplace. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">Level 3&#151;Unobservable inputs which are supported by little or no market activity.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">ASC 820 describes three main approaches, for example, to measuring the fair value of assets and liabilities: (1)&nbsp;market approach; (2)&nbsp;income
approach and (3)&nbsp;cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert
future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an
asset. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Financial instruments of the Group primarily include cash and cash equivalents, prepayments and other current assets, accounts payable, warrant
liabilities and other payables. As of December&nbsp;31, 2015 and 2016, the carrying values of cash and cash equivalents, prepayments and other current assets, accounts payable and other payables approximated their fair values due to the short-term
maturity of these instruments. The warrant liabilities were recorded at fair value as determined on the respective issuance dates and subsequently adjusted to the fair value at each reporting date. The Group determined the fair values of the warrant
liabilities with the assistance of an independent third party valuation firm. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Liabilities measured at fair value on a recurring basis as of
December&nbsp;31, 2015 are summarized below: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;3</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,980,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Liabilities measured at fair value on a recurring basis as of December&nbsp;31, 2016 are summarized below: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;3</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,900,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-12 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group has measured the warrant liabilities at fair values on a recurring basis using significant unobservable
inputs (Level 3) as of the years ended December&nbsp;31, 2015 and 2016. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group used the binomial model to estimate the fair value of warrant
liabilities using the following assumptions: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31, 2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31, 2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Risk-free rate of return</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.9%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Vesting date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">April&nbsp;1,2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">April&nbsp;1,2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Maturity date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">December&nbsp;31,2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">December&nbsp;31,2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Estimated volatility rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">70%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">70%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Exercise price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fair value of underlying preferred shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9.84</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The model requires the input of highly subjective assumptions including the risk-free rate of return, expected vesting date,
maturity date, estimated volatility rate and fair value of underlying preferred shares. The risk-free rate for periods within the contractual life is based on the US treasury bonds with maturity similar to the maturity of the warrants as of
valuation dates plus a China country risk premium. On April&nbsp;1, 2016, the investment amount met the $7,000,000 threshold, therefore, the vesting date was on April&nbsp;1, 2016. For maturity date, the terms state that it shall be the earlier of 6
years from grant and 90 days before the IPO date. Prior to 2017, the Group did not have a concrete plan to undertake an IPO, and as such, the maturity date was estimated to be December&nbsp;31, 2021. For expected volatilities, the Group has made
reference to the historical price volatilities of ordinary shares of several comparable companies in the same industry as the Group. The estimated fair value of the preferred shares was determined with assistance from an independent third party
valuation firm. The Group&#146;s management is ultimately responsible for the determination of the estimated fair value of its preferred shares. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
significant unobservable inputs used in the fair value measurement of the warrant liabilities include risk-free rate of return, interval between vesting date and maturity date, estimated volatility rate and fair value of underlying preferred shares.
Significant decreases in interval between vesting date and maturity date, estimated volatility rate and fair value of underlying preferred shares would result in a significantly lower fair value measurement. Significant increases in risk-free rate
of return would result in a significantly lower fair value measurement. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(n) Revenue recognition </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group has not yet generated any revenues from the sale of goods or from the rendering of services. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Prior to the adoption of ASC 606, the Group will recognize any revenues when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and
there is reasonable assurance that the related amounts are collectible in accordance with ASC 605, Revenue Recognition. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-13 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(o) Research and development expenses </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Elements of research and development expenses primarily include (i) payroll and other related costs of personnel engaged in research and development activities, (ii) in-licensed patent rights fee of exclusive
development rights of drugs granted to the Group, (iii) costs related to preclinical testing of the Group&#146;s technologies under development and clinical trials such as payments to contract research organizations (&#147;CROs&#148;), investigators
and clinical trial sites that conduct our clinical studies (iv)costs to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, (v) other research and development expenses.
Research and development expenses are charged to expense as incurred when these expenditures relate to the Group&#146;s research and development services and have no alternative future uses. The conditions enabling capitalization of development
costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when incurred. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group also has
obligations to make future payments to third party licensors that become due and payable on the achievement of certain development, regulatory and commercial milestones, which will be recorded as research and development expenses. The Group has not
included these commitments on our balance sheet because the commitments are cancellable if the milestones are not completed and achievement and timing of these milestones are not fixed or determinable. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(p) Government grants </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Government grants consist of
cash subsidies received by the Group&#146;s subsidiaries in the PRC from local </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">governments. Grants received as incentives for conducting business in
certain local districts with no performance obligation or other restriction as to the use are recognized when cash is received. Cash grants of $298,072 and $2,065,510 were included in other income for the years ended December&nbsp;31, 2015 and 2016,
respectively. Grants received with government specified performance obligations are recognized when all the obligations have been fulfilled. If such obligations are not satisfied, the Company may be required to refund the subsidy. Cash grants of
$61,599 and $778,434 were recorded in deferred subsidy income as of December&nbsp;31, 2015 and 2016 respectively, which will be recognized when the government specified performance obligation is satisfied. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(q) Leases </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Leases are classified at the inception
date as either a capital lease or an operating lease. The Group assesses a lease to be a capital lease if any of the following conditions exist: a) ownership is transferred to the lessee by the end of the lease term, b) there is a bargain purchase
option, c) the lease term is at least 75% of the property&#146;s estimated remaining economic life or d) the present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair value of the leased property to
the lessor at the inception date. A capital lease is accounted for as if there was an acquisition of an asset and an incurrence of an obligation at the inception of the lease. The Group has no capital leases for the years presented. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">All other leases are accounted for as operating leases wherein rental payments are expensed on a straight-line basis over the periods of their respective lease
terms. The Group leases office space and employee accommodation under operating lease agreements. Certain of the lease agreements contain rent holidays. Rent </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-14 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
holidays are considered in determining the straight-line rent expense to be recorded over the lease term. The lease term begins on the date of initial possession of the lease property for
purposes of recognizing lease expense on straight-line basis over the term of the lease. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(r) Comprehensive loss </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Comprehensive loss is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions
resulting from investments by owners and distributions to owners. Among other disclosures, <I>ASC 220, Comprehensive Income</I>, requires that all items that are required to be recognized under current accounting standards as components of
comprehensive loss be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Group&#146;s comprehensive loss includes net loss and foreign currency
translation adjustments, which are presented in the consolidated statements of comprehensive loss. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(s) Stock-based compensation
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Awards Granted to Employees </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group
grants share options to eligible employees, management and directors and accounts for these share based awards in accordance with ASC 718 <I>Compensation-Stock Compensation.</I> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Employees&#146; share-based awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at grant date if no vesting conditions are required; or b) using graded vesting
method over the requisite service period, which is the vesting period. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">All transactions in which goods or services are received in exchange for equity
instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">To the extent the required vesting conditions are not met resulting in the forfeiture of the share-based awards, previously recognized compensation expense relating to those awards are reversed. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group, with the assistance of an independent third party valuation firm, determined the fair value of the stock options granted to employees. The binomial
option pricing model was applied in determining the estimated fair value of the options granted to employees. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Awards Granted to <FONT
STYLE="white-space:nowrap">Non-Employees</FONT> </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group has accounted for equity instruments issued to
<FONT STYLE="white-space:nowrap">non-employees</FONT> in accordance with the provisions of ASC ASC 505, Equity-based payments to <FONT STYLE="white-space:nowrap">non-employees.</FONT> All transactions in which goods or services are received in
exchange for equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity
instrument issued is the date on which the counterparty&#146;s performance is completed as there is no associated performance commitment. The expense is recognized in the same manner as if the Group had paid cash for the services provided by the <FONT
STYLE="white-space:nowrap">non-employees</FONT> in accordance with ASC 505. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-15 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(t) Income taxes </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Group uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases
of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred
tax asset will not be realized. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group evaluates its uncertain tax positions using the provisions of ASC 740, <I>Income Taxes</I>, which requires
that realization of an uncertain income tax position be recognized in the financial statements. The benefit to be recorded in the financial statements is the amount most likely to be realized assuming a review by tax authorities having all relevant
information and applying current conventions. It is the Group&#146;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense. No unrecognized tax benefits and related interest and
penalties were recorded in any of the periods presented. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(u) Earnings (loss) per share </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Basic earnings (loss) per ordinary share is computed by dividing net income (loss) attributable to ordinary shareholders by weighted average number of ordinary
shares outstanding during the period. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group&#146;s convertible preferred shares are participating securities as the preferred shares participate in
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">undistributed earnings on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted</FONT></FONT> basis. Accordingly, the
Group uses the <FONT STYLE="white-space:nowrap">two-class</FONT> method whereby undistributed net income is allocated on a pro rata basis to each participating share to the extent that each class may share income for the period. Undistributed net
loss is not allocated to preferred shares because they are not contractually obligated to participate in the loss allocated to the ordinary shares. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Diluted earnings (loss) per ordinary share reflects the potential dilution that could occur if securities were exercised or converted into ordinary shares. The
Group had convertible preferred shares, warrants, stock options and <FONT STYLE="white-space:nowrap">non-vested</FONT> restricted shares, which could potentially dilute basic earnings per share in the future. To calculate the number of shares for
diluted income per share, the effect of the convertible redeemable preferred shares and warrants is computed using the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted</FONT></FONT> method; the effect of the stock
options and <FONT STYLE="white-space:nowrap">non-vested</FONT> restricted shares is computed using the treasury stock method. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(v) Segment
information </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In accordance with ASC 280, <I>Segment Reportin</I>g, the Group&#146;s chief operating decision maker, the Chief Executive Officer,
reviews the consolidated results when making decisions about allocating resources and assessing performance of the Group as a whole and hence, the Group has only one reportable segment. The Group does not distinguish between markets or segments for
the purpose of internal reporting. As the Group&#146;s long-lived assets are substantially located in and derived from the PRC, no geographical segments are presented. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-16 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(w) Concentration of risks </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Concentration of suppliers </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following suppliers accounted for 10% or more of research and development
expenses for the years ended December&nbsp;31, 2015 and 2016: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>For year ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">A</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,703,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">B</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,625,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents less than 10% of research and development expenses for the years ended December&nbsp;31, 2015 and 2016. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Concentration of credit risk </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Financial instruments that are
potentially subject to significant concentration of credit risk consist of cash and cash equivalents and prepayments for equipment. The carrying amounts of cash and cash equivalents represent the maximum amount of loss due to credit risk. As of
December&nbsp;31, 2015 and 2016, all of the Group&#146;s cash and cash equivalents were held by major financial institutions located in the PRC and international financial institutions outside of the PRC which management believes are of high credit
quality and continually monitors the credit worthiness of these financial institutions. With respect to the prepayment to suppliers, the Company performs <FONT STYLE="white-space:nowrap">on-going</FONT> credit evaluations of the financial condition
of these suppliers. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Foreign currency risk </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Renminbi (&#147;RMB&#148;) is not a freely convertible currency. The State Administration of Foreign Exchange, under the authority of the People&#146;s Bank of
China, controls the conversion of RMB into foreign currencies. The value of RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange
Trading System market. The cash and cash equivalents of the Group included aggregated amounts of RMB3,541,812 and RMB44,156,161, which were denominated in RMB, as of December&nbsp;31, 2015 and 2016, respectively, representing 4% and 8% of the cash
and cash equivalents as of December&nbsp;31, 2015 and 2016, respectively. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(w) Share Consolidation (&#147;Reverse Stock Split&#148;)
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On August&nbsp;30, 2017, the Company effected a 6 -to- 1 share consolidation of all the ordinary shares and preferred shares. All number of
shares, par value and per share amounts for all periods presented in these consolidated financial statements and accompanying notes have been adjusted retrospectively, where applicable, to reflect this share consolidation. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(x) Recent accounting pronouncements </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In
May&nbsp;2014, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Updates (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2014-09,</FONT> &#147;Revenue from Contracts with Customers (Topic&nbsp;606)&#148;, to
clarify the principles of recognizing revenue </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-17 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
and create common revenue recognition guidance between U.S.&nbsp;GAAP and International Financial Reporting Standards (&#147;IFRS&#148;). An entity has the option to apply the provisions of <FONT
STYLE="white-space:nowrap">ASU&nbsp;2014-09</FONT> either retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this standard recognized at the date of initial application. <FONT
STYLE="white-space:nowrap">ASU&nbsp;2014-09</FONT> is effective for fiscal years and interim periods within those years beginning after December&nbsp;15, 2016, and early adoption is not permitted. In August 2015, the FASB updated this standard to <FONT
STYLE="white-space:nowrap">ASU&nbsp;2015-14,</FONT> the amendments in this Update defer the effective date of Update 2014-09 so that the Update should be applied to annual reporting periods beginning after December&nbsp;15, 2017 and earlier
application is permitted only as of annual reporting periods beginning after December&nbsp;15, 2016, including interim reporting periods within that reporting period. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In May&nbsp;2016, FASB issued ASU 2016-12 &#147;Revenue from Contracts with Customers (Topic 606)&#148;: Narrow-Scope Improvements and Practical Expedients. The amendments in this Update do not change the core
principle of the guidance in Topic 606. Rather, the amendments in this Update affect only the narrow aspects of Topic 606. The areas improved include: (1)&nbsp;Assessing the Collectability Criterion in Paragraph&nbsp;606-10-25-1(e)&nbsp;and
Accounting for Contracts That Do Not Meet the Criteria for Step 1; (2)&nbsp;Presentation of Sales Taxes and Other Similar Taxes Collected from Customers; (3)&nbsp;Noncash Consideration; (4)&nbsp;Contract Modifications at Transition;
(5)&nbsp;Completed Contracts at Transition; and (6)&nbsp;Technical Correction. The effective date and transition requirements for the amendments in this Update are the same as the effective date and transition requirements for Topic 606 (and any
other Topic amended by Update 2014-09). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group is in a development stage, with no revenues to date, and will evaluate the application of this ASU,
but as a result has not yet determined the potential effects it may have on the Company&#146;s financial statements. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In November 2015, FASB issued ASU <FONT
STYLE="white-space:nowrap">2015-17,</FONT> <I>Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes</I>, which requires deferred income tax liabilities and assets to be classified as noncurrent on the balance sheet rather than
being separated into current and noncurrent. The guidance is effective for public entities for annual periods beginning after December&nbsp;15, 2016, and interim periods within those annual periods with early adoption being permitted. The Group has
adopted this guidance during the year ended December&nbsp;31, 2016, retrospectively. The adoption of this guidance did not have a material effect on the Group&#146;s consolidated financial statements. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In January 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-01,</FONT> <I>Financial Instruments-Overall (Subtopic
<FONT STYLE="white-space:nowrap">825-10):</FONT> Recognition and Measurement of Financial Assets and Financial Liabilities (&#147;ASU <FONT STYLE="white-space:nowrap">2016-01&#148;),</FONT></I> which requires that equity investments, except for
those accounted for under the equity method or those that result in consolidation of the investee, be measured at fair value, with subsequent changes in fair value recognized in net income. However, an entity may choose to measure equity<I>
</I>investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
ASU <FONT STYLE="white-space:nowrap">2016-01</FONT> also impacts the presentation and disclosure requirements for financial instruments. ASU <FONT STYLE="white-space:nowrap">2016-01</FONT> is effective for public business entities for annual
periods, and interim periods within those annual periods, beginning after December&nbsp;15, 2017. Early adoption is permitted only for certain provisions. The Group is in the process of evaluating the impact of adoption of this guidance on the
Group&#146;s consolidated financial statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-18 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases (Topic 842),</I>
which requires lessees to recognize most leases on the balance sheet. This ASU requires lessees to recognize a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and lease liability for all leases with
terms of more than 12 months. Lessees are permitted to make an accounting policy election to not recognize the asset and liability for leases with a term of twelve months or less. The ASU does not significantly change the lessees&#146; recognition,
measurement and presentation of expenses and cash flows from the previous accounting standard. Lessors&#146; accounting under the ASC is largely unchanged from the previous accounting standard. In addition, the ASU expands the disclosure
requirements of lease arrangements. Lessees and lessors will use a modified retrospective transition approach, which includes a number of practical expedients. The provisions of this guidance are effective for annual periods beginning after
December&nbsp;15, 2018, and interim periods within those years, with early adoption permitted. The Group is currently evaluating this ASU to determine the full impact on its consolidated financial statements, as well as the impact of adoption on
policies, practices and systems. As of December&nbsp;31, 2016, the Group has $2.1&nbsp;million of future minimum operating lease commitments that are not currently recognized on its consolidated balance sheets (see Note 15). Therefore, the Group
would expect changes to its consolidated balance sheets for the recognition of these and any additional leases entered into in the future upon adoption. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In March 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-09,</FONT> which simplifies several aspects of the accounting for employee share-based
payment transactions for both public and <FONT STYLE="white-space:nowrap">non-public</FONT> entities, including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of
cash flows. For public entities, the ASU is effective for annual reporting periods beginning after December&nbsp;15, 2016, including interim periods within those annual reporting periods. Early adoption will be permitted in any interim or annual
period for which financial statements have not yet been issued or have not been made available for issuance. The Group has elected to early adopt this standard on a modified retrospective basis at the beginning of the period presented as the Group
elected to account for forfeitures when they occur to reduce the complexity in the accounting of share based compensation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In August 2016, the FASB
issued ASU <FONT STYLE="white-space:nowrap">2016-15,</FONT> <I>Statement of Cash Flows (Topic 230)</I>. The update is intended to improve financial reporting in regards to how certain transactions are classified in the statement of cash flows. This
update requires that debt extinguishment costs be classified as cash outflows for financing activities and provides additional classification guidance for the statement of cash flows. The update also requires that the classification of cash receipts
and payments that have aspects of more than one class of cash flows to be determined by applying specific guidance under generally accepted accounting principles. The update also requires that each separately identifiable source or use within the
cash receipts and payments be classified on the basis of their nature in financing, investing or operating activities. The update is effective for public companies for fiscal years beginning after December&nbsp;15, 2017, including interim periods
within those fiscal years. The Group is in the process of evaluating the impact of adoption of this guidance on the consolidated financial statements. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In October 2016, FASB issued ASU <FONT STYLE="white-space:nowrap">2016-16,</FONT> <I>Income Taxes (Topic 740)</I>. Under the new standard, an entity is to recognize
the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs. The new standard does not include new disclosure requirements; however, existing disclosure requirements might be applicable when
accounting for the current and deferred income taxes for an intra-entity transfer of an asset other than inventory. The new standard is effective for annual periods beginning </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-19 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
after December&nbsp;15, 2017, including interim reporting periods within those annual periods. The ASU is not expected impact the Group&#146;s consolidated balance sheet upon adoption.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In October 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-18,</FONT> <I>Statement of Cash Flows (Topic 230),</I> <I>Restricted
Cash</I>. The update applies to all entities that have restricted cash or restricted cash equivalents and are required to present a statement of cash flows. The update addresses diversity in practice that exists in the classification and
presentation of changes in restricted cash on the statement of cash flows, and requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or
restricted cash equivalents. As a result, amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">beginning-of-period</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-period</FONT></FONT> total amounts shown on the statement of cash flows. The update is effective for public
companies for fiscal years beginning after December&nbsp;15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The updates should be applied using a retrospective transition method to each period presented. The Group
currently does not have restricted cash balances. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>3. Cash and cash equivalents </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash at bank and in hand</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,160,696</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">36,531,272</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash Equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">47,417,498</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,160,696</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">83,948,770</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Denominated in:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">US$</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">12,344,841</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">77,463,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">RMB (note (i))</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">545,431</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,365,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Australia dollar (&#147;A$&#148;)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">270,424</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">120,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,160,696</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">83,948,770</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Notes: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(i)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Certain cash and bank balances denominated in RMB were deposited with banks in the PRC. The conversion of these RMB denominated balances into foreign currencies is subject to the
rules and regulations of foreign exchange control promulgated by the PRC government. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-20 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>4. Property and equipment </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Property and equipment consist of the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Office equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">50,514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">49,432</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Electronic equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">33,224</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">66,271</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Vehicle</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">76,636</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Laboratory equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">481,432</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">593,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">214,730</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">465,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Construction in progress</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">252,509</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">779,900</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,503,858</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less accumulated depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(72,316</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(257,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">707,584</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,246,058</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Depreciation expenses for the years ended December&nbsp;31, 2015 and 2016 were $125,774 and $198,224, respectively. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>5. Income tax </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Cayman islands </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">ZAI Lab Limited is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands, ZAI Lab Limited is not subject to tax on income or capital
gain. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Australia </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">ZAI Lab (AUST) Pty., Ltd. incorporated in Australia is subject to corporate income tax at a rate of 30%. ZAI Lab (AUST) Pty., Ltd. has no taxable income for all
periods presented and therefore, no provision for income taxes is required. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Hong Kong </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">ZAI Lab (Hong Kong) Limited is incorporated in Hong Kong. Companies registered in Hong Kong are subject to Hong Kong Profits Tax on the taxable income as reported
in their respective statutory financial statements adjusted in accordance with relevant Hong Kong tax laws. The applicable tax rate is 16.5% in Hong Kong. For the years ended December&nbsp;31, 2015 and 2016, The ZAI Lab (Hong Kong) Limited did not
make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earned in Hong Kong for any of the periods presented. Under the Hong Kong tax law, ZAI Lab (Hong Kong) Limited is exempted from income tax on its
foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>PRC </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">ZAI Lab (Shanghai) Co., Ltd and ZAI Lab (Suzhou) Co., Ltd. are both subject to the statutory rate of 25% for the years ended December&nbsp;31, 2015 and 2016 in
accordance with the Enterprise Income Tax law (the &#147;EIT Law&#148;). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-21 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There is no provision for income taxes because the Company and all of its owned subsidiaries are in a current loss
position for all the periods presented. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Loss before income taxes consists of: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year
ended</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cayman</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,036,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,454,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">PRC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,938,688</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">26,111,094</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">HK</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,869,007</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,010,908</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">AUST</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,177,236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">935,550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,021,737</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">37,512,212</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Reconciliations of the differences between the PRC statutory income tax rate and the Group&#146;s effective income tax rate for the
years ended December&nbsp;31, 2015 and 2016 are as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Statutory income tax rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Share-based Compensations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3.68%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2.92%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(7.19%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.59%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Effect of different tax rate of subsidiary operation in other jurisdiction</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(7.15%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3.33%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Changes in valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6.98%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(17.16%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Effective income tax rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The principal components of the deferred tax assets and liabilities are as follows: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred tax assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation of property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,892</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accrued expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">72,408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Government grants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">16,025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">166,336</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net operating loss forward</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,729,009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,086,361</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less: valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,819,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,256,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred tax assets, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group considers positive and negative evidence to determine whether some portion or all of the deferred tax assets will be more
likely than not realized. This assessment considers, among other matters, the nature, frequency and severity of recent losses and forecasts of future profitability. These assumptions require significant judgment and the forecasts of future taxable
income are consistent with the plans and estimates the Group is using to manage the underlying businesses. Valuation allowances are established for deferred tax </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-22 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
assets based on a more likely than not threshold. The Group&#146;s ability to realize deferred tax assets depends on its ability to generate sufficient taxable income within the carry forward
periods provided for in the tax law. In 2015 and 2016, the Group has determined that the deferred tax assets on temporary differences and net operating loss carry forward are related to certain other subsidiaries, for which the Group is not able to
conclude that the future realization of those net operating loss carry forwards and other deferred tax assets are more likely than not. As such, it has fully provided valuation allowance for the deferred tax assets as of December&nbsp;31, 2015 and
2016. Amounts of operating loss carry forwards were $7,969,098 and $34,716,071 for the year ended December&nbsp;31, 2015 and 2016, which are expected to be expired from 2019 to 2021. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Movement of the valuation allowance is as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance as of January&nbsp;1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(561,672</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,819,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Additions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,258,185</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(6,436,732</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance as of December&nbsp;31</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,819,857</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,256,589</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Uncertainties exist with respect to how the current income tax law in the PRC applies to the Group&#146;s overall operations, and
more specifically, with regard to tax residency status. The EIT Law includes a provision specifying that legal entities organized outside of the PRC will be considered residents for Chinese income tax purposes if the place of effective management or
control is within the PRC. The implementation rules to the EIT Law provide that <FONT STYLE="white-space:nowrap">non-resident</FONT> legal entities will be considered PRC residents if substantial and overall management and control over the
manufacturing and business operations, personnel, accounting and properties, occurs within the PRC. Despite the present uncertainties resulting from the limited PRC tax guidance on the issue, the Group does not believe that the legal entities
organized outside of the PRC within the Group should be treated as residents for EIT Law purposes. If the PRC tax authorities subsequently determine that the Company and its subsidiaries registered outside the PRC should be deemed resident
enterprises, the Company and its subsidiaries registered outside the PRC will be subject to the PRC income taxes, at a rate of 25%. The Group is not subject to any other uncertain tax position. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>6. Other payables </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Payroll</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">350,514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">573,802</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other taxes payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23,721</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other payables(note (i))</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">157,417</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">152,595</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">507,931</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">750,118</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Notes: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(i)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Other payables are mainly payables related to legal advisory fee and travel expense. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-23 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>7. Convertible preferred shares and warrants </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In August, 2014 and April, 2015, the Company issued 6,244,443 Series A1 convertible preferred shares (&#147;Series A1 Preferred Shares&#148;) and 8,442,221 Series A2 convertible preferred shares (&#147;Series A2
Preferred Shares&#148;) with a par value $0.00006 per share to a group of investors for a cash consideration of $8,028,572 or $1.2857 per share and $18,278,572 or $2.1651 per share, respectively. In August 2014, $2,000,000 in convertible loans
issued in March and April of 2014 to certain investors who purchased Series A1 Preferred Shares were converted into 2,222,222 Series A1 Preferred Shares in connection with the offering at a per share price of $0.90. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In January and April, 2016, the Company issued 5,562,335 Series B1 convertible preferred shares (&#147;Series B1 Preferred Shares&#148;) and 3,973,096 Series B2
convertible preferred shares (&#147;Series B2 Preferred Shares&#148;) with a par value of $0.00006 per share to a group of investors including existing preferred share investors for a cash consideration of $53,100,000 or $9.5464 per share and
$53,100,000 or $13.3649 per share, respectively. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On December&nbsp;31, 2015, as an inducement to participate in the contemplated issuance of Series B1
Preferred Shares and Series B2 Preferred Shares, the Company entered into an agreement with one investor to issue warrants to purchase up to 461,808 Series A2 Preferred Shares at $2.1651 per share, as adjusted from time to time pursuant to the
agreement. The fair value of the warrants of $1,980,000 was expensed on the date of issuance (as opposed to being treated as a cost of equity issuance because the warrant would have become exercisable after the passage of time in the absence of an
equity offering). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The key terms of the Series A1, A2, B1 and B2 Preferred Shares (collectively &#147;Preferred Shares&#148;) are as follows: </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Conversion rights </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each holder of Preferred Shares shall
have the right, at such holder&#146;s sole discretion, to convert all or any portion of the Preferred Shares into ordinary shares based on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-for-one</FONT></FONT> basis at any
time. The initial conversion price is the issuance price of Preferred Shares, subject to adjustment in the event of (1)&nbsp;stock splits, share combinations, share dividends and distribution, recapitalizations and similar events, and
(2)&nbsp;issuance of new securities at a price per share less than the conversion price in effect on the date of or immediately prior to such issuance. In that case, the conversion price shall be reduced concurrently to the subscription price of
such issuance. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Preferred Shares will be automatically converted into ordinary shares at the then applicable conversion price upon the earlier of
(1)&nbsp;the closing of a Qualified Initial Public Offering, or (2)&nbsp;the date specified by written consent or agreement of majority holders of Preferred Shares. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Voting rights </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Preferred Shareholders are entitled to vote with ordinary shareholders on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis. The holders of the Preferred Shares also have certain veto rights including, but not limited to, an increase or decrease in the total number of directors and change of board composition,
appointment or removal of senior management, approval of business plan and operating budget, dividend declaration, any merger, split, reorganization or consolidation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-24 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Dividends </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Preferred Shareholders may be entitled to receive dividends accruing at the rate of 8% per annum. In addition, Preferred Shareholders are also entitled to
dividends on the Company&#146;s ordinary shares on an as if converted basis and must be paid prior to any payment on ordinary shares. All dividends shall be payable only when, as, and if declared by the Board of Directors and shall be noncumulative.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Liquidation preference </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Series A1 Preferred
Shares and Series A2 Preferred Shares </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the
holders of Series A1 and Series A2 Preferred Shares are entitled to receive, prior to any distribution to the holders of ordinary shares, an amount per share equal to the Series A original issue price, plus accrued but unpaid dividends (the
&#147;Preference Amount&#148;). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Series B1 Preferred Shares and Series B2 Preferred Shares </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In the event of any liquidation, dissolution or winding up of the Company, either voluntary or involuntary, the holders of Series B1 and Series B2 Preferred Shares are entitled to receive, prior to any distribution
to the holders of ordinary shares, an amount per share equal the Series B original issue price plus five percent (5%) simple interest on such Series B issue price accrued annually from the applicable Series B issue date, plus accrued but unpaid
dividends. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event insufficient funds are available to pay in full the Preference Amount in respect of each preferred shareholders, the sequence of
liquidation right of all series of preferred shares was as follows: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:arial" SIZE="2">(1) Series B1 and B2 Preferred Shares </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:arial" SIZE="2">(2) Series A1 and A2 Preferred Shares </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">After the
Preference Amount has been paid, any remaining funds or assets legally available for distribution shall be distributed pro rata among the preferred shareholders together with ordinary shares. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">A liquidation event includes, (i)&nbsp;any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary; the exclusive licensing of all or substantially all of the Group Companies&#146;
intellectual property, taken as a whole, to a third party; (ii)&nbsp;any sale of all or substantially all of the assets of the Group to a third party unaffiliated with any member of the Group; or (iii)&nbsp;the transfer (whether by merger,
reorganization or other transaction) in which a majority of the outstanding voting power of the Company is transferred (excluding any sale of shares by the Company for capital raising purposes). </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The key terms of the warrants are as follows: </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Vesting date
</I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The warrant was vested on April&nbsp;1, 2016. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-25 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Exercise period </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">If not previously exercised, the warrants shall expire on the earlier of (i)&nbsp;the sixth (6th) anniversary of the issue date or (ii)&nbsp;ninety (90) days prior to the date on which the Company consummates an
initial public offering. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company has classified the Preferred Shares as mezzanine equity as these convertible preferred shares are redeemable upon
the occurrence of a conditional event (i.e.&nbsp;a liquidation event). The holders of the Preferred Shares have a liquidation preference and will not receive the same form of consideration upon the occurrence of the conditional event as the ordinary
shareholders would. The holders of Preferred Shares have the ability to convert the instrument into the Company&#146;s ordinary shares. The conversion option of the convertible preferred shares do not qualify for bifurcation accounting because the
conversion option is clearly and closely related to the host instrument and the underlying ordinary shares are not publicly traded nor readily convertible into cash. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Group has determined that there was no beneficial conversion feature (&#147;BCF&#148;) attributable to the Preferred Shares, as the effective conversion price was greater than the fair value of the ordinary
shares on the respective commitment date. The Group will <FONT STYLE="white-space:nowrap">re-evaluate</FONT> whether additional BCF is required to be recorded upon the modification to the effective conversion price of the Preferred Shares,
if&nbsp;any. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Company concluded that the Preferred Shares are not redeemable currently, and is not probable that the Preferred Shares will become
redeemable because the likelihood of a liquidation event is remote. Therefore, no adjustment will be made to the initial carrying amount of the Preferred Shares until it is probable that they will become redeemable. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The warrants are freestanding instruments and are recorded as liabilities in accordance with ASC480. The Series B1 and B2 Preferred Shares were initially recorded
as mezzanine equity equal to the proceeds received of $106.2&nbsp;million in total. The warrants are initially recognized at fair value, with subsequent changes in fair value recorded in losses. For the year ended December&nbsp;31, 2016, the Company
recognized a loss from the increase in fair value of the warrants of $1.92 million. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>8. Net loss per share </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Basic and diluted net loss per share for each of the years presented are calculated as follow after giving effect to a six-to-one share consolidation effected on
August 30, 2017: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>For the year
ended</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Numerator:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss attributable to ordinary shareholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,021,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Denominator:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted average number of ordinary shares-basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,693,655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,439,028</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share-basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2.07</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-26 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group has determined that its convertible preferred shares are participating securities as the preferred
shares participate in undistributed earnings on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted</FONT></FONT> basis. The holders of the preferred shares are entitled to receive dividends on a pro rata basis, as
if their shares had been converted into ordinary shares. Accordingly, the Group uses the <FONT STYLE="white-space:nowrap">two-class</FONT> method of computing net income per share, for ordinary and preferred shares according to participation rights
in undistributed earnings, However, undistributed net loss is only allocated to ordinary shareholders because holders of preferred shares are not contractually obligated to share losses. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As a result of the Group&#146;s net loss for the two years ended December&nbsp;31, 2015 and 2016, Series A1, A2, B1 and B2 preferred shares, share options, <FONT STYLE="white-space:nowrap">non-vested</FONT>
restricted shares and warrants outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Number of Series A1 Shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,466,665</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,466,665</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Number of Series A2 Shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,442,221</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,442,221</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Number of Series B1 Shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,562,335</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Number of Series B2 Shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,973,096</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Share options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,309,232</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,228,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> restricted shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,948,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,309,490</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">461,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">461,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>9. Related party transactions </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The table below sets forth the related party transactions and the relationship with the Group as of December&nbsp;31, 2016: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Company Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Relationship with the group</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Qiagen (Suzhou) Translational Medicine Co., Ltd.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Significant influence held by Samantha Du&#146;s immediate family</FONT></TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(a)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">The Group entered into the following transactions between its related party: </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year
ended</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">96,656</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">(b)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">The Group had the following balances with its related party: </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">27,865</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-27 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>10. Share-based compensation </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Share options </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On March&nbsp;5, 2015, the Board of Directors of the Company approved an Equity Incentive Plan
(the &#147;Plan&#148;) which is administered by the Board of Directors. Under the plan, the Board of Directors may grant options to purchase ordinary shares to management including officers, directors, employees and individual advisors who render
services to the Group to purchase an aggregate of no more than 4,140,945 ordinary shares of the Group (&#147;Option Pool&#148;). On October&nbsp;22, 2015, March&nbsp;9, 2016 and August&nbsp;25, 2016, the Board of Directors approved the increase in
the Option Pool to 7,369,767 ordinary shares. These options granted have a contractual term of 10 years and generally vest over a five year period, with 20% of the awards vesting one year after the grant date and the remainder of the awards vesting
on a monthly basis thereafter. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In March and October 2015, the Group granted 870,449 and 3,438,783 share options to certain of the Group&#146;s
management and employees at an exercise price of $0.6 per share, respectively. These options granted have a contractual term of 10 years and generally vest over a five year period, with 20% of the awards vesting one year after the grant date and the
remainder of the awards vesting on a monthly basis thereafter. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In March 2016, the Group granted 1,157,793 share options to certain of the Group&#146;s
management and employees at an exercise price of $1.2 per share. These options granted have a contractual term of 10 years and generally vest over a five year period, with 20% of the awards vesting anniversary year after the grant date. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In August 2016, the Group granted 1,760,368 share options to certain of the Group&#146;s management and employees at an exercise price of $1.74 per share,
respectively. These options granted have a contractual term of 10 years and generally vest over a five year period, with 20% of the awards vesting on the anniversary of the grant date each year. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In August and December 2016, the Group granted 416 and 416 share options to certain individual advisors of the Group at an exercise price of $1.74 per share. These
options granted have a contractual term of 10&nbsp;years and generally vest over a three year period, with 33.33% of the awards vesting anniversary year after the grant date. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The binomial option-pricing model was applied in determining the estimated fair value of the options granted. The model requires the input of highly subjective assumptions including the estimated expected stock
price volatility and, the exercise multiple for which employees are likely to exercise share options. For expected volatilities, the Group has made reference to the historical price volatilities of ordinary shares of several comparable companies in
the same industry as the Group. For the exercise multiple, the Group has no historical exercise patterns as reference, thus the exercise multiple is based on management&#146;s estimation, which the Group believes is representative of the future
exercise pattern of the options. The risk-free rate for periods within the contractual life of the option is based on the US treasury bonds with maturity similar to the maturity of the options as of valuation dates plus a China country risk premium.
The estimated fair value of the ordinary shares, at the option grant dates, was determined with assistance from an independent third party valuation firm. The Group&#146;s management is ultimately responsible for the determination of the estimated
fair value of its ordinary shares. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-28 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following table presents the assumptions used to estimate the fair values of the share options granted in the
years presented: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March,&nbsp;2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>October,&nbsp;2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>March,&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>August,&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>December,&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Risk-free rate of return</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.8%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.5%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.4%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contractual life of option</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Estimated volatility rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">70%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">70%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">70%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">70%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">70%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Expected dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fair value of underlying ordinary shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.62</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7.14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="20" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A summary of option activity under the Plan during the years ended December&nbsp;31, 2015 and 2016 is presented below: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number of<BR>options</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Weighted<BR>average<BR>exercise<BR>price</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Weighted<BR>average<BR>remaining<BR>contractual<BR>term</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Aggregate<BR>intrinsic<BR>value</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Outstanding at January&nbsp;1, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,309,232</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Outstanding at December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,309,232</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9.68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,874,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,918,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(84</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Outstanding at December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,228,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53,677,170</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Vested and Exercisable as of December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,107,040</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,634,911</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Vested or expected to vest as of December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,228,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53,677,170</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="16" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The weighted-average grant-date fair value of the options granted in 2015 and 2016 was $1.62 and $6.94 per share. The Group recorded
compensation expense related to the option of $419,709 and $3,524,733 for the year ended December&nbsp;31, 2015 and 2016, respectively, which were classified in the accompanying consolidated statements of operations as follows: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Year ending December 31:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">124,871</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,472,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">294,838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,051,740</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">419,709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,524,733</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of December&nbsp;31, 2016, there was $23,286,577 of total unrecognized compensation expense related to unvested share options
granted. That cost is expected to be recognized over a weighted-average period of 4.0 years. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-29 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-vested</FONT> restricted shares </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On April 3, 2014, the Company entered into a restricted share arrangement with Samantha Du, founder and Chairman and Chief Executive Officer of the Company (the
&#147;CEO&#148;) to secure her services, pursuant to which all of her 3,500,000 ordinary shares of the Company became subject to transfer restrictions. In addition, the restricted shares shall initially be unvested and subject to repurchase by the
Company at par value upon voluntary or involuntary termination of employment by the CEO (the &#147;Repurchase Right&#148;). One fifth of the restricted shares shall vest and be released from the restrictions and Repurchase Right on each yearly
anniversary from the date of the agreement. The CEO retains the voting rights of such non-vested restricted shares and any additional securities or cash received as the result of ownership of such shares, such as a share dividend, become subject to
restriction in the same manner. This arrangement has been accounted for as a performance-based plan. Accordingly, the Group measured the fair value of the non-vested restricted shares as of April 3, 2014 and is recognizing the amount as compensation
expense over the five year deemed service period using a graded vesting attribution model for each separately vesting portion of the non-vested restricted shares. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">On August&nbsp;10, 2015, the Company entered into an restricted share arrangement with an individual advisor to secure their services, for 166,667 ordinary shares authorized for grant. In general, restrictions
limit the sale or transfer of these shares during a three year period, and restrictions lapse proportionately over the three year period. During the three year period the Company upon voluntary or involuntary termination of service agreement by the
individual advisor will repurchase unvested restricted shares at par (the &#147;Repurchase Right&#148;). On July&nbsp;15, 2016 and August&nbsp;25, 2016, 58,333 and 75,000 ordinary shares were authorized for grant to the individual advisor with the
same Repurchase Right. The Repurchase Right terminates over the three years commencing August&nbsp;10, 2015, July&nbsp;15, 2016 and August&nbsp;25, 2016 in 36 equal monthly instalments thereafter. Any additional securities or cash received as the
result of ownership of such shares, such as dividends, become subject to restriction in the same manner. For all restricted shares, the individual advisor has delegated his voting rights to the CEO of the Company. This arrangement has been accounted
for as a performance-based plan. Accordingly, the Group measures the service expense based on the fair value at the date the services are completed which is monthly. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table summarized the Group&#146;s <FONT STYLE="white-space:nowrap">non-vested</FONT> restricted share activity in 2016. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Numbers&nbsp;of<BR><FONT STYLE="white-space:nowrap">non-vested</FONT><BR>restricted&nbsp;
shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Weighted&nbsp;average</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>grant&nbsp;date</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>fair
value</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> as of January&nbsp;1, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,948,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.82</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">133,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.04</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Vested</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(771,991</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> as of December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,309,490</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-30 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of December 31, 2016, there was $1,367,014 of total unrecognized compensation expense related to non-vested
Restricted Shares. The Group recorded compensation expense related to the restricted shares of $476,806 and $954,660 for the year ended December 31, 2015 and 2016, respectively, which were classified in the accompanying consolidated statements of
operations as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Year ending December 31:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">210,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">210,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">266,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">744,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">476,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">954,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>Ordinary shares issued to Red Kingdom Investment Limited (&#147;Red Kingdom&#148;) </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Red Kingdom is a company incorporated in the British Virgin Islands in August 2013 and owned by a group of senior management including the CEO of the Company and
advisors of the Group and third party investors. Red Kingdom has no activities and does not have employees. All the shareholders of the Red Kingdom have delegated their voting rights to the CEO of the Company. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On April&nbsp;3, 2014, the Company issued 8,083,333 shares to Red Kingdom which are corresponding to the total outstanding shares of Red Kingdom for total
consideration of $141,971. One share of Red Kingdom is entitled to indirectly all of the economic rights associated with the underlying ordinary shares of the Company. Of these shares, 7,847,500 shares were held by members of senior management and
certain advisors of the Group, who paid par value. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In April and May 2014, Red Kingdom entered into restricted share arrangements with the members of
senior management of the Group to secure their services, pursuant to which all of their 6,459,167 ordinary shares of the Red Kingdom became subject to transfer restrictions (the &#147;Restricted Shares&#148;). In addition, the Restricted Shares
shall initially be unvested and subject to repurchase by Red Kingdom at par value upon voluntary or involuntary termination of employment by those senior management (the &#147;Repurchase Right&#148;). One fifth of the Restricted Shares shall vest
and be released from the restrictions and Repurchase Right on each yearly anniversary from the date of the agreement. Any additional securities or distributions received associated with the Restricted Shares shall become subject to the same
restrictions. The Repurchase Right shall terminate upon the earlier to occur of: (i)&nbsp;the cancelation of the Repurchase Right upon vesting, (ii)&nbsp;immediately prior to the consummation of an initial public offering of the securities of the
Company, or (iii)&nbsp;a Change of Control. Accordingly, the Group measured the fair value of the <FONT STYLE="white-space:nowrap">non-vested</FONT> Restricted Shares at grant date and recognizes the amount as compensation expense over the five year
deemed service period using a graded vesting attribution model on a straight-line basis. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In April 2014, Red Kingdom entered into a restricted share
arrangement with one of its advisors whereby all of their 350,000 ordinary shares of Red Kingdom became subject to transfer restrictions (the &#147;Advisor Restricted Shares&#148;). Such shares shall initially be unvested and subject to repurchase
by Red Kingdom at par value during the 5 year period following the date of the agreement. The Advisor Restricted Shares shall vest and be released </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-31 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
from the Repurchase Right at the rate of twenty percent (20%) of the total number of Advisor Restricted Shares as each the contractually agreed milestones within each year (collectively, the
&#147;Milestones&#148;) are determined to have been achieved by the Company. Accordingly, the Group measures the service expense based on the fair value of the Restricted Shares when the milestones are achieved. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The 1,038,333 shares of the Company that issued to Red Kingdom corresponding to the shares of Red Kingdom held by advisors of the Group, purchased for par value in
2014 are not subject to the transfer restrictions or other repurchase rights, and so were considered vested immediately at the date of grant and expensed. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On December&nbsp;15, 2015, 1,921,000 unvested Restricted Shares granted to the CEO were deemed vested by the Company and the unrecognized share-based compensation
of $1,152,600 as of the modification date was immediately recognized as compensation expense in the consolidated statements of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following
table summarized the <FONT STYLE="white-space:nowrap">non-vested</FONT> Restricted Shares activities of Red Kingdom in 2016. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Numbers&nbsp;of<BR><FONT STYLE="white-space:nowrap">non-vested</FONT><BR>restricted&nbsp;
shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Weighted&nbsp;average</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>grant
date</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>fair value</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> as of January&nbsp;1, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,526,665</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Vested</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(741,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> as of
December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,784,999</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of December&nbsp;31, 2016, there was $1,136,753 of total unrecognized compensation expense related to <FONT
STYLE="white-space:nowrap">non-vested</FONT> Restricted Shares. The Group recorded compensation expense related to the restricted shares of $1,804,889 and $445,885 for the year ended December&nbsp;31, 2015 and 2016, respectively, which were
classified in the accompanying consolidated statements of operations as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Year ending December 31:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">697,206</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">364,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,107,683</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">81,162</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,804,889</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">445,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-32 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>11. Accumulated other comprehensive loss </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The movement of accumulated other comprehensive loss is as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Foreign&nbsp;currency</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>translation</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>adjustments</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance as of January&nbsp;1, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,727</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(98,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance as of December&nbsp;31, 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(103,620</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(594,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance as of December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(698,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>12. Licenses and collaborative arrangements </B></FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>License and collaboration agreement with Bristol-Myers Squibb Company (&#147;BMS&#148;) </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In March 2015,
the Group entered into a collaboration and license agreement with BMS, under which the Group obtained an exclusive license under certain patents and know-how of BMS to develop, manufacture, use, sell, import and commercialize brivanib, BMS&#146;s
proprietary multi-targeted kinase inhibitor, in mainland China, Hong Kong and Macau, or the licensed territory, in the licensed field of diagnosis, prevention, treatment or control of oncology indications, with the right to expand the licensed
territory to include Taiwan and Korea under certain conditions. BMS retains the non-exclusive right to use the licensed compounds to conduct internal research and the exclusive right to use the licensed compounds to manufacture compounds that are
not brivanib. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">BMS has the option to elect to co-promote the licensed products in the licensed territory. If BMS exercises its co-promotion option, BMS
will pay the Group an option exercise fee, and the Group will share with BMS the operating profits and losses of the licensed products in the licensed territory. If BMS does not exercise its co-promotion option, the Group will pay BMS milestone
payments for the achievement of certain development and sales milestone events, and also tiered royalties at certain percentage rates on the net sales of the licensed products in the licensed territory, until the later of the expiration of the
last-to-expire licensed patent covering the licensed product, the expiration of regulatory exclusivity for the licensed product, or the twelfth anniversary of the first commercial sale of the licensed product, in each case on a product-by-product
and region-by-region basis. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group also has the right to opt-out of the commercialization of the licensed products in its licensed territory under
certain conditions. If the Group elects to opt-out, BMS will have the right to commercialize the licensed products in the Group&#146;s licensed territory and will pay the Group royalties on the net sales of the licensed products in its licensed
territory. BMS has the option to use the data generated by the Group from the Group&#146;s development of the licensed products to seek regulatory approval of the licensed products outside the Group&#146;s licensed territory, and if BMS exercises
such option, BMS will be obligated to make certain payments to the Group, including upfront, milestone and royalty payments. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-33 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The agreement may be terminated by either party for the other party&#146;s uncured material breach, safety reasons
or failure of the development of the licensed products. In addition, the Group has the right to terminate the agreement for convenience after a certain specified time period upon advance notice to BMS. BMS may also terminate the agreement for our
bankruptcy or insolvency. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>License and collaboration agreement with Sanofi </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In July 2015, the Group entered into a license agreement with Sanofi, under which the Group obtained an exclusive and worldwide license under certain patents and know-how of Sanofi to develop, manufacture, use,
sell, import and commercialize Sanofi&#146;s ALK inhibitor, or the licensed compound (also known as ZL-2302), for any oncology indications in humans. Sanofi retains the non-exclusive right to use the licensed compound to conduct internal research.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the terms of the agreement, the Group made upfront payments to Sanofi totalling $0.5 million which were recorded as research and development
expenses in 2015. If the Group successfully develops and commercializes the licensed product, the Group will make milestone payments to Sanofi for the achievement of certain development milestone events. In addition, the Group will pay to Sanofi
tiered royalties at certain percentage rates of the net sales of the licensed products, until the later of the expiration of the last-to-expire licensed patent covering the licensed product, the expiration of regulatory exclusivity for the licensed
product, or the tenth anniversary of the first commercial sale of the licensed product, in each case on a product-by-product and country-by-country basis. If the Group sublicenses, transfers or assigns (other than through a change of control
transaction) the right to the licensed product to third parties, the Group is also required to pay to Sanofi a share of its sublicense income. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group
at any time has the right to terminate this agreement for any reason or no reason at all by providing Sanofi with prior written notice. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>License
and collaboration agreement with UCB Biopharma Sprl (&#147;UCB&#148;) </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In September 2015, the Group entered into a license agreement with UCB,
under which the Group obtained an exclusive and worldwide license under certain patents and know-how of UCB to develop, manufacture, use, sell, import and commercialize UCB&#146;s proprietary antibody UCB3000 or the licensed compound (also known as
ZL-1101), for the treatment, prevention and diagnosis of any human diseases. UCB retains the non-exclusive right to use the licensed compound for its own research purposes. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Under the terms of the agreement, the Group made upfront payments to UCB totalling $0.8 million which was recorded as a research and development expense in 2016. If the Group successfully develops and
commercializes the licensed products, the Group will make milestone payments to UCB for the achievement of certain development and sales milestone events. In addition, the Group will pay to UCB royalties at certain percentage rates on the net sales
of the licensed products, until the later of the expiration of the last-to-expire licensed patent covering the licensed product, the expiration of regulatory exclusivity for the licensed product, or the tenth anniversary of the first commercial sale
of the licensed product, in each case on a product-by-product and country-by-country basis. If the Group sublicenses the right to the licensed product to third parties, the Group is also required to pay to UCB a share of its sublicense income.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-34 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group has the right to terminate this agreement by providing UCB with prior written notice. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>License and collaboration agreement with Hanmi Pharm, Co., Ltd. (&#147;Hanmi&#148;) </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In November 2015, the Group entered into a collaboration and license agreement with Hanmi under which the Group obtained an exclusive right of license under certain patents and know-how of Hanmi to develop,
manufacture, use, sell, import and commercialize Hanmi&#146;s EGFR mutation specific TKI HM61713, or the licensed compound (also known as ZL-2303) for the treatment, diagnosis or prevention of any diseases or conditions in human. Hanmi retains the
non-exclusive right to use the licensed compound for its own research purposes. Hanmi has the right of first negotiation to acquire the rights to the licensed products back from the Group upon successful completion of certain clinical development
work. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the terms of the agreement, the Group made upfront payments amounted $6.0 million and $1.0 million to Hanmi in 2015 and 2016, respectively.
If the Group successfully develop and commercialize the licensed products, the Group will make milestone payments to Hanmi for the achievement of certain development milestone events. In addition, the Group will pay to Hanmi royalties at certain
percentage rates on the net sales of the licensed products in its licensed territory, until date of expiration of the latest of valid claim that claims the composition-of-matter of the licensed product, the expiration date of any regulatory data
exclusivity for the licensed product, or the tenth anniversary of the first commercial sale of the licensed product. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group has the right to
terminate this agreement by providing Hanmi with prior written notice. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>License and collaboration agreement with Tesaro Inc., (&#147;Tesaro&#148;)
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In September 2016, the Group entered into a collaboration, development and license agreement with Tesaro, under which the Group obtained an
exclusive license for certain patents and know-how that Tesaro licensed from Merck, Sharp&nbsp;&amp; Dohme Corp. (a subsidiary of Merck&nbsp;&amp; Co. Inc.), or Merck Corp., and AstraZeneca UK Limited to develop, manufacture, use, sell, import and
commercialize Tesaro&#146;s proprietary PARP inhibitor, niraparib, in mainland China, Hong Kong and Macau, or the licensed territory, in the licensed field of treatment, diagnosis and prevention of any human diseases or conditions (other than
prostate cancer). Tesaro has the option to elect to co-promote the licensed products in the Group&#146;s licensed territory. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the terms of the
agreement, the Group made an upfront payment of $15.0 million to Tesaro which was recorded as a research and development expense in 2016. If the Group successfully develops and commercializes the licensed products, the Group will make a milestone
payment to Tesaro for the achievement of a certain development milestone event. In addition, if Tesaro does not exercise its co-promotion option, the Group will pay Tesaro milestone payments for the achievement of certain sales milestone events, and
also tiered royalties at certain percentages of net sales of the licensed products, until the later of the expiration of the last-to-expire licensed patent covering the licensed product, the expiration of regulatory exclusivity for the licensed
product, or the tenth anniversary of the first commercial sale of the licensed product, in each case on a product-by-product and region-by-region basis. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group has the right to terminate this agreement by providing Tesaro with prior written notice. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-35 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>License and collaboration agreement with GlaxoSmithKline (China) R&amp;D Co., Ltd (&#147;GSK China&#148;)
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In October 2016, the Group entered into a license and transfer agreement with GSK China, an affiliate of GSK, under which GSK China transferred
to the Group its rights under certain patents, know-how, inventory and regulatory materials to develop, manufacture, use and commercialize FUGAN and GRAPE, two formulations comprising extracts from traditional Chinese herbs, for the treatment,
diagnosis and prevention of human diseases. In connection with such transfer, GSK China also assigned to the Group its agreements with Chengdu Bater Pharmaceutical Co., Ltd, or Bater, and Traditional Chinese Medical Hospital, Xinjiang Medical
University, or Xinjiang, relating to FUGAN and GRAPE. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the terms of the agreement, the Group made an upfront payment to GSK China of $0.7 million
(RMB4.5 million) which was recorded as a research and development expense in 2016. The Group will make milestone payments to GSK China for the achievement of certain development milestone events. In addition, the Group will pay to GSK China tiered
royalties at certain percentage rates on the net sales of FUGAN and GRAPE. The Group also assumed the obligation to make milestone payments under the assigned agreements with Bater and Xinjiang for milestones achieved after the assignment of the
agreements to the Group. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">If the Group sublicenses, sells or otherwise divests the patents and know-how acquired from GSK China to third parties before
the completion of a certain development phase, the Group is also required to pay to GSK China a share of its income attributed to such sublicense, sale, or divesture. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Group may not terminate the agreement before the completion of the Phase II Study of fugan unless for causes beyond the reasonable control of the Group. Subject to the completion of the Phase II Study of fugan,
the Group has the right to terminate the agreement upon prior written consent. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As noted above, the Group has entered into various license and
collaboration agreements with third party licensors to develop and commercialize drug candidates. Based on the terms of these agreements the Group is contingently obligated to make additional material payments upon the achievement of certain
contractually defined milestones. The Group hasn&#146;t made any milestone payment under these agreements for the years ended December&nbsp;31, 2014, 2015 and 2016, respectively, because none of the milestones were achieved. Based on
management&#146;s evaluation of the progress of each project noted above, the licensors will be eligible to receive from the Group up to an aggregate of approximately $300.0&nbsp;million in future milestone payments upon the achievement of
contractually specified development milestones, such as regulatory approval for the drug candidates, which may be before the Group has commercialized the drug or received any revenue from sales of such drug candidate, which may never occur.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>13. Restricted net assets </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group&#146;s
ability to pay dividends may depend on the Group receiving distributions of funds from its PRC subsidiary. Relevant PRC statutory laws and regulations permit payments of dividends by the Group&#146;s PRC subsidiary only out of its retained earnings,
if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with U.S. GAAP differ from those reflected in the statutory
financial statements of the Group&#146;s PRC subsidiary. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-36 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In accordance with the Company law of the PRC, a domestic enterprise is required to provide statutory reserves of
at least 10% of its annual <FONT STYLE="white-space:nowrap">after-tax</FONT> profit until such reserve has reached 50% of its respective registered capital based on the enterprise&#146;s PRC statutory accounts. A domestic enterprise is also required
to provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise&#146;s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes
and are not distributable as cash dividends. The Group&#146;s PRC subsidiary was established as domestic invested enterprise and therefore is subject to the above mentioned restrictions on distributable profits. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">During the years ended December&nbsp;31, 2015 and 2016, no appropriation to statutory reserves was made because the PRC subsidiary had substantial losses during
such periods. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As a result of these PRC laws and regulations subject to the limit discussed above that require annual appropriations of 10% of <FONT
STYLE="white-space:nowrap">after-tax</FONT> income to be set aside, prior to payment of dividends, as general reserve fund, the Group&#146;s PRC subsidiary is restricted in their ability to transfer a portion of their net assets to the Group.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Foreign exchange and other regulation in the PRC may further restrict the Group&#146;s PRC subsidiary from transferring funds to the Group in the form
of dividends, loans and advances. As of December&nbsp;31, 2015 and 2016, amounts restricted are the <FONT STYLE="white-space:nowrap">paid-in</FONT> capital of the Group&#146;s PRC subsidiaries, which amounted to $5,699,980 and $39,215,714,
respectively. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>14. Employee defined contribution plan </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Full time employees of the Group in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits
are provided to employees. Chinese labor regulations require that the Group&#146;s PRC subsidiary make contributions to the government for these benefits based on certain percentages of the employees&#146; salaries. The Group has no legal obligation
for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $79,878 and $288,666 for the years ended December&nbsp;31, 2015 and 2016, respectively. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>15. Commitments and Contingencies </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(A) Operating lease
commitments </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group leases office facilities under <FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating leases expiring on
different dates. Payments under operating leases are expensed on a straight-line basis over the periods of their respective leases, and the terms of the leases do not contain rent escalation, contingent rent, renewal, or purchase options.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There are no restrictions placed upon the Group by entering into these leases. Total expenses under these operating leases were $148,274 and $285,742
for the years ended December&nbsp;31, 2015 and 2016, respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-37 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the years ended December 31, 2015 and 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Future minimum lease payments under <FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating lease
agreements at December&nbsp;31, 2016 were as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year ended<BR>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">712,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">659,810</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">548,923</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">198,451</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2021 and thereafter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total lease commitment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,119,485</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(B) Purchase commitments </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As of December&nbsp;31, 2016, the Group&#146;s commitments related to purchase of property and equipment contracted but not yet reflected in the consolidated financial statement was $3,396,524 which is expected to
be incurred within one year. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(C) Contingencies </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Group is a party to or assignee of license and collaboration agreements that may require it to make future payments relating to milestone fees and royalties on future sales of licensed products (Note 12).
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>16. Subsequent events </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The subsequent events
have been evaluated through May 30, 2017, which is the date the audited consolidated financial statements were available to be issued. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On April&nbsp;21,
2017, the Group entered into a license and collaboration agreement with Paratek Bermuda Ltd. for the development, manufacture and commercialization of omadacycline in China, Hong Kong, Macau and Taiwan. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In May 2017, the Group granted 158,313 share options to certain of the Group&#146;s management and employees at an exercise price of $3.0 per share. These options
have a contractual term of 10 years and generally vest over a four or five year period, with 25% or 20% of the awards vesting on the anniversary date of the grant. The Group also granted 4,583 share options to certain individual advisors of the
Group at an exercise price of $3.0 per share. These options granted have a contractual term of 10 years and generally vest over a three year period, with 33.33% of the awards vesting on the anniversary date of the grant. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In March and May, 2017, pursuant to the board resolution, the Repurchase Right to all the remaining non-vested shares of the Chief Executive Officer which are
subject to the restricted share arrangement dated April 3, 2014 was terminated. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-38 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin358845_8"></A>Additional financial information of parent company - </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Financial statements schedule I </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Financial information of parent company </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Condensed statements of operations and comprehensive income (loss) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,114,070</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">24,813,050</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,114,070</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">24,813,050</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Investment in subsidiaries</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,803,171</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">62,042,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,917,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">86,855,395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Liabilities, mezzanine equity and shareholders&#146; deficits</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Current liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,980,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,900,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,980,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,900,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Mezzanine equity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Series A1 convertible preferred shares (par value US$0.00006 per share; 8,466,667 shares authorized, 8,466,665 shares issued and
outstanding as of December&nbsp;31, 2015 and 2016)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,028,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,028,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Series A2 convertible preferred shares (par value US$0.00006 per share; 8,904,032 shares authorized, 8,442,221 shares issued and
outstanding as of December&nbsp;31, 2015 and 2016)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,278,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,278,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Series B1 convertible preferred shares (par value US$0.00006 per share; 5,562,337 shares authorized, 5,562,335 shares issued and
outstanding as of 2016)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53,100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Series B2 convertible preferred shares (par value US$0.00006 per share; 3,973,098 shares authorized, 3,973,096 shares issued and
outstanding as of December&nbsp;31, 2016)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53,100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total mezzanine equity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">28,307,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">134,507,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Shareholders&#146; deficits</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Ordinary shares (par value of US$0.00006 per share; 83,333,333 shares authorized, 8,885,184 and 9,657,175 shares outstanding as of
December&nbsp;31, 2015 and 2016, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Subscription receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Additional <FONT STYLE="white-space:nowrap">Paid-in</FONT> Capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,388,410</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,313,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accumulated deficits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(22,655,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(60,167,437</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Additional other comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(103,620</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(698,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total shareholders&#146; deficits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,369,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(51,551,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Total liabilities, mezzanine equity and shareholders&#146; deficits</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,917,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">86,855,395</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-39 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Additional financial information of parent company - </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Financial statements schedule I </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Financial information of parent company </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Condensed
statements of operations and comprehensive income (loss) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year
ended</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Operating Expenses:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(56,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(534,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Loss from operations</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(56,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(534,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Changes in fair value of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,980,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,920,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Equity in loss of subsidiaries</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(15,984,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(35,057,552</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Loss before income tax</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,021,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Net loss attributable to ordinary shareholders</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,021,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Net loss</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,021,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other comprehensive income, net of tax of nil:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign currency translation adjustment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(98,893</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(594,912</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Comprehensive loss</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,120,630</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(38,107,124</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-40 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Additional financial information of parent company - </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Financial statements schedule I </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Financial information of parent company </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Condensed
statements of cash flows </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Year
ended</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,021,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(37,512,212</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Adjustments to reconcile net loss to net cash provided by operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Share based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">56,806</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">534,660</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Change of fair value of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,980,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,920,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Equity in loss of subsidiaries</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">15,984,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">35,057,552</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Cash flows from investing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Investment in subsidiaries</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(84,501,020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(21,500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(84,501,020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Cash flows from financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Proceed from issuance of convertible preferred shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,278,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">106,200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">18,278,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">106,200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Effect of foreign exchange rate changes on cash and cash equivalent</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net (decrease) increase in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,221,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">21,698,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents&#151;beginning of the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,335,498</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,114,070</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents&#151;end of the year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,114,070</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">24,813,050</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-41 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Additional financial information of parent company - </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Financial statements schedule I </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Financial information of parent company </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Notes to schedule
I </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">1) Schedule I has been provided pursuant to the requirements of Rule <FONT STYLE="white-space:nowrap">12-04(a)</FONT> and <FONT STYLE="white-space:nowrap">5-04(c)</FONT> of Regulation
<FONT STYLE="white-space:nowrap">S-X,</FONT> which require condensed financial information as to the financial position, changes in financial position and results of operations of a parent company as of the same dates and for the same periods for
which audited consolidated financial statements have been presented when the restricted net assets of consolidated subsidiaries exceed 25&nbsp;percent of consolidated net assets as of the end of the most recently completed fiscal year. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">2) The condensed financial information has been prepared using the same accounting policies as set out in the consolidated financial statements except that the
equity method has been used to account for investments in its subsidiaries. For the parent company, the Company records its investments in subsidiaries under the equity method of accounting as prescribed in ASC 323, Investments-Equity Method and
Joint Ventures. Such investments are presented on the Condensed Balance Sheets as &#145;&#145;Investment in subsidiaries&#146;&#146;. Ordinarily under the equity, an investor in an equity method investee would cease to recognize its share of the
losses of an investee once the carrying value of the investment has been reduced to nil absent an undertaking by the investor to provide continuing support and fund losses. For the purpose of this Schedule I, the parent company has continued to
reflect its share, based on its proportionate interest, of the losses of subsidiaries regardless of the carrying value of the investment even though the parent company is not obligated to provide continuing support or fund losses. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">3) As of December&nbsp;31, 2015 and 2016, there were no material contingencies, significant provisions of long term obligations, mandatory dividend or redemption
requirements of redeemable stocks or guarantees of the Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-42 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin358845_9"></A>Unaudited condensed consolidated balance sheets </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="1"><B>As of<BR>December&nbsp;31,&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>As
of<BR>June&nbsp;30,&nbsp;2017</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>Notes</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Current assets:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">83,948,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">92,562,012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Deferred initial public offering costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,032,004</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Prepayments and other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">143,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">287,898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">84,092,297</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">93,881,914</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Investments in equity investees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Prepayments for Equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,417,029</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,246,058</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">7,044,292</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">7,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">6,279</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Long term deposits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">267,980</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">324,181</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Value added tax recoverable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,376,921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">2,608,491</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Total assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">88,907,285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">103,865,157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Liabilities, mezzanine equity and shareholders&#146; deficits</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Current liabilities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">523,338</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,971,317</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,900,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">3,700,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Other payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">750,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">1,958,457</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">5,173,456</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">9,629,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Deferred subsidy income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">778,434</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">879,783</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Total liabilities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">5,951,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">10,509,557</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Commitments (Note 14)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Mezzanine equity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Series A1 convertible preferred shares (par value $0.00006 per share; 8,446,667 shares authorized, 8,466,665 shares issued and outstanding
as of December&nbsp;31, 2016 and June&nbsp;30, 2017)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">10,028,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">10,028,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Series A2 convertible preferred shares (par value $0.00006 per share; 8,904,032 shares authorized; 8,442,221 shares issued and outstanding
as of December&nbsp;31, 2016 and June&nbsp;30, 2017)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">18,278,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">18,278,572</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Series B1 convertible preferred shares (par value $0.00006 per share; 5,562,337 shares authorized, 5,562,335 shares issued and outstanding
as of December&nbsp;31, 2016 and June&nbsp;30, 2017)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">53,100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">53,100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Series B2 convertible preferred shares (par value $0.00006 per share; 3,973,098 shares authorized, 3,973,096 shares issued and outstanding
as of December&nbsp;31, 2016 and June&nbsp;30, 2017)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">53,100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">53,100,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Series C convertible redeemable preferred shares (par value $0.00006 per share; 1,998,961 shares authorized, 1,998,958 shares issued and
outstanding as of June&nbsp;30, 2017)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="1">8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">30,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Total mezzanine equity</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">134,507,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">164,507,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Shareholders&#146; deficits</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Ordinary shares (par value of $0.00006 per share; 83,333,333 shares authorized, 9,657,175 shares issued and outstanding as of
December&nbsp;31, 2016; and 11,264,664 shares issued and outstanding as of June&nbsp;30, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Subscription receivable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">9,313,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">13,756,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accumulated deficits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(60,167,437</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(84,586,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Accumulated other comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(698,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(321,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1">Total shareholders&#146; deficits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(51,551,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">(71,151,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="1"><B>Total liabilities, mezzanine equity and shareholders&#146; deficits</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">88,907,285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1">103,865,157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="10" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-43 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin358845_10"></A>Unaudited condensed consolidated statements of operations </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Six months
ended</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,777,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(20,873,605</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,377,431</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,040,996</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,155,388</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,914,601</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">63,654</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">285,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Changes in fair value of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(920,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">176,559</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,882</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,230</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Loss before income tax</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,835,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,419,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Income tax expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,835,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,419,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss attributable to ordinary shareholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,835,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,419,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share attributable to ordinary shareholders-basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted-average shares used in calculating net loss per ordinary share-basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,242,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,630,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-44 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin358845_11"></A>Unaudited condensed consolidated statements of comprehensive loss </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Six months
ended</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,835,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,419,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other comprehensive loss, net of tax of nil:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign currency translation adjustments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(23,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">376,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Comprehensive loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,858,241</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,042,909</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-45 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin358845_11a"></A>Unaudited condensed consolidated statements of shareholders&#146; deficits </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Ordinary shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Additional<BR>paid in<BR>capital</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Subscription<BR>receivables</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Accumulated<BR>deficits</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Accumulated&nbsp;other<BR>comprehensive&nbsp;loss</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Total</B></FONT></P></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Number of<BR>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at January 1, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,885,184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,388,410</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(22,655,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(103,620</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(18,369,903</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Issuance of ordinary shares upon vesting of restricted shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">727,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Share-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,779,832</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,779,832</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,835,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,835,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign currency translation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(23,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(23,066</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at June 30, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,612,962</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">577</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,168,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(34,490,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(126,686</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(28,448,312</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at January&nbsp;1, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,657,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">579</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,313,646</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(60,167,437</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(698,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(51,551,749</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Issuance of ordinary shares upon vesting of restricted shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,506,655</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(87</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Share-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,377,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,377,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Exercise of shares option</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">100,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">65,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">65,448</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,419,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,419,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Foreign currency translation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">376,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">376,574</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Balance at June&nbsp;30, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">11,264,664</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,756,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(84,586,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(321,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(71,151,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="28" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-46 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin358845_12"></A>Unaudited condensed consolidated statements of cash flows </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Six months
ended</B></FONT><br><FONT STYLE="font-family:arial" SIZE="2"><B>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,835,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,419,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Adjustments to reconcile net loss to net cash provided by operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Depreciation of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">91,822</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">149,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Amortization of intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">878</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Share-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,779,832</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">4,377,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fair value of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">920,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Changes in operating assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Prepayments and other current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(59,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(17,360</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Long term deposits</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(58,945</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(56,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Value added tax recoverable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(207,676</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1,231,570</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Accounts payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">161,712</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,447,979</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other payables</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(203,302</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">169,828</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Deferred subsidy income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">601,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">101,349</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(8,808,778</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(17,677,014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Cash flows from investing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Disposal of cost method investment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Purchases of property and equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(49,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,147,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(49,005</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(3,647,544</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Cash flows from financing activities:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Proceed from issuance of convertible preferred shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">106,200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">30,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B></B>Proceeds from exercises of stock options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">65,448</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Payment of initial public offering costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(224,993</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">106,200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">29,840,455</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Effect of foreign exchange rate changes on cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(4,867</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">97,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net increases in cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">97,337,350</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,613,242</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents&#151;beginning of the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">13,160,696</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">83,948,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash and cash equivalents&#151;end of the period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">110,498,046</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">92,562,012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Supplemental disclosure on <FONT STYLE="white-space:nowrap">non-cash</FONT> investing and financing activities: </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of June&nbsp;30, 2016 and 2017, payables for purchase of property and equipment are nil and $318,295, respectively. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of June&nbsp;30, 2016 and 2017, payables for initial public offering costs are nil and $1,027,011, respectively. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="1"><I>The accompanying notes are an integral part of these unaudited condensed consolidated financial statements </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-47 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B><A NAME="fin358845_13"></A>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>1. Organization and principal activities </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">ZAI Lab Limited (the &#147;Company&#148;) was incorporated on
March&nbsp;28, 2013 in the Cayman Islands as an exempted company with limited liability under the Companies Law of the Cayman Islands. The Company and its subsidiaries (collectively referred to as the &#147;Group&#148;) are principally engaged in
discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical needs in the China market, including in the fields of oncology, autoimmune and infectious disease therapies. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of June&nbsp;30, 2017, the Group&#146;s significant operating subsidiaries are as follows: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Name of company</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Place of<BR>incorporation</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Date of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>incorporation</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Percentage&nbsp;of<BR>ownership</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Principal activities</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">ZAI Lab (Hong Kong) Limited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Hong&nbsp;Kong</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">April&nbsp;29, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">100%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Operating&nbsp;company<BR>for business<BR>development and<BR>R&amp;D activities</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">ZAI Lab (Shanghai) Co., Ltd.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">The People&#146;s<BR>Republic&nbsp;of&nbsp;China<BR>(&#147;PRC&#148;&nbsp;or&nbsp;&#147;China&#148;)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">January&nbsp;6,&nbsp;2014</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">100%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Development and<BR>commercialisation</FONT> <P STYLE="margin-bottom:0px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">of innovative</FONT></P>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">medicines</FONT></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">ZAI Lab (AUST) Pty., Ltd.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Australia</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">December&nbsp;10,&nbsp;2014</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">100%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Clinical trial</FONT><BR> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">activities</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">ZAI Lab (Suzhou) Co., Ltd.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">PRC</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">October&nbsp;20,&nbsp;2015</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">100%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Development and<BR>commercialisation<BR>of innovative<BR>medicines</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="9" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>2. Summary of significant accounting policies </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>(a) Basis of presentation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The unaudited condensed consolidated financial statements included herein are
unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;) and applicable rules and regulations of the Securities and Exchange Commission, regarding interim
financial reporting, and include all normal and recurring adjustments that management of the Group considers necessary for a fair presentation of its financial position and operating results. Certain information and footnote disclosures normally
included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these statements should be read in conjunction with the audited consolidated financial
statements and accompanying notes thereto contained in the Company&#146;s consolidated financial statements as of and for the two years in the period ended December&nbsp;31, 2016. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-48 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(b) Principles of consolidation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The unaudited condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All intercompany transactions and balances among the Group and its subsidiaries are
eliminated upon consolidation. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these
interim unaudited condensed consolidated financial statements may not be the same as those for the full year. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(c) Use of estimates
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the period. Areas where management uses subjective judgment include
estimating the useful lives of long-lived assets, assessing the impairment of long-lived assets, valuation of ordinary shares, share-based compensation expenses, recoverability of deferred tax assets and the fair value of the financial instruments.
Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results
could differ from these estimates. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(d) Deferred initial public offering (&#147;IPO&#148;)costs </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Direct costs incurred by the Company attributable to its proposed IPO of ordinary shares in the U.S. have been deferred and recorded in deferred initial public
offering costs and will be charged against the gross proceeds received from such offering. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(e) Investments in equity investees
</I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group uses the equity method to account for an equity investment over which it has significant influence but does not own a majority equity
interest or otherwise control. The Group records equity method adjustments in share of earnings and losses. Equity method adjustments include the Group&#146;s proportionate share of investee income or loss, adjustments to recognize certain
differences between the Group&#146;s carrying value and its equity in net assets of the investee at the date of investment, impairments, and other adjustments required by the equity method. Dividends received are recorded as a reduction of carrying
amount of the investment. Cumulative distributions that do not exceed the Group&#146;s cumulative equity in earnings of the investee are considered as a return on investment and classified as cash inflows from operating activities. Cumulative
distributions in excess of the Group&#146;s cumulative equity in the investee&#146;s earnings are considered as a return of investment and classified as cash inflows from investing activities. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">For equity investments over which the Group does not have significant influence or control, the cost method of accounting is used. Under the cost method, the Group carries the investment at cost and recognizes
income to the extent of dividends received from the distribution of the equity investee&#146;s post-acquisition profits. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-49 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(f) Fair value measurements </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Group applies ASC topic 820 (&#147;ASC 820&#148;), <I>Fair Value Measurements and Disclosures</I>, in measuring fair value. ASC 820 defines fair value, establishes a framework for measuring fair value and
requires disclosures to be provided on fair value measurement. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used
in measuring fair value as follows: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">Level 1&#151;Observable inputs that reflect quoted prices (unadjusted) for identical assets or
liabilities in active markets. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">Level 2&#151;Include other inputs that are directly or indirectly observable in the marketplace.
</FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">Level 3&#151;Unobservable inputs which are supported by little or no market activity. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&nbsp;market approach; (2)&nbsp;income approach and (3)&nbsp;cost
approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single
present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Financial instruments of the Group primarily include cash and cash equivalents, prepayments and other current assets, accounts payable, warrant liabilities and
other payables. As of June&nbsp;30, 2017, the carrying values of cash and cash equivalents, prepayments and other current assets, accounts payable and other payables approximated their fair values due to the short-term maturity of these instruments.
The warrant liabilities were recorded at fair value as determined on the issuance date and subsequently adjusted to the fair value at each reporting date. The Group determined the fair values of the warrant liabilities with the assistance of an
independent third party valuation firm. For the six months ended June&nbsp;30, 2017, the Company recognized a gain from the decrease in fair value of the warrants which amounted to $200,000. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Liabilities measured at fair value on a recurring basis as of June&nbsp;30, 2017 are summarized below: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;1</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;2</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Level&nbsp;3</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,700,000.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="12" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-50 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group used the binomial model to estimate the fair value of warrant liabilities using the following
assumptions: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>June&nbsp;30, 2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Risk-free rate of return</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.1%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Vesting date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">April&nbsp;1,&nbsp;2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Maturity date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">July&nbsp;31,&nbsp;2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Estimated volatility rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">70%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Exercise price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fair value of underlying preferred shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10.26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="4" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(g) Revenue recognition </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Group has not yet generated any revenues from the sale of goods or from the rendering of services. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Prior to the
adoption of ASC 606, the Group will recognize any revenues when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and there is reasonable assurance that the related
amounts are collectible in accordance with ASC 605, <I>Revenue Recognition</I>. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(h) Research and development expenses </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Elements of research and development expenses primarily include (i)&nbsp;payroll and other related costs of personnel engaged in research and development
activities, <FONT STYLE="white-space:nowrap">(ii)&nbsp;in-licensed</FONT> patent rights fee of exclusive development rights of drugs granted to the Group, (iii)&nbsp;costs related to preclinical testing of the Group&#146;s technologies under
development and clinical trials such as payments to contract research organizations (&#147;CROs&#148;), investigators and clinical trial sites that conduct our clinical studies, (iv)&nbsp;costs to develop the product candidates, including raw
materials and supplies, product testing, depreciation, and facility related expenses, (v)&nbsp;other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to the
Group&#146;s research and development services and have no alternative future uses. The conditions enabling capitalization of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit
or loss when incurred. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group also has obligations to make future payments to third party licensors that become due and payable on the achievement of
certain development, regulatory and commercial milestones, which will be recorded as research and development expenses. The Group has not included these commitments on our balance sheet because the commitments are cancellable if the milestones are
not completed and achievement and timing of these milestones are not fixed or determinable. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(i) Government grants </I></B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Government grants consist of cash subsidies received by the Group&#146;s subsidiaries in the PRC from local governments. Grants received as incentives for
conducting business in certain local districts with no </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-51 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
performance obligation or other restriction as to the use are recognized when cash is received. Cash grants of $179,155 and nil were included in other income for the six months ended
June&nbsp;30, 2016 and 2017, respectively. Grants received with government specified performance obligations are recognized when all the obligations have been fulfilled. If such obligations are not satisfied, the Company may be required to refund
the subsidy. Cash grants of $778,434 and $879,783 were recorded in deferred subsidy income as of December 31, 2016 and June&nbsp;30, 2017, respectively, which will be recognized when the government specified performance obligation is satisfied.
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(j) Stock-based compensation </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Awards
Granted to Employees </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group grants share options to eligible employees, management and directors and accounts for these share based awards in
accordance with ASC 718 <I>Compensation-Stock Compensation. </I> </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Employees&#146; share-based awards are measured at the grant date fair value of the
awards and recognized as expenses a) immediately at grant date if no vesting conditions are required; or b) using graded vesting method over the requisite service period, which is the vesting period. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">All transactions in which goods or services are received in exchange for equity instruments are accounted for based on the fair value of the consideration received
or the fair value of the equity instrument issued, whichever is more reliably measurable. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">To the extent the required vesting conditions are not met
resulting in the forfeiture of the share-based awards, previously recognized compensation expense relating to those awards are reversed. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group, with
the assistance of an independent third party valuation firm, determined the fair value of the stock options granted to employees. The binomial option pricing model was applied in determining the estimated fair value of the options granted to
employees. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Awards Granted to <FONT STYLE="white-space:nowrap">Non-Employees</FONT> </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Group has accounted for equity instruments issued to <FONT STYLE="white-space:nowrap">non-employees</FONT> in accordance with the provisions of ASC 505, <I>Equity-Based Payments to <FONT
STYLE="white-space:nowrap">Non-Employees</FONT></I>. All transactions in which goods or services are received in exchange for equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity
instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the date on which the counterparty&#146;s performance is completed as there is no associated performance commitment.
The expense is recognized in the same manner as if the Group had paid cash for the services provided by the <FONT STYLE="white-space:nowrap">non-employees</FONT> in accordance with ASC 505. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-52 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(k) Concentration of Risks </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Concentration of suppliers </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The following suppliers accounted for 10% or more of research and development
expenses for the six months ended June&nbsp;30, 2016 and 2017: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Six Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">A</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,006,290</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">B</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">951,198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">C</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,519,568</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Represents less than 10% of research and development expenses for the six months ended June&nbsp;30, 2016 and 2017. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Concentration of Credit Risk </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Financial instruments that are
potentially subject to significant concentration of credit risk consist of cash and cash equivalents and prepayments for equipment. The carrying amounts of cash and cash equivalents represent the maximum amount of loss due to credit risk. As of
June&nbsp;30, 2017, all of the Group&#146;s cash and cash equivalents were held by major financial institutions located in the PRC and international financial institutions outside of the PRC which management believes are of high credit quality and
continually monitors the credit worthiness of these financial institutions. With respect to the&nbsp;prepayment&nbsp;to suppliers, the Company performs <FONT STYLE="white-space:nowrap">on-going</FONT> credit evaluations of the financial condition of
these suppliers.</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Foreign Currency Risk </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Renminbi
(&#147;RMB&#148;) is not a freely convertible currency. The State Administration of Foreign Exchange, under the authority of the People&#146;s Bank of China, controls the conversion of RMB into foreign currencies. The value of RMB is subject to
changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. The cash and cash equivalents of the Group included aggregated amounts
of RMB 44,156,161 and RMB 24,724,805, as of December 31, 2016 and June&nbsp;30, 2017, respectively, representing 8% and 4% of the cash and cash equivalents as of December 31, 2016 and June&nbsp;30, 2017, respectively. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(l) Share Consolidation (&#147;Reverse Stock Split&#148;) </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">On August 30, 2017, the Company effected a 6 -to- 1 share consolidation of all the ordinary shares and preferred shares. All number of shares, par value and per share amounts for all periods presented in these
consolidated financial statements and accompanying notes have been adjusted retrospectively, where applicable, to reflect this share consolidation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-53 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(m) Recent accounting pronouncements </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In May 2017, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">No.&nbsp;2017-09,</FONT> Compensation&#151;Stock
Compensation (Topic 718): Scope of Modification Accounting. The guidance provides clarity and reduces diversity in practice and cost and complexity when accounting for a change to the terms or conditions of a share-based payment award. The
amendments in this update are effective for all entities for annual periods, and interim periods within those annual periods, beginning after December&nbsp;15, 2017. Early adoption is permitted. The Group is currently evaluating the impact the
adoption of this ASU will have on its consolidated financial statements. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>3. Cash and cash equivalents </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>As
of<BR>December&nbsp;31,</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of<BR>June&nbsp;30,<BR>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash at bank and in hand</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">36,531,272</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">67,083,748</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">47,417,498</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">25,478,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">83,948,770</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">92,562,012</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Denominated in:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">$</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">77,463,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">88,794,068</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">RMB (note (i))</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,365,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,649,741</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Australia dollar (&#147;A$&#148;)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">120,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">118,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">83,948,770</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">92,562,012</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Notes: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(i)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Certain cash and bank balances denominated in RMB were deposited with banks in the PRC. The conversion of these RMB denominated balances into foreign currencies is subject to the
rules and regulations of foreign exchange control promulgated by the PRC government. </FONT></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>4. Investment in equity investees </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In June 2017, the Group entered into agreement with other three third-party investors to launch a new company named JING Medicine Technology (Shanghai) Ltd.
(&#147;JING&#148;), which will provide services for the drug discovery and development, consultation and transfer of pharmaceutical technology. The capital contribution by the Group will be RMB26.3 million&nbsp;($3.86 million) in cash, representing
20% of the equity interest of JING, which will be paid after June 2017. The Group accounts for this investment using equity method of accounting because the Group does not control the investee but has the ability to exercise significant influence
over the operating and financial policies of the investee. As of June&nbsp;30, 2017, there has been no operation activities in JING. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In October 2016,
the Group invested $500,000 in a private company over which the Group does not have significant influence or control and accounted for the investment using cost method of accounting. In April 2017, the Group disposed its investment to Quan Venture
Fund I, L.P. for a cash consideration of approximately $500,000 and no gain/loss was recognized upon disposal (Note 10). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-54 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>5. Property and equipment </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">Property and equipment consist of the following: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>As
of<BR>December&nbsp;31,</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>As
of<BR>June&nbsp;30,</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Office equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">49,432</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">125,151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Electronic equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">66,271</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">85,532</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Vehicle</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">76,636</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">78,475</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Laboratory equipment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">593,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">657,285</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Leasehold improvements</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">252,509</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,229,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Construction in progress</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">465,428</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,284,421</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,503,858</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,460,089</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Less accumulated depreciation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(257,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(415,797</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Property and equipment, net</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,246,058</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,044,292</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Depreciation expenses for the six months ended June&nbsp;30, 2016 and 2017 were $91,822 and $149,900, respectively. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>6. Income tax </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There is no provision for income taxes
because the Company and all of its wholly owned subsidiaries are in a current loss position for the six months ended June&nbsp;30, 2016 and 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The
Company recorded a full valuation allowance against deferred tax assets of all its consolidated entities because all entities were in a cumulative loss position as of June&nbsp;30, 2016 and 2017. No unrecognized tax benefits and related interest and
penalties were recorded in any of the periods presented. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>7. Other payables </B></FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of<BR>December&nbsp;31,<BR>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of<BR>June&nbsp;30,<BR>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Payroll</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">573,802</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">441,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other taxes payable</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">23,721</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Other payables (note (i))</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">152,595</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,514,346</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">750,118</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,958,457</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Notes: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">(i)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Other payables are mainly payables related to legal advisory fee, travel expense and purchase of property and equipment. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-55 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>8. Convertible redeemable preferred shares </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In June 2017, the Company issued 1,998,958 Series C convertible redeemable preferred shares (&#147;Series C Preferred Shares&#148;) with a par value of $ 0.00006 per share to a group of investors including existing
preferred share investors for a cash consideration of $30,000,000 or $15.0078 per share. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The key terms of the Series C Preferred Shares are as follows:
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Conversion Rights </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Each holder of Series C
Preferred Shares shall have the right, at such holders&#146; sole discretion, to convert all or any portion of the Series C Preferred Shares into ordinary shares based at any time. The initial conversion price shall equal the lower of (i)&nbsp;the
issuance price of Series C Preferred Shares and (ii)&nbsp;Calculated Price which is one hundred percent minus the discount rate of fifteen percent (the &#147;Discount Rate&#148;) multiplied by the offering price of the ordinary shares of the Company
to the public on the date of the Qualified Initial Public Offering (&#147;QIPO&#148;). The Discount Rate will increase at increments of an additional two percent as of the first day of each successive six months period after June, 2018 but shall in
no event exceed twenty percent. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The conversion price is subject to adjustment in the event of (1)&nbsp;stock splits, share combinations, share dividends
and distribution, recapitalizations and similar events, and (2)&nbsp;issuance of new securities at a price per share less than the conversion price in effect on the date of or immediately prior to such issuance. In that case, the conversion price
shall be reduced concurrently to the subscription price of such issuance. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Preferred Shares will be automatically converted into ordinary shares at
the then applicable conversion price upon the earlier of (1)&nbsp;the closing of a QIPO, or (2)&nbsp;the date specified by written consent or agreement of majority holders of Series C Preferred Shares. A QIPO refers to a firm commitment underwritten
public offering by the Company of its ordinary shares in the United States on the New York Stock Exchange or the Nasdaq Global Market pursuant to an effective registration statement under the United States Securities Act of 1933, that result in net
cash proceeds to the Company of at least $75&nbsp;million (net of underwriting discounts and selling commissions) through the sales of the ordinary shares in an IPO, the occurrence of which the company has assessed as probable. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Voting Rights </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Series C Preferred Shareholders are
entitled to vote with ordinary shareholders on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis. The holders of the Preferred Shares also have certain veto rights including, but not limited to, an increase or decrease in the total
number of directors and change of board composition, appointment or removal of senior management, approval of business plan and operating budget, dividend declaration, any merger, split, reorganization or consolidation. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Dividends </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Series C Preferred Shareholders may be
entitled to receive dividends accruing at the rate of 8% per annum of the issuance price of Series C Preferred Shares (the &#147;Dividend Rate&#148;). The Dividend Rate shall increase by an </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-56 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
additional one percent per annum for each successive six months period after June 2018 but shall in no event exceed ten percent. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In addition, Preferred Shareholders are also entitled to dividends on the Company&#146;s ordinary shares on an as if converted basis and must be paid prior to any payment on other class or series of equity
securities of the Company. All dividends shall be payable only when, as, and if declared by the Board of Directors and shall be cumulative. </FONT></P>
<P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Liquidation Preference </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event of any liquidation,
dissolution or winding up of the Company, either voluntary or involuntary, the holders of Series C Preferred Shares are entitled to receive, prior to any distribution to the holders of any other class or series of equity securities, an amount per
share equal the issuance price of Series C Preferred Shares plus <FONT STYLE="white-space:nowrap">non-compounding</FONT> simple interest accruing at five percent (5%) per annum on the issuance price and plus any accrued but unpaid dividends (the
&#147;Series C Preference Amount&#148;). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event insufficient funds are available to pay in full the Series C Preference Amount in respect of each
Series C preferred shareholders, the sequence of liquidation right of all series of preferred shares was as follows: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:arial" SIZE="2">(1) Series C
Preferred Shares </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:arial" SIZE="2">(2) Series B1 and B2 Preferred Shares </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:arial" SIZE="2">(3) Series A1 and A2 Preferred Shares </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">After the preference amount for preferred shares have been paid, any remaining
funds or assets legally available for distribution shall be distributed pro rata among the preferred shareholders together with ordinary shareholders. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A
liquidation event includes, (i)&nbsp;any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary; the exclusive licensing of all or substantially all of the Group Companies&#146; intellectual property, taken as a
whole, to a third party; (ii)&nbsp;any sale of all or substantially all of the assets of the Group to a third party unaffiliated with any member of the Group; or (iii)&nbsp;the transfer (whether by merger, reorganization or other transaction) in
which a majority of the outstanding voting power of the Company is transferred (excluding any sale of shares by the Company for capital raising purposes). </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I>Redemption </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the event that a QIPO has not been completed by June, 2022 (the&nbsp;fifth anniversary of the
closing date), holders of the Series C Preferred Shares may at any time thereafter require that the Company redeem all of the Series C Preferred Shares held by such holder at a redemption price per share equal to the sum of (i)&nbsp;an amount equal
to the original issuance price, and (ii)&nbsp;an additional amount which would result in holders of Series C Preferred Shares receiving an internal rate of return of fifteen percent after taking into consideration the payment of issuance price of
Series C Preferred Shares and all prior distributions received. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-57 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group classified the Series C Preferred Shares in the mezzanine equity of the consolidated balance sheets
because they were redeemable at the holders&#146; option any time after a certain date and were contingently redeemable upon the occurrence of certain event outside of the Company&#146;s control (i.e.&nbsp;a liquidation event or failure to complete
the QIPO within required period). </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Because the Series C Preferred Shares are automatically convertible into ordinary shares upon a QIPO, the ability of
holders to redeem such shares on or after the closing date is contingent upon a QIPO not occurring in five years or occurrence of any liquidation event. Upon issuance, the Group determined that redemption was not probable due to the expected
successful IPO within five years and the remote likelihood of a liquidation event. Therefore, Series C Preferred Shares were recorded at fair value and not accreted to the redemption value, of $30,049,315 as of June&nbsp;30, 2017. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group has determined that there was no beneficial conversion feature (&#147;BCF&#148;) attributable to the Series C Preferred Shares, as the effective
conversion price was greater than the fair value of the ordinary shares on the respective commitment date. The Group will <FONT STYLE="white-space:nowrap">re-evaluate</FONT> whether additional BCF is required to be recorded upon the modification to
the effective conversion price of the Series C Preferred Shares, if&nbsp;any. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>9. Net loss per share </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Basic and diluted net loss per share for each of the periods presented are calculated as follow after giving effect to a six-to-one share consolidation effected on
August 30, 2017: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Six Months Ended June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Numerator:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss attributable to ordinary shareholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(11,835,175</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(24,419,483</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><B>Denominator:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Weighted average number of ordinary shares-basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9,242,327</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10,630,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Net loss per share-basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(1.28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2.30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group has determined that its convertible preferred shares are participating securities as the preferred shares participate in
undistributed earnings on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted</FONT></FONT> basis. The holders of the preferred shares are entitled to receive dividends on a pro rata basis, as if their shares had
been converted into ordinary shares. Accordingly, the Group uses the <FONT STYLE="white-space:nowrap">two-class</FONT> method of computing net loss per share, for ordinary and preferred shares according to participation rights in undistributed
earnings. However, undistributed net loss is only allocated to ordinary shareholders because holders of preferred shares are not contractually obligated to share losses. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As a result of the Group&#146;s net loss for the six months ended June&nbsp;30, 2016 and 2017, Series A1, A2, B1, B2 and C Preferred Shares, share options, <FONT STYLE="white-space:nowrap">non-vested</FONT>
restricted shares and warrants outstanding in the respective periods were excluded from the calculation of diluted loss per share as their inclusion would have been anti-dilutive. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-58 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Number of Series A1 Shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,466,665</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,466,665</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Number of Series A2 Shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,442,221</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8,442,221</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Number of Series B1 Shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,562,335</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,562,335</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Number of Series B2 Shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,973,096</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3,973,096</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Number of Series C Shares outstanding</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,998,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Share options</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">5,467,025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,448,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> restricted shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,220,370</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">802,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">461,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">461,808</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>10. Related party transactions </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The table below sets forth the major related parties and the relationship with the Group as of June&nbsp;30, 2017: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Company Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Relationship with the Group</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Qiagen (Suzhou) Translational Medicine Co., Ltd.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Over which, Samantha Du, holds significant influence</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Quan Venture Fund I, L.P.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">Significantly influenced by Samantha Du</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group entered into the following transactions between its related parties: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Six&nbsp;months&nbsp;ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Qiagen (Suzhou) Translational Medicine Co., Ltd.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">96,656</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="8" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On April&nbsp;30, 2017, the Group disposed investment in a cost method investee to Quan Venture Fund I, L.P. for a cash
consideration of approximately $500,000 and no gain/loss was recognized upon disposal. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>11. Share-based compensation </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><I>Share options </I></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In May 2017, the Group granted 158,313 share
options to qualified management and employees of the Group and at an exercise price of $3.0 per share under the Plan as defined in Note&nbsp;10 to the consolidated financial statements for the years ended December&nbsp;31, 2015 and 2016. These
options granted have a contractual term of 10 years and generally vest over a four or five year period, with 25% or 20% of the awards vesting on each annual anniversary after the grant date. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">In May 2017, the Group granted 4,583 share options to qualified individual advisors of the Group at an exercise price of $3.0 per share. These options granted have a contractual term of 10 years and generally vest
over a three year period, with 33.33% of the awards vesting anniversary year after the grant date. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-59 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The binomial option-pricing model was applied in determining the estimated fair value of the options granted. For
expected volatilities, the Group has made reference to the historical price volatilities of ordinary shares of several comparable companies in the same industry as the Group. For the exercise multiple, the Group has no historical exercise patterns
as reference, thus the exercise multiple is based on management&#146;s estimation, which the Group believes is representative of the future exercise pattern of the options. The risk-free rate for periods within the contractual life of the option is
based on the US treasury bonds with maturity similar to the maturity of the options as of valuation dates plus a China country risk premium. The estimated fair value of the ordinary shares, at the option grant dates, was determined with assistance
from an independent third party valuation firm. The Group&#146;s management is ultimately responsible for the determination of the estimated fair value of its ordinary shares. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table presents the assumptions used to estimate the fair values of the share options granted in the years presented: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>May,&nbsp;2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Risk-free rate of return</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.2%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Contractual life of option</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">10&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Estimated volatility rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">70%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Expected dividend yield</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0%</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Fair value of underlying ordinary shares</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9.6</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">A summary of option activity under the Plan during the six months ended June&nbsp;30, 2017 is presented below: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Number of<BR>options</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Weighted<BR>average<BR>exercise<BR>price</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Weighted<BR>average<BR>remaining<BR>contractual<BR>term</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Aggregate<BR>intrinsic<BR>value</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Outstanding at December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">7,228,141</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.97</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">9.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">53,677,170</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Granted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">162,896</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">3.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Forfeited</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(841,788</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Exercised</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(100,834</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Outstanding at June&nbsp;30, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,448,415</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">55,376,737</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Vested and Exercisable as of June&nbsp;30, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,634,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">14,585,034</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Vested or expected to vest as of June&nbsp;30, 2017</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">6,448,415</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.01</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">8.54</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">55,376,737</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-60 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group recorded compensation expense related to the option of $1,165,797 and $2,191,427 for the six months
ended June&nbsp;30, 2016 and 2017, respectively, which were classified in the accompanying unaudited condensed consolidated statements of operations as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Six months ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">450,866</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,100,961</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">714,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,090,466</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,165,797</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,191,427</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The weighted-average grant-date fair value of the options granted in 2017 was $8.28 per share. As of June&nbsp;30, 2017, there was
$18,592,630 of total unrecognized compensation expense related to unvested share options granted. That cost is expected to be recognized over a weighted-average period of 3.5 years. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><I><FONT STYLE="white-space:nowrap">Non-vested</FONT> restricted shares and ordinary shares issued to Red Kingdom Investment Limited (&#147;Red Kingdom&#148;) </I></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In March and May, 2017, pursuant to the board resolution of the Company, the Repurchase Right as defined in Note&nbsp;10 to the consolidated financial statements
for the years ended December&nbsp;31, 2015 and 2016 to all the remaining 2,100,000 non-vested restricted shares of the Chief Executive Officer which were subject to the restricted share arrangement dated April&nbsp;3, 2014 was removed and the
unrecognized share-based compensation of $ 840,000 as of the modification date was immediately recognized as an expense in the consolidated statements of operations. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">On June&nbsp;15, 2017, pursuant to the Board&#146;s resolution, Red Kingdom distributed all of the ordinary shares that it currently holds in the Group to all Red Kingdom shareholders, in accordance with the
Articles of Association of Red Kingdom. All the prior restricted share arrangements in force as of the distribution date between Red Kingdom and members of senior management and advisors were amended to assign the rights and obligations of Red
Kingdom thereunder to the Group (the &#147;Transfer&#148;). Before the Transfer, 811,669 restricted shares of Red Kingdom have been vested and 1,329,999 <FONT STYLE="white-space:nowrap">non-vested</FONT> restricted shares of Red Kingdom have been
repurchased by Red Kingdom due to the termination of employment by certain members of senior management and allocated to the founders of Red Kingdom at par value in 2017. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The following table summarizes the Group&#146;s <FONT STYLE="white-space:nowrap">non-vested</FONT> restricted share activity in 2017. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Numbers&nbsp;of<BR><FONT STYLE="white-space:nowrap">non-vested</FONT><BR>restricted&nbsp;
shares</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>Weighted&nbsp;average</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>grant&nbsp;date</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>fair
value</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> as of December&nbsp;31, 2016</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,309,490</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Vested</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">(2,150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Transferred from Red Kingdom</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">643,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">0.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><FONT STYLE="white-space:nowrap">Non-vested</FONT> as of June&nbsp;30, 2017</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">802,823</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1.60</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-61 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of June&nbsp;30, 2017, there was $347,529 of total unrecognized compensation expense related to <FONT
STYLE="white-space:nowrap">non-vested</FONT> restricted shares. The Group recorded compensation expense related to the restricted shares of $614,035 and $2,186,239 for the six months ended June&nbsp;30, 2016 and 2017, respectively, which were
classified in the accompanying consolidated statements of operations as follows: </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Six months ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">328,236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">1,689,633</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">285,799</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">496,606</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">614,035</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,186,239</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>12. Licenses and collaborative arrangement </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Group did not enter into any new collaborative arrangements during the six months ended June&nbsp;30, 2017 except for one arrangement listed below: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2"><B><I>License and collaboration agreement with Paratek Bermuda Ltd. (&#147;Paratek&#148;) </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In April 2017, the
Group entered into a collaboration, development and license agreement with Paratek Bermuda Ltd., under which the Group obtained both an exclusive license under certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> of Paratek Bermuda
Ltd. and an exclusive <FONT STYLE="white-space:nowrap">sub-license</FONT> under certain intellectual property that Paratek Bermuda Ltd. licensed from Tufts University to develop, manufacture, use, sell, import and commercialize omadacycline in
mainland China, Hong Kong, Macau and Taiwan, or licensed territory, in the field of all human therapeutic and preventative uses other than biodefense, or the licensed field. Paratek Bermuda Ltd. retains the right to manufacture the licensed product
in the licensed territory for use outside the licensed territory. The Group also granted to Paratek Bermuda Ltd. a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to certain of intellectual property for Paratek Bermuda Ltd. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Under the terms of the agreement, the Group made an upfront payment of $7.5&nbsp;million to Paratek which was recorded as a research and development expense in
2017. The Group will make a milestone payment to Paratek for the achievement of a certain development milestone and sales milestone event. In addition, we will pay to Paratek Bermuda Ltd. tiered royalties at certain percentage rates on the net sales
of licensed products, until the later of the abandonment, expiration or invalidation of the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> licensed patent covering the licensed product, or the eleventh
anniversary of the first commercial sale of the licensed product, in each case on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">region-by-region</FONT></FONT> basis. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The Group has the right to terminate this agreement for any or no reason by providing
Paratek with prior written notice with no penalty. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">As of June&nbsp;30, 2017, the Group has entered into various license and collaboration agreements
with third party licensors to develop and commercialize drug candidates. Based on the terms of these agreements the Group is contingently obligated to make additional material payments upon the achievement of certain contractually
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-62 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">
defined milestones. The Group made $291,515 milestone payments under these agreements for the six months ended June&nbsp;30, 2017. Based on management&#146;s evaluation of the progress of each
project noted above, the licensors will be eligible to receive from the Group up to an aggregate of approximately $356.3&nbsp;million in future milestone payments upon the achievement of contractually specified development milestones, such as
regulatory approval for the drug candidates, which may be before the Group has commercialized the drug or received any revenue from sales of such drug candidate, which may never occur. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>13. Employee defined contribution plan </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Full time employees of the Group in the PRC participate in a government
mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to employees. Chinese labor regulations require that the Group&#146;s PRC subsidiaries make
contributions to the government for these benefits based on certain percentages of the employees&#146; salaries. The Group has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which
were expensed as incurred, were $112,898 and $210,842 for the six months ended June&nbsp;30, 2016 and 2017, respectively. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>14. Commitments and
contingencies </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(A) Operating Lease Commitments </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Group leases office facilities under <FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating leases expiring on different dates. Payments under operating leases are expensed on a straight-line basis
over the periods of their respective leases, and the terms of the leases do not contain rent escalation, contingent rent, renewal, or purchase options. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">There are no restrictions placed upon the Group by entering into these leases. Total expenses under these operating leases were $63,344 and $459,276 for the six
months ended June&nbsp;30, 2016 and 2017, respectively. Future minimum lease payments under <FONT STYLE="white-space:nowrap">non-cancellable</FONT> operating lease agreements as of June&nbsp;30, 2017 were as follows: </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>As of<BR>June&nbsp;30,<BR>2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">July to December, 2017</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">529,521</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">947,861</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">831,608</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">242,325</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">2021 and thereafter</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Total lease commitment</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="2">2,551,315</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-63 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>ZAI Lab Limited </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="5"><B>Notes to the unaudited condensed consolidated financial statements </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>For the six months ended June&nbsp;30,
2016 and 2017 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>(In U.S. dollars (&#147;$&#148;) except for number of shares) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(B) Capital Commitments </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">As of June&nbsp;30, 2017, the Group&#146;s commitments related to purchase of property and equipment contracted but not yet reflected in the condensed consolidated financial statement were $451,233 which are
expected to be incurred within one year. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B><I>(C) Contingencies </I></B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The Group is a party to or assignee of license and collaboration agreements that may require it to make future payments relating to milestone fees and royalties on future sales of licensed products (Note 12).
</FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>15. Subsequent events </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The subsequent events
have been evaluated through August 1, 2017 which is the date the unaudited condensed consolidated financial statements were available to be issued. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On
July&nbsp;5, 2017, pursuant to the investment agreement entered with three third-party investors in June, 2017, the Group contributed RMB 13.1 million ($1.9 million) in cash to JING Medicine Technology (Shanghai) Ltd. </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">On July&nbsp;19, 2017, the investor holding the warrants exercised the warrants to purchase 461,808 Series A2 convertible preferred shares at $2.1651 per share.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">F-64 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2"><B>Through and
including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017 (25 days after the commencement of this offering), all dealers that effect transactions in our ordinary
shares or ADSs, whether or not participating in this offering, may be required to deliver a prospectus. This delivery is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with respect to their unsold
allotments or subscriptions. </B></FONT></P> <P STYLE="margin-top:100px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="6"><B>Zai Lab Limited </B></FONT></P>
<P STYLE="font-size:100px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g358845g61e05.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B><I>8,000,000 American depositary shares </I></B></FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B><I>Representing 8,000,000 ordinary shares </I></B></FONT></P>  <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:100px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="5"><B>J.P.&nbsp;Morgan</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="5"><B>Citigroup</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:arial" SIZE="5"><B>Leerink&nbsp;Partners</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:48px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Part II </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Information not required in prospectus </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Item&nbsp;6.
Indemnification of directors and officers </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Cayman Islands law does not limit the extent to which a company&#146;s articles of association may provide
for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing
a crime. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The post-offering amended and restated articles of association that we expect to adopt to become effective immediately prior to the completion
of this offering provide that we shall indemnify our directors and officers (each an indemnified person) against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such indemnified person,
other than by reason of such person&#146;s own dishonesty, willful default or fraud, in or about the conduct of our company&#146;s business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his duties,
powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such indemnified person in defending (whether successfully or otherwise) any civil proceedings
concerning our company or its affairs in any court whether in the Cayman Islands or elsewhere. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the indemnification agreements, the form of
which is filed as Exhibit 10.12 to this registration statement, we agree to indemnify our directors and executive officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being such
a director or officer. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">The underwriting agreement, the form of which is filed as Exhibit 1.1 to this registration statement, will also provide for
indemnification by the underwriters of us and our officers and directors for certain liabilities, including liabilities arising under the Securities Act, but only to the extent that such liabilities are caused by information relating to the
underwriters furnished to us in writing expressly for use in this registration statement and certain other disclosure documents. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Insofar as
indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is
against public policy as expressed in the Securities Act and is therefore unenforceable. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Item&nbsp;7. Recent sales of unregistered securities
</B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In the three years preceding the filing of this registration statement, we have issued the following securities that were not registered under the
Securities Act. We believe that each of the following issuances was exempt from registration under the Securities Act in reliance on Regulation S under the Securities Act regarding sales by an issuer in offshore transactions, Regulation D under the
Securities Act, Rule 701 under the Securities Act or pursuant to Section 4(a)(2) of the Securities Act regarding transactions not involving a public offering. No underwriters were used in the below issuances. </FONT></P>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">1.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On April&nbsp;3, 2014, we issued 3,499,999 restricted ordinary shares and 83,333 ordinary shares to Samantha Du for an aggregate cash consideration of $50,210. On the same date,
we issued 8,083,333 ordinary shares to Red Kingdom Investments Limited for an aggregate consideration of $141,971. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">2.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On August&nbsp;20, 2014, we closed a private placement transaction pursuant to which we issued an aggregate of 8,466,665 Series <FONT STYLE="white-space:nowrap">A-1</FONT>
preferred shares for an aggregate cash consideration of $8,028,572 and in consideration for the conversion of convertible loans amounting an aggregate consideration of $2,000,000. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">3.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On April&nbsp;30, 2015, we issued a total of 9,619,975 Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shares in connection with the second closing of the private
placement transaction described above for an aggregate consideration of $20,828,572 of which $5,300,000 remained unpaid. On September&nbsp;30, 2015 we cancelled 1,177,754 of these Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shares
and forgave the $2,550,000 unpaid capital balance. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">4.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On August&nbsp;10, 2015, we issued 166,667 restricted ordinary shares to Peter Karl Wirth, which were credited as full paid. </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">5.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On December&nbsp;31, 2015, we granted a warrant to purchase 461,808 Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shares at the purchase price of $2.1651 per share
to OrbiMed Asia Partners II, L.P. for a period commencing on April&nbsp;1, 2016 and ending on the earlier of (i)&nbsp;the sixth anniversary of the date of issuance of this warrant or (ii) 90 calendar days prior to the date on which we consummate
this offering. No consideration was received by us in connection with the issuance of the warrant. As of the date of this prospectus, no Series <FONT STYLE="white-space:nowrap">A-2</FONT> preferred shares have been purchased by OrbiMed Asia Partners
II, L.P. pursuant to this warrant. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">6.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On January&nbsp;20, 2016, we closed a private placement transaction pursuant to which we sold an aggregate of 5,562,335 Series <FONT STYLE="white-space:nowrap">B-1</FONT>
preferred shares for an aggregate consideration of $53,100,000 in cash. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">7.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On April&nbsp;1, 2016, we issued a total of 3,973,096 Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred shares in connection with the second closing of the private
placement transaction described above for an aggregate consideration of $53,100,000 in cash. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">8.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On July&nbsp;15, 2016 and August&nbsp;25, 2016, we issued an additional 58,333 and 75,000 restricted ordinary shares to Peter Karl Wirth, respectively, which were credited as
fully paid. </FONT></TD></TR></TABLE> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="2">9.</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">On June 26, 2017, we closed a private placement transaction pursuant to which we sold an aggregate of 1,998,958 Series C preferred shares for an aggregate consideration of
$30,000,000. </FONT></TD></TR></TABLE> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">In addition to the above, since January&nbsp;1, 2014, we have granted share options to purchase (i)&nbsp;an aggregate of
4,309,232 ordinary shares, each at an exercise price of $0.60 per share, (ii)&nbsp;an aggregate of 1,157,793 ordinary shares, each at an exercise price of $1.20 per share, (iii)&nbsp;an aggregate of 1,761,200 ordinary shares, each at an exercise
price of $1.74 per share, and (iv) an aggregate of 162,896 ordinary shares, each at an exercise price of $3.00 per share, to our employees, consultants and directors. These grants were made pursuant to written compensatory plans or arrangements with
our employees, consultants and directors in reliance upon the exemption provided by Rule 701 promulgated under the Securities Act or Section 4(a)(2) of the Securities Act for transactions by an issuer not involving a public offering or Regulation S
under the Securities Act. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Item&nbsp;8. Exhibits and financial statement schedules </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="3"><B>(a) Exhibits </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit<BR>number</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit title</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;1.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Form of Underwriting Agreement</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;3.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Fourth Amended and Restated Memorandum and Articles of Association of Zai Lab Limited</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Form of Deposit Agreement</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Form of American Depositary Receipt (included in Exhibit 4.1)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.3*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Registrant&#146;s Specimen Certificate for Ordinary Shares</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.4*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Third Amended and Restated Shareholders Agreement between Zai Lab Limited and other parties named therein dated June 26, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;5.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Opinion of Travers Thorp Alberga regarding the validity of the ordinary shares being registered</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="3" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit<U><BR></U>number</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit title</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;8.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Opinion of Travers Thorp Alberga regarding certain Cayman Islands tax matters (included in Exhibit&nbsp;5.1)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;8.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Opinion of Zhong Lun Law Firm regarding certain PRC tax matters (included in Exhibit 99.1)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.1</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Zai Lab Limited 2015 Omnibus Equity Incentive Plan as amended on February 3, 2016 and April 10, 2016</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.2</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#043;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Collaboration, Development and License Agreement by and between Tesaro, Inc. and Zai Lab (Shanghai) Co., Ltd. dated September&nbsp;28, 2016</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.3</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#043;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">License Agreement by and between Bristol-Myers Squibb Company and Zai Lab (Hong Kong) Limited dated March&nbsp;9, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.4</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#043;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">License and Collaboration Agreement by and between Paratek Bermuda Ltd. and Zai Lab (Shanghai) Co., Ltd. dated April&nbsp;21, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.5</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#043;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">License and Transfer Agreement by and between GlaxoSmithKline (China) R&amp;D Co., Ltd and Zai Lab (Shanghai) Co., Ltd. dated October&nbsp;18, 2016</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.6</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#043;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Assignment and Assumption Agreement by and among GlaxoSmithKline (China) R&amp;D Co., Ltd, Zai Lab (Shanghai) Co., Ltd. and Chengdu Bater Pharmaceutical Co., Ltd. dated October&nbsp;13,
2016</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.7</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#043;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Assignment and Assumption Agreement by and among GlaxoSmithKline (China) R&amp;D Co., Ltd, Zai Lab (Shanghai) Co., Ltd. and Traditional Chinese Medical Hospital, Xinjiang Medical
University dated October&nbsp;14, 2016</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.8</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#043;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">License Agreement by and between Sanofi and Zai Lab (Hong Kong) Limited dated July 22, 2015</FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.9</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#043;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">License Agreement by and between UCB Biopharma SPRL and Zai Lab (Hong Kong) Limited dated September 17, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.10</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Non-Employee Director Compensation Policy</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.11</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Zai Lab Limited 2017 Cash Bonus Plan</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;10.12*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Form of Indemnification Agreement for Directors and Officers</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.13</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Second Amended and Restated Founder Employment Agreement between Ying Du and Zai Lab (Hong Kong) Limited dated February 3, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.14</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Founder Employment Agreement between Ning Xu and Zai Lab (Hong Kong) Limited dated May 6, 2014</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.15</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement between James Yan and Zai Lab (Hong Kong) Limited dated March 10, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.16</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement between Qi Liu and Zai Lab (Hong Kong) Limited dated November 1, 2015</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.17</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement between Harald Reinhart and Zai Lab (Hong Kong) Limited dated May 17, 2017 as amended on August 30, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.18</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement between Ying Du and Zai Lab (Shanghai) Co., Ltd. dated July 1, 2017 (English translation)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;10.19</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement between Ning Xu and Zai Lab (Shanghai) Co., Ltd. dated July 1, 2017 (English translation)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.20</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement between James Yan and Zai Lab (Shanghai) Co., Ltd. dated September 1, 2015 (English translation)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.21</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Employment Agreement between Qi Liu and Zai Lab (Shanghai) Co., Ltd. dated November 1, 2015 (English translation)</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="3" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit<U><BR></U>number</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit title</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.22</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Zai Lab Limited 2017 Equity Incentive Plan</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.23</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Form Restricted Share Unit Award Agreement</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.24</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Form Restricted Stock Award Agreement</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.25</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Form of Non-Statutory Stock Option Award Agreement</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;10.26*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Jinchuang Building House Leasing Contract by and between Zai Lab (Shanghai) Co., Ltd. and Shanghai Jinchuang Property Co., Ltd. dated September 1, 2016 (English
translation)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;21.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Subsidiaries of the registrant</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;23.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Consent of Deloitte&nbsp;Touche Tohmatsu Certified Public Accountants LLP, an independent accounting firm, regarding the consolidated financial statements of Zai Lab
Limited</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;23.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Consent of Travers Thorp Alberga (included in Exhibit 5.1)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;23.3*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Consent of Zhong Lun Law Firm (included in Exhibit 99.1)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;24.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Power of Attorney</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;99.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Opinion of Zhong Lun Law Firm regarding certain PRC law matters</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="3" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE>  <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Previously filed. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&#043;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment and this exhibit has been submitted separately to the
Securities and Exchange Commission. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">#</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Management contract or compensatory plan or arrangement. </FONT></TD></TR></TABLE> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>(b)
Financial statement schedules </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">All schedules have been omitted because the information required to be set forth therein is not applicable or is shown
in the financial statements or notes thereto. </FONT></P> <P STYLE="margin-top:16px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="3"><B>Item&nbsp;9. Undertakings </B></FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px"><FONT
STYLE="font-family:arial" SIZE="2">The undersigned Registrant hereby undertakes: </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">(1) That for purposes of determining any liability
under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or
(4)&nbsp;or 497(h) under the Securities Act of 1933 shall be deemed to be part of this registration statement as of the time it was declared effective. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:arial" SIZE="2">(2) That for the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating
to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:arial" SIZE="2">(3) To provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to
each purchaser. </FONT></P> <P STYLE="margin-top:8px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">(4) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors,
officers and controlling persons of the Registrant pursuant to the foregoing provisions, or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:arial" SIZE="2">
otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933
and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been
settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of
such issue. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Exhibit index </B></FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit<U><BR></U>number</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit title</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;1.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex31.htm">Form of Underwriting Agreement </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;3.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex31.htm">Fourth Amended and Restated Memorandum and Articles of Association of Zai Lab Limited
</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex41.htm">Form of Deposit Agreement </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex41.htm">Form of American Depositary Receipt (included in Exhibit 4.1) </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.3*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex43.htm">Registrant&#146;s Specimen Certificate for Ordinary Shares </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;4.4*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517258641/d358845dex44.htm">Third Amended and Restated Shareholders Agreement between Zai Lab Limited and other parties named
 therein dated June 26, 2017 </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;5.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex51.htm">Opinion of Travers Thorp Alberga regarding the validity of the ordinary shares being registered
</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;8.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex51.htm">Opinion of Travers Thorp Alberga regarding certain Cayman Islands tax matters (included in Exhibit&nbsp;5.1)
 </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;8.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517258641/d358845dex992.htm">Opinion of Zhong Lun Law Firm regarding certain PRC tax matters (included in Exhibit 99.1)
</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.1</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex101.htm">Zai Lab Limited 2015 Omnibus Equity Incentive Plan as amended on February 3, 2016 and April&nbsp;10,
 2016 </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.2</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#043;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517258641/d358845dex102.htm">Collaboration, Development and License Agreement by and between Tesaro, Inc. and Zai Lab (Shanghai)
 Co., Ltd. dated September&nbsp;28, 2016 </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.3</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#043;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517258641/d358845dex103.htm">License Agreement by and between Bristol-Myers Squibb Company and Zai Lab (Hong Kong) Limited dated
 March&nbsp;9, 2015 </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.4</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#043;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517258641/d358845dex104.htm">License and Collaboration Agreement by and between Paratek Bermuda Ltd. and Zai Lab (Shanghai) Co.,
Ltd. dated April&nbsp;21, 2017 </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.5</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#043;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517258641/d358845dex105.htm">License and Transfer Agreement by and between GlaxoSmithKline (China) R&amp;D Co., Ltd and Zai Lab
(Shanghai) Co., Ltd. dated October&nbsp;18, 2016 </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.6</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#043;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517258641/d358845dex106.htm">Assignment and Assumption Agreement by and among GlaxoSmithKline (China) R&amp;D Co., Ltd, Zai Lab
(Shanghai) Co., Ltd. and Chengdu Bater Pharmaceutical Co., Ltd. dated October&nbsp;13, 2016 </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.7</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#043;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517258641/d358845dex107.htm">Assignment and Assumption Agreement by and among GlaxoSmithKline (China) R&amp;D Co., Ltd, Zai Lab
(Shanghai) Co., Ltd. and Traditional Chinese Medical Hospital, Xinjiang Medical University dated October&nbsp;14, 2016 </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.8</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#043;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517258641/d358845dex108.htm">License Agreement by and between Sanofi and Zai
 Lab (Hong Kong) Limited dated July 22, 2015 </A></FONT></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.9</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#043;</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517258641/d358845dex109.htm">License Agreement by and between UCB Biopharma SPRL and Zai Lab (Hong Kong) Limited dated September
 17, 2015 </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.10</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex1010.htm">Non-Employee Director Compensation Policy </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.11</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex1011.htm">Zai Lab Limited 2017 Cash Bonus Plan </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;10.12*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517258641/d358845dex1012.htm">Form of Indemnification Agreement for Directors and Officers </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.13</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex1013.htm">Second Amended and Restated Founder Employment Agreement between Ying Du and Zai Lab (Hong Kong)
 Limited dated February 3, 2017 </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.14</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex1014.htm">Founder Employment Agreement between Ning Xu and Zai Lab (Hong Kong) Limited dated May 6, 2014
</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.15</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex1015.htm">Employment Agreement between James Yan and Zai Lab (Hong Kong) Limited dated March 10, 2015
</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.16</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex1016.htm">Employment Agreement between Qi Liu and Zai Lab (Hong Kong) Limited dated November 1, 2015
</A></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="3" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit<U><BR></U>number</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Exhibit title</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.17</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">E<A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex1017.htm">mployment Agreement between Harald Reinhart and Zai Lab (Hong Kong) Limited dated May 17, 2017
 as amended on August 30, 2017 </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.18</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex1018.htm">Employment Agreement between Ying Du and Zai Lab (Shanghai) Co., Ltd. dated July 1, 2017 (English
 translation)</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.19</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex1019.htm">Employment Agreement between Ning Xu and Zai Lab (Shanghai) Co., Ltd. dated July 1, 2017 (English
 translation) </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.20</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex1020.htm">Employment Agreement between James Yan and Zai Lab (Shanghai) Co., Ltd. dated September 1, 2015
 (English translation) </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.21</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex1021.htm">Employment Agreement between Qi Liu and Zai Lab (Shanghai) Co., Ltd. dated November 1, 2015 (English
 translation)</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.22</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex1022.htm">Zai Lab Limited 2017 Equity Incentive Plan</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.23</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex1023.htm">Form Restricted Share Unit Award Agreement </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.24</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex1024.htm">Form Restricted Stock Award Agreement</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;
10.25</FONT><FONT STYLE="font-family:arial" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">#</SUP></FONT><FONT STYLE="font-family:arial" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex1025.htm">Form of Non-Statutory Stock Option Award Agreement</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;10.26*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex1026.htm">Jinchuang Building House Leasing Contract by and between Zai Lab (Shanghai) Co., Ltd. and Shanghai
 Jinchuang Property Co., Ltd. dated September 1, 2016 (English translation)</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;21.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517258641/d358845dex211.htm">Subsidiaries of the registrant </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;23.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="d358845dex231.htm">Consent of Deloitte&nbsp;
Touche Tohmatsu Certified Public Accountants LLP, an independent accounting firm, regarding the consolidated financial statements of Zai Lab Limited</A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;23.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517275654/d358845dex51.htm">Consent of Travers Thorp Alberga (included in Exhibit 5.1) </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;23.3*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517258641/d358845dex992.htm">Consent of Zhong Lun Law Firm (included in Exhibit 99.1) </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;24.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517258641/d358845df1.htm">Power of Attorney </A></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;99.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2"><A HREF="http://www.sec.gov/Archives/edgar/data/1704292/000119312517258641/d358845dex992.htm">Opinion of Zhong Lun Law Firm regarding certain PRC law matters </A></FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="3" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">*</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Previously filed. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">&#043;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment and this exhibit has been submitted separately to the
Securities and Exchange Commission. </FONT></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:arial" SIZE="1">#</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:arial" SIZE="1">Management contract or compensatory plan or arrangement. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Signatures </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements
for filing on Form <FONT STYLE="white-space:nowrap">F-1</FONT> and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of&nbsp;Shanghai, on&nbsp;September 19, 2017.
</FONT></P>  <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:arial" SIZE="2">ZAI LAB LIMITED</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">By:&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;/s/ Samantha Du</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;Name: Samantha Du</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;Title: Chief Executive Officer</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:8px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* </FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates
indicated. </FONT></P> <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Signature</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Title</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:2px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2"><B>Date</B></FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">/s/ Samantha Du</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Samantha Du</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Chief Executive Officer, Chairman of the Board of Directors</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">(Principal Executive Officer)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">September&nbsp;19, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">/s/ Tom Feng</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tom Feng</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Vice President, Finance</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">(Principal&nbsp;Financial&nbsp;and&nbsp;Accounting&nbsp;Officer)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">September 19, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;John Diekman</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">September 19, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tao Fu</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">September 19, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nisa Leung</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">September 19, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Peter Wirth</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">September 19, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Marietta Wu</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">September 19, 2017</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">*</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jianming Yu</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">September 19, 2017</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="top"> <P STYLE="border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE>  <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">*By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;/s/ Samantha Du </FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">Samantha Du</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">As Attorney-in-Fact</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="5"><B>Signature of authorized representative in the United States </B></FONT></P>
<P STYLE="margin-top:8px;margin-bottom:0px"><FONT STYLE="font-family:arial" SIZE="2">Pursuant to the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Zai Lab Limited, has signed this registration
statement or amendment thereto in New York, NY on September&nbsp;19,&nbsp;2017. </FONT></P>  <P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P>  <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">Law Debenture Corporate Services Inc.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:arial" SIZE="2">(Authorized U.S. Representative)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">By:&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;/s/ Steve Sutcliffe</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Name: Steve Sutcliffe</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:arial" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;Title:&nbsp;&nbsp; Vice President</FONT></P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:arial" SIZE="2">II-9 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d358845dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use in this Amendment No. 3 to Registration Statement on Form&nbsp;F-1 of our report dated May&nbsp;30, 2017 (September&nbsp;1, 2017 as to
Note 2(w)) relating to the consolidated financial statements and financial statement schedule of Zai Lab Limited and its subsidiaries, appearing in the Prospectus, which is part of this Registration Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also consent to the reference to us under the heading &#147;Experts&#148; in such Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Deloitte Touche Tohmatsu Certified Public Accountants LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shanghai, China </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 19, 2017 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g358845g02p22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g02p22.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $E 8X# 1$
M A$! Q$!_\0 'P !  $#!0$!              D%!@<#! @*"P(!_\0 <A
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M:RZB4FBT:D5"%04)AT9+CAU"4Y+-"#;.J%KAEAAG&R:DZ\T^\G!0F$;A&H^
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MKJHTTYTVDO&2,5 D.R'3-2B<.Y"5,MH2232I)R6V'EX1INQ";KS,5:_XX89
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M&WI\*%KD4D6S0%/,V],HY6;INEE [:P_-3 KH%D4DR /_<I$4.;K54. )E(
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M.T2Q24+CN&A'T?%T&-GY'&=()8FE3:1*$S%P@P;TBD+*3+"1?@AMU^K8WUE
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M2I_;T3SAL4G^</=B<\0QOL,.9X,/8H D3&F(&-:*!#&FER&,4*O%\TQB!#'
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M_?QR1V*YFSV#'N<<2U:8N*A33[V.C[N)W"!)><L!(QBFY@ET(2#3G[-8YY.
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MJB-]3.B5/[>B><-BD_SA[L3GB&*UAA]*AA[% %A%#E#&M% I^V#(O.*%7BP
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M$ZZ?YDK&0R_-50RY,GY(]OCS7=3Q$70T - 'H2<DT\DD^3KVL$1ASN$BT.1
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M,(8W H_2M97=19O*1_G^C[%_ZQC[P@G7>@E8R&7YJJ&S=\4>WQYKVIX"+H:
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M$;*..8ZS%^ZMFQ%$3<[.>23><.*Q!'F\>:;SH<# (=?#CJ&NJSN^KG6TOT1
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M B=Y6'Y0<)?=.DOR-FM0>]W3N#L=_%;_ *#J([2U*NB]1[GEYPV(?V?R#_O
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M5WL"'TE+ULG]VNN1E]Q9BX"#L"'TE+ULG]V@7%F+@(.P(?24O6R?W:!<68N
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MXRYS"\>2(JD_C8?9?V2.O(*3SY?7?RH$D6.=IZTO&4/K5N*PL[((\*A:>/\
M%Z1_ .NTM2[=91>Z5+]),C';0;1F=KO>04.SEO0=M3;.]V!2N6YC&VTYV I0
M63$1$<76D    W$1$>H #K$=?2K93=39ON_1_2,803KIER$K.4NA50Z?^$>'
MFG:GB(NAH : /0RY)5TV)R=&U8AW"!#%H4B E,LF4P?ORLP]8"8!#_:&H3ZI
M.[BT7;C?FL<21L<9>]FD92VNOI_OW1(KTQGZ;;>OI?I:P<9->6<N$@Z8S]-M
MO7TOTM O+.7"0_0=M3"!2N6YC&$ *4%DQ$1$>    ;B(B/4 !UB.@7EG+A(;
MC0:AH : ,2WG"E#R)/L;19$)PT[$Q+:(AW\59Y^%-$$9VN"NK20C48N0:MV\
MPA8*U#K]LP2,Y79-E8=R9>'?/V+D U+56X2FX/L=0K3 D77*KBF8K<!&)JKK
M)QT)!U%Q&13!-9TJNY5(T8M4&Y57"RRZA4P,LJHH)CC?4SHE3^WHGG#8I/\
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MC9XD57*EM8HT6T/.K*$3JVSJ\OLCX5B5!%'BJ@RMTBZDK*)AYUF Q6[\>P%
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M9%PFD@FN_="GV=VL1%$BKA10Y4DRF @ &%'FWVN&RS,9A@;?D6FSMK1KA+Y
MU6Q,V=1OSJHL'436I.RQ3^'DW:<E%Q3DD89Q7Y.!+*Q["+:3J4HA'-2)@%E5
M79A@^G)TI&%CK 1"@Q>WZ%KZ+F?7<IA%;9(ZU,L2,7W/1 SU&'>7.>L+\53
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MX;_L[\%;M_:$[UO>&T#!/.GOT>L'PW_9WX*W;^T)WK>\-H&">=/?H]8/AO\
ML[\%;M_:$[UO>&T#!/.GOT>L,W;<^4"VV;ILAV#%.*I+*#;(%9IB.0I2M9/P
M+F["K\:<O.)5M*=C@RY0*6G+M#3:I6 C%G=G*L1;G$ J*HD#0TF67)=O&1^
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MI/S1;<IDO)JB>:9&)C;*E",:C7+)C^3?46PP1H%E)1K4DVBZA[A2H)_+V^$
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ME,?J@&V;V@5G_;-TPU9^(M 8+?P5=_\ TAW'W*8_5 -LWM K/^V;IAJS\1:
MP6_@J[_^D.X^Y3'ZH!MF]H%9_P!LW3#5GXBT!@M_!5W_ /2'<?<IC]4 VS>T
M"L_[9NF&K/Q%H#!;^"KO_P"D.X^Y3'ZH!MF]H%9_VS=,-6?B+0&"W\%7?_TC
M(FUS91N!Q5N<M&YK<'N7Q]F^?E\$-<$PD#CW;U(X280T.VR &0!EWSF1S9E@
M\P[.]4=,P030C"E1524[,841(KH9F>R->5(L%)&17WY3OZ5V8A)GK0:!H :
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71;0:!H : &@!H : &@!H : &@!H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g358845g05p60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g05p60.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X4(0:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I#<F5A=&5$871E/C(P,3<M,#4M,C54,3 Z,# Z,3<K,#4Z,S \+WAM<#I#
M<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL
M;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O;#X*(" @
M(" @(" @/'AM<#I-;V1I9GE$871E/C(P,3<M,#4M,C54,3 Z,# Z,3<K,#4Z
M,S \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.DUE=&%D871A1&%T
M93XR,#$W+3 U+3(U5#$P.C P.C$W*S U.C,P/"]X;7 Z365T861A=&%$871E
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^-C \+WAM<$=);6<Z:&5I9VAT/@H@(" @(" @(" @(" @(" @(" \
M>&UP1TEM9SIF;W)M870^2E!%1SPO>&UP1TEM9SIF;W)M870^"B @(" @(" @
M(" @(" @(" @(#QX;7!'26UG.FEM86=E/B\Y:B\T04%14VM:2E)G04)!9T5!
M4T%"24%!1"\W44%S54=H=F1'.7IA1SEW241-=4U!0311:VQ.02LP04%!04%!
M0D%!4T%!04%!14$F(WA!.T%10DE!04%!05%!0B\K-$%$:T9K8C)*;$%'5$%!
M04%!068O8D%)44%"9U%%0D%514)G549"9VM'0E%92D-W9T="9V=,1$%O2T-W
M;TLF(WA!.T1"04U$07=-1$%W441!-%!%03A/1$)-5$9"451%>'=B1WAS8TAX
M.&9(>#AF2'@X9DAW14A"=V-.1$$P645"05E':%521E)O9DAX.&8F(WA!.TAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9B\X04%%46=!4$%%04%W15(F(WA!.T%!25)!44U2068O
M14%A24%!04%(05%%0D%114%!04%!04%!04%!449!=TE'05%!2$-!:TM#=T5!
M06=)1$%114)!445!04%!04%!04$F(WA!.T%104-!=U%&0F=C24-1;TQ%04%#
M05%-1$%G44-"9V-$0D%)1T%N34)!9TU20D%!1DE227A15D5'13)%:6-9155-
M<$=H0GA7>%%I4$(F(WA!.U5T2&A->%II.$-2>6=V16Q1>E)4:W%+>5DS4$-.
M55%N:S9/>DYH9%5:2%1$,'5)24IO34I#:&=::$I21E)Q4S!6=$Y62T)R>30O
M4$4F(WA!.S%/5#!:6%=&;&%7,7AD6&PY5UHR:'!A;71S8E<U=EDS4C%D;F0T
M95AP-V9(,2MF,T]%:%EA2&E);4MI-'E.:F\K0VLU4U9L<&59;5HF(WA!.W%B
M;DHR96XU2VIP2U=M<#9I<'%Q=7-R839V;U)!04E#05%)1$)1545"45E%0T%-
M1&)114%!:$5$0D-%4TU514954DYH26=:>&=:17DF(WA!.V]B2'=&34A2-%-.
M0T962FEC=D5Z2D121&=H85-5>5=I63=,0T(S4%-.94I%9WAD56MW9TI#:&=:
M2FI:1D=I9&MD1E4S.'%/>G=Y9W F(WA!.S K4'IH2E-K=$U453504FQD65=6
M<&)81C%E6#%2;%IM9&]A5W!R8D<Q=6(R4C%D;F0T95AP-V9(,2MF,T]%:%EA
M2&E);4MI-'E.:F\F(WA!.RM$;$I75VPU:5IM<'5C;EHV9FMQ3VMP86%N<4MM
M<7$V>71R<2MV+V%!07=$05%!0T5135)!1#A!:T@O2W!F.$%N2G(O04MN=40O
M<$\F(WA!.W9F.$%S;7A3-R]L578O3U18+U4Y=V8X05-D92\Y:S)+=2\U5DPO
M>FLQ+S%08T@O4V1E+SEK,DMS3#AX2BMF3V<K971*.&PS;FY+4U0F(WA!.U9.
M6E-*-U=A1S=U1&)Q2G!8:5@Q1V%.6$AX4D=T14\R2W,P+S563"]!335.9CE4
M,T(O,&Y8=CA!,E19<3<O;%5V+T]46"]5.7=F.$$F(WA!.U-D92\Y:S)+=2\U
M5DPO>FLQ+S%08T@O4V1E+SEK,DMV8E!),FUE661,.' V9%EE67(P86AR54--
M=#=E2S=Y0U)I-TU#2&M61U!W:T0F(WA!.V1C54EZ6'9-5VEE6#E08E5D879)
M-T=X5FQ2<FE5:TM'9EI2=%AR:7)9,5,P=CE"8E4Y3VY%,7)C5WI45W1Z1V1M
M56]3<DMC5F9,+S4F(WA!.UDV9"ME2#5G-E)D86YP,VYM93!I=$QJ-G,V6$4X
M+TET=U8V:F='1DM0:6QM6"]+;V8K8VAF+TQH+W=$2F4V+S5O>%$W+VQ54"]/
M478F(WA!.R]L=R\K4SDQ+W=!,%EQ:S-K:E5V>DTP3#@O9$LX;2M9+TTQ>'$P
M2$-A4S1J17-J44]'<TI::W%R9T@T5T%05'%-579F+TUN;2]W07,F(WA!.RM7
M64E:.64Q1TA4;V)H:6M,>D5G37=&4T)12'1I:$]-5EE2*V%F;&)Z,35H,"MX
M:#AO-C<K9W)M0U9N=7!U8VEE;VA79U@Y,D<V2&8F(WA!.V9&6'HU-4$O-5A8
M-3$Q-U8Y1W-F3S%Z8E0V3U-*<$HU-75$,&M-9G<X47@V<C-X4WIZ+VQ54#A!
M>FM,+T%/6$0O=T-3.3$O>E)I:$LF(WA!.R]-6&MJ.#5V3&1G=6]A-2MA361H
M6DY+:T-Z>3-&,D9-:VAO<3=2;G=*.6AU9'-64CEP*U9N-3E8;'1&9%=N-6Q2
M,TYR3V]E1V5+-74F(WA!.TAJ9%1U1U9L56=G*TEX5E8O=T-642\X04]1=B]!
M2F-0+VMV9&8X,%EQ-R]L55 X07IK3"]!3UA$+W=#4SDQ+WI2:7%E95-F>3$O
M3VHF(WA!.U-V3D9H<4=V961F,&YP1G4W3F0R4')81&5O<%)L06\V:&1M24\K
M2W95.68Q>E1D0C!A-S%J535$1EE755IL=4I&57519S)Q1E5%;C8F(WA!.TU6
M960O=T11>E@U468Y6%=B+W!%=5 X06UJ1F%D+S!-,2M52"]6,6TO=T-K4S0O
M-6]X5VYJ;B]/3U U<&544$I/;C8U1#5I=3-T<$PF(WA!.S)70C=C2D1*3%52
M<31A=G!Q,5!T1$9*97@O.$%1>E@U468X058Q;2\V4DQJ+VUJ1D90279Z52].
M9GE4-6<O33-Y4G(R;#-J>39B;W0F(WA!.WI"3'%-<E%Y;U533S=35FE&6E%Z
M9D%P-EEP1#$S+V]:<CAO4"MR<DXO=T));'@O>E)I:6YF.41.9FQ"+S%D6G8K
M:U,T+W=#84U6<#8F(WA!.U9Q;6]1-F)P;#-Q339S,$9L0DIC4W%G0F-P16AD
M9V]*07)29'0X5F5-+SA!43-8-6)F.$%6=#%N+VM282]W1%I4:6UN9CE$9&9L
M="\F(WA!.S%B9%HO=T-21G(O,E4T<E1Y;GIX*V-N;&I8=GIH.'1E9$Q/,799
M.4PP84LR4S9H;6II1G=X:'5*6E<Y3E9L6D0X36]P5GAV:7105G8F(WA!.RMH
M=79Y,B\V='5S+SAI3%@O<W!X5VYF.41D9FQT+S%B9%HO-457=B]!1U4T<E0P
M<CAV=E K:F5E=$%/=#921&-15V=N93,T6&%O:VXF(WA!.T]-2U-A4G9+=%!I
M.&-536QX5C5(+W=!-5-F.$%K<#=N+VU-=&8K2FY&47E8.'1F+T%#5'5G+SA!
M8D=I+S5-67$K8V9Y52]+>GI8-7<F(WA!.S!#*W9T1S@Q>C9"0F(S9F]35S!0
M<E5D+U12=5HY3U=)5F\Q3VU+4SE%+S9&>B]-;B]W075492]F9&8X05I2:71U
M+S9&>B]-;B]W074F(WA!.U1E+V9D9CA!6E)I='-3.&ME5CE6.'-F.#5/85)O
M*W%A<DIR5C5$2$TW,SAV4&MW:S R6FQ(-WAP1RM%1VY81E=7+SA!3UE8+T%#
M:E F(WA!.VPO.$$U:EIF*U172V@Y031O9&ER-70O-7AL+SAM5#4T*V)F.5)4
M-'$K:C4U-$QE0U,T;FM72T-&5VML;&-H5E9&1E=::61G04)V:7(F(WA!.S0X
M+TY0.#!.1"]-1#AW<DLQ,4,W;'10275L4VQ694I'95-91"LX;4-$.7%7;D)+
M+UI89G)567!E>5=8+T%$:W8K5&QJ6G=75G!*9%$F(WA!.U=T=$=S3G9#;'$T
M5DDP059607(P04=+2U9V.$%O850X<"\X06QP=E K:U8O-C1R5'8K:'!0>6XO
M04]7;3@O-E)8+W)I=%!4=$,Q<7@F(WA!.S%Z4G),5TQ!<S%L9G=P8U<W3T],
M1DI"5F%Q96TR2W$R;S9D66%L67I71V]7-EA6;&-,=VYT-59$239N<WEN<4U6
M67HO04UQ:2]++R\F(WA!.T%+;&)44#A!<$=J+T%+67%L3"M4=GE+5'I#4$QS
M;6MA2VUU1TI:;'-(:&E75FMC;6Y%169%9FA*-&IE;2]41EAM+SA!>FIZ*U5%
M47,F(WA!.TYA2&YN>7-V<F5R0CE2+U-6=4-E4$8K9G X>#!R4W5+4SE3,6HX
M=69Y9#!B5$QN5DY4.'4V5F$R1FUH;'5:,W1K259",V]&2E!S04LF(WA!.VY&
M1'EJ>C,K6$=G-G@U-SAJ86@U2C!',W9F2V-T>$%D6'5.3FA2-U)O=G)397 V
M-50T9&\K6$E(;TU5=EDO.$%L55@U6"\X055R85HF(WA!.R]W0DDP9CA!5$9$
M=BM64F9L9CA!.5-T<&XO4TY(+U1&53 X-V8X;UIR+SA!,GIR=B]K=RM+=DI0
M*V-99DQF;#-59GDP830Q1%,W3S@F(WA!.W50,&AC3#8Q>$)&2R]%2DA18VY5
M;6TK2VPV,R]!24HX;68X059G,#<O<$5G+W=#84U694)F;6QO5VE7,R]/4G9K
M;7=T.5!T;V)'94,F(WA!.WE-.7!(1$=S5&QR>315;#1W07)604$S1TME:C,S
M+T)0:WHO<7=A9"\P:5%F.#!9;UDW*UDS;$1Y;&(O;#<U;VYG,%-W:6YI,&DO
M94LF(WA!.U9,5T985C%T<$-R2W=7;TE0431Q>&8X035X4R\X;&$O+V)2=5 K
M25(T<5AS;4MV22]W1&Y+5"]Y53EZ+T%->&QR+WA--'%'4R]L<B\F(WA!.T%/
M4V0P2"]T:E)F.&U-5F902#5'9FQ&9&5D=DPQ+V9W*UIB>E)6=')S=T<S=%%3
M<FXP:V9M85-2-R]&5$9*96MF.4-X86@O,5!U<68F(WA!.SA#,R]!1E=X43<O
M;U=,55 K<#DQ5"]G5R]W0W$R2W-+.&YE57!F2V8O3U0K:V%,3'%5,G)01$A-
M+W="9'5!4DDS<6%B33%$5FXK>E<F(WA!.VY81DQ+=CA!;DU,+T%*4FYY+SA!
M.'AS=B]*<D91*V=C54]X5C@R+S@T>2\K5$HX.&9.=BMO<#A66E(K94=K+VUX
M-7,Q<7@X;39$868F(WA!.U902S$X03DW<7EU4VHX9#-7-$E!36%P,E%6-2M0
M64MS<#AU9FM4*U=E:F%.8F%F3F]T<G%C.$LO=G(K.&E34V%6>G5Z16UT0EAO
M;S(F(WA!.T%X5C0O=T0X-5%E5%!+96E1*U=,8E%.2W1.3G5T46YU5F(V=D5S
M6'%"0D5">4MJ;W)39FII:U!C+W=$;%58-5@O=T15<F%:+S!J4B\F(WA!.S!X
M43<O;%58-5@O.5-T<&XO4TY(+U1&5U0R1FA:869:43)6;$-L=%HR>4-/0T--
M0E521D9!<6=D04U65CA64U1Z<C5U,'9Y:C5:=G0F(WA!.V8Q2G%15V%%<$5#
M03!S<#)J:5-V-U1T="M05$98:3,O041J-S51,51Z2C5I,40X,2]--F,W=3EL
M:T=K2W<R<69G95I19C)5565L2#DF(WA!.U!T:6PY0DQ,17IU:75R4$A13V])
M2E=O<4MJ=%59;V9/4"]/5T@U:$HV9' U1W-:9T=C<&0V>5%D;%5B=U).4W95
M+W9#4%IF2$9)5'HF(WA!.WED*V9V-4TK5B],1VTV0EI83C193E!H5TQN.599
M1C,V>5-%5C9U-4Q(-31O5&HO;V%4.' O=T1L<'90*VM6+S8T<E-0,$@O;DEN
M.'0F(WA!.V1C,6UY,&5W;G5M=F(K5EE,9%AT,E93-VUG<7A/,DMS>C@W9CAO
M6G(O=T0R>G)V+T%*35!I<C5A+TM,>4HK8S)U955Z92M4+T%$4$8F(WA!.W!'
M:V976DEZ85!C,TU*.596574O1TM'5F1W4C-X4WIB+VQ5=B]/5%@O53EW9CE*
M,3<O,E19<3@Q.#1E5"]W03 W2#@P+TPK:F%Z-6<F(WA!.VIV4$YD-4AB='!E
M<4QC5'5S2W902VM936IX3$EV1U)88C154%A&6'!8+TMP9BMC;78K<#=G+S94
M<C,O<VUX5DLO3E U62\X04]1.6XF(WA!.S59,64X,5AZ;D1D85AB5U9Z3F8R
M;W9,='I,8GAX33!S659R9%9B:V=);U-":7)/9BMC578O2E=V+W="=$<T+S1H
M2&EG=EI-5F52+S@F(WA!.S539BM3;G5F*UEY,2]W0TIN1E%Y4#AR3')4;B]!
M0W$X=5<P=#%%:&93;TDS0F11=W)%061I8U9E8B\X05%Q;C5B9CA!57E8=B])
M,C$F(WA!.R]W0W%E2V)6;W8X06Y%9GE(36Y/3%AD4FM4<'E2<F1H.31J>%<Q
M:S,O3TIN-691349M.'=8.%1%5D%D-UI45#99.%9T3R])=C5"*U(F(WA!.U!*
M,VUQ>#AX,D]V6$9X9%=0<2MN1%!*8BMM,W)1=D-E6$963W=K2C8T;W1J;B]/
M6&PS87HK5W1!14UY4VM8<W!)4F<Q4#-8<V-5:#DF(WA!.T19;V1I<C5P+W=#
M8V):2&HO34AZ-TI'=D]21FM:14<Y4TQL>4)T-#165%@O04I8<BMD9B]!2F)+
M.2\V4F(O.$$V<%E%,#<O;&5V-3$F(WA!.R]W1&QS<C,O04M28B]W1#9P67)4
M>DPX,5!Z0S@W96-V35AL,GDQ9GER3G!U<6%823AT<'!F<%A!=4QG6$1X;6=J
M9%)*42]6-D1I4$@F(WA!.T98<'8O2SEF>G(O.'1L92\Y270O+W="57-6<#,O
M2SEF>G(O.'1L92\Y270O+W="57-6<#9$*U4O;G9Z=#5Q+U-V*THO3$TS;'HV
M;C8F(WA!.T@Q5#$T<#1V6#E8,5!5-"MU<58T96UV5'AX47HV4U-/2TYP2D=#
M4F]#>G5X055+0E5K:SE!359F2UAN+T%-*V%,*V%0-6@R,FHS97(F(WA!.W<V
M5#5!,%=1>51853!G:DYY5E!&-4DQ3S=/.65%9$%E2S%B,GA3.4,Q>B]N2F(X
M<B],=6I(5'9+>7EA:$Q:=RMH<#%V0D$X5G%H4F4F(WA!.TUA<S!V<$YW5VXW
M25!T-#1R5$102DXU<E!K>E-.6"]/2'IP97I(5CEE5F\Y23!:;F%,-C-)-')(
M2DQ'2V9U,4$K055O<6(O>31Q;FXF(WA!.S5$+VQF+VE(-B\X06U$-3=S-&14
M=61D6FYS8E<Y:5=63T1T>6$T355G6E)Y;T)(='-V5%EJ1EAR+W=$>7),.'1V
M*W!4,&(O=4@R=B\F(WA!.T%&5'A1-R]L5U@U8F8Y4VYO,R]C4'1F*W%E2W9&
M4%!0;"]1=$LO-7E5.&M73VLV9&)A8F%.8C(Y=S!&;D1(8F\P;W5,;C0R5TY6
M0E F(WA!.S=T4CE'2U4W.'EF.#509FQP<5!L,U9.4'0Q,40V>&578SEV1'ET
M,$,X-5EM4F%N,41T531O<&@S-4=F;FXU2CAK*U-7,&)75G9$94<F(WA!.SAL
M=4%B94I:13132V='-61D+VA08D9*1#!,+V]A,SAR9C5.4B]W0VMD4#A!<7!I
M:6YK;FYV.#-F2V5U9FY.-5DX-%=1=68P4G!%5G,F(WA!.VPR2DDQ5U=S3GI.
M2S-"07A"*T=59#A5=E<O.$%O83,X<F8U3E(O-E(P+S9Q66]P2B]/9B]!1&MX
M*U<K<V54.60P:3!7+W=$<F5O-F8F(WA!.V0R;'9Z9U95.5-E0C0P-4@Q1%%C
M;3-X5%1&9GE-+U!0>50U2CAK=&\R<W)E1SA.-4QC03(X4WE*=VM604YY-C<O
M0V4R2VM0;S-Y9C4F(WA!.W(P=GI:-6-T4$U';$-15T8W-FYO:5I1:VXW<59O
M5W%O3%4K2TTY.%5)4#A!34QY2G S;FIY,TIO3V]813%T8E-3>'I'5S,T.#9X
M;6\F(WA!.TAX:&@K1TMV3% X06]52'E2+S%E9%0K*S,O-G T<'1+9DXS+T%$
M:7HU4#!8>7!R5W,R*W)A:$I0<&QH8S-K56-H9S1-.$5,4TMR56HF(WA!.T)O
M4W4Y359T;5@O3TQF.$$U2V4R+W=#67DV+S1M355&:%@O3U%U9U<S;4@X-5!*
M;6@S56IX5RMO=U(R.'-S5D]A<DIC=4-6-4%I=C F(WA!.UEP5&XO;U5(>5(O
M,65D5"LK,R\V<#1R8G8K:%%F2D@O049E9%0K*S,O=T-Q94LR.31X43=&6'IB
M+W=!-'DO.$%K>6902'IB+T%+:6XF(WA!.WA6.4I9<6QN;5AZ2F\S;'928FY7
M9%EU1G1R0S%8;$I),U5N.6Q%2%9M63=+0C%X5C1(*U17;F%R*UEV-7%A;BMA
M1W%W3D1P;&TW4C8F(WA!.U1%+S)F531E;$=I.6HV35<W;BMC9RM/2U4R.#8O
M;7 K86XU92ME-3=Z>D9P,&0O-4=V6D)(6B]65D%%55DV1EI307=M<'5Y4V).
M*WHF(WA!.U%B-&]E=RM64$XS;"]W03$V4$9Q*V@S83-6;DQS86)01S-D2D5/
M-G-002]Q>%9/35915W1A5&%A>&\Y.7!.-$]6<'%%16QT3T(Q-%,F(WA!.V]5
M86YV43=9<3A".#!F:W0K4U U8V%!,G(K6EIB,U8U=#%T<D=3-$546$UT3F\T
M,6=%5$%F>DU7,B]$1DYP4"M3+S5-3#5T,6XO1R\F(WA!.VU$4S1D3SAT;"]5
M,')2159H2$U&,E%K35-X:%=N5G%M42LS5E8Y0V%Z62M2+TY!;#AU86UT;'%J
M=W%*<&1/6FME5TI62550>%4X-#DF(WA!.SEQ-V5'2T5S+TY(>3$U<3%N>590
M<&9L1%52<$8K;U@P>$@K-SE33TUF,T-3<5%983=F15!L<T-C5EE"*U5V-34S
M.&UQ1'E2*UE58F$F(WA!.V8U;F=F-G9"951+23%N8V)#3UAO1FM0-TQ$-%@K
M9$]3;#=J:6@X*RMA04QV+VY,6'DU0T%0.4AS>%AL=5!G=#=M8F)&3#!B>F8K
M6% F(WA!.S5E,B]L3%<U-%!+*VM25'A71C X57%71G-R<39W<U9:5T5D45%E
M:'A1."\O04]C6B]*;FLO5U!Y,V$W,691=% Q1S<K=GIP.5EU-U,F(WA!.T-E
M5&=Q>#!8;DEJ3E%6-EEP3#%F+VQ76#5B9CE3;F\S+V-0=&8K<65+2&8X<7DO
M3&(O<54Y1R\W:#ER+T%.53A69"]Y<DPX='8K<%0F(WA!.S!B+W5(,G8O0494
M>%9J+S5I9FPS*U@Y<"M8+VUA-G1F3$]K,CDQ8C949E-W5'A73G-K:5-*8D]Y
M=6I+9TMS<$914FEL:$@O3TTO:WHF(WA!.WEF<D@U8G1D-G9O5VXV:F0O6#4P
M*W-89'!"4$IW5EDV3'IK4FUO2SE-5DPS4%1D33 S4S=+3W@P>3!H<V)+2&PV
M5G)B4G!$16Y*:7HF(WA!.V-544MO<7I%;6<V-&]E42]M,2M4;7)A,W%M<2MB
M679/3GIO.7!$82MQ*VYX47E-:6DR:"M).#%U26@X6$-V,DU6958O;$0K5F9M
M<C@F(WA!.WA03#DS<D(X-#-U;$IB6%17:7@X6F)J;59J4U%T>2MS43 O=D%+
M57A3>5AZ6B]Z:FPU:#!N>71R3W%Y*V9B=3AI,"MX=6)Q4S!E,VPF(WA!.U9:
M;&AH85%X:VTW8T%/1G Y:R],1E=D9C@T="\K4VYT=BM9>38O-&U-549H2"]/
M4D=I>F$U*V-0:S-2-$QT<D-A+W0T-$5V54):;VDF(WA!.SEY-#5G0F]Y868V
M=WA3;5@O47(S;6(O>30Q-R]!3DDP=B]:6FER1&9Z6"]+3'I.-4$X<D18=CA!
M1S$W<59B;4\R*W)C2EE0-W=-95@F(WA!.U V>DPP-&1/3TMV<'9Y63=Y950Y
M0V0R3'4K;C)R37I'<$I-0T5K:S1O5&I&6'I:+WIJ35%0>DDX.&MM9T)C:VXO
M;4MF1E=D9690.$$F(WA!.VY*5'E"-6)34S,P,E@O14=Q3%5#0WI996=R1"]!
M2#5C54M5+S%/4GA7;FXR;"M2=GI2+T]B5G)F5W9016HV3C54:&)N839E<6U*
M;54F(WA!.SEO25=Q,WA$<DY*+W-A:F]P9E(R:F%.<&5I-EAB-EAP9'5L<%E7
M:4-/0T--55962#9Y97!*,TIX478Q4%1.3S%3=VXP+U5B94\W<W(F(WA!.VQ3
M:SEV2V]:1U4Y:41I<C5R.#)E4V9.;C5*95E0.%EE5$I*3'IY<$TT6%5D3VM,
M34DP2C)J;G!8:VTO-W57;%9/>"]Y;$PS>GE(-38F(WA!.S!,>G0U96@Q<E(U
M0UEN4$,T=#-O2EE*9T%7:6M!-VEV>4DS1TM%>#AX6#)O,D=G-FAF86)A9E@W
M*S%T-4IR87E,8U!6:U)3>7!Y;V8F(WA!.W15>%8X6G9"*V(S;B]W03),-6EU
M4$PX*W1Z2S,W:4,U=#5&,"M.2VMP1T]2:6HT2U18:5<K3#ER;'9I;#9M4'EP
M+S5Y0S@S2W%E868F(WA!.TY+84IP-6]P<TQ6=G-Q0E%,-D9P-E5,0E(T>5EQ
M>B\X<R]Y3CAQ9FPO<4HQ1WIV8G$W,65E1G)D-5HS5D5A36Q76E5H441A<4MD
M>3(F(WA!.TM(<%=+=DYV>FPO2GI44% R;&973&9J82M:8DY$.5%V855$9V)I
M0V%N5D-E:#9Q9'@S0E92=C5,2#AW1CAK=U%E9#1$1G%6=$DP3G4F(WA!.SAJ
M8W)I4T).;&%E;%)Y<E5!,7%Y,$HX4W$X-C!75#E)+W=$3UA'<GER=6UN5U)6
M96XW3G!$13%A5G(X8VAX4SEN.#=F.&]:<B]W1#(F(WA!.WIR=B]!2DU0:6@U
M<B]W031P9CA!:W)8+T%/,FIC9CA!14DX5DPR5$9867%K6&TS>GHU5SAO,C%T
M9&59<C,V:&)88W9O451'2V%21$HF(WA!.U%T>%EX22](644O1E1&6&Y0-6HO
M04HW9FQ:9&52=&4P-G@Q=&)Y+S%(5')Q,'1,94='8VQP2C17:5=R1TU);T)E
M=GA%8F1-57(O.$$F(WA!.VY&84-74#A!2W!89%-Q>C,Y>DI%5"LP;S1*568W
M2D--548W0FER=S<O;DI(.'I93$Q2;3AI-DLO,79Z0G)81T,V:&<K3F]92D-0
M,UHF(WA!.T,Q4'%4,4-Q=CAP2B]L<7!$,$0X;R]*5"M49DE/;6%,3T%,-59-
M*V]%14@O045I63@S1E)S94919U!G355)>CAZ9CA!>5<S;7HO=&HF(WA!.V%H
M+S%#>5EQ=VHO;D9V.$$X;%!B9CAX;#$O>$U9<5=/+VTY+S8P3"M8;B]01"]Q
M2V9&6'8R2W9'+W=$;DLS+WE6<68Y=$<S+T%/25,F(WA!.UEQ2'!8:VXO04I1
M>E%0.$%T;E=N+TIH3594<D98>50U9C@S6% U3F9M<#5N6%@Y2G5*-U15<$I2
M0DI(4D=E27I'5TM73&Y22%9L8F8F(WA!.V99*S1P:6Q'85(K8C,U0C96<FPQ
M<FQT-4UV1S%/-FUA8WI40T-663-9.&HV36)Y;$DY.2]H1F-6<&U8+T%%3CDU
M22\V<S)P+V1B+SDF(WA!.U9-5G S+U$S,VMJ+T%+<S)P+V1B+W=$5E1&860O
M=T)$9F534"MR3G%F,U<O+U941F%5-VXO;DQB>4)C,CAL=&,V1'%%,79-<&IM
M:&LF(WA!.U<S6DA2:%)L6E1*46=J1F%B+THS.#-F>7145TQ8>6HU4SAU,VUL
M='$P.&IT3$PV8D%U16%4-#,Y4C-)5E8T<4\R2S Y:C@S*UIR8GDF(WA!.W8U
M878Y9G5R96$V='10:D5S<T9S14UP6&M&2D%D:U=I.'548CE!97941D1X3U0O
M;DIJ>FIR6CE0>5@U1W5B,VM3175*4DYC3%AP=D@F(WA!.V)O;T9/+S=Z1DY+
M6G-0.$%N2S=Z6E%4,TU(;&UZ9G-R4E<U03AF,U@Q:31(,&M9<7EJ.'1V>4<Q
M2'EZ-7!G.#$V,S5N=619,65*2D4F(WA!.TUD1SE.:$MH47$X:W)34T]">35$
M-T\T1TM(<T=+<&(U:#AX-DPU9#!U5%9D875H6C9F17ER2F--<DUQ;#(T<EAG
M1T\U3DU66690.$$F(WA!.S@U02]L1$1!.'8X06E+2U1G<&(P-#1P,F1Q9&Q(
M<#E4:7)Z<B]N2%-39GI.*UI(;EAZ,EE(:71,=&UG=&DO54,T;45W:G%.:7E2
M=W F(WA!.WEP-&IX>%-8=FUS9F\W.44S=C94<"MJ9G$X=C$S;%=N;V-$-FQE
M4'AF67(P>%%X+SAT9BM69CA!*TA7+W=*-E@V12MS4%@P9E8T978F(WA!.U)E
M9CDY.%A4:FER2SA69&ER1G9Z22]W1"]H<R\T-CE(.4(K=$@O9BMP>#EB9FA4
M,'9J<C$V67$X<E@O;U54:TMF;RMT9'$O6&%F5%@F(WA!.V)&6'0R9R]O5#E$
M5U@V1#E$.40K:W8Q2#9R>#E$,'%F1#9F2#1A67%J.%99;'%F+T%#<E O2'5M
M+W!$.4@O-#$Y3B\P9GHT+U=U4$@F(WA!.SEF2#=(3&9R>#<T<7DS1E5"-6@O
M4D@V03%0.$%46$@Y1&962B]W0DIC*UA(-G0V8F5T>30O1E0P-CE..%939CAU
M9CA!078X06AP4#@F(WA!.T5E;BMG9E9K.5 P9E4T97)8.34O92]&,7A6065A
M9CA!;%8O*T]D1"]!35%E:B]I,S10,$AZ.6(Q4#<P.$](1#DS+V56*S%I<DYS
M5EDF(WA!.W K6E@O2W8O05!$<2]W0T\O4R]1;C%H2V5T-G9$,39.=R]U9FDV
M8W-66D)O+W=#:G8P5%IF;WEN-DXK<GAF575.865H=TAP,#5F1CDF(WA!.VEN
M6$956&EQ:&5F54]#+UA04S16*T@Q=4Y+*S-,1E5*+W=!-C,O>34O=T1*3$98
M9C@V,R]!375F+TI,1EAF.$%/="\X=68X07E3>%8F(WA!.S,O3W0O=T1,;B]Y
M4WA6,R]!1')F+TQN+T%-:W-65DQF.4(K<W8Q9C9R-C,W2' K;GDK:6TK2V]Q
M-"MR*VA*.5HT96AX4'$K<%1H>' F(WA!.W9Y<G141E8X9D1G=G P.4]G-&-E
M;$\Q2V1S5F)X5C)+=7A625!0=BM%=CA!0T=P9C1U-"\T8SE.9C!J>3E7;D1M
M=D@K-2]E,34X86,F(WA!.V0V-'$X3W1V*VA.9EA4,"M(3W9W*W K;75(,"MP
M.$@S-'!E-RM54#A*+V]#,B]W<#E5+U%L1#E8*V\X4%)R6#1V<V9T5BLQ6&5V
M6$8F(WA!.T0O+UH\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP
M.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @
M(" \<&1F.E!R;V1U8V5R/D%C<F]B870@1&ES=&EL;&5R(#$P+C$N.2 H5VEN
M9&]W<RD\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ
M+R(^"B @(" @(" @(#QD8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^
M36EC<F]S;V9T(%=O<F0@+2!!8W1I=F5?-C Y,3DT-C5?,C9?6F%I($QA8B!,
M=&0@($9O<FT@1BTQ(#4M,C0M,3<N1$]#6#PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI!;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(" @(#QD
M8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:3YR<C(Q,C(X-CPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI397$^"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @(" @/&1C.F9O
M<FUA=#YA<'!L:6-A=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!44&<](FAT=' Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @(" @(" @>&UL;G,Z
M<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE
M;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI-87A086=E
M4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(#QS
M=$1I;3IW/C(Q-2XY,# P,# \+W-T1&EM.G<^"B @(" @(" @(" @(#QS=$1I
M;3IH/C(W.2XT,# P,# \+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I;3IU
M;FET/DUI;&QI;65T97)S/"]S=$1I;3IU;FET/@H@(" @(" @(" \+WAM<%10
M9SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI.4&%G97,^,3PO>&UP
M5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P
M87)E;F-Y/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*
M(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/E1R=64\+WAM
M<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/@H@(" @(" @(" \>&UP5%!G.E!L
M871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM
M<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A
M=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @
M/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @
M(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @
M(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O4F5S;W5R8V5%=F5N=",B/@H@(" @(" @(" \>&UP34TZ1&5R:79E
M9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \
M<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.D5#-40V.$$Y1D8T,$4W,3$X,$0T
M0S$W-4,T0C Y0C$X/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \
M<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.D5#-40V.$$Y1D8T,$4W,3$X,$0T
M0S$W-4,T0C Y0C$X/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z14,U1#8X03E&1C0P
M13<Q,3@P1#1#,3<U0S1",#E",3@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\
M+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV
M961&<F]M/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.D5$
M-40V.$$Y1D8T,$4W,3$X,$0T0S$W-4,T0C Y0C$X/"]X;7!-33I$;V-U;65N
M=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.D5$-40V
M.$$Y1D8T,$4W,3$X,$0T0S$W-4,T0C Y0C$X/"]X;7!-33I);G-T86YC94E$
M/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z
M14,U1#8X03E&1C0P13<Q,3@P1#1#,3<U0S1",#E",3@\+WAM<$U-.D]R:6=I
M;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D5#-40V.$$Y1D8T,$4W,3$X
M,$0T0S$W-4,T0C Y0C$X/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#$W+3 U+3(U5#$P.C P.C$P*S U.C,P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#I%1#5$-CA!.49&-#!%-S$Q.#!$-$,Q-S5#-$(P.4(Q
M.#PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C Q-RTP-2TR-50Q,#HP,#HQ-RLP-3HS,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @
M(" \>&UP34TZ4F5N9&ET:6]N0VQA<W,^9&5F875L=#PO>&UP34TZ4F5N9&ET
M:6]N0VQA<W,^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI2
M1$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A
M8VME="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_P  1"  - #D# 1$  A$! Q$!_\0 %P ! 0$!
M                " D'!O_$ "<0  (" P " 00!!0        4&! <" P@!
M"14 $Q<955:5F-78_\0 %@$! 0$                   $"_\0 *!$  0($
M! 8# 0           0 1 C%!41(A8:%Q@9'!T?!"L>'"_]H # ,!  (1 Q$
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<VE(1B)$A/==W^K&F?YR7_8XW^R^B8XK[#PO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g358845g09j45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g09j45.jpg
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M!0$! 0$!           *!08'" D$"P(# ?_$ %<0   % P$%! (($0D'! ,
M  (#! 4&  $'"!$2$U65"135UA46&2$X051VE+0*%Q@E,3165V5T=:2SM;;3
MU"(U-C=8=WB6F!HR46%QM]<C4G.7)G*"_\0 '0$!  $$ P$
M  <!!@@) @,%!/_$ %D1  $# @(#!@X-"08%!0$    ! P0"!081(5&1!Q(Q
M0;/1"!,4,S0W87%R='6AL;(5%A<V4E9S@9*TT]7P&"(U4U65M<'A,E2DTM3Q
M(T)CDY0D)6)DA8+_V@ , P$  A$#$0 _ );;I@G5\N7$'H\HA;49*]Z-.2 S
M#D<8EL-.FN:'6^/KC Q [J[O\<E^*D:7*Y=S9C!O458TL(QH0)E#I7--6K:B
M)_71QYZ3CDNO7WLL^YW.[GGQII-U<7L$TC>,XC'YB^$N\S:V9,E>'<Y6XR,
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MSD2>W>7QEAE">RMC(?VM&ZDL\IA[BPR-M+6DA. C>F96]]Y;'$D(K 5(C_\
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M%^E]H\P@O G!GITIEJ3)-&G1K77QY'2?@/\ S-GZ&M\PT.(X#_S-GZ&M\PT
MX#_S-GZ&M\PT X#_ ,S9^AK?,- . _\ ,V?H:WS#0#@/_,V?H:WS#0#@/_,V
M?H:WS#0#@/\ S-GZ&M\PT X#_P S9^AK?,- . _\S9^AK?,- . _\S9^AK?,
M- . _P#,V?H:WS#0#@/_ #-GZ&M\PT!Q)[7,"\#[@SORE(HO=IGW#ND1'(K
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M=/=1Q%_=[3_XTK_6CVPSO@1O^VY]J/9[M:GW*:??\CS7_P ET]U'$7]WM/\
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M[JM[_N%J^A+_ -66M[8IGZF-]%W[4?[01JC^\]@+IV1//]/=5O?]PM7T)?\
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MWL."8(12=:N"<@.>5Z-!=.@7/%S2Q.C@0>Z#N;=0+?H5+PX#_P S9^AK?,-
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M :GZYO<G9K^+*/\ :!FJ(]WCM18X\EL_Q&$2CN*]M'!WE%[ZA,(J]:FS9N*
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M]Q_RK)^KPR\\/=@U^,N<FT=K-Q_^$L_R%;XC4CGNC<?_ (2S_(5OB- -Q_\
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M"@-3]<WN3LU_%E'^T#-41[O':BQQY+9_B,(E'<5[:.#O*+WU"815ZU-FS<4
MH!0"@))W9B>Y59_CI,OGQ%;->A:[4T+RW>OK%!KQZ)#MG2_(]HY&LR'VA7N'
MM4_]RDX_5!U37BOWMWOR;*Y-3'BX]@2_D'/0?/\ JQ7(\% * 4 H"8GV"'N*
MY9_B#G'[$XSK('<N][C_ )5D_5X9>>'NP:_&7.3:.VM2.>Z* 4 H!0"@% *
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M;NSW]NW;[6RL@=R[WN/^59/U>&7GA[L&OQESDVCM9]?_ ,#_ )[4CGNCZ_\
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MG6-$XE&I6]Q".N4W<(>X3%B<F4\Q3&;J))%\<3?)*=D1.:EK<4%S7*.15GE
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M?Q_+^NCNF<L7J,@G8SB*C("0JV0#&9*)^3+#$"$VZKB"L ;K=@3K&=,\F(.
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M_P L9^N+?+U2.>Z.._\ +&?KBWR]0#CO_+&?KBWR]0#CO_+&?KBWR]0#CO\
MRQGZXM\O4 X[_P L9^N+?+U .._\L9^N+?+U .._\L9^N+?+U .._P#+&?KB
MWR]0#CO_ "QGZXM\O4 X[_RQGZXM\O4!Q)[7,:\;[@SOR9(GO9IGW#LD6G+;
M#MWR)[UQW.;T%R[VOLW;!L9O;;[;AV6L+!/HR/TA@'Q/$7+6<S.Z%#L+&_C5
MAY*ZG'6L*S+H4 H!0'H2?;2;\8)_2!KFWUQOPZ?60X.=;<\"KU5)G''?^6,_
M7%OEZMWIIZ(NWT0D-</(&F?OR9(G%:'9&X=DBTY985O3<7WKC$<@07+O:^S9
M8(3+"M>][W#LV7A/=8[*LOB\SE&"U,1]<B^ [ZU!'8J(RVA0"@% 5J-;?6-@
MV>W?TTU;+7OLMM[\1LVWV7V?]=E_^EZ[6.OL_*M^NA5.%.^GI/I+<=_Y8S]<
M6^7JS#)/''?^6,_7%OEZ@''?^6,_7%OEZ@''?^6,_7%OEZ@''?\ EC/UQ;Y>
MH!QW_EC/UQ;Y>H"K!WK@#Q A".X;;X0"N, 17M_*"$=P%B&&U]M@BN6"XK;+
MW &]]E@-*L+=G?I$T^/$P?<4XL.C[C/H0]8YE@U<XR!(2'>'2%4WK'AG&DD4
MH=4R8*T]L17$L1%)UY0"Q%DJBRS30CM^U87LEDD.2[;#6.^ZS4PY6LF4]OFJ
MG*'*J=Z^\Y0F=;="[Y*4J3+)%R547XHUNB1*U<CM+1750M"KTQRK\U5IJ5,J
MZJDX:47/+/1WS*QNEC )I;X6''+>DO)%XW)[/;7:1M2Q>K.4Y%4*1&+VQY2+
M2R5A>6LCMB](0H*2+X_+G2-+"#X_=.V$7 BY<!]F2<'%L]!6%>G?"Z[TI93
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M(^Y@@E'N1+<0L2MSJI;[)UCJWHB!)$3J:J0I@$IR@6+H5+PX[_RQGZXM\O4
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MA"*]K;P0CN$%QAM?;:PK@!<5O;W0[=EA4_5 * 4 H!0"@% * 4 H!0"@% *
MU/US>Y.S7\64?[0,U1'N\=J+''DMG^(PB4=Q7MHX.\HO?4)A%7K4V;-Q0"@%
M * DG=F)[E5G^.DR^?$5LUZ%KM30O+=Z^L4&O'HD.V=+\CVCD:S(?:%>X>U3
M_P!RDX_5!U37BOWMWOR;*Y-3'BX]@2_D'/0?/^K%<CP4 H!0"@)B?8(>XKEG
M^(.<?L3C.L@=R[WN/^59/U>&7GA[L&OQESDVCMK4CGNB@% * 4 H!0"@% *
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M]KVO:]K7M?;5%1,ET)P+Q%45<TTKPIQFY/9^^X,T2?X1=-O_ &:AE=)]%?\
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M^XT1KC7_ &5^;TH<J/[2?/Z%.X5=)W"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% <M^U-G$*QM%-(,WR+,(O 87']:D(4OTOFL@:8M%V1,?A'4 B)4.[^
M^*T#2VD'+%*9(4:M5DEF*5!! !7--+ *J<*=]"N2JE2(BJJTKH32O"AKU[(-
MH(_MO:0O]2F&?.E=V::TVH=/2W/U=?T:N8>R#:"/[;VD+_4IAGSI3--:;4'2
MW/U=?T:N8MZ6ZV^SGG,:>HA*]96C9[CT@0'-KJV+]1N$U*92F.M;[)1\Q,+L
M<08$M0E.W>(F5%$J";A-* (/UP+A*M<V-<($BN-,B.TO,/M5K17173_\J51=
M[4BK173GO:Z*JJ*D6FI47Y)UM8N<.1 G14DQ)353+[+K6_HKHJ_^-5*IOJ51
M*Z*LLZ*Z::Z52JE%3"JO/79WE2*.R&(=H/I7QV9#(:X0V&$0[..EI&-A;W))
MW8XHQ8O4."E\:2E CGQ-''RZYC*DQXGT20Q80B[K<K>,I%4.9$N$*/=TN5Q9
MN-QKN,VZN)*>9<Z9352VU/9HBR*J$IBUS(O2I*PJ4BHXC=3F_MQS!K=,R)+M
M\J5:%MUO=M]OHMT&UMK%:=;WBTJX[;WJY,>FI:I-$.3TV,DRI92MJY2WO/Z*
M<^=G0Y%9U*=^T TM+;9ZBQD0D9:74+IV8DK<W=TE*(ET3)6!];"W*663RLY*
MLE3W=>[+T#+&T)QH2&@%C>-&,93*X65B+&;]JLZFX0ZJWIDIQY[ID!VMFMR7
M)?5F!OX%+C<",C4=EV3-=II6N15E6O!K+U.)T?D2W/;3!6WRTHCQ8U#+/2YS
M5+]%$6,PCT_>3JJ')TGILAUJ-":6I*8Z;[UO^H[L]I&;$G)1KYT@,[VSR!OF
M<M-CN;].Z=CR%-V] @2)9+(V![E$@ :H:CD9JV. .7+#F%6>G7IUASLTM#FB
MX1,5NPZ;@S1'21&DQ';; IF3I=<JT6QUUURN%#EQ7(:I0_2Y2U,6EINF6W36
MU6W3'D2&'.R7A.F95 >K>JCR8\IJXSUAP(M$:[7)IIINB9,BR6I:55,5-U.0
MTJ=<JBN54.TN52(\=]OVN6JK1 J/<)&1VE&F<[(:?'DK@D,F+GJ!TU'WAQ\K
M?#7U7(D;$F<4K"L<;&HH@V'EJVXQ,K:(:V$G%76+7=<NZ6<0Q6Z6H=5G@TVB
MN[P+I<K<S(GT>R-$"-3%HAN2JYCDMMG>NW!ZA6WDK;D7%^JFKI;4=MKM>PY,
M<K=F4W6?5=J+3/MENN#T:#5['U3I*RG);<:B%1%<>S:M[-:.,K0XQ;F::J>F
M./N.>Z8:F^S;FDWBT_<];^DA/((BGVMZI%J)P$6>N<T1;B&,N;VI/D:@YUM#
M%+R].L8:3Q6943TZJW)0@5FV("3UV[$TZVVR?:6%HKBW"K)VAUU]:6F'%96:
MQ&HI>HI8]DJ(T9B=(H_]2[&8;9H=;IWRU=EPPQ$N5R@W1^AVF5;Z<VJVF64J
M=>;1[J)Z374S54_['5R9+\)BI>IFY,AQZMIRK>[W'$LS3H$F2UU<WSM(]+S@
MY/\ C])C"1+3\XZ:$)TBB:QSB"N7"?S(P]QLYX?'=%&%Z.-+%QIS3!#I9(E3
M*Q&DJK(+>S QQ['-1V(MHB-,Q+LY>X;=,VXNTQ)[;-P;M_4M,V3,ICQH[DUE
MR:VU30_=:;?#;E2J:J.FGD3L#U7%R0]*N<QU^7:F[++=J@P&JI<%QZWN3UE+
M"C0ZI$F0W"=;A..U51[55/EN1HM5-:-&U'L@V@C^V]I"_P!2F&?.E6+FFM-J
M%[]+<_5U_1JYA[(-H(_MO:0O]2F&?.E,TUIM0=+<_5U_1JYBWY;V@&@Y3%9,
MG3ZV=(ZA0HC[R2003J1PV:<<<:VJ0%%%% F8AF&F#$$!98 B&,8K!#:][VM5
M%5,ETIP+QE4;<S3\ROA3_EJYCIGV?ON#-$G^$73;_P!FH972=U?]NKPJO2IM
MU0XB@% * 4 H!0"@% * 4!QMU^9CQ%A'6_H]E69\J8XQ%&'#2OKB8$$CR?.(
MQ 6%<_*LM:!W%,R(WB5NC2WJ7=0WM;FN(;25 UAJ-N7*2R1$)% R^="Y+IU<
MQ2JFJJE=ZBU?G4\"*O%5J+$]D&T$?VWM(7^I3#/G2NS--:;4.OI;GZNOZ-7,
M/9!M!']M[2%_J4PSYTIFFM-J#I;GZNOZ-7,6'.M7'9F9++82ISJVT4R4$9?$
M<A90NVH3!JZR)S1C", RN]2X[82=<  JR+;"U998 'V&$ ;6]6UWRYV5955K
MGR(2S8KD22L=ZMKIK+B*BI5TNNG\ZG-5;K_M-JJK0J*JGEW.PV^\I%IN=N:F
M)"DMRXR2(]+O2WFU146GIE%65-62(Y0GYKB(B5HJ(ABCZ>W9]J63(<9=^TAT
MY.K%E9PEBC(!)VH73(6Z25JE\<DT;61]=(@K!/EF]I2OS8*-&$+254?2Q-@9
M6TXEA"N;%?O)C.MN5:)L>TVUB586K?3::J7KDK$*1;ID&8W+:B=7I&Z:_7$?
M2:E3=5$NNX2Y+U-4M6GV_"]I>_BW>$_<KD_%OKL^JZTU1[>C\QBX0YL-R(Y+
MZA63TIBB4QU'52Y2Y$;@18S-5,7IK+GM-U#]G^.'R]F'VA^EEQE\PR%"LJKI
MP]:@\"''>O..#L?F0I6:PLDOC[<-G;B,8Q)$O:$IB$QT3DN0AN"=4Y#4%=5.
M+:DN%OD);XS-OMUHN=B:M<9]^FGV+O--W2Y-TRI54QY)#U5\N#C4AREU&*ZF
M$1JNAE**NU<(JMOGQZILMZ?<+M;;X[<Y,=FJKV2L]5I6W5K%C41&5CM4V6 V
M[';J:5ZBEY5=HK>6NGV2?4/V<3Z^Q!Y9]=VD>#@ALA<Y>VIXGG734E5VE3OW
MF[H[EOBYU7O"0+Z,\FTJ;DRH#?*$R%*B=B#D@UQ*SK@XMF18MPCR6Z+FMRAL
M6]ZJ?+N#C?4,?>=(CU16I;4=Q8J4U+ >K;5Z"XZX['KI<1JIOLFX1C2I5OD1
MU<MJ6Z6]<&:($*"VYU:_OU??22Y#=D-I*6JGJYJBM&IM#3;3]%3?3*7/(V:F
M=%3)(7J7H.T[TV+I3(CH 0\/3YG32VL6&,,0<XV:\,*$XE20)I:9.TM<A(/:
M6JR%I;GN9/<E;4:5X&4I!S?Q/"E1(UO=L%O:@PZ;M7'C19EU:;IE7!B;3'E.
M4U3Z^J'X4A^'72^^KK[T:W1H3SM<=*J%ZV<+SXTN3<&KW<7)TRJTTR),F%;'
M'*HMO>AK(BMK3 HZG8G,,2Z:F(Z-,,R;C)F,MT2%2M+V<-7>@93+9%.4/:$:
M8&>3OS5"8ZG<4FHW3TLM'XS$9 JD*YC94CP^.2,HF9'N#BDE"Q20I<#TIJ&Z
M!2A5,C.H1>:U>]Y;X=K=A0Y$**_<IE;+E<IOJN;<(E$-J5)<CR67*JK;2RRY
M!:HKH9I<I=Z;0[1*DT.^F[8JZY\NYM2IL>;*8ML2EZAJ.XD6% EURW8T9N1&
M>;I2X5//-S7:Z*WJJ*FE:K:KC1JV\4(<K=F<PNBA3%]>NFEM9W:;8OF3\P/&
MK?'TO3*!XF?ETTCJ-G527*:]4T&K9V-ID#RO/$ZB5)D"UJ3)T?I8:U+[SN/K
MG+8HHG,0'Y$>VWRW194>)"M]="7^*U;9CDAN%%:;D4M6M'XD9JE&$;K=;?KK
M<ZG1ISPFL V^*]77"<N++$BY62X2HLB5.N%%:V*4Y<HC;%<V2[6Q4Y<^IY4A
MVM7UKH:<8;H;ZH5VC:;V0;01_;>TA?ZE,,^=*L;--:;4+VZ6Y^KK^C5S#V0;
M01_;>TA?ZE,,^=*9IK3:@Z6Y^KK^C5S&N&K;6MHVR!@";0R!ZM=,LVF$B701
MNC\4B.><6222OK@9D2)C+0,S$S2M:Z.:P80#$!*B2GGB" 0@@O8-[VXU*F]7
M2G%Q]TK316BYK14B)GFJTJB<"]PDN5U'8* 4 H!0"@% * 4 H!0"@% * __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g358845g23n28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g23n28.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X45?:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](EA-4"!#;W)E(#4N,2XR(CX*(#QR9&8Z4D1&('AM
M;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN
M=&%X+6YS(R(^"B @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*
M(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+R(*
M(" @('AM;&YS.GAM<$=);6<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]G+VEM9R\B"B @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+VUM+R(*(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @>&UL;G,Z
M<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O
M=7)C945V96YT(R(*(" @('AM;&YS.FEL;'5S=')A=&]R/2)H='1P.B\O;G,N
M861O8F4N8V]M+VEL;'5S=')A=&]R+S$N,"\B"B @("!X;6QN<SIX;7!44&<]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @('AM;&YS
M.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM
M96YS:6]N<R,B"B @("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O9R\B"B @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC
M;VTO<&1F+S$N,R\B"B @(&1C.F9O<FUA=#TB87!P;&EC871I;VXO<&]S='-C
M<FEP="(*(" @>&UP.DUE=&%D871A1&%T93TB,C Q-RTP."TR-%0Q,#HQ.#HS
M.2TP-SHP,"(*(" @>&UP.DUO9&EF>41A=&4](C(P,3<M,#@M,C14,3 Z,3@Z
M,SDM,#<Z,# B"B @('AM<#I#<F5A=&5$871E/2(R,#$W+3 X+3(T5#$P.C$X
M.C,Y+3 W.C P(@H@("!X;7 Z0W)E871O<E1O;VP](D%D;V)E($EL;'5S=')A
M=&]R($-3-B H5VEN9&]W<RDB"B @('AM<$U-.DEN<W1A;F-E240](GAM<"YI
M:60Z.4)%,C$P-35%0C@X13<Q,3DS-#9%1D)".3DR-S0Q134B"B @('AM<$U-
M.D1O8W5M96YT240](GAM<"YD:60Z.4)%,C$P-35%0C@X13<Q,3DS-#9%1D)"
M.3DR-S0Q134B"B @('AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#TB=75I9#HU
M1#(P.#DR-#DS0D9$0C$Q.3$T03@U.3!$,S$U,#A#."(*(" @>&UP34TZ4F5N
M9&ET:6]N0VQA<W,](F1E9F%U;'0B"B @(&EL;'5S=')A=&]R.E-T87)T=7!0
M<F]F:6QE/2)0<FEN="(*(" @>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0]
M(D9A;'-E(@H@("!X;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3TB1F%L
M<V4B"B @('AM<%109SI.4&%G97,](C$B"B @('!D9CI0<F]D=6-E<CTB061O
M8F4@4$1&(&QI8G)A<GD@,3 N,#$B/@H@(" \9&,Z=&ET;&4^"B @(" \<F1F
M.D%L=#X*(" @(" \<F1F.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/GIA:6QA
M8CPO<F1F.FQI/@H@(" @/"]R9&8Z06QT/@H@(" \+V1C.G1I=&QE/@H@(" \
M>&UP.E1H=6UB;F%I;',^"B @(" \<F1F.D%L=#X*(" @(" \<F1F.FQI"B @
M(" @('AM<$=);6<Z=VED=&@](C(U-B(*(" @(" @>&UP1TEM9SIH96EG:'0]
M(C<V(@H@(" @("!X;7!'26UG.F9O<FUA=#TB2E!%1R(*(" @(" @>&UP1TEM
M9SII;6%G93TB+SEJ+S1!05%3:UI*4F=!0D%G14%304))04%$+S=107-51VAV
M9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%"04%304%!04%%028C>$$[
M05%"24%!04%!44%"+RLT041K1FMB,DIL04=404%!04%!9B]B04E104)G445"
M055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$
M07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W
M8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!
M04519T%4045!07=%4B8C>$$[04%)4D%135)!9B]%06%)04%!04A!445"05%%
M04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%!9TE$05%%0D%114%!04%!
M04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-!44U$06=10T)G8T1"04E'
M06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP1VA">%=X46E00B8C>$$[
M571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY546YK-D]Z3FAD55I(5$0P
M=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L
M85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E6' W9D@Q*V8S3T5H66%(
M:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP
M<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#04U$8E%%04%H141"0T53355%
M1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA
M4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z
M=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P8EA&,658,5)L6FUD;V%7
M<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[
M*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!
M44%#15%-4D%$.$$Y531Q-T9867$W1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ
M:&16,4-,5&1,=DY2;$)A2WEG:W5*1DA5<D5H8VHW:&M:>319:SEZ9' X2GDU
M27=(3U)!*UIP.&IE6F9.5W1E63E2:R8C>$$[=G15=4=L6C)*:FAQ9E1J6'-S
M83E!0FUG;DUY3FYM*WEA2%%9=$Y!47AI=E!Q9F5Z9CAL9E!E<E=(;4\Q,$=E
M9' Y2W9Z-E-1>45T-B8C>$$[36Y%;$=J<CEK16EH2%1-:E-::D=12%%U:#EP
M=7ES951"3$U"5U-'.3DT-C(K:DTS3#5M-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<28C>$$[-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ;V%H6E%8.6AC,DYW3U5&,44X16\X56M5<3,T2$EZ:B8C>$$[
M>$%J=F)-3U4T-6EC96-30U!G*U9F3E U8BMA=DPR;WE7,'1J3F,R,TDO5C<R
M0TYP235%-T=Q9SA4-'%C,%=41$M";W9R=6<W83 K<"8C>$$[9TI#46I,<D5M
M:5!X,W-Z+T%#8B]!0S Q>'1F="]-1W$R,&QL63)*3#(V5$M5:VQL;U97:4=J
M0E9R5W V.74K6D=L,#AJ25-024]J.28C>$$[<$\R.$EW;D1J26Q/6$]T=T(W
M*SDW.6TS9D]N67$W1EA9<3=&6%EQ-T9867$W1EA9<7@S.'<Y479T3SAK-G9E
M,D5H:74T64-9<%9.1R8C>$$[5W!!3$$K24)Z2#%5:DA'4TA:.6HT65I.5FIH
M35A%>5-Z.&YT8C%,5U!).71D86I/.7ID3$Q.1S X:'$W0EA*1E0W03!Y1VIM
M6E$S-R8C>$$[,TLY;SE,:G<V<WAG3T=.03$X1V$U;'5I9&ER<U9D:7)S5F1I
M<59E6G9-;6YE6$Y(;#%B55))8E=&:U8O4U5-,5A92TM!;&4U>7),;"8C>$$[
M14DR6$PP3VEN<6-O>'=R:5!F-4U,+S58+W=#42]W0U<Y+S5%<B]Z6&U.+TM%
M3S0O6BMT,W8K:$A79C!0;BMX,R]++R]!0T@O04,S=B8C>$$[+TEL9BMA.&8U
M46@S2#=0,7(O;U(Q;CE$-2]S9"]W07(O=T1)9CAT-R]W06E6+S5R>"]L0TAC
M9G,O5W8K:$A79C!0;BMX,R]++W=$>28C>$$[2"],92]W1$EL9CA!;79(*U5)
M9'@K>CEA+W=#:$A79C!0;BMX;3-L=GI"6BM93DII,5=Z:6UI=%IY,V\K=6=2
M;4-M;DE!1G1I96U:3R8C>$$[3$M*>'-/:3%U:FQP.&AX>4E-:'IR9%4Q<EAD
M23!3>&4K,5<V4S!T53(U=61Y9C56559::C=!6DQ*:VI!5U-W,'5K>34U.$=/
M2FQ*-28C>$$[9'$S+T%$:V)P14UR2G!E:WI8:4$P17,X:7=!*S153$MA9D]M
M64UU,$(P1#%M;CEJ37-H951)22M12$8K<%IP9B]/4BMN4U-Q;7 V3B8C>$$[
M3&)X;EIP<F566G9P-$US6"]%<T5E,$\X37,O<UA-0SAE45-08U)8,C)8;TDX
M+SA!;&U4>7A0-6MT<FLS5VTR>6=Z:4E6;%%K:&5,228C>$$[>%5H=FDV2$UR
M.'I$9S1H>65C+VMJ3TY1345H=WIL>79L.#)-9CAR+T%0268X=#<O04UI5B]W
M0V$X<"]L0TAC9G,O5S=8+U%J<E V2"8C>$$[>B]9>DQY=#5O,'IZ3G!+-G!P
M;VM&<7IT1U!654LQ54Y$<T,R6D](34UG<T]K,2MH>6%82C1C-C1V2FED.2ME
M;FMM>79B:7IM5S@Y828C>$$[,FQE1U1J17!(2TYI<&]E9FE->&IR-$$Q4BMZ
M.6)T.%AS<G$U=T5H=U9)6'HW+V=N2&Q$.'DO3&YM>3EN<SE+1G=*8F50,7!$
M3D=%2"8C>$$[2&M&,DE:=#9N3&-/<6IK3D%&=RLP97A-*VIG2EI/1VEA,DMB
M6%AM;E%,6%AB8E%B:3A74%9R>%!5=#=5:&E76&8Y;T1I2SA4444W-28C>$$[
M86,P4DQH2C-C3$AO33 X2GI2:F5/4$TO:F1.8W-C4C)+=7A6,DMQ1B]F,F5N
M,E4Q-V5Y<D)A,C9L-7!N-DMO-S5'56A%5V546FAW>28C>$$[>5-%24,U2&M'
M268X<G O3% O<3@O=T14=&1F.55S;R].-"LO-S-D9C9'9&8O<68K>6@O>%1V
M.$%L9% U6B\X058U+S9D<G(O04MP628C>$$[+VTX9F8Y-B\V1V1F+W%F*WEH
M+WA4=CA!;&10-5HO.$%6-2\V9')R+T%+<%DO;3AF9CDV+S9'9&8O<68K>6@O
M>%-/,&HX>G9)97(S2R8C>$$[,G1J<D546$1N:DA(2W-K0EIJ,$,K<W-D4V9B
M1$A667EA0F-F561H-GI$2&EN:DYE5D@W:5AF;6@O=T-3+W="8R]W0UE:=C%J
M0G$O-R8C>$$[<R]J<7996"M/-'8V>D10>7,X,39&-6$O3$<R=DY9=69Q.$UL
M-4Y(14%R3WI.5W1!<6=N65IJ85A.1T=/>C,O<60S,CDR9FTQ5W9-8R8C>$$[
M47-I04MF9CAR>"],;B]L=FPO-E(U=CA!;6Y,=GHR4'IC1"]1=')V-6\O,'<O
M5S<O04I8:BM84"]!0S-Y+W=$4U!.+WI4:BME>"MA+R8C>$$[-D9T9"].2"MM
M2#8R,"]/+SAU1UE+9%%K544P-4<S;6]0;E)$:"]/-#!(,E@Q=R]G2"MM:BMT
M;5=M-G!P,G%78V0W<#%X2&17:V]Q:R8C>$$[,%1";%!T=#!)-V<U:W=M2D-W
M-E!09VYI:UE40FI)9$-I<VLQ3WA69U@U-"\K4S5V+W=$:DQB+SAN;'I$,3,Y
M,SA8;W9:8B](;RLV6"8C>$$[,T8X>%IP,S%6,DMU>%90+T%#3C56=5!-+VU7
M,#!Q2V]I8RMP9'EJ.6E"0T]B9G=(=5)L;4Q'6GE!1')U,61F2%,T2EI$>C9E
M6C90<28C>$$[:2]V9$HX=&%"2F-Y,'0Y3C R14)56'-I1&EI2U!%-T%:=353
M:FIH-4(X:G<T<VUQ>D-),VY-+V=V;&IZ<#5Z,5AZ6')%;"]E=59H0B8C>$$[
M271,44=Q47@Y;%5E2B]A8G9M:WDU5$TR6#%Z<WIS,TAP35%H1&XQ4%5N.&-M
M4#57-T8R2V]U>3%7+W-O3'4S='!3:T8Y1C9.,T8Q5B8C>$$[,$1">%5E25IA
M9S1B86-U;FA->&Q)8G=.:GE1;4)U9E,O=T-1+W=$-4PV2"]!2FE:+W=$:5%Z
M8C9$-D0W,WDS,G,O># O=T)73#4X."8C>$$[,68X04M587@O=T%X,7HO>61B
M3E90;5@P9E%F-'9J+W%2*S104G8X06Y(4"]!2E-B5E X06U#+S5M<&U8;U W
M>C1F<$1Z4'1N+V-1+R8C>$$[<B]O2UIE8UHS2#4K84HP*T$R:UDK5$9Q+W=$
M16IH>FXY*U!F2#E$:3EM=T@X:C50.#<Y1#(W3G,X1S=&6%EQ-T952')/:U=/
M<V%88R8C>$$[-EIF;UI,4S94:$MO2E4P<EA9:F]14EA)6DE#8V%,9G!T4E!$
M:T=31S!O.&U%9CA!2V@O>2LO,WIC+SA!23EV-EII+VM)9#5D.2]O<R8C>$$[
M,79F2"]3=2\U55 K6#,K*V)N+VME,SE-9GE%3SAR+V]S,79F2"]3=2]W0U9$
M+VPY+W9M-2]W0U(W9C!X+TE1-WEV.$%O<S%V9D@O4R8C>$$[<U X07I++TIJ
M461%.',S3W1A3DQ/<W1M5F%A0UHQ9%=J9'=H-&YI<$)8;%AR,'I(,4=K14DX
M44QU=7A085A.;GIJ1FQ%86QY23<V="8C>$$[3F10,2LW,6XX:&11;79(36QX
M8E%3,FIY=#%94G-V06XS-$UO.3A)>4=7;DXY3G9U8U!.<$DT3S))0TEQ36E*
M9E!N.7)F-5EE54Y#."8C>$$[,&9L:F$R97-11U=/1SAN:VA:2%I'5G9S,4)5
M*T(V2&)$<&--8VU/:C,O<5AT,W1(3G!.9DM723!40TE05D]V*U9$+VPY+W9M
M-2\U2"8C>$$[="]43'9Y14\X=40O04M,3F(S>"\P<G8K5D0O;#DO=FTU+S5(
M="]42#AH1'9++S9,3F(S>"]W0DMS;2])5'E#.%1O:3-55'-#1FM7828C>$$[
M<%4K3D="1T$V0TAE57@Y<F191%HT5#A'2V9K3F18;6XK8F1E.'1.25I,5TI*
M2E-0,F96=#5L:$Q!9'519F8U1$M.0U-*:V54=5!A>B8C>$$[2$A*<'-797%K
M84AW;$5Y*WEN=4]B5C1&,DMQ5C%A5VPS0UE,<4=/-&AA:&%+5E$V:VIC5E9G
M4FM:4D5H4D9S.&53541C4U%F2D$O-"8C>$$[6#AS+SE7:7DO=T-K94PO;6Y)
M9FPX9CA!3DAY1&8K97HO=T-Q5"\P>%DS*UE%+VQ,>7(U875.4V)38D9R<'8S
M5FI%8F5,-#4R0C0W8R8C>$$[96DO85!S37@Y4DA(:FIF1$<K;7=D<#)21%4V
M=D]-9FE4-&5C:GA(;"M.;GDY23=34TY)-7%Z:W-X-F)N8SE-,40V=T)1;U!P
M3#AK+R8C>$$[2F8V0SAT:E5R<5!J<5=R0EI70D<X8TA72DXK:$YE4BM9.$TR
M*VEW.$UE23AZ.7HU9C=4.7 O;4TO:'A0;W@W93@Y5"MH:FXO041K6"8C>$$[
M-6AD261..'9X3E%3,79,<%%D>7%K<$50;%AM9F]Y;EAZ,T5F:3=0,DXP64IN
M;5!4,&HW>BMH-&1M=64K9E%0-6%F:WAP3G!P,$]Q928C>$$[6DQ:8GI5<FA2
M26QL2TMX44MD,41*,&0V9F$U8D1P5'9M,# R:T9C56YZ;G1V,FQY5&UC94$X
M34(O14]:*U!1934V2&0K579+.35B1R8C>$$[,G5D2G1*25-+8T1$1TMF-G!!
M0E@V37EJ<#A:+VA$>E=0=$1546QX4GE30CDU9E!F-7(O;&]F2V0V;#=91G!.
M179(2W<X=#)H:W!8,"8C>$$[;4HV9VEP52]F,#,Q5W P+VAN>4PV4C=0.70O
M;DEM13ES<V5F;4\O.6)Z+TU:-DXY3"]K4"]W0U,K:"\U:5HO*TI$3G9O4&]0
M=F9,9B8C>$$[87HO2%0O5FDK9E!.6"]+56%X+WI(6% O04-D8DY64&U8,&91
M9C1V:B]Q4BLT4%)V*V-C+RM5;3%4+VU#+W=#6G%:;#9$*S@K2#91."8C>$$[
M>C=:+S-%4#8O=T-G;S=Z;"]W0U0X,&(O048W4#E:>'IF,R]X:BMH>"MZ9BM-
M9DHW<'9C<S(W=TQS5F1I<G-663$U+S@X5U!K+U)F<B8C>$$[.#A:=4QM6G93
M<S=52&IZ96Q45G0V2V\V;DM.4FY'365B=&5Y3WDU-C-,=T$Q16)K.7<O5SAH
M6#@T9GI7,45M-# O5&Q.<U0X270W3R8C>$$[5U9"=B].5C8U<F9Z954X=G5E
M>5!S-3)D:CE--2MR>FU!=2\U5V8X06Y2+S%B2E K-&9*+U1(.'IM-R]S4B])
M6%IF.$%02"MN1'8X028C>$$[;%HO-3!F.$%6<VLO-V@X;CE-9GI/8G8K>&8U
M0S=,+VYJ+U1H3DIF32]N:EA0>3,X,6YZ3%EM,FIG:6<K<7I.03EU6$Q3:FUT
M1RLQ4R8C>$$[9S9:3U=78W-5=4QY*SEX639(4UE.9&<X0UA%4UI73TQI-F))
M5'DQ+S9Z.7)V+T=D+W=$:6-/4F@O:3AV-C,O171U="\T,F-8.55F9"8C>$$[
M2FUV-40O.$%K=F]F*UEM9B]I47I,,$@P2#-U:CER4#AD4#A!5FDY1'I.96%D
M:7)S5F5&+VQ"+S5.,WI,+W=!67(W+W%.:7I685 X028C>$$[=D0W=C!V9BLP
M6"]'8F@Y.% Y>$HW<&TQ94%D:7)S5F0P,T]+=FPO.#-F3S4X>F5:6&IT<$]7
M:S9D>6AS*THK1C)R*SAL+S)21D(W028C>$$[6F\Y5&TX4U8Y0GEF5B]:,W-V
M.$%+-$QK4#-K.7HU9'<K2#-Q6#54951$-6XX,'AR3VY,5$Q#;'AF13E'05!W
M4B]W0WI99F-$9S K2"8C>$$[>$I6,#9S+V%$=% X<G!Z6#DU4&%0-E0X4'9P
M.5-G04%!0V=(45IV6'E6.#!F;G9/.&XU:%A#3C!H=#1%5#5&968V,T]A5%9N
M.31F>"8C>$$[,&95=EI324=I0C<U4R]5>"]W1$QR5%ED4S@X84QA5$%.13%Y
M<G5P-DUS5EI#<"MF0VU666\X57=03C)88D]C-'1*:VM/9D0Y*S,V6"8C>$$[
M,79N45!J8G-666XK875M4F%H-4$Q;4]295)G9TYZ1V%62W1"*SAQ4&]5:C5:
M:F%U3C1Y-VIS1$]C97-X:V1:8U!Z,F9+3V%2.69F4R8C>$$[+W=#42]W1#5,
M-D@O04II6B]W1&E1>F(V1#9$-S-Y,S)S+W@P+W="5TPU.#@Q9CA!2U5A>"]W
M07@Q>B]Y9&).5E!M6#!F468T=FHO<28C>$$[4BLT4%)V.$%N2% O04I38E90
M.$%M0R\U;7!M6&]0-WHT9G!$>E!T;B]C42]R+V]+2B].4S9J,%0X,SE&,6TU
M4G9Q:4IA>GE-3C9R2"8C>$$[2WEV5#-51'!J<794;4(Y>&%U=V-:>CEM6DU5
M9G$Y42M91E!76690,VME5TI:1C$O5'=R0V]$,U533CE+<WES4'!'8DE:-$58
M665/;"8C>$$[,E1Q=V$X3$HO<%-V+W=!8RM3=BMP9S S+W!-9R]W0V$X4&I1
M+VY$-6\O:W)69C9L:R\P:W8Q3R]X>C5++W=#<&<P,R]!2U1)4"MA."8C>$$[
M9D=H+T](>E@K4W16+W%75"]34R]5,E!02&MS:T%A+W!P2C)!1C-"+WI89SAA
M2#@T9DYF-4PQ6"MP6E Y2DPY5'DS+VY)=4M2:C5E=B8C>$$[865T640Q,4I5
M+T-78C R07%0-3%862LR64AA1SE(;SE:-T=Y03A72$MF<"]4.7HP4%)0>D0X
M9UA/;#(X;'1Q.6Q:=VA&5DQ796%/,R8C>$$[94U!531E;357;DAP='1M6FDQ
M1TUX1D5"-7969&HV>4]1:5=/8VIF34%Y=GIS23<O04)Z-4LO-FU$5&8K:WE$
M+T%*<GEZ>&]F>F@X,R8C>$$[2"]K<E9F-FQK+S!K=C%):B]&2&QN+W$W,E@O
M4U)&+WI69R]-62\U=RM9879Y3V8O049/9BML3$)V>F4X."M6+SA&,RMM,G5O
M,CDU9B8C>$$[,VY#2T]#,VQ35FQO-G-Z4'=,8U%&6'9M3'$X.$1#9V)T-D0R
M9#=+,4@U<4]354I2:$=Z6D9D3VQP3#52,&4X8CAH3E94,&EZ,V%83B8C>$$[
M>D1'4G5546IC1'8O04A227EN2$$K0DPS,SDS-FY/-U(Q368U66=B*VYH0B](
M>%@O04I)965F3$YL-5IF4CE3=C1B0S=G;FMK6#9Y-B8C>$$[>$DV4U5)2W4U
M0S%"<4M6>65I>E)I1$5M=#)0=%(R5FYY86IX8V-43TII3U%U:5!*-E(O:FYY
M5B\Q34=M+W=$4UI"+WI8;60T,% U=R8C>$$[*V)Z2#AL87(O57-N*VML*W S
M*T]F2E@O049-1VTO.$%36D(O>EAJ-#!0-7<K82]Y5G%V.5-Y9C936#9L3S0O
M341Y4$)#.'HV+UE-<28C>$$[0W!73S5I:V,P.$52;5DO44UJ3%51075W>6@R
M4G$U1VAI;CA9:V9E.&XO2391-F@K679M1%9O5DET6EE*,G%E;RMS6%-3240O
M04Q&1"8C>$$[;4)O5&51;GEE=SEQ4C1E:7A9>CE1368Y:D5G+V4Y06PQ-WI8
M1C5W,5A4;75B5G1/<TQ&=%%20D%W;$MU2D9J478V;$MQ>4%K.&1X-"8C>$$[
M6F9,3&M%-4-X44),>FMD2G!Z<&]4<5A(3V9".5<R,5=A<G)B1F)J.#5.851Y
M0D)Q2U%W+S1I931A2V%%;S-P<D-Q0V(Q=4A+=D5X>28C>$$[24]V53539&%E
M069Z<F1V1#)B>$A71T)*.$AH<T<Y-W9H<C5G=EEC,FIX5'IJ.#=03S0P3'DY
M*VER4U1J<6UQ<7E!<69I:F<V4U!T,"8C>$$[3&9:6#9F1$U(5S5U1U!#3UHK
M-39F,EDW3"]-6G9%:U S95 W6F1"*VLO=&9.>4DW=7%)<%HR24-Q0E5K;EE!
M05IQ6# X:T%76#%:*R8C>$$[5UAK,5!+,VQE0S!K569P0S0O9C9G+SA!>&%W
M*WA8=U)F:"LX.3@S96QW.$5D*UIF264S3S!J<3E16D0V23=2.3-F.$%&;&U:
M3' S>B8C>$$[4BME.$1X+VU&8T\S4V$S9V10:T4T9G)1-7!.5U S:"](4CE3
M.6Q*039)1'5L3#EA469L>'%-3VYE971&=35I1FE7-5=.,E!10U5'3R8C>$$[
M<"M84$MS375'65!M-TAT<D-C;6MY4DA0:"LW9CE$-C)Z;TAX>#)+<U8O3E!5
M63=$>4)R57)T>#E7,TYU;FE7;DEI<"]W,EDK<FQ7328C>$$[=3,W0G=N2G)-
M64A35B],9#AN-6\S,D(Y3"]K4"]W0U,K:"\U:5HO*TI$3G9O4&]0=F9,9F%Z
M+TA4+U9I*V903E@O2U5A>"]Z2%A0+R8C>$$[04-D8DY64&U8,&919C1V:B]Q
M4BLT4%)V*V-C+RM5;3%4+VU#+W=#6G%:;#9$*S@K2#91.'HW6B\S15 V+W=#
M9W99=DXO:VY19DYL:28C>$$[;')Q<U1%>$5T8C--4D-Y>&QH43A724DS-V=G
M:DYJ;7=2>41D-')S-W143F\U.%=-."M94$EV4'HO=T$T-#9&53 Q939!-T%P
M1V-W+R8C>$$[-5 X0398,E!29C9.33,K<'@K6F$O=T-H8V1%+S9V1GHO=T%I
M-#AF-5 O<&9:*S%0*VI43"]Q8V9M6&8Y0S0V2B]W0EAI-2\U1G@T+R8C>$$[
M>68X03!V<R]A=CA!;S!Y+S9N2#5L,R]1=4]I9CE8:34O=T-28V50.&XO,'9S
M+V%V*VI43"]Q8V9M6&]L,350,%,X.'-195<W,DDS3R8C>$$[;E<X159V2'I.
M2$AO;T52=W=P4G=",4=::W--5$%24%(U<D@R:FQH<41N9V5'6FM4-6)M>5!C
M."ML+S5X>3AV;5)J1G%T,FM:4'=O>28C>$$[>'-14&1G1G(Y,EEH-U!(4792
M>#ES.#%B=VIF>%=F.$%1=4]I9CE8:34O-49X-% U4"]P9EHK,6PO;S!Y+W=#
M<'@K6F0O=T)#-#9*+R8C>$$[,65,;B]K6$AJ+THO.4PW4#)R+V\P>2\V;D@U
M;$9A8B]!330X*U9R939383AV8G$Y:5$Q*W)N:D5R97I&4GEP.&E-;$A10SEZ
M8E1M.28C>$$[<V122TY2:D=*-RMB,4<S=')E,W0T-V%#3EER949"2$9%9T%6
M55550V=$<T)M94%!2T1Y8S5M56I);7E8;3)V+T%*0F563E-V2DQQ>"8C>$$[
M;FTP>'!35V%#24LX25DY,5)Q1F0K,TMN:%1-2$IO26LW1VYQ3DHW5S9J1D52
M;4)/=7 U+VHT2E O=T)#,V%F+T%.6'E8+VM1=B].928C>$$[5B]Y968U,S)F
M=&,S+U)R4"]5>"]P=C)/+W=#:&)T4"]!3W(U3"]Y25@O;79(*U1Z+T\K>CEQ
M+S9.6B\V;5 X051F<UAX9CA!3TXK:R8C>$$[:'8S=714=79G:TM+9G9,3FA(
M6B\Y3#=0,G-:93)M5'!J:CAY.4@X<&54=$0X<39C8DA3;VEQ=65C.#!H-5-Y
M34)3<G119E%!2UIM628C>$$[8TUC66]033EO9'!:9%A0:GE(,T1O1E=8>7I9
M4S9T9F%O,&MO=4PK>E=W;55&94%I57-15DA'=DPT>C%.4&)%-$%35#-I;45D
M9$U9-"8C>$$[-#9&46YX1#,W9EIS>#4O>6<X<79$3$=:3&]'5W=J,#%P03AF
M25)X1D-*0BLW<#9H15-Q5%-L0C!Y;CAJ1'ID:U!A4%5!9S%(85IN>28C>$$[
M4$TS='HU8FLK.6PK;S9H86%D65A&+V530TLQ=&\R;&UK4%I61E1M5D]9:4-3
M-F)$:&QK;4E21GEK840U23@T*UHW=GI.-6AU=%AU828C>$$[9U-T>'0T:C!J
M:%A:14AY2%@S<6,P1U1)6GE*3#=(,F)O63981$A(2'!Z.'HQ3$QF>50X=6%F
M92M91')/<511>%=E;&M.06MZ<79Q6"8C>$$[0C-39UEJ6E!T9D]M6&%7351/
M-4=G2%0K,"MT;FIW*T9J0DUS;D]U:V8R.'9M*VAF,#5O=B]6=W1V*U(P9CEC
M,B]J42]N1#5V;3,U6"8C>$$[3"].;#AI-SE/84PO04Y80S(O-4A2+S%X.&%(
M.#1F3F9Y=5@K8DPU1C5(+WIK3&]1=7),5%!-;&]23$9&5S!U2D5O=S1/4SA4
M5DAB;"8C>$$[>4@P-7(Y9$<V;4]82C=,,E Q6$)+94-7>%!Q2#9F,%!$9U-$
M561C,3<S>C9++TQ,.#1.2S%85#1.33$R-5,P,6E&4D=*-6E&:G5!=28C>$$[
M=V)M84M(4&-(<65N9TYR<'170TML<UAZ5'1Z,F-Y67!N2FA(1FE046,T+T1U
M96E897-A5&%7<'5R<3EG9W1G0WAM95)65V<Y>6-Z1"8C>$$[;&E"6DEE6G@V
M8DI/6$1'2DUU-FYZ>"MB+W=#6E5F;6DX:C S4S)0-D9S,C5H>4-V<GI5<'IO
M9C)60DE8-E1M;S%/;SA1-V932#!R,B8C>$$[9#=%3VQI8VU4*SEL+W-2,V9R
M96-::794=G!F.&@O.$%Y6#!0+TU44"]W05-'8F919E%F92M7*S%N*T]N*W)&
M."ME878K56\Q:B]M3R8C>$$[=68X06LV,F%Q9DUV;RMG+WAF2"]!1DDO8TAO
M,R]/3V8O2U1A<"]Z0F8X>E5Z3#!(.34X4#!H-6XR>B]U268Q+S!&.4%:=#-Z
M;#)+=28C>$$[>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=D50>BLX-SAM:CAQ5TUM>3A:=%5:5'-4.7%/12],-UHK:DY8<B8C>$$[
M<S%N:$AX93DY:V5Y-G95>DAL2#E*+U(X,VEM83DW<#)+=7A6,DMV<5AY4G!.
M;')(-58V6G!L.&YQ5W0S6F5N2W9E:$IO465X0C-(=B8C>$$[;30P.$),0T%F
M>'4K4SEQ86EE2'1#95-',&]Z=#@X*V1F2C)P*U9.86LP*SE5;4EK=&%85E!G
M;6ER<W<Y>"LP3WAZ5C5C4F=A3#94,B8C>$$[6C)L:C%E251J>C9J=5 T-4I"
M;&)S6%EQ<C(Q:F0S2U1Y45).26QT2#9T=S1'>4I53'E9.70R07AA-359>$E"
M3F-2;V5:54U7>#E,+R8C>$$[04I$+T%0:W9O9CA!;4IN+T%/2D1.=F]0;U!V
M9DQF87HO2%0O0499=FYZ>E8O=T%P4G)(+T%$2%A0+THQ<S%5*UIF4CE"+VDK
M4"MP2"8C>$$[-V<Y1R]W0V-C+SA!;$IT52]W0UE,+VUA;5IE9R]V4&@K:U!-
M*S)F.7A$*W8K9W9O1$YU*V-U>%8R2W5X5C)+=7A6,DMU>%8R2W5X5B8C>$$[
M,DMU>%8R2W5X5C)+=7A6,DMU>%8X,6$Y+W=!<6\O5%8Y*VQV.%1F<% Q-5!R
M;E V:%@Q95(U9FIM;%!G,W9X,SA(,4A39GEJ-%5F1"8C>$$[+TPX2$-++W9/
M4T(O-4%P+S,X;B]!13194#-0.4PW2$DO=T)D9BMG9B]P63<O:T-N+V9Y9CE/
M1U W;BML.6DO-C8O.$%14#A!.4Q(9B8C>$$[.&=5+S<K5"]!2V--9C-0.4PW
M1B\Q,2\V0B\X07!9-R]!2D%P+W="+THO,#19+W5F-E@R3"]R<B]!3D$O+U-X
M.4,K42\P6"]G+U-V,"8C>$$[5C8O-D\Y0696=G)81#%U1E0O965N.$YF;&TP
M,#-$=T1H-5!M+V$S:69M6BM*6$AX8CA.,3A,,U%V-6EF-$HO=RLO.$%I,S O
M<594-B8C>$$[1F$K=#9L3G91-"](>BM8,#=93E0T9D0V+W="<F(R3BMA.&(O
M04%A*TQR,U8O4S96*T)U*UA.82]19C$K5#E#+U=F<494-F8Q>F@V="8C>$$[
M2S=6.5 T8S!H<3EU5#9Z<'9&-$(T=D1X+W="1S8K,5(P+SA!4C,Q>5 Y22MT
M.51R*RLK<CAF5G O:S@O:"LO07IZ8V9#94-U3'!F3"8C>$$[-TAV;&XO>7%Z
M+VQ71W)F;VXQ+S!4=U0Y2RMH=R]31F956&IZ.5@T83$V9G,P<E1.:U!".$DQ
M9E,K+VTK95IF-5$O;$-(:58T;2]"9B8C>$$[,&-U;&8R.3=Z2"]K0VXO9GEF
M.$%4:&U.*S4O<&99.58O<G(O04Y!+R]3>#=H*U5V*TAV.$A29F]$-C,K:G98
M;#0O6"]!1797-3$K2R8C>$$[=G!F0E1W>EDV5&@T9E1D6#%E0SEO9D<O36YX
M=4AJ;V949&9B=3AE.'=F.$%+;G8P.7%8,78O15 Q<C8Q4#E9.4PV;#9F<65O
M,U!H>28C>$$[*TQJ>396>D%L-$XO>&99.7)P4#54.$=(1#1(1'=I<C0W<75R
M3E!Y5R]W04%F<'DO+W=!3F9P6#8Q.58O9F9P3#9T-F9P*V]V,F92,R8C>$$[
M-59P,7DO4V5(>"MN:75U=&54;W9A8C@U-%5F2#A,:#1T=41I=38O<%!933)4
M>&)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:28C>$$[<G-69&ER<U9D
M:7)S5F8O6B(O/@H@(" @/"]R9&8Z06QT/@H@(" \+WAM<#I4:'5M8FYA:6QS
M/@H@(" \>&UP34TZ1&5R:79E9$9R;VT*(" @('-T4F5F.FEN<W1A;F-E240]
M(GAM<"YI:60Z.4%%,C$P-35%0C@X13<Q,3DS-#9%1D)".3DR-S0Q134B"B @
M("!S=%)E9CID;V-U;65N=$E$/2)X;7 N9&ED.CE!13(Q,#4U14(X.$4W,3$Y
M,S0V149"0CDY,C<T,44U(@H@(" @<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/2)U=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X(@H@(" @
M<W12968Z<F5N9&ET:6]N0VQA<W,](F1E9F%U;'0B+SX*(" @/'AM<$U-.DAI
M<W1O<GD^"B @(" \<F1F.E-E<3X*(" @(" \<F1F.FQI"B @(" @('-T179T
M.F%C=&EO;CTB<V%V960B"B @(" @('-T179T.FEN<W1A;F-E240](GAM<"YI
M:60Z,S=&,$(U.39$.#@X13<Q,4$R.49#03=!,44Y.$1&.#4B"B @(" @('-T
M179T.G=H96X](C(P,3<M,#@M,C14,#<Z,CDZ,#@M,#<Z,# B"B @(" @('-T
M179T.G-O9G1W87)E06=E;G0](D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN
M9&]W<RDB"B @(" @('-T179T.F-H86YG960](B\B+SX*(" @(" \<F1F.FQI
M"B @(" @('-T179T.F%C=&EO;CTB<V%V960B"B @(" @('-T179T.FEN<W1A
M;F-E240](GAM<"YI:60Z.4)%,C$P-35%0C@X13<Q,3DS-#9%1D)".3DR-S0Q
M134B"B @(" @('-T179T.G=H96X](C(P,3<M,#@M,C14,3 Z,3@Z,SDM,#<Z
M,# B"B @(" @('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E($EL;'5S=')A
M=&]R($-3-B H5VEN9&]W<RDB"B @(" @('-T179T.F-H86YG960](B\B+SX*
M(" @(#PO<F1F.E-E<3X*(" @/"]X;7!-33I(:7-T;W)Y/@H@(" \>&UP5%!G
M.DUA>%!A9V53:7IE"B @("!S=$1I;3IW/2(U,2XP,# P,# B"B @("!S=$1I
M;3IH/2(V-BXP,# P,# B"B @("!S=$1I;3IU;FET/2)0:6-A<R(O/@H@(" \
M>&UP5%!G.E!L871E3F%M97,^"B @(" \<F1F.E-E<3X*(" @(" \<F1F.FQI
M/DUA9V5N=&$\+W)D9CIL:3X*(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI
M/@H@(" @/"]R9&8Z4V5Q/@H@(" \+WAM<%109SI0;&%T94YA;65S/@H@(" \
M>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(#QR9&8Z4V5Q/@H@(" @(#QR9&8Z
M;&D*(" @(" @>&UP1SIG<F]U<$YA;64](D1E9F%U;'0@4W=A=&-H($=R;W5P
M(@H@(" @("!X;7!'.F=R;W5P5'EP93TB,"(O/@H@(" @/"]R9&8Z4V5Q/@H@
M(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD
M/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_\  $0@ -P"X P$1  (1 0,1 ?_$ !X   (" P$! 0$
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M4Y4&A<<X5 73L;([3W.]6Y6.8!4=QD+*3Z1=60!UC38]#47;>U<Y16^IB/\
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M4Y./-FWS+>W>W/:/EVK$J]D8.#MEV2<[79Y,3E$0 R;NNRTJT,0X!UE$5BF
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g358845g24j00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g24j00.jpg
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MLM:I06JF_%+7C.PP<<L2[BXGZ[A&ISNR8/LF8R%T%C''F?J!)3!PT?1\D^1
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M=<JEIBP!.>K VILVWA+&[F)XHE6Y(ZF(91V01]C=ZJ5R/CXI'$(_8;PX_0S
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M1O!:AGDORS1=8:E4"*W;Q'@?KYME(3*6TMB,(?!\>1PF6YR758P),7D@XW
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MLI<*L(Z"<)MD47^WFK0E($#0C"<,9R7)H=]XQ)F;Z&+V++ANQN["<F^[D;Z
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M19\5C[3)4^X)V+9MHZH@WCPAX[5QOE&A (S#*1_5*/!E%HS=QL/,SN+!.\9
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M?&GS1]*O_B*7_I; >H3S-> 'V3D?;1M_[STZOC?(/[U8^-/FCZ5?_$4O_2V
M]0GF:\ /LG(^VC;_ -YZ=7QOD']ZL?&GS1]*O_B*7_I; >H3S-> 'V3D?;1M
M_P"\].KXWR#^]6/C3YH^E7_Q%+_TM@/4)YFO #[)R/MHV_\ >>G5\;Y!_>K'
MQI\T?2K_ .(I?^EL!ZA/,UX ?9.1]M&W_O/3J^-\@_O5CXT^:/I5_P#$4O\
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MNJ/T/@/V4GU4G +T -_:1N#Y@T[BXWR;^VL>M3OY=*?NJ/T/@/V4GU4G +T
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MM7ZUP#!6J>P-GL%4(C!!+UT*!(YLYLVP5R00Q603?/L7+U7)6V;MRO?&U[2
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M0\C];[WX'9_0FOYOM?3R^,THB41*(KEB$,E^P9&,B$$B\@F<K-+9("(W%@Y
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M%M7Y+'M25#2B)1$HB415P)&9')?&_DZ!,'?)\&_DQWQ.->$O$T<%W1L3/%?
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M16-]1C/=:<>?[=+YP_C3J]?[1#YH/DIY&Q#HK&^HQGNM.//]NE\X?QIU>O\
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ME0QS95Q_B;L!.36H"F".28Z\4TE49GM1P2SQG%',<(Q'(.Z).[MK@_QD1_\
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M@N[N>U&HRZ1*(E$2B)1$HBEWQU_)P]^N\?W!M6WQWU.3[]OS67C'29]=,?\
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M,FA:7.6\-!7S&O3+-E@Y6O[DV;FT<5.ZU06FX%NQ-CQBAI%C^KA9.W!PQAB
M9JK/().$3/,?LA BT:SNI7J8"2W4ZT[Q<:K!#=>6:V-][!UPJ3;Y2RF45EVC
M=F*5VB#V+FPZOV^Q6;N>R>&[CXW2O:\[W7,^,T];MP^U]H"9H%GVT=.[59KS
M;7DS/-MA"@<I<NA)V\^U6L[=#$T,[ZU34;KN$5TE<Z;3TVCFJ9&*K!3AR,#N
M=6L4)P5;=5VAGA!X".)F./J]IF8M?XR^K,[*NSEMY(K6/DLS6Y<?,S!:L#*,
MUFI99Y:\IM,(2.0GQZSNXZ.]?5G?5:V^QSS?<4YGG 44!*\O(EL0]J\EOOD3
M->2/*8]M73')3160.4PHC?4&K#V[MLI83!KM(KK\IWQG%-32'6P3O;V2![C9
M4$9D.BV@AIP09PI Q,M<+ T<?#CL9'5N8Z]OPS#URS'2JZPE6&<&WI;4=@]6
MC/?B-QT."FM33X40+*13G7.Y>FOY$[-2_3W)(BZI6.W9;BM8* N45:2N'.0=
MV4&+8=!-7-N<&\^8Q+>NS=VBQV@-^*Z%U/IS5>\]K:+%:\CX'6FOI@PVP71U
M#+X09ETWV02FQ*0!3LR<G HR--A J/L$\6Q3-?03V7PM+$#1K4R*_1:];MVJ
M56Z5B0[-B(JH/;BF"*"N, 1F$+ 92N92%JXK=PUFR]S*E<L7!&E=ZE6JUKEF
MF$ !7@E:P35983EFG*9Y!.5S 8V 0%M"69^Q^2&3; U].,M@3 _L\]Q_Y";Z
MXXQ#;Y0N]2?[4@&KYF_"1N22UJ'7'Q64RH4U>NX7(I+</G<I)XL6-872?NW&
M=0\]'%!8AX$,=:._0HY"6H(-NU9[,(G)'$YL4L41.S31Q[_L8Y1#Z5F92\(<
MD\$W&EDL'2O7:$5HS?>LP5IB".25@W8I)!$GB.3<]G)&1\B=UL+K0+>)1$HB
M41:V)'^4)W]<E/WY>N:D^J2??E^<Z^H\;];J'X%5_01KSZK=D9Y 1>4<?MI'
M<!IOCUL+6W(C=.Z!#2/CL#.I]1,^0<=U'JB8C'+%CXX*(ZL'2V&$]I8.5'>3
MT(YGTBNVPQ$BFHV3U<':06Y2 48!_P 9N!$8O]\XONZ=FC-SYN_+/G[T<M"R
M;"=&Q7R%RX+1COU:@WXJE647%M\FK#-"=GMUC>Q)IH ,-PZ6[)+M_.&:P>2.
M(+;GV'LG3_8^L!L;1+1/6<>6V?RN:[R3)G[F6L4).18O(CKD=<TU70(LQH_N
M%X\,2<)O&A0=<-XF8MP1.?5WU)]V+<T;35M7]EHW9J_:LE/:"UP*Y20O<L6*
MN"88V.*N#V,H-W>/>:(G$=ZN.^S[S"/.,6=G8\J3SLK2.MY)N,'(]%Y/F>KM
M9;[G8TW$]DN) *DQWC@_AHC8T*7.YZU&PQ@0;E9=9DG:.2Z<2"/K#_!-B12"
MEB+(7G:-;>8'8]-XHQT<='9I-=U]-[7L;7FS,^OL7)N:E3[2M7DMA)3WFK5K
MTXG%8>0)#QY0A8A<^KC"),<N[]#EFDC<=VQ%"9"*KD\[)D=UZQV. /<?F:6Y
M=:S0<$):U:[=RD#4Y$S.F5]WC)-%#$)UC+I=)2R<81\ /QP-K5Z-BQ'*Q,[+
MF<.R2E2U&KL^Z^_[ A=][=TT=CW'9V(F9N?8[EJ_)F;>?17S;0' -D#HLUNM
M,(%7:UQ&.(ZCW!EB*&O++(?#;=.,*Y#$7LCE:'25[>/=D@F$UC\I-Z]U.4B$
M'B$BX+MB&RGLSC#XXZ<\N2?&V3#(>T@#^(E6U\6T-W.6$RDXH:2N.N)2<QU5
M0D615 U:!F=F(M2=IM!9GT^A-)SWM6\(<F]_GR[<9Y^68)3@JE%##)AF>P4T
M;F[Y0\=(,30%$3<H;AC*>^V[N:QOO&SA84(Y_P#( WI0X.DD=$!]D2B!<[IY
MHO<+(K&S0F2%.'^V)&/6B4\UBA'F.$0#+1SR;C6)ML9-$#;=L9(*VCAUT,=+
M5* &)M"U%GA8PT=G;BBW,2UYOKJ_@9N7:RCPYR\=.09(P"Q)#FYJ5MB PD+$
MVI X4]=HQX0N'"CWV,R-F,OH9N+ON+US,FNQ=>P/8+)HLP93N&1>9-&+B_=.
M&363A&)MNT7R[G#NEFZ3[!%6_<8=O/#*_<X_\K12;=)Q^Q=V_(^BZR"5K$$,
MXL[#-%'*+/VLT@,;,_OLQ:*\ZHLJ41*(E$4N^.OY.'OUWC^X-JV^.^IR??M^
M:R\8Z3/KIC_P!_\ ,2J0M;%>;)1%CG;>IX'O+7,LU3LP$A(X3,Q>8LT,6RR3
M4[GOB;AH^8ND^TLP*BWR+8D)(M\L7# BU;.T,K*(XWJ#DL=3RU&QCK\(SU;4
M>Y+&_)^UB$P)N821FPG&8^R Q$FYLNCV2VLSVPVT>)VKV9O28[-X:T-JE9!F
M(==THYH)XB]A/4M0')6MUI&>.Q6EEAD9Q-UY5>0/8).2<,DA!QQ_+QK<<'<.
M%5 S0J=%0J>CFV6?=)LS;<\H.BKY1MAGBC8J,/(>,<D5'680/91-I;Y]S/1)
MG*LQEAY(,G5(G>())8ZMP!UU896F<*Y[K:#Q F;?=G)XHF=A7ZH='_\ #JZ-
MLSC:\>W]3);'9R.,1N35:-K-8&S*PZ%-2DH#8RL RDSGU2S0/JS&,37KFZ4R
MX] =@EY,321L%]^%8QIJ$-W*>9EN-/"IM/"#7#/NLVH-K'U245:*.<,<D?&9
M0_GXNR53=8A2]DU&>5,/T2YVU,#YB2#%U&)GE8)H[5PQUYC",+R5Q<FY<229
M]QW8N%+HXJ[;_P#AU=&F%QU@-@JN3VRS<D9-2DLT+6%P->5QT&6]+D!K9688
MR=CZK5H#UA@*)[M/>&9O59J'4L"T7K>)ZGUD#1CL*A@O 6&')7NHKE:ZBCEZ
M0(.<K65?EBS]=T3+D5^VN_(NW+M:_=JWKZ#QN.IXFC6QU")H:M6-HX@;F_:Y
M$9D_,Y)#<I)#+V1F1$_-U^5VUVUN>VZVCRVU>TUX\CFLS:>U<LFS"+:",<->
MO$WL(*E2 (JU2O'I'!7BCB!MT&62*G+FTHB411WY$Z#5WPRU;F.V$<UG)=0;
M5:[:B4E!@HM)<O':$!V#KE8>2"3 67"OAKH#L<WGECFUQ<(O4&+A!;"Z66.9
M59]/?_?7_11K'=C1U'Y([8BDJF\\F%]WZYV_!-D&'S2!B7!!]NG8&6QY-*PH
M(%#A\,!/!9ZS; "#2C#J.*-F22TI&2@F^.$2Y5WGY<FY::=O^K_O]Q8V,]B7
MU6=C"T:7F[0,Q-/I\O+@$/T/QZB6MC.,ZB$!A:!IMJD1KE*$?2) QL P?:ZV
M/+1TV/18G-MAX-\%@1P0#CA-[GKIXNW5_'X===.?9KXM=55BW8K-;F7,S5<;
M4FHVTTT9(M'$R,9BNM(O+"@60Z8&Z62SFLM"1-H3V<$B8P?>702+[#QD3>+S
M%QBY0(N @L&#%DWGY?=U_KU_%^+352FVAQK-[#D$,G(;=\\UGL8#J^4:=DTV
MA0B&^,)7"YL^AYB1.F;,\#,LH?,FAV&LRT0DH/"Z4;6)F$G(@XGF-L,*FOO,
M_P"_O:*+C#L5^MT-D$=FE-IS<Y(7N,G99%'T=U_:5F!,EY*:4Y-V1G<_PC=Y
MML$B!D^C8O"XT[D1M47']?N7XL."8EW+PX]*KD_9\>G8[=FO+DZS ^X/-&>Q
MIKM'7F[]G:PE6S"DXQG[^,M(:[<E(I/"<2+O 0%V;CQ%Q$S0![%E_)68"L\B
M0Q&42')ZU*/DHV_CI4UU_$S,WXOZN?A6*(EV*G1D,DUSH,DV'(#9]$)U%_$^
MJ-* I@QRBW*?5?+#Q)*MIB( TV1/1RLOU''(:PR/22RJ$&6=^/?*>9HC)@P*
MKD[_ /R_B=O'IV.MH=%:E$2B+'.X?ZI-I?Y<S?\ VR3J51_EM/\ "J_Z4%#R
M/UOO?@=G]":_G10QB$)S"*#9,]N-CA"2@F,@(XY6PR'A'91J@5>XYY6O;&[5
M@HNO;*]KVQNGV[VO:U?3,Y2!!,40[\HQ2%&.FN](P.X#IX=29FT\.J^.JPQ'
M9KA.6Y"<\0S'KIN1%(+2%KX-T'=]?>6W,QQ<XI8EQ)S<19'3N,TVC*4'K=AL
MZ%QQF(:!N9!S3I2&1_6SV/JFQ<9!Z<%2.4+['=$7H(6:AS5B1R\),)M"7&!E
M\PX''1#KO J0N)%4GE(RDP<=X9Y;0R\,II+QQ1-58!,PG<A]C'J/H<F"P'$C
MER4@XWK-Z=B$+M: 8QBVCEQQUXJ11/+'!%CHYIWN.91!+783YR,)XYTIK3@H
M2MJ2=S(PU'#C4KC#@_%)9N^+J9,29/;9J+$]:2N*81<)*!D2C>KT FS7VXGJ
MXV)F'BKJ,]VS4?W9A95^UM '7:\ $91PS-'+#0E]D 4XY@MPS/-)$<\MMY*K
M418I@%AE;73>DA8RELH?<ZU8D8 EGA>:"QDX'W9),A+ =*Q7X$<X5X*+17CR
M).%>0G*#V+GNQ4@=H3AFL*A*Y/9#-@9(MF:_B]/?&NW;>72M?4NS)-(8%(%T
M(]DEI@#$]R -=ZI&[.E3QU'IJ!ECV;B%,A..1,)>61SC'.PUB(!(F<NYUH7@
MA:Y5BBLQ,\NM^2:E)9N'4B$9*\D(P'[+V$F,,3LT\=4CN ,IB+[C9:F[6+#X
M^]--5F=HM,=%7R4-.C'>F)X;45A[,;\-]^*MP/3?"X43C4CD4XC*?BG:\=S-
ML"6[X-. 3#)EO6"@5=9O(QA#(\3V' RFHWTKFAK=(RP^$-E!UP^:ZMFEDY'B
ML7LZ82QQ02^SIRM&XX^Q7D+>Q]B1K0R\>4:U@+HPP1T2<IR8]_1M=8LM7&;,
MQR0S36H-([\/$$\I5M1"XY6K$](H.K026ZAXXK%F7) P5A<.&Y>QTFCC"M?:
M'D<(W9)SIT1:5 Y=(D(T$5VI&];M1$.1CTD*@Y-' A*,R0IM=X3E30/&L(=$
MDT'C5BM@H\<B&)?&4QW:36<C%/CXHXSX4D$3S'U.6TYSO)$$D4L@31!3$(B.
M;C3.[$3.S,9!P9=+5J8F:KDYY98^L16)F@B>_#2&.LT,QQ3PQ'!*=\CL-'#U
M:ONFP/J11@?'BSI,=%\+(->>K7V0UFW>#TT;Z^81G=4(=^$Q@AN\#$M;'C#P
M0%-65=L]1&74^D "V PGFX%KMRN,;S:E&32!!D,[8ZLW52KZQUWLE+0L-I*-
M"6:U& F8:,5P!KQR>R#0F<'EW@(MK:Q6S-7K3]=&UI+::H$&3JEO0'DXJ]&6
M0HXY?9!CY2MS1: >]$XR-#NR"U<'Z1['X;\:.<=DR&/LF_(=KKY#)SMK6[N[
M/6X[:.MXCY4NT232/G3(B90$IL&?WF<7CA6.1-9@,9D'"30*]\IL97]I(V%N
MJQ2$^,>R^E*T.]:*G:GX(N)21QG!9"M6:":2.6=B-Q%R,>%E#%[(RL;]=EA%
MLP--G+(4GW:87J=?K!-(T4LD=FH=NV]F"&2&NX@)N(QEQZYK.'\%V(AJ7MG$
M73UZ6TU('S/9.V(H6=Q42]:\EXM/!"8]P*CK:3HW)1W3YXR);C,S(M6; 3:?
M@<=#.+O<=F?: C<'XS"(7X@*K3E!II&?%RUC<A*5X?8R78XS<^$3021DY2GR
MS4:VRH1C)K6(BDQTIC=OUY"@C(<U!:CW2CA:=G.''2R1B'$C>S%*VY%&6_&_
M<VE=%ZU,\:VR1:5,6>XVD1V;.4#CSO+_ %[J^5MH:'R /4<P39?"2"I6)VZ^
ML8S07;E(?Y"%F@W#%XKF\VE"_D+4>4=PA(J)35*[QC[&S;A><^(+\1V>(X3I
M#N:LX3=8!S?1F'29/&8JE)A!8YQ')#7O6FE/0Z=&<:T?!)GB'28)PR!\1V=C
MK]5D$&8GWLS"N/O"<(9CH*<[58D5S)R( "Y"*;N@#H1&&<MW5R"B[Z6*EQ@:
M1"232):EBVG)@1')O4,&Q"2W7+OFC8I@+;P3R6=DCEDK4R!HPFD 9J%@3F>"
MAC9AAW#.(P>>Y+>@$M-7&+0!=PWGV<>(V8BDABM7P-Y):\,IP92H4< V,EEX
M"L/($<T9C!0@QUB0&)MTIM9"%CX;7;%M.<&7D AD?,SB.X/"JP"68GT]O:S0
MF<Q)J: S-%8N6R+H@4-*@&FWG1>-*A9V79W>Y1T/; LV5.#I"3PS7MH!LV)(
MX)-T&EBX;TK100"V1:,) X;R/?D>DPS-)6 F;BR:@31E$$B#&[+%3K0R6H&,
MWBL-+W1I#9LGW)>22"1Y&B'&1#D2D@>.U(._P8])!XH3'%K;$#XH@9;I>*0"
M82-['9-+)/GL_8SV51X\XBT);\@-CP,$WRC,<$+L6,@;ZFCL5GKM[@9*-#EC
MC1^*&-Q;]K97;T[&7DAO36((AEBAA:I5&*6-IIWQM6Q(_&E,2*,KDLU=AW >
M/AD)&YB^FAR%3 16,97J6)2AGL3O>N%8BF>"JV6N58A>&&-Q&4<?#!:(VD,9
M>*)Q@T9BIAF=9\'EQL&A3T_"(\BW7BHZ06B&V=,3*5.[*[ YBOKD'VU7*$;!
M.\E0;31GCFUC\79,HV:CL>/$VY%F&)C-&-O/L5B<8[$COQBBXU*]!$VE;"#N
MC39Y9!TD*_P]8I2*6.66,"$I!/HY:6R[A5JE+4A87@"7J^0QMB<F>WM&>^=]
MQ@B)WB'%<366 1AEAAF,3&,X\5+Z"X8CS;!MGM *7B^>]@\:E\I:;[B31W#-
M>N]B:U%J(@(A>!O#6RD\X ?G1DE/P:K6& B4>RO8\02"(-9Y-;(YP@)^JG'+
MW.DEAA?'3$T]D:UHF>2?K(QU7ZS%7 :TC%,82_4Q>36M ?$;-!*(O>BD@?*1
MP6)QRU<2K5"MT@TAK]5*2ZW5);4AVXG:K%)%]5-HF&S3;<=^)@_6LVN8VT#O
MM,!J9O(F^0_<^LR<.QGB">R5W4>'Y!5RQJ4D'JP*%#QXR%B9DT<*%\DR9:)L
M2C.4M*]T\P5N#<IR=3DN/&[%1M!/U8GJ,TA<1@CA$&DL$1SG [;C;@3.!1%9
MW'V>"G9XF0BZ]#CVF9PR=(Z_6V&ZY0APGDEG,BBK  5H[(OQ-#D@$QG'(A31
MO!,3)W\>'[?%MH1)Q&N54G!'86L9),1[C+:;MB404D@ 5*P$-<EHHD-N4?B3
M#Y<,P6>2B6QH"(O:(HQPO[0'",ATC>Q$=IG8*UJ* FZH)"[12%#).P3.6X)@
M+2$S0PRRG]'>9)BME(YRA#(QC5GCI/O'<HSV0=[YB;<:*.>*L1P,'$*.0GC!
MRGL011OU=L=%M-<*V#,ZT6G*S>4OX[*%F[$;NJ$R4%KN8!^.1_8S()A(A,95
M$;2&$-OB VO1Q8&1'CW>4C5CS,H7.LFY9:2%W.D\;M Q1#+$SD5"Q%):@/)Q
M52DX9RL=0AI&=D@D$B;A-(X!&Y T.3&[, ,HO:=ISBG=@#*59HJ5B/#2W!B:
M<('CO >1CCIA)&8@_&>$3DE$9"M7C_J;AG,=.+3/<6V"4-V$%+%F[F"I2$6P
M<R47#;XSXP^&X.A#M9EE-8-9?6L(3MX7FMLY-!?-)9LM9CGFR5S.076@I4PG
MK2 #C8>,R:(Y_P"+@)Z&+%P+&EJP_L6:IJVK.V\H^(Q^S5G&O9R.0.M<BDD8
MJK3 !3QUG:W(4;%&6YUFIO4JS>S=[VCZ.WL'SO89PH'P!<TY8:ZDIQC"CB!B
MZ&P(6#-D2;OA%IHU'0X2-MP^=D">.\,]CAT9:)!$"(F;!B324O",ID(U2VN<
MLZ5D8Q.U%&4X.&M:>2, ;/7XY3DE>1MX>H-5/A'((G7D HA&&(F?:[FS(4WE
M(*4TP591DTMUHI#D+9G'20QQ0C&^DG=/KD;6(XC..U&8V#.>8'6'8#&]'Q;:
M')F/:W.:7DA<22CS;CV8Y"&(07UL^A^4M14G"K@S+$F&NBLI;1I1@W&O2;5N
MN[&I21>,-$Y/D*2PG6);\U3%RVH[\49C*^2#&1SQVQG:%VKL,<3E:"$I-\B$
M2=F/@M,[P[ZUU.'%P7LW#3EQDTD<D#8B3+R5I:95GL-UIWEL,%,YQ@<6 I!9
MR!IG@9I]QEF2)3/B8,)\78*>$:)>X2+?#MYN0^ AT+=Z[905CRF-J][)2[8H
MQQN*-Q!SK5B.Q L3)AFHYUXNQ0DB2V#TA9:#/!F#'+V(CR \+'B-&.2>=K+V
M"Q$?TD-8FI2SM:(N*48.PV6)XG;0=-C7L[/QG@JLL>)/C98BR,T->J5,*H9V
M5]#L7 ?(PUWI"#1#)(.]3<6F9V(M>U$,.(@.7PO8O()SQZ<G(?K,B/V9 ]8M
M0\@@,REDQV84!1?,< U<JXC#F0Q[35I":*F(-@H%C<G2UL\-V3/N2%L[9N[,
MD,]7&MDVCGMB56Q;<XK,$,%0))6*2TS2C')>X0"$^ARQ/:&/6-A5U?YG8K-:
MYEGPY2UJ4@7:M(8IJEF>S>DBK[L-%R@*:'&\:622JSQ03]2*5FE<F4,.4>N8
M-KD=J(?$"\<D*JPG9["\KBZC-4;L*(QO=4^ 0'9"BC+M(J/I"%9+AUL[XI+^
M#Q=HF]2L03>**[[$VK%HKI3!)$S'4+@RL3%6FEH5I;%5M[5]V*0F-N;\YGW7
MW-UFYO/4JM*/'#7DAE=X[P]8@<7CN5H<E:BJ7-1Y.4T0O&[\BT@%B9C8G?T#
M?R>W^HO?O^;(;_9[*O-^DGZX8[\#D_3$O6>B'ZUY?\/B_P NR]!=>;KUU*(E
M$6O/=7 T#.N0<HY+P$JQB6P9[QGV]QYGS9RDXQ$RK.9 6#"!3-[=EAFIB7B2
MS"X@HIDBLL6CJ@I/!5%6--&[_H*6>FKT(<;,Q2UJ^2J9"#1VWHN#(130BSZ>
MPEWM\6WF8)&)]/HA.//W<#%8R$N2A-H;$^,MXZ?D^[*TX,,,Q:?[\.CB3Z:F
M#BVOT,6>1'%GC= N)FC()HO7:6:@>(#,<29QTDFF6E\H>]IQ(Y>;RPRS[HF>
M)9*NLD;**(#6?@8=AWL:.9()0,KD[&7OV+]I_HDY:B#.^Y#$/*.&/7_<C#06
M=^9/J9:F1.\_%8ROB*%?'UM7C@#0I"^GFE+G+-)_QRF[D[-R%G8!T$19K_/Z
MFU_)]DZ[V\< >';$U0'GH" 2'QH:;>(!.SDXRC.&GBEF1;@RGCQ.'1S'OYH:
M1<C?%W;$+,,G;Z[J,%J>.O8J >[7M'!)/'N@^^=;B/"^\XN8[G&DY 0L6][-
MBT'24=:"2Q!:,-9ZP3QP'O&VX%CA\9MUB8"W^%'S,2<=WV+CJ6N)MX\.M!\B
MY7&)SM$%.E9A#H\9B<?D< W?O/3!5M&I"2%&# 5VZTSL> YF![TH#$/LT#/C
M#%)R/;J(=ZOA^.52R]['Q205C@:*:0)9(YZ5*X+R1B0 ;-<KS[A,)D.H;NK$
M^NJC7,73O21RV FXL0'&!P7+E0FCD(",'>I/!OBY #Z'O:.+::+]G?$'2NQ(
M%K;79Y/:3(7J&^.6N9)%]^;UB.S8XI<4J"<JY;;C>Q1FSCJQ$.NN.++2:6&E
M"R"V>9')RO;!;!!EKM>>Q8!ZSE;_ )1'+1HS5I&WM]FZI)7*L#";,0-'$# [
M>QT;DDV+J3PUX#ZPPU?Y/)'=N16(_8;COUJ.<;!N0.XD\DIN3/[+5UW([Q$X
M[12):9@@#7#8?$M 3Q;:.K N,AER[</L=RUE39S.#JCJ0+N)])W*LVE)=R8V
M"M*7B\F+JRQ57*3(,RS>V3*Y"66Y,=AREOP-6M'PXF<ZXO$[0AI&S01MP(A8
M(&B9HP:)FX;N#U#&48XJD(0,T5*;K%8.)*[#.[2:S'J;O/([S2&Y3O([R$\K
M_1&8FR5]$FO;;=^G?&/][VMEKFVI5Y4B6-H^&:^PDMY@V $ :1+"-D?%TB4=
M$1)5\'<&P_C,RT%DF;$V7:O8_6K'5.H\3^*]8ZTT3B#Z6.'P7D$W'B#O1LPD
M(FP'N@Y"Y #C(ZM!UGKFY_&>!U9Y&(VU@XG%8"!BW"W9'<A(A<PWC829C-BQ
MF#XA<=XT(X\A &O?%++BFY=.-!+LI;.43$ P( 7L8+#4Y#C)O'\D G 1!<?(
M8W,"4@ 2%--BJ;&OW P:LTDGELA(60,[&\^486OL\4.Y/NF,@$\?#W(S Q8H
MY(ACDCU)@(6,F>.&+HQC1 (-UL:[O2=I9MZ'>!XR'?XF_(!@3L<<I&!Z"YB[
M@+M0MN\)N/6ZINYV5*0,YCD_*!&,7D\OU#N7<>BCTZBHVZ_@$9V$_P!,SR"J
MSP*R3<N&[!M++ELQK195H-69ME5$L[ZF9OTX6KQ20R0"921Q6Z=.\$$A:;TE
M=KD$_ -W9G)XMS>=F(M79G5EK$4;<SV) FCG(&CDEJVK5,YHQUW8YRJ30O,#
M:NPM)O;K.["[,[LL]:XUO ]0P:-:TUC$PD'@4.&IB(U%HZR38"1+'#-1;+!!
M!/\ &HNY<K+O7[UQFL])$'+HB_<.7SIPX4@V+$]N:2S9E.:>8M^260G(R+LY
MN_@9F81%M!$6819A9F:9!!#5ACKUXPAAB'=CC!MT1;MY-[[N[N[\R)W=W=W=
MU>U85F2B)1$HBUL2/\H3OZY*?OR]<U)]4D^_+\YU]1XWZW4/P*K^@C45]<\6
M-0Z[$D@J<9%29FY;[@C@S*2B1I!R%UENV>N=D3/4B"V3:UGFO\Y&YLFT#/L%
ML<0P\.+<Y.4QB2F=2D(N>KM]*[Z/VD [K%]]IX?&[OX59!C:D D/#&1G:W&/
M%$2<*]V=[$U5N7.N\CLS1DSMN" /JPLJV(XR<? &<?4"Z=@ S.*H:U;1O)G'
MF*-PB&G/'_T5I#KXIV\&P@'E5(_)?%/M6%>.B/@W<^$Y]NCR&^NID^N]KJ[\
M]_3>_I:-KX]&60<?1#<W*D \-J[1[L8MN-4XG5MWERX'%DX?V.^6G:ZQ%MK@
M'QBVI%MQAD]:QJ!2G=L;V!')7LV$@0P^=H8[0P3O-R(XB[8O&J3V1/$L"QC!
M9FJS*&>^%R#9R167<J7#/(+@^\Y,#B["3N[>P^EU^XW)O"S<NQ1;6$QUF.V'
M5XX);D<\<MF&,!G_ (SIQB$G%VWI"9C/5G8S]F3.3N[W=;A)Q%M'6T2MQSU'
M:-M)41FR(?&%A\6?E,7#8QLJ253P;XW<8D8U@C&GH]>Z@QS'&S0 JRR$,VK)
M&G&EUUXAZ[N[KO/V,^NGY>?CUY]JR]R,7PVB[GU.&TI3L'!#3BF'"(NS5]Z+
MZ$3.[B\;-&[.#,S7N/XWZ&% 7\7':F@[2/%'NLB)$.B#:XL7K[3#.+#]4.W*
M%\;XJKZ^8PB(-(JIGV\A*$<$IMKXXLTK6M<S=]7(M?9<]7U]GKO?TMY]?'J^
MJS#0I"!1C5A:,GK$0-&.ZY4QB&J[MX7@&"%HW_W6C'3L6+Y!P;XW.XYM41"=
M:1+5)_<D(EFN9I/M?QL.)FB\1V ]4=3UBP+W:J9,'DKLNXR(DT<+.E'V(TDO
M=PY"BO!K^-)J.I.3 3$PES;5NSE_IV*-)AL>06ABK15CMPRUYIX(P"9XIW=Y
MQ8]-1>75]XFYN6Z3ZN Z2O&#6 8</$"FB# 6*9-!HUBUPLDV9,&*";5FT;I8
M_P U-!LW2312PM^+!/#'&WXK5B6S$6$6$681%F$6;DS,S:,S-X&9N3+NT54H
MB41*(I=\=?R</?KO']P;5M\=]3D^_;\UEXQTF?73'_@#_P"8E4A:V*\V6)BV
M^]& =DBM-'-SZG#;?/8-E >JBNQ(@.V.8P>H.'+/,7!W9A&3$,7C9F\<-+M!
MBOA*#1TLCW:;=;+ FGA\"NW">P92/"Y:G,XFI%#9((&"R;"1!\H\7,24^SB<
M<%"S6+RXU^2/RDB/C01BT<JNBI]\S#,4ER+I!MF1791$HBL-;:FL&X4!)'&Q
MX&A'96X*M(N?6E\>2"R1T" 2.5G&P IF1Q8F' :+0Z724JB.7<*#@$6D9AWB
MB.!DW+4FC^+]_P!W;\JJ+&=P<H:'1L;,HH1D1B*ISH2 8R(0[-%(0LZ;L4IB
M.%-WBCY[%57KMJS3D+9!41FZ<MV^+RZJR>&1-/B5UT1*(E$2B)1$HB41*(E$
M2B)1$HB416[+P%I9$I1%LG5V-I+'38"[ZR/A-V=C(UR.NZLWNJA9Q=O9SWZR
M-UT>^]QW'?4^Z[NV6"3@S0S:;W"ECDW==-[AFQ::Z/IKIIKH^GB=8;$7'KSP
M;VYQH98M[3>W>(!!O::MKIKKIJVO9JR\YOX.R*^UL0]B#;YL5Z;WS#]IA](/
M^IKQSO/1^Z _1@_KZ[SW^3V8$\D\R/,8\0R1QSP1R>Z:LZR2Q55S74Q3NOMQ
M2^&*BZJBV=L>U;-53-3*U\\\KWM'I)W-=W"1CKH[[M[371F%M=*3:Z,S,WO,
MS=C*\^B+?TW]HYCTU9M_';VFKZOIKD'TU=W=]/"^JZ/X.R*^UL0]B#;YL5=W
MS#]IA](/^IJSO/1^Z _1@_KZ?@[(K[6Q#V(-OFQ3OF'[3#Z0?]33O/1^Z _1
M@_KZ?@[(K[6Q#V(-OFQ3OF'[3#Z0?]33O/1^Z _1@_KZ?@[(K[6Q#V(-OFQ3
MOF'[3#Z0?]33O/1^Z _1@_KZ?@[(K[6Q#V(-OFQ3OF'[3#Z0?]33O/1^Z _1
M@_KZ?@[(K[6Q#V(-OFQ3OF'[3#Z0?]33O/1^Z _1@_KZ?@[(K[6Q#V(-OFQ3
MOF'[3#Z0?]33O/1^Z _1@_KZ[C[^3U)%'%W9/F(<(N[I((7=/M,XNW%T6J*;
M9LC=9QMM12Z3=NDD@@GW7<(HIII)VQPPQQM:/23N-NAA(Q'5WT&]NMJ3N[OH
MU)FU=W=W?PN[N_-7'T0M(^])M'*9:".\>-WGT%F$6U+(.^@BS"+=C,S,W)ET
M_P '9%?:V(>Q!M\V*N[YA^TP^D'_ %-6]YZ/W0'Z,']?3\'9%?:V(>Q!M\V*
M=\P_:8?2#_J:=YZ/W0'Z,']?3\'9%?:V(>Q!M\V*=\P_:8?2#_J:=YZ/W0'Z
M,']?3\'9%?:V(>Q!M\V*=\P_:8?2#_J:=YZ/W0'Z,']?3\'9%?:V(>Q!M\V*
M=\P_:8?2#_J:=YZ/W0'Z,']?3\'9%?:V(>Q!M\V*=\P_:8?2#_J:=YZ/W0'Z
M,']?3\'9%?:V(>Q!M\V*=\P_:8?2#_J:=YZ/W0'Z,']?3\'9%?:V(>Q!M\V*
M=\P_:8?2#_J:=YZ/W0'Z,']?3\'9%?:V(>Q!M\V*=\P_:8?2#_J:=YZ/W0'Z
M,']?3\'9%?:V(>Q!M\V*=\P_:8?2#_J:=YZ/W0'Z,']?3\'9%?:V(>Q!M\V*
M=\P_:8?2#_J:=YZ/W0'Z,']?3\'9%?:V(>Q!M\V*=\P_:8?2#_J:=YZ/W0'Z
M,']?3\'9%?:V(>Q!M\V*=\P_:8?2#_J:=YZ/W0'Z,']?7.M_)XF;FR-G'+XN
MXLV0P;-[+:525L@V3OEDFW1[O;67>D,,L\\L$L.Y3QOGE?'&U\K]NC=)3MKI
MA0;5]7TONVK^-]*7-^3<WY\E5^B 2TWMH9'W6W1UQK/H+=C-KD.3-J_)N7-;
M3NQ^\%&W!&#SV%MMG+[/QG$K92C(BO#TX?D,R9B$1/@5FJ<FDUGEE+(V7\(N
MX;7POEWOO.7:[N_([2;0/M#8KSO4:IU>$HMUI^/O[QN>]KPHMW37331_'JN[
MV1V5'96K;K#>>]UJ<9]]Z[5]S=C:/=W6FGWM=-==X?%IX5/^N<76I1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(M;$C_ "A._KDI^_+US4GU23[\OSG7U'C?
MK=0_ JOZ"-4:K%-2B)1$HB41*(E$2B)1$HB412[XZ_DX>_7>/[@VK;X[ZG)]
M^WYK+QCI,^NF/_ '_P Q*I"UL5YLM70"%[2U](=Q:G*\27&\+;5YB);W#[@/
M&M6X:@5B9J=PR9@Y?.W1J4N-F"YYQS#1YG%82#&ZS/.R!#7.M<HH5:AGA K#
MRK[^O@TTY_<^YS[7^Z_;X< ZTXL<K=1Q_1HF#Y[A'M2&>F#.ZP3[>Q4W'PAB
M*<_M$SB0LH['C.PGT?B0?+C4MN=G(P>M6 L',HBWSBQ]G(#2P@:Z*NK?U>+_
M (=/%X'TT_+[ZMH7H'G)K_3FN0C>_(J:')MQUX8X\@7$BY*3^?2(!OD&4F[W
MD$8"(7Y':]E3GN._Q$/+HKJ3<FJ(W+P?@JS0\?: 'X R35G=^QFYZ<FY^)NS
M_1;!N#!3<L?U-%M.\@X[L9#;D2"R^2FY),2@Z4-%HJ<WIM\'K&/.9:GM#:YH
MG)V&N(S&7[E(Y,YF^Q!OP_C&?2R1IR%PV*CZ:\OWY-[S+7>XX+\HFFD.*(Y2
M8[<FI2$ROD^]EFC)$]XY-8!J]IL3AMSAUI#BD?-1N 1>>%G"TXVG (>P2+;4
MFR3=O.79(ZRS;BUCD>*KNS[W)N?AY\^;*0_$/5VWN$:1P=L^)3;>3':D8X[&
M'>[FF&O7VU0&P7F>O=(G="3<:S+QM!?6FKGYN^P=2/(>S=@(YKM79L?=(.I<
M$#$MID?1^SEV\N?W=>S\3_B\'9MKHK4HB41*(E$2B)1$HB41*(E$2B)1%3#3
MM5@&+/D.Y[^R&/W:/=X]UAWUNU563[K'MV[K'N\+=UCV[=NW;MV[5K<S:EHX
M?*W8-WCT\;>M0[[;P<6O5EFCWAU;>'?!MYM6U;5M66>K&,UJM">NY+/#&6CZ
M/NG((EH_@?1WT=:S_.WVW_;C74N7OM?FI\]ITL_9;->AC_75[UWMMF_%?^%-
MZI/.WVW_ &XUU+E[[3Y[3I9^RV:]#'^NIWMMF_%?^%-ZI/.WVW_;C74N7OM/
MGM.EG[+9KT,?ZZG>VV;\5_X4WJD\[?;?]N-=2Y>^T^>TZ6?LMFO0Q_KJ=[;9
MOQ7_ (4WJD\[?;?]N-=2Y>^T^>TZ6?LMFO0Q_KJ=[;9OQ7_A3>J3SM]M_P!N
M-=2Y>^T^>TZ6?LMFO0Q_KJ=[;9OQ7_A3>J3SM]M_VXUU+E[[3Y[3I9^RV:]#
M'^NIWMMF_%?^%-ZI/.WVW_;C74N7OM/GM.EG[+9KT,?ZZG>VV;\5_P"%-ZI/
M.WVW_;C74N7OM/GM.EG[+9KT,?ZZG>VV;\5_X4WJD\[?;?\ ;C74N7OM/GM.
MEG[+9KT,?ZZG>VV;\5_X4WJD\[?;?]N-=2Y>^T^>TZ6?LMFO0Q_KJ=[;9OQ7
M_A3>J3SM]M_VXUU+E[[3Y[3I9^RV:]#'^NIWMMF_%?\ A3>J3SM]M_VXUU+E
M[[3Y[3I9^RV:]#'^NIWMMF_%?^%-ZI/.WVW_ &XUU+E[[3Y[3I9^RV:]#'^N
MIWMMF_%?^%-ZI/.WVW_;C74N7OM/GM.EG[+9KT,?ZZG>VV;\5_X4WJD\[?;?
M]N-=2Y>^T^>TZ6?LMFO0Q_KJ=[;9OQ7_ (4WJD\[?;?]N-=2Y>^T^>TZ6?LM
MFO0Q_KJ=[;9OQ7_A3>J3SM]M_P!N-=2Y>^T^>TZ6?LMFO0Q_KJ=[;9OQ7_A3
M>J3SM]M_VXUU+E[[3Y[3I9^RV:]#'^NIWMMF_%?^%-ZI/.WVW_;C74N7OM/G
MM.EG[+9KT,?ZZG>VV;\5_P"%-ZI/.WVW_;C74N7OM/GM.EG[+9KT,?ZZG>VV
M;\5_X4WJD\[?;?\ ;C74N7OM/GM.EG[+9KT,?ZZG>VV;\5_X4WJD\[?;?]N-
M=2Y>^T^>TZ6?LMFO0Q_KJ=[;9OQ7_A3>J3SM]M_VXUU+E[[3Y[3I9^RV:]#'
M^NIWMMF_%?\ A3>J4N..>SI/L\#(2,GN/NX&%T&3;Q>TNTP[RHSP7R[YC=9;
MN\^[O?M9=NW:M^+M5]:_P=NDW:;I.P.T&1VG?'O8QF7@I5NY]1Z@<&2F$Y<0
M7FFWSWR?0M6T;EHO-MN-G\?L_;HPX_C;EBL<LG'D:1]X97!MUV$=&T\'/FI%
MU]$+ATHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$6MB1_E"=_7)3]^7KFI/J
MDGWY?G.OJ/&_6ZA^!5?T$:HU6*:E$2B)1$HB41*(E$2B)1$HBEWQU_)P]^N\
M?W!M6WQWU.3[]OS67C'29]=,?^ /_F)5(6MBO-EK#D/93-21_8,^UMAKN<2:
M30[,\@-$PF8:.EAJ1OHSR#U)QM)B'H85MA5SKXX0F^ZH49C0?9*D4?$8BH3?
METHZ8'J@KE73P_'XM?%[RMK<?9*S('4F^'NKN/\ L%_N[1^L=VS*?Q22.M</
M(YJ-SJYZ2CPDW-7H[: O&:1B1&6*\A9L=<%2<@6@X.2N'J 23-A<<*D9N;<V
MYZ?U_OI]U9=Y"\MIAHSF%QBU0]90Q#0>TH7LPAMV9FDB+>000VR,PF*:J,-#
M5C#<&SC1J>RL1 C+0B%>.G!>:1MXT)C6XY\B]*K-JS^-M-/Z]?ZE$N']ESO#
M]&R3<?(K7C(??*?;\,QN-Q&2:_A)X9H_6@Z#36."WD>VYM #(=@;OP@>PA'C
MV-:_&N6;T^&D&*C:)H>)&Y8FG/1O!HW/Q^'L;LU[->?-O?TF:6YT@A@'94^Q
MTWLI?4&OC^PH8WW"]D&FXM Y!-=6[49Z7F@9P_FFT(VYA MCL/(^)9RR?MHW
M'WS2"S$GX6W:813*6E33LYMJ^G+[O/\ =NWP::JQ(EV3K3DMUQLK8K6&SG%K
MJ?5VV]HRM@P>P.1(N1^G)PZ@I\?%Y#'Y>1C<DR..FZ)N*E6A-,20 OVBK]T*
M)6=#&Q5<7;\;LWA\+:^%OQ?=6R:BM2B*WS<KC,:=QEA(#PD*]F<@\E(DT)OV
M[-Q))-<(;DOB$(DNIAF2+>3\;D!KP!K95QXL"DWO>^\,U\\"*X*(E$2B)1$H
MB41*(E$2B)1%0Y/^34A_49;]P<5I-I?]G-H/_),K_D)U+H?RZE^%UOTP+1W7
MXA+ZU2B)1$HBRMJ/)MB9D'<9BTY)E$2V,)4+Y,,&F$INX'W0NFH5OB.2(7%V
M*X"U'F6*6)#)OW&5G%T+UZMT1G5#,[0;AXR/:0MDLJ.Q,F7*@%0-J'L4.!PY
M,IICH\@6,;*!C#N.,37B@W":P\"YW:1I'JTM6L%2;)UGRHU6F>1\=N3[^\-?
M6<H6L=6>PT3.3P-)O,\>^LF )%) \^<-)(8B63QW #;LOXI2!KH^.1L1D+@(
MF:<I-;L%9.U=^"W<W8++8++79HK*+.<%$L/2\#M%M+A]OIZNT68V3*Y;V!S=
MO,]R8<'-"V9QNR.T$^%#-68JKT)=IJUL:CV'HS3!/*].&:2:P,D0:&Y1HVL,
M$E&KDN%%F:D=;K)6Q/JMC)T@ME5C*3C#CY(WD:/C #B/$,1 '$G[<'3B9"'N
MQ<ND,?0E.WERJ^2K]HIF\8W9759Q!?%TR9Y#P??90BZ=O\7BX[%P+R;]S:Z5
M\<KS-B(]E+^Q]O%[7;0[/P[4=+LV5F*6]5D*Y2>EQ*>R4P6Z5,\?A.+M-%9N
M7QN3XX;&-*ONB4;L3X\N^2AR<5G&T;IX_9H*X,,,@M%*TK#+DQ>.65IKF[CB
MBBAX03N%CB:NQ:LK&T["HO(GI3"8X,KM&I8$(6LJ<L.>#TB2S])X210L[8(+
M-VN3=+!4@N^709JJ()8""RKU/%'ANAW8O9?:*WE!VP"D56KEL'B)6ESG<ZY0
MBR4UZ*WD88&MX^"6"N5>*.2_/=GAJ2R0Q!B,K+<C"+;;497(4HJ[XMY6EDK7
M+([M3CQ3%7"$HH"/AS&)R,9.,(0B4HL9/9K#"3G=N.M84G'@RSUC9I<A%@A9
M,]E)4[O'LD=S3Q)>/H@._=\NW?AL'+OPI%O_ ,'-NHX1<8)MW"676CT:[%Q[
M/8>>[0&IW0V8PF4CSQ[2!UR[M';VR[BO@(=GWGXCP9##A8MM:AK:0G7EGBL!
M'6GC?6OG<J]ZT$4W%:#(VZSTVH/PHJ,6*ZWUTKK@P[\-IXX^&4GLFD$"C<I
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M/WX,C'0CQ=&D6SD-S9NK6SS69MH\H966SUW:'-R3]R8*]2&8(,$4DM\X@"&
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M3-L[%6[=XBDD_LHFLBI=SA@]M93)1!PX05RO_.4;N%T,[Y(K*X9:^GT5=/\
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M6=(+-'"*^;].ZB2P]T]?,5$\O#?YF31X1?N6]\>UWI9XX4P[62N=[Y['1_\
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M+[BQ"I5"HW*&DJ"NPCEZ;;.6J+OO7=+(8,,$LE,.]**6[FREKXW[=[7[=O\
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M?D+NVO@[6\#_ '5OIHK$HB41*(E$2B+'.X?ZI-I?Y<S?_;).I5'^6T_PJO\
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M6#DS36LRCNO)PWUK(7D$2";7, IU+HO$O$&M'\K.%SQ\8. CBJ[BV-BIH_\
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M*<BEF^Z,]J,-8D<F.CKQ&,WB&91+9"+F[34:TARG.6PWL93P(750'IDEL4\
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M(L0[IF^$8W65:.K)8K^8R%FA9JMQ!L#3S/66C@FCDBGJY*"&D D+-H153<W
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M,",CA0H3*/1Q%DS9JNF#Q%'<EG,6$+6"M,T3G-&[\*?> J["\_$CX7$B&%C
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MD<+F#L25 Q.2*U#"UF6L-"T5B*N0B36)(6B>0(7$A)I2%HW$A=BT=ENWM5F
M9'L0-&1\,9'EC8"DU=MP3<MUSU9VW6?75G;3DN"[!]BT3?Y,G>+%52Z*3V[=
M:S11;'NNVDFYOAWG-2W<Y=M/'.^5NYR[=OQ7K ^/OC4COE2MC1EE>&*X]:9J
MDDS:L\4=APX)RLXDSQB;FVZ_+DZO::)Y7A:6-YA%C*)C%Y1%]-">/7>87U;1
MW;3FW/FNPD&*K%&@6S!RF5?.6K1JR<IW:+*+OE,$FN%[.N\XIXK9JX=RHK?!
M*V.5L\L[8=O*TF+"Y6;*5,*U"S%E;UFK4JTK,;U)I)[L@151=K7!:,9CD#=D
ME<(V$M\C8&<FL*U7&O):XP%7BCDEDEC?B@P1"Y2.W#WG+<82U86<M6T9G?DJ
MI)X@8B2K' IX LB3;*NA[X429%ASQ)L\<#W5D'K!9=#)1H^:N&KE*^5E$U4K
M]O&^&2>>>SVGV1S&R4M&/*=0FAR=:6UC[V*R5/+8^Y%6MV,?::&[1FF@*6I>
MJV*MF)R:2*6-]1W" RCT,E5R0S/7XPE7D&.>&Q!+6GB(X@FCWXI@ V&2&2.0
M"T<2$NW>8F:V*YA3THB41*(E$2B)1$HB41;$N%_Y)S+_ *B:?Z:G7Z'?P,_]
MD]L/^8JO_ML2\2Z4_KCB_P "E_3NIG5]E+RQ*(H1S+DU)X[L8^.Q6UP*UDR%
M7L'DAI0DY)JFAJ&;XRL:5;'&# >%<"+.Y.$LW;.W;^$Q:629EF2=-AT>>=%!
MAX9:D1Z6SN$>LD,; P-&9;@-&SQD9R-)NPR:N(A9FAA+<$BE'0SY66*U(.M4
M*@A["61R<^(+.1O([&(A&0:RQNS$10133#ONPQOE'CIMV3[/C;WZ0!T>!S5B
M0(9JB8^HYQ;IA<GN>(]N_9/GY)T-E09#-JRF(>S]\F,?N&+G!Q@U,,4<(65H
MPTYAZJ4LE<@'0Y6;5Y-UMX@(1 3@D?4H)-T=\6(='*,G4O&79K<1=9&..<2+
M4(M=W<WG86(2(R&:-M!G#>+<)Q?5F,6:E1WEUJ62[<7TVS3F30_](TSU -.E
M(J]81,[M'7L(3V3+X2))*J7?9$!4$R5DR!-\+81HV/:/,8^<*NVRK:V27!7H
M:+7R>N475*]\X@G$IXZ5JR]."Q(#-N[IV=(7 3*:,B%Y8P$F=619JG+<>D/'
M:3K4]$9#A(89+E:NUJ:N!/[)R"OK*QD Q2")<*0W%V6?&DK#O'LL8VN4990E
MTV:'GI< >!AK9.@(^28N0QXP-8A).-;C";>Q K&GY<:+)I/P9)VU-"R0]KK"
M@D$8"]@76!<HACEBDDY2G#I)%&920FY@^X$PQF8.,H"49@9;$9@(IA]F/5R8
M9".*2,.<8RZQR& QS"P&V\<1& &Q1D[2 8M:,IW+KZ)ZA>;T=F<BFLVL18SM
M*01UHX.8$8H3:-7XXR+;LL,UGK-XP>MGJ2R>-D[-%/"5<TT,,\\<\./M3WAQ
MHQ[EQYRK/%*31N$X$0G&;D[,)"0N+L_/>;1M7T989;U:&D^0<]^JT(V&DC9S
MWX3%B$P9N9,0DQ,_B?5]&5,E&^];0O=&L-"R<NL'V#N6.3R1ZU;NFU["I3AK
M1,,[F09F2P4RP1D H2<:'<!CM)O=^&0*/!ZKKQ223;7PXRW8Q]S)P@TE7'S5
M8;CB7LX>N/(->0@?F\1R1%$YB[[DC@)L/$!WLER-6"]4QTIN%F]%8EJL[>PF
MZJP%/&):\I "09-QV;>C8R%WW#W>;1F\=?<B]>MMJ:L?NS,#)2.;1L(?<L\F
M*!Y> 3$Y SY(4@JI=UF'O)HV99CGCI%IF00:6?H-[L7+1PO3)8VUB;3TKHC'
M9"*O-)$Q;SQ-:KQV8@-V;=XG!FC(Q%R8'+<=]\29JX_(5LG6:Y4(CKG+/%'(
M0[K2/6GDKR$#.^NYQ8I!$G9MYAWF;=<7?+]0%-6!]D\B(-K*<1S7!$9-9/-)
M'&#$X2 0:*OI._&P@!((U%S,L)-VN2:N0L>:EH1LX0%X$R^+=9V2L+N,&D'C
M;9U,59N5I;@'7AKPSQUGELSC")V98IIHX <M6WRC@D=G/<#5A#?WS$7U]K)U
MZEB*J06)9Y89+#1UX2F(8(I(83F)AY[HR3QL[ QGHY'N;@$39XK6+8+$0W=T
M%*[3RTZVM*$9KA&IE++(%87*0(QR&@D@B$9D#H66.B1K,ZA@5G$?P8/@.9,6
M307778OUL&^=3CQUD*7=!^"];C5X-0L0R&TEF*Q-$QA&9E&^Y6EWAEW#!V9B
M%M5""_7.X]%N,UAHIIM#@FC!XZ\D$4C@<@",C,=B-A*/? V=W$G9E7=5[,BN
MY->1/:$(6?.(G-!6!D$L3'.1)!1BHJJCCD[&O,<';);NT<[9-W.&"R?:[2F&
M&7;QMCNTYL?:GIV6%IZYO'(P&QBQ,S/[$Q]B3:.W-N3^!9*=N&]5AMUW)X9P
MWXW,7 G'5V]D!<Q?EV/S;PK(%15)2B)1%K2E?A%S,E\$NC9UXS,>#7<8YY-[
M./"G/>;KXI98*9(V4[FZN*>6.=\.ZMAE;+M7MS4GU0_OR_.=?46.U[FT--->
MHU=->S7@!IK[RT;(=C^Y>FM)\D-8S_8G&^13KDT0M+-D;OQ#[.RG<BEHF3!2
M\*%.D'+CQ.(UQ" (C")16'A&J+./B,>^,4[D2!9^\S\:/>!V$V&-M!#4=&9Q
M=G?L^F)^9$_:_P")<[W"RAT\A6GL4))LB7%L7.'8X\DHR 4(NSEN#7@C#A10
M@S" ?2^R(R*>]M6\D9T-$2+9^RP4/V-KXR6.00-H60SJ-:GFJJH\8J)$[Q"R
M-(F<E<?1.C;X.QP=Z-OXC?DD6ZWA;ONT\6]&W(1=Q+3>W]')M'Y[CMIH[L_Y
M=%O.K7YA"2S8".> R.$*1S159M1'="X$F\<H,8\Q A]@1,W-]5$2#\+^6X33
MFW8C/)CQ>VML3=DS;G]Q2:<1C:1-GO0"1CTCCY6-SEVD<9/(6,B"2\+QU>$U
MZ,:1@ "C1&.*!<,Y$\.IY'EC<@=FD$0'069Q]@[::./+F[\]YRU=W?77DS+5
MPXG*!4M132XVU8MRL=N2>*RXW8R"0"CG=CWH1A9X>K! +11A&4?#;B.;='7G
M8U-GPG8^HGQ?=X.<P&*R#BYL_8Q8Z ,([.D^TN+6E#NG0"(9Q@3=!$8A+L'<
M>D!9<NL[D W(&[&64,JFEBS:I6!<29@W7=I!%F?V+#(;&^OA=VT=F;DW/7EI
MHK:^S]F&Q5([@S0Q'C;,YF!M9DM8VF=0-Q]YP:*76.0]]RD'<<-3<W-IZZ!T
M6^TS*^2YQ<F(>#=W[WPVO'1@AFLSQC(1+3VI=9H@7B>>.#?)RB[UR\?)W8XV
M:)L7[-#"UE$E<;83/>:-M.8!N/[_ +,RU_\ ]M/Q+=4:3U),@;D)#<O=: 19
MVX8=5JUV!_!JSUW+ERT)F\#J2=8UL$HB41*(E$2B*7?'7\G#WZ[Q_<&U;?'?
M4Y/OV_-9>,=)GUTQ_P" /_F)5(6MBO-E$S9_)L_%]C2G5VJ=%SG?$JUO H[L
MK9S>*2"$QA&-@)@\E32(1T&M,C8K&7;*E6$(E#X/$F=V MJP8,G$HE4;\H8W
M@7*K-KX6;5]/W][GS_U5F(=D$T)D9W/$2A5>)SW4"QQ'*%S>]HD3DRH'CO%>
M2SYFB^+)I!X\;;0"1$'3^,R)^QD@YC#I=(G GR="O"21-'_?GX=/![ZO];F%
MQ3?DY3$#>X=>MR40$2PO-AYY[@@% (Z^%MI!.F90Z2;)1C,K# ;EK(I &3)*
MEAD=7:R1RQ3".$'^=I")LXF(F+]HDS$S_=9]662*2: QE@DDAE'Z22(RCD'>
M9Q]B0.Q-JSNVK/S9W991U#M/5.U@!5_J0V-*B(O('$4/CF8@C''\7DJ8P3(5
M 1Z,&1H8U'RBP.1 I"@S*"F2ST(>#FVN*XTJQ=N   "P@(@+=@@+"+:\WT9F
M9FY\TGFGL2%-9FEGF/3>EFD.60M&T;60W(BT9F9M7?DS,W)1QF_/S24!OO4>
M>(L&TLT;NB!:6=P5>61)E,IF4V "TH=%R"*1]X70).@C='=0Y!?)5MBX56C1
M^[=-3!-"ZERQZ/IKIR7>TOS=@F_YNUU[J^*R*0R(,9V2TV_DB[#>)]'B(+L/
M8&LX^\GY5-ZJGC(]K']?$2&O(&)2?2=U%<G$M/M0(!J@_($TT;7[FGO_ '/N
M>%36HJ)1%%[D_P ; G)AOI$%*FL?+0[7&\A&U);&I(S7?,94&%:\V5$D@J*2
M/\S%YB8FHHNDHYOBWLD*7QO?ON:5KE5GTU^Y_JRBC$.!<QX_;7,[JXU+:D%D
MT-D;K=1K5<H0DT?@2NH-]ZYXGA9C&%I!'F!TI%IF.V5Q1B,U%'V<:E(MR%?&
MHVZ%(.35C08J[VK:/[W/WVUT_J=V[??U\"R(ST/RZAD[2WK'=BZ3V-NB=:H0
MU5N ?/(_*(1K]JRC.T-I;,U$[UPI#$#AOQ5J9#<<R@3H))6N9S:8!M'#QN<Q
M:2,2*Y4J<NSL_K\#:^+Q?B4W8 'E4>@T/!3F89;"FH>,A!LNG=P(R+6F$E9C
MFZ!R2IQD-;Q5'D31+!R00",,UFPI%=-BFY<V0\(5*BNZB)1$HB41*(E$2B*A
MR?\ )J0_J,M^X.*TFTO^SFT'_DF5_P A.I=#^74OPNM^F!:.Z_$)?6J41*(E
M$2B)1$HB41*(N=JK9!RW7RM?*R*Z2M\;?\[V34QSO:W;_%V[VMVK=NL]65H+
M-><F<AAGBE)FTU=HY!-V;7EJ[-HVO+562#OQF#/HY@0L[^#>%VU_K6>G&]2;
MO8=I&M99*+-I,5D3$&P'!!KRR[MD18L7)!R.:M,BA)HB^OAX:1=.U\<<E[X+
M7R5SOG[U/TZY*UTA-M%,TT>RM;:7+;0TL'0QV$QESCW*.1H4;-^QCJU4LGDJ
MD-YPZ[D;5N=A*;<G<I"<N/#9&"+"/1!Q+(R4*U&:W-/;GBW(I8)90ACGDD:O
M!(46O"@CB!W8-1T%M*I&-VAQ2P!^6:2=X5"@HJ,5>I$<E<22P&32,T\P>-U2
M2"#K!XT+L6K)^03?KC,F;BS=G:SJRR>SV7Z;<-BIL#?RU3::YE<-@MEL;+<B
MR!2AD9L!M-M%FK8W*\N2KPVAN5,O2JT[^0COSXTJE@8*>EEI@CY#9.S8"[!6
MDH15K=S(V!B*!A> ;F/H5(GB,8#.-XI:LTDL$!0A8:4-^7Z'N$;;M M1 =LH
M$*E'88Z')LVSM5LP9)-Q,MSD/>%%QBZ*))NNS459M1Q@*^S%O7&9!(NZ[RDA
M>L'3;@:V(P]:3"Y7)V\-G,1DJE>U)6HTXZ^*VLDV@X$LV-GBBR=::G))4K8[
M+X:Z>-NV#OQY>SP887J>RER2S:D&W7K1VJ=J"4X@.:4I+.-&EOB%@2*O($HC
M+)/5MPM8AC& JT6^9JQYY.@,TD,:7<(G% (C') ADO9BD:<,W9ET3>-FF=EW
MEL>]I.LTVJCU^ZMX4HNXP2:H*8LT^&V\VYP&VFT6S=B>'.28'$B\&0*<:,6;
ML4[69M9.[6J&UBXP[D5HXJLEV_:9K4D]@8ZT$@TH]KA\1<Q5*^ %4&Y9??A8
M'F*H$L=6.O$<C;D6NI1B4@Q0QZQB .4AB\I4G94I RHH/7C38J-##1V(P<%?
MIL$6@9DBNJJBS&XL<U,E,,\UEG3UV]45?/7ZZ[IPKGDI^+5=)6U& VHRF/GV
M:KY7'8?'8X<9C\+D(J$-7#4H9I)8*>-&C),4H&<TUJ[<NRRWKMZ>>S8E,I.4
MG!8^YCZ\P7Y*\]J>=[$]J%YBDM2D B4L[RL+"[, QQ11",,,(!& LPK'%><+
M>)1$HB41*(E$2B)1$HBV)<+_ ,DYE_U$T_TU.OT._@9_[)[8?\Q5?_;8EXET
MI_7'%_@4OZ=U,ZOLI>6+C62P7150SNI;!9/-+.Z2JJ"ML%,;X97370S3614M
M:]^X514P53R[6:>>.=K96JSZ.S\N3Z\V9VY>-GU9V]YV=G\*H[:L[/X6=N3Z
M/S\3MS;[JTB;HT;$9"]&\9B<BE05/4[!.1L"QTY*C#!48Y:JCHV_082B0/(B
MZP?Y+/I0]QA8T,:&VB;^(C\R\Z)A"C;T/'Y&>(3S 10R==+@D$44,9L;/OS
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M.T];>JCO31]1E$6WX6=YF=RW=\"D_P (.*,_XVV-*S,G"&J3W66L]>XQG7!
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M?"8?EIY-R+] &NJWW\"GS-;1^Y_-^BK_ *A.OT?+:GPF'Y:>3<B_0!KJM]_
MI\S6T?N?S?HJ_P"H3K]'RVI\)A^6GDW(OT :ZK??P*?,UM'[G\WZ*O\ J$Z_
M1\MJ?"8?EIY-R+] &NJWW\"GS-;1^Y_-^BK_ *A.OT?+:GPF'Y:>3<B_0!KJ
MM]_ I\S6T?N?S?HJ_P"H3K]'RVI\)A^6GDW(OT :ZK??P*?,UM'[G\WZ*O\
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MDY;XN7%[7MW+=#OB^=\L<<$\LLK6OK,IFL1@Z_6\SE,?BJVNC39"W!4C(OL
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M2C% 5N37<SBQ&(;3T^]<%$'0I!:5 'C4Y&\BK582K.HA$6IKO8-P3SM5O?\
MR^%O?5'_ '^YX?ZE_-&6<; UC)RPA;*5:_EH$WBW-AE<2<8-!ST?(]^3:%16
M=F3ID0"DT>[P:O&Z:S!VE^)-)3#\4[1G9M=']_M_&W;_ (K!SY^#Q^!>HOLF
MG91=0<K^(NE^+>ECL^W+N+=D;U^<V$SUN+>AWC2:M1(U<=KZ1 4!+A,X2-3]
M>Q,I$XQD4099QELP1RLJ4%%!\< <2<G9A9O'V?E]Y9'+5F9G=W\/@\'Q^!;B
M^PX<%#O!KBDB$V(W0;;FVT=ML79;!%5%UY+Y*#FPZ,02[UMGFW>+1H2CFY*J
MH9+-DY*;/MF3M\.09O%K)"8BU;L;DRN%M&YK;-6-7)1$HBBIRX.\=1L)@X+D
MCJ%AO..SO9HN)0;6[S3C3>2IG8UHG,Y0P6&PEX&.(8/Q\4C,P>6-7:)9,6:3
MQ#%SAX9WM8JMKX/\=%C;48/L?6P(M 4(=I30,/0A6SI@$@&N9GHR%:NENO=Q
MQ\D(>3-C%]=RJ*@C$;G"+T?&SCPC&AF#@PT3C,F8D2(Q8*34([OXW_+VJ]6'
M'S@*"'['&"](<0 XI.PP%MT>PUKI<>/3Q\<,388-L=JW"HM\;>4#$87&#Y,G
M:WCAFQ(-4?#6[=7 FK\NW7P=O]2NB)8\54@,9; XQIF(@R9P) 8$(=1J#Q1J
M?=Z&GQ9UKP?!1:C5FB9%P6;7>RW55P"*[4*]*HRJ)8,G!3!XL3G[_P#\_&J/
M)-<<-2TD;ER>GM 3F:1J;,(FL\8:SUS,I="99L&<%I6IXV60#OC,46+SR3R&
M;FW;O-DHM(#9^5OKJDGY%\L35_&ZS#J4?JP+%G@34#V,NXLPETX?/THH99&Q
M[&8RR7&9Q.$'"S!V[29$G,KDQ8H^%WR1\7JD/!TFK5MB@C@5%DZB)1$HB41*
M(J')_P FI#^HRW[@XK2;2_[.;0?^297_ "$ZET/Y=2_"ZWZ8%H[K\0E]:I1$
MHB41*(E$2B)1$HB[3'+'%\SRSOCCABZ;Y9997M;''&RV%\KY7O\ BMC:W;O>
M]_Q6M_SJ50(1O4R-Q$!M5R(B=F$1:8')R=^3"S:N[OR9N;K',SO%*PZN[QFS
M,W:[[KZ::<]=>S13/+;5C!'9R(3)TN1&,)\<+^4ATX)7$,1Z(0Z.3%1ARV;)
M8M 9+-VDK;)P0<X9Y-V5DD\E/^)7V?D^E39G)=)L.#*S-D<;1V\SN6;:/.YK
M$3XBC0APF=Q\>+V9LUZL35,+D9+4,C//?L 15Z0Q 4GT1>6UMG;\& *VT0P6
M)L-4K=0J4[(6I9BMU)RL7P.0GEMUQB(=!@!V:29R)A]BK,BT;U27>A"9%O#F
M+!]'(HN>"*R<@E@,?$)+(1IIRQR(3@0\:YM! T8Z>8.RIITPS)-7+6/$4W>"
M:7&[+;-]%&8NX3)Y"OLA1HWMG-E)L[A)=IK\88R[?VDVAQN:LT2R&VV(MUCJ
MXG&8VU<&UE,S:H'D:UBKL_D N1Q1[7(7MHZT5NO">4FFBO9(*5H<? 3V(8,?
M1L5 F:#$68I&ELSV(HBBKU(Y^KRA)=@*-R+@;Q'4BT="*O'H87DE(A#0T1R/
MIOBI!@O+51Y+)CX%*5\6?@X++!XNB[A39-LS;^,$#3RZV%G&"#9'HDEV=PDM
MV[AL6\6T.(JYC(EGPNY7(T)MKI<=DRI]2VHF:IU?!D%N>&UL56BK4Z_="OFK
MA3 -B^3);2!>MC%#:L,5&S)5@:D4->"<,8,\#2\7'"\O$N,4(%'EI'DE/@G4
MAW"<+0FPF-#)K#T(1XC%O55VZCKPDF((1=H\P/+X"GKM9:53=H@SR8IMERB!
M,NLBHAAX9DP:H/+LT^/VVQ.S6,VUV/@V);"8N[)8KR6NLY/$Y#9>K<#/3!BK
MEN:7:K;:M!4*E'6GRD.2RTL,L -;.A6AN%3#98JS?L8K)GEFMV(F"08VCKV8
M<C)$],'LQ1 .-Q$ARM,\@5SKUA(3?A--(<7%+YW@Z46,@6BA<;)<A891DI+&
MAD$8>2-?(D\>N'KNP-Z]Q&,FZCN[$$,?9V>MQ+9O=6V&6=T$+>G"U)-F<#4D
MRV-VE/%X:2E)M75S&#RUS:.<LE<NV+EL<)=NCC*5>2V]+!XV])UVOBJ\#R[K
MF\,-VRD;#5MRM5GQ[6;;3#C9*MRM%1!H(8@BC>Y#$]B4QB::Y8B9XCLR&PZL
M.^>$:\175)1$HB41*(E$2B)1$HBV)<+_ ,DYE_U$T_TU.OT._@9_[)[8?\Q5
M?_;8EXETI_7'%_@4OZ=U,ZOLI>6)1$HB41*(H%=DKUT4V+Q&V D%06=$8:Z"
M3[%HAC?+-PPCCW_X[EW-OQWQ8Q]X5*96[5[Y> ]S:W;O:]O(>G+ 6-H>CG+P
MU!([&.EJ9<(Q;5SCI2_QOEX>'3EL3:>%XF9N;KZ _@Q[25=FNF'9T[IQQ5LU
M%>V>>:1V88[&2@_B#:OV//D8:E5GU;3CZOR9V?5N-OFJ(T#-X])M$".1KK0@
MJ%C2>UY3-8!+&J!8=(('%W;6%+AU(.3?8:^=#QL2EYB1HLI&FX:2!S'U4<QS
MEQ\^C$80;'Y2I?V0K;<ELA7Q,$^T>2RN'R,8V8;V&H2!BBK%B;$PX:2"OCLE
M:NA'=WPN242'@F7U5:=AN](.!R6+V^N=&D72!:S=JILCB<)M#B99*=K'9_+1
M2YR.X.=JUWVBBL6<QAZ>-.;&E'-CHLB!M9BCPV@^CK34Y_6O)B6Z?E;;7<#E
M0'6^(E8]YP6K]C#/#+!];H+LH^R2,QIC+<G8\VQD+LO#F;/)=]'Y)@V098+<
MD$M*/9R[@=O<ELQD8\)A\E3P;5CN-MIL_G*[2]5P0'#2B&U0AR3R0VXKLEK&
M11N<M*^T81,?;209*;:['[3]%V'VSQ$NTFT&)R&TKW H=[O:K9JUP>N;321S
MY"<Z63L8=H;%&?&PT\U--PX,CC"E.=X[MY9;BU+R7*RZ,"Y^)CI#6SL;(-2R
M:V)@7 ]HC2D+B;>81V1(YC\+"-@BC Q=&-S$DQ:M#8EIY+F'B"3$$_OL.DG:
M;9G;ZSD\?#EZM27!2P7=F[SC9@PVT,%G%8V/*4KP/"+5LU7LP&-'*6(8X[=:
M/N?:EC&&G,M3T0;&;8=%U+$9.WL]<R5;:>&SCMK\9K3M;0;*6JF;R\F%R6-D
M&P3W-G;=*U&>3PM:Q++1MS=U:4!G8R%=]L78TM!&=+:"1.S!LJSFVU7365DF
M+C#O;H1'$6V:,1#NL+VME@ZLR<O#;E-2V"S5<[FP<)X+LU+7^AOX/^P!;&;(
MR9"[!P,SM5+!DKD9#NR5Z,,1!BJLC=N^,4T]PQ+0HCO% 8L43KY$_A.](-+;
M?I#EHX:49L'LI'+B:T\;[T5S)$8OF+D1-R*)YH8:,1BY!+'0&Q&3A,*V)5[N
MOG!*(E$2B)1$HB410:-?TR6_6;_]Z5K;!](/WH_X,O/)_J\W\[)^>ZT=Z$['
M/G+2&AWV_P 0\O'N.>K.3V@'T<PDFPH/(I9*)!R3!2^#[9#'825CF1B'2R 1
MMT?72<&E,<R<M:(/1=RP=Y89B&)GW=[L$2'3FVKN3.Q<O [-K^/L;P;.?(;K
M3- [,5B6M.Q;L9B(C6(#B(38M#$R9M6;L!W9]';6Y-B< MZ2#:L[,CIS"&FI
M37*;9?*Q@YC^<@1W>D7V+PR.<97<4",WJ0R$-'\<,NFTDCA9W+&Z)FSNV)%Q
M%\A%KE:D!.[\VW=]SY?3:N&YIST;\K_D5L=Z$8@9P-Y6K1U78MW@Z1W!L[Y.
MVINQ,VZXL'+P;VO*!/'+A#R2V./FC$?IC6.DA873_!O6[AEL/1F.KA>S'N@Y
MAM@K.>[8S"*[94&;0=AB<0(O]S (?+!0TH[;QZ&'3BHE6<8XQC)V^E8688VY
MMIKNN[OVL7/L]EH_O:]JFV+E>,HW>:29WENR:A-Q'C:P$+!S XF>-B$VX+F#
MNWLC$==Q2' ]AYFS76JT8D$FTV8F(?COJG3>OY2L).O5(6>UYS+VOR->R "^
M( E2H!H2A4VCD9:7%J^,6YD0Z:*J9B$FK]S=P7T_W=6%A9_$[&Y:MRU;D_\
M4L!94'D8A&5@>Q),8L3-OB=2&NPDS%H6AQD3Z\M'\>K+9UQ(@4JBQ3EC-9,'
M(QQ#=/+?8>P(H"*MU&3U")1V%ZVTL--J,%L<56J,W=:F(3L9=3!-1X$DPH@H
MG@HZRM?,+.V^[\MXW=F^XPCK^/=U]]M'6NM2";50%V+@U8XR=OLB.29VU\+@
MTK _B<793"JY1$HB41*(E$2B*2&E/Z%,?K3#]T2J#:^G'[W_ %==5@/Y//\
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MXWE)G+V#.PZ:NQ.[:N[-N\Q;GH^KZ:Z<M>;K9!CX)!K;MB83LD7#CEK@!<,
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MSZK&42]H!9BY",:A,T6! ,S>X**KH87L052MGDW:XK=S@1=^0\:;B>-8K9N
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MRDST:JJQ\(QBC]B*=I#7=WN;KP<\I=M:^3%%0GB165I_4L5GD<VGFZ5S6EK
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MM\(^]U$3RC-] 91^WPC[W41/*,WT!E'[?"/O=1$\HS?0&4?M\(^]U$3RC-]
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M3L4SKRR1/+7F>)M93JS#9A =\(V+C1;T4@N1BVL1R-S6Q"5C$2W3#>^E:0'
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M,7+2A [8QDX0=Q H%8C'3X#)QF*A$>530[Q;&V>=[[;9\<O7EMYG$3M7EPD
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MKWU;'_PJ(GFP\>?0UKWU;'_PJ(GFP\>?0UKWU;'_ ,*B)YL/'GT-:]]6Q_\
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7K(71*.,LLDF:3JRF"=L'."5UTEB+_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g358845g30j99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g30j99.jpg
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MI.3$E$=!O28@A1'2YB,:]SGL:\,<]Q;:,&5K+TR41*(E$7J!787Q=5+Y@?\
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MU"3T4JO'?*# FIGD1RI@R37OF(F1)X"'"K>180@N=,P88&)?&EA%A,:,7.>
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M")XS^)/G;^4GZP2?X%D[A3\//A'[')+^K4S^)3-63=A$\9_$GSM_*3]8)/\
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M?R;=3 Y)9LRXT1W9'&W3"(?6\ZTHNGA.=NGH_'VKS8$!,Z\E&R'0TW,MHP$
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MM_\ =U%F+HH>CH'1H4<ZR?:+[Z!:-:FHZ10GL) H2,2-*^=N'^LK3".SZVD
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MJ ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J
M;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N
M7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7W
MGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ
M7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7Y
MU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1
MO*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*
M9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9D
MEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEM
MK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'
MWP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP
M_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_3
M3K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K
M;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D
M/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J
M ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;
MN7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7
MWGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WG
MZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7
MYU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU
M1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O
M*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9
MDEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DE
MMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK
M'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'W
MP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_
M33K;D/J ;N7WGZ7YU1O*9DEMK'WP_33K;D/J ;N7WGZ7YU1O*9DEMK'WP_37
M!R#_ +>-_P#JY+_[BU8G_3=_M._F5TI7_1I?_J(7^[:JP<O") /Q.Y/EQ#]X
M+*B^.^ZB(PF.=+L2 X@QUM)7+)^P>MLTG+-XS<I).&KINJFNW73P52SP4PQR
MM TCXC^:M&-(,4C B%$((Z/8*H.=G/,]OLC0U\06JF<L^YKRAE>M8Y%MC[ G
M G8TYC2?&5\#';#%G8-KI!DX?9N\@PPPS>R!V*6DYIVE]'%/),G?V:FMK%P!
MT?ZVC[UK.='M0L&6KF*Y@#W.#W 0R X%K:5T ^U2I./3]4N<DWV87UM)XCMK
M3>BM%[P7Y#%]63W;D07=D"$1T1&M2CK.'2)/8$-')D#>R2.VR3C%5;!)SJR.
M,'(JS8FM8]@L@5%*D4K]_9T4TXJ><.>6EKV0X<2]+'O;C2&(8Z7M )>7X'_"
M.O%<CK/Y0?D-L+9.MAY77D>@K(^?XG1HYKDZKKL21>L^0&F]6[*FTG'OI9O&
M.;BN0AA6?RD;%Q,;T%+@9)OJ:3!S9S \^D*VL9<QH!H:G'17"A/Q'1TFJADS
M$<Y@+0VI@@L-D&D2&Q[C5T0/]DN< !#(-@@FI-CAR7++E+$HWQ\Y&2O84+E#
MN?\  'EIR!&Z8CT+?Q&'&)(!PXAF8H%>H$=FO%Y.8A(^42V:/#^#H4^:PP?L
M4:/1!BBK\V)DM&+::'@5QZ 37KIT??55,:,UL.*7-<72\:((8:6M)%R6C%_M
M%H+G5P-D/ H"2)D@/*WDSL:10C6(F0ZW"O97R"1UHIL\C&]<S1ZWBZW%G:>]
MB+%:&Z9Y&;-A3*7,CD'!?8Q!UL7%)2&2X4Y*0]P[8Y/I#!:P FA[-(Z>T ]A
M-/@KMC17EK 6BL2S;+6NPNGQ#[,.*YM:M%#;^B<6U&.DB//+=!&7<<KRXEK<
M?&)^"X]C)FRB,?"FBZDYVWL>1ZS).2T3/;ECVT(M%Y,7'B.K0SKZ(;E$QIXE
M)\MF/<@XET_%S8;C0$Z:8T^'9]W2H;,/+H5HM <(5: $ESW%IP+P]H)H6EH>
M!C:P!ISVMN:NUF^NX82;R#547SB,.XE?96DS8J0F9YORV]RXP2>>P>0G=AJR
M1N@W5(/HE!%$1<R<83>(2->7OC Q7!@,%H)Q!QKB#HH,.S'_ (*&QWV6FK&V
M6P/8(<YT6\I6R2ZN%2UOTC::2ZHP5G>.G(/>TTVAK ?L4WKXM#]SQ?EJ8% 8
MU!RL<+0AQQUWA!]=1CZ4C>30^G)<9/&Y:\=2;!<&*L@99CU UVC/!XW?5+6T
M=08MLXUTU!JLL*)$<YH>6D/$8@!I!;=1&M&-HVJAV. QI3IKZ.5C6TE$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB414IV TE(KF]Q^*Y['F[B)R35/(%K;62*P]M!AKF-(ZI<82*PL8*
M2+R.4.UBCK#![(B9I 2RQP8Q@8'S?GEC=P?9(ITC[\="P.J(\,VG4+(GL_X<
M+&- *DX])/8!C6"^'<GCEN1TPCVMMGO]IZFF''#7&PXR;QVM,=IE'IAE+I .
M/3K=C29XM,M9;8V)E(6J V+QX,%9D1T$E+0LP9N(8," I?6F.!M:*#"HT"E<
M!\5C@.%ZX,<7L=#:\&VYYK4@N?:^@]U?H@ $--0"V@TAP[&Y_K6;2'9>R48K
M/ICRDY6QO7L7G&W-@:;U.6):%EFPM*0B,S"905/$P)"BM9:WMN$9&&10:D;F
M;PO-V+1\2;6-#9.% ,6V6U- 3CII\>GIHH)#F.+GT<8T8-#GNAL_LW.AM!<W
M$ ,9; !%7$N'6.\CF^]A.N$.@EX%;86PMT3/4VB1LO.L!(>8;3@X6;Q-^W+<
MA9-"T7F692Y?&&R\E!'"C)<#+YRJ'0>X81S&1NQ<$"V>AM:BN@[U81'<WAV;
M3HCF0ZF@<]H<,8I;7&MEQ;7!SJ X5I'/%W8DGOJ;Y,.38/MAN"FP2,VT1.4]
MANRSD_*8KCHK;FU>F)NY-V[7-EF,PT=$LA4M)**/,1<CDS5NX2RDKEN[EV-O
M13!V'0<!3KQZ/\U2"\V)0U?5Q=#=;TN AO?4]9#H8H[J)I@<?6^L2W4HB41*
M(E$2B)1$HB41*(E$2B)1%0\?'I[GS)W[',-U;$30F'&/7)N+6RPBC@3J-T0V
M1MH"DOKZ+.HVO&E2*#8:V?NC,U&2\F:*8IIFG#Z/, \=&9*BR,!@[$=>'2M:
MCK^(V\<*P6$:"&$O>/9:19Z-+@XDZ:@ #7Z F\M@7R?Q:?8$9!L:9:[A?(D\
M.?2\DZD$DEQ6!S+9ZX5,X24OBZ)/B689DU<*862NI?/Z#=-'"R:>$.^G]X_H
MHA.<V5+ZE[FMBD%Q)+BUSZ5.DUHJL;$*:U:'>/NI@?(>16Y%$];<?92XFLKW
MRO"8/JF'HRY>42K;C@ F>C[&?[0Y$$5)*"2A3II+E9Y@V8M#C*,:Q%%EGMZG
M$TPJ= ^E3#'3_3MZ%B?8!A,$4WI;#-IT2C6"U4OI46XD4U :;5J@J&M!KO?E
M&YT1/'XR#U_M>(QEK']!\NI&[)27=<HU1"&>P(2^U?'1QT#)==F&CX]N[3)B
MYW$="#BS8,(:R"0NS+L.8;#%DX8*"I!Q(QIC3^@/7Y*9IQ):&O I#C.J8CF-
MM-+!4%AQB0S6C3@*FM"K=:4FQ@CR"EP--:3*1J<\8^.F]'8F5H6:'HO.)*_V
M/!BBID;A?)N!(2Z-0>+(/8^/LV%L3T%DCYJWR>%"BZE7##M#B,.K3_PQHL\-
MQ,1VFRZ%"B8Z0XVVFHZ"X-;@#2K30:2KH519THB41*(E$2B)1%)I?7LJ=EBC
MI!BEDBY(O7".5WK3&^22SE51/*^.2ULL;WPRM?Z.5K7M_P!5[6O69T)Y<XBE
M"2=/65R(&5)-D""QT1P<R%#:X7;S1S6 $5 H<1T8+4KZNE#I!9JZ$M'+9RDH
M@X;KNAZR"Z"V%TU45DE%<DU4E4\LL%$\\<L,\,KXY6OC>]JBY?V;UESM([1W
MAOX5H))H^1R,*1$?5O +AZ'(A6<AC98:,DL?0)H)HK.8Z5O9QD+>)W0;+HJ8
M(J)67:-<U4%<4<,+2(40=1ZZG _%0<JR)!%Z\5!%1#>"*](-G2HO%<)(8&3U
M$U9P-DH/T?"3&O\ 7PLD50,#V,>.=#<G]R:)9R]R.F,W$#CK[$Z64=%KDD79
M)5VJ^?.7&<W<3$X8]1INHJ#*.3A=T>ZD-I:P&'$( -G35N)]D&IJ:XZ<5,"N
MF2BY=J?7BX58ZQ:K,F)M7$.H79LW-[W<-&I+.]WC=JO>][K((K8)*WO>^>&5
MZK=1-&%/BKYUD*@WAJ-!NGU%>HV5_>IHK_PO_P#S ;_@=E+!?]!'_"+*M%&"
MMA?^O_#[*,5562GHGU7TVBBC?+YT<\L+S=1/VY,ZR&']H<-']D_#HP]G#!?
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M)RIW#"-80B2&MCB(N;@<:=+AY81GT:BDG.A)!.PT9>MP"%DW%B38E#4CJK_
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M12\ Q\O2^?V;DS3([-WB1.).LF7]HI> 8^7I?/[-R9ID=F[Q(G$G63+^T4O
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MV@'[U[Y&EP=8;BISW+;*/NA^HG5(?[0#]Z]\C2X.L-Q3/<MLH^Z'ZB=4A_M
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MNQ-4F3YH1MB/V8:^:1?IO(\SWV7-V9>,EH#)8\+8Q]>#HB'9YH:)7L"XN/\
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MHHA#LUA)N-B2JRS7')VB@P?DD'*ZK6WI2:2>>;:]EK87L::.!/05>*TOA1&
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MZF&(UE-00:$?XB.F@LBFD==<>A4L/9#8"V(&BX86A^)=?1+8:0[0YI&@@%I
MPT#H=TZ@YEF]7$HQ!=>[=9I*17DZ5T,@[G<AD4V@9"2S9=UI>)&GXGDQK 1
M95'@;9E(H=L28D]P7@,8?=7(H R*BWP(\:6UQ+>BIP^_XCL_X)$9'+++6/\
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M_P"BG4[?\Q6]TW_DJ7 UCN"9]^R_G_HIU.W_ #%;W3?^2I<#6.X)GW[+^?\
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MC$G0HVB':$LYO'I(K,8['QV56D#"I -DZ.JN'\>RJR1H3HCFN+&/L"(RPYY
M<U]@AQ(::$%@]FA'^(&T MWH[6FP(UN?6C272 I-"&AN%D'TMLC9[])_BEM;
M:LE-18H0*8.GU\UR!,&TUJ]DY;)RJLX:8;<&?376=.W]D3B",.EQ('8,,?CY
MJ8;'"(RT;1AR[8;WX^V\EI)Q.D6"XUQ]L8XJ]M46PE$2B)1$HB41*(K&O-6@
MWKQT]5?%<5';E=TIBFJSMACFX5R5SQPMDSRRMA;+.]L;9997M;YOGRO?_6ML
MP6DDU=B2=(Z?N7E(>6)F&QD-K(!#&-8"6Q*D- :*TB@5H,: ?!8W5( [0,=Z
MR\C47#.MV\>2OGN:V<OW(GJIU2 .T#'>LO(TN&=;MX\DSW-;.7[D3U4ZI ':
M!CO67D:7#.MV\>29[FMG+]R)ZJ=4@#M QWK+R-+AG6[>/),]S6SE^Y$]5.J0
M!V@8[UEY&EPSK=O'DF>YK9R_<B>JG5( [0,=ZR\C2X9UNWCR3/<ULY?N1/53
MJD =H&.]9>1I<,ZW;QY)GN:V<OW(GJIU2 .T#'>LO(TN&=;MX\DSW-;.7[D3
MU4ZI ':!CO67D:7#.MV\>29[FMG+]R)ZJ=4@#M QWK+R-+AG6[>/),]S6SE^
MY$]5.J0!V@8[UEY&EPSK=O'DF>YK9R_<B>JG5( [0,=ZR\C2X9UNWCR3/<UL
MY?N1/53JD =H&.]9>1I<,ZW;QY)GN:V<OW(GJIU2 .T#'>LO(TN&=;MX\DSW
M-;.7[D3U4ZI ':!CO67D:7#.MV\>29[FMG+]R)ZJ=4@#M QWK+R-+AG6[>/)
M,]S6SE^Y$]5.J0!V@8[UEY&EPSK=O'DF>YK9R_<B>JG5( [0,=ZR\C2X9UNW
MCR3/<ULY?N1/53JD =H&.]9>1I<,ZW;QY)GN:V<OW(GJIU2 .T#'>LO(TN&=
M;MX\DSW-;.7[D3U4ZI ':!CO67D:7#.MV\>29[FMG+]R)ZJ=4@#M QWK+R-+
MAG6[>/),]S6SE^Y$]5.J0!V@8[UEY&EPSK=O'DF>YK9R_<B>JG5( [0,=ZR\
MC2X9UNWCR3/<ULY?N1/53JD =H&.]9>1I<,ZW;QY)GN:V<OW(GJIU2 .T#'>
MLO(TN&=;MX\DSW-;.7[D3U4ZI ':!CO67D:7#.MV\>29[FMG+]R)ZJ=4@#M
MQWK+R-+AG6[>/),]S6SE^Y$]5.J0!V@8[UEY&EPSK=O'DF>YK9R_<B>JG5(
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M"3L6WUWH;C)O;=^QM1B^76[^*D_G:(H_KIPSDH\II9@B[-,8P"BLNBP=W)I
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MHW$,/LR*QQMBVPP#Q&/1X$C?-N+1RN12%]\KC;[1_P!GSS^KT1/OE<;?:/\
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H(GWRN-OM'_9\\_J]$3[Y7&WVC_L^>?U>B)]\KC;[1_V?//ZO1%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g358845g31s68.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g31s68.jpg
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M:***>.*:22>..">&..&&.V.VVVOSNHJ)Q/.!/, )I  )'ZO#=_I+_27)O)_
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MAQ7W,)ZV;#HI,DG5M.:P3P;DP]KH3A\<TU=I7.@:Q@I8J>>2=SG!L;(GN<;
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M\4FQ-LM))#3Y+LI<9%9&<2D=/)!CHE=4P[ED$D(C; Z2F;#&W/\ R\L.C95
MBC"&R&JY:8=W2J?IM.LJS6@#VLN/WD\6;)0*=NE(5$/&1C<HO',6XU5Q*G35
MX%,F,CR:9?%%[RU\M,^,B-T#W&HSX-#"8C#2YC@(I28V9SLXL\&[RUS7'. =
M8_5Y X5E-18G!)B-)CE!3QY.-I<H3C6,MQ2/&<JMUP/.*87&,1Q#0T^@;6%\
MS6T+)(ZFFI]RN-/G1^<&O*7Z\FB)HBT/Q/\ _,-6'_K+W^XBNNNA_P K@_\
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M$:#*#0XAB5?H64,]1AU\+9ATU)C\M'51NK!'!24]7@---A#2Z<U6?'I)J(Y
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M*OJDOESR<D_2QCN)VN)_[3D/_)K;\_3]R^5?5)?+GDY)^EC'<3M<3_VG(?\
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M_+(/_/\ <5\CE[G^]#'-'FZ3<K-'GWS,_=$.;GYOA9N=;.S==KVUKX=KB?\
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M]4E\N>3DGZ6,=Q.UQ/\ VG(?^36WY^G[E\J^J2^7/)R3]+&.XG:XG_M.0_\
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MG!S9(XRK+@W)3DQ,["S2A#",RH\5C(@*'KMI55?EHD+ U?N5F<=3B%?N(ZJ
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M34DDL.#2T#JRKI(M\GXS!)-#3T;1.]TL].]@IJAHN!4O9"QSW/;>D9=3UK0
M"$E$WKJ91..R3=+$&:/QXF+&DE'#+ FV0;NW;9)+PAR-4P)-FV>6"[@?EB]1
M3S:[]]UHD@GB:U\D4C&/_A<]CFAVJXL2.$&X'"-8U+Z2@R@P/%*JIH<-Q?#Z
MZLH\XU--2U<,\T(9(87N>R-[G9C)@87O +62@QN(>,U5OK2O86A^3_ZR8Y_P
M_<3O_P!6:<UU5G]JS_5:'_DJ=?)9%?\ 8]9_M7EW_P#W;*!5'"(6>L.5"(=&
M4F*IDTJO@VW)E1H,8V09LW!$@_)F3#ID+%C1HYH[(/WSYT@W;-&RRN>?]'M;
MZ(XW2O;&RV<Z]LYS6M%@22YSB&M  )))  "]_$L1I<)H:C$*QTC:>F:TOT,$
MU3,]TDC(HHH:>G9)-/---)'%%%$QSWR/:T#6MC@. 5B'K$M.N,9Y AY.LI]&
MZN\/<)3)^QDDXEPPT6!,VF("+&78  JUCY+9]+I6W" !ZVS9)5WEFLILAWLP
MR9\LT(DB#H96PDG2$.D>'EH&;&XM;9CKO>&M&K7Q?GM5[J>$TN$8'C&]>*RP
M8UA59C>C8[#HI*/#:":F@JI)#55U/'5537U<.BH*!]552M+W-C :"ZGJ=XRS
M"Z:_OB?1LU'V:-"1YA(SH4@J[R)R-HZ'R\NZ0C>3)LZ:.'(X3"39%?%PNA@J
MW2QR;YJ;;9[X:*>C?4PU,S', IF->YIO=X(D=X%@02&QN)U[%]!E!EGA^3N*
MY+X564]5([*FKEHZ6IB;'H*21DN'T['5FD>R1C)I\2IH6%C7$/=9X%Q>96-P
MANV"F*NC(8,O9DJLZM4;,2C=>B39LG%ANSC%B4'21/$?A@U=A".7BTFYPRS'
MHO\ N6VSK=51+#/9+AU1&Z%C6F9\T.F#(FN>Y@O9P< -K3X)(U7U7NO/PGW2
M<F\2I\:K*FI9@U#@N,NP5U9BT]-305LV898)J-QF)?'4P_MH&$"5T7AYF:"1
M48KCE?IQN<="*8LXBWC+\\*D2C6$R%78(6B[=J[D0DGMLP[IF6#M7S1P_&+X
MX/D$5\%,F_<]UOMH;2U+@XMIYB&%S76C?X+F %[3JU.:""6[0-=MJ]Z?*[):
MF=3,J,HL%B=6Q4L]('XE2#=,%:]\=)/#^UM)!4/C>R*9MXGN:6A]]2N_?@)R
M,VB[T_C#WSPEA#:TFX>)"Q1TE(3XFS23\>R;,$$!6S?$E'$F.S^5-E%^]!VS
MI#%9QNXQ<(H]&]E7F%VC<7:.*5L;6N<][9B0+ -VMM=X_N@[;W ^;^%/)#=L
M=(<0BCA.(8SAM17S3TL-)23X+#%+*^9SY\_0U9ET5"\-O4/8XM;F%CG4%O0U
MUXQZ2RS.J+!3C<-?&!LK,JQ,TDRCSZ.N,&DA;%E%&>.[)2/NE,&YWOVV.(9?
M/%(ENVSRVVWY=S5&8]^AES(RYKW9C@&%ILX.U:BTZG7_ (3_ !67U/OHR<-7
M1T(QW"368A'3S4-.VOIG2U<56TOI'P-$AT@JF OILV^Z&@NASP"54VM*]U;P
MIC]6L;_^\?W^4UZ5/_8L_P![_B<OS'*'_MBL_P#U_P#E8%"1]IM:1YN&;9>A
MUY U@5^S:0KA6KM-@X))M98<QR;(O%4'*;?//OG;V4S05QV[7Z<=^WK6V84^
M(&<MSA%4O>6@V)L]VJ]C;J7HRX(_*3W-Z? HZAM*_%,E<.I&U#XS*R$R4%-9
M[HVN87@6U@.!Z5)JOYA[5GCQQQ;PYP52I":7I(S3-<LTP9RD==0L."50:-W0
MH@S9%8Z,:DE&#PFQ+LLR#EJHHPR;IN$%\X:_0[DM'?<TE2]PSA9XJ&M;8 M(
M#F .L7!PN0;;0N+&_<^WY.5Y?B#8'92X=DS24\C8)#)0S9.3U%4U[W,GBDE@
MJYWPB5D,E/*(F/:V4/+'MM\#SMK8-*V!MY5!P\A"Q]2L*Y=.V])C7P=E7,IE
MDM*A<8^&IUE!8X-D965YK,C$<C>TVBV8]7('*&^1A7(?O9B4+9 \TY=HQ (B
M13@M$,CY"W-;3B)H>YY(<UFD81X+QG:O JO<QQBHH)*6/'::E=B,V.RXPR-^
M4DT=3)B]#04$%2:JIRAEQ.LFHX* -DIZNLWMKA*W=-"[<[1+$Y!S3AQ>%28,
MV@,J:24[55]U&D0WDPO<*B"M^^,;I&$U6*8;!_D1$8KO8Z4;XO\ P-^EWETW
MV0V450PUNQ!CHW-$3P]T%3!?/&;FSU.Z ZV;>XN6.%[.U'5>R[Z7W.L0@Q*C
MJ7XK0R4=-CF2^/&(44VZ75. 9,')V:%LIJ3$(:@LBJX'&'21.SF/S[-<96([
M(>S"V#(IRG6[\CL>LRK)IN-(R!@OLV#0F@I919T8GF["/VF1,DTE2IP*]<#W
M3!@NR;-GXT@EW>V^P8J!*^40DYT\,N:7#4V.FDIG-UL(SG!^<"6D"P!#EPU'
MN325.$TF&'&(HMS8-CF'::&DE87U&)94T&4U+,1'4Q2"&&2A;35,;)F2RMD>
M^*:)UK0.;\T11Z,RF&!8M($ ;X70P.,K/-ZZCJHH73TZFD]?-<@E9P&#QQJR
M,%9BMN+'M6#C(2LV4=K$7GA"39GKDQ .9)&UC@TMIFL)T3<T4\LDI&9#%$RS
MG2$@ >"1>YO8>IAGN=3TE;18C4UU*^IBGRGJ:QL>^]6)YL?PS#L+B>*G&<5Q
M.LDDIX,/;IY7S-$[7AC88LUSY(1R5Y,Q7D!&]FB4.D$;D8^][LL\.YS.#GX3
M>+700#F2(4DTQ%-WV9\.2CPI)D1:O$1RC+,ENNR47<-MV6JKK&5++:-S'"IJ
M9VG.!;F5#FN+7#-!SFEC0' VM?5K%O1R.R-KLE:S2.Q"DK*27)C)S!:A@I9H
MJG=N3L513Q5,,AG?$*6HAJYS)"^-THD$.;(&L>),::X%^AIHB:(FB)HB:(FB
M)HB:(FB)HBT1R1_M%6'_  [T!_E='==-5_'%_JU-_P"PQ?)9'_Y)C7^UN57_
M ,W6+.^N9?6IHB:(O1KAU+XQ$:^:R F12"H0+FAQ.L>S"622ZN;:IPBE@,,B
MJZ#-%P^="@,J(L=WJ39NOE@_,!]L4LW"[;'+U:"1D<8<YV:(\0HI9C8FT#=*
M,XVN2UKR+@#:YO#9?D?N@4%;7XL^EAA=4.Q3W.LN\'P:$%K0_':EN%2"!KY'
M,B9/5444NC+WL&BIZ@EP8UY&N9?S XS2"N90*('U"KFVXE'Y->(9$>;1>2N9
MQ"?<>H6W!CE]V#5ND[*UG6<WF&*^;M-ML\E#ONW[=^X\&W[7U](^%[2XDSL8
M^H;9]WR1RTL>:TYH +H89)+WVO.L';\%A_N?Y8TF,44\5*V!F UU719,U#I:
M9T=!AV(87E;B+ZF9NED<Z.#&<9PS#\P1ND,=#':)T3"\PLS=G&$>3*DS4AH:
M>&TGO(HK4CR(THD'CD0J\Q4AX=45;3@$^K>.LC,B\NU >8IB4'2C>-Y-":I.
M3;-RW=*:W5%&"YSG4TCKU;J<QTV:V.%T#A3Q2-,+ 7Z0MLUS7YECG2>$O1I<
MG,M)8(8:>DRHPNF,>24&/1XAE(:BLQ#&J?'J67'\8PRJCQBKEIJ/>MM4)Y(9
MJ+=@DA$-$7P>#S85RAI[>--$MY[6D0-%$>$$[L/'&MVX?"02NNY7+,+HQ9XQ
M^ +-TI4T$>13M+-CB-9=S@1< 'R"[HWNYRCK8,P?M88W'>Z67]C;/?"^3=%L
MR(_M -&018?Q%A!+KZL1R*R@W:]V]>,U]- [W2L,PDG&'U!I:'%Z&@.3FD-7
MBK7NH9)]\F.$IFDN86U<3VLIM'U 'D=0$FE"$GF"E,NI2A8O*(8*?EH,E#N\
M5])'D")5:_;R&/U7+![,]NLE,]X]))A$94X9[O#2)W9FZ-IDML65=*]X?)H"
M\2UC071Z.T3]$8"'M@>W._CS7OC>1X0=8NNNBJR0RJHZ-U'A_OB91.PG(F:>
M.#$W8AGXK11XI#C43J2JQR@E?2YKL/W728?7T+)='3NIC(VF,)HV^BM;KT_R
M/?0@XC)H-+^3U/KU43PCXB+IN#T?JF;.;<=B@X.-0P5L-%K2>.!G)!A%0&!C
M%X!,N1#59_AMCSU+H3!5F-V?&^KIS <QK 7-AE,Y:UK(V@-+VM)$;,Z[7%HO
MJ^ER7AQAN/Y(1XE2NHL3H,B\H&XY":NHK7,IJO',-9@+)ZBIK,1GTT[:*LJ6
M12UU6:?1U=.RH>V(D^;FO)7[ FB)HBT1QY_UKO\ ^'>S_P#E"-=5+_XC_59O
M_JOD\K-F3G^UF"_\<ZSOKE7UB:(FB)HB:(MH<%AH0C;$XS/)Q3%H)X_7L>;$
M9M&F\NC0 D%KTL0'20I'G HYL3; 72*9-9JB((N5T6ZB+=DZ44V;J>AAH:9Y
M,[,LVEJ7 R,$C&%L3B'N86NS@T^$1FDFU@#L7YW[ILU3%@6&BE-<9)\JLF*5
MT.&UCZ"LJH:G%J>*6C@JV3TN@?5,<86R.J(6-<\.?*QH+QWEK7=%H1R0I"VZ
ML)1212BM(K5SVS)+ 8_E$8;/K-C[IXO,W8<5XCC&&PTT#4'1PL]2CH9 PZ1*
M/TV6*;S956S5#(ZNGG@<QSX60F5\3=''),PG/+6YK/!<VS'',:''.-M=SRX'
MDW78GD?E)@..0UU)18S78U'@]'BM6,0Q'"\%JF1MPZ.HGW56WFIZELM7!&ZK
MJ'4['0Q&2\>:W8JUV\3PLXRA]=6* :5/643,R:"Y2>&-O I+,K8MI"9V"QP?
MR*I;4<!5X; &D9AK1$="4#$J8Q]^"&R,,F_4<J=YJ*%LFCBE:((8W/CSXQ9\
MD\XDE +X)\W,B#(["(&0,+0YM]?Y^W)O+JHPS?#%\)JI,=QFOIJ/$Q0XB_24
M>'8%@+\.PJ0Q4F/8&RI;B.*25N(O,N)/IZ&6KBJ9J.I=$UC>@G-H\5)<(FU<
M 9K78,02'<S6E</2D5D:,1AKV>W-3TUK1RU391 @\C:16'Q63LA*P<3DL)Q_
M[G6198O$D%<99J*1KX6R1-:1B A+F/S(S+44\L)%HR6!T<;PTM;X-\PVOKZL
M-P3+B@J,-QBIPW%JF>&7W/'XQ'!74CJ_$8\+R=RAP[&62&7$(HZQT&(5U%+.
MVHG#:@VJ&ND,9>V4[W)PC9)3](9O6!='PN.;'DB,<5C;&QH>RXU5_%D1<;P=
M4)/I B[;6B-F"ZK$02JXRTE!%K,71XDVQW48[-T8<!*&Z%PNS.#F%@F8*.)@
M#?W65X(F;(2&F!P>1(7.&SB][WNDR.PMTV_5.[,JS3.AJVUDN$8A)ECBM:^>
ML+,J<*I'1OP2;#V-DGAQRGDHH7X>REA?JE\1-?.K^D4T1-$31$T1:'XG_P#F
M&K#_ -9>_P!Q%===#_E<'_G^XKY/+G_NGC7^KQ?\S L\:Y%]8KPXXW.YX_7'
M$K5;C'!E,#B?'D1;,GF%?NP\IC1>*&-AAC!N[R%EFXTTY=B"'@KC%H3;M%E$
M%4\,T\NBDJ-RU$<UBX-S@6AV:2U['1NL[@<&N):;:G %?-97Y.LRKR>K\#?,
MVG-4:66*:2$5,3*BBK*>NI]-3ES!-3OFIF1U$6>PR0ND:U[201>JW+8"AR1I
M&Y1\2E)"-4A%(U#6#.4REF7GLQ81U"0=HQ*9.D(:,533A>0J-DN]#<D&0<:+
M'89J[-N^[])KF[KIZ@1O+*=C(P'O#I9 S.\)[\T#..<=C;!H:W@NOF&Y!U3L
MC\I,GI:^BBK,I*^LQ&62BH9*?"\/DJWTG[O0T3JB21M.QE(U[LZ8.DJ)IYB&
MY^:KGR[)0ZP"05JE6B:Y>&QN@L7*[LPCNPDT^J&>1V4267E44QO?4LYR&AT8
M#;]YWS>"W8_QANX=]RBCAT;['-B&ANZ-E+>[A9\L$K'OD-AJ,C8XVZM8(O?4
M OGA[CS#48F]V,N;3XA6Y4F-L=.[2T6%8_A=914>'P.=-FD894XC6U SK1S1
MRZ+,9=SC"'W-*#AX;,*[K^OYPUC4OB_(#%T2FTY'2.4-)E?:,1:$,VC]C'1"
M"41 LHFGAD/[UD1D+X@Z)D'3=;MI9ZW8A&(WQ112!DC*JYDE#WB2JS ZQ#&@
M1M#/X;7>27$@KT8_<YQ*HQ'#L6Q7%<,?68?79*N9%AV&2T=%)A^2[J^2(/BE
MK*AQKZJ6O)$N=HJ2.*.&)CVC.$IC'/F&#G$.>':UE3UW 99Q?FP+,;*Q2"9
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M,,K*^3%*JAHXJ>?$)6:-]5)&VQD+,YY:/[K<^220M:#)(^0N>84%_P#&1/\
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MCY6W)&9HV1".2E\T<\2G;IV?#XAXN3\UP[)1:,FG^#99;O+/)PJJH]5ST;0
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M+^F23&:1"M\4L(*!MP<VLU!A=K.,X((IC<K?;3=QBCALW6660RS2RH=(/_\
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M&Z*S-ZX0<)*KHIYIXYJX;9$75R6TJZC#<.HX,ARCN0O(LW!!@3T03-F&LMD
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M;R\F#!F$CC.NHG)4%Y$=-=X)YE=5^"U@>'DWZR?-KV*U)J=N"D+EXY*(\D;
MM^#9W=6''2Y"9%:G,XM$<C5,CP(2+V-!XN'1G1*Y[BN _#;*6F0?&,,(2)FH
M--80PK=HX9R4G =7!?AZ=G0!MX[<:TQRMD<R3D7%6JXM-)#70R^^0Q*NYQ,X
MCD*;RQC%8UQTO^ZDP\;*F11ID#(RB35/' 3PKB/S?IQUV>:!W(\R\'D6A0</
M0/O ^]9S8<O)M"N%4'F,F.+';7F%M6AQPBEGE8<^,@/"H#;5KUX+ORQ@\"#(
MC\1'F[K):T28P,QCH6:RAR,@L95C^<O#9LRMKG5T&WEMJ^?;YU5U0\@+\L/C
M+V*&W1%W-2(.T3%$1/D N[@F&TYMV8'J].XRKPR0N510>*QY&2@R!$PRCL*W
M>2(OXNS#R,)&63P9)2AL"?FU\'WZEQX99O(:;.H(79WI+6T@Y/#^? 92+O&D
M2\EJ//T)/BPZGC\1'MHXR*LL:RSCX^ 6"QD!8P,GI"1NG,N;+$,F&"!7CU;+
M<.W_ *[=7!UKU'X^VCY\:%I&ZO%>0/SP5#6UH^)<LL\\@_G A@66>*\LE-L5
M,LA_C;P3?)3;;/?='MY;;9;[[:+$ZM2M[1%5=V_JME_^YL_[U8:(K4T1-$31
M%XCWUPSO>T.1MIEA,9FC#&P[UA4UC5K,["A+;CC'ZD8<; ]+RK>?4AG*VLTD
MW(]IEE-A\.L%&MI 288[U*\;6P"B\,WA(,L@1;[K:[WOMMLZ#JO?5KNIQ ^+
M\VL5-24\@>/<NB:5.\1:;IB)0:+6W'0<UL&U:KWL0C(SU7SJIK+8N(K#"# \
MWA, *R^3P"2'1DUF;";PZ'@\EL"Y0^7;Y0/U_AM5A<6:DY54A;[6%&A[/"E'
MPAW)9<^!(UMC6RL@+0.#[XLXTOEGC>WE?#I^V/UE"A1I)2KPG&*$UN)35WFP
MWOBY4V\_S^?8/M)*]/M%BFB)HBJNBOU(TY^ZNO?\)"-%3M/E/VJU-%$T1>1/
M);C+?Q?DW8UIU0/M<B2M"'<90M93V%WBC7M<TE+*DL&=.YZ0O2L5;!B65MP8
MK$94-?A 6T)NE,HME-HSY,P3(SG)9"60(Z.JY_7G'G79U/4%BW[:$O/\O>+%
MH5DU&Q\Y%*08"9Y1P^J:8@0BT8'8(%*#EJ4ODW;KN\)O*JTK2RC=CKQ*(B8H
M0KV/Q6')1S$,_,V(2]OX3Y>G40=H M8D6_0X7'ZE^5%+6_6N,8B#R*TW/6<5
MD-DQW(K6LD%P02U"W2%WK&=2B1&C=O%Y16L1%\91T5,5L8,1><6X<Y#V).'9
M)&99DVI";])N=?1JM^K<0NO7#18IHB:(JHIG^R!C]Z]\_P">5B:*G;YA]@5K
MZ*)HBQOS'K!2R1--.U:7L*\!E>6RYFCV.U+=ZU&68!4>U19U?-I1%3.=A5$)
ME&R2<[= #T5-6I#&N<>D),XVS/D C2,ERH-K\%Q;6+C:#]W$?O7GS"N+', 5
M$S%7V%%35@%KXF?#*PI!=1"RH;(<:9%4!9L2.R.#V26D4F8V/8$WB]<UU'6D
M1FT,C,X;6%9A@F7EAJ+MMWTG>%;CR:B/+<'@V#7MUZN 'AG5H<4[BJ>5F)GP
M_@4HC#*#OFL1A P5*X1-YB_9E:8D_?YC!&W(F4GH!&(3%)DTHVC(K$'>\:<U
M]5"/*!: A66]B@2SHE[[3V7\P\IZ3:^Q>OX+<SD$#92/$?A(=Q0_<]@)W6R%
MX&=VB.Y3$;DY_P"T9#\7W?\ 9GNX_KMV^R>ZO]/NM%BNUT1-$31%F.GA5R*5
M)5N8Z>5DU'YUS",V+9[4LJ?O&S/*,C-VR#M\A=0U!ZY10WP37=HCF"3E7'-9
M-DUPSV03(K&\3WATB53U-2_Y[Z(GB>\.D2J>IJ7_ #WT1/$]X=(E4]34O^>^
MB)XGO#I$JGJ:E_SWT1/$]X=(E4]34O\ GOHB>)[PZ1*IZFI?\]]$3Q/>'2)5
M/4U+_GOHB>)[PZ1*IZFI?\]]$3Q/>'2)5/4U+_GOHB>)[PZ1*IZFI?\ /?1$
M\3WATB53U-2_Y[Z(GB>\.D2J>IJ7_/?1$\3WATB53U-2_P">^B)XGO#I$JGJ
M:E_SWT1/$]X=(E4]34O^>^B)XGO#I$JGJ:E_SWT1/$]X=(E4]34O^>^B*JZ>
M$79O$B^Z%@U8GAYT[SVWQ5IZ6K9;JXW98.R^>V>%YH;;)J+[**(I;X;Y()9X
M(YK.,T\EU"R-N&^P<-N =!5I^)[RZ1*HZF9?\^=%-7$>L=B>)[RZ1*HZF9?\
M^=$U<1ZQV)XGO+I$JCJ9E_SYT35Q'K'8GB>\ND2J.IF7_/G1-7$>L=B>)[RZ
M1*HZF9?\^=$U<1ZQV)XGO+I$JCJ9E_SYT35Q'K'8GB>\ND2J.IF7_/G1-7$>
ML=B>)[RZ1*HZF9?\^=$U<1ZQV)XGO+I$JCJ9E_SYT35Q'K'8GB>\ND2J.IF7
M_/G1-7$>L=B>)[RZ1*HZF9?\^=$U<1ZQV)XGO+I$JCJ9E_SYT35Q'K'8H!.1
MUIMR-8JR:90 N&QM6);.6 *M9%'":N>6Q'9OD@6(6Q*6K?%)?=-1;%0*ZW72
MQS1PS;YYXKIDU<1Z_P#!:6T431%6UHT]5UU@&D7MB!QJ?@AY5,X-'R48@0P&
M&4F+\7L4&+9[;.1K]006+!G#IBLW6=!2Y8.YS5&$W[5P15Y..(7%ZRFPME.Z
M$JV3,@>49R!LB40$YLPN\+CQN(Q'8.U2;I-Q>,:BTD/QT)@Q30P&A#)(8UQ2
M9NUD<RMR-A/%]_VJP(53-4USO'\X+7\6BRD3BQ&$1I8.);-%P<0+G$)*4C8U
M?'#OS4.0/M6QAVQ3SV07(-T'*F&2B*>^)2ZC4UH" S^?.9O*!C$VTD532&E;
M&A9L4.-1&RX$6-,Y ''2P61063>*1 CO)L8_MGW;/!A/IHU>,G2A)DZ&DN?O
M\Z^#*M..O'Z,,Y,VBU<U;%:M'6#)D9(X1& 6,58GF>4EL^2/3CS-/+!0NQ J
M'9B<(NUG3UN*4(%7:F#7-7 FLGC)49K60\6+'ACF701O"<HG4UG36QRN9F,.
MX2YK*V)&U/SV;S21 )F)CQR%2J0"[6/SDB;.#!CDP#L!:5IN'(F1(D'177TZ
M_GX/M'S*DL[4['?(9%ARBS0KTM8+"4@8JQEWFPE+JV'TQ(P$@0B3D%!O)'*Q
M)*<?U)L:)Q*7AHJ4=.JD;'20$TI F15=$FNUN#YOU?YUV*,GX&/:ZHCBJ2DD
M GT#>P.E,*@$DF[B4@%0#IAB*H4[Y<"AF<7BDAFN\=72JM\\-1HQ,BS!ZU@B
M3]VBJUP)KN3K!N;]''TZN'BX5?U3;<<6,OG$)I5O6[&74[&ZWJ.>1^ LQC1:
MOXR$92"2UE7)5L(139!FH,?+) 9!QC'O:@AI(UG>3-LD60R7)KVGAO;IXU/&
M54UJ-C4!AS"#1AG%:L6C[FMX\W$,TA$(<10<J(C2T998I;("% 0M=8>+R9X)
M[LVBN:*/<X9;[:**JY)Q1IHBE;Q*'0^/5C8-UQ:61"96I"0 H=/,!L]S24FC
MT.4W0WP&')"Z10-D2:2.^)26, \GD#4X1%-NV5N=7#;C5^@ (:*@0D8C@UJ&
MC\<$#0((0Q3V18B@P=FB/%C6:.WZ$FK%DW0:MT]OT)HI88[?HVT47;Z(JCOG
M%WG44YP8+MVS_,6CBR<O&JKYHW=Y$&6S9=TR1>#UGC=);?!1=JD_8JN$L<DD
MWC;+/9; B^OB>\ND2J.IF7_/G175Q'K'8GB>\ND2J.IF7_/G1-7$>L=B>)[R
MZ1*HZF9?\^=$U<1ZQV)XGO+I$JCJ9E_SYT35Q'K'8GB>\ND2J.IF7_/G1-7$
M>L=B>)[RZ1*HZF9?\^=$U<1ZQV)XGO+I$JCJ9E_SYT35Q'K'8GB>\ND2J.IF
M7_/G1-7$>L=B>)[RZ1*HZF9?\^=$U<1ZQV*KZ0$79E2U0[H6#5B:&]7P#=%-
M:G9:NJFEO%!.Z>"JV%YM\%E,<.UCFK@@ABIEMOGBBGMOMAB5-KG4=IX?\%:'
MB>\ND2J.IF7_ #YT4U<1ZQV)XGO+I$JCJ9E_SYT35Q'K'8GB>\ND2J.IF7_/
MG1-7$>L=B>)[RZ1*HZF9?\^=$U<1ZQV)XGO+I$JCJ9E_SYT35Q'K'8GB>\ND
M2J.IF7_/G1-7$>L=B>)[RZ1*HZF9?\^=$U<1ZQV)XGO+I$JCJ9E_SYT35Q'K
M'8JLIX1=F\2+[HV#5B>'G3O/;?%6GI:MENKC=E@[+Y[9X7FAMLFHOLHHBEOA
MED@EG@CFLXS3R74*FW$=@X>@="M/Q/>72)5'4S+_ )\Z*:N(]8[$\3WETB51
MU,R_Y\Z)JXCUCL3Q/>72)5'4S+_GSHFKB/6.Q/$]Y=(E4=3,O^?.B:N(]8[$
M\3WETB51U,R_Y\Z)JXCUCL3Q/>72)5'4S+_GSHFKB/6.Q/$]Y=(E4=3,O^?.
MB:N(]8[$\3WETB51U,R_Y\Z)JXCUCL7.1%V_BGCLXG-;*K;=ON\T:IDZ">7]
M+??'N4L[E<98=K'N=M^VMGW66V^6W<[;[88E%YO\FI=8H*JNQL12OU+S=)6A
M9X*'S.,<=93 (9:,PC GA%R(L9N'$R*S93"8>Q8CI;!8Q*C&)"5"%G8V/.6;
M#)\]70%OBR;;PKC^[PWL-8%]75Y2J,C7(OE?QTFI@/=!22+^/(B^<4G6EVD&
M4\LIB!FG(N*PB$)V UXJQ>SU[0M@+''<K?!XO6"<G?G8VA'P<DF#0FWE$V'$
ML#>UN#9LV'CM:YMY]G %<%4]D-N6XF\E8QVLZABAREH[:$RN\A;<YF-6QET
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M)%S)C6;XJ_*L&C@Z2(.B>RS]55RYT6).H:^/S;%KC11-$31$T157=OZK9?\
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M5&X/"^#5;8N\8/!24>V=.8*HEX+"KR6W##JRE:,XK^*1;)X)<Y0^OHC*D,3
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MY3?2':FY*KQ:H]3)W5_-N0]38[=K$K)<=MO]&VU:6;MM^G?M[_HVAW:_3O\
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MY=97V,4C8X*0$$Z1D3&VMJ)BOKN1JL#LN>A9^DW9/:W&3W.KH71/(:WK"SY
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M%98N%>W_ %[C95;?''=3N=FA9Q'K5.+5W.-V#_-Q\(OR5._1TQZ8[9^ST_\
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M+!P7DGR)7LCD'8,8A+VF+7D5SW#'R[*60-C-B%:ST! NPMTI-1\6)F1VV)Z
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MG'!=!3'8H=6I3K1%5=V_JME_^YL_[U8:(K4T1-$31%X#V?9=O8\O;J)NYVD
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M58]D1X_3KDE4_8ZJ_K\E,XH<:<@(7*V5FPP6_(KU(?C7&*YBD"L4TJS:N46
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MPAXN"#1.??%$*HW2R[ZHQS6P[G_1@ICCE_2VWUL;'8 7^;_%<,V(Q22.>&2
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M]A7(P@THAK"9A3W*@#2;8'D#E=_DXM71WC94-\"9I/(=2I/8G)I09*V:.A)
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M0&L7Q!;%-FS<KI%+N.PGYU*BM8<:08T>8,5O20T46)QT*+(NX3!TF1(M+BS
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M@>G0>7ARY).6KB(X_+L8R*?JBE%(Z*>EW$A6"*LR,C'1PL\<1P64(U WO?\
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M[,UA]RROXUT1/6$W/[,UA]RROXUT1/6$W/[,UA]RROXUT167'^:UJ%1#1^X
L5_@LX\([O%$5(\4MN].ED<>YQSE:F6W;Q3QWR[>>_P#2WWWV[6W:VV(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g358845g35d56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g35d56.jpg
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M 0$! 0$! 0$! 0'_P  1" "V ET# 1$  A$! Q$!_\0 '@ !  (# 0$! 0$
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M$4':K=^CY-&9E^;Q&LQP\.8V(T@4< 21BO;5V(\%IJW&=FHX&A"^@<E^4/\
MWDD)B:=(Q<'QI2>CX/CP7O=&@OB0608K8\E,N@RYFI2+"CPS#C&!!=:"+"?#
M:^$Y0A6NO2)1$HB41*(E$2B)1%8_:SCJ*Y0R87C4Q9+OQ+3%&9I4@@W>NF"E
MIJ'8OE,F N-5V:J2MR;4P+9N%6]U^J+E-.Y!Q8HBI?9=MR<)D:,61 2T09A]
M 2/:AP7O;G&IS0:=.@YEY#EOA>>P)@:!.8/B-A1XF'>3LBYSX;(H,OA##4E)
MS3,6('-!?+QHC ^F,PNQF$. (W3;/MV:9\BLQ9VN1@@YKEO;SCH-)7MIETN
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MF0BW00V=7 @H^.!%#Q(4]=L7)PL-?%KD'"VFCRVZ^Z[79=/3;G,<8IK#+G,
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M_M7B'Y#IE*<]ZWN8'E)ZM.1G[+F?WYA_^:)[<.YK^O ?]J\0_(=,I3GO6]S
M\I/5IR,_9<S^_,/_ ,T3VX=S7]> _P"U>(?D.F4ISWK>Y@>4GJTY&?LN9_?F
M'_YHGMP[FOZ\!_VKQ#\ATRE.>];W,#RD]6G(S]ES/[\P_P#S1/;AW-?UX#_M
M7B'Y#IE*<]ZWN8'E)ZM.1G[+F?WYA_\ FB>W#N:_KP'_ &KQ#\ATRE.>];W,
M#RD]6G(S]ES/[\P__-$]N'<U_7@/^U>(?D.F4ISWK>Y@>4GJTY&?LN9_?F'_
M .:)[<.YK^O ?]J\0_(=,I3GO6]S \I/5IR,_9<S^_,/_P T3VX=S7]> _[5
MXA^0Z92G/>M[F!Y2>K3D9^RYG]^8?_FB>W#N:_KP'_:O$/R'3*4Y[UO<P/*3
MU:<C/V7,_OS#_P#-%NF-]U6ZK)F0H+CD3DB*#BD]F$;AHY^5QAB1$8R?28PS
M#-7;]5/'ZJMC-NN\L5<:HI*K>BLNT1244UMLNR09Z=C184)L9@,6(R&"8,"@
M+W!H)_1:!7.N=ACD/R'P-@G">%X^!YZ- P7@^<PC&A0,-8>=&B0I*7B3#X<(
M.PJUIB/;#+68SFMQB,9P%2)>R[E/=AB <9,',P1=<<F]@#*)6*85QB*+RI6;
MP 9DE\BL%(06QW'WD%CAZ-HS)D^].J/,24"Q;ZNT'WUY+-'F)Z TN=,,(K"$
M/_1X+7/M(38Q]ET(%IA-<P1 <X<]H%0:C@8 P'R$Y019>7EN3\ZV,86%8L^1
MRCPS'EY%N#<*Q\#0BV8A84+)J'A.;E9QV#HD(-;%EY*:B/LWPK)U;?;AW-?U
MX#_M7B'Y#K5RE.>];W,#RE[#U:<C/V7,_OS#_P#-$]N'<U_7@/\ M7B'Y#IE
M*<]ZWN8'E)ZM.1G[+F?WYA_^:)[<.YK^O ?]J\0_(=,I3GO6]S \I/5IR,_9
M<S^_,/\ \T3VX=S7]> _[5XA^0Z92G/>M[F!Y2>K3D9^RYG]^8?_ )HGMP[F
MOZ\!_P!J\0_(=,I3GO6]S \I/5IR,_9<S^_,/_S1/;AW-?UX#_M7B'Y#IE*<
M]ZWN8'E)ZM.1G[+F?WYA_P#FB>W#N:_KP'_:O$/R'3*4Y[UO<P/*3U:<C/V7
M,_OS#_\ -%W ^AXS9DK,H[< KD4ZQ-J1Y[C),3JRB\2C.C:PFA/;GNBEL5!!
M+7GI;F#76VY]HYN0]'=HWU2T56T4]%@&9C3 FK5P=B&#BT9#93&M:_(:VN@:
M:TZ.E?FW_M <F\#<GHO)5N")6)+";AX:,<1)V?G,<P78+$.AGIJ9,/%$5];/
M$#JC'QL5M.:>YG89N\FFXS/$OB^#I28C<IS#DB0@"S9Y';&Y,,8EY<@,?H6K
MFD5[47;-PBNG:LDFII8III?99=Y;=./-X-GGS<R]DL]S'S$9[7 MH6NB.<TC
MVND$%?8N1OI/Y!8.Y(\EY"=Y2R,O.27)_!$I-0'LF\>#,2\A A1H3BV7<TNA
MQ&.:2UQ:2,Q(SJ$/LY][/Z?)?WZ,?SU:^2L(;K$^SXEZ7UM^CCYUX/[N<_+)
M]G/O9_3Y+^_1C^>IDK"&ZQ/L^)/6WZ./G7@_NYS\LGV<^]G]/DO[]&/YZF2L
M(;K$^SXD];?HX^=>#^[G/RR?9S[V?T^2_OT8_GJ9*PANL3[/B3UM^CCYUX/[
MN<_+)]G/O9_3Y+^_1C^>IDK"&ZQ/L^)/6WZ./G7@_NYS\LGV<^]G]/DO[]&/
MYZF2L(;K$^SXD];?HX^=>#^[G/RR?9S[V?T^2_OT8_GJ9*PANL3[/B3UM^CC
MYUX/[N<_+)]G/O9_3Y+^_1C^>IDK"&ZQ/L^)/6WZ./G7@_NYS\LGV<^]G]/D
MO[]&/YZF2L(;K$^SXD];?HX^=>#^[G/RR?9S[V?T^2_OT8_GJ9*PANL3[/B3
MUM^CCYUX/[N<_+)]G/O9_3Y+^_1C^>IDK"&ZQ/L^)/6WZ./G7@_NYS\LGV<^
M]G]/DO[]&/YZF2L(;K$^SXD];?HX^=>#^[G/RR?9S[V?T^2_OT8_GJ9*PANL
M3[/B3UM^CCYUX/[N<_+)]G/O9_3Y+^_1C^>IDK"&ZQ/L^)/6WZ./G7@_NYS\
MLGV<^]G]/DO[]&/YZF2L(;K$^SXD];?HX^=>#^[G/RR?9S[V?T^2_OT8_GJ9
M*PANL3[/B3UM^CCYUX/[N<_+)]G/O9_3Y+^_1C^>IDK"&ZQ/L^)/6WZ./G7@
M_NYS\LGV<^]G]/DO[]&/YZF2L(;K$^SXD];?HX^=>#^[G/RR?9S[V?T^2_OT
M8_GJ9*PANL3[/B3UM^CCYUX/[N<_+)]G/O9_3Y+^_1C^>IDK"&ZQ/L^)/6WZ
M./G7@_NYS\LGV<^]G]/DO[]&/YZF2L(;K$^SXD];?HX^=>#^[G/RR?9S[V?T
M^2_OT8_GJ9*PANL3[/B3UM^CCYUX/[N<_+)]G/O9_3Y+^_1C^>IDK"&ZQ/L^
M)/6WZ./G7@_NYS\LGV<^]G]/DO[]&/YZF2L(;K$^SXD];?HX^=>#^[G/RR?9
MS[V?T^2_OT8_GJ9*PANL3[/B3UM^CCYUX/[N<_+)]G/O9_3Y+^_1C^>IDK"&
MZQ/L^)/6WZ./G7@_NYS\LGV<^]G]/DO[]&/YZF2L(;K$^SXD];?HX^=>#^[G
M/RR?9S[V?T^2_OT8_GJ9*PANL3[/B3UM^CCYUX/[N<_+)]G/O9_3Y+^_1C^>
MIDK"&ZQ/L^)/6WZ./G7@_NYS\LGV<^]G]/DO[]&/YZF2L(;K$^SXD];?HX^=
M>#^[G/RR?9S[V?T^2_OT8_GJ9*PANL3[/B3UM^CCYUX/[N<_+)]G/O9_3Y+^
M_1C^>IDK"&ZQ/L^)/6WZ./G7@_NYS\LGV<^]G]/DO[]&/YZF2L(;K$^SXD];
M?HX^=>#^[G/RR?9S[V?T^2_OT8_GJ9*PANL3[/B3UM^CCYUX/[N<_+)]G/O9
M_3Y+^_1C^>IDK"&ZQ/L^)/6WZ./G7@_NYS\LGV<^]G]/DO[]&/YZF2L(;K$^
MSXD];?HX^=>#^[G/RR?9S[V?T^2_OT8_GJ9*PANL3[/B3UM^CCYUX/[N<_+)
M]G/O9_3Y+^_1C^>IDK"&ZQ/L^)/6WZ./G7@_NYS\LGV<^]G]/DO[]&/YZF2L
M(;K$^SXD];?HX^=>#^[G/RR?9S[V?T^2_OT8_GJ9*PANL3[/B3UM^CCYUX/[
MN<_+)]G/O9_3Y+^_1C^>IDK"&ZQ/L^)/6WZ./G7@_NYS\LGV<^]G]/DO[]&/
MYZF2L(;K$^SXD];?HX^=>#^[G/RR?9S[V?T^2_OT8_GJ9*PANL3[/B3UM^CC
MYUX/[N<_+)]G/O9_3Y+^_1C^>IDK"&ZQ/L^)/6WZ./G7@_NYS\LGV<^]G]/D
MO[]&/YZF2L(;K$^SXD];?HX^=>#^[G/RR?9S[V?T^2_OT8_GJ9*PANL3[/B3
MUM^CCYUX/[N<_+)]G/O9_3Y+^_1C^>IDK"&ZQ/L^)/6WZ./G7@_NYS\LGV<^
M]G]/DO[]&/YZF2L(;K$^SXD];?HX^=>#^[G/RR?9S[V?T^2_OT8_GJ9*PANL
M3[/B3UM^CCYUX/[N<_++=L<;#MX<+F\=E9O:W*Y8.CS^TOK&W!B+LV!E\P34
M=!V9>[4JZ^L ]3*0]0X.T2MO*"4W@U-RS5=6/$,D+!L]#B,>Z2?$#'!V(2T!
MQ;G:'9S5N-3&&DMJ 034<W"_I/Y 81P;-R,MRVD)&--PC $XR!.1(LO#BD,F
M(DN+&'B3/-W16RT;&(@1W0XSF16L,)\XYAV_[W\P8J@D#+;4YFE)8R7<'3TT
M=RF)$?795U86U*OA0BS5@L!=2Y^7O/SA18P8]?R%DR(V6L;4M$*V(\KA&/!A
M0W247'8XN=$+V'&<<;&+6YBTQ"[&BDN=CO (Q="\UR?Y5>C; &',)X4E^7&#
M3)SDNR5E<'0Y*>A<V@0S+V$*/,$Q6S3)"%+B5P8ULO+\TE(D2"3%QL958^SG
MWL_I\E_?HQ_/5IY*PANL3[/B7M_6WZ./G7@_NYS\LGV<^]G]/DO[]&/YZF2L
M(;K$^SXD];?HX^=>#^[G/RR?9S[V?T^2_OT8_GJ9*PANL3[/B3UM^CCYUX/[
MN<_+)]G/O9_3Y+^_1C^>IDK"&ZQ/L^)/6WZ./G7@_NYS\LGV<^]G]/DO[]&/
MYZF2L(;K$^SXD];?HX^=>#^[G/RR?9S[V?T^2_OT8_GJ9*PANL3[/B3UM^CC
MYUX/[N<_+)]G/O9_3Y+^_1C^>IDK"&ZQ/L^)/6WZ./G7@_NYS\LGV<^]G]/D
MO[]&/YZF2L(;K$^SXD];?HX^=>#^[G/RR?9S[V?T^2_OT8_GJ9*PANL3[/B3
MUM^CCYUX/[N<_+)]G/O9_3Y+^_1C^>IDK"&ZQ/L^)/6WZ./G7@_NYS\LGV<^
M]G]/DO[]&/YZF2L(;K$^SXD];?HX^=>#^[G/RR?9S[V?T^2_OT8_GJ9*PANL
M3[/B3UM^CCYUX/[N<_+)]G/O9_3Y+^_1C^>IDK"&ZQ/L^)/6WZ./G7@_NYS\
MLGV<^]G]/DO[]&/YZF2L(;K$^SXD];?HX^=>#^[G/RR_5GT=.]M.^U1/;],;
M+[+K;[+['\9MOLOMUTNMNMNM/::VW6ZZ::VW::Z:Z:Z::Z:^6F2L(;K$O;XE
M!]+?HW((/*K!Q!%"##G""#I!'-<X*O1%L.;K0<5/PXOLVG,I%*XV:Q:/N#1R
M!/R*\G)QB?-Y\9D[HHY)KN64PG<[83"]0:X:FV3/%^-0%A%2T,B1:=%DO.M8
MZ&[!\1XL@QN,YA)>YD417/+B21$BQ!$.*0X"#!9C>Q5?-)[E!R'FIZ5PA+^D
M/!DE';AA\[-,EY;"<*"V2@SN"GX+EY*' ;!:R+(8,P9%P>!&;$EHD3#6&)LP
M09AT&)17[.?>S^GR7]^C'\]7.R5A#=8GV?$OIGK;]''SKP?W<Y^63[.?>S^G
MR7]^C'\]3)6$-UB?9\2>MOT<?.O!_=SGY9/LY][/Z?)?WZ,?SU,E80W6)]GQ
M)ZV_1Q\Z\']W.?ED^SGWL_I\E_?HQ_/4R5A#=8GV?$GK;]''SKP?W<Y^63[.
M?>S^GR7]^C'\]3)6$-UB?9\2>MOT<?.O!_=SGY9/LY][/Z?)?WZ,?SU,E80W
M6)]GQ)ZV_1Q\Z\']W.?ED^SGWL_I\E_?HQ_/4R5A#=8GV?$GK;]''SKP?W<Y
M^67:WZ(G;OFG ([/:.88 7@BDI>XU4C]A5<8MJ3L#(3FTG<AZN?/=+=&=Q-A
MHIZ;5/77ZS9YGG^2_P WT. I68EA,V\)T+','%QJ9\6UQJ4)T8PO7YR]/?*S
MD[RIB\EW<G\*R^$Q(P\,":,!L9MB9AV##!#K6%#K:"#%IBU^0:TS5FWZ3/*V
MYW&.-,2H[5G1"V7R_,; 1/!^/QF()=N&>XF&0V82&5K;=<99Q.@H%D>?#2 N
M/NRH-WZX?LX9I(2K$*M>TO?CN^OSXT"IKT GJKUTT<:*M>V+Z3]X[@&(XEDE
MT7S3DLY!=^<GFTR?8^6V[R^)F-D1R&6FL999PT40)HQ/+;@5D,*)E>D<?]D6
M!L.])AVRPLHU:M"DMT] JT::_*!-:ZLUU*J( OTP&51,TS+FD[A8K,-I #;7
M]&IN ,,!DL@P>6;>H_O" RIY)G:2+@.V-YH+:/GL>65#6/ K-B+AQMR,>LWQ
M5B&)DQ10#];VOH-/PZOC32LL;^F<MP^1G\))8UF^>\@BL_;\FZ86PG#H&X!8
M:VIYM3QI8(B>H>,NTYS,";HJ. XUBSQHU,R?5FY<36;B'5R#Q^3$T= (;KTN
M%?X5.I7 CGTB4WRQD7(<>V^[4Y9D[&N,C87'\LR@;R? L8OQF4I/@D1G8*$4
MQI,[F<A<1,:+E<,C,OD2!'62BCYQWH @4J8!'SS4HQ: $FE<X&L5I4='0?JZ
M51S%/TVT]!X7V2RK<?M[& 3.Y[%L4R2=RHID-IC+"&B,NR$ZB#</!Y=*H\3@
M;>;#0R2<W*XYR9DZ N!<6>@T&DRE1XG<@F4EF=P!K0T_ZC3<#]2Z([[?I#8]
ML1<Q2R88MDDZ;9$QYE MC92-&&K=Y,LRP<ICP?$<#,QRPQTLG)\II3MRZBA5
M%1[IIK%#;:X,YOT2OHH:W&Z>D5Z@:Y_J_BJ0O?I?B.7R.(9=MOAA=W Y(<S&
M#C=Q(K$KXOFZ60KZ.@KO"4BI=^^"*R"&AH'*RD>@Q8U&B;=Z_F0,ZP>7V"&+
M]BL4XI&GJ^D5=3^!T]2@^+_2][LX>%QIFK*6#A\ZQ[=]$MA/?'FB"0F70N,6
M1UW*<M38#)LH14R6$/C99W*,?C8\?CF'57UK +I>1#%)6@9'>M#93BM)H#^O
MBC,?JN/T*]/TO6^22[4=ON+Q>&\MXNPMG3<MDP%!<7Y+S(ZC+*!P"/!QJ\^R
M)/)-9,]=(Y>/9Q@0WAC9,IYUNDHG\9L1LU<WI76E5C:G02 *D"OT#0"=)U%1
MJ'^F1OE.!]J^3\4;?G&;I%G_ &@9LW0R0<)R;'H #@B^V36#BLX1%T1-"3JK
MQX.E$B/1^/7,6[I5Z8##FCM!H++.SX0I+*%P)I0@?36M#<*J4P_TM$,/S: 8
MU&8:E=L]S.7V5O,(QDC)13-]D3%6\3'TCR.IE>RU(:[O&AL(A,<9?1R2P:IF
MM$GV/M$6A.S22BKK"C$-*ZL:O46FE/B+UX_I)95N[QKE#9ZO@7=@_P 00_<?
MNBQCM:D$*MPGB*?( ;95"<PS8KD88?FH,D;<&;]8.'$)@5U[ J3?TSI/2QRI
M?Y\?61=_$(VF>HK0$Z3U*IT7W';\Y5OLW X"1R_N=D&.L"9JV_8GTD&'=I.U
MV7X]<LI%A?$,LFQ_+<QEAJ-RR&7FY!)I!(2Z41$G$HW&W^MT?MUN8LQUCZS]
M&;A531H:TTSD'23T$CH_Y+WC?I>G;KZ8!SMIORWB)3;(YR(6V5L,;V$8O;EQ
MGN>!P<7D.[+;IK:I?-+X 5FBQO;,ULUMTC';L:U5LLM)+++5*G$]BM#723GI
M2M*#-IZ?H7N^CHW/[VMR>8D#>3)]N7(8Q1SQN>ABZ8[:WMM';8UHQBF>Y2A\
M6$.,W,#S/,;=ZFE%@[!P[0B.KES.$] SAPJ'<N"MT?6?HS<*HX-%0*5H#I-<
MX'50_5T+_0E4K&E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B*H&]W=A'MH&$E9Z\7BRT]FLH!8FPE')G(V,0C
M$KS%-_K:,4'R>4$G#5C&X6$;LBLSR#(W#A/0# HQ)2C>UT_;,V+HI J:='3]
M']:.M< 9!],;NV4V^[+\J0N28L-E9AM'8[B<_.@.*W&08V,E:6<X/C VRS:3
M!3<,GMIPBP!%Y6\>9$2:20RRD$=--UAMB$=<M2!9,08SAG^509^HGZS^'35=
ML/I)LD[J\/[=9'F3:R9C;5QC"-3"=RX.IA\YG";3BT2"\^%Q.'Q05+8<.'QX
MC(%M'^39B]+*OXQ!1S\I'V+I\G?I:6,4KG_&BN!A2>\5<-XER?\ 6XV0XCXS
M@D\U?0TBL7B#S67185(+G45*N+$G!..+ZD-50A!=)-=X,N;.%4[%%+K="A2;
M1$HB41*(E$2B)1$HB41*(E$2B)1%PF/_ $K9^3_2+%-MF&%<>RG$4)P]NR"Z
MCVA<03RGES=;M]'8Y*OH/%H_82L+L(Z*=RQY X[Y&2;W(,XCF441MC@/"&A)
MR5\7V:]-6W$'ZL^;Z/K4U?1?;E-R^;&>8<?[O9(]$;E<=1C"4GEF'CFV\5@]
MYBUGE>+20J/)#2X+.N9Q>6HD?,@S8H.9<W8XE(E>%DVLL@<;(ED1[,H<!F(T
M&N>M='U"F:BSVQK(&\F<;B=T\7S)GO%F=,&[?R(/#+"60O;RM@XD>W#WBP4U
MR(-')W9=RCH^BV+8P>CD8*/E5VUYF=R$^*0;L;($LX.D-*"@()UFN;H_5"ZH
MT54HB41*(E$2B)1%4O<GB7;5N6 C\>Y_A#B9CH=+&DMC;EB6E</DL0F(IN\8
MM))#9U Y!%YK%3*3$B087$8Z?&.7#!Z[9.+U6KA5&_&8K :&M1U+HPL&3<5C
M(K!#+7M#FU>-!U@CX%5Y(;%/H[24'QMCI;!/U:*XF<Y)=0U 3+<H S.E^9;4
M+<NHRR6!9TPEF16.4;6K.W(0W(AN5#YE:R96R%L0M9MM$HMF==RR9)GL^:'G
MI_B#HT='1T:NA><GL-^CL*$XJ9<X)L5?0N*X9A -LK*\J71UW$MO#)JRPI%Y
ME$D9^WC>1(WC_P"H#W@P).QT@8O"C%J8*)O3"")!-;,Z[DR3/:*0^G]<=.FF
M;-]7\5$N+_H[-L:>,;XUNA>N]Q>32F7MR&8Y+E*-#IYMXT($]TD]7G64X,Q
MXWRHN9TQ0>6T%#S.-Y3-IC%Y$F(;+FF#K2U!LU6S.NY2<%3W0(8%&BEH#\D4
M'0K,/MK&QHCG$7N,=889:Y8$$(V;:%$'\P9Q5220V*JP>'S EC!G)D,7&9Q$
MH>KK&HO."\,?2V/ADV[ 299H-&MB*V9UW*,DSU*4AT_UQ^-*_2.E12V^CO\
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MXB?D%C)2[5CQ*5QAH!- ,U:4KFZU(P?@\OQ.;N%2X-<8D8-<6_*#?TM<VL@
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M."&0[8^]50;)96F8L6V-L==;"< TH,4XM,^8U.O3F1T$N<^):TB%S70QC L
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M3P)>$7J2864MU9RR,+!]4C5FU%<SA6F<#5QT?BL,5@?BD-@Q*8PI%.C&IG!
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M2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H
M7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/
MAS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/H
MTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0
MN"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<Z
MF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC
M][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\
M2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H
M7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/
MAS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/H
MTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0
MN"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<Z
MF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC
M][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\
M2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H 7)1/AS/HTH-0N"<ZF=XC][$\2>H
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MB3U "Y*)\.9]&E!J%P3G4SO$?O8GB3U "Y*)\.9]&E!J%P3G4SO$?O8GB3U
M"Y*)\.9]&E!J%P3G4SO$?O8GB3U "Y*)\.9]&E!J%P3G4SO$?O8GB3U "Y*)
M\.9]&E!J%P3G4SO$?O8GB3U "Y*)\.9]&E!J%P3G4SO$?O8GB3U "Y*)\.9]
M&E!J%P3G4SO$?O8GB3U "Y*)\.9]&E!J%P3G4SO$?O8GB3U "Y*)\.9]&E!J
M%P3G4SO$?O8GB3U "Y*)\.9]&E!J%P3G4SO$?O8GB3U "Y*)\.9]&E!J%P3G
M4SO$?O8GB5;-S&8$-O<0MF++#K*;AV V2R.7G7\E@^-X7"8Q%!R3YXY/S*7W
MICD3T@=.F0*#@-$-$SYI=6PB7CPID]+(*#4+@I$S,G_S,?H_Q8E<^H8R]\\R
M8H$PF!S5 \-L96.*1X5-S(.;'HQAUW#((^BCN5DI!+'\M9N60AS'&Z31J>#.
M/,<,%7#M55>U(8Y\J@U"X*.=3.\1^^B>)9[;S-K,XX4QSEX]B!QBA[D2.HRE
MO I.F(?GPH4HX<+1Q<HHT:-]&SHY'M1<@N%NVK(L%M*VB#;%B88OFB*@U"X)
MSF9WB/WT3Q*9O4 +DHGPYGT:4&H7!.=3.\1^]B>)/4 +DHGPYGT:4&H7!.=3
M.\1^]B>)/4 +DHGPYGT:4&H7!.=3.\1^]B>)/4 +DHGPYGT:4&H7!.=3.\1^
M]B>)/4 +DHGPYGT:4&H7!.=3.\1^]B>)/4 +DHGPYGT:4&H7!.=3.\1^]B>)
M>MJP8L?/T9,VC/13S=5-&K=%OZ3S/+YOG^BLL\_S?.N\WSO+Y/.U\GD\NM30
M#0*+&^+$B4M(CXE-&.]SJ5TTQB:57G5-AD%+T5RPQ%9.[6Q1)5^U343NT_SM
MOLO5TNMNT_XZ7:::Z?\ *HJ-8O5VR\PX!S8$9S3G#FPGD$:P0VA^I?/M !YV
M(\29]:E1K%X4\UF=WC]U$\*I-FC9WAG<AEV0Y"SE-2DKB+C"&N#H?C>+Y%GV
M+6<= RTX:,9M7D!S'62(ZO/6.84$,8B#$8/#K8^/'XM$:WM"S@FX5:JC6+PI
M$O-#1+QZUK6Q?]7ZO1GI]*K1D#8+D;).)Q>%)YNJPQE>)J8OA^/",MS+MS&S
M?+, /Q.+-H4MEW;U-F>9H^EBW)1P0+#2NXH8$3E./YC:.,D@_0CW=T'L5&L7
MA2)>8!)YM,#/H$.(!]'R-%?AFZU?EOC,"WW$L<]:9#'+6L<$7X3TC#KZJX=.
M/.G+.9Z2AQ)+C/G*K:Z-/5ZPVX-K<LHK<_U)VZZ?5;E1K%X4<VF:4YO'Z?\
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M>GM !YV(\29]:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\?NHGA3M
M!YV(\29]:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\?NHGA3M !YV(
M\29]:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\?NHGA3M !YV(\29]
M:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K
M%X3FLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K%X3F
MLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\
M?NHGA3M !YV(\29]:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\?NHG
MA3M !YV(\29]:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\?NHGA3M
M!YV(\29]:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\?NHGA3M !YV(
M\29]:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\?NHGA3M !YV(\29]
M:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K
M%X3FLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K%X3F
MLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\
M?NHGA3M !YV(\29]:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\?NHG
MA3M !YV(\29]:E1K%X3FLSN\?NHGA3M !YV(\29]:E1K%X3FLSN\?NHGA3M
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MEN^E>RD/[G+?[)JUNJ+;5+,ERS/\BW,<&<29(@F-@XK C#*3EY+<4O,F7EI
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MH0 ."I,V(4>W0@PWD4.)U:<WT9E+<)2C7EX;-5<XN():6DD4SM,6F89@.@
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ES0V%@(-,YZ/^@7)PG-PYLP3#:]N((E<<-'RL2E,5SMDUK1?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g358845g35e94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g35e94.jpg
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M  (1 0,1 ?_$ !X  0 !! ,! 0             &!0<("0(#! H!_\0 >!
M 0,# @$%!PH,#@H,"@L !0,$!@$"!P ($1(3%!46"5-4E)66U!@9(3%155C2
MT]47(C,X059UDY>QLM$C-E=Q<W>!D:&TMK?!UB4F,C=A=J7#U_ D)S12:')T
M>(>2L[5"1&)CB**CQ.'Q*#5#149D9F>#IL+_Q  = 0$  04! 0$
M     0(#! 4&" <)_\0 8Q$  0,# 0,%!PH0"@D$ @$% @$#!  %$1(&$R$4
M,5&1T0<5%B)!8907,E-457&3L=/P&",S-E9B<G2!DI6ALK32U @T-7-UL\'A
MXN,D-T)2=I:CM?$EHJ2VA(5$94-%8V3_V@ , P$  A$#$0 _ -CF\?>%NCA6
MZ7.\3B>=\E1^- ,CR 8%""Y*]:CA@]LXY*#-FW3NI8B@E;[%EEM.%M-<3/GS
M6YLEMN2Z("Z2"*%P1.A*]W]S_8#8JX[$[,3IVS%GE3)5HB/29+T-LW7G3#).
M.&J9(B7BJKSUC5ZNK>)\(_+/G8_^/K#[YS_;;WXU=AZF?<_^Q"Q>@M=E/5U;
MQ/A'Y9\['_Q].^<_VV]^-3U,^Y_]B%B]!:[*>KJWB?"/RSYV/_CZ=\Y_MM[\
M:GJ9]S_[$+%Z"UV4]75O$^$?EGSL?_'T[YS_ &V]^-3U,^Y_]B%B]!:[*>KJ
MWB?"/RSYV/\ X^G?.?[;>_&IZF?<_P#L0L7H+793U=6\3X1^6?.Q_P#'T[YS
M_;;WXU/4S[G_ -B%B]!:[*>KJWB?"/RSYV/_ (^G?.?[;>_&IZF?<_\ L0L7
MH+793U=6\3X1^6?.Q_\ 'T[YS_;;WXU/4S[G_P!B%B]!:[*>KJWB?"/RSYV/
M_CZ=\Y_MM[\:GJ9]S_[$+%Z"UV5<'$N]C=J8RKC,04W"Y2?C"F088.(L7,I?
M*-WC%](QK9VT<)UNX*(N&ZJB*ME?8N3ONMK[%=76+C.)YD2E/*).MHJ*7.BF
MB*GX4K57WN<;"1[)>7V=E+(T\S:K@\TX$)I#;=;B/&V8JB90@,4(5\BHBU5,
M[;T]V(#-^9 07<#E 8&"Y5R&($C6<H?(M!XP;+B[-@Q:HVW<E)LT:HI(()V_
M2V))VVT]BFIDW&<$B0 RGD$7G1%$+@@BX2(B>\B8JQLSW.MA96S>S\F1LK97
MI$BQVE]]YR$V3CKST".XZZ9*F2-PR(B)>*DJK5JO5U;Q/A'Y9\['_P ?5GOG
M/]MO?C5O/4S[G_V(6+T%KLIZNK>)\(_+/G8_^/IWSG^VWOQJ>IGW/_L0L7H+
M793U=6\3X1^6?.Q_\?3OG/\ ;;WXU/4S[G_V(6+T%KLIZNK>)\(_+/G8_P#C
MZ=\Y_MM[\:GJ9]S_ .Q"Q>@M=E/5U;Q/A'Y9\['_ ,?3OG/]MO?C4]3/N?\
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M.<.':=DWHL8H;:M,.RRV@24XT&, 3_)V-ZJ>NW09]:E8T^KJWB?"/RSYV/\
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MIWSG^VWOQJ>IGW/_ +$+%Z"UV4]75O$^$?EGSL?_ !].^<_VV]^-3U,^Y_\
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M404$E)41,U1ZH%M)$:;M-_>N??"YVX[(Q#BNW1MVSQ8LVX.D SUB&RS&G0G
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M&,L$\LH,6Y@+$$D4XH5?E5QA-H^4,D;'MM)(T73I6R.HEN8*I#I>0%; 4(3
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M)Q6+HW).-*>17##E,;>&SO&TH3K=AFIX[C1-8U'>NXP/?#&\C2@D*1DAA!_
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M,U+GC!RHU?-LN\MNN-1$%MYZ,,ULI[,?6KKD5&GDTH#9(XX R%8-UH,D8"O
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M/%R!(MC&#D'SYTI59R\=NHX.67<N%KJUO5774NN455OK6]2^ZZ^^M;KJUK\
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MP==!IS>M X8MNJ&[WK8DJ YHU%HUBB%HU%ISC4N,U1=5U;II2FE*DD/6Z/*
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MTB+;L C5565][F3R\<XQ\2>;@F*S-- -EV,\6N'4D1V[0'"^3,= <4K/3Q"
MQ?&DZQC:WG$ACT*L>D73*,R"-.&L_P A'F(]%9TW?I2F2EK:.+2#UQ>J..?+
MG\_SX5%Y'C;8.;FT\<2H;MS(SQC!2TBR6T-GH<N:&P8Q D88<GTS#NRM;QR!
M+&!E"*$\D&&2!!U RJ(-S(;X^^L:JJ97FX^;WZN(EE/:64/PV7M\H8 (2&?B
M7N+8";;S^ .7<Z$7&Q=SZ!Q19(Q?;*T4I X%)W@1="%S4D^0;VMTER-4W"F%
M\_#\U>[%^Z3 V9&*9?'F2HH>!NX]?*A9JP\&;M# %J1D@LL18-G!!,K1L =Q
M8K:=7>CF:(VVU.JRG&CBUNJ,+T5<2,Y3QC-3AR,0W(T#ELEC* ]U)(]&9?'S
MQR/-2R-K@4Y."11!V_$H$V]UJX]9^W;IO$;K56UREE:7:4J>:4II2FE*:4II
M2FE*Q#W1#-J@LIB.<[B8L&,R<QD*'8$Q(15'%2$EK*,WSF* 6<<#4#JIO&X8
MB=9 #DM<JUL%,!49M-%K^:#M^"G/\?4F:]&-LE[>,IE9K 8U&W ]NE(#65KW
M1F-.8Y'LC/8OD5T"DN4(B5N43MD;0%DB,6MB)A7HCBZ[LY(&[=U%)-%31A1?
M/\_G_=5GMMN5-HT$#A0FWC$\E@(F:6X13$1QE$[XMTG'&4+I*-P=D07')$>:
M.+,=G&H&9JC&(-A=+  >,2A](X8$'1HHLP5*Y\O'GSQ_ N?/S?FK8KI44TI3
M2E-*5KADGZ8C_P!VBG\>7US3GU1S[LOTEKU#:OY+MOWA#_5VZTE%.Y0C,LX3
MOQUDR;$(C)8[A5YMY@4HC#)J2)QP5$<HY6>Q'*C,C0LT4=.LAXLG[B+9"A#Q
M)E8X$225@%RRE'EKVS(Y4HGJ%,HIZU1>"+D0R..@2%%%<\Z(M:$MF!E0UCR'
MB:-N&4!AQL14FQ:DR5:E(2$.5?C/JT^RJ#D'7FU)4+-7U8=SI#,)K,YREE)W
MUS)(GN9 @7-\$!O7$*-;BXY@*/62\/4P1*CW):!)X,L<#D7@RYJ;I*WC1]:U
M:L+DR=O?KI0=/!";5>*\=&O@N/(NO\&//PS4L(H\\_RE=;K5Q %W *K)SVX+
M>]#61BI,<BR**.#WJH6$'QL87G<KLG"C8$3'<SQDN*EBVY,CDV=2S')66W@;
M\SX$V_X$ZJCL4G>7)7(RKEZ"Q29+#3Q+(#NL8)OV[%X/.QA*X ]O<J%47(*B
MIN]*(6,Z3,\JHBB)Q).&GCYEXIKEV:DB;8!+;(7%N)2'G8YNJ'+(,""@-MO2
MW7"50BD0N$^N[)4%1-OQ%GQ[N3#21FY$L6W G2L7?P^20*/ C<-?EGHB*20S
MA$NJ.*JK9%3AI-=A9A 0,M)@,?PTG(&9AXYG#J6&& XHE0DK"(B-HBH2$JYY
MU1#3_=S_ +:KQ)43_9TIPJ\YLNCAN*4YPFR:<8 ":4B%MQR&Y@E5_<DH\C =
M;;#).(:J^KIH))<#+/<V>WLVR#-HIE\3#',^/9E>JARV'Q<U!A0&;-O.!-ND
MA"#&*DQCUB3T-&<(W&H\83J@@@5D]K,B&) Q#P9(8&1@1%0SIT<4/2JJ#AN)
M_LKSJ6%][**B\U^5L_OGWWVI0LJ\<M=!Q1> &YD&# ,!'>MX(&X6ML^"(3ND
M@( 47,E=M.!R>&Y)G$L^O5M&2^18RC\&:NB*10I=CW#N%(!BT&:D;MO2U"^2
M20P DIAU1.VV^P,N!2=IHOTG;=&VX:&@8\B$J]"*1D6$\R(J?AS6QM\(HCDP
MB]:ZY'!A%)"+<1(;$8#<5.=QPVW#7[16T7!(J)ECJU6SII2FE*:4K9HC]22_
M8[/R::ZBO*)^O+[HOC6OB)[JE]?YN)^[4-_FSA6ONNR7UO6W[A_];?KS?MM]
M=%V_G(_ZG&K7SKHZY6KN8:CV-9/(RPO)THMB NL9?.@9==9XW8]HFI 4JFU(
M*L YQS1!<+0YS%B;*ERY&QBA8K2]6Q)7#FN2FF@.*UOCWHHX"(BENR$TR**;
M:91S=Y52X#J5>"*J9UO:AO.N!,>W ;DB;<520=Z) N"TMN+A6]YI33Q/2F>.
M%RVI ]AU"ZZ++($B4L$KU487F).\:!9;5R+).ZHOG;7%Q![&VH15@WLL4M8E
ME3A%\B.NM;(.[%F.GY1M!H12CMHII@D!H2-G!BF1190BZKB$O^T.[$5+BJ>-
MO>3;,:U093RZ,J"N/&+;ZJ!E@E2$1,HVHIA=)JX9(&!0LC4LD!]CL?6D\\QA
MD"9.92BIDF01$#&C#F(,FIRV=-D(:.#N:1AV4!C@P)XJ[%6J*I+'!3'G:$1S
MNG"RB*=^=1J/+CLHTJ16WG'0%XE;6.JOD:;U <(W!P?!4 RQI)%Q5<QO9MI7
MI4*5(5]%ENL-,FK "XDI$C@VNX4V@;:)2#*HK@#E# DJFQ6W:>0Q!<7GTW4.
M99EK5$E)#,C)F#<N9F6V,]R+(@+;(/((1;!&%)9?A6QF3H8EI RY5&E4;0]P
MQRV;5N]]QF:([&[ALJHM T -LD"RK8H$JC(%7"W7+M0J# @B$*ZT-"6ECO&<
M'>2I2NSGT0WG'C<<>%Q(5X @35%-&PWZVU$/>2",E!Q-WH41[C&,MAS22KV"
MLL%B,7K,X&B26?2$N(*Q^#/2$?2DSP$T&8PF+.;'JM59)>Y:T,!V89JV%/JO
M.G.G8%C 2[^K2*<,1=W$A006P,''Q%Q6A<4Y3*L-Y1K"Z#)PB(4' H92Y#V9
M%[ 3G"9Y1%0U)UP#:C&;2/*V(0Y R'=*O*J;QL6T$"4M1$V/C%8LV.H1T?;(
MLQE%I2T/XZ;GJA"3Y0,_&D+X(A/$0J[B$)N4%1EY&>.63Y5F_$.FX-M58R"O
M0&63F3EWY7"W4(4:5N2H;P!UB0I(5A31'U14/3'11U"8J:^(YJ-8]#<+9M&@
MWUP-7Q=B([NC-6C EC))1HBC:D4-<DA)1)LD:'+K6 Y54+H#L44O>B7&52-S
M$2:D%&1%NHZ$$*Q9ZJ$64+U<(0*1=II1&;+GC2/PV]^F(D2]I"UI,:,F[<D8
MI21?TTFD0=1@WJ%=)CO10T0,+(:W33JX5U]!UM^+EC4J@%?)=F54VUFGH;<=
MTFBD![@E;53RD5W?O,^,C4?6@/+KTR-*"9VH-1#:6O,\7B0<WD8N+'"\GBF0
M9"_(K&;(U8O%(G6(9'JW0B QS:$8S.1G[C<=9H$W[H!"E6S9RD^?V/G&8V]=
MT8EFXPV;K8-/1FA!&U=PZ]OHV5>)-X3+;:-N*H"CCZ*J*@Z4P7&+$LB$VW)>
M;9<<>8END:N;E%88W$S"1P7=C(>=WK(H9$U&415"-#6^%@78"(:RQG'I&_E%
MCF.NC446G+I^.?##Q<3)) -%+NQ<30J\<1 4M'(<58.%*!)!.6I4BSOL9.12
MC+!U[0F31.MBSI<1MU(Z"0FV!M-$:"3RX1TT=? D\=MA0$LJ)(6RW>RS:/@R
M\3Z$R3C*RE,"!TVWG0!2;83*L K3#@*N[>DB9"J"K:C%FTBVYP_<.M*<1R9.
M+ 9!C[."8CKTI(UX5&<A/Y?EJ)P(2=O! 1!5>!R. ,(,>5".QQ<(DYE: R6=
M+C2)E@VNJU<GK:C4QI77&I$!3W8-(^['%F&](,-XX8I(;D$^WO!('%1I2:47
M5 EL(]:6+LK\![<-.Q;DC>]-U8[,HWYS$4'%::;/DSL48SN[('&T)] ?RRC@
MC*A<WVJ,2>,HT5"8?(/".2)4_P C2V/Q$BCCMD':E+% J:+>6@B$_0CKQ1+E
M,V@X@W95&7KHJA46:J#)&R;%V()3H'-%!BLC&9=>'E*F0X-55EP8RN(B^,1"
MI(2(J'J15J^$FR"<-DVX!D<MXI;[3#B1!!',MH@OM%*1DL>*@$@Z,HK:"J"G
MG=I;+'<9GS,W((:ADF<P@#'0Y2#Q>65@<+R/$8B^DI>3!*OZAU@ &=S)S!8<
MZ>-@99BFD)R;42":!20(G9(]_!=CD#;RQ6'W'#!]UGE#\5YX6@:<0=:..1V4
M?>1%< E4XNMQ3%P5@O!TF90N.QTF2(S3+9QF7^2QY<>.3SC[>M 5MJ5(6-'(
MD:,40)B@TC9MFF%N>14="9>G0N*HLV@EH7LMO'C;K;Q@@RHQ:+28(+NLN4LJ
M+!R10L(&\A16RC%DWI:JK;2BEV\MYNN0XYNJ2F0>N+UYAJ5&C/[<VD RYO&)
M>"5SMS!IN?)!A!%L7/6CZQMQ1%7FP^T;>4VP^U%.*\]6CUF5@U[!Z_1GK9QQ
MX<RK:IQ]SD^SK3[0?R)<_O-[]&M[LQ]<-G^_V/S%FOOBV<+=(VF;:5^_8+Q:
MK_UX8'N_IU\ 7G7WU^.O30\R>]626HJ::4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*M1FG%J&8X,E"7!E4 FE/L13K
MK%%C81ON5Q/EJ$950&]&O=,[:)FUX6F%5=<]6Y@D0O?6(.KVUK593^_\_"L)
MMSVQ0ODV*9B(0*5#^W$\RI)\P"11J-CU JAV2;=89MTL"&5G)1-(D/'"XFC*
M5'#M*SK*EU(RHV;M;+"-55(O-YN'_NU52I5W-]Y,9$7R06SBX9Y6-34;DAT7
MBT5F<&A"4R&%[J(5'QZ$YGC^0A,;OB-$1:XL1E]@=<2ZQ6>.)4LN[<@U%-7D
M\G]G''5GXN'"LA1&T4&+@.VJ#5D]SA/;L4E9Q)ZH&<.TY05F>'LL8J-*6)&Y
M":*!6W.9:+G6EKT[)B5K9DD#?E2%SMR8TJ,\_G_N[*PH<]RT=P6)/:1#)AK(
M+J(#1<IQW%#*TN'.%<J@PN.&%"3VP_E@QA]:+D7./[G%\,0Q?$"9P<3;PF29
M;1 -KR]BIU=F5X\./X<\>G\%>N*]SYS1D-G;,LKY=;X\D$FR\1RO*,?QF+&F
M ])5AN)3S9&TUFD SDUB#E^<:B0HN71[(+K<* C]]+W4'D2$IN/S>5*C*>1.
MOCY,?^/BYJN.OW,\44B[F.',P$%%+W,)"MB@&%HA7/T, +W.T:FL"(VNY2;J
M^<9-P?N!F>,3LB;*C+!)],?DD$"9OV R/C5$7"YQ\_\ SV9J\>!=EC#!F:97
ME5OD G)AA%;/2L/C)*L]6<Q1/<;F43F_(+)1P>RE)X+8R;RL,Q9 DL?8QQ@H
MN(0;J39:;2!LB>M45<_FS^!,)_?QK.+2HII2FE*:4II2FE*Q'W*;0(AN2+P6
M3E9KD*%2G'Y_'I((4B4E)LF-H>&YLQCFDP'N")/&S!-[*B>+(Z/OD*?!^+68
M!"W-D:Q]DPO5*+C/GS\2I^;-4O%&U:0XJEC>0,LG"#(Z)AS<"Q<&>XZ<H*1/
M%4VRVTR=/XS(B24^OMF4H),1,=A\5F"(^,,8RRC[(L5B$O?NBMK]15SY/?\
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M$(23F(21"%4421%14KQZQ*NU:?.J_1L.Y(7K7A1&)%U./N<EO=7CKZ3W'O\
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MM$4X\K<SM5KQ]O\ V[([3C__ '75WO->?<FY^A2/D>KH\E6>_P!8/=NTK_\
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M"(F3;(J!<81##XQ=.CL2HJU>,X+!8R.;DF*S4F@\8J%47B9%Z^<."V6 HF*
MZ.M#0E!]X%5#EO321=)HBBLB0Z2B2**B2 J*(BB!OUR16U5QDT:T* N1F#1%
M;AL0 5-3:JA#&C,@ABJ&A"IH2&1$M54WN;B54)?9=*@=KR>2FDNEAE"#PQH;
M-D;94&FMC9^29@VZ[D:E(H^(=-6:]5.@LVG4K%1L$<.ARU'>*VY97=.8CL[E
MD%??( '<FQD1)Q40E;<-%5/7$NLD4Q$DK7:.[*CZ*^WJDO\ *'W$CQQ<<-'F
MY&DC%M%4$=:;417.D1W8*+2D"^:F]'<%:@WMI)P="#8NS)62*D'AM)6H/'Y+
M^C$QB+B44!]>.8,UR72V6)1)9]>'M>I(-*MZBVZ#!.>\=NROTIS2H$.ZW[VY
MU%%Y$3R-:]VDA8OTE7D'7A5+.M5*H\(;KI%-\UK$Q)'N31^4: F=\!CJ_N]X
ML89F'T84MWJ1!QH% 2WUV5YG.SN.VDK)(/FD-*2!0'8D/8LKFM9C+BTV/\XH
MT01O<]+D9LB\3Z153HJ:UK1MS39))*S&O$5F-9[P;0J).PUUJI$6=Q'%AO"*
MJXPVV(KCG5-2Y55K-L,V1+OUA!\T(6)Z;I$ 1T\HE')=RHHBKJ><,DSG2BZ4
MP*(E?<UM55Y_;-M_6X\>=PYCE3C[O+B@J[['L?9U\(+UQ>^OQUZ/'F3WJO)(
MY"$B,>.RN2DVH6.1@,4D,@,/U*(L1(0*Q7)%2;Q:OL)-6#!LNZ<*5]BQ%*^Z
MOM:BIK2]%^Z/9QR+#X.+CD<C03,,MW%1V-O(TTP_-IP:$8)RGMGS9N'QP[1Q
MP5RCBY^4GD<.8J.X6GIRR<M(P0D6,<D2J/AFX]Z%"L55:43SIQZ$XHJ(J>7I
MS^%*E(_?3N') (-/G[/'49@ *("G&;CJ.*9A,D8AD$'FK*6,LK1C+D<CF8'6
M4MLHD"(QS2YG)WF/<WPF-3.D\;2.>%XQC-T2E*F$\_F][R>3C^;/#"<>$J*;
MO]RP*0Y/9$6F(VC@HUW L=N8,[%G(N!9$-P.1OV6)J1G<@.S<8Q3+SI^/L+G
M$ZQ=D-7;O,+9*J^%!W@(;%)"3TIA.'X,\?-T8S^'C5P,)[K,L23*$"Q-/+H\
MM("N2)[&)F-)XAFV'9]&0H?"0_)$92*Q0U.Y[&57KT[<53;3.#3B?0.41M-N
MW'.A4D&'VS5483\V>=.?./FG/6R?2HII2FE*:4II2FE*:4II2FE*P4Q)N"RH
M_';BY)DDMB*20/#<-9%FN38  F<2QLED<$VR*\S/C)O)#\AFC_(H##R<>AC$
MYE:.  #%U(#4IC%\392Z&26, 53A.&,\?P^]T5A_%-^&ZH^#DD:-QW&./<L0
M_&N2\ZE4LB8KF$=;.8%CS">#)\WBBT+89P/J!7LNG.7388/D"S(IY-E%<=2.
MTICI"3M7=C54X3AT+PY^//[R?-4Z:REV^[J,E9;R7$*'!<0'8VRQZJQK#8LS
MCYQED:!N=KN8(QB55Y,Y&ZEA$+)V<\4(&C]R8Z&Q"Z)U<Q0+STCN>/"MRH5,
M>_P][BF?GQXU;Z&[JMT$U)1)O'H1!9BEE44 RG'Q46"JAI!BC%0W.-\*FX:;
M*R[)J0J>2E>%N0K9B6#]A>II2G,2](G(AP1K'KE%QGR_WXZ/?YZVCZ5%-*4T
MI32E-*4TI6O+<WO9K@7<3AG%R*<>7A;I"/&\_D"0N1O#L7C669VTQ#AXA'28
MM5./ VJ,RMETUR$7EMJS(7CK'ANYJBD[)($AZIQPSU='!,K_ &===VWG>,6F
MD2S]/LRTB<9AN#XJE-"I8 /*M:,XZ/6R<YDC\C:0,EJN+6(:"MG2-C:UO=SM
MSWCSM%D$VZBIS8\O8B_VUBA&^Z';@YW!<4A \<B8C/)K/;K'V38\"PW-LC6B
MH7(=MT\W%PEW$,?F,N8C.$'(FX,UQ1*Y:_F-@0K,,=Y0) 0K5E>,'BE3I1%Y
M^&,_GT^?XJF48WR9^D;?#L\)-<<1C&!2,8)1RJ7'XSETZ&1[)\QF;J+Y=@F1
MG<;RLMD;;84CMM!S:)*S/$$]@@HXZ<5F&4" 1H3?!51A./X<<>KR<?[>I%]]
MN\/= T=3=@08XE1D\ECD[*X C!&(*C8C.EA^6(3#,?N\89X0SV1PSFZZ0Q*9
MLG-L$E,NVWS^2STC%PS,?$1)F0*0E3"?/H\OG3&//VW;V_[J,G3C+40Q'-%H
MX\)7KYY93A)QBB=X@GL<?XZC.VV51 3(85*);+!0HHY&YL)NGI6)RK($*F("
MD1DD:D 5T[.Q@4HJ<,^]T+SYZ/>KUE^Z"A 2IY(OB:2B[53^9X[C1R2F4 9M
M\ANL";F(OM8R"XK;4VH] VVSN;Q<W& ;=E(IK+XN[?(QZ*/IHT:0XDIC^S\Z
M9^?D\^.-6.]=-;HKO9O(,9GHKAX#'D) 43N%==Y+>O(_B;>[.<CQ;J)P?C5@
M)X,-[27(V,/GC)ZZ(W77CC8$)=);2L+4QE<>][W'&/CJYSKND3)B,)/7FW?+
MK1U#XQFR?9&;E+&$70C^/L"B\!2&:RB-73=.+%9U8X!;AHQ0$T&A&%K^11F;
M1U9XSN$,R!-3'ESP_O5//T54\>;]BA6;1B!9&Q 2BKB69ES)B\=-VQIDWQ[P
MA6Y;+^W^%#6TD-U:!7\])+XQ;.C\,7.")&45/BG&-04T7?.X^"?WU.G@O'R(
MO6B+^;//YEK8_I5--*4TI32E6>SS,#4!Q?()<$F6.<>WA5PKDK-LJ#S)J)1V
M/WFQZ!UWV>CYB.E9+(G(Q5P,B$>;2 /4M*GP=K5PYY=!KY2L3L@[C=QD3V\[
M>Y+9 F#3.N9\@*0Y:((XT-GCEXM"$97R&T+@\.E<L0)P*DY:(8[&R&00.:YK
M#*8W8$Y.,=R67RJ+#H_*E583*\>"?W>7'GY\<:QI>=T9S79C45F=@$Q"_BTG
M* \6A(HV"S=1R/R)(-@PS>2SR63FKZ4"%E\9M3CEY#7,+7QX"DRD/O&S%68C
M"5[J/6J8Z/?X\.&<?/XJRP>[B,N@<7Y9;$K\>E<KXXW48;VO-)HQB,B&8Z*+
M9QE^WL2%GRD!5GI0[R86%W!,T#D71R2G212B%DFK601IJ922#*A$^+/4G]W_
M )J3;<LR9YRG)$K)I# *$#C]^XW'T@R!&6K<>&DF4,&[C"F&&+X8$(S>02>+
MBY2!BA^1H1MVWD"8M[5^/7FQ3JYFH]45/G[Z(O1\^BLTM*BFE*:4K7#)/TQ'
M_NT4_CR^N:<^J.?=E^DM>H;5_)=M^\(?ZNW5%U16?32E-*4TI32E-*4TI32E
M-*4TI6S1'ZDE^QV?DTUU%>43]>7W1?&M?$3W5+Z_S<3]VH9_-G"M?==DOK>M
MOW#_ .MOUYOVV^NB[?SD?]3C5KYUT=<K32E-*4TI60.WG.#W!9?)19@\DC)Q
M-\,Y%QHU7C3^H]RW)RT58W#OWJM'36ZX>,*(-2"U$KE'":C=)9LC>NG9PUUQ
M@#/",!"T2,38TI4='4BBR>3%$POC&"D*9X*BJBKBMK:;D5L.88D\*R;?+ABK
M):%0WP1&R)=0KI T0EPNI%1%%,HE9QR/NA4)JD2(0Z-S\?(G4?R99!G1"D61
M1P"ZF&-Q4-CD Q$Y'N;G26/8X?8=JT2%Z0$@T>M!3IA';35A,N2T36SK^1%]
MR,;2.1=^@[Y5N",R3>=DS$),+)=;+<J*;P2$C0G-WI >C>VJC8,X[,H'E:F)
M%4MRB6M9$-N.S$@*):DBLNAOT/#1(0MJ+*.(;AXQ8JW<R##N(7T8B0P6XRBM
MG%EEP7.95%(M,DHZNSB+L*D7 4DS8FH+F[4TLD38FT&%U[>RV^^US:M6EM=I
M+L[<V8+KQ&D1(!0SCM/.L;U">0U!S=*&MA0115M2PN>*8K3P;Z[;X!LL !35
MN0S@DOL,R$946";1QK?(:A)1Q4,7$#*8RA9J^\6WUPZ@J!1F>A\DFXS"1&W.
MT:S'D1Z:@.68D8S-K,I='^489+,R<F5D >M'K!^$.F!P>T8\.@KFXI^PU[U@
M>UR'8YQ0=?.Y:B(2P;,PF%99<P!(HM(VYXI";8$>H6W,F);-C::/NXK,IN8Z
MS&;M&[$#'+3\ 9"2'VOI@*)O*\WXP&VZ8-Z%=:5 ,)?)=_6)9$&S.'>1+(;I
MMDR @8\O;^BBR,GE 3#EF-K)#)Y,TRBX.*)J'VK64NFV05,Z-G[91TTJP9RB
M]Q-GUEO9Z8V<(T>C(L60XZB\#%IIR;RI6VFRB("8;4FA6,D!17"ZE:PP-][:
MB"ZW<&R8EJDR*TROK@-YYJ D3>O/#.5WBZ(OJDI;F))D= O*LDK#;K=T^-]P
M5^+$0<%.1P+$2Y H6$6*V#GT?"$QL+&J8\@)Y](9N@VC(FV,OW0"Y".16."W
MI/IK3'C9\Y/NSNPM%IDV[E:N2&W3> 0 L:A<,2>)),AL6V%5T]Z*.9<>=,1P
M4E41M&]7?+U$NJPD:C.--L&9FWG0331A'#DD5TGI*(RVC)DUI989 G%(8@DK
MI.VDW*9<@N45\5C8"PEEH?%^.?H?H&YJTC8<Z98IS&5R82@M'H9?=%1] (^1
MI!URK"U,C,23<A+Y"G89,NK+,RV0Y$1)9R"9URI/*%;85TVP+<M-&J./_32W
MA-ZT O%9%19;\0$K"O$^--6"$47]W"B<E%V2++;K@)(?>;16HZJP&Z!Y&U,<
M'(-#D.IO'"K&;6TK34TI32E-*54!2_1B+-QQX<RO8IQ]SDUXZT^T'\BW/[S>
M_1K>[,?7#9_O]C]+C^:OO@V=K=)VG[;'''CSV#<7J\?V2&A[OZ=? %YU]]?C
MKTT/,GO5?.41B.S:-GH?+P@R2Q64"" "21TTS1(ACH,LU58E Y8>YL4;/QI)
MDLLS?,G*:C=VU65;KIJ)*7V5BIJW&1]O.#<ODF)G)^*8/.3 Q-BD/+R( Q?E
M&20RR0I#4VQ!1/I:-K!*6RI%G;8M2C9&2GDD>0F7?VN%,^3R5'G.TO;$[6AR
MRV <24N@ \>(A]B,$CK5N#$"3;F3B1#=HV8(M5A0F3O7LG%C7:+AD.DKQW(&
M2"!ATN]45.5Z5ZZ]--J^VSKN9R*_!.*5R^0V$J%S=RZ@\?=IR8?/%K7,\:E6
M3IBLQ72G;JRQW.*=&MK,'=B;N1U)N$[%;51E>FJY!MOV$L:5'7P+%L)BK@48
M*2%B^$@62!-(\:!MHN4,J%:IWD7)1Y&6;&-JOG3I9S0 P8!;%+1K%HV14RO3
M5X-*4TI32E-*4TI32E-*4TI7Y6E*TK2OM5I6E?UJ^Q72E8Z1+:1MP@#,:,@.
M(89"0XPH-*V!8N);B SI0.#DT=%LWPUM;:T<"F8N7'D$QE4K62ECV]%=)5M<
MJ@HI7*FT;;!2,IPRN!<67Q9,YVDH#5AP=5A>8J 3B57"R2K:^KA"Z'HHPRX>
MO<H.OAB"$0N:5C:*0RQ4Y7I7KJ7VX%PM9)Y1-+,70BR636Q).52&R/#["IRU
M-\$)W]-=VHT5NN>$HS&GY.^RMEY9Y'(^Y*7.U@HR]JJ,KTU589B'%V.SDMDL
M$@$3B1^>/JD9B8 !&(U_(7=29DY<H2<-D4[UK+STDDD@40I6UNI())(CJB5Q
M8Z6>/%*N-I2FE*:4II2FE*:4J"&<7XYD3/((\_!XN98Y8#TCV3&I,*Q>H3P#
M0*O'+0TJ3<(J6FA=H)RZ%6,7U%FUC)TY1M3I:X6Y:E4=K@_#S('(8TTQG"F\
M?ER+)M*0J4>&VC9$W'/79%DW-M.8YDF@W?/WSFQ%Y8LGSKQU==;=SZO*4S\_
MS?%5(R+MQP/EPPC(LF8D@DW/H(@VZ)N01YB^+)H1E*:(1Y&TC>GTNB01#(\_
M1%I\]R&2,TE"2%++#A&UPI5+OVJ;:;RL,-TP-B= ECP;&0T*7:06/,DXZ(A1
M!4Q"1@]HT8(,[1\*,KKFH:S5;JH10RNN7CZ8XBLHYN5.5Z5KK2VG;9$7<U>V
M8$Q-<OD4?(!$VM6@T?<-I"+EI9O():.>LEV*C.UE+)"T9R&4MFZ"*,CD#-F<
M,V/BK1N[34RO#BO#F\U2B"8'PSC&\<MC_&4,B;L2K(W#$@'!LVQ2QU+TH\WE
M+Q<KS=Q)X]/MHC%&A9Z]=.'3UE&@#-=:]J('I-U1FK7Q?95MJC(^:LU,71F3
M.\A9!G62Y2?E 8._D;V1SS,4ASFYY@PT'#W+!K'IY(:NXS>RY@DR2"@'+\B3
M-#>N%E3GY^\F/BJ6,-JNVD75IU?@?$[-)@)? &;1O!8\F.0!$D<C-GX:P;:P
MZOJ*=-,OY49*C[FUS2K'(<Q8T2HTD!)%PIE>E?G_ .$JH"-M>  (<B $X>Q\
MS$& ,UBYEG9&1JE#4>R,A%6D\#F5ED%'!9C+&4%A(\Z@06<VOQL0C(Y;E,00
MQNU5&57G6NM#;-M[;2U*=M\-8[0F",D?S&V0)1<781OE1*1D)BZD"ZMJ%+71
M:DQ+F)@T>N;%5A\M,F9./N;'2Q%^Y4S\_G[R5?+2E-*4TI32E0+)&+<=9AC7
M8W*,,CT\BO6H<[U#)AR!090S'WZ)4$5M;.+;K+" <FW;D1KNVE%F3YN@Z;WI
MKI)WVJ5;Q?:SM_=L% [W%\7>@J,(JP8@G3*BPD);#',X= 7L?;75Y00LC]$B
M:-')<:HW)/AAUX(=.51BES2JF53F6JE3;3MZH1<E*82Q;1V\A-^-W5*0B/49
MKP-2.-8:I%%!M&%!MP56&L6,-59]$YM6(,6,74Y0%FV'I*97IKN0VZ8);1:V
M%)8G@U(K:.DHNH2\ R69J-9B?"2N4W+T6344</CLHC4>DA(HNHH3<'@HPQ<\
MZP9(.+%,KTU<6)1"+P*."HC"P F+Q@(A>W% @C) >-9)JKJNG%46S>RRSGG3
MQPX>O7%]+G#UZX</7:JSIPLK>I4CTI32E-*5K?D]]B1^0J*7VIIIF"UZBE]U
M+++++'KBZZ^^ZZM+;;;;:5NNNNK2E*4K6M:4IKFG/JA_=E^DM>H;7_)=N^\(
M?ZNW6AV+[Q-Q:[Q[E(=G/'>0=N1+<_MNP#CLT4Q[&8O(9^%FF?(G ,RY3&)"
M) OU7C4>-)D(CCR0$K5592^1?SA*UH!MCW7.3NF\:5$D<1IQPD0E5!P"D KE
M/7<RDGDX)SYKFVKK<%4I0S6)%O*Y6^#',F&VW'P>GLQY<D4 UTQQ$R:8<+BX
M2$]A&]WKSVW/;HXIC>&RIL&R<EC,J)B0:?N\O'<.Y$R-BL1#*3=E&CHX'*P0
MUKCF29=+TM>@(%C*LS5E3^4D@*ZD3+CE[&;^PVVI$F1U(JJ.E#$25=*JBX7Q
MD%%XD6G&$5,YK>7&Y-QV74"0D<@:!]93D20_%%K?"V8@Z""PY+/Q@8C;[>$Z
M0?2C1=):\Y'W3/-\",;2H1,8U'4)?)8_(#>=;:1LO;VH,F<.YRF6(H-"JAEY
M* &2&\CCZ'N,PT'2(LUBDBEX>, WSYBSERP.^D<"1U15<(HH&5];XX":ES+C
MQET<.*#E>.$71N;0S&#MC+S8(ZXVX<U-V67"*)->BLLZ%<;%Q28:67I<)&W'
M0;;)11U0JL4WP[LB>WZ9S-L4PW+R\&RELT0D>1$010&PI!MSL2V]2X[$XO$!
M[R1"S$JC);+S\ U+E90(28Q"\.7?,3$B3OM?E9:UBGCHA"[@<HJJK9.(BJN$
MPBH&51$7*\$5$YC5YNA07GD*&\3,BT[Q] ,!W-P9@.N--M"K@DZV4H@0B=##
M2@1"1^NWEZPZ[.FE*:4II2FE*:4K8^D="<TG_9@5]3L_^\&G^]I_Y[745Y0-
M4UEQ3UQ>5.E:U>[B.YQ[5\W97E.7)>TD):4S=4>\-+AITLR9T<"Q \$A8DQ;
MUN3;VT8#&GM5X*7\Y=_=<K72P=J[O;XK,.,XP+#"$@(;(FOCF3BY)>*^,1<?
M)P3A7'W+8VQW.8_/E-R#D2% G%"20!D&P:3 IG'B@/#R\5JP"_<E]H%O'FXY
M.*^WPX3]]=Q]S_P?8UF^&U\]FC>C!\6>'X??QBL'U/MF_897-[;/H][\WX%7
M/!:.OW)W:A;QYJ,3NON<)T^K_P#XKQ_U]GV]3X;7SV:-Z.WVU'J?;.>PRO2W
M.RJ,OW*;;#9QYJ)SZ[A_^M']?WN"?LZ>&U\]FC>CM]M/4_V<]AE>EN51''<K
MMNEO'FH9/Z^YPEQ"[_-_G_IT\-KY[-&]';[:GU/]F_8)/I;M4)QW+;!%G'F8
M/D*[W/[:"%WXDOQ^W3[&GAM>_9HWHX=M1ZG^SGL,KTISLJ/N>Y@8>LX\S ,B
M7?K2 C=_FOZ/X-3X;7OV6+Z.';3U/]G/897I3G94>=]S+QJGQZ/CC)%_N<#1
M&[]_]"_U]G]QX;7OV:+Z.';BGJ?[.>PRO2W*C+KN:T1LX]'QADF[A[7]DB5W
MXDO9_<I^[J/#:]^S1O1V_B_OIZG^SGL,KTMRHRZ[G$*LX\QBC)EW#VN#DI?^
M)+V=3X;7OV:*OGY."?VI\^:GJ?[.>PRO2G.RHR[[G>M96O,8?R==2G'APZVO
MX^S^PZE=MKTF,/15X<?I ='OI_;^"H]3[9SV*7Z4?9^'YXJ,.^Y]2%/CS&&,
MHW_9IP;%[_W/J/\ 134>&U[]FB_ !V]OX:GU/]G/897I3G946=[!I[92O1\'
MY4NK]C@.,7?YCV=3X;7K/U6+C[W#C^?Y_FIZGVSGL4KTH^RHN\V)9:3X]'P/
ME>_W. 4S=_F*4_U]W4>&][]EB^CA^U3U/MG/8I7I1]GD_P#-11[L@SPG2[HV
MW[+=]:<>'"-F;O\ W?V:_CT\-KW[+%^ #MIZG^SGL,KTISLJ(O=ENYFRM:-=
MNF7;O<_M2-WT_?Z/P_P_X=/#>]^RQ?1P_:IZG^SGL,KTMSLJB7;+]V-:\;=N
MV6K:?8IV-,5K^_5#6/*VNNTR.]%>=CJT^V3;B"R DHEP7!97"X\M9,/8FQ09
M3$R.U(%^,X+K2E),A0P7*9%>"ITHO/7VE;3+.R>U[;S&)->B"D4>POC4,="E
M'"#,D)+#8B):$!S]HLI:LV>,W22J#E!6VU1)5.^R^E+K:TURB\Z^^M=FBIA.
M*<R>6L@^O0GOR*\H-/EM14Y3I3K2G7H3WY%>4&GRVE,ITIUI3KT)[\BO*#3Y
M;2F4Z4ZTIUZ$]^17E!I\MI3*=*=:4Z]">_(KR@T^6TIE.E.M*=>A/?D5Y0:?
M+:4RG2G6E.O0GOR*\H-/EM*93I3K2G7H3WY%>4&GRVE,ITIUI3KT)[\BO*#3
MY;2F4Z4ZTIUZ$]^17E!I\MI3*=*=:4Z]">_(KR@T^6TIE.E.M*=>A/?D5Y0:
M?+:4RG2G6E.O0GOR*\H-/EM*93I3K2G7H3WY%>4&GRVE,ITIUI3KT)[\BO*#
M3Y;2F4Z4ZTIUZ$]^17E!I\MI3*=*=:4Z]">_(KR@T^6TIE.E.M*=>A/?D5Y0
M:?+:4RG2G6E.O0GOR*\H-/EM*93I3K2G7H3WY%>4&GRVE,ITIUI3KT)[\BO*
M#3Y;2F4Z4ZTIUZ$]^17E!I\MI3*=*=:4Z]">_(KR@T^6TIE.E.M*=>A/?D5Y
M0:?+:4RG2G6E.O0GOR*\H-/EM*93I3K2G7H3WY%>4&GRVE,ITIUI3KT)[\BO
M*#3Y;2F4Z4ZTIUZ$]^17E!I\MI3*=*=:4Z]">_(KR@T^6TIE.E.M*=>A/?D5
MY0:?+:4RG2G6E.O0GOR*\H-/EM*93I3K2G7H3WY%>4&GRVE,ITIUI3KT)[\B
MO*#3Y;2F4Z4ZTIUZ$]^17E!I\MI3*=*=:4Z]">_(KR@T^6TIE.E.M*=>A/?D
M5Y0:?+:4RG2G6E.O0GOR*\H-/EM*93I3K2G7H3WY%>4&GRVE,ITIUI3KT)[\
MBO*#3Y;2F4Z4ZTIUZ$]^17E!I\MI3*=*=:4Z]">_(KR@T^6TIE.E.M*=>A/?
MD5Y0:?+:4RG2G6E.O0GOR*\H-/EM*93I3K2G7H3WY%>4&GRVE,ITIUI3KT)[
M\BO*#3Y;2F4Z4ZTKM2+"G%U;$"8]:^EM;JVI/6REU+:5I2MU;;%+JTMI6ZE*
MUX<.-:4^S32F47F5*UVRI%)P=D:"Z2:Z"Y8PBLBM9:HDLDH\<6*)*IWTNL43
M4LNK9?9?2MMUM:VW4K2M::YISZH?W9?I+7J*UIFUVY%XHL"(BHOE_P!';K3:
MYRAL6:-W0W&&P4?EFIJ#S"?R\+BO;_MV3JUPA!\I'X6-R/($I=)(4PD,7G$M
MQP5D>,HJ#7D<ZDK&.IFT(:S>LDD4[^E[AJ?4?&044C<XFHHJHF$)444)$)5P
MB9QGCQTBR;*B*,:R#*ULNONA&@P$Q#9DN,C(<1YQD7&WG8Y.1FP5QYQ&]:,H
MJ)5Z[=QO<Q'.+@^/GLVVI,,4.@ :?#<6'1L!&15H+D0 'E045OQP2&HCQQ!X
M F8J=='4"HE*-";H\HC2UL2=-Z%;D(2EAS5E1UHI*N4R*^,G%>91Y_-YJS.7
M[.+&!@GK8D50!\8QBP+2"XV,H2Y.0H(DK;HOXT(>"4U3@2I=QCF'9'$%[,>#
M)OMUC%N#@I?)+*,#W<$#"<7AT(]TR02T&V;6MQ$8Z/%,A])-O@]6KIO'YS18
MA6P=)Z7/J=+R^-AQ=:H.>*J2YX(OE7QA3&?*G#BE922K.TNX%Z WR("D(V),
M ,8$;R;H(F!:PT_DR'"HV]DO%=\:TN-=SO<]W43/P^..L(8ZQ[7-Q>#L(^1#
M8ZBL+R!D2.68SEA*8QP$,45&D&PZ0SJ!M7<G.#Q)05.*,&A1)@4M$*.JB;>1
M<KJ(M"$JHI*HBNH<*O/S"7!,II\V:Q8]QL1-&RVL-B/RPV!;(([;+[[?)W">
M; 542$7'F45TQ A>PA():%7)9CNCVY$Y>2@(_-N-'LT$2MA!B4::RT0L7:R\
MF5> &<=N:)N;K[RBDA8/8XHV2YR]M(VRH!US)BWH6K>Z<1$+06%34BX7&G&<
M^]CC[W'FK8I<8!.DP,R.3P.BR3:.@I(Z1*"-JB+Z[>"K:IY'$4%P7"K?3#?7
MM7B4=FYMMF.$S,G!L93_ "PXA,)DT=,34_&L;QB12^0M8R*<%Q[4B=O!14V_
M'#'!%C5TQ9JE[UD :2Y1*H6725$T$B*0CDD5$125$3/#I5/_ #5AZ]6QIMXT
MELO$Q&?E*RRXV;QMQVW'7$;%3%"/0T9"*D.434JH'C5VV;X-M8YD\?3W)D3Q
M18C)I3&6*&19?!Q;DTI#$(6O)B@],1*#EK<<$I/XS0RB94$F02;ZUX=$#!UR
M#U9N7%]:)%P15TBO#.<>3RX7&,Y\G'A3OQ;Q%2?D-1L..-BC[K(J>Y1E7"%
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MY:GKU6QCWLRG^#D3_633P$OG3"](+Y&GJB[-]$[T4/EJ>O5;&/>S*?X.1/\
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M_P"J0$_"J[_K/IZIG<Z^S[8K_F>Q?OM/!Z_>XEX_)T[Y&G:;#_ZI 3\*KO\
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MDC0YR-&N6"Z+Y.UFX'#UFR::K%K<DI7D,[:<,R&/#HP;C!0D,$7";Q*[J<Y
MO/#%@HV4A&CD?*NU-)0S=N0$WE\;-.VYA-S(XS(R\<D"I,&]687*9J\XD2+
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A1.UM>I2WH[6SA?15&VE>-B-M?:ONIPX\/9]KC2FE*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g358845g36n30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g36n30.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1@<4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 9>            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ /      0 " \     !  (X0DE-!"8       X
M    /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _0
M     !( -0    $ +0    8       $X0DE- _<      !P  /__________
M__________________\#Z   .$))300(       0     0   D    )
M #A"24T$'@      !      X0DE-!!H      S4    &              'E
M   #Y          !                          $              ^0
M  'E                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  'E     %)G:'1L;VYG   #Y     9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M:UO?Z;3HW=^EK9<]GZ/_ $5:2G__V0 X0DE-!"$      %4    ! 0    \
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @
M %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU-
M "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0   '8!
M*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0
M +"':0 $     0   +P   #H !JS\   )Q  &K/P   G$$%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,#4Z,C4@,3 Z-34Z,S0 <G(R,3(R
M.#8       .@ 0 #     ?__  "@ @ $     0   ^2@ P $     0   >4
M        !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H
M  ,    !  (   (!  0    !   !1@("  0    !              !(
M 0   $@    !.$))30/]       (          #_X0%(34T *@    @ " $2
M  ,    !      $:  4    !    ;@$;  4    !    =@$H  ,    !  (
M  $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I  0    !
M    O    .@   /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H
M5VEN9&]W<RD ,C Q-SHP-3HR-2 Q,#HU-3HS- !R<C(Q,C(X-@       Z !
M  ,    !__\  * "  0    !   #Y* #  0    !   !Y0         & 0,
M P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P    $  @
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M\"8X0D525F?!T_$H1D=B9&B%DY35X0HIMKG10TAF@X2&AXF6_\0 % $!
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M>C]\G6KT?]=?7)_'^_+0'SG.'>K\TG6K[=;7)[GS9:"B3:/,1#/<0F9,UJB
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MC$F.9 6NC><)0CBDM87MB=WV./#<J;W=%P"\1:U,6(],,0;P: H"@Q%+-/\
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M+V'-<<4HBK\95D!$$:]R#UPJ==&ATF72=L9&#*6&I'-M/65F-A4.2AL!)L7
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MM%IIBDC3^J %K:YAC)H+E;<_Q^)K7C.$VBJ* S^<^15+7UYF:T\ 5JAN5K#
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MD=*6IQNSL$/Q-BLMR41Q@<XBJC&0&?)H)=D!LB3I/X8XSA;DQ2<M)@"HY"X
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MQ[.)7.#U1_S_ %@U^6+W,^28XQ\6WE%%W3ITI*0#F-0,9PS1)@E L<&W:@*
MH"@*""^C/Z8M6OX8F<O$<<4$Z* H"@6.'F[1WS_FYPH&=!&;6'D+YFNG/)3T
M%D8']4^-2;'S<AF+TDC,#+=<EN"2!-B[(,G7_M*.P5 ND)"J4NJC;<MJ+/3I
M0&+E*4L846F'4I%,\0*(."5@?H0\.3$>-$R2)J7MS5(B8VJY%>GG&+^N2(D.
M1X,0I B6-DNC05#:K87R-N9O%0O20H025=^Q+IWN6^+&T%L2?&F.9V:B53>
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MH.= 4!0+&?L>5W57XX?0,Z H"@6)NR;GZA!X,Z@9T!0%!!?= OJ"W^_AHO\
MTU<"4$Z*#S2[H.L2R[=#\5.K=$VYW<X:]:<HS'<@/F,!%L^#WU!GA4=.';*
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M),8?G4W/N0V4#I+L?K%<!F3FB;AZ:W3@6EQE49>%S*,MT<B%+0H0JD[@M).
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MC[B2@9T!0%!2J?+)?NH/@C:"JH"@*!>[=BW+O>L\7,H*TOS,OU ?Y-J#G0%
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M!8H[*-G<''W$E SH"@*"E4^62_=0?!&T%50% 4"]V[%N7>]9XN905I?F9?J
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M1L;:<XYI_P 3*3'63XQ"[OJZ#PMU>E;(QL2O/)SF[PV?O2Q"!2O8GTE.J7"
MPLQB(-!VYUX=W6331G?+DF>,8ZKR8"X0O,;,UQF:PK%2K'29,J8%6H- 7CJ(
MILP-4?C2A_U'N65<>11.0V$B;<?S/'B12J0-L>5-J0-H6YM1/=)H+C[4>3F-
MXS B<U*U'J)909.Q3!7=YFV5\J1 Z59LQ+C/?9G5IV>)QC*;8N:\:)%XV"/I
MXS)6-.6E90HEI!07'N8L$W2)*HU#DZ@)?D+&X\B3XK.2)3E7%,=D+>AF<\,<
MVB=0&$&!S1(%;9$F!)%8A(&1J0HVF-(3)4[H&E F$@/-7!=&ZM+]<&.M-"UO
MQ5D"79(DTQ6*T#*FQ-A]C9I(9-V9")[Q9$"E1.3TC^$J?Y,2Q9D>C6)&XC2P
M@F9*UQ B"0)E8;+])&J?%.L; V-\Z8GET1DC=-85#9&_L\6EK!*U4"D4GB[5
M(UT&E8F%>OLSRB/"<[(71G<N*N24\D5E"4D7D;!(-F[&(^Y?KBH&= 4!0+$?
M7[OW=)XB10,Z H"@6*.RC9W!Q]Q)0,Z H"@IE/EDOW2'P9M!4T!0% O=NQ3G
MWO6>+&4%:7YF7Z@/\FU!SH"@*!8S]CRNZJ_'#Z!G0% 4"Q-V2<_4(/!G4#.@
M* H(+[H%]06_W\-%_P"FK@2@G10:.-5C68MW2/$(>6LO8,9H^QXC?A3G%NG[
M*V96?/K@]9"E!#EBZ8/"(V2X0Q>UL(D+>>_S&2XR73CDR8G.#--HI=E(<"0W
MCT&H'=7LIZF<6I\$/>GR6S%I1-JW)$GF./(%'9.IE^?7".M,=%"\*1::M>&L
MP1J%2:7K%SN4PCEJ>/(W5R+3BLXF-S6\W3!:FY^9NU@S.>Y^#E$K)V0%#)C,
M$B>H'D*-(,<LN/M0GS>]1#"##N-Y2IAL>1JHVIQ''<9. U*E?+TZ5L,BLR,=
M"RYUPCF$A= L@F[P7J@=)5C_ )FR-7J\S@8Z1;G4T2'DA1=)CT-TW+C:26@<
M-Z )8^&3E@!?A=[:VTL6T-A7'GCM'^<TOP* X\\=H_SFE^!0''GCM'^<TOP*
M!<N6NUSFK?,N]O9QVAMRBFOOA<07VWOE?(^1N(6^OMMY'9LVWM0,>//':/\
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M*KE<5G9#8-.)01=$CF+*]I$PB5!Y R"2S"#SB1EFC#,GS5=1GV*:K\MN.O\
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MJ4%66N>.#!^X?^ '_&:7ZUO^90<^//':/\YI?@4!QYX[1_G-+\"@.//':/\
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MS-\<X[B^18^&6X*QC/)BU26-+I!8]"'K1H"@*""^C/Z8M6OX8F<O$<<4$Z*
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M'<(K!$&][A$$(K7M8+KH"@*!8S]CRNZJ_'#Z!G0% 4"U-V2<^YH/!G4#*@*
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M#\ZUK6^WY] PYML?:XGUS?\ :4'WFVQ]KB/7,^'_ &_'>@.;;'VN(]<SX?\
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M8J6&H0'1!H-BH'*9HRS"A'*5L83.B5*C$4M4&EI32S1!&O.NN6*XGEF+H&?
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M^/6YT;&A<@"?5 4'2H(*5$')C@W$2H),(-#80@7$4: 19@;# ((P7N 5[6$
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M@4KXBT$!L5H"@*#6IKFU59.P/D_3=CK$DXPD":YEE2)H08>G\?=W*83QI39
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M3-)M"TF.H)H8!JLB,6D1Y\NQBH<LGY)>S"FPQS1":VIA:DS^V-$>DRY"B>E
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M7=&*42)K8FMO?9()N*$2WB?W=(E*<'BZ$D8BD=W%0INF*$(LC>!O>UPN6@*
MH+*%C7'(W:-OXX!"A/L-*6$1!Z%%6(3M%"'#?\?)C;C=!=8QE+N$,XX6UG)0
M*>$'PUA[\6T+UH"@*#%)N",'GI'A =AK%)R&1')5,@1&X\B)B1]4(EEW!&H>
M$PV>Y+F<D7B$N2FK0'F)U@KJ2A .O<=!E0(0@"$  A   ;!  -K!"$(;; A"
M&VRP0AM:UK6M:UK6MLMT4'*@*#&SUAK$$D=7!]D6*<;/[V[%@*=7EZ@T7=75
MS*++)*++<'!<UGJUA8"DR<L %)Q@0ED$@#:P2@6"%Z,;$QQEJ1,4;9FJ/,;:
M6(EN9F-N1M+4@)$8,X12)N0$IT:4L1IAAH@$$@#<PP8[VWPA7N#6@*"S7_'.
M/96[M<@E,$ALE?F.Y-V1[?XPR/#NSW3J>.I[M;DXH5*QON0LM963=(<3<I3^
MS@WIODZ"Y4C:W(#5YZ%O1(CW59R@Z')$I"8UR7\63(N/+S"2P#6+.)HTB3C*
MBYAW%DJ8C?\ !$% "%;0%!:LK@L)GB-,WSF'169MZ-1QQ(AE<>:)$C2J^#&3
MQI,F=TBPDA1P1@RN'* $W@QC!OMZ*]KAU,F/H%&7A?(HW"(A'Y ZMK8SN;XR
M1IF:GAQ:&4D"9F:E[F@1)UJQM:4Y99#8A4'F)D!( %)2B@!L&P7?0% O=FAJ
M?FU:S/K8WO3.Y)S$CBU.R),XMK@D-MO34JU"L*.2JDYH>@PD\HPL=N@0;VH+
M$087PZU*8^L:\3XT;5D27K'6*JD$$BR-3&71Q+*)<'*/GIVHLUF7KBB"2EBQ
MM$F4*BR2@'F#"6"U@R70% 4&,R<+8<3H4K8GQ-C,AM0RKGTB;R8)%BD*.;;Z
>X^>*5(!J"0GE6_$(7.$HL#MOA7%QO;>]Z#)E!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g358845g46w45.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g46w45.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1AR4&AO=&]S:&]P(#,N,  X0DE-! 0
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M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q 9>            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ /      0 " \     !  (X0DE-!"8       X
M    /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          (X0DE- _0
M     !( -0    $ +0    8       $X0DE- _<      !P  /__________
M__________________\#Z   .$))300(       0     0   D    )
M #A"24T$'@      !      X0DE-!!H      S4    &              ((
M   #Z@         !                          $              ^H
M  ((                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  ((     %)G:'1L;VYG   #Z@    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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MC^8K_JM_(H5?TJ_X,_[\DIR,DLP/K#C-ON!PNH56,9CV-;L9;2&VBRNST_\
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MCBAM=V;C-+,QC-P?6V76>F'FNBS:-]M?N_FU8^TU-8'O)K:8U>TM +B-H=N
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M4DE/U4DOE5))3]5)+Y5224__V3A"24T$(0      50    $!    #P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T *@
M  @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,
M   !  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I
M  0    !    O    .@ &K/P   G$  :L_   "<0061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q-SHP-3HR-2 Q,3HP,#HQ,P!R<C(Q,C(X-@
M     Z !  ,    !__\  * "  0    !   #ZJ #  0    !   ""
M   & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P
M  $  @   @$ !     $   %& @( !     $              $@    !
M2     $X0DE- _T       @          /_A 4A-30 J    "  ( 1(  P
M  $      1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$
M @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
M    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#$W.C U.C(U(#$Q.C P.C$S ')R,C$R,C@V       #H $  P
M  '__P  H ( !     $   /JH , !     $   ((          8! P #
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M:\_9[4T1*:!L7'>"IK&XR\Q:U"RJF]V&W[)9*VA/UVE)H-(6*2B7,JS3EY(
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MU&X@(_Q"( .!??&5\5_X#%OO_:_AC_QP#XROBO\ P&+??^U_#' /C*^*_P#
M8M]_[9\,L"Q;<+N+0O) IM(*G(11N":?E!;![T!FQ#& 0&X= [9A$_F$>O7K
MYA\V!??&5\5_X#%OO_:P_!<< ^,KXK_P&+??^U_#' /C*^*_\!BWW_M?PQ_S
MZ'H8%B?A;Q:\9($#2"P)BQ=G,EY06WY(Y5V0$4Z>6/3Y ICEZB("'?.@ ("/
M0+_XROBO_ 6K]_K7\,?\^CZ.!Y\97Q7_ (#%OO\ VOX8X!\97Q7_ (#%OO\
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M-P&Y#^#&;-2I%ZQ/0%RJ/!7$"_%[\PF(=N F_P!;LA_W<"[^)!QR^P%Y#?\
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M)Z\U..G),U/8\&>+T^SK2KETF8ZT*UFI.0E$(]43MTWKQRN4@'5.(AV-
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M:GL'34_K1QQOC>1]8<TQM*P5.U7Q\L]>79[/J5D6;2DL[V7#1S]!F^G[5 -
M_9^4P& #%$#%, &*8H@(& 0Z@("'F$!#S@(>80P/< P# 6P_J8R^XA^$<!E@
M& 8"QIZH2WW5G[S3P&> 8!@+3^K#7V-?>^H[ 98!@& LE?W!O[)Q7XP;=/\
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M.X]NY>,I8C<8]ZW;.5&CE8K9<4PW_P"$-^@#W]'H*7?P'OI.@H?1@^2_<O\
M]3Y3^/ 1L+;6)6>G*O&S\2^L=90B75@A&KU!:2AVT\W7=0J\@T(<56R4FV;+
MKLE%"@5=)(YR")0ZX#)^H16+?*)G(H0S%T)3D,!R&#O"@=2F*(@(=?-YAP.6
MO<\?](=P_H*]S._]A=[X'5K , P# @OQQ^:2[H!_2RUO_<"XHX$Z, P# YT\
MG-G<5:'R?XZ?%'39--TIR$>TC;.RTF^O!ZW 7Y6ST?7K;8NW8ZM2;?2M>LUW
M<V%A0I"Q3D*UL=@96:,CA\"+9G* =%L#%KK1Z=LBKRU)V!5X&Z4^?11;S=8L
M\6SFH*60;ND'S=*0BY!%=F[31>M6SI(BZ1P(X015* '3*8 Y%[@[C_0-@W>Y
MVJI)\;J RMEO3D^\I\9%W]B94%SK2-UM8M9#98C<-62&$GD62]I5EHZ%B9N.
MMB[68BWC1:+C^\!9=R'VI64)SF!QB9QL!776O]S$WYK6(J42WK%'D>/7(N,2
ME==S=(J"EUNLM48QY+U:S3RU/DGK=6M0ENIA_!T4IQNB0.R\-ZELON!?PC@,
M\ P# 6-/5"6^ZL_>:> SP# ,!:?U8:^QK[WU'8#+ , P%DK^X-O9.*_&+; 9
MX!@&!:/_ $B]]:.?<3X%;3TJV];H^YEP+C , P%K#TQ+^R1?Q;'8#+ , P%@
M>K)O8Q/WTI@,\ P# 627HQ_LFU_ K@,\ P(VE^:_5_HVH?\ O/<8$69;N:VO
M[)R7E-^VJ'T#8V4ULB3N4M$2?'M!U=9*J2.M#4H-;/KV[V"YBW%?3MHAM91T
M-$*^7NZKUV)R(OETQ#)-\]S=T%M1C3(ZGZFXWU&/@;,\G;3#6K0<?=(*],#U
M>?@XR#E6<#;=>OD&D/-3+*XM#EE%P\HJY .11*#(04#.J3P*X[UC5]8J$QIW
M15HO$!28RNO+\ZTU6VS><L4;#)1WE2^KIG+M</#GJ)9-]&>4)SK'.LB623%0
M%B!B'#+@/5N(TY/6!@EJ%_*S='I%47EZ#IM?74](3-;3E$K/>+',O]@WMU,6
M/8P.8=S;A:A$,GDE ,Y'P87"RYC!(;DYI!_R,U2ZU$E>7] @;+9J:YO,K#Q4
M9*S<M2*]98ZQSM1BBS:+Z#9GMQ8EO 2;N9A;!&F@'TNR<PCT'A>]A'ZE\)9>
MH\8MS<8U=BPD]%WC5FR=.4#9$C0VK;85:H%O>;)/2JS<W,/*1D+;(75<3?&\
M#58Z#B:<R3CXQT"+5CXR[#4(A%[C3&H<DE=GDW*SD]#DA==5Z(XWV/7H3-<A
M*W4-O5S<<U2$)!6TIQLC09.Q,+0WKE6E:TZ94^&MAJTR\*K$-'PX!KJ8[DON
MIO=4Y U\TMLF$V!;7+V^1UCU"TA*17G+37?(V&:[2>TBNVJNH6N^O9G;%-28
M/03=6&,?TV(E9BS39VK>4B0VM =R7LRNWE[WLW>5:V94GLW .;16IO4T8G([
M2AZIM>G;$K*&U)%I+-6]UEHJ$K#FH*2MN:VMR[\;R$DDJPB'9JFB&RN*/<U)
MGC7NQ+:KG9-*L?8G+#//YN'UW)5S9EH:S>IJ'JUIKVU6UQ<YIM)ZW@'%*+?(
MR$\6%,2U.&"Z/@IHU=U*!UFP,2OE$J&SZ;9=>WZ CK33+A$.X*R5Z60!Q'RL
M6^3%-PU<I#TZ@(=#IJ$$JJ*I$UDCD53(< C;JG@QQQU3&P[%O18JZNZR_BGE
M2F[W!U.3E*>WKS..85R+J@1-<@XV"9PB$6U72<,8Y*7E)<SRPV"3EY^0>R:X
M4SW!?CM8MR3VZG]/;EG;F:/=;#KR+"NA5=CR\/'R<7#S%T16@5Y^258-)9R*
MD4WL#*MS#UO$RE@A):3A8IVT![LOAMQ\V90*GKMSKZN5:'UY:$+MK=Q5*S4D
M5:!;470NU)NNQ4[7IZK"J^.95.592]>E(N4164!\Q64!)1(-N:KU-1M,U"/I
M="B"QD6R0:%=.UC^%3,^^:LFS \Y8Y4Y2N9F=>HM$1?23H167.4  ")E33(&
MM^6VB9'DKH.XZ<B;2G2Y*QRE!EV5D53L!RL%Z+L:IW\B7?*I9*?9F9I$:QXL
M))U^S0LQ$G>%DXY\FZ:) 8-+\=^&TQI76VTJ),7"K6:1V:GM98UN)7[E(6R"
M6VC8)ZP.H5>[;"V'?=@72N1\E./)P1NELEYYU8)&562EV,,:*AHH(PV;N1=>
M;TC5;#6FS'C'8E,U;7-67N[[:-==\%V+6:VVK+=I66D9M^\7B.I%)1*TNQHN
MFQ\?+5:&7O3YTG!/#ME$W@:YC.X_WZ/UU)T!SOFAS#Q^6"!O?Y#4TJ:[Q%6K
MKB&!+0<$Z5OCJ+C./$^TA"^4E!6C9&,=.9VQ]ZB@0>H)M0O&W<?K2W*0K+>5
M5@)-2GI5[R^@M>6!'9D*R;4C=U22UK 6<^P">":3=+;@CW;VBM&T6U28T"$B
M8E*,1\1*U .EW&O1#WCWJZV4]V^J7>IRWVNZ1]6UW6G-.UIKYC-L(YL2G:^K
M#J3EE8>OIN(QS8GB0.B).K/8K#(H,V2+PC5((C]SQ_TAW#^@KW,W_P!A=[8'
M5K , P# @OQQ^:2[H!_2RUO_ ' N*.!.C , P.17=(-([#MVRN/.T-8ZNF+K
M*UBUTM&25@)>/85^PV6#VQ27>K8??T1)V2+;6/3U%4LFPMC1"C>N6B8K-SCT
MY6'?U1RL*5J#KK@&!\7#=N[;KM'2"3EJZ15;N6RZ9%4'#=8ADUD%DE ,15)5
M,QDU$SE$AR&$I@$!$,#DSQZX7ZEXW=T L4[K6QKQ+V4XZW&>DJ3&5G4E6CG<
M7LS>:LT=*1:TJAUN=D8>JR-?91=&<23YR> C&RT&U=F8JN&IPZM0_J8R^XA_
M'\\?GX#+ , P%C3U0EONK/WFG@,\ P# 6G]6&OL:^]]1V RP# ,!;*_N#?V2
MBOQ@VP&6 8!@6C_TB]]:.?<3X%;3TJV];H^YEP+C , P%K#TQ+^R1?Q;'8#+
M , P%H>K!A__ &TG_!T?_P"> RP# ,!9)>C'^R;7\"N SP# CI?-:[7<;=C]
MJZPMVO8=3XG"NOI>&OM-LED(N0MF"QLY.->5Z[54S0Q#'7:N6SIN]!4#(JI+
M(B0Y% H78<LT4%EO+7CL;O22BG3XEVRO/V"";I_I@^?TZ8 BPY9JHI*^6O'8
M.^IIJ=/B7;*'IVR@;I_I@^=UZ8'U\6<L_KVX[?[KME?XP8!XLY9_7MQV_P!U
MVRO\8, \6<L_KVX[?[KME?XP8%LT:<M'*)E1NG'4O9</$.@:OV4/I5VNU W^
ME_\ UP1[?3YW:Z>?I@7/BSEG]>W';_==LK_&# /%G+/Z]N.W^Z[97^,& >+.
M6?U[<=O]UVRO\8,"V(TY9F>+M/+3CL'>6S5?M_$OV5\EX0H[3[/3XL'F[/@P
M#U^?V_XO.%SXLY9_7MQV_P!UVRO\8, \6<L_KVX[?[KME?XP8!XLY9_7MQV_
MW7;*_P 8,"U5:<LTG+1OY:<=A\)%?J;XE^R@['>4^^>A\5_S]KT/G=,"Z\6<
ML_KVX[?[KME?XP8!XLY9_7MQV_W7;*_Q@P#Q9RS^O;CM_NNV5_C!@6KQIRS:
M-E7'EIQV/WL"CV?B7[*#KVCE)Z/Q7Q_[V!=>+.6?U[<=O]UVRO\ &# /%G+/
MZ]N.W^Z[97^,& >+.6?U[<=O]UVRO\8,#X.8?EDNV<(C>..Y06052$P:MV4(
ME!1,Q!$ '<'01 !Z@&!&CAQ2U];\A=V:[=22,RZH7$CN>U+<S#=F>.;RKBK0
M/(6#6DF\>HZ?*,47RC$SI)FH]>':D5! SIP8@K'#I/@& 8!@07XX_-)=T _I
M9:W_ +@7%' G1@& 8'-KNE\UR/A=74)WQYHB=XDHO9-+M3MH"+5=0]JJ-\I$
MQ0(>3.]E(MI&5&8?DEW%EE57#4R@P\76DYJKC9ALT4'1M@=XHQ9J2*"+604:
MMSOFS=8SENW>&1(9R@@X,FD9=%)83II+&22,J0I3BF03=D NL P/RI<CN:6P
MN*G=GB["F:H6_0\QJ_:G'-_4M>2]^M4Q8$YRG5C:/%ZDN:\UHCB)H\Y9MI4P
MU4AK* S35[;MO;&C D7[.MHQ\>'>77'-OC]::3J:Q.+!9ZJVVLM0(*JJ6S6.
MU*W#N;=LEY'1-3J/E1.TB,K7CF7L,JSKL<FI)HD?S"R3-L8RRR:8A,C , P%
MC3U0EONK/WFG@,\ P# 6G]6&WL:^]]1V RP# ,!9*_N#;V3BOQBVP&> 8!@6
MC_TB]]:.?<3X%;3TJV];H^YEP+C , P%K#TQ+^R1?Q;'8#+ , P%@>K!O8PG
MOI3 9X!@& LDO1C_ &3:_@5P&> 8!@6K[TD\]:N/<CX'K/TFT];(>Y%P+G ,
M P%L5Z44]D)?\;/<!E@& 8"Q+U8?>QT9[XE<!G@& 8"QUZHQ7VWOO<,!G@&
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M)9+8,136^EZ;8K#/[<3<,(N0JM>#<<7MJNU^<GX]JU=HN:>R@0<UJ2KK]<(
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MX2K[A7P@6,: N6S%V60(S73:&09M DIXAC/H3C[X2'Z5@>^(HSZ$O[?D/TK
M\\11GT)Q[?D/TK 7Q,)&GC6AC)+")D0$1!Z_*'G$?0 '( 'V@ /_ !P&'B*,
M^A./;\A^E8&KMK:8UCL*&8NKQ3Y2W#1G3^VUIE&3]HCIAO.HP4K%&5A%H:>B
M7 RSV)E).&;@9T4JB4FNW$Q2.%!$.5'<A%Y:,L/-C24S3[I6HC7VY=>WF/A+
M(TDH='5,WN32&O[=8>.C '-EFGDFRT\W3@4X.P'.W1G:[9(Q<S9"2;29!#LN
MUA(XSZ4**2_0BC4"]'S\/1:)F'J(.0$?/\\1$0#S!YO-@,O$49]"7]OR'Z5@
M>>(HSZ$X]OR'Z5@>^(HSZ$O[?D/TK 7'A([QLV)WI?LC'O3#^WG_ %[0.6 !
MY_">UZ!C>8!Z>AU#J!>@,?$49]"7]OO_ -*P#Q%&?0E_;\A^E8!XBC/H2_M]
M_P#I6 NDX2.*BW$J2P=9&,*/5Z^'S&?MRB'07(^<0$>@^B ^<! 0 0!CXBC/
MH2_M^0_2O/\ [< \11GT)?V^_P#TK /$49]"7]OR'Z5@6KZ#C2LGA@27Z@U<
M"'[>?CYP2.(>87(@/^T//\_ K:P<:+9N(I+]101$?V\_#SBF7YP.>@?:#H&!
M]_$49]"7]OO_ -*P#Q%&?0E_;\A^E8!XBC/H2_M]_P#I6 N8PD:9>5 4E_D)
M$"E_;S\/,,='F\_1R':\YA\YNH_.Z]   !CXBC/H2_M^0_2L \11GT)?V_(?
MI6 >(HSZ$O[?D/TK 7!"1OC8Q.]+]/%Q#=/#GWH^$G#T?">UZ >AUZ?Q8#'Q
M%&?0E_;[_P#2L \11GT)?V^__2L \11GT)?V^_\ TK 72,)'%%AV4EP[4BV(
M/[>?#\B(*=0\[D>GH>B'00^</G' 8>(HSZ$X]OR'Z5YO]F![XBC/H2_M^0_2
ML#SQ%&>AWIQ[?D/P^%=<"W>0<:5FZ,"2X"#9<0$7S\>@@D80\PN1 ?M" _:P
M/6D'&BT:B*2_46Z(C^WGX><4RCZ .>@?[/-@7'B*,^A+^WW_ .E8!XBC/H2_
MM^0_2L \11GT)?V^_P#TK 71D)'&:G$4E^H/Y4OF?/@\Q)1X4OH.0^<4.H^B
M;T3"(B(B#'Q%&?0E_;\A^E8!XBC/H2_M]_\ I6!YXBC/H3CV_(?I6 O2A(X9
M9Z7O2W9"/CC!^WGW7J9Q)@/G\)ZCYB%Z (B ><0 !$>H,?$49]"7]OO_ -*P
M#Q%&?0E_;\A^E8'GB*,^A./;\A^E8"]S"1Q7\84$E^AQ>=H/#GX]>B "'01<
MB(>?]X0_>'S8#'Q%&?0E_;\A^E8!XBC/H2_M^0_2O\_[1P#Q%&?0E_;[_P#2
ML!=+0D<6/<F*DL @"?3J^?"'G5( ^87(@/4!$/.'H_QX#'Q%&?0E_;[_ /2L
M \11GT)?V_(?I6 >(HSZ$O[?D/TKS?[,"D\%&]DP]Z7\Q3?]O?\ [WKK A3H
MELBVYK<N2H@8 4T7PI5/VU55?DS*<ENT("J<XE ?^Z40*'SBA@)N5'="*3Q?
MW1KC1DG3$[';=B4M_?FK^;W'H?3%?9P$?:HZHJIL9'=FQJ*>VS9)&137<P50
M;S4@Q8BV</$T1D&!' =!B&[9"'_[Y2F\P@8/D@ ?,8HB4WH^B41 ?1 1# JP
M# @OQQ^:2[H!_2RUO_<"XHX$Z, P# 5S(",>J ")1%9F &#IU*(O6_G#J AU
M#T0Z@(?O@.!S]X[\*]H:6<WYPIR6O,<I<IR&F9-W4RQUB=W29C4Y)"8NUS2W
M=$;5815JN23F-&?0H;6NM2*Q*(%?NV81S*("1VVY24U+"WS<<OL_93^M1=<\
M"8:TB(+5#B+0GY8\? 03N#>/J0PLAYAS/O&@HC9[V>J-G#]9:801AF_1H&O>
M'_*&N[OTSI1S/R]F1VI9JK.0]BB[S424ZU3-YU$>+J^VI)[!1#0E=A5B69<L
MBI$,3LTF:4JFT;QS,[-VP8A,K 6P_GC&0_\ Z(?A' 98%)^V)# 02E.)3=@Q
MBB8H'Z#V1,4#%$Q0'H(E Q1$/,!@]' _)GM>S<I^YC<C;5RYLRQE*9LF_P %
M3^092:XHM;J-TTC1=T1-JV!R6EI%SNJXVLUND([8>R*O4&["$A481;86CJ<Y
M*W@JXSJR0?IRB]NZ\=[BE]+MK&W6V1Y 16U@KI$71CFH;R2\FF\Z1\"'B]1-
M282,V%J1T9Z0ADG)VY6RR*IPVY@& 8"T_JPV]C7WOJ.P&6 8!@+)7]P;>R<5
M^,6V SP# ,"T?^D7OK1S[B? K:>E6WK='W,N!<8!@& M8>F)?V2+^+8[ 98!
M@& L#U8-[&$]]*8#/ , P%DEZ,?[)M?P*X#/ , P+5]Z2=^M7'N1\#UGZ3:>
MMD/<BX%S@& 8"V*]**>R$O\ C9[@,L P# 6)>K#[V.C/?$K@,\ P# 6.O5&*
M^V]][A@,\ P# 63'J:Y^TG[LG@,\ P# I/\ *&_DF_ .!!G2'S;'+?\ F'X3
M^Z<EL#D!W7_D([B^2E4I$!=7M?D*5K9RU<D/R=IFD'.F9Z<L58GX7DW7:%%[
MJK<QOR281)GE28Z<VG7J_7)Q-G*&:R9XN7>MY\/TOLQ,9HU,945C&;H"982D
M(*IA2*(JB1,13(*@_)B4@B0HCT*(E ,"XP# @OQQ^:2[H!_2RUO_ ' N*.!.
MC , P%DOZ04^[LO?K? 9X"Z7B(FP14E!3L9'S4),,749+P\LR;2,7*1KY$[9
M['R,>\36:/63QNHH@Z:N4E4%T5#I*IG(8Q1#GELCB_OM+DKQVMN@+C2=4<?=
M2EAF4IKV'!6 AVE8<3KU_LZM1FMX2LEK<H[OT02(C8RPN9UAY-N2N)!"(2>Q
MS=Y,!.+6<]+V6FQTS.OZO)R;A]8D%GM,<N'E>41CK)+QK)-HX= "YG39BT;-
MI<I@[*4RC((I?L29,#*H?U,9?<0_". RP# A7S"X54#F$EK9&\Q.K99OKR5M
M+X8[9^G(7;<5/,+34Y*K.H-RUDYVO.&46D>12L7@S=ZH@O98*K3)T2O:['+)
MA$K2G<C=1:XN]9GK.AH[8S>HR#9262D.+E#AI>VQ7Q(836I*X]DDK!)1,;!@
MZKM?OBK2/K13J7)@\E"*HJ3<N9V&Z>5?"?1<QI&TU35W$'5LU8+RM$4>6<4'
M6NE86ZUJBVB3;1>Q+74)&Z.*E!M;?"4A>=5ICA>7_:=O4@GRK1TS;.T\#D5#
M]TRN7<\N1/'#C-R(V+87?'BD:[M>I-WO-G(:,>["UO>4*A>[MQ1C8M'32A)*
M7FK)IO3)5+^R)(7])M:MR:H@EG47)ST:XE _07Q2Y4::YI:*IO(S04^\L>L+
MTI/I04A)Q3N!E@6K=AE*U)(R4'(%3D(M8'\2NNV1>))*N8U=C(ID%L]0.8-\
M']6&OL:^]]1V RP# ,!9*_N#?V3BOQ@VZ?\ ' 9X!@&!:/\ TB]]:.?<3X%;
M3TJV];H^YEP+C , P%K#TQ+^R1?Q;'8#+ , P%H>K!O8TGOH^ RP# ,!9)>C
M'^R;7\"N SP# ,"U?>DGGK5Q[D? ]9^DVGK9#W(N!<X!@& MBO2BGLA+_C9[
M@,L P# 6)>K#[V.C/?$K@,\ P# 6.O5&*^V]][A@,\ P# 63'J:Y^TG[LG@,
M\ P# I/\H;^2;\ X$&=(?-L<MOYA^$_NG); YI]U3@U);E?KBLT"+?R6S-E<
M=9&O2TA#5RO1\]JRLQNZJ3-16\*;;Y??&C6]HOM>LD+&P[2A3)[;$^*2_P#2
M7BVLS=EJVQ _0<W*8K= IU#JG*BD4RJH)@HH8"% RB@)=$@.<>IC@F )@81[
M'R/3 ^V 8$%^./S27= /Z66M_P"X%Q1P)T8!@& LE_2"GW=E[];X#/ ,#%+V
MTMK^D7%C092/@[T]JU@:4R:EF_AD7$6MQ%.T:])R33O2_A+!C+':.G:'>%^^
MH)*$[RKVN]F"&G<\X;=<!J;8$/NBSP-A6B-Y[3A*6TB#BZ>URM0=A6BWD/8Y
M0K%@VDYX;2UL#^1<,B.F"KIXLZCW3:.=LX"""<D/ZF,ON(?A' 98!@& L:>J
M$M]U9^\T\!G@<:NZ4]R.UASGC]@6QQ.A3;5,4F%9.4ZEI_2LW;;$]I+Z3LJ!
M&%VMT(SLL?8;:^;4^&=2R]N9HMH^F5V-(X90JL\WD@YM?^3\;PIO'"T\E>!6
MP;9*1<_8=YUG;NBX"Q(5%FFM#[4T<>P6^+@8RE3%CC*O2X^9TU:)BH"_FC,G
MU?L=0[P8)RP*)/0_4UXTC%9IFFG(L5#GCWI2$([;G.<QG4=T*4I5!,8P^@
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M8"F3()0,;M& HE 0 QNT;M& /,)NT;J/G[0^C@?3 ,""_''YI+N@']++6_\
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M&$PJM>V RKX +^U$^SV!"&,)NI?./4"=!\P (?)8##OMD^D(/[[O_P!2?O\
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MMA\/C>TQA0/U>=@ EGPE']@^2[0C# )>@><.A3=1\P@'HX#'OMD^D(/[[O\
M]28!WVR?2$']]W_ZDP#OMD^D(/[[O_U)@+Y56P^+W'?&$*!.B?422SXQ@_94
M^G0HPQ 'S].O4P>;J/G] 08=]LGTA!_?=_\ J3 .^V3ZGP?WW?\ ZDP/>^V3
MZ0A/ON__ %)@4G5L?9-^T(3IV1__ #=_^\/7_P#)/_# A9H<SLW-;EUX6DW2
M,&B^%()@V757*9+OG);LF.*K=N)%!_UB%*<I?G*&P./?=3=Q;\V=N#:6CV&O
M[@RUMJ]@1":K:5'N3J&W_KN6K6NW+"F0UYC:0+A#8V_]J[%9:=UB&M;PI(Z_
M:T>^W.WP$P5$K6$#]-3$.C)F H';"#5N ME%!54;]$B!W@ZHB85#I?N9E!,8
M3F*)A$>O7 NL P(+\<?FDNZ ?TLM;_W N*.!.C , P%DOZ04^[LO?K? 9X!@
M&!$GF;Q^E.2&J(^BQB+"0(QN,58Y."=W.=U@[L$>PCIEHBRAMK5.O6JVZWEX
MJ:D(>VM)VNP;US*FK8U"2!&!LLLX2#F/7+%R&X=\JM=S7(OD+.;%TP^HE;;[
M6L19JTGIVLX2U5F+UOKR2O-:EX]M4*]%R.ZJI,HL]AQDH^M\SX=(S%O81C1Y
M.N1#M;%;9UA.R53AH;8-/E):^0#ZUTJ,86&+<O[968LZ!)*?KS5)R9:7B&!W
M+<KM^Q(LV;BND"JA>V7J&P< P%C3U0EONK/WFG@,\ P# 6G]6&OL:^]]1V R
MP# ,!9*_N#;V3BOQBVP&> 8!@6C_ -(O?6CGW$^!6T]*MO6Z/N9<#F)W7/@W
ML'N@O$MYQ^U=*:IK=JE[O5WLC:=J,["HE&4%NLN:^1-/EJNPDYBMV>YQ)4Z>
MO-(LEB)U6:LK0Q1.[3 0U)W,#N6T[P[XOI:#WQ>7MK7JFR=A2&JVVF]]<FZ_
M4J5J&T3(62LT [=:ZU(KZ1J\M*6)LI+I03,))BJP77 7?A %#DIR<[I?R'X\
M6B^4GBUN'4<?5]S7]ON'3-EVEOMY?IG7VF=*Q+BJ;/UW987<4-?I*(L6[SUJ
M-OU!;A."]3=6]2NL(MC.=LA0_13I[>G)+;6O*OM"KZ)TDYK^P8&NW")4-R8M
MJ9RLK!6H:2015('&=7L+H$< BX3$YA1<$51$Q^]]LP:0YE<G.6VI]>1$#7Z?
MQOU#L?:4TZK- OMLY$R<O7*T\@822NLY)3#"P\=X:(60<P=>=UF,\,>@EY46
M2O)J)F244.F&;3'-K8E-T?KOD??M2:C@]/WR0TDU\>1O(:R2DVQ:;NN5.ID*
MZ;P#_CY!MWKN*=W)J]DHY><C4T&C"1.YD6J#99RF'1<IR'#J0Y3AZ'4I@,'7
M][J C@+P]6#?O>+2>^C_ /TP&6 8!@+)+T8_V3:_@5P&> 8!@6KWTF[]:K^Y
M'P/6?I-IZV0]R+@7. 8!@+8KTHI[(2_XV>X#+ , P%B7JP^]CHSWQ*X#/ ,
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MP"4 R? , P%DEZ,?[)M?P*X#/ , P+5]Z2=^M7'N1\#UGZ3:>MD/<BX%S@&
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M,6&QS%4D8@)6QVM9J^3I@=>VGJA+?=6?O-/ 9X!@& M/ZL-?8U][ZCL!E@&
M8"R5_<&WLG%?C%M@,\ P# M'_I%[ZT<^XGP*VGI5MZW1]S+@7& 8!@+6'IB7
M]DB_BV.P&6 8'*GNS3*PN>".RGS-S2GM.@'<3/[$UU<&UG<J;RC8Y50U)T36
MBU5ZP?J3VU-LJ:^K",>LN1E/MG3BN/3I,Y=PL0%W<9>0S_?/!S2$5<S2[;=&
MBM?PNAMZP4W"3,/)5G9NL.^5*8@'ZDP GEY2+)#I,)N8:*':/IUK)JIIM0'P
M1 .L^ 8!@+)+T8_V3:_@5P&> 8!@6K[TD[]:N/<CX'K/TFT];(>Y%P+G , P
M%L5Z44]D)?\ &SW 98!@& L2]6'WL=&>^)7 9X!@& L=>J,5]M[[W# 9X!@&
M MF/4US_ "4_=D_\_P 7HX#+ , P*3_*&_DF_ .!!G2'S;'+;^8?A/[IR6P.
M3_=A-71VX>8''2MWJD^5FL(_44FZ.Z=UW<:D,A=4-P4N5+!+6S1''O==C*\=
M1C",D75/O,E5JA)1R23IJ5V*LX.!^D)N4"MT"E*!2E12*4H 8 * $* % #%(
M8  /-T,4I@^>4!\P!]L P(+\<?FDNZ ?TLM;_P!P+BC@3HP# ,!9+^D%/N[+
MWZWZ?\<!G@& 8!@+8?U,9?<0_". RP# XF<[]A5O5_//AQ/V?D39-=QCVRT1
MK+5B'J$Y8F$+7EI+8J1FEBG6JQ82B5#=DPV;PEDGS UEW47K22&6"=J$(\\D
MPZAQW(#13AE>K.WW+JU>MTZ3BHRVSZ5]JZD-6)%ZGX(S86"2)*"SAWCITDJV
M;-Y!9NJLNFHDF0QR&* 9";=FG"2%,BC[5UT64V,U:/M?QQKG70>W=D_5[PR=
MU)J,CW^PMGB_["V7B2.TUU?V-(QC>; 95K:FLKG,3M>J&PJ3:)^KOO%EEA*_
M:(68EH"2[3TG@$S'L'KAW&O>W'2!?!7B2*W5B\#L=6RW8#/<!:?U8:^QK[WU
M'8#+ , P%DK^X-O9.*_&+; 9X!@&!:/_ $B]]:.?<3X%;3TJV];H^YEP+C ,
M P%K#TQ+^R1?Q;'8#+ ,#4.[M!Z<Y(T<=:[TU[7MFT09V"L_DS9D%G$:6PUA
M^24KTP0J"[=5-_#2223Z/<$5*=L[2373$%$R&*''3@CJ':FF-\<AX/CEKV.T
M#IO=KA]N&-H>T^,V\(:MZZG:I9 UT,6TLLG;*!&2]FVM5!JVT9A!LI+.@L2E
MW(+A=LP3=*AU1>LN7#%F[>J7[CRN1FV7='19Z2VH]>+$;I'5,DT9MMY*N7;E
M0""1!LW34775$J21#J'*40@QPSMO/JYR^USWF=8PWEDM5-U,$=U\9=]U6-U^
M_P!@,Y"&F="4E6R;(K""T?JIK3:^\?%CU95N_EKE)2Z3PYG;GL@_YJRO/".I
M=:H]&N]?825TE7TH[OND^-._+3)U)MKQ!M;8Z)DW-0V3<7,4AL*SMZ]3'*3F
M/0)(U61N)DW8"P407"2]8><P+C2Z!;GEBT;5'-JB*M8UZM9-'[4B['67,Y$(
M2:L!88UWO!%RPFH91T:.EF#A%!PU?MET%4TE$S$ -K<?MA6;8M/L;NXO*=(6
M:H[/V;K>7?41K(1]==.:!<92M JC&RLY8Y"->]Z8IEDV#F9>';2!7! ,F7LH
MIAMN#L,#9V!Y2MS45/QJ<G.0JDA"R#239)S%9FY"M6.*.Z9*K(%D8"Q1,K S
M+(QP<QDQ&OXUZFB\:+HI@5^PP-L@XFS5::B;'7)Y@VE82?@I!I+0TQ&/4BKL
MY&+DV"J[)^Q=(G*JW=-5E4%DS%.F<Q1 <"^>^DG?K5Q[D?\ ?\V!ZS])M/6R
M'N1<"YP# ,!;%>E%/9"7_&SW 98!@& L2]6'WL=&>^)7 9X!@& L=>J,5]M[
M[W# 9X!@& LF/4US]I/W9/ 9X!@&!2?Y0W\DWX!P(,Z0^;8Y;?S#\)_=.2V!
MQ"[L?JKL\I(^^U#7&R=HQU@UNNYV(]J8Z':4+7<M0PC9B<8RMBD>*NV]B46_
M6^G,*I7V%VE-BUF2@92\Z^GFCEGKRNVN3JX?J;8^=DS$$S)!X*WZ)'4*J=/]
MB)^QF5((D4,3Y4RA1$IQ 3%$0$!P+K ,""_''YI+N@']++6_]P+BC@3HP# ,
M!9,>D#_=V7OYM@,\ P# ,!;#^IC+[B'X1^U^# 98!@:?V#H#3.U;72+QL/7=
M>MEKUR^;R-/FI1!8SB+<,Y)G-L2+IHKHMIAC'3\;%V2-C)Q"2C8VS1,39&+1
MO.14>_;!LIHFGX?+AV"=#+,Q$.R'01\#3\XAT\_^W :=@GR/R!?D?E?D0^1_
MD^;S?[,#FGSTMG)*E77C39=,4*K6>J5O;E0>STI8UC,XZ.G+K-DTXN67E&XK
MNXA,M0V;.C! 2+48S$DZ>&=S\/+0=<K5^#I=@+3^K#7V-?>^H[ 98!@& LE?
MW!M[)Q7XQ;8#/ , P+1_Z1>^M'/N)\"MIZ5;>MT?<RX%Q@& 8"UAZ8E_9(OX
MMCL!E@& 8"T/5@WL:3WT? 98!@&!A][&REK4D:F)PJUP!J]&J)61P]:5U6RA
M'/1@DYYU&M'\BVA3RG@I91PP8O'J+$5U&K1PN5-$X<M]*<#=R:QHN_&2=G?U
M:Y7EL%WHC>G\N^1*]1?[[L5;?-=E7FY(L:?1$:Y#7*YLH"[.8RNURPG&5EK=
MV2MD%&#<P8W0.YY;GU_H3<NLJQ;INIS=KFXEQKUA#<T>2*T!'-+9'5J/WC8)
MF::T2O&C[M;9M._;1CY%&DV9K(;'NKIU/IF8%6*N$A>,/"%SJS6 T*XV;8U/
M85^T65+7=/U5RKW]+U.HZS>/@D:M56[I]\3T2'K@.WL,V;M:V@U1B&46!7"Z
MXK]@-_O.,=2!FZ$-D<CNH-E^G7DMN\0Z@D;IU ;N/4/WP'KU^?@#/C'41:-1
M^*/R/\[= ?-R6W?T\Z9?0#RW\P?O!\[ TOR*UW7-':N6V>QW%O*ONJ[?=.-T
MY&S<B-JRD );%N*AUA>.E8RQ6]Y"R+.9;S*L.JQD&JZ#H'_>>P)SE$ WEKWF
M!Q9VS=(?76LN0.IK[>[!4PO<'4ZI=H.;G9:FBBW<>4L?'L7:R[J'!!VU6,]2
M*9(J3A%0P@54@B&ZZU;ZM<F\H[JE@B+$VA+%/5*8<0[YN_2C+/5Y%:(L< ]4
M;G.5O+0DHV7CY-DH)5V;M%1!8A%"&* ,8KTHI[(2_P"-GN RP,=&W5<MM3H1
MK!$!=5JZM;DJJ+YOX]4J[>20AE[ 6,[?A0Q*4LY;QQWP)^#E>+)MQ/WPP%P,
MBP-5K[9UE'1=^O;^^U1I3-?)OHV\6AQ-L$H*IR%2D9EG9V4_)&6!K&.H!VDH
MVE472B:C)<ADERD. A@;4P# ,!8Z]48K[;WWN& SP# ,!9,>IKG[2?NR?7_A
M@,\ P# I/\H;^2;\ X$&=(?-L<M_YA^$_NG); B;R4[DE,\@-Q;9V5'<K[-K
MJM[@"Z)6&@,]1TNS$:-=E:IUGI^^(1]HE)5M)$&7K&K*^K'*J-#FA9!9\N@#
M@JI2%#LHV0!LW;MBF$Q6Z*2!3#T 3 DF5,#" >;J(%ZCT\W7 ^V 8$%^./S2
M7= /Z66M_P"X%Q1P)T8!@& LE_2"GW=E[];X#/ , P# 6P_J8RZ>AWD/PC@,
ML P# 6-/5"6^ZL_>:> SP(1\]-]0VA=.14S(P$I9G4KL*@N$(N-@(JPBG#4B
MWPFPKE)JLIEPW9]_CZG6)8\.H@*TDTGE(N40(R91LC.0P;NB>16HICXDA$+,
MX:N-Y0D3/:S:R-=LK)2P,YJ%>6%@@HNM$ RBI)2)CG[HT7+NV+XI6BP=X$0)
MVPVX?U8:^QK_ -]1W^?_  P&6 8!@+)7]P;>R<5^,6V SP# ,"T?^D7OK1S[
MB? K:>E6WK='W,N!<8!@& M8>F)?V2+^+8[ 98!@& L#U9-[&$]]*8#/ , P
M%DEZ,?[)M?P*X#/ , P+5]Z2=^M7'N1\#UGZ3:>MD/<BX'.SNF7$?;'-?1K7
M1M!L6O(:JS$BZ?7YA?'ERB_'@-TFS:NDC9:F-GC]@K""\FK%'N#("I'W:*HT
M\GX2VA'T7)!P1XO?^3R\P>/&_(3>I-V\>E[%$."MBRL%<.24'+#5G577@;!5
M \EQIJA8NP/$XV4$K*5C B%47:+,BS19!HW#N-Q5[G8PTNRN<5?9J>>1E@4J
M<VT2HW(;DVV=2%]3A%(G9EYLJZU\K[9>6V&[CJ]8GZ;1B)"V$]C?=\31DF[1
MJ$I(OBGJ S5016W#Z?E0\W)3D@'F+*/"AZ&V ^< =1]$P^<PB(B. Q^-2U!]
M&W#_ &E>2/\ BQ@0K;=SHE_CH3;J>V)9>L%L;Z);+AR Y2CL)KH]:@H1C75B
M+[R^(W*BGM-N;:JKPTPH0TG(2$:)%&!6*+0)=63B=0%:[/I5-]LUK:5(653K
M3J<Y'\FG$*VL!V*Y89>809[;3>+Q:,B+9201:J$<J-"JD0.54Q! .8<1W**[
M-*Y/:Z?3=4EJ;:9_7EPV/4WV^.5:L1LB495JW1NPW]C,%K(B+G8ET8Z[O$NA
MXK<)C(PED1*NDVGRMVH=$=1<-:M5]6Z^K.QY_9=CO==J$!!6NPP?([DPWBYZ
M:B(YO'O)EJW<[2;K(>-#M_#ED10032<+JD0130*F0H;%^-2U!]&W#_:5Y(_X
ML8%/$WPE/2Z#)Q)SDN6&VAR#KK%[9)^;M,R$-6N06T*_ LG<_8Y"5G),L7"1
ML?%M5I*1=N2,V;=$5C%2+T#?SKU1BOMO?>X8#/ , P%DQZFN?M)^[)X#/ ,
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ML'61 0_9TO.'BZ.#J'R?G#J A]L!#YV Q\.9?3C7VPE^7@'AS+Z<:^V$OR\
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MDV_-8'GB>(^I4;[1;?FL!>>)BO&S8OBR/[(QST1+X$VZ"(.8\ 'IWOIU !,
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M ]\3Q'U+CO:+;\U@'B>(^I<=[1;?FL"V>Q$2#-V(1D> @V7$!!DVZ@()'Z"
M][]$/G>? &<1$BT:B,7'"(MD!$19-A$?V,H^?JEY_/Y\"X\3Q'U*C?:+;Y_H
M_P#58'OB>(^I<=[1;?FL \3Q'U+CO:+;\U@+HN)BC-3B:,CS#X?*AU%DV$>A
M91X4H>=/T"E*!2A\X   \P!@,?$\1]2X[VBV_-8!XGB/J7'>T6WYK \\3Q'U
M*C?:+;Y_H_\ 58"Y*)BO&STOBR/[(1\:(%\";=D!,XDP,(!WOH B!2@(AYQ
MI0'T P&7B>(^I<=[1;?FL#SQ/$?4J-]HM?S6!'+BK$11M2/1-&1YA^+5R>#J
M+)L(]"\F=N@4/.EZ!0   /G   &!OQU$Q02$64(R/ IA>=0!DV !Z-P$.H=[
MZ#T'SAU]# 9>)XCZEQWM%M^:P//$\1]2HWVBV_-8'OB>(^I<=[1;?FL!;+Q$
M26.<B6,CRB )]!*R; (=54_0'O8=.OS^GHAYL!EXGB?J7'>TFWYK /$\1]2X
M[VBV_-8!XGB?J7'>TFWYK I/#Q'9,/BN.Z]D1](MOWON6!"712"#?FORY*@B
MDB!]%<*5#@DF1,#J&4Y+=HY@(  8YN@=3#U$>GG' G;@& 8!@07XX_-)=T _
MI9:W_N!<4<"=& 8!@+)?T@I]W9>_6^ SP# , P%L/ZF,ON(?A' 98!@& L:>
MJ$M]U9^\T\!G@& 8"T_JPU]C7_OJ.P&6 8!@+)7]P;>R<5^,6V SP.9'-5WH
M;6FTM5;?V'KS8ER<TI^QW9L%[5[8E%4/7=#T2C,-F&^+_4I:P1;&X/=8RFR
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MYI+N@']++6_]P+BC@3HP# ,!9+^D%/N[+W\WP&> 8!@& MA_4QG]Q#\(X#+
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MP*X#/ , P+5]Z2=^M7'N1\#UGZ3:>MD/<BX%S@& 8"V*]**>R$O^-GN RP#
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M(B( '41P*O*5K]?U)_J-OA/@+9>SL2,5#*WZD]@%F8#T\%3^2%ZW GR1K*8
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MP(_<D.YO\8[O4*+&ZRXA\7(^:B>0/&ZXV!5KI34]?.OKJC[SH5LV:P4=I59
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MMNGM>W2&JKI'0VI(M9M9)2MR3&#<)29*FF>.51DUVJB;\BB9V9B@X*<HI@8
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M.1/C#QWJ8TS8]2V"<U;T)J1F:QI59PX7/4IP2U$OA5;G._\ >I=F;M%7323
M2CV0P-D?&(<'OL-.*?\ 9XU%\#\"/?*GN;O&/8.@=BT_4O$+BW&[#FF,,E6G
MS32FIJTY;KMK+"OGHI3B-6;J,!/%M7R8G*L3OQ#BV$1*L)1"0GQB'![[#7BG
M_9XU%\$,#'[9W//A!::M9:R7B1QCA#6* F8(LS$\?=1(2L0:7CG,>$I&+A4
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M5?O(4/TLME@<-F[@ .4%T$E@*HF=$Y053*< .DIT42.':Z&3.';(/4IOD@'
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M@*8HO_!VS=-+PQ$44A2==COZ8I)]@X=@O0'N 8!@8>OKV@ND9)NYH]/<(3(
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MF*)WU9N4$QL4&Z41$1,BHO&2+911$PB9%0QDS?)%' SK , P# , P# , P#
M, P# , P# , P# , P# , P# , P# , P# , P# , P# , P# , P# , P#
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LTKT#OK@RA_\ 6P-DX!@& 8!@& 8!@& 8!@& 8!@& 8!@& 8!@& 8!@&!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g358845g54z99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g54z99.jpg
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MTM48(S)S>)*6M-36&1HFE\8E0F$H,U)8<8&1T?_$ !T! 0 # 0$! 0$!
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MT:3SS/Y<QU,FBKI5X!E&8SCGS9_>:>O5&+J&E\MML]/+?'5JS)L+62W0"F+
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M=\NS;J9R0$65K;+/ CY)9]$QX?RPC]\B#B/ V?X(V_0)?NZ!87$7B('@;/\
M!&WZ!+]W0+"XB\1 \#9_@C;] E^[H%A<1>(@>!L_P1M^@2_=T"PN(O$0/ V?
MX(V_0)?NZ!87$7B('@;/\$;?H$OW= L+B+Q$#P-G^"-OT"7[N@6%Q%XB',FZ
M5,I2=(SO)*0I2%+G>Z@4I0 I0#PT.X #@ !_^VKCT1=*G\,E_1%8:LO(]<_6
M^T9_HB"E/TE.SXARE.4V6&H&*8 ,40[$FNX0'B __P Z\J\N>_\ ,3]:F/2C
M[S,_.R]6H.EUX&S_  1M^@2_=U3T6:L+B+Q$#P-G^"-OT"7[N@6%Q%XB!X&S
M_!&WZ!+]W0+"XB\1"''I(0!OD^AE;@"!34+F$J/\T43>F&7#F$"<H"/  #B/
M?P  ]S5'\Z...&K*=*&.*$OZ.F=D,1E_O*<XC%X,UQ).*DZBW2<$5E1%9NH(
M3L_NV2XR$=?7K_?E?TA__P#=5C[,KRJG_P XOYBSG8$.12^C@_D$@]$\(I)T
MSH]C)I)IB>)ST)Q(0I!/PBMOXAS"4 $W 1$>_CZX_='6\&;UHIPPNFM6GAAK
MEM*QVEB+N%OC4'<+G,J*E.K&"#AU NC=:-3='[LJ,9LW,8VU[" F,9%,3&$<
M>0 B(B)>(B(]XB/>.J8U=>FHL:<M;5%I*;(OZ/,G<+14A^;_ )9,+UG]FT#!
M&:Q!JW 0Q)D@0$$$@$!"G3/ 0'E[A#7YJ<O"Q8RUZ\@/=\(MY7?N%HMP_-_R
MBH637&'5&M7.R-Z=3[7;W7@?@M5K4[9'/:$@E$L/!X.+=2:WATJNFLC&,^K:
MF\)D%DE4F:/.Y43.1,2B 1*UWI,,DRE77D)7#T#"V>DP=YO63ZO-.[579QO6
M:.TVP/G50K]?DHM9ZA?95MN:C'5>?/7<A6YZ%@:[8X_C'9-C25I9^/Q^/K 2
M9;@1X8&S:(\> 8BR2/< B/=39KU@ !$1^X  (CZP!QUV:<O"Q8RUZ\@.6^:%
M>,+<-46"B]N,OO$Q_AZ?_AFN,.H&I;VI5JYVTY!132DBG.O3^ N(:7:)!RW>
MNF'F<.F**!.X! O.H7F-P(7B<Q2C#>7[@HJ;PC'[0-8F/(%PKTQ\A\]GG40*
M:SC&CH=9;7J*/1#;\VIR.Q46IN6Q(9)@^7;AS8ZJA0ZUVBV4:(" E$3 LLF)
M"\IS@4ABF'1?,JT;*_.&ILM@&>&>5IM3H CM1_%"/6K(S.%PWT+8_094G>6"
MQ'I^LM.$A+X)&R#\ Y8G)G'G%BU< D(\P<H*"03]_+QY3<( RU]\T]X!Q]9)
MB9LE7>[UX:2]"9%KOMQE]XF/\/3_ /#-0<):!VXR^\3'^'I_^&: #MQE]XF/
M\/3_ /#- %9C(A@/D"]'#F #7&SF #%,0P :;?"',0X%.0W >\IRE,4>XP (
M"&LFZGO+4...VOS UCI>[-.X$T;/EPY#8JX3:[BZTLJ5<Q"PEJ 0;M7+Q7B:
M#=@'!!HDNN8./](2IB!0[S" =^I4S>.%!JP]XV>L(LSA^"]UQ!GV@B*A/2G*
ME6Z17>.J0% *IG>[&*"J*J"@ +X. '17(FLD;[I%$R'#W2AK=>B+I4_ADOZ(
MQ0JR\CUS];[1LW1"+$0Z2K:$L<%3$3RB F!%!9RJ(>EN?#U"#=-590>_^BFF
M8W#B/#@ CKQKZY[_ ,R_C)#THZ\S-SLO5J#I3]N,OO$Q_AZ?_AFJ?"S8.W&7
MWB8_P]/_ ,,T ';C+[Q,?X>G_P"&: (=ND<=I/,GT4Z)'1"EH0$$'3%ZQ.(^
MF&8'B5-ZW;J'+P$/5D*8G'B7FY@$ HYG27NIWHY]YSPO'FMW1J+I']V2(CPU
M6(6=".>B<WJ+NG]'N5(CL@HQ&>P/X2P?,BB)HO;\ =49XV0*N'J!YA0%0"@)
M1,( <@FWES>]%N.&4WJ\\,,<MVE97$J@UF4%3+5BQ!HZ>_1QS#1+8#LL2,C*
MB9/:]@XAA2@IM9,1+CJO@(D61CU$E2"(>I43.<APX&*80$!U3&KKTU%C3EK:
MHM+35WF3"I#5DP]'MQE]XF/\/3_\,U\Z.V#MQE]XF/\ #T__  S0 @.Z#)\_
MC_"-QME(>R,-9HM2MECI%S6G"J+<KZTPL<\ Z<[#K19NN8NW*)?"4S"!E %'
M@N"1@C7*[4#M2V3Y]?&.:*2=)*)J*6F30EYDDRF7AOE%O[&;270CW:"ZL']=
M*+<[K=0[F.&&(I*R14^TU3E!8F-\E3G6N=A=3F98EYB6-0Y9G<)M'^VE%4%X
M-PN@E'_45AW6YW,6Z@BBA.)7^6_N<_*.G_@ZB_[:U2SW?<J_QG@\AT]U4+I^
MX%DH^+$?ERH>M1)%M&SS8;QB"W7?+]G\*4KUNFT7-A7@VL5$Q%:BZU795=:1
M=PD2RB&C9B9U(O';Q\8BB#<PJ.%BMDTA+;+(15]0UI2+BZ5)/DX3TO44W()+
M%*2<F4$JDVM,Q EV.1EY9**Q6:7C[)%!$H>[W)QG#####4W+O2%/475S<UTW
M(&WR*].RD^JB<W.3AQS2KD[2\:O99Z8F58;495"#<0QDF6XW10%%%&<3A*OG
MC#=XD&\32LCU6WRCN-?S+6-J\FG8'[F'BI48*4E6[.)!VX6C8V; 8=^^33,U
M9RH#'N%4W?\ ,ZFL0H,Y5LHT"\LWDC2K,QN$?'2*T/(/JLF[L#-C+-D6[AQ%
MO',2V=HMI%!N[:+K,ECD<I(NFZITBD72,8 V;MQE]XF/\/3_ /#- !VXR^\3
M'^'I_P#AF@ [<9?>)C_#T_\ PS0!KALF44CE5D>Q-"/$))M#K-#(O2N49=ZH
MJBSBE4!; JG).U4%TFS$Y <KJ(JD22.9,X  ?>E=ZPO*N8)"046FV2!7+R'2
MC9525:-C@@8CAS'D9"[00,5TU,555$B9@<H"!A!9/F .:/TIZI5ND6WCJD!0
MI5,[74Q0515;J@ O2]QT5R)K)F^Z11,A@]T U<>B+I4_ADOZ(K!5EY'KGZWV
MC/=$8J1#I)MH"QP5,1/+#4Q@116<*B'8DR'J$&Z:JR@]_P#133,;W>' !UY5
MY<]_YB?K4QZ4=>9FYV7JU!TKNW&7WB8_P]/_ ,,U3T6;!VXR^\3'^'I_^&:
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MJ[9M5\8T:(HU91=QQI^Q%>V%PSC5GL_.H.H]I(KN6[=E!Q3./01. .(T &@
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MF<+C7H6'["-YWOJPC\T9-U &6OOFGO ./K),3-DJ[W>O#27H3(MC:@X2T#0
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M_FG;]K>3-ZT5/X736K3PPPRW:6EL1?\ 6945)=6,$'#J%=&Y[7WLI_LNX/\
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MRV 9X9Y6FX^@"7[_ .]'[\=P4(M:LC,X7#/0M;/PJE[S1\*>-N2T80[FJP)
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M]'3VG.B\>:U=*HN[;_B(MFR7$([M5A%G@CWHG)IX-3>CY-X2[<=;%9Y'E<K
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MZY[_ ,R_C)#THZ\S-SLO5J#I3^EZ \AP_P F,O,:I\+-@]+T!Y#A_DQEYC0
M>EZ \AP_R8R\QH AVZ1QBR8Y/HJ;)HU9IGH0'.1JW2;D,?TPS!><Q42$*8W*
M !S" CP  X\ #5',Z2]U.]'/O.>%X\UNZ-1=(_NR1$>&JQ"SH1ST3FP8LJ?T
M>YF;)HT,O$9[%<S9LB@982Q>WX2BJ*1""H)1.<2B?B("<PA_2'CO+F]Z+<<,
MIO5YX88Y;M*RN)5!K,H*F6K%B#1T]^CC@H1;8#LL66AXI557:]@Y1156/:**
M*'/CJOF,<YS(B8YS"(B8QA$1$1$1$=4QJZ]-18TY:VJ+2TU=YDPJ0U9,/1]+
MT!Y#A_DQEYC7SH[8/2] >0X?Y,9>8T -3WLPT0TVTY#<-8J-;+D6I_(LW8M4
M52<UXK9#<JB:13EYB&,4W 0XE$2CW"(:AS+[P45/\MC]H6H3'D"X5Z8^0^>S
MSJ($]9Q#1T.MM;!BOT0V_1VLR:+.T*9ET$72K9%1PB!,<U4Y 26.05$P*<QC
M% A@Y3&,8. B(ZT7S*M&ROSAJ;+8!GAGE:;4Z ([4?Q0BUJR,SA<+]"UQL>_
MIF\T7S!D]%*SX0!,7;5!P*8'BLG\P$%8A^0#<I>;EX<>4./'@&H!RU]\4]X%
MR].2$RY*?R#WX60]":%KWTO0'D.'^3&7F-0:);!Z7H#R'#_)C+S&@ ]+T!Y#
MA_DQEYC0!69R,0J>0;V0A2D(2Y6<A"$ "E(4LV^ I2E   I2@          '
M#63=3WEJ''';7Y@:QTO=FG<":-GRX<9L7:MGFXRK(.VZ#I T/:Q,BX2372,)
M:^^,4135*8@B4P )1$.X0 0[]2EF\\*+/S%YV;,"+LX;@N>.?,VTI<5#>E/1
M2;](MO'1023113SM=2)I)$*FDF4'I>!2)D I2%#W *  'W-;LT1=*G\,E_1&
M)U67D>N?K?:,]T1B*+CI)MH"#A))=%3+#4JB*R9%4E"]B3(\ITS@8A@X@ \#
M (=VO*O+GO\ S$_6ICTHZ\S-SLO5J#I7>EZ \AP_R8R\QJGHLV#TO0'D.'^3
M&7F- !Z7H#R'#_)C+S&@"'?I'&+)CDZB)LF;5FF>A\YR-6Z3<AS^F"7+S&*B
M0A3&Y0 .80$>  ''@&J.YTM[*=Z.GM*=%XLUJZ51=(BV;)"._5819X(]Z)R8
M,65,Z/DS-DT:&7BL\BN9LV10,L)8K  E%44B$%02B<XE$_$0$YA#^D/'>3-Z
MT5/X736K3PPPRW:6EL1?]9E14PU8P0<.GMT<$'"+]'_LL66AXM957:_A$ZBJ
ML>T444.;'D )CG.=$3',81$3&,(B(CQ$>.J8U=>FHL:<M;5%I::N\R85(:LF
M%XS[ 02>"<U*)PL20Y,2Y'.0Y(YF4Y#EITR8IBF*B E,40 2F 0$! ! >.OS
M4Y>%AQEKUY >[YH5XPMPU18,I:V./2S@TEWVXB"<3L?GUSCU#;^C.Y_9925(
MZR2\AVRKFBN-]<A3).#;0<B%_-.2&$7,0KBELG;&E"8UEM'1#'C#J"4!V=TF
MU<G8H(N7I&ZQV;9RY.S;N'14S"W0<.TVSU1JBJJ!$U7)&;LZ"9C*E;+F*"1P
M"-.'Z14[Y<C1_AY-HO6+.WA<MBUOLD8*E$R^<*Y@>O3-2C+!C6KVNTO7ECL(
MSLI6;M6<2S,95HMQ)LDYL\K5D+  /7W B!<#9M$>X Q%DD1'[@!39H1UV:<O
M"PXRUZ\@.6^:%>,+<-46"B]OP_X<G_<5\WKC#J!J6]J7C76VG(*#=T114Z]/
MY2 50!'EN]=.;O,0 [BE$?7]S4-Y?N"BIO",?M UB8\@7"O3'R'SV>=1 IK.
M,:.AUEM?-$>B&WYM%5BD<+4W+8I)"!Q$X'QU5"%X"!1+WF*8.\0];O\ <UHO
MF5:-E?G#4V6P#/#/*TW'T 1VH_"A'K5D9G"X;Z%LD&;&D[RP=KE1%2TX2$G,
M!QY@+$Y,YN'*4WK<P>OP]?4 9:^^:>\ X^LDQ,V2KO=Z\-)>A,BUWV_#_AR?
M]Q7S>H.$M [?A_PY/^XKYO0 =OP_X<G_ '%?-Z *S&1#%/D"]'*/$I[C9S%'
M[I33;X0'O[^\!X]^LFZGO+4...VOS UCI>[-.X$T;/EPY#8JY0:;BZTNX4!)
M(L):@$X@80 30;HI>XH"/>(@'K:E3-WX4&K#WC9ZPBS.(X+W7$&?:"(J$]*<
MJFOTBN\=9(P'34SO=CD.'$ ,47P<!#B #_\ V #K=>B+I4_ADOZ(Q0JR\CUS
M];[1LW1"+)-^DJVA++'!-)/*(&.<0$0*'I;GPXB  (^N(>L Z\:^N>_\R_C)
M#THZ\S-SLO5J#I3]OP_X<G_<5\WJGPLV#M^'_#D_[BOF] !V_#_AR?\ <5\W
MH AVZ1QZU>Y/HJC58JQ"4("&,4#!P-Z89@W#U12CZP@/K<._5',Z2]U.]'/O
M.>%X\UNZ-1=(_NR1$>&JQ"SH1ST3F^:/*?T>Y&RQ53(1&? 5  .'()HO;\
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ME7ESW_F)^M3'I1UYF;G9>K4'2N[3>_B],?IX#^.:IZ+-@[3>_B],?IX#^.:
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M546*X ?%U5.?JB$2,F8.3EY>=0O$W, \  !'1?,JT;*_.&ILM@&>&>5IN/H
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MZ>TYT7BS6KIU%TB+9LD([]5A%G@CWHG(7PTSH^?#"-"E[*SSU ME%E#"'96
M.;K0523 H\.3EY!,'$3<>' ..\F;UHJ?PNFM6GAAAENTM+8B_P"LRHJ8:L8(
M.'3VZ. TW_P_]EG4I18I?R7\(]6*KAV502>+R Y1.4C8Q0-PX<P%,8 'UA$-
M4QJZ]-18TY:VJ+2TU=YDPJ0U9,+QGTT[XB<U<Z,2!/%+D?G$KEX)@+Z3IGF$
MH"U !-PX\ $0 1]<0#OU^:G+PL.,M>O(#W?-"O&%N&J+!<M<8=0&@#YUG;5N
MJV07<MT%GJAT6:*RR::KM9-(ZYTFR9S%.NH1!-18Y$@.8J29U! "%,( "5[@
M/8'S9\$>2/H;,Z[-.7A8L9:]>0'+?-"O&%N&J+!7-<8=0-,WQ?:R9$_KZ;].
M:WJ&\OW!14WA&/V@:Q,>0+A7ICY#Y[/.H@"UG&-'0[>T>T_;^/>=EW]G%2UH
MOF5Z-E?G#4V6P#/#/*TVIT 1VH_B@QK5D9G"XUZ%A^PC>=[ZL(_-&3=0!EK[
MYI[P#CZR3$S9*N]WKPTEZ$R+8VH.$M T &@"L%D?V0[Y[\[1\^/M9-U/>6H<
M<=M?F!K'2]V:=P)HV?+ARNPW[9"L?F.V?,3O4J9N_"@U8>\;/6$69Q'!>ZX@
MS[01%0;I5/;&MY?P\W?_ #P:W7HBZ5/X9+^B,4*LO(]<_6^T;/T/WME^S_X4
M@^C4_KQKZY[_ ,R_C)#THZ\S-SLO5J#I=:I\+-@T &@"&CI)O92H?O #Z13.
MJ.9TE[J=Z.?><\+QYK=T:BZ1_=DB(YM5B%G0D_HGS[#>CR_,^??FK;WK>7-[
MT6XX936KSPPQRW:5E<2J'6905)]6+$&CJ&=&][7YLI_LMX-_9S7M4QJZ]-18
MTY:VJ+2TU=YDPJ0U9,/4U\Z.V#0 TW?#]K'D7^NIOTZK6H<R^\%%3_+8_:%J
M$QY N%>F/D/GL\ZB '6<0T=#N+/[3]OX]YN7_P!F]3UHOF5Z-E?G#4V6P#/#
M/*TVIT 1VH_B@OK5D9G"XQZ%A^PO>A[Z,'?-.4-0#EK[XI[P+EZ<D)ER4_D'
MOPLAZ$T+9&H-$M@T &@"L'DCV1+[[]+3\^/M9-U/>6H<<=M?F!K'2]V:=P)H
MV?+AR.P_[9&J?F:V_1Y]J4LWGA19^8O.S9@1=G#<%SQSYFVE+BH5TJOMC6\K
MX>+K_G2ZW9HBZ5/X9+^B,3JLO(]<_6^T9_HAO;*]GOPLM?F.:UY5Y<]_YB?K
M4QZ4=>9FYV7JU!TP=4]%FP: #0!#3TD_LHT+W@_^13&J.YTM[*=Z.GM*=%XL
MUJZ=1=(BV;)".75819X)3Z)[^POH]/S3GOYIV_:WDS>M%3^%TUJT\,,,MVEI
M;$7_ %F5%275C!!PZA71N>U][*?[+N#_ -G<!JF-77IJ+&G+6U1:6FKO,F%2
M&K)A>MP'L#YL^"/)'T-F=?FIR\+%C+7KR ]WS0KQA;AJBP5S7&'4!H 8)N@V
MN7[,^7:#=JRM1U(N)C<>1(S%IDI%G9\2O:3GVA9?E[KC!HTJL\A)6&Z5VJN*
MA))'FZ8=)>-K!W4E)11G[=D /7N578W>H6NER;AZTC;?6YRKR#J-.W3D6S&?
MBW42[<,%';9ZT3>HMW:BC4[IF[;E7*F9=LNF!DC_ *I&;4D)V3GDH4XU9*:E
MYM.!4HC2C4EE8%H(5"@C3C-.** BC*"."(X3/<QPG89?GFY:"<E9F44BC@3F
MI=:6CB3.$E(8%TXDHHH#BACA*,H8C.$XH(H;2*V&(NX>C^+BY_E^RQ\B8*^I
MC7[M\Y+XO,_T[_UX/R=H37PTY_1,W5(TS(.WE[D^IR=)N&<\O/J],&8F?-6\
M?A-@LH,=(-91IRNFF'$ET^1XS;J&Y#ASE**9N)#& >%4C?3M6,TVPO=+M<PV
MSIRYS"24[4DO'$<K,HS:-BR+] I#N5T$XCW,1;HB.$[2,R'<IMT?Z3>91^9:
M@GY=RD2F"EU59-AF((2FI9:46M169XTX]T@NI"6ZA/<F91%9$1&&V_\ #(Q#
M^53./REBSZIM1=[AF2'XC2OG!67_ '()2]W?*W\<E?(-*=0C='FP>D/L(9'V
M\.,P9K-B[*[&;CKI#E6Q$5\_:V"+90TH1M,AB+M*/,LPCVR1#LW"1D3$,JD)
M5#F,,H4$VTYDU2@1I*EVN23@<S=X2F)ZI9XRGC1ED#4MFG]0SA['*(EV,_ZE
ML)G9;%%;&-=/%191Y@YFJZBGYQ8VV%I.*7DF&2+M*%:97)/<RS,F6Z[)-K'V
M2S=V1$5MD)61P?\ +5='K^,>Y#_N-4?JVU,?NSU-\&4]_EG3K@11[EK#^O/7
MT[?U:'R;/^C P[L5C[W&;<LIYRJS/)#ROO[829D\66LSUS6$)9O$&;J6#$ST
MS(J"4W( H1J*95Q5(*H&%)/E^:?ZZFZECEHW9E8UHI2%6% TR>D-R2QP&I:2
M3U#NK33@LW5MEG<]\QW6>D99AA7@;75V2AF8DXE2C-J6M-(HR@,C4:HCAL*.
M*VSW_P!P>9XN+G^7[+'R)@KZF-?/[YR7Q>9_IW_KP=KM":^&G/Z)FZI!XN+G
M^7[+'R)@KZF--\Y+XO,_T[_UX':$U\-.?T3-U2#Q<7/\OV6/D3!7U,:;YR7Q
M>9_IW_KP.T)KX:<_HF;JD-)E.C9Q9,R<C+O\KYO5?2KYW)/5"OL4I%4=OG"C
MIR<J:>)2D3*=94Y@(0H$( \I0   -0S-Y%LD\]-3,[,41*13$W,+32\1/U80
M%$M,*1*JQ%##4A0PD<<<1E#"1$1=PBL(3-*9;<JLC*2LE+5@M!+R<NC*H0FQ
MTK&<*,NG"DE"<43"<41E!!"1Q1&9F96F9F8VK'6PVEXKM+2Y4S,&:F$\Q;O6
MK=RY5Q%()%1?MCM7)3-GF(E4#"=%0Q2F,03$'@8H@(:[%,9,\G-(.Z+XQ4;(
MR[B@DNBFJJ\59,P%!,IQ)*D:2U11IF<4$1D1G"9PGW2L,<>I\J&42KVA9C?:
MKF9AN7506422:*9EHSCEE(54C)5%C@4(H8X2,R*(BB+N':09)F+H ]E>=\HW
MK,>2+EN&E;WD>QR%JM<BRNU%B6KR:DU.M>+MXV/QB@R9)G/WE;M44T4P[B%
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M8%UM;A9)O''<PS*2MM@6?7O+<I4*^TM<4K,]CR5?;A99".CU6 !+@0P'*4X
M8 ,4# !RB0P 8 '@8A@ Q3!QX"4P )1X@( (: /UH - !H - !H - !H - !
MH - !H - !H - !H - !H - !H - !H - !H - !H - !H - !H - !H - !
MH - !H - !H \4F[= [A5%!%%1XL5P[422(F=TX*W0:%7<'(4#+K%:M6S8JJ
MHF.#=N@B!NK23*4 Q\/ P==:JLJ_"Q,$S7=N9!9I#QS.,:K/WJG6O'JK=DB@
MDH[=J_SCER<@K+J>K5.<W?H RV@ T &@ T &@ T &@ T &@ T &@ T &@ T
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M(9]&-')K!!,58R&F152*89*+8+R<TJT8//\ [[9$TM(\J1R\KQ<H@H8 V'0
M: #0 QZ2W!9^B\_Y4QHSPFE:Z57(9[-XYGF!)V"-;3,(K;N$K 2%D63GHAK*
MP,EDVYRXN$X9%"R1"$9$0[9&0I5SDWH!CD=QV7W.0&=:1KE9/'IY66I2K-O6
M+,ZD;!&FR-0JW,Q\9+DLG@,1.XMHEIFLA6N3=QDBSM,; N'$9"UE@PEE6P!H
M%TW;;@:?/O3,,6,[S"1F57];L5>KU*N"-HJM28VK-D"R0=2IK"]CY.P6*LT:
MC9(CI9.'91;:OS:A313MA<Z;-MP!<MK68LKY3;. R^A4:G:6-2QX^<4.'J%H
M@I)P[GL7XVM=CN;&0L=IDU#5 ;O:;;3(J+&)5<L7%858/K$\FHJ<;E '?Z #
M0 : #0 : #0 : &@YHS;F/'N6JQ5*=C1"Y4B<8X]9O)A&-G7$C&VBW7R88NT
MWCUDY"-9UQ&D5:>!65.S<KP-KDJB9\UDHR8.W1 -$M^Y;,4%*.DUJC4*QV7$
M8KL,G3'[&:M=V<I6>0SXPL]0IYD;#3&EQOC_ -(&,'-0A48V)4:A<W3>11EO
M#H=T@ ;Y"[A)WJ,>NK0K5X^*M-UW"4Z5L3:"GRQQ%<<7:?KN-7,:T[;?JD6N
M$/&,I8S)5Z^-/"YYH!9JBNAP $MQ3N3SA;LAXZ@IEOCR:KURAZU/.6E4H5PC
MIQM"VJ:W"$5?/IY;(MIKM:D<?0..<7%R!!O&LTW:VV[O*RRL(KOZLL_ )#]
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M]D&!XI^\CV3I[%JJD74C7;ALDLY8*+I@":QV:QSMSJI@!%#)B<H 40T 9#0
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G@ T &@ T &@ T &@ T &@ T &@ T &@ T &@ T &@ T &@ T ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g358845g61e05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g61e05.jpg
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MQ;3<7Y4=VUN/FI&Z5JN4*="9-UQR2[!;A2))D\^1%7%XP@(==&5 ?C#EQRA
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MTC$CF+\8QL\<B1 \@W$Y39Z%QTFN,6*](A7-B>ZRV3G9BC.1G'4!%)09)'I
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M(KAW/,XC=M&5BHN7651KEVA'))VC64Z)3'42BK V(0B3\B1#K'A9AO%3R38
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M>E1CDCQNJ*:R!K(^K;)TD+9\L8F&YQD:8[9G#9-$N$WCC0$_= :C\-D[>A&
MN(5YIUQ,B2*)+M:KH@Z$'KEJM!BW2*;F#XEV>_YDZHKU,J,V\O>W'U--DZV_
MRVB8=!"!Q+5'NLADT=C@A4.UEEG"RKAPJHNNNH=9==8YE5EEE3"=1550XF.H
MHH<QCG.<PF.81,81$1'*M*JJJJJJJJJJJJNZJJ\U557FJJOC6OHL  : &F@%
MMML1!ML!0   1!   401$11!$11$%$1$1$2I1>DMPU'EIR:BWMIB_7=/:;-&
MWK8WK"/F1\V[3='-3Z,MXBF35"SRS-9Q)M5"^!Q6(6PH@HDX5:B;-\!QSO\
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MI GZTOB^19,)/K-2/^:5Z7=053S4Z2)Y4Q_*%7V%N-I1/P5^[4>_%L!+URY
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M;'XSJ#:+TRTS.?9MMS04%QE\T:COFB;*<5]Q>#8UYHPX:/"J\ ]:B=8NA[I
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M-ZQ'/T2F\)O,;N4G+%R[:./WNEKA7F"];[@RCT=\=E3Q&V:?$.M'LJMNMKS
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84Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g358845g64l44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g64l44.jpg
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M! 8# 0           0 1 C%!41(A8:%Q@9'!T?!"L>'"_]H # ,!  (1 Q$
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<VE(1B)$A/==W^K&F?YR7_8XW^R^B8XK[#PO_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g358845g66p51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g66p51.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1D*4&AO=&]S:&]P(#,N,  X0DE-! 0
M     &D< 5H  QLE1QP!6@ #&R5'' (   +-H!P"4  (<G(R,3(R.#8< @4
M0$UI8W)O<V]F="!7;W)D("T@06-T:79E7S8P.3$Y-#8U7S(V7UIA:2!,86(@
M3'1D("!&;W)M($8M,2 U+3(T+3$ .$))300E       0UG%"N^2VLS4; &MS
MJ10D"SA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  (#P     $  CA"24T$)@
M#@             _@   .$))30/R       *  #_______\  #A"24T$#0
M    !    '@X0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          (X0DE- _0      !( -0    $ +0
M  8       $X0DE- _<      !P  /____________________________\#
MZ   .$))300(       0     0   D    )      #A"24T$'@      !
M   X0DE-!!H      S4    &              'E   #Z0         !
M                      $              ^D   'E
M      $                         $     $       !N=6QL     @
M  9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M      !,969T;&]N9P          0G1O;6QO;F<   'E     %)G:'1L;VYG
M   #Z0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I
M9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4
M>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG   !Y0    !29VAT;&]N9P   ^D    #=7)L5$58
M5     $       !N=6QL5$585     $       !-<V=E5$585     $
M  9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (
M8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E
M2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI
M8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    1
M15-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M      IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M       +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M       X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
M#N8    !    H    $X   '@  "20   #LH &  !_]C_[0 ,061O8F5?0TT
M ?_N  Y!9&]B90!D@     '_VP"$  P(" @)" P)"0P1"PH+$14/# P/%1@3
M$Q43$Q@1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# P!#0L+
M#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,$1$,# P,# P1# P,# P,# P,# P,
M# P,# P,# P,# P,# P,#/_  !$( $X H ,!(@ "$0$#$0'_W0 $  K_Q $_
M   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M>KL2SW=/9AY#L>O'NM UK>_TVG1N[]+6RY[/T?\ HJTE/__9.$))300A
M  !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M$P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X
M0DE-!"(      49-30 J    "  ( 1(  P    $  0   1H !0    $   !N
M 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0
M  "< 3L  @    D   "PAVD !     $   "\    Z  :L_   "<0 !JS\
M)Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$W.C U.C(U(#$Q
M.C$R.C$U ')R,C$R,C@V       #H $  P    '__P  H ( !     $   /I
MH , !     $   'E          8! P #     0 &   !&@ %     0   38!
M&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M            2     $   !(     3A"24T#_0      "           _^$!
M2$U- "H    (  @!$@ #     0     !&@ %     0   &X!&P %     0
M '8!*  #     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "
M"0   +"':0 $     0   +P   #H   #P     $   /      4%D;V)E(%!H
M;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3<Z,#4Z,C4@,3$Z,3(Z,34 <G(R
M,3(R.#8       .@ 0 #     ?__  "@ @ $     0   ^F@ P $     0
M >4         !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !
M/@$H  ,    !  (   (!  0    !   !1@("  0    !              /
M     0   \     !_^% )&AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M 0$! 0$! 0$! 0$!_\  $0@!"@(E P$1  (1 0,1 ?_$ !\   (" @,! 0$
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M,4*U)HAGJE)AJ@\PPXP8[A6_6+IOD&I>$8]CD9FMH,[P#,$2RH0Y<X9!9#7
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M !%*3POVZ.<"8WV,Q=Y?V]KD<T,=28DQKY&H2NLE-8T07)Y+9$)S@!0Y&-:
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M5J](2-Q2)F^4,X;GA4GQF0,:Q8E0JE)R).%LV[NKIY3'M_U1'_NH&= 4!0+
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M<M 4!0+6ON*KRDY]>/H&5 4!0+D_?)Q\4@^*HH&- 4!0+%GS^T>/5]1/H&=
M4!0+'GO6N\0+[MJ!G0% 4!0+6;O2V>\4OWD% RH"@*!:A^?'CW\1_5;=0,J
MH"@67[\A\F&=:+H&= 4!0+'/YE#Y31??+T#.@* H%SQWI=/)RWJQM!3G1_[-
M=='PTW_\'?3A0:P-:L1.>>$BC<?QG'5RZ82EATC2.?S:/Q5N:9!A-JA>>99(
M&F6,+J?EG&K;DY3DU*SO$+E:"1L$T+A4?:RE5TTD1N0L?O(>A:@* H*+:.?9
M%JO^&=G/^SV+_P!?UZ0O30% 4"QT[DD\IMO7"J!G0%!$7HB')"M;E/'63+TB
ME$HNG4')3[$*B1D&\0J3&%*$QW%F"XM0G-+.)'NF%& &$(K!H2X)J"88PAJ*
MU<X5QV5EIQ>HS$,:PQ)(9DF@+1&KXVP&-XQ3%T2J.8WC$49&S(BMU-?%DH=7
M=(JDDI6IW-S=4L;7E.#8H#?4V=[6_P!XI.KET$Z@*#PI:OL"3_@C.%)QGJ_C
MN4,L37'I^8YCG.;)N0S*3'N>!,YSA@)U&161',6/5+6<NCC(B?9D4H>IX80A
MCV%(Q(7=(0\2HA&L#VT0;(D#FRIU31"8QR2*K-<6FHT;.[HERTF(SQM.40J2
M'HR#AJ4[+*R&9W-8' XHM,ZA;'#D9AMT:BQ89%H"@*!8'OR?Y,2=:64#.@*
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M9S_L_C#VO]__ !H+TT!0% L=.Y)/*;;UPJ@9T!0%!6N%/,).U':@V=H5(.S
MN$8;525.1(F96>>607D I(,<;2% =VE4W)U:0MQ7N1RD"].XL99 $@$X+*0L
M,V=[6_WBDZN703J H*-ZXM(J355!T32C3#4R "=3"'9,MS+EW$;"]X;FS[&%
MN98*XJL6"6F+@Y%CL41112-S85_)4"M0>E4)3B2^,#S-8%TP<(5H_P"%2A,J
MB< EQ<&B2(S3(^RL]SS[J4Q5,,"Y(/;3L2W429T(A#FD0Z<&IIQ?&7>RT].1
MNQAZD@4#>J,<!.86FX9'7)PAVDZ>8U=,=2!O3FX7:VK)[6Q0C3_J,%C'5).I
M^OD$*M@N02AJD+]$G!-C#&C3/,W2)G>91'@ 7HH0<AY>X)% 6L-J^B;A;M+^
MM"08FQ(Q.#S"M260-.J?4#(L-/S#)DX8>G;G\$+G,223)Z8(^T3%SB$T)=FD
M:R/DG)'1O:5;RGXHD!I)(;3*!8'OR?Y,2=:64#.@* H%CIW-)Y3;^M%T#.@*
M H(+GWM</>*OJYE!)([@3XHOXEJ#EH"@*!:U]Q4^4G/KIU RH"@*!<G[Y./B
MD'Q5% QH"@*!8L^?VCQZOJ)] SH"@*!8\]ZUWB!?=M0,Z H"@*!8S=Z&SW@E
M^\@^M]R@9T!0% L0_/CS[_(_JINH&= 4!0++]^0^3#.M%T#.@* H%CG\RA\I
MHOOEZ!G0% 4"YX[TNGDY;U8V@ISI ]FNNCX:;_\ @\:<*#6!FEPX._ G" L
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MDGBA*S[ N&XER/D%RTN\VM ;<XH+VW7M8+:+E(-T-[780; WOLWA6WKAMTV
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M/+XXW<WQ!FET[VN/O%7U<R@DD=P)\47\2U!RT!0% M:^XJO*3GUX^@94!0%
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M/B7H(S9WM;_>*3JY=!.H, ZG\*"S_@W)&,VUT*B\PD,5<T\!G%N7%+8-.DX
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M<DB>5QE.:@0*8VI-6KE8;'J!8'OR?Y,2=:64#.@* H%CIW-)Y3;^M%T#.@*
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M*X=VH"@*!8L^?VCQZOJ)] SH"@*!8\]ZUWB!?=M0,Z H"@*!8R]Z&SW@E^\
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M$:8ZPK&$#"8,(BA!O88K7WKA%#WY/\F).M+*!G0% 4"QT[FD\IM_6BZ!G0%
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M/E2;Z8(^RE_C4!RI-],$?92_QJ Y4F^F"/LI?XU!Q'JDW$G?M@CN1G_2E_\
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M\:@.5)OI@C[*7^-0+DZE-SBXWY01LN4A_P"E+_ZJC_*H&/*DWTP1]E+_ !J
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M)'66*F-2]& ?) Z2$:0=V)GC[.G;VLUU,;&1 VLZ!(V,B-O;B2;@2V&,.[O
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M#()'"S$,V1,:5P4NL)=#HX^JVX^-R"4,CHS%OB%P;DCLW/*I*L/;U=R!"*
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M VFO+ GL[H7 I(F=FNRHAR6HR2W0EMLK"W*T2DP"LD,&:/E&H<W+F;09:'E
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M2C%L",R,B>#&\UV3S<47:^RD#F-I+);+K^>N6B5V0%%)0GB, 246 -@!#+]
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M#_QH%SFI=+%I>,?(W>UW%NL'=;U ;\9=458%[WN_BVAW]FT-K6N*W180;]-
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MO<(P"M<(@WO:]KVO08N*P5A$A%9M(PYBLEN"[M\@"@*Q[$2T07YIXSFI[LE
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>C'!V6)FI*D)4N:X80C6+S@#5*AAL(\T=[6O0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g358845g68g30.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g68g30.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( .L!R@,!$0 "$0$#$0'_Q  ?  $  04  P$!            "@4&!P@)
M P0+ @'_Q !;$   !0,! P8%"A$*!00#   " P0%!@ !!P@1$A,)%!55E=46
M(3$X5A<8&51WE):VU-8*(B4V05EE=GB3EYBDM+77V",R-3="45=T=;<D.7&R
MTQHF1)$S-%+_Q  = 0$  00# 0              " $&!PD"! 4#_\0 91$
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M<- #@/\ UFS]AK?G#0!BW*F:\:8+;6AXS9G+#&'VB0.G0C"Z90D+% 6]Z>>
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M,X_=$:J"9)<&Y<R!*30"22!(SKD 4!A;FVK+(^$:H*NC$K!QAE ,ZTXDD0Z
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M[,6][4 5!-94$K8L,3FG;U]HDQ)A!6[_ &;<,T]0/>M]F_$V7^P&U 'L4 *
M% "@!0 H 4 * % "@!0 H 4 <XN5*\V /NCQ+]4?:C5KK=ZPO&64>BCQ(/6S
M[Y*O%Z:>F@1'$K6H-@H4 * ).?)P^:#C3_/SSX_26MI&MIWG+,=\3_\ Q!,Q
MK?UP6^O:3N,C^@9:(BG*B>?WJ:^_I'\5H_5KVTZZ9SWT7H6A%::;H17=3YB&
M@]6N.@% &^/)A^?QIC]T$7Q?>ZNBQ?73)N^C]"Z._*]T(7NI<QB>O4H!D$*
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M1JRU4-\6V_C/.>FO#YZ$@_IY[_U=R_7#JC^][J[W1?SC$=3QGVSYQ2*^8H%
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M5K&5;%L,X8C5ZLLP0.A$F[<8 MI@0BO;9O!"8.UK^05_+6WS4CWK[ >*<DZ
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MZUPV+O:UK!O85[WO:VN'7;[YDL\397]+3X3[UK^]Y,?&R8_1<D'-&HNB1P4
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M5)]#S?U5ZD/= A'Q<=JS?J3^\9OWW#^A6+LLY[E%=T;^:H2)*RR+D"@!0 H
MYW9<Y3/ 6&-3C)I/E4:RNLR._O\ CV.HG5BC\45PTM=DHQI+83%+DNF[:\ 2
MIA/*7I4PN/FFI[ /NE)6[A=C;3C[92N73EJ1/LQRHQUV$92XVTPJ'PHPVR:,
MUJB4.$E)N%AT:,RH>"2KJ^:]-(=B*3!K0\;BE-I)24H-NKM,&IFX2J%A%A42
M9XZ$8O)^UQP>.3UWQVYQES(?6;/<;PZL"-S2  7%Y%'270.7S;73[Q<20/W/
M8@J27WE73*0.Q18"D(079D'I>O,,BLFK#&+V*,DA0S5N6R^4,L/86YSC0BEJ
MQ]E#%%9A%$PBTJQ661:10*5!GJ2YYI8VV,1J;FR,MD=(@^-20*5Y?+C[5?4A
MA5DUR@/,:'Z1P<IDQD>GBJAUGA3LH6EA1.VE+(6J5^>&=B+;NGE:5G98>VL!
M#<O;6UR5FN2I:789R<IL,J97T]<=."H$=U?7%7AH,[H=3N/EKVUQ-2TS-KE[
MLJES>7%7)C2]()72 HC':8MK@N1.BZ.I3V!F,97D]4)[$V+$$JC%VM>O4N?-
MB%/7U]2X0J7'CIBX<?KH%JE:P8 ^160OT/:9"]*XQ"\@S&2DW+93VN$(H&HD
MK6(^7O#(^NZ-2A>GR+.R!H.@ADU4+24BA<6GLD*$=931Y<@$=?7^.+UXC&2H
M#GF'9"EBV%M25]3.Z)%)E9:M<W (97<4(DB&)3(IF5V4C6'>#[XZLY!QC@WM
MI:TEV2'-@EMT[H!NH*UX!FV@#47.,PU+,T_0-N+X0J6XXO G$]VE;>DCCTX)
MY*;(F(*]2F:UKQTN)PC4- \+8DSIXZ[)Y;)5O,EZ8]*W%$*:W?Z9?7AQ<510
MZW$6?)ZW4QUO&<\7.,Z<L9Q)QGC>6EG*IE3FO*)2 #68)1<8[$'.*5*6J*:G
M)6@LG6.C:G)$2W.1RE 46660$(*"O!Z_^!>''?>K&KMI7W%5;LIYBTCC57P>
M4@X[[U8U=M*^XJ793S%I"JO@\I!QWWJQJ[:5]Q4NRGF+2%5?!Y2'.KE0370>
MF0-E:)"03ZHL3_E$[D>J,WN:/F[;A&-:0.[?Q[1<7;;Q; BV^*-6NMI^"LJ5
MZY9/P?\ LQ_&8D)K9S/\))U33^3TUOJ798$1TZUIC8,% "@"3%R=)KL'2/C8
M*5"@.(LOG>X8>YJ$QHML\DEQ;Q);4J"'8+:&VPX6]:UA7L&]]VVTG6TT_ Y9
MB\_?%H.#_P#89GQC6]K@S,M5BT="K^1D?#3_ *%+1$@Y3ZYPM>VI>Z@LLHZ\
MY2<0LDX1Y8;^"\?V6 :,E.(=MFR^VY)>R][VV7V;;VM;7KIG/?1>A:$5YINA
M%=U/F(:&5:XZ 4 ;V<F3<X.O/3-=.66:=;( N&6<:(@L0O!]Z\0S0$J! MLV
M^.Q)GCV6V>/;:Z+%]=,F[Z/T+H[\L]_PO=2YC$\7COO5C5VTK[BJ4-V4\Q:1
M?]5?!Y2#COO5C5VTK[BI=E/,6D*J^#RD''?>K&KMI7W%2[*>8M(55\'E(..^
M]6-7;2ON*EV4\Q:0JKX/*0<=]ZL:NVE?<5+LIYBTA57P>4@X[[U8U=M*^XJ7
M93S%I"JO@\I!QWWJQJ[:5]Q4NRGF+2%5?!Y2'(GE;C' <'PY9:E1IPVE<FW!
M)EYRNXA=$-^VP@FMZ*P+6MX["L(=[W\5PV\M0VUXM.H-BJ?K>:\%/^3AN,Q+
M'6I&?5JU]2I_LN6\-?\ FX@<-*@.)LA0 H EA:5#GFVFO!=B6]M,*MBV&6+&
M8[*2C!@Z$2;HAE!9C@EBO;QW!8TRP;^*PQ>6MONI'3\%]@+SZTY)P?\ P&>,
M:L=5 S_"-;>B:_RGG%]2^.O#Y\C_ /T\][?+TNY;=GC_ /F'?9V6V_\ U;_I
M4?GO=7>Z+^<8CL>,^V?.*17S% H [E<@,-6#5UD^Z,A.H-];C*+" I5&) 6!
MZIN)MHK&%I%@A"L*P;6!<H-KVN(6_:X;!%DW4JW>CJ_JA[IL#QD/=L]7;KM"
MK^:KX:?\5D2Y^.^]6-7;2ON*L^793S%I%XU5\'E(..^]6-7;2ON*EV4\Q:0J
MKX/*0<=]ZL:NVE?<5+LIYBTA57P>4@X[[U8U=M*^XJ793S%I"JO@\I!QWWJQ
MJ[:5]Q4NRGF+2%5?!Y2#COO5C5VTK[BI=E/,6D*J^#RD''?>K&KMI7W%2[*>
M8M(55\'E(1[.54&K'J.C=UA"=.;ZD4:M8"948K+N#PJG.P5S#$B,5A7%O6N#
MA7M:UK7W[W%<(=<&NWWS99XFROZ6GPGYK7M[R8U*G\K)C=_]7)!S1J+HD<%
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MD@*8W>O;A@.L?;=MY!<2Q9?E_NW?%_?>@Y%QE3B'GH 4 * % "@!0 H 4 *
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M=(/,'M%X]E]W9;9X[V\51JUUN]87C+*/11XD'K:-\E7B]-/2P(CJ5K4&P4*
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MS+#$?@K4WSN'1^;1-6_Y(5Y(%!6V9O"*0!CZ;%!CZ*>F35CD<;);3AH$:QS
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MUXTBR/&+ &5.7DN',R <L3J)R7I.RAJ.B&%\ /\ ZE^G_"^HYZ7L>1Y^[0-
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M'"F24+I*ID9!CH:P3R'F,,+]I..OZ2<>?C&]>F/5MIVF$GC>FK'"/4@Q2A)
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M+,\*(0RW+76R)#:D'%/MFM]3:VH/O26)MB:H6'F$*Y1-FE;8BHLH(B5:-#<
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M-#4]\?!5\#QGVSYQV. OZJ?FD.BE4 * % "@!0 H 4 * % "@!0 H 4 * %
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M? >,ZYH2C;D +,/L6.Y)9QHB"C#;!O<L!IP"5 R2QCV!&: @\18;W&$DR]K
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M?&1?MC>M3X&<G[_ S3#5EY"T!1'8TYU_7#V/C(OVQO6I\#.3]_@9IAJR\A:
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M#)"<:U42FJC(CK?KCVW_  >U%_D6E?\ XJ^/L><_6UG_ #Q"_6'/;Z?BD?\
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M6HLOSIAUQ3L%%P[:6X=6SF:G'F6T7J:0E*<*JE*(B([Z;I59X]8* % "@!0
MH 4 * % "@!0 H 4 * % "@!0 H 4 * -?-3.+EN7<;-<4;6U.ZK$F6L%2LQ
M,I/2IBP,D1S-!I!,%-C58RRKC30I!(S0)PBNH6W#S%*6<I4E$F>]9N9HE,Q<
MBG'%-)5*IW"DI)+4>S1<GC8>$31!&JBHQR'(U?HH_34:4I-1=&80YQ3"6TI)
M9E%0;AD9D7M&HIE;IU,R*YDG+L9_HD1F9#8.O!'>"@!0 H 4 * % "@!0 H
M4 * % "@!0 H 4 * % "@!0 H 4 :XZML7K,SZ>\AXU;V>S^MDA4:LG:;G)$
M_.AM,QCSX*]CEQZ9*7<@ML&IM<T\&VY.Z#>,$  KALK,T2>?R^8N/; B&.)-
M3N"I6#LL'$,%[5"5*/"-PDW)/'?=4QT9E#G%03\.E.&;FQT34BK@NH7C,R(J
M8-?(-C;6L&U@AM:UK6M:UK6V6M:WBM:UK>*UK6\5K6\E6\.\/[0 H 4 * %
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M^OL TW'0ZT.F(L6*IWUQW7$?&9#J[0<0H 4 * % "@!0 H 4 * % "@!0 H
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E5/*,RT * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g358845g94t04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g358845g94t04.jpg
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M  (1 0,1 ?_$ !X  0 " P$! 0$!           '" 4&"00# @$*_\0 31
M 00" @ !!P@'!@,&!04!!0,$!@<! @ (%Q$65%64TM0)$A,4%9*3T1@9(5B5
ME],Q4U97EM<B=;0C)#4V07<R.%%AMB4F-T*S,__$ !T! 0$! 0$! 0$! 0
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MS3J%![E1/Y:#X$\[I7_B>0_QHE\3Q7?K.]X\TZA0>Y43^6@^!/.Z5_XGD/\
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MS3J%![E1/Y:#X$\[I7_B>0_QHE\3Q7?K.]X\TZA0>Y43^6@^!/.Z5_XGD/\
M&B7Q/%=^L[WCS3J%![E1/Y:#X$\[I7_B>0_QHE\3Q7?K.]X\TZA0>Y43^6@^
M!/.Z5_XGD/\ &B7Q/%=^L[WCS3J%![E1/Y:#X$\[I7_B>0_QHE\3Q7?K.]X\
MTZA0>Y43^6@^!/.Z5_XGD/\ &B7Q/%=^L[WCS3J%![E1/Y:#X$\[I7_B>0_Q
MHE\3Q7?K.]X\TZA0>Y43^6@^!/.Z5_XGD/\ &B7Q/%=^L[WCS3J%![E1/Y:#
MX$\[I7_B>0_QHE\3Q7?K.]X\TZA0>Y43^6@^!/.Z5_XGD/\ &B7Q/%=^L[WC
MS3J%![E1/Y:#X%+2,JD_@215\XSWTN+:"IX5^V"'TF$\PX_ME/&_UCYWS,[8
MQMG7R_-SMC&?)Y<8YWKNZL>T[_?C.?1NVKX;J#0O^TL)O4Z++(=(,NKPI3Z_
M11.524Y7342^=TK_ ,3R'^-$OB><*[]9WO'FON=0H/<J)_+0? GG=*_\3R'^
M-$OB>*[]9WO'FG4*#W*B?RT'P)YW2O\ Q/(?XT2^)XKOUG>\>:=0H/<J)_+0
M? GG=*_\3R'^-$OB>*[]9WO'FG4*#W*B?RT'P)YW2O\ Q/(?XT2^)XKOUG>\
M>:=0H/<J)_+0? GG=*_\3R'^-$OB>*[]9WO'FG4*#W*B?RT'P+W"S4\-DQP8
M.9EA0N7?-!@L8P)EG3XB1?N$VK%BR:HK[K.7;MRJDW;H):;*++*:)IZ[;;8Q
MFM,1Q#6E[G.(:T DDDF0  Q)-P"Y1J-T71H,6D4BCT"! @0HD:/&BP:/#A08
M,)A?$BQ'N:&LAPV-<][W$-:T$D@!3Q9E#=EJDCKN53)1S@*),-8[)G$:M&,S
M9>%R)[JMNT SAC#I6<>Q HX^KK)HMS[=AA1RGLST4V>:Y0QZ8U%I<!I?$\UK
M@QY9&9$LWF<FQ!#>XPW&1D'@3-V-R_,=#>5'D;T]2X=!Z/#.LTBCOIE";3.A
M*;T:WI*APZM>E=&1>D*#1H72$!E=I<^BOBU6$1"!#(>:^9E,OQC.<R.28QC7
M7?.<ERGDQIMG&NN^<_6/)\W;.<8UV_LSG.,8SY>>6N[6==]H\U^KZCT?AU.A
MXD?X>#B+R/,Q Q">=,OQ]'C,CDF,JXQE+'VN4_[3&=LZXRG_ -X_X\9VQG7&
M=?+Y=L9Q_;CBN_6=O/-.H]'W_P"QT.['_9X-V>_L77:5N4L$VU!V\.<R4C(F
M",^AC.P(KLG)E'VQ&)OR9D.V**)L"3E1AG<A'RR&[(CJU?HZM?IEFVB"R"BO
M1[8T.H7EPM(8BL[<ZS"7 .N)E>UUQD;ID2DOG4"/T#TF_I%E"@T2*[HKI&)T
M53@:$(0@T^%!H](? !BP6"+*#2H#A$@F)"=7JM>7->&Z9YUR[YF=_.21_,QM
MC7._VP3^9C;.,YQKG;ZSY,;9QC.<8\OESC&<X_LSSG7?K.]X\U]'J- G+J=#
MF;Y=7@SW5$UE<MWVUTTDLCWWVSC7774R3VVVVS^S&-=<.<YSG.?V8QC'ESQ7
M?K.WGFAH-  )-#H8 O)-'@@#UFHI0"PBZC\*3L-B6>(P]9_-12!@K88@'HX*
M5]&!<PE QLU,R%B]<$&X$R-7',D6^[D\[=:"P21$IKNSU[-AQW0[4'L$Q&UG
M16M[4)C8CQVG S#'-($NT35;-UR^+2>DO)RB](NZ)BP(;J>V%T='=1X'1,>D
MEL#I6FQNCZ%&>^CT2+#9"?2J/&9%B.>&45D,QZ4Z# (B&+\RN6XUQOF2R/&F
MV=M==LF2?S=MM?)G;&-OK/DSG7&VN=L8SY<?.QY?[<<XUWZSO>/-?:ZC0)RZ
MG0YB^75X,]U1-I9+=-LZ;R61Z;:Y\FVNQDGKMKG']N,XRYQG&<?_ $SCBN_6
M=[QYH*!0")BAT,@X$4>"1_\ !?GSNE?^)Y#_ !HE\3Q7?K.]X\U>H4'N5$_E
MH/@3SNE?^)Y#_&B7Q/%=^L[WCS3J%![E1/Y:#X$\[I7_ (GD/\:)?$\5WZSO
M>/-.H4'N5$_EH/@3SNE?^)Y#_&B7Q/%=^L[WCS3J%![E1/Y:#X$\[I7_ (GD
M/\:)?$\5WZSO>/-.H4'N5$_EH/@3SNE?^)Y#_&B7Q/%=^L[WCS3J%![E1/Y:
M#X%+542J3J:6;])(SV_T=2RY33YY@AM\Q3583\U33YSC/S=]?+GR;8\FV/+G
MR9_;SM!>_P#:]IW^Y?\ O'9M7PNG*#0@>AI4.BB?3M!!E1X0F"RD3!DR\'.,
M%$OG=*_\3R'^-$OB><:[]9WO'FON]0H/<J)_+0? GG=*_P#$\A_C1+XGBN_6
M=[QYIU"@]RHG\M!\">=TK_Q/(?XT2^)XKOUG>\>:=0H/<J)_+0? GG=*_P#$
M\A_C1+XGBN_6=[QYIU"@]RHG\M!\">=TK_Q/(?XT2^)XKOUG>\>:=0H/<J)_
M+0? GG=*_P#$\A_C1+XGBN_6=[QYIU"@]RHG\M!\">=TK_Q/(?XT2^)XKOUG
M>\>:=0H/<J)_+0? IAK2MKUMV-6A+((^,E@U/1?,QG2BDMW9.1X#5N4>*NV;
M-V02<%-T6@8DY6;L-%U]$6VV^=/VZ^7O!@TB.R,^&26P&6D3MR(8 XD@$S,@
MTF0S!?G^F>F/)CH&F="T#I2'1J/2/*"FY/Z+ H B,C4LO@0VPXD2'!<R"'1*
M1!8U\4M:7/ G<5]['JR_ZI&5>4F:L@9HW%$VLU@;=E)URI$F!>MV+MLLY'#W
MSAV.=*-R+-7Z@]22=ZZJ^39+7;3?&MC0*3 ;!=$K#K#!$A /F2TR() )(-XN
M-ZST1TWY*].QNFH'1S:+$=Y/TZ)T;THZ)06P(4&E0GQ&/:R+&A,9%8U\&(VU
MAN=#-6YQ!"B30Y.U,Z:Z&)=OLHNHU3UT(&=L[N4L?.5;:8PMG.RZ6/VJ(Z^5
M33'[=M<8YPK1-+\98NQT>M?>-%Z+$R:/0!)H>9PJ.),=<UY[-S2<'&XYBK&0
MGKQV*L%ON\C4C&NF&NM7(:$%;6$(LEC=Q:[;P6)HKY-;:[2YYA-;4I'<_-(1
M]9!1N;28N-D4E?5#HM*BB;'-(_8B=LT NI'^ZA@UO]X;ZS,6$2=(R!_(])>5
MGDCT4X,IE$C,B'+;C";T%2'1&4;R>('2=.<SJP(H$.;3!I8G!I;7!]&=%;6<
M(%,K60!(F1A$M*=5P!Q[&R:J!8HY9(&F#E9HX8ZO4'&[51;Z9!3Z+717;*VF
MOTB>-M,XSSS.M6EP)?-KBPWDBL)@B8,IW+]11V=#TJ%1XT&!02VE4:'3(+74
M> R(ZCQ6->R*8;F!X;5<)DM%4W&1N6/U,S_=75'0K,-UMG>&&J6KXULKL^SC
MYV&6J>%<[9=YU_;AMC'TV<?MQIY.2<2<IOG.4ING/1Z]BZFC=% 5C Z/#1#M
M2XPJ, (0_P#$G5E9_;\W:F#,_P!EGK?4K,-G Y-98@AA\:RLP2;[8U75>I85
M^>U30VSC5;=?735/;.,;YUSGBM$OO?=>;W72QGHDAH_10;#>8'1X;&+6PG&%
M1@V*YXFP0S5D\N%[0TDN&$UL)EG98;8!IM(BA;>21X3)6&D;E:LCW09&M7F[
M-D4U#/WFPDYKHP<[NP1#"!5EIIC9RU3UVUSG;FQ6U>T75VM>*CZ]SIR!JDR=
M<9M/:&<+R4>)T-2!2CU.# %$I<>AQ33* VAA\2CF&(D6 :1"AV]%)B,$.E0J
M\"(20QY(*T_SME?^)Y#_ !HE\3SG7?K.]X\U]#J% [E1/Y:#X$\[I7_B>0_Q
MHE\3Q7?K.]X\TZA0>Y43^6@^!/.Z5_XGD/\ &B7Q/%=^L[WCS3J%![E1/Y:#
MX$\[I7_B>0_QHE\3Q7?K.]X\TZA0>Y43^6@^!/.Z5_XGD/\ &B7Q/%=^L[WC
MS3J%![E1/Y:#X$\[I7_B>0_QHE\3Q7?K.]X\TZA0>Y43^6@^!/.Z5_XGD/\
M&B7Q/%=^L[WCS3J%![E1/Y:#X%-_6:4R=?LAU]16D9Y9%:[JH2525+D%$E4E
M)X!T4343W<9UW3WUSG7?3;&==M<YQG&<9SCGIH;G=;HO:=_B8&<^E:OS7EG0
M:$WR/\JW-HE%:YODUTZYKFT>$'-<.BZ4000R8(-X(O!O"^';W_YKNS'_ +^V
M_P#_ )^?YFF_XVF?]72?\^(M^0/_ '&\C?\ TMT!_P#5455VYYE^M3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X12ZC_\
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MNDHU+@T)G07ECTETU3*-!C4IMM%$#HZE0 R4H3HU>CT4-@0X2WY'OM43^R)
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M>S?"-SH9H,4SB.>^)S#Y\A?VA.$3A$X1.$3A$X1.$4NU+_\ !:'_ +13#_\
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MU+_U.)G2=Y2P@>AA<-G)/M(CZ>]]J7_J<3.D[REA ]#"X;.2?:1'T][[4O\
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MS<,*0B<F,-=_HW(J/2)61:!S1)NI_P "[$:\<ND=_P#A42UV_9QV_M?%2K1
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MQ-BU.2"+1L8 B8E1L\D!V124,,8X?#V^'"KQ\U;JZ <9F9 &))*Y111X54&
MU[GS#&,A,+G51-TIR$@,22!>%!:7RGM1*- VZT5OL.;*U7.+7=Q&6107!)1&
MQ]<W+!**E\7DC*<S*.,Q\L&SBP1&S=-(@ZCA<(T(D@\D?[9%-BEJOUMF)SB?
MX'<N=>BRGU< U'/+3!AM<*L00RTATI.#G#/*6?,K+R+M53@%*<-FMP0R4RR
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M<XSG&<9QY,X_9GFF$UFWGSAGVA<*3!@BCT@B%#!$&*01#:""(;I$&2\\G_\
M,A__ )T4_P"M7XB>>[UKI1/\+1O^G@_Y;5@^87H3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A%S(M/K)V[B=_=@[EZ?652$9SVMAU9 ;#=7.#E94[4TSJN/%H3'[,J]E
M'VA"/S152)E&VR\$G2(H-M(@+!^L:<C"!,/OL%L@' S!.&<',5Y7PHS8D1\%
MT,6S6AUH'38Y@+0YD@0ZXWM==, SE,*LMR_):7;9D_MZ8IVM7KW>QY-?)Y(@
M:;FQQ1RI;/R;N>F ]\8'A(YN(8/M;#SO-#+,/E0>TBJNR8KZ<DFF*YML1K0!
M(W>K6K:?8N42B1'N>:S>T8EYF#VZ-8@D!LAV[R!<&X3-RR[_ .2NFB=APN11
M24UI#(P!7^3O<%A\9;F I)1ST_'7,+G908FPCJ;#[7D#6QP>L*>.M]5,_8[G
M!K<;JDUU6EH)$7D]J_UD$9]E_P"*G4W5V$%C0WJTZLP38AX<1)N)K"J=E\EI
M$;^35[7Q2E8948;?HZPWJ0734( S4-798?:UT0BM)^2E99[-[7.UY,"%-R0V
MW6'E&7F9%+*?B)WDQ*A4O%NB">S>VC9S[5Y)]4[KKQ^:"BQ@QK!U<5*C0YK#
M7>UKB36>6NJ$W'LM?VINK":GWH/\GO:'4^P(;*YI,8$?&16B;NJ7+2+/9:]>
M+D;.[>2SL6'()*R86@OD<,CDD2 $=GQ)X34-M5%L*/FZV7N<O>'83S8[!);H
M]&?!<TN+2&PGP^S/%T9T4&\"ZJ9&_'2+U!V?DLKV/7P5L(S*>N5?Z%%K^;SB
M[J4C\W@UP=B8M;40G<7C43O"I 3>.T:MM'7,P%G9'+6N\@D$E*Q$>2;9#ER9
M,HIJT  N-TKC(R((,P<;Y8?%8ZI$,2L70V_[RM$8'-?$#VN ;$8)0[JP)-Y-
M7,;UKN/DN>UT@1KJ1S29=;59725/]':X@T-:+6,9K>PU>F%C3*5IL;5<%8DR
M(H1^QA\IP05W$ C&\6D#8>VT$2!N'U+%EHT72/[WS<E.J1G5'.="G#9 :UO:
M+76+B9/FV<G3G<#(R$KIF22WR=W8I:9#+(8QGY/I^7FE0GZ@L:L)#3LF<T;6
MC4MV"DMVHS.M(6F-4TLR3$4)2L+L#65:5?Y_R0$$EKHD(WU5%Z+1LI=H2,[C
MC=Z[MAS*FC1:P<&T4SANAO8Z&ZS;.*8E9K;ZQO,P:DR 9XJ($_D<K4RK;@<S
M):8FH,BU[%.*XD<LDMWM)+)B%\7&!MG1E8(N /8)B'?8"X='5>4!Y=93Y]+
M<.ES("):B"L8/+478YIX9A(XXW>K\5GJ3^W,PW VE4N+YN+WAXKAM64I8@N[
M0:0!(@^>2_).]J3U31X$O9-4DK("SJ_BX"1/[ GP^302'W3&JV$[1TS: :H6
MX/LHP=FH&L<L85>'7S<I.&+H#'&TXCK:.JOS2T;H,KLPOE/-.[V.TJ&AQBP
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M6E5M@BL^#D+OZ_V:)F$ZDT*81.74'94*B77.(1N"S*K9#9+N.6.7=6_J@]0
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M?=V';2X4#=EQBJGU4DP;KLG.N45M^&7$^HK-*#G,AM:2UQBMJD&4G .+?96
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M00H'/%JR2C72SM!;<7E&2!\0T9S]BM X)I+URL69$I&.Q7<.EDE9J% 0TL2
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M?.98Z.]5&3\S(Y!BTNCDI+6(2/EWQ[!>5=>K(J6$0>Q!Y1_GZT286F)MV=%
MTM(Z_;\[A@"&$3CE\Z$840K\#L=+-HO]L\?BLP'N)@@DFO <75C,DPGL:UXV
M/KN(<;W-#9WA=3.<EZTX1.$3A$X1.$3A$X1<90.D<>=Q#H^03FN+L<7A>%[5
MC+X&#+W-%;BH&%Q6GI%L@<D(][9+6/IU\@/A$?A:[UE4\18.3ELP^<0ZRI,E
M) ^#'6^K=,$-$L)&\#'3?IGL7A$K<S<V(8CXC"T%[7PVB&;R*TJLFALZ@O>'
M->9B=J?D^H&%'4Z\NL/H:8LNS!=.W(K'"$GE$@'1"I"3;Z*E@ I&3%RR[%XZ
MKO81+IBM\_#E].I7),;;ZB68,<,R\WRT7&>G.NU&:!#KB8$4UP)N(##Y@[1-
M]63G'.XG, !?'F%Z$X1.$3A$X1.$3A%I5E$W@6N9^9'D,"7XF%2HFQ*9%ES>
M!KQ@"?NFQ#(6/L29XOAFLEHXR+"#2!<A]']4&L7;U5%NI1B/6%EYDQQ!D0UQ
MG(F4@;Y"\RT"\YEP6K M#HL7J2EY!9M:6-UXS+Z")W=V+KB?V4+KV9-Y3U][
M6K0ZL[A/3:W; ;CC2-IP.K)>4>CY9%VLW>V/70>2P*.HFQ0V3=;Y$Y^U(&5P
MF+Q+\0=ASKY\.JTLAE['0YPS$B-<\-,X<:3'ESW2-=K'8MK%S06B8#KHQ672
MHKU&ZQ!'QXX0C-J=D0M:[3 D6(D"QSKQK<D[?U>H0D;YPN3-L[9J^)5Y"7QP
MB\=$).'GRSI5\N1*ZO<YP>XRO )T7RV27<.<8,($F3XH96,YF%7<63)O(B,:
MUI)Q#YXF:JI2TH!%;=FA:VI:WD5?RN"=YI;:<0 6;.7UK@!->]@8M+HNMV6C
M*4@:LH(3K","'E?5SK$L ] J!!]#&^%P;O*:6CA=A-H!(&?5TRG??G"X,<"]
MY>9L<VD.>UKG%X#(@+3%$P&56BJVK*4ZLY%7OZR5M7D!ZQ#8W;Q; @WV""R>
M^)I C5CR9P^ CRPP+(C,(A"S^1[ROS7IJ*+Q.($'T?<)9<N6&\K,YT,RQ\N\
MR2XNN_=[,Y#/=?(9UZ(+&-@U7F5J'1'-+G7 @$M$W5I,;5:9'-,WE0/4D1=5
M10/72^@.9(&FMY=G:7L',(?2J3GFH"M.R)L/6S:HTVQTR7W^SZ[I65C)7)T$
MG&[,K:,$(V#OIHMAJFSI,RX8@-(]NG 9]/LDL,;4APH@FUT2+#=5+G$!L4AE
M2\GS6$$_;:7:%V!YR7M3A$X1.$68CW_CX/\ YP,_ZU#FF>>W_B;]X7"E?X:D
M?\B+_EN6]FZ]D[XR6>MVK?9!V2?.4-MGC?7.R2[E55/.==M\;:YSIMC.=<X\
MN,_LSSJ^$]SB1*1.E?-H_2E#AP($-SWAS(,-CI,<>TUC6F_/>%BLUE+,^3RL
MFN?)GRX\KUMGR9Q_9G'_ !_V_P#WYFQ?LWKME>A:[^&[DM#LOK4O;,'D%=R]
MF2Q%Y2SU&'V\<F16($2(?=PDL0#;G8N3%&D!9MNFH+-M&C]OJ3$.WH]QME!T
MIKFB'$&@^LS]OK67]*4![2QSXE5UQ 8]LQG$Q(R.!OO$P;BMR0J,\U19-VP8
M6W0&(Z-QR**K!))@@FCALFBR3T^;HU23;XPAHFAC335'&$L8QICYO%E$OPOQ
MO6LK4'7?=A^S==\%JDPZW:3QJ&9R>.,W[<#,XS8 U-(MEA\R61 FW+@";C9@
MY;;/?JCYJ@HJT>979O$T\-WB"Z&<IY"%$&C C'2LGI6@.E-SS)P</V;QVFW@
MW:-RV[>J)&HCAON*';M\:)IX0W<,MD<:)9QE+3"6<YTQHGG77*>OS?)IG7&=
M<8SC'%E$^BM97H6N_ANY+];55)=E$EMAC#95#Z3Z%79RSRHC]-C&%OHM\Y^<
MG]+C&,*?,SCY^,8QMY>+*)].3*]"UW\-W)?3PPE7D\GU%IY/)C7R?7&OD^;C
M^S7_ ./^S'_IC^S'_IR6439O3*]"UW\-W)?A.JY,EG?9(:Q3V54V65V3=,],
MJ*[XUUW5WSKMC.ZF^--,;;[>7;;&NN,YSC7'DME$^BF5Z%KOX;N2^GAC*_)\
MWZDU^;GR^7'UUKY,^7^W]GS_ "?M\N?+_P#7R\EE$QNGZTRO0M=_#=R7S5JR
M3K)J)+#6*J2NGT:J2KIFHFJGG&<934TVVSKOIG&<X^;MC.ODSG'D_;RV43Z*
M97H6N_ANY)FK)/G?17(UCE5/39+13+IGG?1/;9/?9/3?.WSM=-MTDM]M,9QK
MG9-/;./+IKG"RB?CBF5Z%KOX;N2_?A?*O)Y/J#3R>3YOD^N-?)\W^WYOD^?_
M &>7]OD_LXLHGT4RO0M=_#=R7XQ5DFPHHM@:QPJMJGHJKATSPHKJE\[Z+53?
MYWSM]4_G[_1XVSG&GSMOFXQ\[/E643Z*97H6N_ANY+];5=*=\;:[CV>V-]=M
M=\;.VFV-]=\8UWUVQG;.-M=]<8UVQGRXVQC&,^7&.+*)]'1AN3*]"UW\-W)?
M/-4R/.B:>18_*:6Z2B2>7#+.B6Z'S?H-T]/+\W3='YNOT6VN,93^;K\S./)C
MBRB?13*]"UW\-W)??PSEOH;;VYM[_)8OV;TRO0M=_#=R3PSEOH;;VYM[_%B_
M9O3*]"UW\-W)/#.6^AMO;FWO\6+]F],KT+7?PW<D\,Y;Z&V]N;>_Q8OV;TRO
M0M=_#=R3PSEOH;;VYM[_ !8OV;TRO0M=_#=R3PSEOH;;VYM[_%B_9O3*]"UW
M\-W)/#.6^AMO;FWO\6+]F],KT+7?PW<D\,Y;Z&V]N;>_Q8OV;TRO0M=_#=R3
MPSEOH;;VYM[_ !8OV;TRO0M=_#=R3PSEOH;;VYM[_%B_9O3*]"UW\-W)/#.6
M^AMO;FWO\6+]F],KT+7?PW<D\,Y;Z&V]N;>_Q8OV;TRO0M=_#=R3PSEOH;;V
MYM[_ !8OV;TRO0M=_#=R3PSEOH;;VYM[_%B_9O3*]"UW\-W)/#.6^AMO;FWO
M\6+]F],KT+7?PW<D\,Y;Z&V]N;>_Q8OV;TRO0M=_#=R7D6J0^X:+,' <6NP<
M)J)+LEEF"K1=);.V54UFV_SD5$U<[;94TWTVUWSMM\[&?+GELHF.?3-,KT+7
M?PW<EZ=*PE2>FB:;%HFFGKKIIIH\:ZZ:::XQKKIIKKOC77777&,:ZXQC&,8Q
MC&/)R6+]F],KT+7?PW<E^O#.6^AMO;FWO\6+]F],KT+7?PW<D\,Y;Z&V]N;>
M_P 6+]F],KT+7?PW<D\,Y;Z&V]N;>_Q8OV;TRO0M=_#=R3PSEOH;;VYM[_%B
M_9O3*]"UW\-W)/#.6^AMO;FWO\6+]F],KT+7?PW<D\,Y;Z&V]N;>_P 6+]F]
M,KT+7?PW<D\,Y;Z&V]N;>_Q8OV;TRO0M=_#=R7Q<57)G:"S5T,8.6SA+=!PW
M<.6:R"Z*NN=%$5D5-MDU4E-,YTW3WUVTWUSG7;&<9SCBQ?LWIE>A:[^&[DO/
MM3YO?##7<&(VU%[Z*#,;;C]L#MTT=F^F[#&<9PSWT;[[(:;-_H\ZH[;)8SC3
M.=<VRB;\;TRO0M=_#=R6OFNO3L]*(;,WXA+$E@>Y_$?*-BR;5=-A*1>!<@"/
MLHJZX( BGT DF[$.OI&:AR.QLQE/Z\#8*HA"B">%^W0LGI6@DM=7?-LY&S=@
M1(C# W&6D Y@MB;5$=9,\#V844T8:ZJ::L6RC!!GKHMMONMIALE\Q'&JNRF^
MRFN-/)OMOOG;&<[9SF640XRWK65J#A7?+_ENY+\NJ@-OD'#5Z#$/&SK5+5TW
M=;CW"#G5#.-D=7"2N-TUM4=M==DL*:[83SKC.GDSC'+91/HJ96H.LZ_']F[D
MM?9]>G3&;G+$2$);RV01R/1%X27+:+:MXW%WQXH*$CFNROU8>W^U),9(/U&R
M6CDFX<-L$%W* L2BQ6424KI>M3*M!K%]=]8@-G9NP!) %VEQ)TW3P$MN\,Y;
MZ&V]N;>_R6+]F]:RO0M=_#=R3PSEOH;;VYM[_%B_9O3*]"UW\-W)/#.6^AMO
M;FWO\6+]F],KT+7?PW<D\,Y;Z&V]N;>_Q8OV;TRO0M=_#=R3PSEOH;;VYM[_
M !8OV;TRO0M=_#=R3PSEOH;;VYM[_%B_9O3*]"UW\-W)/#.6^AMO;FWO\6+]
MF],KT+7?PW<D\,Y;Z&V]N;>_Q8OV;TRO0M=_#=R7DUJ0_H[6(:!Q>C]RBDV<
M/=56&KMPW0SOLB@LYQY%E44=E%-DDM]]M$\J;YTUQG;;RK%^S>IE:@SG6=/3
M9NG]R]"=7RI+31))@S333TU3333>-=-$]-,8UTTTTUVQKKIKKC&NNNN,8UQC
M&,8QC'%B_9O5RO0M=_#=R7[\,Y;Z&V]N;>_Q8OV;TRO0M=_#=R3PSEOH;;VY
MM[_%B_9O3*]"UW\-W)/#.6^AMO;FWO\ %B_9O3*]"UW\-W)/#.6^AMO;FWO\
M6+]F],KT+7?PW<D\,Y;Z&V]N;>_Q8OV;TRO0M=_#=R3PSEOH;;VYM[_%B_9O
M3*]"UW\-W)/#.6^AMO;FWO\ %B_9O3*]"UW\-W)/#.6^AMO;FWO\6+]F],KT
M+7?PW<EC/!DKADY&XCH/ YZHNJ\8>09]2=JNE,JN5'+7YOT"ZCA7.5%]U4]]
MEE,YW4SMMGR\ME$^BIE:@WBLZ1Q%DZ_UW+!SCKRZL.,N8G)@Z+@4L]!%6^6I
M5)D]%FXL<&R>+'A+Q!355@8C4E#"#P5ZE_Q,R@UFXUUV^B^9D(40&=T_7I4=
MTK07"J7OE<;H;P00000<Q! (VA;%I4)Q-9\Y3""='!/5/4DOHH/U6(:HI901
MU?*Z^3=WJDCME%/"^RF-$LY3U\FF<XXLHGT5K*U!UWWX_LW<EZ-JKDV^=,[C
M6.^4]-TM,[.6>V=$U<:ZJIZ9SMGYNBFNNNN^F/)KOC77&V,XQCBRB?13*]"U
MW\-W):J>Z\N9,9@YPT&1=NJZ-/9)$D/M5-)@.D#V.%XE@QLR25T1=/&4=D)\
M:.^LX5;L]##IRDAAZFS<M5E$OPOQ,[_HYUD]*T$EI+W]DS'[-V,BV>&@G>MO
M\,Y;Z&V]N;>_R6+]F]:RO0M=_#=R3PSEOH;;VYM[_%B_9O3*]"UW\-W)/#.6
M^AMO;FWO\6+]F],KT+7?PW<D\,Y;Z&V]N;>_Q8OV;TRO0M=_#=R61#UW*&98
M6[7:-]4&I%DX6VP\;[9U20<I*J9QKC?R[9QIKG.-<?MSG]F/V\K83PYI,I @
MXZ"N4?I2AO@1F->\N?"B-:+-PF7,(%^:\JQ'/4ORZA+L)=3*@ZR?3Q6.$IH<
M>2*$P&!P4,Z:,2DYLJSIB#KZO8FW)/\ _N(9J7ELC%)&I"]U581@!J5DA!)5
MB)<Z;$Q57I]VUO>@VP;7L%046:K3&RJ.@L%-4E8$QML)(E[)EI1E8<<;Q[PF
MC=I/9Y5L"CA^=#1H.ORX>Q&F!K-L4B[[)9F**RGAMT"X8'&7KONVK+A?E!JC
MD<S7'1X9-)'",UO6TJ%F(S75HR6?F)M9,SOB+MZW1J$'!'TW'EXJRZ[6$:FJ
MY=BQ\UVS9KN9;L6:Z3Y4DM]_PV_7W+(N_E'NHK;8%]!/)@81/C*M*-W<;I&\
MI,T&XNUZ6$U.'D:X&N2.L:E\[.AG<< 00[]0F[F1*- VT>3?.DD<DJG[QB,V
M.=;> [R]9Y'&95*F<Z+,V,)8A74H''*]L:/R46]D-W6;UN$1G$5,Q1E(B$U=
MWI3T_K/6%"AKZ4:204.1W%:M9-%W1DDC]>H'[B#-1 O\I?0*]E0V)@5946A<
MDK.3V1M.U*XMIDI(&ZD_JJMZ=8TY&5*]V*WFWO&06#(-X(:K3!T82%P P88*
MD!#UB0W)(_4CIT>I;T8^40ZI@1_V@5F<R;:L@,TE,M9Z4O=#LG649K>7[06P
MI#;HUE '#RJ D+D:3E \4L!*/,FXUHZD""[F/I9*9)(_6?U:<,V>[%:*V^4>
MJ-/'8%K(TGT0?U"<[)CHH1.1:UEX)/!_6#5F'L1RG/ -9&@JAT9-<& [Z#PG
MS\FN@X>FZ%@#)A58"W*U3=MEG&?#/\3(?">P5]W\K0L*;K62-/PTB]M&75VW
M=Q>&6C8L!'LAO869];(!*Y990*O=(C"AML3N%/7$03E! 7O]B$1A9]NW&*+/
MTBDONG\)KY=E.XY6G+LC5+1;/78<]7IR27/-97V.OQS1D9CX)E+1$2BHT2Z9
M5[/EC3^1+)S@B\771&- K"'**;[O-W^NC<@$Q._1<)\@L93'REG7RRXE7Y.6
MN)#6$MDS:&,)H'+PRR'T#K*<32F@M\BHE)KF<0()7[+4E61X;+0),\^C:Q(,
M^8_: D&;76!-2$2^/PV?6?,IDB'=+KU-2 <0*DTI'&I(9KX/& DMJRTX.;DV
MEJM)H0KN0  \PAH0D4A\J8UQ/7C&7MFN\<;-X@?4)$6.!ZOD)(_1&;_5:2?^
M47ZDQPJ2$/9]*GS@(8" S[J.TW=,J$Q]_)[VL+K/%M3AJ-5^5$C4I7>573"
MQ15R\TUDSMJ,, ?M"-GP1D@21_'$9A/[BO0I\H7U81#N3:\MFR+0,WF!&<H*
M4M<VI.IP,!F)J RZ4W,)\PLD:AB@B51N1L,R.Q&T=$/FD<DYP:Z>@(O(R@HD
MC]$?#3[%YY;\H+UN -;'293 BH4KX7?F%21RN+E%5X_EO7!R4%6E#F=@CZT.
M"CIR+'13IB2"P="8R=VDV=JQJ/2)RDDR7)5/W9Q._9.:V!SWCZ^Q\@8!S:32
M"+%X\*E#QX]?5=;[:'RHC I3&X!-PU2RTE !XVW2HJP);'(<)"P')N0RLV;&
MCXP'+/%5FZ!)$X*<:KN"$7().E86X.Z*162N8;+0,LB,J@<NB<I;" LAV!R6
M(S0.!D89XXCDDCLD'9>#4VY:.GPAT6N\$E&+M<HI/X1.$3A$X1.$3A$X1.$3
MA$X1.$3A$X1>1^ZW8L'KU-F[(J,VCEUH/8:H[OGV[='=75FRU<KM6^SMSMIA
M!MJX<MT<K;Z8572T^<IJ1<N)G\HK.JJUD@2X:&@-<384*Z\R+;[6[&Z*U77(
M'L1,9?# /Z2UK[4\T0I$S'24,?H%$!,7M"-%GY 0SC,N,-UW9!B6JLY2OQS:
M)$RTX[-L@KP=:[J0[$T?7]SM@'FTWG0U^^0&HE])&)62'&R8/0W%9.F/$:2R
M#2?47B2P&7ZB!&)9"BP&18$C/M/ZBW+)N^OKVJ<N$3A$X1.$3A$X1.$48VQ*
MK#B4:9N:MK5&TYF6D00"/ DY>E HP+;$G&WVE*)C+L 9<3#1D"P1<.7:@"&3
M Z[>;,![$ MAVJ[9D7-;'RIFCX]6,180BBHU))4G8>)H\MKL^3@,##J03L))
M>N+!Y6,T#T!._%&-3^7PJ4E(/*#@2K1;\.E'D2.PPY)&XEJ^OJY:J^O-@-D[
M[^?W*Z787LTWHMXH+'P0]9)P725\]A)!&XPMC!_2NJ)C8Q=ZTCK'#1W@Y-II
M.9;!X;#XTNJ*3)($)0<T)[;1/<24* 3]I V3*J/6ORD\AN1\&A-4573-AV*=
MF\NCPF0Q#M%N?ZQ&X]!:C@-LRDO&NP@RCW).0R@,C9$=B1"#CZCRJPD:!]5\
M=; P!$JD5+98SNE.Z\3GB)_4PK%O.W*TBZN5#VCJ6&1,O#K5B<:GY(Q<EP1Z
MD:XJ*!FH20F1"4VK8VH2PMV# .Y9M(9Y(=$YI]<E9L4JJH/B.I>6"2DKR#B+
MI2F29RD!SEON6;H'M:PN]Y631W""L!4N3K7#>RM>-31#1T0*Q\F\&C+! .6J
M;%KJV>UP_E=;*.".JRK8^,L< \:H,E4'[1(A$I[#)6WX43A$X1.$3A$X1.$3
MA%SYMCNG85*R]RSG/6X@K"S"787PR2B5C-I3>,\QUYJN86D5D2M+M(6W$@H#
M.FT)=1F$R1O:D@,9D\SJD5*(G&GL^3:ART!//HG.X"9EC^6E;[TW[;,^V<?L
M,NR%UY]%7TK!QK:64Q;B5[T[*MC\#BT\TTB=H)PFO/M,Y'6TH0"S8#M%D,QP
MRDFWP0(ZNM=TBA$OSN*N3PHG")PB<(G")PB<(L+)2KH#'3YQB#*2=\&"E2K.
M- _J.#<A=#F*[QN##Y)O!PW[4++(Z,!_V@08L?K;A'ZV\;-_I%]"+EW8GRD4
MRJ%220VSZ3J^*6^*DU 1\:$W['%R-5:KWZ N*5L0,PM)G0.T@C%C0J,4=+C\
MG@8:J9FHZ%'ZX>QPV9;S9NHP+4L^:_-HEALOV9U;);LNFVH&L;=3'U_+9);Y
MRNH= @566<M/ZZDDLL^4,HX#V 6FM"(N[,Q 0R=NI=*)%I &A ;& $C<-(Z1
M>CD63TI*\C1INPT^V[UJFSCY5D2WE=NQ76J8^5)U^[L($)CP"YV!"> I7$.S
M%?\ 5J*">R\2<P,<AUL'6[,;'#SJM3K@_9")FH@TOG"K1OF/_93TK5POS3ON
MND3=IP(]=RM_7G9&7SJ'=B$$*D9E+VZVS5[6LLJ*!V6+DD?DD[7J^ 6[$Q\1
ML^6QZN$=A!Z)6A$-"1240^,/8Z:UD8Q4(1^QFK@P4(PT'#?+;G"C2J>\Z4\9
ML2!Z&PUH&;=HM^J$JG-7VOFV:K2G)6!1V4P\_!9XI X*K.8P0F\F&41*-U(W
M&R<0NK!*+*,2K (2-)$(EIPF)B_=FSGU+H#PHG")PB<(G")PBA6_J5&WU7VL
M+=20["3 B7P.QH1.(TF+<&X;8-8S -.H7(6S XQ)!"[1L=!M&YL"78.1Q\ Z
M*A76$DW^7")4&7X[0H:CW4LZK9L$N6U[WG%K3V#3%S-1K)V+&QBM11%O55DU
M%'&D/KH8Y=#XLV$ +?L@H6*JD3DPEYR2)XD$I< (S#0,<)/0)??]?6F=;!_R
M4<%$A(N)0M4P>R"1C XHE8=>P.QHU(V$?I>&U9]MD8+*&3J'NK%:28%,;<B<
MQ-"3H^*S6UY\CF*&1!%-JF0'9^%_LV72"E&C_DZ:\I"*5;#Q4VD9L56EGTK9
M/T;X8);8D7@+U2CO66 QE_JWUVRV$,RD6%W8NHCNHZ4L=0DIA35B05UU*ETY
MW:;M$S6_*_-Z@HKBWR>J!"\8UM-43^:<IFJY;&VI-W(06"'8RX+9DLPGY:UC
ML?!)KKQQK49BU+:4C#0ZYU<D[)GV\T8AV6:^B<A-DG=I)W@#1Z\^P;5N 3Y.
MLD*?P>7O>Q4H/V73T;HF*TG)2=>0I".0,11(^X(ZR;D80)^S6THQ8D4N$HQL
M538P'<NC8, >B#F')"0P@24GC<+_ ,C\)*.([\FS*GE@]CV\MN25ZU5>T6B=
M=6JW4&PTC(NP,6)2JS[@MYT]>-AK7%4HS.97?-JI<#H^R5^AIT6.CXA(:2%Q
M68"BI.$AA,^HW#\ ?6IN*_)WP@T JZ/DK"E+EM7 V8M'FVXT1\V:/[4[/4]V
M>N,P?0^;\S5[9)NIE882V;9U4'QB>3+ZFML]?X5X4G?/Z%Q P^KE%(?Y)ZO1
MQ6K'1*RR$K95?(.LDS9.9=74$D4X7E/6XC##F&P.P"C1R8@4$M"60[Q%GL-A
M+<,L0LB0R0ZI(7 (V5BCXK6-^V?JOG.[3FGF]<B+PH=;J^7O6P[\DXX9-)7.
M(;5,#&-I-'@A1O!XY4S^Q38EM&7+QHX=M5BLAM&4F2CC51+=191BECRZ,D<X
M*3NEFG/[N2@BS/D^ZVMZ(RF#SJ7RYY'YY;G82W)M@9@:,)'B=\T?9O79 9]?
M^KN<-F];5;9&HR(.MF[E;[5B$6,.]-E1^J/"3,P=$I>PS^O6H\AWR:4=@12%
MS6%V!%H'9\/LL7.TY16G7&CJWCSD<)J"U*6:!?,F)QU@T<%FL>N6?R0?))*5
ME"(V;'GCMK']8CE&%H$K'#[R3*\'?<!^"VNJ/DZH+5T7CD9S8DPEFHBR.NEC
MFBIUF(P2ESWK?%1'FPP-J-DM$\IG+E9E[Z-.D=,*ZS61DFC+1%CA+?!"=%V/
MQ_*06$V^3= )-K. L+DF3*&]B IR-=F0/F]&G)"UH[(KLO>[Y (#R)9+Z[ $
M)<2[&69")CLQ;F=G<$(,VT5Q#)0UVE2SZ_%)_##=+\ 5GR_R=\&.QRH(T3L&
M4N&%6-)AJ^QD:'QK.BUG]E*<[(VN=D"7S,IHOYZ2JLO"'VS/YN647L^<9146
M?.FRR9)XW"_X"1$MQ^ 4!.?D=*I,[;/97/DI6=81)&+B3YFGZP?$Y(Z%WS37
M8(7+[U>$!CY_?TK-2JDHL%L=U.7VHN6QI<BB $P0N^(EWY4.(^.<YYB0T7%=
M"^MO7J(]:J]=0>*MXYJL;E1V<2HA%:\@E6ABTG/Y:H*K,H;780&!&#Q 48$B
MP+1QH6/:1N/AFQZ1R$FW<%G10F9_.?WJP'"B<(G")PB<(G")PB<(G")PB<(G
M")PBQIEL2>!RK0,33"F'0U\V$F%6"95(227:JI,2:@M5=LD238.MDG6[!1RW
M3>:I9;[KI:J94U(N8T$^3VLV'Q6-#R?9&+RZ=P:X@W86/6.;H'=8S-+K:1B5
M0<]-+^3=7&_>VWH=B$P(#1HL8:KS$ <B(:I7;V,"81%P0PM$SS9I8YA+"Z[#
M:KN]=Z6:T!5@^N&Y]>4.<2JRYX>.J"V8!H_EMN67+K8F6P.-CU%V,7BZ$JFI
MAM%8RW=/L (XB,%+$RSIJN4>%DW_ %HN4W<(G")PB<(G")PB<(JX=J:3FO82
MI'E6PNW7M-?;AT&O+#C"//)"I)X4/<;NCU>.]14N@QT6%F?S&HN1D $H%%UX
M[DJ%0=(I&%UDBH,BH F?2VSI]5+FD3W86."ZJFU.K=?[:@4(H$#$8J^JK+Z0
M-D6E+BV\Z>^"\K5@LD>5X2-NE['C^0S $3CT-C)X0W([$G?.6V_3=CA-;+V<
MZK.+VGR65%B*,#M7K9>/5FV'@5X);GHF(GB\5F<(L 6W.ZKCC#,(6B$BB1B.
M;CS6#CF?Q]<H)<Q<+(_(0&7KF"/9F^M"BZ6?)Z')]O*91.K-IZ:V)-9E$)')
M&TQZF0B846JR@==DZYB"PFFY;-3A@18 )@7>%FUBI6FNY=O,MX^7!$J]9,(4
MU*SV?&\[,UVSFIR#=9+!K6LJNJ^BKX6@ &E \#CD!8RBNA\\#&X]%H 6@IX5
M;@]C)H01G6LH=$6<[2>1T[7CX#-@0MTDY(@5"T?)E)WS(Q^KOHK4J#ZFO*9M
M.JMFSMX^@/7?K3.JAA$B)*!4"<[EW82U899UR%%8^#PBRB@"..J7KM")!VK-
MD.:(R<T"$,6XB-,'! J3,':?N$AZ\?AM5]>%E.$3A$X1.$3A$X1.$7,V2] 9
MO/YCV:*V-V'92N+=GXK8]:2%+:G4&]FP6H)='C 2(U57%BO[%,Q^-0^"O'P^
M1O1*%9;"K&D+0F9G8PJ5/NWZ)6>$AAMN^CZU9BA:".U9*K4LB<SP//+%MO6O
MQY]W#Z_2JR#L 57@GX")-Q4*Q*9N[P>5;%B*DDDA*5$7!;3 82P9@X]' 89D
M0G,/K[M"LUPHG")PB<(G")PB<(M<F P^:B,I#122^9DH+1PV,C<PP(:2'S4/
MOQCIJ'DOV _508G/L(BJV*?9#U=%H2^J_4G*J:*V^^"*AE/]-[UI>O&42B_:
M&-><H6=LK&;S%>@572]C2E^ E4>L(IV(^UKE+2RX"4\3D(LVH>'3JOI*!D,0
MCGU$TO%FV\3V*S&C9B/A==^-ZV UU/)0.A:9AU<D'<ZFU%]@ _8O5<QL( K6
M)*)'9\KF=Z)-6N%&,=CSR8";3M;,##*.V,<CAM]%ACPFV"#ER&A)W^R7JND#
M]>P*.4?DX<ZM%8^YN,>[A\4B%_0^H@SRE849?#!W8R=!Y[/&5WNY22D8&^P2
MKP*D"4 N(K 49 #?D2,P<R*?:AYR')/\,^@2N^C*Z6><CU-TI(4Q75A0JM;4
M$U64MD[,)M-3%,4_$ZY AIV2AM?0* D:I@RA.2AX%&8!'JY#Z.8J5<S96<DR
M!XS)CRA,R_<KDG,WW^W-]?Z2N6K/NGT[4-L5Y!*Q<Z.VYVPI?L;?\U 1=E64
M.!C^LP&)E*Q!0:OE97,CNQ2036JJO8G2)>42@B_%N9B1?R$<-$0R'Z%9_!I
MOTSQWG"7WE='N%E.$3A$X1.$56I%(#R,@.(HFRR**1<BFDDD2>)IIIIO%M=$
MT]-%L:Z:::XQKKKKC&NN,8QC&,<\CWO#W .,IK]C1:+1G4:CN=1X#G.@0G.<
MZ%#)),-I))+9DDWDE:L4G3X&.=ES<Q=!Q+!'9P_)E)"L/',F^N<8V7=O7;M%
MLV1USG&-E5E=-,9SCR[?MYFT?K%=S1:(!,T:C@#$F#" _P#BLAYR2+U^:_BC
M[^OQ:/UBG5*+W:C\&'X5YW<P+CVCI^_E!)DQ9-UG;UZ[-NFS1HT;)[+.'3IP
MLYT1;MVZ.FZJRRN^B:2>FRBFVNNN<X6C]8IU2B=VH_!A^%?IO+33QN@[:28H
MZ:ND4G#9RW,NUV[ANOIJJBN@LDYV36163VU4253VVT4TVUWTVSKG&>+1^L4Z
MI1.[4?@P_"OMYR2+U^:_BC[^OQ:/UBG5*+W:C\&'X5@M+,T4,[QQ.P--Y"GN
MJFH!TE>-C*:B#%B373W%X?Y?:[HC28T@KKLAC9-B08N]\80=MU%+7B8S=+2I
MU6ASEU>C3T64*>8X5=HWC2O:6G3T"+)'#LQ=!0H9@[*%S!:0JCA8H8P04=/R
M)(@\>(M&+!DU25<NW;I9)NV034664T3TVVQ+1^L531:( 2:-1P!>28,(  8D
MFJM9A5WQJRFSUY7-O Y^S&K)-R+N%3]A*FP]POILHB@]7!%GZ3599/3?=))?
M9/=333;;37.-<YQ2^(,2X>M9;1Z$Z=6!172QJPH1EZY-6[><DB]?FOXH^_K\
MEH_6*UU2B]VH_!A^%/.21>OS7\4??U^+1^L4ZI1>[4?@P_"GG)(O7YK^*/OZ
M_%H_6*=4HO=J/P8?A3SDD7K\U_%'W]?BT?K%.J47NU'X,/PKPMYP_=O" YK,
M'CD@(V;:E6#>0++/!FSU##IGJ0:IN]EV6SMKG#EMASHEE=#.%DOGIY^=Q:/U
MBG5:)>.K4>8Q%C"NGI[*\ "S$Y6UW?1:P=)(Q3PPRH\ 2O4PU3P5##)$+SNX
M'/W*.N"4?-!CK#YV^/K@8L,)M_I&3]JNJKQ!BXJ"BT-UXH]&(NPA0CB 1@W.
M""-A!P*SOG)(O7YK^*/OZ_%H_6*O5*+W:C\&'X4\Y)%Z_-?Q1]_7XM'ZQ3JE
M%[M1^##\*><DB]?FOXH^_K\6C]8IU2B]VH_!A^%/.21>OS7\4??U^+1^L4ZI
M1>[4?@P_"GG)(O7YK^*/OZ_%H_6*=4HO=J/P8?A3SDD7K\U_%'W]?BT?K%.J
M47NU'X,/PIYR2+U^:_BC[^OQ:/UBG5*+W:C\&'X4\Y)%Z_-?Q1]_7XM'ZQ3J
ME%[M1^##\*><DB]?FOXH^_K\6C]8IU2B]VH_!A^%/.21>OS7\4??U^+1^L4Z
MI1>[4?@P_"GG)(O7YK^*/OZ_%H_6*=4HO=J/P8?A3SDD7K\U_%'W]?BT?K%.
MJ47NU'X,/PIYR2+U^:_BC[^OQ:/UBG5*+W:C\&'X4\Y)%Z_-?Q1]_7XM'ZQ3
MJE%[M1^##\*><DB]?FOXH^_K\6C]8IU2B]VH_!A^%/.21>OS7\4??U^+1^L4
MZI1>[4?@P_"GG)(O7YK^*/OZ_%H_6*=4HO=J/P8?A6I*7$'19.R:MIC$AK L
ML ?$%)NUT9,SK?7;=<*[=[$\(-RR&FF^ZPU931XGKKMMNCKC7.<6O$TN6>K4
M*4["BRG*=E"E/1.KCL6<%3MX=8HE <R<F1CG*N&Y$5(E2+%?**NZ"V$7;1XL
MW5RDNFHBKC13;Z-5/=/;R;Z;8Q*\08N*HHM$(F*-1B-(@PB-X:LCYR2+U^:_
MBC[^OQ:/UBKU2B]VH_!A^%/.21>OS7\4??U^+1^L4ZI1>[4?@P_"GG)(O7YK
M^*/OZ_%H_6*=4HO=J/P8?A3SDD7K\U_%'W]?BT?K%.J47NU'X,/PIYR2+U^:
M_BC[^OQ:/UBG5*+W:C\&'X4\Y)%Z_-?Q1]_7XM'ZQ3JE%[M1^##\*><DB]?F
MOXH^_K\6C]8IU2B]VH_!A^%>$G.'X0>[+&9@\$"AZ.[E^3)R!9@/9-T_VJ.'
M;QT[2;-D=,?MW564T3U_]=L<6C]8H:+1 )FC4< 8DP80'_Q6'?VR/%I"ER=E
MLQR)U'5P$6?S)%FD90WU0VT6%*."2>A!';5RVVU4:96TVU<(9QMG"J?SK7B:
M7;EDT:AB4Z/11/"<*$)^KLWXC!9MS,RC)1FD\E;]HJ0<;LV";DZX04?.TV;L
MBHU9Z*NM-G+C0>P?/MT$<;JZLV3MSMKA!NMOHKQ#@7%:ZI1+O]FH]]P_8PK\
M]W9T GV+',++U*!=Y(,G^I&.I)/%U3S"58=A4T!^5=7ZVY1N_48Z),=D%]7B
MFR^-&V45<+9TRGOY)7B85C-046AD3%'HQ&D0H1%V-]62]!2P' ,6X.&YLL'"
MM$M%W1@I)-QXML@IMIHFLX(.WJ+1%)3=1/3111;73;;?377.<[:XS:\32Y#1
M:(!,T:C :3!A ;ZJ^S2;D"&ZJ;"7O'JB";59=-H?6<[HHOD?K+%575%WOLFF
M\;_]NUWWQC5PC_VJ.=]/^+DKQ-8J]5HAPHU'X,+PKW><DB]?FOXH^_K\6C]8
MIU2B]VH_!A^%/.21>OS7\4??U^+1^L4ZI1>[4?@P_"GG)(O7YK^*/OZ_%H_6
M*=4HO=J/P8?A3SDD7K\U_%'W]?BT?K%.J47NU'X,/PIYR2+U^:_BC[^OQ:/U
MBG5*+W:C\&'X4\Y)%Z_-?Q1]_7XM'ZQ3JE%[M1^##\*><DB]?FOXH^_K\6C]
M8IU2B]VH_!A^%/.21>OS7\4??U^+1^L4ZI1>[4?@P_"M?6M!!L]+#7%B(H$0
M(],L<8+2W1)Z%%*Z[;I$RS7<AJN.'J::[;)O7B:+;?77;;53.,9SRUXFERG5
MJ&)SH]&NO/[*%<-)[-WM7Z!V<E*-7.\:L).0Z,]DM'>X.6:EM6NRV-\HZN=F
M#]QA#97":F4L*YURIA/?.N,XUV\BO$&)<$%&H;O-H]&=+1"A'[FK/><DB]?F
MOXH^_K\EH_6*O5*+W:C\&'X4\Y)%Z_-?Q1]_7XM'ZQ3JE%[M1^##\*><DB]?
MFOXH^_K\6C]8IU2B]VH_!A^%/.21>OS7\4??U^+1^L4ZI1>[4?@P_"GG)(O7
MYK^*/OZ_%H_6*=4HO=J/P8?A3SDD7K\U_%'W]?BT?K%.J47NU'X,/PIYR2+U
M^:_BC[^OQ:/UBG5*+W:C\&'X4\Y)%Z_-?Q1]_7XM'ZQ3JE%[M1^##\*UG2V1
MZ@4A)$[,9J1T2LZ;%3^DR0W"C'#)7"+Q @4U)98LEFBVVJ3I)RNGNW5SA-77
M3;.,<M>)I=N4ZM0Y$]7HTAB;*%(9KS5665G3U 7N<6F+I$*FQR34+JR%9,6F
M-U0^M;$-R&[S#31CJV_[QEWLKAOA#_M<J?1_\7%>)A-T]"O5:)*?5J/+&=C"
ME+3.JL6M:K)OL<T<60U0VC&S322ZK3!)+:/;/\:[,=3F-R.N1.SW7?3+3#_#
M?+G&VN4<;XVQY5>)I<IU:AW_ .ST;LX_LH5WK[-WM7H$67K(6;@B G^IP>T4
MW1=/Q$JP29MEDDM%U$G#ID_601430436WT4WUVT24T4VQC3;7.5>)I<@HU#<
M)BCT8C2(4(C>&K^"[,3.(#702P=##8RD\7$.!<KU((%41RFB)!8:JT?K)ODF
M*RB:3Q1KLKHU44TT7SIMMKC*O$TN046AF4J/1C.<I0H1G+&79OEG6=\Y)%Z_
M-?Q1]_7Y+1^L5>J47NU'X,/PIYR2+U^:_BC[^OQ:/UBG5*+W:C\&'X4\Y)%Z
M_-?Q1]_7XM'ZQ3JE%[M1^##\*><DB]?FOXH^_K\6C]8IU2B]VH_!A^%94%(#
MRQP,DJ;+JI*E1R:B:A)[NFHGN[1UWTWTV6SKOIOKG.NVNV,Z[:YSC.,XSS37
MO+F@N,BX?>N-(HM&;1X[FT> "(,4@B##!!#'$$$-F"#>",%C)/\ ^9#_ /SH
MI_UJ_,Q//=ZUVHG^%HW_ $\'_+:J)=[W#U2FHM'4XQ/9,"EE]4"/GNE=UU/;
M2,C*UCMIQNP[!</8I6\;E<I6#F(I"BD/=NVP9PBW7DS357;399+&T9<2;O-=
M*>F5V<?6U6D7L:*KG!T6$'56N?V \/=,,!,BUI;.6)"J=V+M/LI9EI,$:,2N
M^'00I5T2UI9_O3782#.G%Y&[$GL=F$ALH":KJ.M&@"M1 *OS'FA?Q6OZ^D\2
MD9TT+VERSUB\B^VAH;,R)F9X&0S:<?:N,5T5[Q9VC6U&U.Q$;^T+G EX+0),
M ::L0ACFDD5CA!,BL[L/8YT)#8K*^QV+:L"*781M>/)Q,_BH@PB<7'!.N-2N
MZTT>1C>,GX)6L8N@E9S.Q:]?F(I(8[7)"?V?(#)00BJ)L@)^: ,-.$S><]UP
MVW+D717$-:Z)7<'E[9&H Z(V$RI=5+&->7UFD@AM9Y)"WMN?[>R$+"&T,>]F
M0%ESR/C(GV67-0*5"X'3$ZL6]Z7C#%&E!<IB2$15'4;73^Z";"85ZF:A!B!1
M(?(K,.2.02F&EW@@#&K+$&Z;KK_7/-A?H6YQR&U;5KW "+-C@UCG1& 68(JR
M8TO[3"6U6S<7$M)PUED>YL?F$WBH-[V-5J9Q*[MWIQ=$7;IZPR\P!)UE (JP
M(3")1$FY'QM28A['M*NT;5.0ZD94"GV=C9MS7,+&-!852!<)RON$ACIGZM/W
MJ/MP7-%K4G$J&3RXN%5K16#20*P<]M=S6.K7FJ!+45P'9(59\[M$]!+B92>1
MR221L]8$1AD_CZ;-"=V/&Z<*S$8TBE8VA,\@C-7_ ">]<;:IU[&',KCD7[)Q
M"0LY1 V4G\_A>KB )M.R[,)RO]>\*2BASGN:^L2X%S6N$JSQ#K -8]TBRC-/
M9%8"*#-@-963>@>QEI_)ZXK>1C9LK9=T7F\J_1*P83.9 4A-%'>UCT#L8L@*
M9<QV<EHT*ZZC71=\ZEAX,7.CWP\<2F&CHDE(5><VUYX "=TA,RP$KL\OP74B
M(^C537K1(E3M-<2V&8TIN!DZK9"9K$$@R+KYK8CG6ZX@_8&O)45LHKAU.191
MK<4CZUU 0I2'-*9IR'6.J"KK">)5;4D1FEAV==08ZD77G:LG6%P!PWK-E%WC
M \77!P(E=C^\9XD>K !4PGVK27'M3KF$PL AL:Z3<7FL][P9UJTF]@-()5=J
M@D??4A,:I&6"I<XTZ,SUH?"AKN*V2H+4K)6N8!9%\XL@SB,BZ:D,T(F"5FT6
M45LF=:6-'3\6B\@B$/:FB6#$LT:E\JN?"6-X$IYK@=NG.N3#2"Z&'6@/[*0(
M?YE5KXE<R$,NO=#-=U8.:"!,S=M45G';VX&W6"&L5NRD 5=U_2;6^;"?UA,X
M-JVL:P)]BWK@:-U["A3#1-"M8CU[EE--SKT+M'F"-_QH4@H_*28"EM.Q>;L3
M(782_$WB6?$*M='?9-_:M-6&(CBTMDYSJ\259LNP(98"01^T $ZRQ:K?N/%0
M\ /BI3VF6%R0=;3ZR-RH22S.0UK2\H[E5& K,-'8F]BQ,F9N2ONKABTY+N7?
M#)/;"Q /J_),I0P0$1E"BJ9B39W 82)E?ISR^-^B&V :08TB'UIASBR&8[ T
M!LB3$;!+R#)SYWD.$FK7#-G7.]LBQ:T''NYZ-=@X#;LYHD)'8Y9+JXI*O.1]
M30[KZQLPX1C+V=PH2[NBKNUI^#%;I6C@=S#E "=B2!M"T-P1*U0!@TFZ=XD)
M$SEIGZU"Z)6<P&D!@:]T.0>8A+@QL(/,BYHM&1G"T([,JY#;C[C$;[BP\1-K
MKCZ%SN[RL:R>P;R312/1P[I WP^F>IQ?K97NVT5;1_Z'+6T;^@]7VI!#Q1%?
M9>&N",@A.K8 2/K%4VX&K<!(B6),SGT*D1VAT05[1SXI( -64."83>S*7;B-
M8]IU;VW3G'99IVIA+.=1^N8OV(B<N.2T[)(28#16TT1$D,/K<?==JWF9P!"*
MJ<QI5.NZ#I.JYO)X]<5CC(<M$I:BBQK$MG[-,/9V?L^NZ6$_QWSSK!$9M8,$
M4$N):0U\B2\PV$U65>S#AM<X/>&D.\PXG_0WSBOIIPB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G"+'%\XP)*9V8O2>,#GN<C1JJ:!$AC#97RL6"ZSP<BB]=X_
M[!JJJ08IIKJ)[[O&NN,KZ!B$.!S[!B?5>/O'K7$ /&QJ3;L^>IGK]YPQ UU^
MZZQ*GH3/>L1B%A:AML9);,@L#@TC@4K".D+'D=<:6>G*+3G;35T_CT:8;!31
ME,.J+60[S-P-QK$SG(D2F;]NC;)?/#1^V+(58&'"#&NA50R("]K6EKAVW-KU
MGOODVXF1"Z^TE3T*H&J8/3U>#M!L3@H1$2PU^C03=$7>ZJKXU(2V[=)%-T?D
MYQV1D4A(?1Z[D391^^5Q](XWYQ))))SKVPV-AL:QHDUHD-NDG:3,DYR25*?(
MMIPB<(G")PB<(G"*O79G>#)5PV7L.%&IG'F\NC#E)45!']G,(1(6[S=:*6/*
MX$*<Z$I'%(5)-!9<HDT8&<"U$VAYZR:#!3TZ'TV<[C*X[)[!ZUSBU:G::2)C
M!M<-.9SFYVM,B;CI(D"1Q40KF31ZOXU)$HU9S^W8! ;A:]8H6?ZDB9-4U\FB
M_:"U95'&Y09*X/*Y!U\;V<ST@!4O#FJM,[556I>,'HS,5HG%)"%B_:=YS"=\
MG2($KIX:)"^\XXA>"H0T&3J[6OL6F "R(3&B. (+28=859M_9U&D%KI AO0+
MNE%2%DSTU7!-Q(VHDQT7[8.X6E%@#J8%74X<%JFCTF<B8BU?BG,JDK"(&VX
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MA@E5O=$_=EA(SG<%M,Y^4!GL.B#"RM*U@Q&)6H&N?-#1[,U)M)H_+UV:916
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M7+L+&V;8K)'IL?%Y4;(7F^>C 8GECIP6C'>'1.RPL9)M85_]ZYP:V'V6N+G
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M-):2-A()&PJ?.971.$3A%F(]_P"/@_\ G S_ *U#FF>>W_B;]X7"E?X:D?\
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MY3QM[):I ZHZLL)X#UU(") U#!N-<,XZ3?.WHM%LNY6WWE6+H==/XX[UKK5
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M'"<Y%[3?IQVE:'^A'2664/';]=(>JQ@*SM:(MEX>BX2"X?'&\G=MD=5T5/K
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M-AWU0.0<H%0)@F8 $A?///0#H*\U3]P^O-N#ZYU%65$HM-[0'$7T8IZ=2V'
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M^UCC*/+GD'8]N5EM$M/Y8_!2X6[' MZKJ2V*XKVU+M%7BQBY>MP-91T.F=)
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MT*6&7R:)U"JD:W=2*O7+C/36J.JQ ]H)?(.W[^9VD8F7?&;J9T%_/T6OT.H
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MN,]=:RH7=U1/8,) H-7U=SX/?697@5V(BXZMB46F[69%',8LYQ#'&)EB.2@
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MG2U:TG=]>1ZC)7H;.HM"A@A/:LNU]]I3(PR:2&>L8B *',+.A?S6T>!)QT.
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M(MWC(<I(IK(!D<$;$R:V&PL4@]*N6R+HL4=9U:BQ;;94@2=;:MF39=?;5/)
M"<!/U)6]I5M<46;S>J9W$[%B+IV^')2.&'ALA$X)BG&S,J+6>#'#A)L5%/$U
M&906YRD_&NTU&KUN@OILG@A!&(EZUOG")PBKJ"[>=5Y/9"].Q_L72I>UF\FD
M4*4KEC9416FNTQB+HHRE,40CF"OVJYD<<=A#2!L(V:JDAB@@GAXV1^H.OHBL
MCC(RTR5BN%%&IJY*ECBDI0D%EP4(O!]GFLP;E92%8.(UL.C0&9$,&6[IXDLQ
M^H1.41N2/?I]-,-0AX037^C:$&JJI)*2N$6CV/9=>4_#BUAVK-HO7<$!*B43
M,OF1IA'HX+6.F1\="(OBY-=LR;*ECY86%')JK:[O"A%DQ;ZJ.'*2>Q)3PO6.
MJVY*DO"/.);3=F0.U(RS*N 3X[7TK"2T6P.,T&KIV%(/ ;UZBP+MFKYBZ7&/
M-D7J+9ZS<*(:HND-U"2EBI >/&8YF[($';9@P8-EWCY\\72:LV;-JELNY=NW
M*^VB+=LW1TW6776WT212TV44VUTUSG!$9/69)FT(CG;9^/?MD'K%\R72=,WK
M-TEHNV=M'*&ZB#ELY04T6071WW262WT43WVTVQG)%C&<FCQ$Z;C# V+>2.--
M@[R0@VSYNL5"-9#H^4!."C%-39PQ1+Z#".XY1PFGJ\U8NLH9WP@I\TB_1^1@
M8J/3*R0N/"#EBH(&B\).4FJ"YJ4'!\:C8E#=7;7Z8D>D186#$,DOGN2)4@S8
M-4U7+E)/8BS7")PBP+F41MG)@\+='1+>72 '(I,"C*S]LF<+QV(/XP+E)P:,
MW4P\>"HZ2FT/8&7R"6[8<[DX)NZ425*,]52+/<(L*\D8$><"QI\7'LS\C;%W
M8$2Y<IHOC#<!JQW,[CD%-M=G>PU(DR6=IH_/5206^L9T^A2643(LUPB<(G")
MPB<(G")PB<(G")PB<(G")PBT2,6E64W\ZL0RQ8)+LP4DY#3;$8ET?/\ F<89
MZJ[NQ4J^RB#OS>)-=$%MW+$O]4=(:HJ[*I:X3WS@BVX:2'&1S P'?LBHDJR:
MDA90:Z0?#B0Y\@FZ9/V#UJHJV>,GC95)PU=-U5$'""B:R*FZ>^NV2+V\(G")
MPB<(G")PB<(M=E<NB<#CY&63B3QV&141JAN6DTK-#8['Q>CIV@P:[D3)=RS'
M,M7+YTV9H;.7*6%G;A!NGG999/38BT/3L%0JK>"NT[NJ%1I:#]V*K1UI94,W
M;V(4'D,B7XV"K:FLIRU^R*XR,=LP&Q!PV(8RR63T<X^CX22D@H?! ]QJ1LT)
M#J&7CD>'3*$F8_<J_9ARDA>,1NCM9'9\\:@ 9HXY;-<*K(!Q!0FKIJR'NUT2
M*,,]C.OF(2WLS-[4UBN'9M2,M; S9\)Q"7,D23<*JQ]O*_MS["6-I)-'2B@E
M-_L_T3;.-]F^-45,ZDD<)7Z%LQ^V*MBD':V=*;*@$:K9\S$D65A'YE'0T'>#
MSR:*H-\UEA$BV N&9E)RW4$ND7^Z!%-='=GNMJKIG8DLV=;"&E,8D>V^D>D8
M$]LD.#EU-0Q<>4V3$R)LH\CY3?#%POG0<<9HK.P[W;&&Q-LDHNR572TVVP19
M[A$X1.$3A$X1.$3A$X11QI<51J3US52=IUQO:#-+9=W6^DXC.T]:HZ"DSNZS
MF'ZE,R%!+0(JD8V45':Z:BE$R&<X:;ZK9)(XRNTK)P6R*\M 0O(:SGL+L0 U
M).PSHY!92#EPAL8'_1_7Q*Y( ^(,D23+Z9'ZVQ46U=-OI4_IDM/GZ^4BW3A$
MX1.$3A$X1.$3A$X1:#([7JZ'")2?EUDP&*@H,39!)L:D<QCH,1#S)-@'*C1$
MI)$R+5G'R9 9(0!)DP++-'3M@<#O$$E&Y-DHN22V)Q*(TSCF\P=R(&UB28G4
M^I*7!9@A'- 6[;5[H:W-JN-1FHG9GMJ[U([.L,]FVVJ^%LI9QOPBT5[>]'CG
M$Y:$+EJE@[K##'-EM7MB1!JXKS!1PDT&9G**YC12)8(NET&S')_4?];<+)(M
M_I%%--<D61BEP5+/(T9F<&M&NIG#XYN]3D,KBDVC4BC0%0:P2*D4S)T03>"Q
M>[ 6N@2>ZOG2&S5@LD\7PFW4T4R21T+Y0NYJ>LC1NK7=KUK/4G;XB,:J0N=1
M>4Z.20ADR)%A[?<&4?:K/A8XD.($6B>=EV3)^R=.4TD'2"BA)$8A25PB<(G"
M)PB<(J/]IXW,QMO=5[\$5Y);>A5'2"UM9K!(4V%EIH#<V3 M8M&[?BD:+DA6
MDH)075$[$R(D(Z5EVL5LZ1OXZ-,*LG0IX5$I&^4Y??ZB5S^B]:=O[!L4I-I/
M#+C:03SGO"T8]I$W+/IM.[TFT;HZBQ%3$[Q#5;8#WY[I[/H>3A\(WMI-596,
M1$3I-8=M$_FBRA6Z1]@TRQG*?U?BHVH^DNX<PNBNHW.E>TX7KG(I-U_.6+Y;
M$[+5LYT=ANOWR@S6VQ)B0SKLE8=LOV;BR2'5<--3@EU5\0L0ZWBYH!7>K4>M
M*RA4D2NE._,-+92NEISF[.K*]::7[L5ZI5ZL?FLN'2:3=7AN+>,=JI-<'8*(
M:VQ';$1:C6VD:<W* <QV;;P8@Z;J$XP7&LS U@FM*6QXHU8/&Q0D&\XSP$@)
M;EC(?TG[(2JD;,1/6[)HK((YVU[P]B:*IG:'5P'B^EHN.V_8BT>M\T/31X$D
M$W=0@J>D$-MO00D;'K.V)!B"-.W4;^U0! J2)Z>RT'<)@8>K\5"4HK7LR0%C
M-JW9=XX!5H\51:MCB;3DEU7!()!=@J-7NSLK<K'XQV3A%^E*T54,5JA,C5!6
M.QB1>S6U:S.,QR;06,6KAR^OK.EVPF^6 N]4I3Q]FV2BF7TGWID.6MF2&ONS
MPJRA%7V="JP1!7=/964KV42WHYT^%BME3@Z;LL.&I6V8#<*9R1$F[Y-2TU7)
M(Z0?R$BRD#PH2)2&?9C>?R*L9<E3_*"O7-DQ2.2:V6E:T380H/#I,,D\SDTE
MOZE[RO07;\^=Y#1*W*KL.4$NM57AXE2(O+.R(C8DACRMMM(83>'3 O0^5%7/
M*\>J1%PS2OO.$L)R%ZWJ957V/,?)POXF5?7E+)^R[6438<-49P5!E>,8J* ]
MYZ<LO4E%HA;UF]DB90A"H'%S\Q@8JZ)9,9)YOL0,>G<6T<,748U*73S8'U3(
MV <L\R% SBNNU>3MCD4(MVJD=>V_>,'DI.Y[2$JQ6]2KF,]?SD*5$3ZF.E<Y
MZS$3E3CBPJ#@*\<,B=-CQLL6.2NS4I*(%@9&_*S%V&B0PWF?KF)BY86/TYV^
MG- G8#V)A?<Z6W]+:3K:$5@]B]VRF(5Z$C&G7P=#K:$70\'V<[@9.8KVMI9A
M69/)GB4SFRA4AK3,*FI%Z(1DL4), S$KC?.5]^8'9+U2.F_!BJE[[)+;I18K
MV7ACAF!AC:H0& %OE4!--".K,?!GHA)IH>[>Q^K(V?5M)K-QA!"649,;U0L)
M_')O#BIR-,(H3BC/]<_P4,I9IWWW8S]4_B I5DU,]J(*N"@PYEVCDE:'A% $
MI'+35N]D;;=!I_K4MQN[)^U8U#+YKRVI$UD]E&X^W+#P=LP*M8E(4XP9D#?,
M?!B6HY]:4F+_ %G "\72Q!EG^L;(QUM=P2B/DH%K_:2E>8Q*U(D+OUO-"6CP
MUM8"O5^_8-7.9\;<%Y*W*.2%\E*W%,33P_(E"%D%X4<^VRSOR%%B7=J6?#>#
M]P7/T; /E'B""+P0V[$1"*2F!TZ5O8(=7[!2\^+D .TA[JTHF$=&^V8&86)+
MQ(8UC>6RWKBKUFBUI5^--@ZL$2;06'B0]]:5;@!>#*>B9NN)NV&XETC*<IDJ
M7@U =V2\;E\A*RWM<:VAU<PYW50=G8-E4H;(14MVUMU2WXR+ASWLI93LE:B_
M4Q_]@U ;NFQCEB19,]6SDT^BECQAHXC3ZT?6Q)C0,^C0)9L)XB5\C)>604]:
M3Z\FT^)55WQ+=<1,/[>QF@1T:M*UA5[1$A8$4Z$K1QK(SCFU1EOAX++[>K:Y
MBL!!V+*'+.)FA;&5R$7&:['QQP *3NS3NS C$YI$8$?=L6NLJC^4Y7+'4;+L
M6_L7*N#EC8T;I&.G%HR2A;GJD_C[/2!S>6=MH=UB GM;85;J1AAMU['VB/NY
MFREKTGK6[LK/-Y?]?Z_@59MV<K\_9)PT$W;5.M4"KN&!Z(B\T#S9"5M_E!(.
M8IZ4S!Q<0XK)( PZ_FU+Q.-:ZOFT+JM"J(PU@J5LQ!X).VA(8^<EIAT9B_U-
ME, J)"J77XX7REID-%V!P_+N3PLIPB<(G")PB<(G")PB<(G")PB<(M%M 3)S
MU:6(#A+_ .RID9@LM$Q(IE?9K]FR<B (,P+_ .LZ?\;?ZF56:./I]?\ B2^C
M^DU_;KCA%Q.ZS=?)%,JBLJIK"KZTY-!4^D%*U_*1]JT0TZ_'PUQ0'2=K.NN4
M#>0:!542NNB(XNOAUN.+D+E@I)R;69)V;8S&<REIJ6CING,X&8]>-QW>R2Z[
M=70I>-=9^NT=D(Q^$/@**J,*<#%&JS$F(+BH!'V)(819.-$W#-^P>H+-7;5=
M/19NX2425TUWTVUP65.O")PB<(G")PB<(G"*FG>F'#IQ3 (,=TNW$897+3<L
MD3Z@8(#LZ>!6T&G@F9A3RM?F8I/W4IC8:7 HV_/,8U )O)&S9'0HRCCEJ/?N
M6A48YO;_ *A<L9(0D\KB(JC+?HR^6C2W0,TBMA=ID.E=SRRQBG3^-]A;*=4E
M6K6'T)23^,UIV&L.+O%I?+29R.5<I5C ^)GY"#YLIX)B41?7U]>M:TD2$LU8
M"^6:9OD?7-6Y[^QR93>=2^"B8?O8*LO^3C[M1NK8-LY>M6LJL&2E*:C4S%H*
M,"P!UO+U8,78-8BW9'X^=>BG\Z8!3H=L[.DFI09O^(?7/V*F0JHBCR6&Y?/"
M/>1_7:%X!+!B?8"%],F 6S#%A-.HN*/<LIKU=/=>)&9'Q6-1[5Y'8=9D8ZUC
MQ!0U('D;DQCZF"'R(P39(8:;I3GIT[5;N<W79T3ZS=8G]F=99O/NV<99UGJJ
M[&];;BL"LZ*LZ8T_)14HMDW'J,ATT6)L8?&"<FBQB(U7J5QI,94SKEK(X: +
M/IW'22F3(@"_%P$QF%\MF(6P=7(8!K6\^M4$J=U.7T-"]"[(:6N^GT"D=62\
M@3:7K5JU!DIC6TICT4-P-8@3*=NW<.B3R-A68,4J=' 6"(=JWQPAP,\:PSS&
M!G(S.S3M75+A93A$X1.$3A$X1.$3A%_GA[+4[?YAYVFA?609V.)67=QCN$E;
MD2MJD8.)J'S%D/7Z?B*WDE.=@A\!CV#1Z7S(-2<#@\>0O\\>0ALMEPZPH?#W
M$3</X66P1=.5TI&9F+YF8OVYO5MZ'=%ADF:26_B"C*Q"E=$W-1Z0FQ;IZ^@>
MM]N2<P(@[@5+HJ5A(2IJ15*P2N6S:*"8#(RE?-UM<DY+%1L@D(.+"W*)0YM.
M>^8Q]OMO71#A93A$X1.$3A$X1.$6E61O82=>SC>I&T1>6EK$Y!X<MI\^+#(,
MK-\BG6(OK,'X$:8-M8S@UEEL<5$#'I+ W#G#)#=QE/R$&W#/)<!('0?8JGW-
MFRBP:O= #E?_ "@]?WX!F0&,VSW4!VC,I9T"C]2VE9L]@,2K*C;$D<3?R8\3
M?"IY3<>/.8#?!;,:Q7 *K*Q,R)Q.>[Z^L%N8NPO;*5P_>GC??Z\V>95H(C!K
M*K7I1TSB-JM7 UBX[EUT=LL2X!8BF0%?SSLW,)U1<7(1!,D9UA;4)-)!0<7?
M0;[6(MHDW;*1%V[=,1SC92J9SZLYGFOOSY]BACKO K.@-T$IU)*DM>;;PBN_
ME$#$YJ [1!Z.PFMBEJ=AXQ>0"'4S:[R,(->SKZZ#L59N6F<2.WW3=1LB<#JU
M9HHO"#1#AF_=SB=PD/5+#-MGBK2JT:C _D^9E0<HB%J%[.[&T=;$NO\ (497
MS0A+#UE69&&2MWY!JFF684'/)I2IW%*?A,J?IN5(A% L$AS$HG$FPY$F<$2D
M")3PQSCXGVJ'Q"MDH#HH@.7LPP#9?*%]9T^K$KN&FQM$W#)8V1C8C7M*F3@(
M^KZ7?YC *GG/8<<$.R&L8T<(QUG(D=MS49$@) 1)G.&!G*_U9],L,/8NV7"R
MG")PB<(G"*+B-I#AS]\/W%O5-V+MPTW4T50QKOLV6W1VWUQG/EQKMG3.<8S^
MWR9QY?V\XNC!I(D;MJ^Q"Z'C18<.*(L,"(QCP"'3 >T. -V(FO'XO"_5#_\
M%;_GR6XU3O"WD./Z:%N?R3Q>%^J'_P"*W_/BW&J=X3(<?TT+<_DGB\+]4/\
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M^=KC.%N-4[PF0X_IH6Y_)9;Q>%^J'_XK?\^+<:IWA,AQ_30MS^2>+POU0_\
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M*9$H_I8WR>!?S-MFL^3RC!.?)GRX\NKO/DSY,X\N/^\_LSY,YQY<?^F<X_\
M7BW.J-Y3(E']+&^3P+^^+AOU:*^Z[^*XMSJC>4R)1_2QOD\">+AOU:*^Z[^*
MXMSJC>4R)1_2QOD\"_F+;-8SG.!@G&<_MSG&KORY\F/)CRY^L_M\F,8Q^W_T
M_9Q;G5&\ID2C^EC?)X%_?%PWZM%?==_%<6YU1O*9$H_I8WR>!/%PWZM%?==_
M%<6YU1O*9$H_I8WR>!/%PWZM%?==_%<6YU1O*9$H_I8WR>!/%PWZM%?==_%<
M6YU1O*9$H_I8WR>!/%PWZM%?==_%<6YU1O*9$H_I8WR>!/%PWZM%?==_%<6Y
MU1O*9$H_I8WR>!/%PWZM%?==_%<6YU1O*9$H_I8WR>!/%PWZM%?==_%<6YU1
MO*9$H_I8WR>!/%PWZM%?==_%<6YU1O*9$H_I8WR>!/%PWZM%?==_%<6YU1O*
M9$H_I8WR>!/%PWZM%?==_%<6YU1O*9$H_I8WR>!/%PWZM%?==_%<6YU1O*9$
MH_I8WR>!/%PWZM%?==_%<6YU1O*9$H_I8WR>!/%PWZM%?==_%<6YU1O*9$H_
MI8WR>!/%PWZM%?==_%<6YU1O*9$H_I8WR>!/%PWZM%?==_%<6YU1O*9$H_I8
MWR>!/%PWZM%?==_%<6YU1O*9$H_I8WR>!/%PWZM%?==_%<6YU1O*9$H_I8WR
M>!/%PWZM%?==_%<6YU1O*9$H_I8WR>!?S-MFML9UV&"<XSC.,XSJ[SC.,_LS
MC.,N?)G&<?LSC/\ ;Q;G5&\ID2C^EC?)X%_?%PWZM%?==_%<6YU1O*9$H_I8
MWR>!/%PWZM%?==_%<6YU1O*9$H_I8WR>!?SQ;->7&?LP3Y<8SC&?FN_+C&?)
MY<8S]9\N,9\F/+_]?)C_ .G%N=4;RF1*/Z6-\G@7]\7#?JT5]UW\5Q;G5&\I
MD2C^EC?)X$\7#?JT5]UW\5Q;G5&\ID2C^EC?)X$\7#?JT5]UW\5Q;G5&\ID2
MC^EC?)X$\7#?JT5]UW\5Q;G5&\ID2C^EC?)X%[A=I&'Q,<R4'C-$WCYHUWWT
MU=?/UT<.$T=MM/G.<Z_.UUWSG7RXSCRXQY<9Q^SE;&)(%47D#>5SC=#P(<&+
M$$6*2R&]X!J2):TN ,F@RF+[U&TG_P#,A_\ YT4_ZU?G*)Y[O6OK43_"T;_I
MX/\ EM6#YA>A<JK;[4SNAN[%D;R^0$"O705UTBK=G VS(;E=I>!(/>UHQMX'
M?:,L%=WDYB%'3:$Z#G3QRV(RIQ!!HEJD3?Y1)= T%HNOG,G/*<OA]9EY(D9T
M..ZL?V0A"ZX?M"(CVRNG-S8;FRG>:HE-0/7_ '[O.E*'WQ;K,+>5FUB=[&E;
MH+--)[J9R"@?;F]*A#M!PRK*>FD2@$?1!UB88Q&96T?A$:/+1K[#0)$WC&5G
MP6RP$W7"0SC0"9Z3>,+]BY-I,2'#[<HCV6IB$5Y]F-$8 *C'-8),DUT0M!PF
M;R+1R'NK<+*$IV3'J;J\G%)Q; VGJ@8&;L?@)>2D)+ME >K+(G.@?AP0V$A'
MCB7DIT1WB&\R(0]D$8QTRR=DI!JY%X#&WB9N$SHP)T;,-NQ=C'?5K"&RJY]1
MDXA#IVS8(+FU+AVBXU:U60!O-T1W7WHNX/1)V8[0>'P-K-SG8ZDJ\E\.GY"5
M2Z.W)UU!W$]DITK%Y!7841I!SC^@K/2CCK8FX.C6^D&VD8! E*RPF'::P5@#
M,RD2"+I'-\<UQS+G%I$00W.JM;6,1C'-<2X/A5ZQ+2P"J;-TKYBZL)D@>22]
MS+LD->7(RJH&/8[4]82H^=3V;6"AB9-V<A[I6U3PMC P3"L=8^8&BHG6+M7&
MA]R(7P-,,(DR*GY$!)R8C*K9[3@)"6%Z.CQ"R)4 %1PK.+A6 ='>R314D0&M
MSD&1E,N!)L5UG[N'NPE@B :E.26,P2<QNPI3!YDM&K@8(LV4%E <$P82LQ-Z
MCA->DR4S$&,2!AO64ZG@X"Z'$(Z0>//*-.DHY@#20;Q*Z[/L!F+]*ZPJ08C@
M+-S6N#G-<0\>:0 "7,:TEP,^PYP$I$SD336*WOV'>6/%-=9/V/$/YQ\H%>E1
M1Z:3=]UOVZA':RJKMA9\</U<BR8JE;L$3):AH(=BE;(E043*R:UP;-<=(B0;
MZPH4Z2;,B3?-%P!K"8QT8^O$+B(D2NV^**U(B,#G&%8EK(SP6@7Q ZS:6MF&
MDO%Q(QEN(_*66-.X6RFD6ZQ3 F/G==@+3K/;6-WNQU1B9JPZVB:S:29/40#T
MGDH90ZRV5D,@'7=6X=Y&G&Y7$P[E3*$9E,LQ9WRK879L=YEHOEIN&&FTISFU
MA"<:S0]G9BCLES!?6ABL:KZTH5I, C5)^:/R@L[?%B)2(5MM-G2D/IE.2#8\
M2M"6Q6O%BM@=Y(I*I!X:QR@,]C=S;8KUU QV;QU> NY#%UY(+T/Q6*MJWEI>
M64L:!>3=/,)GS3IT&[-M04ET[F5B6LK!I<6L[5(#C5$.UG.$ X521,3#:I)^
M40[[VT7?V 60$59*!4FL"I0M/@XX;L^?.AH62=4X-=LSP*"5-1<HLFS&XX](
M44OM1I$V>HUJ:(OY$M%QT>'"S2HV0%^?1ISG8/QD$;2'FL9,(+F"& 7ND#";
M$=<R&7NE/&5TS.J  =BKOY0ZS;.CD<L #1T*&P)](>J4*/;F+4D&LI:2SM<T
M@ X&F($)5;JT> H+,+##-S;\J_#%#<;U>$68066:8#.<E@$YDS$SFS&_X'ZG
M=64E\0!PAM#:T%KIQ#,&,&8"I>&N> 29$B^0-RN%TOL*P;:ZF==+0M580ZL&
MPZ>@<SD[T'Y-!S]_)(^R+:$=&^@L,@P=$&KMN\(BV0],>*(+NAPY9XQ:MWCC
M+P X@7?7U[5W@.<^#">\@N<QI<1@21CLGC+ &X7*S?,KJG")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PBY0M;.[&.9C-J>F]NIMRLF^4)C%';SJN8H'C
M.*[JM_T/A?9[:(PIM)])IJDN3EK1>#J2R2;&#CU:9DRXC2./EP#"/]9- ! _
M=)&TAP;?[)G,/O7CKQ)N8Y][J2(=9H JL-';%DVM6S]F9F;R1(RE<SJ=-I9.
MZ;P_FQI>3R"+VMV%JG>5NV@QB^EPJE>P-G5!'984:A&(L*F9DD>@XLR;V"C!
MH=8P\?+BAS$>HV:I8=CZP"1H)$Y8E=X+BYDW&9#XC)W3(9$>P$RD)D-!,@!,
MW*R7,KJG")PB<(G")PB<(JAWI*+>C/8/INTCLS"AZEG]QRJ 3N'HQK+N3S!Y
MKUF[+V,PW=RMV1W:AHT#+5S&'Z D2"U,%R_SEGDA:"F&X@QMH!#YB\-)&R\?
M&]<8A>(D"3@&.>YKFRO=^RBO%^8 L%P$R<\A(P/U6MRVY/-NN9696(<F+#M)
MULNB\I/"BPZ*-1-4RF!SZBF@&/P?(*.!S+$&)#7*5@Q]E)BDB>D"$5CY91VD
M<4DKPU7 2,A*J0 =,QGO/K^&A<X+WET(N>76T)\0M-63'-=#D&R ( #RTS)O
M#<"2L=-[@OTUUL+7C!["%Q#0IVI="'[)]&$SY,=5$<[/!^OP:#PW=9\R'1Q_
M*@$>WE$V/'6$K>LBTFE(D S'J+A"\:2;6 E@/83(DSFLN?$LC$:Z4XTC=>&"
M,(0:V^Z8$W$@WDRE=*.+U[*7G6+6WKZC\V,%\P7L1:])!*!7$QA6%/XI!^MT
MIG 9QOJC'TYRI,GLOC[:RUC2<K^B6B3Q>.Z#=!&6[AO0!<)8MG//]?Z+,2+$
M97B!Q-6*^&(4FU:K83G X5YS%>=;"Z0"G^L;%L^O#M\Q$U8LAOI&#=3J3[&Q
M\U*F,30+*S2?9[!#)''FN\%C458>:<@<4Z".QL7LQ</1#@Q(&;,AL&V"CQD(
M!D92[1;<) B?KQQ%RZM<]AB@N,2K!9%!-6=9UH"T!H'9-2;<2)D3E*5?_'"[
M*QKZ82\A<DDM3$7Z=4?W:*/#0V&-]=2+6124C;$'"I16, FR,'MN$@B F'""
M"11]%"@UP4"%7#C775MKLDRJ@=HMG[,?9]RY6D1K2XO+ZL"'2">S>9NKM$F@
M57M!#09D$3%^'8WG%>Y.$3A$X1.$3A$X1.$5'^W[GL(].5+&*',%!:2C2S)M
M/VT4L>IJ^FYH'#Q,>'B1056TH%9R;H>J9ER*Y!Z,AV&#$LWC8V22J*CSZ+QQ
MMLI&<L0 2"0,?K%>>/:S8(9EY[G2>QCB&@ 2KL?=-UY D#($@%62I.=A;2IJ
MI+-C;P^1CMBUE YT!(2MLR92E\&EL6%'Q;R2LQB#8:U/N61!!8PW'MT&*)'=
MPFT12;ZIZ:Y(D2-!(^L5UAN#V,>)D.8UPK2G)P!$Y73OOE=-2=R+:<(G")PB
M<(G")PBU.>FWD9@TSD@[4=N0C\3D1MAH7)#PPG9X*#O'[74H8+.60L2.V7;Z
M8>DB3QH/8MLJNGCE!NDHKI1B/6LN,FN(E<TF\R%PG>3( :3.Y4;Z=SBUXYM8
M%:]CY+9,HM^&5#3UMR!S()15,XBKR-S5"Q!."<(>5;6E:?9!(A*:YF3<[%#:
M$E;,TF,>5BLND#!R_>XVX R(D 21.4I877F^6F[.N$!SQ6;%+C$:QCS,L<).
MK";:C&2F6NF#6P$G$7K6 EH=A"D-^3PLA2Q S"-W_-8H?M>-)1M(F=,JW#5M
MF6P-@PB4+/4AP*O*YT2$1\7HTCKF529(&&>$),/U;FF\G&K-PE@#LE+\9_!9
MKQ"VBNK"45S2X2O-=CX@:#F:VX"ZL9 EV,ZZ2?LIV&C<4JJ>,K;/N7_:-U9<
M;+ 'P&". ]!?1]I:@J #+X&TQ$=':"E1PRQ# B1H3EU+A)^3M@QJ1-=ED'C,
MGH $D5?-E+2;B;R?@,XWKF8L4!CJYG&K@B32(4HK& MNGV&N(-8D%TB1C.RA
MFX;8KBE.\PII/2TID'7RV ]:5Q:$M'1E_(A8:P:>Z^S_  <DR(P$'C!]]5Y:
MYSZK9=X!U;OH_' B$HU+/M#+U]F0-2[SIS&:Z<I:,W^BZE[V0X\G%SH;PQCG
M $@.9#=-T@ :IB&^4I 3G>O.C:EHU7.I5&2%C2BQXO5/;;KU4RI&6H1G>12&
M%=H(37T;Q%CSN-QZ/#79>OK0L0!88TX@(9F$X=E.-OE'#)PN_=) B<@)@F[-
M(^W;MP2N]CB*Q<&1H;)NJS+8K6B1D!,M>\.!E.K<9XKIMSFO4G")PB<(LQ'O
M_'P?_.!G_6H<TSSV_P#$W[PN%*_PU(_Y$7_+<MGD$1DKDZ:<MP[Q5!P5(+(J
MZ::YU425=J[I[ZY^=_\ #OIMC;'_ -L\V]CR]Q#3*:\=&I]$91Z.QT=@<V#"
M:X=JYPAM!%PS&Y8CS*E7J-]]S7W^9LWZI7;*-"[PS<[PJ,Y+UEB<R)O#,LJ(
M'(BI G71IX^,!&3]PX+5%('LKK(BINX^?_WN$2(D0+QY?&,;L'CURHGGR+*:
M[6K$& (E/XXK)IW1[C,QH9)JF\._<)<W]W]TDD*/9+T.HZ8*D%I-UVAYG8PG
M)DS6CP&CLW.Z2^8R:Q#V#S71;1L<^GGTTELW8Y+)/-@DMDAF1 \CBY!R[4LH
MNAWP6#2^C78Q81QG<Z1K.+C,59'M.+A/!Q)$BLSITOJA.3E)GI0T5Q)S!X?*
M7I?[#;97Q(QT[CMHIG&*>V^6PHF\LF(Q>>FG@M%FM(9?'@\A/;$BH]JZ358N
M@X2S88?<KUSHZ9=:PID@DU78AP?/S<:X#B<[@"9E?)_THJ(I(95*B- Q)Z>F
MS8\UE#YR!:J_:FDJ3:HRM?9KOOEDT(2Q)DS3E11@V:DI)JU;X-NW_P!"G\T&
MQ1@#=L"&E]&DN)BPB73K=EU];SKJLIF0F1>97E>8[T<IF3/1Y ]U\B!-X,?D
M";99P!;_ /:/R4Y+V<NY?IZ*:)%=T+&/G)V+P4T>:!9:8)R /JQ*/G+E15BC
M,?@H:7T:X@F)")$Y=EV=Q=JW]HEPG@XDB16SP[J? Z^F!F?PJF0,:F)[0TD1
M/"A"#=YA&3&49'*$!VN-\MPK>52-LVD4I;AD1Z,ED#9N;.:/RB"3K2%L4B1#
MBM-IO1[7%S8T,.,YD!V<S,NS=,WF4IF1,R%DG?6>+OHHZ@SNIQ#B(O)L\LEP
M 4%-\C\V _L):V74S33QMC9O)=[,<+3K0PWW2>HR=3)9!9-UC53"K%G.1GA.
M[#!7KW1\JMM#E6+Y2=YQ=7K>;C7-:>8WA1[IT0I!-.3I)]=H<FG+\M\F== *
M&GS/J<G2F[3 /;57&T5U:S9NWF;;2+9#:(2YLUDR6NAQL@^3LHN@[@L=:Z,[
M7[2%VL>R[36N[-W:ONE??BOTMT3I588W$YZ^Q=!LTU#X:.&0O(\NU7!$[$,C
MB#4^Q<MSK<Q@I;EIOGQI$CH7+.+%FNY9Z]\Y2^':K%T'X9Y<@G6^C92M8<A+
M /!N+B+P)SF]YG.?:=/$KSO.A-%/G+1WOUSAK5PP9QD<QW$@D0>&8Z'QMS#8
MZ/:Z!EF";=@QASM:(J,TM-&Q"+80CI))X':M62*470=P3K71A_\ $A9OW7#S
M06C!NJ:ITMN,PMOCW4:NHD!3BT8I&,@8XB:@4B0!B@+)D+;FJM>!']<D&[)#
MYB#=:$NXV 6C6$=-$A60X_1JFFFV3TUA;%.(.C-GQ6A3>CFB38L(";3(-<!-
MDJI\W]V0EHD-"W.!46VJ^*C8/7M?I1&(!MGN0\<"MM6H@5H0?NB;IN-9X5V2
M8L\O7CE1!BVPDS9Z*8;LT$&R:2.@LB&\M)*K:?0&-#6QX;6B<@ Z0F9W=FZ\
MX9EN'F5*O4;[[FOO\EF_5*UE&A=X9N=X4\RI5ZC??<U]_BS?JE,HT+O#-SO"
MGF5*O4;[[FOO\6;]4IE&A=X9N=X4\RI5ZC??<U]_BS?JE,HT+O#-SO"GF5*O
M4;[[FOO\6;]4IE&A=X9N=X4\RI5ZC??<U]_BS?JE,HT+O#-SO"GF5*O4;[[F
MOO\ %F_5*91H7>&;G>%/,J5>HWWW-??XLWZI3*-"[PS<[PIYE2KU&^^YK[_%
MF_5*91H7>&;G>%/,J5>HWWW-??XLWZI3*-"[PS<[PIYE2KU&^^YK[_%F_5*9
M1H7>&;G>%/,J5>HWWW-??XLWZI3*-"[PS<[PIYE2KU&^^YK[_%F_5*91H7>&
M;G>%/,J5>HWWW-??XLWZI3*-"[PS<[PIYE2KU&^^YK[_ !9OU2F4:%WAFYWA
M3S*E7J-]]S7W^+-^J4RC0N\,W.\*>94J]1OON:^_Q9OU2F4:%WAFYWA3S*E7
MJ-]]S7W^+-^J4RC0N\,W.\*BZ2]7XE,!LQ$R6IQA9E/Y0$F\OU78:IN#,SC0
M:+Q^.RU1ZW61?-9,!#0J)#PQU@X:E!B$>%?4G2.[1/?%#8HE(&Z8'MQ6#3>C
MW!P,:&:S@XW.O<  '>;YP#6R(O$A);?$J=W@4:"PV%P5&+Q6.L$1@, %8-V
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M1^/-.MM3FJ7K<Q##Y$65?D;L[-V<DZ$9=[,]!%W]D[9NF/,%,O6S5;[2$@+
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M5K"I8)$^P\.N4C45<F2,; F"S+#6/&G8MTZB,/#XE,G>LQX"+Q=L/:,R3O\
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EWFFL(<TW></O]2Y1Z=!?!C,#8@+X41@F&RFYA G)Y,IF^XK_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
